,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1189,1,5,,48414671,31703,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
1,1190,1,3,,48414671,31703,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Dog & Primates Bioassay Results,Other,,
2,1194,1,3,,48414671,31703,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
3,1195,1,2,,48415928,31703,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
4,1205,1,4,,48414671,31703,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
5,1332,1,1,,49698493,31703,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
6,2240,1,1,,85787258,31703,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
7,2241,1,1,,85787258,31703,Active,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
8,2275,1,1,,85787258,31703,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
9,2313,1,1,,85787258,31703,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
10,2316,1,1,,85787258,31703,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
11,2322,1,1,,85787258,31703,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
12,2330,1,1,,85787258,31703,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
13,2517,2,1,,124886887,31703,Active,6980812.0,,12.5893,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
14,7220,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Confirmatory,10411476.0,
15,7223,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human bladder carcinoma 5637 cells.,Confirmatory,12431049.0,
16,7225,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human bladder carcinoma 5637 cells,Confirmatory,12431048.0,
17,7502,4,4,,123097261,31703,Active,,,0.466,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Confirmatory,10479282.0,
18,7681,6,2,,123097261,31703,Active,,,0.017,IC50,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Confirmatory,11123989.0,
19,7702,6,3,,123097261,31703,Active,,,0.07,IC50,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Confirmatory,,
20,7895,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Other,12113817.0,
21,8096,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Other,8627602.0,
22,8098,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on kidney carcinoma (A-498) cell line,Other,8632402.0,
23,8247,6,2,,123097261,31703,Active,,,0.033,IC50,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Confirmatory,1447730.0,
24,8261,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against A 498 tumor cell line,Other,10602713.0,
25,8279,4,4,,123097261,31703,Active,,,0.0528,IC50,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Confirmatory,12392727.0,
26,8309,4,4,,123097261,31703,Active,,,0.0027,IC50,Cytotoxicity against Renal cell lines A549 was determined,Confirmatory,12392727.0,
27,8424,6,2,,123097261,31703,Active,,,0.56,IC50,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Confirmatory,1447730.0,
28,8425,7,1,,123097261,31703,Active,,,,,Cytotoxicity of compound against 8226/DOX1V cells,Other,12570378.0,
29,8426,7,1,,123097261,31703,Active,,,,,Cytotoxicity of compound against 8226/S cells,Other,12570378.0,
30,8462,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Other,8627602.0,
31,8464,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on lung carcinoma (A-549) cell line,Other,8632402.0,
32,8470,5,1,,123097261,31703,Unspecified,,,,,The compound was evaluated for antiproliferative activity against A549 cell line,Other,11055343.0,
33,8480,6,2,,123097261,31703,Active,,,0.3,IC50,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Confirmatory,15177438.0,
34,8481,6,3,,123097261,31703,Active,,,0.12,IC50,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Confirmatory,,
35,8485,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Confirmatory,8648600.0,
36,8486,6,3,,123097261,31703,Active,,,0.1,IC50,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Confirmatory,,
37,8620,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Other,11354370.0,
38,8631,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against A 549 lung cancer cell line,Other,11354370.0,
39,8632,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Other,8496904.0,
40,8633,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Other,8496904.0,
41,8636,6,2,,123097261,31703,Active,,,0.97,IC50,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Confirmatory,14643344.0,
42,8666,6,2,,123097261,31703,Active,,,1.99,IC50,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Confirmatory,9873387.0,
43,8681,6,2,,123097261,31703,Active,,,0.004,IC50,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
44,8690,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Activity against A549 cancer cell line.,Confirmatory,8960558.0,
45,8823,4,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Other,,
46,8825,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human kidney carcinoma A-498cell lines,Other,,
47,8826,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Other,11551759.0,
48,8827,5,1,,123097261,31703,Active,,,0.0035,ED50,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Confirmatory,10498214.0,
49,8828,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against A-498 cell line was determined,Other,11551772.0,
50,8836,6,2,,123097261,31703,Active,,,0.07,GI50,In vitro antiproliferative activity against human A-549 NSCL cell line,Confirmatory,14971893.0,
51,8851,5,1,,123097261,31703,Unspecified,,,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Other,,
52,8852,4,1,,123097261,31703,Unspecified,,,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Other,,
53,8887,3,4,,123097261,31703,Unspecified,,,,,Synergism with indomethacin in A549 cells,Other,15012986.0,
54,8888,3,4,,123097261,31703,Unspecified,,,,,Synergism with tolmetin in A549 cells,Other,15012986.0,
55,8889,3,4,,123097261,31703,Unspecified,,,,,Synergism with sulindac in A549 cells,Other,15012986.0,
56,8997,4,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Other,,
57,8999,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human lung carcinoma A-549 cell lines,Other,,
58,9000,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Other,11551759.0,
59,9012,5,1,,123097261,31703,Unspecified,,,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Other,8027979.0,
60,9015,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against A-549 cell line was determined,Other,11551772.0,
61,9020,6,3,,123097261,31703,Active,,,0.02,IC50,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Confirmatory,,
62,9208,8,1,,123097261,31703,Active,,,0.028999999999999998,ED50,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Confirmatory,1875350.0,
63,9210,5,1,,123097261,31703,Active,,,0.0062,ED50,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Confirmatory,10498214.0,
64,9253,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of A549 (human lung carcinoma) cell line.,Other,2002477.0,
65,9259,5,3,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against A549 tumor cell culture,Other,,
66,9819,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),Other,11311062.0,
67,9822,6,2,,123097261,31703,Active,,,0.0096,IC50,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Confirmatory,11123989.0,
68,9858,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against ACHN renal cancer cell line,Other,11354370.0,
69,9870,6,2,,123097261,31703,Active,,,0.4,IC50,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Confirmatory,10411476.0,
70,9873,6,3,,123097261,31703,Active,,,0.7,IC50,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Confirmatory,,
71,10003,6,2,,123097261,31703,Active,,,0.0096,IC50,Concentration required to inhibit A2780-cell growth by 50%,Confirmatory,9703471.0,
72,10011,4,4,,123097261,31703,Active,,,0.063,IC50,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Confirmatory,8831755.0,
73,10012,4,4,,123097261,31703,Active,,,0.055999999999999994,IC50,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Confirmatory,8831755.0,
74,10013,4,4,,123097261,31703,Active,,,0.35700000000000004,IC50,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Confirmatory,8831755.0,
75,10014,4,4,,123097261,31703,Active,,,0.005,IC50,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Confirmatory,8831755.0,
76,10019,4,4,,123097261,31703,Active,,,0.0199,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Confirmatory,10479282.0,
77,10043,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against human renal adenocarcinoma ACHN cells,Confirmatory,12431048.0,
78,10044,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against human renal adenocarcinoma ACHN cells.,Confirmatory,12431049.0,
79,10173,6,2,,123097261,31703,Active,,,0.0096,IC50,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Confirmatory,10411474.0,
80,10174,6,2,,123097261,31703,Active,,,0.017,IC50,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Confirmatory,10411474.0,
81,12796,6,1,,123097261,31703,Unspecified,,,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
82,12797,6,1,,123097261,31703,Unspecified,,,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
83,12798,6,1,,123097261,31703,Unspecified,,,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
84,12799,6,1,,123097261,31703,Unspecified,,,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
85,12800,6,1,,123097261,31703,Unspecified,,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
86,12801,6,1,,123097261,31703,Unspecified,,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
87,12802,6,1,,123097261,31703,Unspecified,,,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
88,12803,6,1,,123097261,31703,Unspecified,,,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
89,12804,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
90,12805,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Other,10698441.0,
91,15472,3,3,,123097261,31703,Unspecified,,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,Other,9207950.0,
92,15625,3,3,,123097261,31703,Unspecified,,,,,Statistical significance of IC 50 values; Expressed as R value,Other,9207950.0,
93,18765,6,2,,123097261,31703,Unspecified,,,,,Tested for cytotoxicity by using brine shrimp lethality test,Other,8027979.0,
94,21036,3,3,,123097261,31703,Unspecified,,,,,Tested for the partition coefficient between water and n-octanol.,Other,2296017.0,
95,21758,5,2,,123097261,31703,Unspecified,,,,,"Solubility was measured in D2O using 1H NMR integration of the C-20 ethyl group against internal standard 1,4-dioxane",Other,8576914.0,
96,21847,3,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for the change in Tm of isolated helical DNA in solution,Other,3761328.0,
97,21848,3,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for the change in Tm of isolated helical DNA in solution.,Other,3761325.0,
98,23271,4,4,,123097261,31703,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
99,23436,3,5,,123097261,31703,Unspecified,,,,,Partition coefficient in octanol-phosphate buffer at pH 7.4,Other,3761325.0,
100,23437,3,5,,123097261,31703,Unspecified,,,,,Partition coefficient in octanol-phosphate buffer at pH 7.4,Other,3761328.0,
101,23702,3,3,,123097261,31703,Unspecified,,,,,Partition coefficient (logP),Other,6699880.0,
102,23734,3,3,,123097261,31703,Unspecified,,,,,Micelle/water partition coefficient (Pmic) of the compound was determined,Other,8691461.0,
103,26811,3,3,,123097261,31703,Unspecified,,,,,Partition coefficient (logP),Other,7392035.0,
104,27162,4,1,,123097261,31703,Unspecified,,,,,Stabilization of helical DNA toward thermal denaturation (delta Tm) was determined,Other,3806572.0,
105,28644,3,5,,123097261,31703,Unspecified,,,,,Rf is the resistance factor and is the ratio of the IC50 on the resistant cell line over the IC50 on the parental H69/P cell line,Other,11806724.0,
106,28905,3,5,,123097261,31703,Unspecified,,,,,Partition coefficient was determined in octanol-phosphate at pH 7.4,Other,3806572.0,
107,31432,5,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity against D100 daunorubicin (100 nM) resistant AML-2 cell line was determined,Other,14643344.0,
108,31433,5,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity against DX-100: doxorubicin (100 ng/mL) resistant AML-2 cell line was determined,Other,14643344.0,
109,31434,5,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity against wild type AML-2 leukemia cell line was determined,Other,14643344.0,
110,32544,4,4,,123097261,31703,Active,,,0.11199999999999999,IC50,Inhibitory activity against AUC375 cell line,Confirmatory,8648600.0,
111,39115,6,2,,123097261,31703,Unspecified,,,,,In vitro inhibition of B16 (human colon) tumor cell growth.,Other,12161130.0,
112,39122,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of B16 murine melanoma cell line,Other,12113817.0,
113,39126,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration,Other,15013011.0,
114,39135,6,2,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration,Other,15013011.0,
115,39252,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration against B16 murine melanoma cell line,Other,11354370.0,
116,39258,4,4,,123097261,31703,Active,,,0.0076,IC50,Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay,Confirmatory,10377224.0,
117,39272,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 1.5 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at eleventh day was determined",Other,15013011.0,
118,39273,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 1.5 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at fourteenth day was determined",Other,15013011.0,
119,39274,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 2.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at eleventh day was determined; ND= No data",Other,15013011.0,
120,39275,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 2.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at fourteenth day was determined",Other,15013011.0,
121,39276,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 5.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at eleventh day was determined",Other,15013011.0,
122,39277,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 5.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against (B16) mouse melanoma at fourteenth day was determined",Other,15013011.0,
123,39410,6,2,,123097261,31703,Inconclusive,,,,,Inhibitory percentage against B16 cell lines; NA denotes not assayed,Other,12161130.0,
124,39414,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor activity against BDF1 mice bearing B16 murine melanoma cells at a dose of 3 mg/kg/day,Other,11714613.0,
125,39680,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Aspergillus fumigatus was evaluated as compound minimum inhibitory concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
126,39730,3,6,,123097261,31703,Unspecified,,,,,Tested for activity against murine B-16 melanoma in mice and percent treated to the control values with the number of 60 day survivors,Other,3806589.0,
127,39735,4,1,,123097261,31703,Unspecified,,,,,Compound was tested against sc B16 melanoma at % tumor growth inhibition(TGI) in mice at 4 mg/kg dosage.,Other,8648600.0,
128,39742,3,5,,123097261,31703,Unspecified,,,,,Optimal dose per injection in mg/kg required to inhibit growth of murine B-16 melanoma in vivo,Other,3806589.0,
129,40219,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Bacillus cereus WSU-60,Other,3018245.0,
130,40736,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against B16 tumor cell lines.,Other,9871531.0,
131,40767,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Bacillus subtilis ATCC E6051,Other,3018245.0,
132,41058,5,3,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against B16F10 tumor cells,Other,,
133,41896,3,7,,123097261,31703,Unspecified,,,,,Beta-blocking activity measured by applying the stepwise linear discriminate analysis; Inactive,Other,,
134,42106,6,2,,123097261,31703,Unspecified,,,,,Compound was evaluated for the growth inhibition of BRO melanoma cell line.,Other,9873640.0,
135,42388,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells,Confirmatory,12431048.0,
136,42389,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells.,Confirmatory,12431049.0,
137,42410,6,2,,123097261,31703,Active,,,0.013999999999999999,IC50,Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CA 755 cells(murine carcinoma 755 cells),Confirmatory,9526570.0,
138,42897,6,3,,123097261,31703,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells,Other,,
139,43028,4,4,,123097261,31703,Active,,,0.0759,IC50,Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay,Confirmatory,14971910.0,
140,43176,4,4,,123097261,31703,Active,,,0.0465,IC50,Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay,Confirmatory,14971910.0,
141,43177,4,4,,123097261,31703,Active,,,0.0287,IC50,Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay,Confirmatory,14971910.0,
142,43178,4,4,,123097261,31703,Active,,,0.0303,IC50,Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay,Confirmatory,14971910.0,
143,43180,4,5,,123097261,31703,Active,,,0.01,IC50,Tested for cytotoxicity against C38 cell lines measured by MAT assay,Confirmatory,8057291.0,
144,43190,3,6,,123097261,31703,Unspecified,,,,,Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 2.0 mg/Kg measured as % inhibition of tumor,Other,3351854.0,
145,43191,3,6,,123097261,31703,Unspecified,,,,,Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 3.0 mg/Kg measured as % inhibition of tumor,Other,3351854.0,
146,43192,3,6,,123097261,31703,Unspecified,,,,,Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 4.0 mg/Kg measured as % inhibition of tumor,Other,3351854.0,
147,43329,3,6,,123097261,31703,Unspecified,,,,,Mean survival time of treated / untreated group x100. (number of over 100-day survivors/number of total mice in the group) at a dose 3.0 mg/kg,Other,3351854.0,
148,43330,3,6,,123097261,31703,Unspecified,,,,,Mean survival time of treated / untreated group x100. (number of over 100-day survivors/number of total mice in the group) at a dose 4.0 mg/kg,Other,3351854.0,
149,43331,3,6,,123097261,31703,Unspecified,,,,,Mean survival time of treated / untreated group x100. (number of over 100-day survivors/number of total mice in the group) at a dose 5.0 mg/kg,Other,3351854.0,
150,43346,3,6,,123097261,31703,Unspecified,,,,,Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 2.0 mg/kg; value given as 0/9,Other,3351854.0,
151,43347,3,6,,123097261,31703,Unspecified,,,,,Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 3.0 mg/kg; value given as 0/9,Other,3351854.0,
152,43348,3,6,,123097261,31703,Unspecified,,,,,Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 4.0 mg/kg; value given as 3/9,Other,3351854.0,
153,43349,3,6,,123097261,31703,Unspecified,,,,,Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 5.0 mg/kg; value given as 8/9,Other,3351854.0,
154,43375,8,1,,123097261,31703,Active,,,0.066,ID50,"Inhibitory activity of compound against CCRF-CEM cells,a lymphoblastic leukemic of human origin propagated in suspension culture.",Confirmatory,7086818.0,
155,43559,6,2,,123097261,31703,Active,,,0.1,IC50,Antitumor activity was evaluated against leukemia cell line CCRF-CEM(human acute T lymphoblastic leukemia).,Confirmatory,10411476.0,
156,43634,6,2,,123097261,31703,Unspecified,,,,,Lethal concentration required against bioactivity using brine shrimp lethality test,Other,8627602.0,
157,43636,5,2,,123097261,31703,Inconclusive,,,,,Lethal concentration against Brine Shrimp; NT =Not tested,Other,8632402.0,
158,43689,6,3,,123097261,31703,Active,,,0.08,IC50,Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line,Confirmatory,,
159,43703,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line,Confirmatory,10476861.0,
160,43723,5,3,,123097261,31703,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells,Other,,
161,43840,8,1,,123097261,31703,Active,,,0.066,ID50,In vitro growth inhibition against CCRF-CEM (human lymphoblastic leukemic) cell line.,Confirmatory,6827523.0,
162,43843,8,1,,123097261,31703,Active,,,0.066,ID50,In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells.,Confirmatory,6951049.0,
163,44011,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells.,Confirmatory,12431049.0,
164,44012,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells,Confirmatory,12431048.0,
165,44036,8,1,,123097261,31703,Active,,,0.03,ID50,In vitro antitumor activity in CCRF-CEM culture of human leukemic lymphocytes,Confirmatory,3806576.0,
166,44038,8,1,,123097261,31703,Active,,,0.06,ID50,"In vitro growth-inhibition assay utilizing CCRF-CEM cells, a lymphoblastic leukemic line of human origin",Confirmatory,3806575.0,
167,44040,8,1,,123097261,31703,Active,,,0.066,ID50,Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture.,Confirmatory,7057426.0,
168,44202,3,4,,123097261,31703,Unspecified,,,,,Effect on cross resistance of CCRF-CEM cells resistant to vincristine.,Other,2362268.0,
169,44207,8,1,,123097261,31703,Active,,,0.05,ID50,"In vitro inhibitory activity against CCRF-CEM cell growth in culture, after 48-h incubation.",Confirmatory,3839851.0,
170,44366,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity was evaluated against leukemia cell line CCRF-SB(human acute B lymphoblastic leukemia).,Confirmatory,10411476.0,
171,44369,6,3,,123097261,31703,Active,,,0.05,IC50,Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.,Confirmatory,,
172,44371,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells.,Confirmatory,12431049.0,
173,44372,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells,Confirmatory,12431048.0,
174,44716,6,2,,123097261,31703,Unspecified,,,,,"In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay",Other,12620075.0,
175,44803,6,3,,123097261,31703,Active,,,0.05,IC50,Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.,Confirmatory,,
176,44904,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against CHO cancer cell lines.,Other,,
177,44990,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Candida albicans was evaluated as minimum inhibitory concentration of compound at which no macroscopic signs of fungal growth were detected,Other,10411476.0,
178,45222,6,2,,123097261,31703,Active,,,0.06,IC50,Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius),Confirmatory,9526570.0,
179,45400,3,4,,123097261,31703,Unspecified,,,,,Effect on cross resistance of CHO cells resistant to colchicine (CHRC5),Other,2362268.0,
180,45413,6,2,,123097261,31703,Active,,,0.4,IC50,Antitumor activity was evaluated against Chinese hamster ovary carcinoma cell line CHO-K1.,Confirmatory,10411476.0,
181,45416,6,3,,123097261,31703,Active,,,1.2,IC50,Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.,Confirmatory,,
182,46154,3,4,,123097261,31703,Unspecified,,,,,Thermal denaturation temperature (Tm) of isolated calf thymus helical DNA was measured,Other,7086816.0,
183,46278,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against COLO 205 colon cancer cell line,Other,11354370.0,
184,46485,4,4,,123097261,31703,Active,,,0.0201,IC50,Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line,Confirmatory,11806724.0,
185,46486,4,4,,123097261,31703,Active,,,0.3193,IC50,Cytotoxicity measured with the drug resistant human non small cell lung carcinoma cell line COR-L23 (COR-L23/R) which over expresses multidrug resistance associated with protein(MRP),Confirmatory,11806724.0,
186,46563,6,3,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity tested in vitro against T-lymphoid leukemic cell line,Confirmatory,,
187,46885,6,2,,123097261,31703,Active,,,0.5,IC50,Antitumor activity against human foreskin fibroblasts CRL7065 cells,Confirmatory,12431048.0,
188,47485,6,2,,123097261,31703,Active,,,0.0063,IC50,The compound was tested for cytotoxic activity against CH1 cell line(human ovarian carcinoma ),Confirmatory,11123989.0,
189,47509,6,2,,123097261,31703,Active,,,0.0063,IC50,In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cell line,Confirmatory,10411474.0,
190,47510,6,2,,123097261,31703,Active,,,0.45,IC50,In vitro cytotoxicity was tested against human Ovarian carcinoma CH1 cisplatin resistant cell line,Confirmatory,10411474.0,
191,47668,6,2,,123097261,31703,Active,,,0.0063,IC50,Concentration required to inhibit CH1-cell growth by 50%,Confirmatory,9703471.0,
192,47670,6,2,,123097261,31703,Active,,,0.45,IC50,The compound was tested for cytotoxic activity against CH1/Cs cell line(human ovarian carcinoma),Confirmatory,11123989.0,
193,47692,6,2,,123097261,31703,Active,,,6.0,IC50,Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line,Confirmatory,9526570.0,
194,47880,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Candida parapsilosis was evaluated as compound concentration at which no macroscopic signs of fungal growth were detected,Other,10411476.0,
195,48066,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Candida paratropicalis was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
196,50624,8,1,,123097261,31703,Active,,,0.18,ED50,Inhibitory activity against the [3H]thymidine incorporation into DNA of Rous Sarcoma virus transformed chicken embryo fibroblasts at 24 hr of treatment,Confirmatory,6302253.0,
197,50625,8,1,,123097261,31703,Active,,,2.5,ED50,Inhibitory activity against the [3H]thymidine incorporation into DNA of Rous Sarcoma virus transformed chicken embryo fibroblasts at 5 hr of treatment,Confirmatory,6302253.0,
198,50626,8,1,,123097261,31703,Active,,,0.1,ED50,Inhibitory activity against the [3H]thymidine incorporation into DNA of normal chicken embryo fibroblasts at 24 hr of treatment,Confirmatory,6302253.0,
199,50627,8,1,,123097261,31703,Active,,,0.9,ED50,Inhibitory activity against the [3H]-thymidine incorporation into DNA of normal chicken embryo fibroblasts at 5 hr of treatment,Confirmatory,6302253.0,
200,50739,6,2,,123097261,31703,Active,,,0.34,IC50,Compound was tested for its antitumor activity against HT-29 colon carcinoma cell line,Confirmatory,9873394.0,
201,50756,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines colon 4).,Other,2296017.0,
202,50757,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (colon 4)determined by clonogenic assay.,Other,2296017.0,
203,50758,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity was evaluated against murine colon carcinoma (Colon26) as body weight change in BALB/c mice upon intraperitoneal administration at a dose of 4 mg/kg,Other,9873387.0,
204,50760,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity was evaluated against murine colon carcinoma (Colon26) as tumor growth inhibition was determined in BALB/c mice upon intraperitoneal administration at a dose of 4 mg/kg,Other,9873387.0,
205,51910,6,2,,123097261,31703,Active,,,0.06,IC50,The compound was tested in vitro for growth inhibition of Chinese Hamster Ovary(CHO) cells,Confirmatory,1354750.0,
206,51911,6,2,,123097261,31703,Active,,,6.0,IC50,The compound was tested in vitro for growth inhibition of subline (CHO/DOX) with acquired resistance to doxorubicin,Confirmatory,1354750.0,
207,52335,6,2,,123097261,31703,Active,,,0.52,IC50,In vitro cytotoxicity against human Col2 (colon cancer) cell line.,Confirmatory,15177438.0,
208,52346,9,2,,123097261,31703,Active,,,1.1,IC50,Inhibitory concentration against Clostridium histolyticum Collagenase,Confirmatory,1322986.0,
209,53778,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines DLD-1 of colon.,Other,11311062.0,
210,53779,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against DLD-1 colon cancer cell line,Other,11354370.0,
211,53952,3,4,,123097261,31703,Unspecified,,,,,Synergism with tolmedin in DLKP cells,Other,15012986.0,
212,53953,3,4,,123097261,31703,Unspecified,,,,,Synergism with sulindac in DLKP cells,Other,15012986.0,
213,54074,4,4,,123097261,31703,Inconclusive,,,,,Drug interaction towards DLKP cell line was determined in terms of combination index in presence of Indomethacin; Not available,Other,15012986.0,
214,54144,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Corynebacterium diphtheria WSU,Other,3018245.0,
215,54436,8,3,,123097261,31703,Inconclusive,,,,,Compound was evaluated for DNA intercalation potency using ethidium bromide displacement assay in calf thymus; Not determined,Other,,
216,54443,4,4,,123097261,31703,Unspecified,,,,,Compound was tested for the extent of DNA binding in calf thymus at pH 7 TRIS buffer.,Other,7086818.0,
217,54463,3,3,,123097261,31703,Active,,,,,Tested for the binding affinity for DNA by intercalation between adjacent base pairs of the helix.,Other,2296017.0,
218,54643,4,3,,123097261,31703,Unspecified,,,,,Binding affinity to Calf thymus DNA type XV; value ranges from 2E6 - 4E6 M-1,Other,,
219,54808,3,3,,123097261,31703,Unspecified,,,,,Compound was tested in vitro for ability to bind with double helical calf thymus DNA was determined spectrophotometrically at 480 nmby spectral shift method and the value expressed as the ratio A/Ao,Other,3806575.0,
220,54999,6,1,,123097261,31703,Unspecified,,,,,Increase of calf thymus DNA denaturation temperature (delta Tm),Other,7932579.0,
221,55019,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Cryptococcus neoformans was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
222,55805,4,4,,123097261,31703,Active,,,0.0528,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145,Confirmatory,10479282.0,
223,56893,3,8,,123097261,31703,Inconclusive,,,,,Inhibitory activity against Topoisomerase I was determined by the supercoiled DNA unwinding assay method; NT=not tested,Other,14643344.0,
224,57470,4,6,,123097261,31703,Unspecified,,,,,Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate,Other,6699880.0,
225,57539,7,1,,123097261,31703,Unspecified,,,,,"Compound was tested for amount of net intracellular accumulation per 1 E6 DOX-resistant (DOX/R) cells, after exposure to 1.0 uM for 2 hrs",Other,,
226,57540,7,1,,123097261,31703,Unspecified,,,,,"Compound was tested for amount of net intracellular accumulation per 1 E6 DOX-resistant (DOX/R) cells, after exposure to 2.0 uM for 2 hrs",Other,,
227,57541,4,5,,123097261,31703,Active,,,2.7525,IC50,Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells,Confirmatory,,
228,57729,6,2,,123097261,31703,Active,,,0.02,GI50,In vitro antiproliferative activity against human DU-145 prostrate cell line,Confirmatory,14971893.0,
229,57907,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human prostrate carcinoma DU145 cells,Confirmatory,12431048.0,
230,65965,6,2,,123097261,31703,Active,,,1.8,EC50,In vitro effective concentration against DuPRO cancer cell line,Confirmatory,14667208.0,
231,65966,6,2,,123097261,31703,Active,,,1.8,EC50,Concentration required to kill 50% of tumor cells in PSA nonproducing DuPRO human prostate cancer cell line,Confirmatory,11708923.0,
232,67108,3,4,,123097261,31703,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.004 ug/mL dose from experiment B,Other,6685770.0,
233,67109,3,4,,123097261,31703,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.04 ug/mL dose from experiment A,Other,6685770.0,
234,67110,3,4,,123097261,31703,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.04 ug/mL dose from experiment B,Other,6685770.0,
235,67114,3,4,,123097261,31703,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.4 ug/mL dose from experiment B,Other,6685770.0,
236,67123,3,5,,123097261,31703,Unspecified,,,,,EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.004 ug/mL from experiment B,Other,6685770.0,
237,67124,3,5,,123097261,31703,Unspecified,,,,,EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.04 ug/mL from experiment A,Other,6685770.0,
238,67125,3,5,,123097261,31703,Unspecified,,,,,EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.04 ug/mL from experiment B,Other,6685770.0,
239,67129,3,5,,123097261,31703,Unspecified,,,,,EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.4 ug/mL from experiment B,Other,6685770.0,
240,67455,6,2,,123097261,31703,Unspecified,,,,,"In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay",Other,12620075.0,
241,67634,8,1,,123097261,31703,Active,,,0.012,ED50,Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.,Confirmatory,7452674.0,
242,67635,8,1,,123097261,31703,Active,,,0.0001,ED50,Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.,Confirmatory,7452674.0,
243,68285,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against EVSA-T tumor cell line,Other,10602713.0,
244,68776,6,2,,123097261,31703,Active,,,0.02,IC50,Inhibitory activity against F460pv8/eto cell line using MTT assay,Confirmatory,10780913.0,
245,69132,6,2,,123097261,31703,Unspecified,,,75.0,IC50,Inhibitory activity against tetracycline uptake in everted membrane vesicles derived from Tc-resistant Escherichia coli bearing class B tetracycline resistance efflux protein (Tet),Confirmatory,8176712.0,
246,72413,6,2,,123097261,31703,Active,,,0.09,IC50,Antitumor activity against human skin melanoma G-361 cells,Confirmatory,12431048.0,
247,72414,6,2,,123097261,31703,Active,,,0.09,IC50,Antitumor activity against human skin melanoma G361 cells.,Confirmatory,12431049.0,
248,73473,8,1,,123097261,31703,Active,,,0.1,ID50,Compound concentration required to reduce by 50% the number of fibroblast-like cells (Vero) after three cell cycles,Confirmatory,1548681.0,
249,78419,6,2,,123097261,31703,Active,,,0.004,IC50,Inhibitory activity against H460pv8 cell line using MTT assay,Confirmatory,10780913.0,
250,78564,6,2,,123097261,31703,Active,,,0.87,IC50,Compound was evaluated for inhibitory activity against H69 human lung cancer cell line,Confirmatory,1479585.0,
251,78568,4,4,,123097261,31703,Active,,,3.8739999999999997,IC50,"Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4",Confirmatory,11806724.0,
252,78570,4,4,,123097261,31703,Active,,,0.13699999999999998,IC50,Inhibitory activity against drug resistant H69/LX4 line overexpressing P-glycoprotein,Confirmatory,11806725.0,
253,78575,3,4,,123097261,31703,Unspecified,,,,,Approximate percentage for level of inhibition of cell growth in presence and absence of inhibitor (Value of drug + B669 / Value of drug),Other,15012986.0,
254,78576,3,4,,123097261,31703,Unspecified,,,,,Approximate percentage for level of inhibition of cell growth in presence and absence of inhibitor (Value of drug + Clofazimine / Value of drug),Other,15012986.0,
255,78577,4,4,,123097261,31703,Unspecified,,,,,Approximate percentage for level of inhibition of cell growth in presence and absence of inhibitor (Value of drug + GG918 / Value of drug),Other,15012986.0,
256,78578,3,4,,123097261,31703,Unspecified,,,,,Approximate percentage for level of inhibition of cell growth in presence and absence of inhibitor (Value of drug + Verapamil / Value of drug),Other,15012986.0,
257,78579,3,4,,123097261,31703,Unspecified,,,,,Approximate percentage for level of inhibition of cell growth in presence and absence of inhibitor (Value of drug + alpha Tochoferol / Value of drug),Other,15012986.0,
258,78581,4,4,,123097261,31703,Active,,,0.0273,IC50,Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line,Confirmatory,11806724.0,
259,78583,4,4,,123097261,31703,Active,,,0.027000000000000003,IC50,Inhibitory activity against parental human small cell lung carcinoma cell line (H69P),Confirmatory,11806725.0,
260,78609,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against HCT-15 cell line was determined,Other,11551772.0,
261,78630,6,2,,123097261,31703,Active,,,0.23,IC50,Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay,Confirmatory,12039588.0,
262,78720,6,2,,123097261,31703,Active,,,0.62,IC50,Compound was evaluated for inhibitory activity against H 358 human lung cancer cell line,Confirmatory,1479585.0,
263,78722,6,2,,123097261,31703,Active,,,0.23,IC50,Compound was evaluated for inhibitory activity against H 460 human lung cancer cell line,Confirmatory,1479585.0,
264,79013,4,4,,123097261,31703,Active,,,0.1,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT(human colon carcinoma)116 cell proliferation,Confirmatory,11606141.0,
265,79101,5,1,,123097261,31703,Unspecified,,,,,Tested in vitro for cytotoxicity against H-29 colon cancer cells,Other,8027979.0,
266,79134,8,1,,123097261,31703,Active,,,0.01,ID50,Compound concentration required to reduce by 50% the number of H9 cells chronically infected with the HIV-1 (H9/IIIB) after three cell cycles,Confirmatory,1548681.0,
267,79806,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against HCC2998 colon cancer cell line,Other,11354370.0,
268,80256,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration against HCT 116 human colon cancer cell line,Other,11354370.0,
269,80364,4,4,,123097261,31703,Active,,,0.08,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) resistant variant cell proliferation,Confirmatory,11606141.0,
270,80365,4,4,,123097261,31703,Active,,,0.05,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of HCT 15 (colon) sensitive variant cell proliferation,Confirmatory,11606141.0,
271,80366,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against HCT 15 colon cancer cell line,Other,11354370.0,
272,80368,6,2,,123097261,31703,Active,,,1.67,IC50,"Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.",Confirmatory,14643344.0,
273,80641,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against M19 tumor cell line,Other,10602713.0,
274,80656,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity on H2981 Human lung adenocarcinoma cells.,Confirmatory,7731023.0,
275,80659,6,2,,123097261,31703,Active,,,0.7,IC50,Inhibition of [3H]thymidine incorporation in human lung adenocarcinoma cells in the absence of PGA enzyme,Confirmatory,8464046.0,
276,80676,6,2,,123097261,31703,Unspecified,,,,,In vitro inhibition of HCT116 (human colon) tumor cell growth.,Other,12161130.0,
277,80681,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of HCT116 human colon carcinoma cell line,Other,12113817.0,
278,80718,6,2,,123097261,31703,Inconclusive,,,,,Inhibitory percentage against HCT116 cell lines; NA denotes not assayed,Other,12161130.0,
279,80865,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against HCT116 cancer cell lines.,Other,,
280,80867,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity assay was measured against human tumor HCT116 cell line using camptothecin as a standard,Other,,
281,80965,6,1,,123097261,31703,Active,,,0.0072,IC50,Compound was tested for its anticancer activity against HL-60 cells.,Confirmatory,,
282,81308,4,5,,123097261,31703,Active,,,0.0078,IC50,Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound),Confirmatory,10479282.0,
283,81365,6,2,,123097261,31703,Active,,,0.01,GI50,In vitro antiproliferative activity against human HeLa cervix cell line,Confirmatory,14971893.0,
284,81369,6,2,,123097261,31703,Active,,,0.01,GI50,In vitro antiproliferative activity against human HeLa-APL cervix cell line,Confirmatory,14971893.0,
285,81374,6,3,,123097261,31703,Active,,,1.7,IC50,Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.,Confirmatory,,
286,81381,3,4,,123097261,31703,Unspecified,,,,,Tested for cytotoxicity index against HEP-2 cell line by MTT method at 0.1 ug/mL concentration,Other,8277512.0,
287,81382,3,4,,123097261,31703,Unspecified,,,,,Tested for cytotoxicity index against HEP-2 cell line by MTT method at 1.0 ug/mL concentration,Other,8277512.0,
288,81479,6,2,,123097261,31703,Active,,,0.51,IC50,Inhibitory concentration against HL60 cells,Confirmatory,14971909.0,
289,81490,6,3,,123097261,31703,Active,,,0.0072,IC50,Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells,Confirmatory,,
290,81692,6,2,,123097261,31703,Active,,,0.023,GI50,Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line,Confirmatory,11755363.0,
291,81858,6,2,,123097261,31703,Active,,,0.1,IC50,In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay,Confirmatory,9873661.0,
292,81859,6,2,,123097261,31703,Active,,,0.025,IC50,In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
293,82995,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against drug resistant HL60/ADR cell line,Other,10612603.0,
294,83012,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity tested against drug sensitive HL60/S cell line,Other,10612603.0,
295,83125,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity tested against HL60/Vinc cell line,Other,10612603.0,
296,83588,6,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against HT-29 colon carcinoma cell line,Confirmatory,10476861.0,
297,83595,4,4,,123097261,31703,Active,,,0.331,IC50,Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay,Confirmatory,7853331.0,
298,83600,4,4,,123097261,31703,Active,,,0.33,IC50,Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line ),Confirmatory,8576914.0,
299,83602,4,4,,123097261,31703,Active,,,0.0564,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29,Confirmatory,10479282.0,
300,83618,6,2,,123097261,31703,Active,,,0.026000000000000002,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line,Confirmatory,10411474.0,
301,83928,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human colon adenocarcinoma HT-29 cell lines,Other,,
302,83947,6,2,,123097261,31703,Active,,,0.15,IC50,Antitumor activity against human colon adenocarcinoma HT-29 cells.,Confirmatory,12431049.0,
303,83948,6,2,,123097261,31703,Active,,,0.15,IC50,Antitumor activity against human colon adenocarcinoma HT-29 cells,Confirmatory,12431048.0,
304,83956,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines (HT 29).,Other,2296017.0,
305,83957,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (HT 29) determined by clonogenic assay.,Other,2296017.0,
306,84091,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.,Other,2002477.0,
307,84093,5,3,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against HT-29 tumor cells,Other,,
308,84125,4,4,,123097261,31703,Active,,,0.2312,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx(RI),Confirmatory,10479282.0,
309,84127,8,1,,123097261,31703,Active,,,0.055,ED50,Cytotoxic concentration required to inhibit 50% cell growth in HT-29 colon adenocarcinoma cell lines,Confirmatory,1875350.0,
310,84288,4,4,,123097261,31703,Active,,,0.026000000000000002,IC50,In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.,Confirmatory,11806721.0,
311,84291,6,2,,123097261,31703,Active,,,0.026000000000000002,IC50,The compound was tested for cytotoxic activity against HT-29 cell line(human colon adeno carcinoma),Confirmatory,11123989.0,
312,84306,6,2,,123097261,31703,Active,,,0.055999999999999994,GI50,Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line,Confirmatory,11755363.0,
313,84360,6,2,,123097261,31703,Active,,,0.004,IC50,In vitro cytotoxic activity against HOP62 (lung cancer) cell lines by using SRB assay,Confirmatory,9873661.0,
314,84455,6,2,,123097261,31703,Active,,,0.28,IC50,Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.,Confirmatory,9003520.0,
315,84628,6,2,,123097261,31703,Unspecified,,,,,Compound was evaluated for the growth inhibition of HT-29 colon cell line.,Other,9873640.0,
316,84640,6,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against HTB-54 lung carcinoma cell line,Confirmatory,10476861.0,
317,85439,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against HT 29 colon cancer cell line,Other,11354370.0,
318,85440,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of HT 29 cell line by MTT reduction for 3 days of incubation time,Other,8496904.0,
319,85441,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of HT 29 cell line by MTT reduction for 7 days of incubation time,Other,8496904.0,
320,85449,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxic concentration against human fibrosarcoma cell line (HT1080) using MTT coloration,Other,15013011.0,
321,85452,6,2,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against human fibrosarcoma cell line (HT1080) using CV coloration,Other,15013011.0,
322,85749,6,2,,123097261,31703,Active,,,0.026000000000000002,IC50,Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line,Confirmatory,11563932.0,
323,85760,6,2,,123097261,31703,Unspecified,,,,,"In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay",Other,12620075.0,
324,85939,4,4,,123097261,31703,Active,,,0.0618,IC50,Cytotoxicity against Colon cancer cell lines HT-29 was determined,Confirmatory,12392727.0,
325,86066,6,3,,123097261,31703,Active,,,2.5,EC50,Compound was tested in vitro to inhibit 50% colon carcinoma HT-29 cell growth after 72 h,Confirmatory,,
326,86070,5,1,,123097261,31703,Unspecified,,,,,Compound was tested for cytotoxic activity against human colon adenocarcinoma (HT-29),Other,,
327,86071,4,1,,123097261,31703,Unspecified,,,,,Compound was tested for its cytotoxic activity in MTT assay against HT-29 cell line (human colon adenocarcinoma),Other,,
328,86072,4,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human HT-29 (colon adenocarcinoma) cell line,Other,,
329,86073,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human colon adrenocarcinoma HT-29 cell line,Other,8627602.0,
330,86075,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on adenocarcinoma (HT-29 colon) cell line,Other,8632402.0,
331,86076,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against HT-29 (human colon adenocarcinoma) cell line,Other,11551759.0,
332,86077,5,1,,123097261,31703,Active,,,0.037000000000000005,ED50,In vitro cytotoxicity against Colon HT-29 human tumors following a 6 day exposure.,Confirmatory,10498214.0,
333,86088,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against HT-29 cell line was determined,Other,11551772.0,
334,86092,6,2,,123097261,31703,Active,,,3.1,GI50,In vitro antiproliferative activity against human HT-29 colon cell line,Confirmatory,14971893.0,
335,86101,6,2,,123097261,31703,Active,,,0.05,IC50,Antitumor activity was evaluated against human colon adenocarcinoma cell line HT-29.,Confirmatory,10411476.0,
336,86104,6,3,,123097261,31703,Active,,,0.02,IC50,Compound was evaluated for the cytotoxicity against HT-29 tumor cell line after 3 days of incubation,Confirmatory,,
337,86108,6,2,,123097261,31703,Active,,,0.18,IC50,Compound was tested for cytotoxicity against colon adenocarcinoma,Confirmatory,8182705.0,
338,86109,6,3,,123097261,31703,Active,,,0.12,IC50,Compound was tested for cytotoxicity on HT-29 colon cancer cell line using a proliferation assay (MTT reduction),Confirmatory,,
339,86110,6,3,,123097261,31703,Active,,,1.1,IC50,Compound was tested for its effect on the proliferation of HT-29 human colon adenocarcinoma.,Confirmatory,,
340,86210,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against Hep-2 larynx carcinoma cells.,Confirmatory,12431049.0,
341,86211,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against larynx carcinoma Hep-2 cells,Confirmatory,12431048.0,
342,86237,3,6,,123097261,31703,Unspecified,,,,,Antiproliferative effect against Hep2 cell lines at a concentration of 1 uM,Other,4009608.0,
343,86368,6,2,,123097261,31703,Active,,,0.12,IC50,Antitumor activity against human hepatocellular carcinoma HepG-2 cells.,Confirmatory,12431049.0,
344,86369,6,2,,123097261,31703,Active,,,0.12,IC50,Antitumor activity against human hepatocellular carcinoma HepG2 cells,Confirmatory,12431048.0,
345,86525,3,6,,123097261,31703,Unspecified,,,,,Antiproliferative effect against HeLa cell lines at a concentration of 1 uM,Other,4009608.0,
346,86974,6,2,,123097261,31703,Active,,,0.07,IC50,Antitumor activity against HeLa cervical carcinoma cells.,Confirmatory,12431049.0,
347,86975,6,2,,123097261,31703,Active,,,0.07,IC50,Antitumor activity against cervix carcinoma Hela cells,Confirmatory,12431048.0,
348,87470,4,1,,123097261,31703,Unspecified,,,,,Compound was evaluated for the inhibition of colony formation in HeLa cells,Other,3761328.0,
349,87571,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity tested against Hela C1 cells,Other,10612603.0,
350,87591,6,2,,123097261,31703,Active,,,0.03,IC50,Inhibition of 10e-2 uM estradiol induced human cancer cell HeLa S3 proliferation,Confirmatory,8784443.0,
351,87733,6,2,,123097261,31703,Active,,,0.027999999999999997,IC50,In vitro antiproliferative activity against Hela S3 cells.,Confirmatory,8151613.0,
352,87758,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity tested against Hela T5 cells,Other,10612603.0,
353,88224,3,4,,123097261,31703,Unspecified,,,,,Tested for cytotoxicity index against HeLa cell line by MTT method at 0.1 ug/mL concentration,Other,8277512.0,
354,88342,3,4,,123097261,31703,Unspecified,,,,,Tested for cytotoxicity index against HeLa cell line by MTT method at 1.0 ug/mL concentration,Other,8277512.0,
355,88361,6,2,,123097261,31703,Active,,,0.2,IC50,Antitumor activity was evaluated against human cervix carcinoma cell line HeLa.,Confirmatory,10411476.0,
356,88526,4,3,,123097261,31703,Unspecified,,,,,Compound was tested in vitro for cytotoxicity against HeLa cells.,Other,8709115.0,
357,88858,5,2,,123097261,31703,Inconclusive,,,,,Tested for anticancer activity against human ovarian cancer; NT means Not tested,Other,11514168.0,
358,89680,6,2,,123097261,31703,Active,,,1.72,IC50,Tested for induction of cellular death in Human lung H-460 tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
359,89683,6,2,,123097261,31703,Active,,,0.03,IC50,Tested for induction of cellular death in Human lung LXF 529L tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
360,89684,6,2,,123097261,31703,Active,,,0.07,IC50,Tested for induction of cellular death in Human lung LXF 629L tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
361,89960,3,4,,123097261,31703,Unspecified,,,,,Tested for induction of cellular death in Human ZNS SF-268 tumor cell line in Propidium Iodide Monolayer Assay; Not determined,Other,12852768.0,
362,90127,6,2,,123097261,31703,Active,,,0.01,IC50,Tested for induction of cellular death in Human breast 401NL tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
363,90129,6,2,,123097261,31703,Active,,,0.05,IC50,Tested for induction of cellular death in Human breast MCF-7 tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
364,90136,6,2,,123097261,31703,Unspecified,,,,,Tested for anticancer activity against human breast cancer,Other,11514168.0,
365,90628,6,2,,123097261,31703,Active,,,0.28,IC50,Growth inhibitory concentration of compound was measured against human melanoma cell line (HMV-1),Confirmatory,10698436.0,
366,90629,7,2,,123097261,31703,Unspecified,,,,,Tested for anticancer activity against human melanoma,Other,11514168.0,
367,91425,9,5,,123097261,31703,Active,82312013.0,,0.9,IC50,"Inhibition of HIV-1 integrase, under 1 uM for the 3''-preprocessing",Confirmatory,10841789.0,
368,91426,9,5,,123097261,31703,Active,82312013.0,,2.4,IC50,"Tested for inhibition of HIV-1 integrase, under 1 uM for the strand transfer",Confirmatory,10841789.0,
369,91531,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity was evaluated against human neuroblastoma cell line IMR-32.,Confirmatory,10411476.0,
370,91543,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity against human neuroblastoma IMR32 cells,Confirmatory,12431048.0,
371,91665,5,1,,123097261,31703,Active,,,0.15,ED50,In vitro cytotoxicity against Breast avg 1-3 types of human tumors following a 6 day exposure.,Confirmatory,10498214.0,
372,91780,7,1,,123097261,31703,Unspecified,,,,,Compound was tested for amount of net intracellular accumulation per 1 E6 J774.2 cells after their exposure to 1.0 uM for 2 hrs,Other,,
373,91781,7,1,,123097261,31703,Unspecified,,,,,Compound was tested for amount of net intracellular accumulation per 1 E6 J774.2 cells after their exposure to 2.0 uM for 2 hrs,Other,,
374,91784,4,5,,123097261,31703,Active,,,0.0794,IC50,Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells,Confirmatory,,
375,91800,4,3,,123097261,31703,Unspecified,,,10.0,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of J82 (bladder) resistant variant cell proliferation,Confirmatory,11606141.0,
376,91802,4,3,,123097261,31703,Active,,,0.03,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of J82 (bladder) sensitive variant cell proliferation,Confirmatory,11606141.0,
377,91914,4,4,,123097261,31703,Active,,,0.0096,IC50,"Inhibitory concentration to reduce cell number to 50% in a panel of cultured, wild type human Jurkat leukemia (JL C) cells.",Confirmatory,11806725.0,
378,91916,4,5,,123097261,31703,Active,,,0.0096,IC50,Inhibitory concentration against Human Jurkat leukemia (JLC) cell proliferation,Confirmatory,9207945.0,
379,91917,4,4,,123097261,31703,Active,,,0.0096,IC50,"Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures",Confirmatory,9191970.0,
380,92293,5,1,,123097261,31703,Active,,,0.0187,ED50,"In vitro cytotoxicity against various human tumors (6-8 lines) as determined in the Purdue cell culture laboratory, following a 6 day exposure",Confirmatory,10498214.0,
381,93480,6,2,,123097261,31703,Active,,,4.4,GI50,In vitro antiproliferative activity against human IGROV ovarian cell line,Confirmatory,14971893.0,
382,93483,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against IGROV tumor cell line,Other,10602713.0,
383,93497,6,2,,123097261,31703,Active,,,2.4,GI50,In vitro antiproliferative activity against human IGROV-ET ovarian cell line,Confirmatory,14971893.0,
384,93592,6,2,,123097261,31703,Active,,,0.06,IC50,Tested for induction of cellular death in Human renal RXF 944L tumor cell line in Propidium Iodide Monolayer Assay,Confirmatory,12852768.0,
385,93860,6,3,,123097261,31703,Active,,,0.021,IC50,In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells,Confirmatory,,
386,93933,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of L1210/ADM murine leukemia cells after 3 hr exposure in MTT assay,Other,8496904.0,
387,94005,6,2,,123097261,31703,Active,,,0.021,IC50,In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1,Confirmatory,12443763.0,
388,94107,4,4,,123097261,31703,Active,,,0.179,IC50,Compound was tested in vitro against L1210 leukemia cells,Confirmatory,12570384.0,
389,94164,6,3,,123097261,31703,Active,,,7.01,IC50,In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells,Confirmatory,,
390,94165,6,2,,123097261,31703,Active,,,7.01,IC50,In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1,Confirmatory,12443763.0,
391,94350,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against KB3-1 cells,Other,8632413.0,
392,94355,6,2,,123097261,31703,Active,,,0.65,IC50,Antiproliferative activity against drug-resistant tumor cell line KB7D.,Confirmatory,10411476.0,
393,94356,6,2,,123097261,31703,Active,,,3.0,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
394,94357,6,2,,123097261,31703,Active,,,0.4,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
395,94437,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity assay was measured against human tumor L1210 cell line using camptothecin as a standard,Other,,
396,94498,6,2,,123097261,31703,Active,,,0.06,IC50,Antiproliferative activity against drug-resistant tumor cell line KBCamp.,Confirmatory,10411476.0,
397,94499,6,2,,123097261,31703,Active,,,0.026000000000000002,IC50,Ability to inhibit growth of human myelogenous leukemic cell line KBM-3 was determined in an in vitro MTT assay.,Confirmatory,1995877.0,
398,94500,6,2,,123097261,31703,Active,,,0.49,IC50,"Ability to inhibit growth of human myelogenous leukemic cell line KBM-3 variant namely KBM-3/DOX, was determined in an in vitro MTT assay.",Confirmatory,1995877.0,
399,94501,6,2,,123097261,31703,Active,,,0.5,IC50,Antiproliferative activity against drug-resistant tumor cell line KBMDR.,Confirmatory,10411476.0,
400,94502,6,2,,123097261,31703,Active,,,1.8,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
401,94507,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against KBV-1 cells in presence of reserpine,Other,8632413.0,
402,94508,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against KBV-1 cells,Other,8632413.0,
403,94510,6,2,,123097261,31703,Active,,,0.4,IC50,Antiproliferative activity against drug-resistant tumor cell line KBV20C.,Confirmatory,10411476.0,
404,94511,6,2,,123097261,31703,Active,,,0.06,IC50,Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
405,94655,6,2,,123097261,31703,Active,,,0.62,IC50,Antiproliferative activity tested as 50% inhibition of DNA synthesis in human K562 erythroleukemia cell line,Confirmatory,11720862.0,
406,94727,6,3,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxic activity against L-1210 parental cell line,Confirmatory,,
407,94729,6,3,,123097261,31703,Active,,,0.315,IC50,cytotoxic activity against adriamycin (ADR) resistant L-1210 cell line,Confirmatory,,
408,94802,6,2,,123097261,31703,Active,,,1.77,IC50,Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay,Confirmatory,9873387.0,
409,94803,6,2,,123097261,31703,Active,,,0.12,IC50,Growth inhibitory concentration of compound was measured against human leukemia cell line (K562),Confirmatory,10698436.0,
410,94804,6,2,,123097261,31703,Active,,,0.28,IC50,Iinhibitory activity against K562 leukemia cell line using sulforhodamine B (SRB) protein assay,Confirmatory,12039588.0,
411,94924,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against L-1210 leukemia cell line in BDF1 mice after injecting 2.0 mg/kg ip dose,Other,2391681.0,
412,95159,4,4,,123097261,31703,Active,,,7.0,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of K562R (resistant clone) cell proliferation,Confirmatory,11606141.0,
413,95160,4,5,,123097261,31703,Active,,,0.0156,IC50,Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound),Confirmatory,10479282.0,
414,95161,4,5,,123097261,31703,Active,,,2.474,IC50,Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound),Confirmatory,10479282.0,
415,95162,4,4,,123097261,31703,Active,,,0.05,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of K562S (sensitive clone)cell proliferation,Confirmatory,11606141.0,
416,95164,4,4,,123097261,31703,Active,,,15.0,IC50,Antiproliferative activity measured against K562adr leukemia cells.,Confirmatory,9876111.0,
417,95291,4,4,,123097261,31703,Active,,,0.0096,IC50,Concentration required to inhibit 50% growth of human Jurkat cells,Confirmatory,10395479.0,
418,95293,6,2,,123097261,31703,Active,,,1.7,IC50,Inhibitory concentration against Jurkat cells,Confirmatory,14971909.0,
419,95307,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines KATO III (gastric),Other,11311062.0,
420,95332,4,3,,123097261,31703,Active,,,0.1,IC50,In vitro cytotoxicity expressed as conc. that inhibits 50% of KB (human) cell proliferation,Confirmatory,11606141.0,
421,95455,4,4,,123097261,31703,Active,,,0.0096,IC50,Growth inhibitory activity against human Jurkat leukemia cell line (JLC),Confirmatory,12620081.0,
422,95674,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against drug-resistant tumor cell line KBwt.,Confirmatory,10411476.0,
423,95841,6,2,,123097261,31703,Active,,,0.22,IC50,Growth inhibitory concentration of compound was measured against human nasopharyngeal carcinoma cell line (KB),Confirmatory,10698436.0,
424,95872,6,2,,123097261,31703,Active,,,0.015,IC50,Inhibitory concentration that reduced the viability of KB cell population by 50%.,Confirmatory,9003520.0,
425,96037,3,4,,123097261,31703,Unspecified,,,,,"Resistance factor (RF), ratio between the IC50 on the resistant cells and the IC50 on the corresponding sensitive cells of KB cell line",Other,12443763.0,
426,96039,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against KB cancer cell lines.,Other,,
427,96041,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity assay was measured against human tumor KB cell line using camptothecin as a standard,Other,,
428,96134,6,2,,123097261,31703,Active,,,0.03,GI50,In vitro antiproliferative activity against human K-562 cell line,Confirmatory,14971893.0,
429,96146,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against K-562 myelocytic leukemia cell line,Confirmatory,10476861.0,
430,96219,6,2,,123097261,31703,Active,,,1.8,IC50,Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant KB subclones passaged in the presence of doxorubicin 0.09 uM by 50%,Confirmatory,12431048.0,
431,96220,6,2,,123097261,31703,Active,,,0.06,IC50,Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%,Confirmatory,12431048.0,
432,96221,6,2,,123097261,31703,Active,,,2.8,IC50,Compound concentration required to reduce the cell proliferation of Wild type and drug-resistant KB subclones passaged in the presence of etoposide 7 uM by 50%,Confirmatory,12431048.0,
433,96361,6,2,,123097261,31703,Active,,,0.4,IC50,Effect on the proliferation Wild -type and Drug- resistant KB subclones passaged uM,Confirmatory,12431048.0,
434,96384,6,2,,123097261,31703,Unspecified,,,,,In vitro reduction in viability of KB cells by modified crystal violet assay.,Other,8277498.0,
435,96724,3,4,,123097261,31703,Unspecified,,,,,Percent of L1210 cells accumulated in G2+M phase of cell cycle at 0.1 uM compound concentration,Other,11128630.0,
436,97133,3,4,,123097261,31703,Unspecified,,,,,Ratio between IC50 values on L1210 and L1210/L-PAM cells,Other,15115402.0,
437,97253,3,4,,123097261,31703,Unspecified,,,,,Compound was tested against L1210 leukemia at % increase in life span (ILS) in mice at 5 mg/kg dosage.,Other,8648600.0,
438,97329,7,1,,123097261,31703,Active,,,,,Cytotoxicity against L1210 leukemia cells,Other,12182872.0,
439,97421,3,4,,123097261,31703,Unspecified,,,,,Increase in life span of treated animals relative to untreated controls expressed in murine L1210 leukemia at a dose of 4 mg/kg x4 after ip injection.,Other,7086818.0,
440,97575,3,4,,123097261,31703,Unspecified,,,,,Percent increase in life span relative to untreated controls in murine L1210 leukemia infected B6D2F1J male mice at 4 mg/kg optimal dose,Other,6827523.0,
441,97833,8,1,,123097261,31703,Active,,,1.6,ED50,Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]thymidine in the DNA,Confirmatory,3806572.0,
442,97965,8,1,,123097261,31703,Active,,,0.58,ED50,Compound was evaluated for drug concentration for 50% inhibition of actively growing L1210 cells in culture for the inhibition of incorporation of [3H]uridine in the RNA,Confirmatory,3806572.0,
443,97971,8,1,,123097261,31703,Active,,,1.6,ED50,Compound was evaluated for the inhibition of DNA synthesis in leukemia L1210 cells,Confirmatory,3761328.0,
444,97972,8,1,,123097261,31703,Active,,,0.58,ED50,Compound was evaluated for the inhibition of RNA synthesis in leukemia L1210 cells,Confirmatory,3761328.0,
445,98006,6,2,,123097261,31703,Active,,,0.025,IC50,Antiproliferative activity was evaluated against murine L1210 leukemia cell line,Confirmatory,11128630.0,
446,98029,8,1,,123097261,31703,Active,,,1.6,ED50,Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells),Confirmatory,3761325.0,
447,98030,8,1,,123097261,31703,Active,,,0.58,ED50,Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells),Confirmatory,3761325.0,
448,98033,8,1,,123097261,31703,Active,,,1.5,ED50,Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells,Confirmatory,7086816.0,
449,98034,8,1,,123097261,31703,Active,,,0.58,ED50,Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.,Confirmatory,7086816.0,
450,98048,5,1,,123097261,31703,Unspecified,,,,,The compound was evaluated for antiproliferative activity against L1210 cell line,Other,11055343.0,
451,98143,6,3,,123097261,31703,Active,,,0.04,IC50,Compound was tested for cytotoxicity on L1210 leukemia cell line using a proliferation assay (MTT reduction),Confirmatory,,
452,98202,4,5,,123097261,31703,Active,,,3.884,IC50,Antitumor activity against murine L1210 resistant cell line by using MTT assay,Confirmatory,7699715.0,
453,98203,4,4,,123097261,31703,Active,,,0.035,IC50,Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay,Confirmatory,7699715.0,
454,98209,6,2,,123097261,31703,Active,,,0.23,IC50,Antitumor activity was evaluated against leukemia cell line L1210 (mouse leukemia).,Confirmatory,10411476.0,
455,98300,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against L1210 cancer cell lines.,Other,,
456,98357,9,1,,123097261,31703,Unspecified,,,,IC50,Inhibitory activity against L1210 cell growth,Confirmatory,1992140.0,
457,98376,6,3,,123097261,31703,Active,,,0.033,IC50,In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.,Confirmatory,,
458,98384,4,4,,123097261,31703,Active,,,0.035,IC50,Antitumor activity against sensitive L1210 murine leukemia cell lines.,Confirmatory,8960558.0,
459,98386,4,4,,123097261,31703,Active,,,3.884,IC50,Antitumor activity against murine leukemia L1210 cell line.,Confirmatory,8960558.0,
460,98395,6,3,,123097261,31703,Active,,,0.9,IC50,Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.,Confirmatory,,
461,98403,6,2,,123097261,31703,Active,,,0.069,IC50,Tested in vitro against murine L1210 leukemia.,Confirmatory,3806589.0,
462,98493,6,2,,123097261,31703,Active,,,0.025,IC50,Inhibitory concentration required against L1210 leukemia cells,Confirmatory,12182872.0,
463,98528,8,1,,123097261,31703,Active,,,0.02,ID50,Compound concentration required to reduce by 50% the number of murine lymphocytic leukemia (L1210) cells after three cell cycles,Confirmatory,1548681.0,
464,98577,4,5,,123097261,31703,Active,,,0.03784,IC50,Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,Confirmatory,15115402.0,
465,98578,4,5,,123097261,31703,Active,,,0.039560000000000005,IC50,"Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)",Confirmatory,15115402.0,
466,98720,6,2,,123097261,31703,Active,,,0.05,IC50,Growth inhibitory concentration of compound was measured against murine leukemia cell line (L1210),Confirmatory,10698436.0,
467,98730,6,2,,123097261,31703,Active,,,0.025,IC50,In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line,Confirmatory,12443763.0,
468,98910,4,4,,123097261,31703,Active,,,0.035,IC50,Inhibitory activity against resistant murine leukemia L1210 cell lines.,Confirmatory,8648600.0,
469,98911,4,4,,123097261,31703,Active,,,0.035,IC50,Inhibitory activity against sensitive L1210 cell lines,Confirmatory,8648600.0,
470,98930,4,4,,123097261,31703,Active,,,0.026000000000000002,IC50,In vitro cytotoxicity against L1210 (murine leukemia) cells.,Confirmatory,8057291.0,
471,99059,6,2,,123097261,31703,Active,,,0.05,IC50,Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210,Confirmatory,7996544.0,
472,99062,6,2,,123097261,31703,Active,,,0.06,IC50,Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210/L-PAM resistant to melphalan (L-PAM),Confirmatory,7996544.0,
473,99082,4,4,,123097261,31703,Active,,,0.0343,IC50,Inhibition of murine L1210 leukemia cell proliferation measured by the MTT assay,Confirmatory,10377224.0,
474,99164,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity assay was measured against human tumor L1210/Adr cell line using camptothecin as a standard,Other,,
475,99165,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against L1210/Adr cancer cell lines.,Other,,
476,99212,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity assessed in the LXFL529 human lung carcinoma using the BrdU,Confirmatory,12459020.0,
477,99358,4,4,,123097261,31703,Active,,,3.884,IC50,"Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.",Confirmatory,10956214.0,
478,99359,4,4,,123097261,31703,Active,,,0.035,IC50,"Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.",Confirmatory,10956214.0,
479,99487,6,2,,123097261,31703,Active,,,0.2,IC50,Ability to inhibit growth of L1210 leukemic cell lines was determined in an in vitro MTT assay.,Confirmatory,1995877.0,
480,99493,6,2,,123097261,31703,Active,,,0.3,IC50,In vitro inhibitory concentration of the unconjugated compound against human L2987 lung carcinoma cell line,Confirmatory,12798317.0,
481,100109,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,"Inhibitory concentration to reduce cell number to 50% in a panel of cultured, murine Lewis lung carcinoma (LL) cells.",Confirmatory,11806725.0,
482,100176,3,5,,123097261,31703,Unspecified,,,,,Effect of compound on L1210 cell cycle was determined and percent of treated cells in the G2M phase of L1210 leukemia cells was determined,Other,12182872.0,
483,100239,4,5,,123097261,31703,Active,,,0.022000000000000002,IC50,Inhibitory concentration against Murine Lewis lung carcinoma (LLC) cell proliferation,Confirmatory,9207945.0,
484,100240,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Inhibitory concentration required to reduce Lewis lung carcinoma cell number to 50% of control cultures,Confirmatory,9191970.0,
485,100256,6,2,,123097261,31703,Active,,,0.02,GI50,In vitro antiproliferative activity against human LN-caP prostrate cell line,Confirmatory,14971893.0,
486,100393,6,2,,123097261,31703,Active,,,0.7,EC50,Concentration required to kill 50% of tumor cells in PSA producing LNCaP human prostate cancer cell line,Confirmatory,11708923.0,
487,100493,3,4,,123097261,31703,Unspecified,,,,,"Percentage ratio of tumor area of treated group to the control group for L1210 mouse leukemia treated by 8.1 mg / kg dosed intravenously on 1,5,and 9 days",Other,8496904.0,
488,100510,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in stem cell assay,Other,8496904.0,
489,100511,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in untreated control culture,Other,8496904.0,
490,100528,6,2,,123097261,31703,Active,,,0.7,EC50,In vitro effective concentration against LNCaP prostate cancer cell line,Confirmatory,14667208.0,
491,100551,6,2,,123097261,31703,Active,,,0.01,GI50,In vitro antiproliferative activity against human LOVO colon cell line,Confirmatory,14971893.0,
492,100554,6,2,,123097261,31703,Active,,,2.4,GI50,In vitro antiproliferative activity against human LOVO-DOX colon cell line,Confirmatory,14971893.0,
493,100989,4,4,,123097261,31703,Active,,,0.042,IC50,Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay,Confirmatory,7853331.0,
494,101007,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against LOX-IMVI melanoma cell line,Other,11354370.0,
495,101077,6,2,,123097261,31703,Active,,,0.025,IC50,In vitro inhibitory activity was tested against L1210 leukemia cells,Confirmatory,10890167.0,
496,101085,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against L1210 leukemia cells.,Other,2296017.0,
497,101086,4,1,,123097261,31703,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against L1210 leukemia cells determined by clonogenic assay.,Other,2296017.0,
498,101492,6,2,,123097261,31703,Active,,,0.01,IC50,In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth,Confirmatory,12852768.0,
499,101545,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against H 226 tumor cell line,Other,10602713.0,
500,101601,4,4,,123097261,31703,Active,,,0.2,IC50,Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation,Confirmatory,14971899.0,
501,101613,7,2,,123097261,31703,Active,,,0.3,IC50,compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells.,Confirmatory,9258351.0,
502,101620,6,2,,123097261,31703,Active,,,0.005,IC50,"Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)",Confirmatory,10780913.0,
503,101742,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against MCF-7 tumor cell line,Other,10602713.0,
504,101746,8,1,,123097261,31703,Active,,,0.9,ID50,In vitro cytotoxicity against human breast carcinoma cell line (MCF-7),Confirmatory,9022792.0,
505,101799,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against MDA-MB-231 breast cancer cell line,Other,11354370.0,
506,101820,4,4,,123097261,31703,Active,,,0.3,IC50,Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation,Confirmatory,14971899.0,
507,101911,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against MCF-7/ADR cells,Other,8632413.0,
508,101912,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against MCF-7/ADR+Reserpine cells,Other,8632413.0,
509,101913,3,4,,123097261,31703,Active,,,,,Cytotoxic Activity was evaluated against MCF-7 cells,Other,8632413.0,
510,101941,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against MCF-7 cancer cell lines.,Other,,
511,101943,4,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity assay was measured against human tumor MCF-7 cell line using camptothecin as a standard,Other,,
512,101977,6,2,,123097261,31703,Active,,,0.4,IC50,Antiproliferative activity against MDA-MB-435 human breast carcinoma cells in vivo using MDA-MB-435 monolayer growth assay.,Confirmatory,11606134.0,
513,101991,4,3,,123097261,31703,Unspecified,,,,,In vivo for dead/total against MDA-MB-435 human breast carcinoma cells implanted sc in mice at a dose 2 umol/kg; value is 0/8,Other,11606134.0,
514,102020,6,2,,123097261,31703,Active,,,0.024,IC50,Cytotoxicity activity on LoVo human adenocarcinoma cell line after 144 hr of drug exposure,Confirmatory,11806721.0,
515,102021,6,2,,123097261,31703,Active,,,0.86,IC50,Cytotoxicity activity on LoVo human adenocarcinoma cell line after 1 hr of drug exposure,Confirmatory,11806721.0,
516,102030,4,4,,123097261,31703,Active,,,0.08,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) resistant cell proliferation,Confirmatory,11606141.0,
517,102031,4,4,,123097261,31703,Active,,,0.008,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of LoVo (colon) sensitive variant cell proliferation,Confirmatory,11606141.0,
518,102032,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells,Other,10698460.0,
519,102123,3,5,,123097261,31703,Unspecified,,,,,In vivo percent T/C against MDA-MB-435 human breast carcinoma cells implanted sc in mice at a dose 2 umol/kg,Other,11606134.0,
520,102132,3,5,,123097261,31703,Unspecified,,,,,In vivo for percent body weight against MDA-MB-435 human breast carcinoma cells implanted sc in mice at a dose 2 umol/kg,Other,11606134.0,
521,102172,6,2,,123097261,31703,Active,,,1.0,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line,Confirmatory,10411474.0,
522,102184,6,2,,123097261,31703,Active,,,0.043,IC50,Inhibitory activity against human colon adenocarcinoma cell line LoVo.,Confirmatory,7853345.0,
523,102186,6,2,,123097261,31703,Active,,,0.057,IC50,Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line,Confirmatory,7996544.0,
524,102188,6,2,,123097261,31703,Unspecified,,,,,Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo),Other,8145234.0,
525,102201,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells,Other,10698460.0,
526,102203,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.,Other,9876113.0,
527,102210,6,2,,123097261,31703,Active,,,7.6,IC50,Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX),Confirmatory,7996544.0,
528,102326,6,2,,123097261,31703,Active,,,2.4,IC50,Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 144 hr of drug exposure,Confirmatory,11806721.0,
529,102327,6,2,,123097261,31703,Active,,,9.7,IC50,Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 1 hr of drug exposure,Confirmatory,11806721.0,
530,102330,6,2,,123097261,31703,Active,,,6.0,IC50,Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.,Confirmatory,7853345.0,
531,102331,6,2,,123097261,31703,Unspecified,,,,,Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line,Other,8145234.0,
532,102333,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.,Other,9876113.0,
533,102334,6,2,,123097261,31703,Unspecified,,,91.0,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line,Confirmatory,10411474.0,
534,102508,6,3,,123097261,31703,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against Lu-99 human pulmonary large cell carcinoma,Other,,
535,102588,6,2,,123097261,31703,Active,,,0.05,IC50,Antitumor activity against human breast adenocarcinoma MCF-7 cells,Confirmatory,12431048.0,
536,102589,6,2,,123097261,31703,Active,,,0.05,IC50,Antitumor activity against human breast adenocarcinoma MCF-7 cells.,Confirmatory,12431049.0,
537,102597,6,2,,123097261,31703,Active,,,0.063,IC50,In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system,Confirmatory,1447730.0,
538,102699,6,2,,123097261,31703,Active,,,0.06,CC50,Cytotoxicity was evaluated against lymphoblastoid cell line.,Confirmatory,10411476.0,
539,103073,6,2,,123097261,31703,Active,,,0.01,IC50,"Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)",Confirmatory,10780913.0,
540,103085,7,3,,123097261,31703,Active,,,10.0,IC50,Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).,Confirmatory,9548820.0,
541,103088,6,2,,123097261,31703,Active,,,3.1,IC50,In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.,Confirmatory,1447730.0,
542,103091,4,5,,123097261,31703,Active,,,10.0,IC50,Inhibition of MCF-7/Adr breast cancer cell proliferation,Confirmatory,14971899.0,
543,103092,8,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against MCF-7/Adr cells.,Other,9207950.0,
544,103093,7,3,,123097261,31703,Active,,,10.0,IC50,compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells.,Confirmatory,9258351.0,
545,103101,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity was evaluated against Lewis lung carcinoma as body weight change in BDF1 mice upon intraperitoneal administration at a dose of 4 mg/kg,Other,9873387.0,
546,103103,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity was evaluated against Lewis lung carcinoma as tumor growth inhibition was determined in BDF1 mice upon intraperitoneal administration at a dose of 4 mg/kg,Other,9873387.0,
547,103106,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Inhibitory activity of tested against Murine Lewis lung carcinoma,Confirmatory,10395479.0,
548,103185,6,3,,123097261,31703,Active,,,0.15,IC50,In vitro antitumor activity against MB231 (breast) human tumor cell lines.,Confirmatory,,
549,103223,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity assessed in the MCF-7 human mamma carcinoma using the BrdU,Confirmatory,12459020.0,
550,103233,8,1,,123097261,31703,Active,,,14.2,ID50,In vitro cytotoxicity against multi drug resistant human breast carcinoma (MCF-7/VP-16) cell line,Confirmatory,9022792.0,
551,103244,6,2,,123097261,31703,Active,,,0.015,IC50,Antitumor activity against breast carcinoma cell line (MCF-7M),Confirmatory,2547068.0,
552,103262,8,1,,123097261,31703,Active,,,0.031,ED50,Cytotoxic concentration required to inhibit 50% cell growth in MCF-7 breast carcinoma cell lines,Confirmatory,1875350.0,
553,103272,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human breast carcinoma MCF-7 cell lines,Other,,
554,103275,5,1,,123097261,31703,Unspecified,,,,,Compound was tested for its cytotoxic activity in MTT assay against MCF-9 cell line (human breast carcinoma),Other,,
555,103294,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Growth inhibitory activity against murine Lewis lung carcinoma cell line,Confirmatory,12620081.0,
556,103367,8,1,,123097261,31703,Active,,,3.1,ED50,Cytotoxicity against human MCF-7 breast cancer cell line.,Confirmatory,1613753.0,
557,103373,6,2,,123097261,31703,Unspecified,,,,,Compound was evaluated for the growth inhibition of MCF-7 breast cell line.,Other,9873640.0,
558,103386,4,4,,123097261,31703,Active,,,0.0012,IC50,Cytotoxicity against human breast carcinoma cell lines MCF-7,Confirmatory,12392727.0,
559,103403,6,2,,123097261,31703,Unspecified,,,,,"In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay",Other,12620075.0,
560,103419,4,4,,123097261,31703,Active,,,1.172,IC50,"Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
561,103420,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,"Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
562,103421,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,"Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
563,103423,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against MCF-7 breast cancer cell line,Other,11354370.0,
564,103569,5,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human breast cancer cells (MCF-7) by using SRB assay after 72 hr of drug exposure,Other,,
565,103579,6,2,,123097261,31703,Active,,,0.14,IC50,Inhibitory activity against MCF-7 breast cell line using sulforhodamine B (SRB) protein assay,Confirmatory,12039588.0,
566,103693,5,1,,123097261,31703,Unspecified,,,,,Compound was tested for cytotoxic activity against human breast carcinoma (MCF-7),Other,,
567,103696,4,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human MCF-7 (breast carcinoma) cell line,Other,,
568,103702,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human breast carcinoma MCF-7 cell line,Other,8627602.0,
569,103708,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on breast carcinoma (MCF-7) cell line,Other,8632402.0,
570,103711,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against MCF-7 (human breast carcinoma) cell line,Other,11551759.0,
571,103727,5,1,,123097261,31703,Unspecified,,,,,Tested in vitro for cytotoxicity against MCF-7 breast cancer cells,Other,8027979.0,
572,103785,6,3,,123097261,31703,Active,,,16.7,GI50,Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line,Confirmatory,11755363.0,
573,103892,6,2,,123097261,31703,Active,,,0.25,IC50,Inhibition of 10e-2 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation,Confirmatory,8784443.0,
574,103913,7,2,,123097261,31703,Active,,,0.3,IC50,Compound was tested for its toxicity against human breast cancer cells(MCF-7),Confirmatory,9548820.0,
575,103934,5,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against subline resistant to doxorubicin (MCF-7/R) by using SRB assay after 72 hr of drug exposure,Other,,
576,103944,6,2,,123097261,31703,Active,,,0.013000000000000001,GI50,Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line,Confirmatory,11755363.0,
577,103947,5,3,,123097261,31703,Unspecified,,,135.0,IC50,Antiproliferative activity measured against MCF-7-mdr cells.,Confirmatory,9876111.0,
578,104106,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
579,104131,6,2,,123097261,31703,Active,,,0.006,IC50,"Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)",Confirmatory,10780913.0,
580,104317,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells,Confirmatory,12431048.0,
581,104318,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells.,Confirmatory,12431049.0,
582,104437,6,2,,123097261,31703,Active,,,0.01,IC50,Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells,Confirmatory,12431048.0,
583,105071,4,5,,123097261,31703,Active,,,0.018000000000000002,IC50,The compound was tested for extracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase stCPG2.,Confirmatory,10395490.0,
584,105073,4,4,,123097261,31703,Active,,,0.012,IC50,The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase).,Confirmatory,10395490.0,
585,105074,4,4,,123097261,31703,Active,,,0.033,IC50,The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing carboxypeptidase G2(CPG2).,Confirmatory,10395490.0,
586,105115,6,1,,123097261,31703,Active,,,0.035,IC50,Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.,Confirmatory,,
587,105204,6,3,,123097261,31703,Active,,,0.05,IC50,Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.,Confirmatory,,
588,105213,4,5,,123097261,31703,Active,,,0.15,IC50,Inhibition of MDA-MB-435 breast cancer cell proliferation,Confirmatory,14971899.0,
589,105263,4,4,,123097261,31703,Active,,,0.00195,IC50,Cytotoxicity against Breast cancer cell lines MDA-231 was determined,Confirmatory,12392727.0,
590,105288,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity was evaluated against leukemia cell line MOLT-4(human acute T lymphoblastic leukemia),Confirmatory,10411476.0,
591,105300,6,3,,123097261,31703,Active,,,0.05,IC50,Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.,Confirmatory,,
592,105506,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells.,Confirmatory,12431049.0,
593,105507,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells,Confirmatory,12431048.0,
594,105709,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity was evaluated against leukemia cell line MT-4(human CD4+ T cells expressing the TAT gene of HTLV-1).,Confirmatory,10411476.0,
595,106097,3,5,,123097261,31703,Unspecified,,,,,Antitumor activity was measured on MX-1 human mammary carcinoma cells. TWI%=tumor weight inhibition. Optimal dose at 7.5 mg/kg/day,Other,9876113.0,
596,106133,4,4,,123097261,31703,Active,,,0.62,IC50,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Confirmatory,12431060.0,
597,106134,4,4,,123097261,31703,Active,,,0.052000000000000005,IC50,Inhibitory concentration against the growth of HET-SR-2SC-LNM cell line after 72 hr of drug exposure by MTT test,Confirmatory,12431060.0,
598,106292,4,4,,123097261,31703,Active,,,1.172,IC50,Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
599,106293,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
600,106294,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
601,106296,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.,Confirmatory,8960558.0,
602,106303,6,2,,123097261,31703,Active,,,3.1,GI50,In vitro antiproliferative activity against human MEL-28 melanoma cell line,Confirmatory,14971893.0,
603,106307,6,3,,123097261,31703,Active,,,0.02,IC50,Compound was evaluated for the cytotoxicity against MEL-28 tumor cell line after 3 days of incubation,Confirmatory,,
604,106317,6,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against MEL-AC melanoma cell line,Confirmatory,10476861.0,
605,106319,3,5,,123097261,31703,Unspecified,,,,,"Resistance factor (RF), ratio between the IC50 on the resistant cells and the IC50 on the corresponding sensitive cells of MES cell line",Other,12443763.0,
606,106325,6,2,,123097261,31703,Active,,,0.04,IC50,Ability to inhibit growth of doxorubicin-sensitive (MES-SA) uterine sarcoma cell line was determined in an in vitro MTT assay.,Confirmatory,1995877.0,
607,106327,6,2,,123097261,31703,Active,,,0.25,IC50,In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA,Confirmatory,12443763.0,
608,106330,6,2,,123097261,31703,Active,,,4.2,IC50,Ability to inhibit growth of doxorubicin-resistant (MES-SA/DOX) uterine sarcoma cell line was determined in an in vitro MTT assay.,Confirmatory,1995877.0,
609,106337,6,2,,123097261,31703,Active,,,12.0,IC50,In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5,Confirmatory,12443763.0,
610,106430,4,4,,123097261,31703,Active,,,1.172,IC50,Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.,Confirmatory,8960558.0,
611,106431,4,4,,123097261,31703,Active,,,0.027999999999999997,IC50,Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.,Confirmatory,8960558.0,
612,106483,6,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic concentration against mouse hepatoma cell line (MG-22A) using MTT coloration,Other,15013011.0,
613,106485,6,3,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against mouse hepatoma cell line (MG-22A) using CV coloration,Other,15013011.0,
614,106661,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human pancreatic carcinoma MIA PaCa-2 cell lines,Other,,
615,106665,3,3,,123097261,31703,Unspecified,,,,,Maximum nonlethal drug dose which could be administered (ip) to non tumor bearing nude mice for 5 consecutive days,Other,11708923.0,
616,106666,3,5,,123097261,31703,Unspecified,,,,,Percentage PSA reduction relative to vehicle control following intraperitoneal injection of conjugate dose for 5 consecutive days to nude mice bearing LNCaP tumor xenografts,Other,11708923.0,
617,106676,3,3,,123097261,31703,Unspecified,,,,,Percentage weight reduction relative to vehicle control following intraperitoneal (ip) injection of conjugate dose for 5 consecutive days to nude mice bearing LNCaP tumor xenografts (2.8 umol/kg dose),Other,11708923.0,
618,106843,6,2,,123097261,31703,Active,,,3.13,IC50,Cytotoxicity of compound against human gastric adenocarcinoma cell line (MKN 45),Confirmatory,9822542.0,
619,106844,6,2,,123097261,31703,Active,,,0.64,IC50,Growth inhibitory concentration of compound was measured against human gastric adenocarcinoma cell line (MKN-1),Confirmatory,10698436.0,
620,106876,8,1,,123097261,31703,Active,,,0.13,ED50,Cytotoxic concentration required to inhibit 50% cell growth in MLM melanoma cell lines,Confirmatory,1875350.0,
621,107214,4,4,,123097261,31703,Active,,,0.11199999999999999,IC50,Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.,Confirmatory,10956214.0,
622,108243,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 10 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
623,108244,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 15 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
624,108245,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 18 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
625,108246,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 2.5 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
626,108247,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 20 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
627,108248,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 25 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
628,108249,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 30 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
629,108250,3,3,,123097261,31703,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after iv administration at 5 mg/kg dose 3 days after tumor challenge,Other,2002471.0,
630,108371,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity against 3LL metastasis in BDF1 mice after iv administration at 10 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
631,108372,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity against 3LL metastasis in BDF1 mice after iv administration at 18 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
632,108390,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after iv administration at 15 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
633,108391,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after iv administration at 2.5 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
634,108392,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after iv administration at 20 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
635,108393,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after iv administration at 25 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
636,108394,3,3,,123097261,31703,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after iv administration at 5 mg/kg dose, dosing on days 3 after tumor challenge",Other,2002471.0,
637,110535,6,1,,123097261,31703,Unspecified,,,,,Evaluated for survival time of P388 Leukemia implanted female CDF1 Mice at a dose of 25 mg/kg,Other,14971908.0,
638,110536,6,1,,123097261,31703,Unspecified,,,,,Evaluated for survival time of P388/ADM Leukemia implanted female CDF1 Mice at a dose of 100 mg/kg,Other,14971908.0,
639,110626,3,3,,123097261,31703,Unspecified,,,,,"Cures is the number of survivors of the total treated mice (20) with B-16 melanoma, at 60 days.",Other,6806475.0,
640,110635,3,3,,123097261,31703,Unspecified,,,,,"Cures is the number of survivors of the total treated mice (6) with P-388 leukemia, at 60 days.",Other,6806475.0,
641,110672,3,3,,123097261,31703,Unspecified,,,,,Number of mice(with Colon 38 tumors) cured after treatment of 2.6 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice,Other,12620081.0,
642,110719,6,1,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(day+/-SD) at an intravenous dose of 4(mg/kg).,Other,10579838.0,
643,110722,6,1,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average survival time(day+/-SD) at an intravenous dose of 3(mg/kg)..,Other,10579838.0,
644,111061,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 3(mg/kg).,Other,10579838.0,
645,111063,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 4(mg/kg).,Other,10579838.0,
646,111069,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 4(mg/kg).,Other,10579838.0,
647,111072,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 3(mg/kg).,Other,10579838.0,
648,111189,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC healthy mice by the administration of compound at dose of 1.5 mg/kg/day cells isolated on the 9th day by using CB assay,Other,15013011.0,
649,111190,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC healthy mice by the administration of compound at dose of 1.5 mg/kg/day cells isolated on the 9th day by using MTT assay,Other,15013011.0,
650,111191,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC healthy mice by the administration of compound at dose of 5.0 mg/kg/day cells isolated on the 9th day by using CB assay,Other,15013011.0,
651,111192,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC healthy mice by the administration of compound at dose of 5.0 mg/kg/day cells isolated on the 9th day by using MTT assay,Other,15013011.0,
652,111194,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC mice with transplanted sarcoma S-180 by the administration of compound at dose of 1.5 mg/kg/day cells isolated on the 9th day by using CB assay,Other,15013011.0,
653,111195,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC mice with transplanted sarcoma S-180 by the administration of compound at dose of 1.5 mg/kg/day cells isolated on the 9th day by using MTT assay,Other,15013011.0,
654,111196,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC mice with transplanted sarcoma S-180 by the administration of compound at dose of 5.0 mg/kg/day cells isolated on the 9th day by using CB assay,Other,15013011.0,
655,111197,3,3,,123097261,31703,Unspecified,,,,,Physiological change in cardiomyocytes after the treatment of male JRC mice with transplanted sarcoma S-180 by the administration of compound at dose of 5.0 mg/kg/day cells isolated on the 9th day by using MTT assay,Other,15013011.0,
656,111212,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 3(mg/kg).,Other,10579838.0,
657,111214,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 4(mg/kg).,Other,10579838.0,
658,111217,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 16(mg/kg).,Other,10579838.0,
659,111219,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 4(mg/kg).,Other,10579838.0,
660,111303,3,4,,123097261,31703,Unspecified,,,,,"In vivo antitumor activity against murine pancreatic adenocarcinoma and measured as number of deaths on a schedule of 3,8days and at a total dose of 16 mg/kg",Other,12825938.0,
661,112763,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against P388 (adriamycin sensitive tumors) in terms of % increase in life span in mice at an optimal dose of 3.0 ug/kg administered ip,Other,2985784.0,
662,112768,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against P388/ADR (adriamycin resistant tumors) in terms of % increase in life span in mice at an optimal dose of 3.5 ug/kg administered ip,Other,2985784.0,
663,114248,6,1,,123097261,31703,Unspecified,,,,,In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 2.6 mg/kg/day dose given as 3 times in a day for 4 days,Other,12620081.0,
664,114985,2,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as maximum tolerated total dose upon intravenous administration,Other,,
665,115160,2,4,,123097261,31703,Unspecified,,,,,The maximum tolerated total dose following i.v. administration in mice.,Other,,
666,115198,3,4,,123097261,31703,Unspecified,,,,,"The percent increase in life span of compound was measured against P388 Leukemia cells in mice at at a dose of 4.5 mg/kg on days 1,5 and 9",Other,7699715.0,
667,115256,3,3,,123097261,31703,Unspecified,,,,,"Log cell kill of tumor bearing mice on a schedule of 3,8days and at a total dose of 16 mg/kg",Other,12825938.0,
668,115295,3,3,,123097261,31703,Unspecified,,,,,compound was tested for maximum tolerated dose administarted iv (mg/kg),Other,9733489.0,
669,115636,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity was tested in mice and percent increase of life span at a dose of 10 ug/kg was reported,Other,10780911.0,
670,115642,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity was tested in mice and percent increase of life span at a dose of 5 ug/kg was reported,Other,10780911.0,
671,115664,3,3,,123097261,31703,Unspecified,,,,,Compound was evaluated in vivo for antileukemic activity in B6D2F1 male mice,Other,3806576.0,
672,115665,3,3,,123097261,31703,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity utilizing the murine P388 leukemia system in B6D2F1 male mice.,Other,3806575.0,
673,116135,3,4,,123097261,31703,Unspecified,,,,,In vivo growth inhibitory activity was measured against murine P388 leukemia cells as Percent increase in life span at the dose of 4.0 mg/kg/day,Other,7057426.0,
674,116151,3,3,,123097261,31703,Unspecified,,,,,In vivo percent increase in life span relative to untreated controls in B6D2F1/J male mice at dose 2 mg/kg,Other,3839851.0,
675,116153,3,3,,123097261,31703,Unspecified,,,,,In vivo percent increase in life span relative to untreated controls in B6D2F1/J male mice at dose 3 mg/kg,Other,3839851.0,
676,116260,3,3,,123097261,31703,Unspecified,,,,,In vivo percent increase in life span relative to untreated controls in B6D2F1/J male mice at dose 4 mg/kg,Other,3839851.0,
677,116262,3,3,,123097261,31703,Unspecified,,,,,In vivo percent increase in life span relative to untreated controls in B6D2F1/J male mice at dose 5 mg/kg,Other,3839851.0,
678,116267,3,3,,123097261,31703,Unspecified,,,,,In vivo percent increase in life span relative to untreated controls in B6D2F1/J male mice at dose 1 mg/kg,Other,3839851.0,
679,116321,3,5,,123097261,31703,Unspecified,,,,,Percent increase in life span was calculated against L1210 murine leukemia cells in BDF1 male mice at the specified in vivo dose of 3.5(mg/kg)/day.,Other,7086817.0,
680,116330,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 3(mg/kg)..,Other,10579838.0,
681,116331,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 4(mg/kg).,Other,10579838.0,
682,116537,2,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as log10 cell kill of tumor bearing mice,Other,,
683,116687,2,4,,123097261,31703,Unspecified,,,,,Log cell kill of tumor (indicating the tumor growth delay) in mice.,Other,,
684,116693,3,3,,123097261,31703,Unspecified,,,,,"The log cell kill of tumor-bearing mice, based on tumor growth delay.",Other,9733489.0,
685,116825,3,4,,123097261,31703,Unspecified,,,,,Percent increase in life span when given at a dose in P388 leukemia cells of mice (Positive control for compound 44),Other,8960558.0,
686,116826,3,4,,123097261,31703,Unspecified,,,,,"Percent increase in life span when given at a dose in P388 leukemia cells of mice (Positive control for compounds 15,34 and amonafide)",Other,8960558.0,
687,116990,3,3,,123097261,31703,Unspecified,,,,,Percent increase in median life span of BDF1 mice with B-16 melanoma at dose 0.8 mg/kg administered intraperitoneally,Other,6806475.0,
688,117169,3,3,,123097261,31703,Unspecified,,,,,Percent increase in median life span of BDF1 mice with P-388 leukemia at dose 5 mg/kg administered intraperitoneally,Other,6806475.0,
689,117263,2,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as long term cures,Other,,
690,117264,3,4,,123097261,31703,Unspecified,,,,,Survival (Long Term Cure) of tumor inoculated mice after 100 days.,Other,,
691,117265,3,3,,123097261,31703,Unspecified,,,,,The long term cures (LTC) value is the number of mice in a group with no palpable tumor.,Other,9733489.0,
692,117484,3,3,,123097261,31703,Unspecified,,,,,Compound evaluated for optimal dose per injection against murine sarcoma 180 cells,Other,8151613.0,
693,118821,3,4,,123097261,31703,Unspecified,,,,,Median day of death was calculated against L1210 murine leukemia cells in BDF1 male mice at the specified in vivo dose of 3.5(mg/kg)/day,Other,7086817.0,
694,119828,4,4,,123097261,31703,Unspecified,,,,,Percentage rate of O2 consumption by liver microsomes and NADPH in the presence compared to the rate in presence of doxorubicin.,Other,7086816.0,
695,120038,3,4,,123097261,31703,Unspecified,,,,,Median survival of treated/ control animals (%T/C) was determined by in vivo antitumor activity against the B16 melanoma cell line at a dose of 12 mg/kg administered intraperitoneally on day 5,Other,6302253.0,
696,120040,3,4,,123097261,31703,Unspecified,,,,,Median survival of treated/ control animals (%T/C) was determined by in vivo antitumor activity against the B16 melanoma cell line at a dose of 1 mg/kg administered intraperitoneally on day 5,Other,6302253.0,
697,120042,3,4,,123097261,31703,Unspecified,,,,,Median survival of treated/ control animals (%T/C) was determined by in vivo antitumor activity against the B16 melanoma cell line at a dose of 3 mg/kg administered intraperitoneally on day 5,Other,6302253.0,
698,120046,3,4,,123097261,31703,Unspecified,,,,,Median survival of treated/ control animals (%T/C) was determined by in vivo antitumor activity against the B16 melanoma cell line at a dose of 6 mg/kg administered intraperitoneally on day 5,Other,6302253.0,
699,120048,3,4,,123097261,31703,Unspecified,,,,,Median survival of treated/ control animals (%T/C) was determined by in vivo antitumor activity against the B16 melanoma cell line at a dose of 9 mg/kg administered intraperitoneally on day 5,Other,6302253.0,
700,120111,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor efficacy expressed as number survivors in 60-days out of 7 male mice at dose 3 mg/kg; Value represented as = 0/7,Other,3839851.0,
701,120116,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor efficacy expressed as number survivors in 60-days out of 7 male mice at dose 4 mg/kg; Value represented as = 0/7,Other,3839851.0,
702,120122,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor efficacy expressed as number survivors in 60-days out of 7 male mice at dose 5 mg/kg; Value represented as = 0/7,Other,3839851.0,
703,120376,3,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for antitumor efficacy at optimum dose in mice aagainst B16 melanoma cells at 7.5 mg/Kgon day 1 (intraperitoneal),Other,3806572.0,
704,120404,2,4,,123097261,31703,Unspecified,,,,,Percent tumor growth inhibition in mice.,Other,,
705,120406,4,3,,123097261,31703,Unspecified,,,,,Ratio between mean survival days of treated group and control group,Other,14971908.0,
706,120414,4,3,,123097261,31703,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 0.78 mg/kg,Other,15056007.0,
707,120415,4,3,,123097261,31703,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 1.56 mg/kg,Other,15056007.0,
708,120511,3,4,,123097261,31703,Unspecified,,,,,"Compound was evaluated for antitumor efficacy at optimum dose in mice against B16 melanoma cells at 10 mg/Kg on q4d 5,9,13 days (intraperitoneal)",Other,3806572.0,
709,120517,3,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for antitumor efficacy at optimum dose in mice against P388 leukemic cells at 7.5 mg/Kg day 1 (intraperitoneal),Other,3806572.0,
710,120519,3,4,,123097261,31703,Unspecified,,,,,"Compound was evaluated for antitumor efficacy at optimum dose in mice against P388 leukemic cells at 8 mg/Kg on q4d 5,9,13 days (intraperitoneal)",Other,3806572.0,
711,120550,4,3,,123097261,31703,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 3.13 mg/kg,Other,15056007.0,
712,120552,4,3,,123097261,31703,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 6.25 mg/kg,Other,15056007.0,
713,120678,2,4,,123097261,31703,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03,Other,,
714,120699,4,3,,123097261,31703,Unspecified,,,,,Compound was evaluated for the antitumor efficacy at optimal dose against P388 in mice,Other,3761328.0,
715,120736,3,3,,123097261,31703,Unspecified,,,,,"Ratio of the median tumor weight in the treatment group over the median tumor weight in the control group on a schedule of 3,8days and at a total dose of 16 mg/kg",Other,12825938.0,
716,120899,3,3,,123097261,31703,Unspecified,,,,,Survival rate was determined as the ratio of mean survival days of treated group of mice to that of control group,Other,15026076.0,
717,120915,3,3,,123097261,31703,Unspecified,,,,,Tested for antitumor activity against P388 leukemia when administered intravenously at a optimal dose of 15 mg/kg,Other,8057291.0,
718,120918,3,3,,123097261,31703,Unspecified,,,,,Tested for antitumor activity against P388 leukemia when administered intravenously at a optimal dose of 5 mg/kg,Other,8057291.0,
719,121018,3,3,,123097261,31703,Unspecified,,,,,Compound was tested in vivo antitumor activity against Ehrlich ascites in mice at 1 mg/kg ip,Other,8709115.0,
720,121056,3,3,,123097261,31703,Unspecified,,,,,"Tested for antitumor activity against early and advanced colon 38 adenocarcinoma when administered intravenously at a schedule D2,9 and at a dose of 15 mg/kg/day",Other,8057291.0,
721,121260,3,3,,123097261,31703,Unspecified,,,,,Survival ratio (SR) is the number of mice surviving after 80 days among 8 mice,Other,11055343.0,
722,121420,6,1,,123097261,31703,Unspecified,,,,,"Survival time of CDF1 mice inoculated with leukemia P388 cells determined after 40 days of intravenous administration of compound at 20 mg/kg on days 1, 5 and 9",Other,15026076.0,
723,121473,3,3,,123097261,31703,Unspecified,,,,,%T/C value measured in antitumor activity using murine sarcoma 180 cells,Other,8151613.0,
724,121524,3,3,,123097261,31703,Unspecified,,,,,"compound was tested for murine tumor growth inhibition,T/C value (total/control) in mice.",Other,9733489.0,
725,121963,3,3,,123097261,31703,Unspecified,,,,,In vivo antitumor activity measured in mice against the Colon26/A murine solid tumors.,Other,9733489.0,
726,121964,3,3,,123097261,31703,Unspecified,,,,,In vivo antitumor activity measured in mice against the Colon38 murine solid tumors.,Other,9733489.0,
727,121965,3,3,,123097261,31703,Unspecified,,,,,In vivo antitumor activity measured in mice against the Colon51 murine solid tumors.,Other,9733489.0,
728,121966,3,3,,123097261,31703,Unspecified,,,,,In vivo antitumor activity measured in mice against the Mam16/C murine solid tumors.,Other,9733489.0,
729,121967,3,3,,123097261,31703,Unspecified,,,,,In vivo antitumor activity measured in mice against the Panc 02 murine solid tumors.,Other,9733489.0,
730,122371,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor efficacy expressed as number survivors in 60-days out of 7 male mice at dose 1 mg/kg; Value represented as = 0/7,Other,3839851.0,
731,122373,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor efficacy expressed as number survivors in 60-days out of 7 male mice at dose 2 mg/kg; Value represented as = 0/7,Other,3839851.0,
732,123018,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity in mice bearing B16BL6 melanoma at a dose of 10(ug/mL); survivors for 90 days was reported,Other,10780911.0,
733,123041,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity in mice bearing B16BL6 melanoma at a dose of 5(ug/mL); survivors for 90 days was reported,Other,10780911.0,
734,123411,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 3(mg/kg)..,Other,10579838.0,
735,123412,3,4,,123097261,31703,Unspecified,,,,,In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 4(mg/kg).,Other,10579838.0,
736,123687,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor growth inhibition in mice when administered subcutaneously at a day 1,Other,14998330.0,
737,123688,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor growth inhibition in mice when administered subcutaneously at a day 15,Other,14998330.0,
738,123689,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor growth inhibition in mice when administered subcutaneously at a day 5,Other,14998330.0,
739,123690,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor growth inhibition in mice when administered subcutaneously at a day 9,Other,14998330.0,
740,123691,6,1,,123097261,31703,Unspecified,,,,,In vivo tumor growth inhibition in mice when administered subcutaneously at a day 12,Other,14998330.0,
741,124253,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against iv transplanted AML Leukemia 1498 tumors of mice,Other,11356111.0,
742,124254,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against iv transplanted Leukemia L1210 tumors of mice,Other,11356111.0,
743,124255,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mam-16/C tumors of mice,Other,11356111.0,
744,124257,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mam-16/C/Adr tumors of mice,Other,11356111.0,
745,124258,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mam-16/C/Taxol tumors of mice,Other,11356111.0,
746,124259,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mam-17 tumors of mice,Other,11356111.0,
747,124260,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mam-17/Adr tumors of mice,Other,11356111.0,
748,124261,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Mel-B16 tumors of mice,Other,11356111.0,
749,124262,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Panc-02 tumors of mice,Other,11356111.0,
750,124263,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Panc-03 tumors of mice,Other,11356111.0,
751,124264,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted Squam lung-LC12 tumors of mice,Other,11356111.0,
752,124265,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted colon-26 tumors of mice,Other,11356111.0,
753,124266,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted colon-38 tumors of mice,Other,11356111.0,
754,124267,3,3,,123097261,31703,Unspecified,,,,,In vivo activity against transplanted colon-51 tumors of mice,Other,11356111.0,
755,124616,4,3,,123097261,31703,Unspecified,,,,,Body weight change between days 0 and the day when the animal weight was the lowest,Other,10780911.0,
756,124625,3,3,,123097261,31703,Unspecified,,,,,Mean body weight change between days 1 and 10,Other,10780911.0,
757,124780,3,3,,123097261,31703,Unspecified,,,,,"In vivo antitumor activity against murine pancreatic adenocarcinoma and measured as % weight loss on a schedule of 3,8days and at a total dose of 16 mg/kg",Other,12825938.0,
758,125428,5,2,,123097261,31703,Inconclusive,,,,,Lethal concentration required against bioactivity using yellow fever mosquito larvae assay; NT =Not tested,Other,8627602.0,
759,127618,3,6,,123097261,31703,Unspecified,,,,,In vivo for the optimal dose for activity against P388 leukemia per injection,Other,3397990.0,
760,127620,3,4,,123097261,31703,Unspecified,,,,,The compound was evaluated in vivo for the optimal dose for activity against murine B-16 melanoma,Other,3397990.0,
761,129568,3,3,,123097261,31703,Unspecified,,,,,Number of survivors out of 6 ip implanted P388 leukemia in mouse after ip administration of 2.5 mg/kg after 80 days,Other,3385725.0,
762,130066,8,1,,123097261,31703,Unspecified,,,,,Antitumor activity measured as optimal dose for sc administration of compound and iv inoculation of B16 melanoma.,Other,3397991.0,
763,130067,9,1,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as optimal dose, for ip administration of compound and ip inoculation of B16 melanoma.",Other,3397991.0,
764,130069,9,1,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as optimal dose, against C26 colon carcinoma.",Other,3397991.0,
765,130791,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against ip implanted L1210 leukemia in mouse after ip administration of 2.5 mg/kg for 5 days expressed as increase in mean life span,Other,3385725.0,
766,130800,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against ip implanted P388 leukemia in mouse after ip administration of 2.5 mg/kg for 5 days expressed as increase in mean life span,Other,3385725.0,
767,130814,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against iv implanted L1210 leukemia in mouse after ip administration of 2.5 mg/kg for 5 days expressed as increase in mean life span,Other,3385725.0,
768,130967,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against iv implanted P388 leukemia in mouse after ip administration of 2.5 mg/kg for 5 days expressed as increase in mean life span,Other,3385725.0,
769,130982,4,3,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as % increase in life span, for ip administration of compound and ip inoculation of B16 melanoma.",Other,3397991.0,
770,130983,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as % increase in life span, for sc administration of compound and iv inoculation of B16 melanoma.",Other,3397991.0,
771,130985,4,3,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as % increase in life span, against C26 colon carcinoma.",Other,3397991.0,
772,131303,3,4,,123097261,31703,Unspecified,,,,,Effect on ip implanted syngeneic B16 melanoma by ip administration for 5 days at 2.5 mg/kg was measured as increase in mean life span,Other,3385725.0,
773,132862,6,2,,123097261,31703,Active,,,0.069,IC50,In vitro for its inhibitory activity against murine L1210 leukemia,Confirmatory,3397990.0,
774,133459,7,1,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as median survival time, for ip administration and ip inoculation of B16 melanoma.",Other,3397991.0,
775,133460,6,1,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as median survival time, for sc administration and iv inoculation of B16 melanoma.",Other,3397991.0,
776,133462,7,1,,123097261,31703,Unspecified,,,,,"Antitumor activity measured as median survival time, against C26 colon carcinoma.",Other,3397991.0,
777,133637,3,4,,123097261,31703,Unspecified,,,,,Compound evaluated for optimal dose (mg/kg) per injection against murine P388 leukemia cells,Other,8151613.0,
778,133638,3,4,,123097261,31703,Unspecified,,,,,Compound evaluated for optimal dose per injection against adriamycin resistant murine cell line (P388/ADM cells),Other,8151613.0,
779,133782,3,3,,123097261,31703,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD16) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
780,133783,3,3,,123097261,31703,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/2) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
781,133787,3,3,,123097261,31703,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/4) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
782,133910,3,3,,123097261,31703,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/8) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
783,134227,8,1,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia by measuring maximum tolerated dose,Other,8145234.0,
784,135066,3,3,,123097261,31703,Unspecified,,,,,"Long-term survivors among 10 mice infected with P388 leukemia, scored on day 60 at 10 mg/kg dose",Other,10377224.0,
785,135067,3,3,,123097261,31703,Unspecified,,,,,"Long-term survivors among 10 mice infected with P388 leukemia, scored on day 60 at 20 mg/kg dose",Other,10377224.0,
786,135709,4,4,,123097261,31703,Unspecified,,,,,Tested for antitumor activity against P388 murine leukemia,Other,8145234.0,
787,135715,3,3,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 6 (mg/kg/day) dose,Other,8145234.0,
788,135718,3,3,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 9 (mg/kg/day) dose,Other,8145234.0,
789,136703,3,4,,123097261,31703,Unspecified,,,,,%T/C value measured in antitumor activity using murine P388 leukemia cells,Other,8151613.0,
790,136705,3,4,,123097261,31703,Unspecified,,,,,%T/C value measured in antitumor activity using murine P388/ADM cells.,Other,8151613.0,
791,137240,3,4,,123097261,31703,Unspecified,,,,,"Inhibition of sc implanted syngeneic colon 38 carcinoma by ip administration at 2.5 mg/kg on 1, 3, 5, 7, 9 days measured as inhibition ratio",Other,3385725.0,
792,137406,3,3,,123097261,31703,Unspecified,,,,,"Percent median survival time of mice injected with B16 melanoma, at a subcutaneous compound dose of 2.5 mg/kg",Other,10377224.0,
793,137541,4,3,,123097261,31703,Unspecified,,,,,"Percent median survival time of mice injected with P388 leukemia, at a subcutaneous compound dose of 10 mg/kg",Other,10377224.0,
794,137546,3,3,,123097261,31703,Unspecified,,,,,"Percent median survival time of mice injected with P388 leukemia, at a subcutaneous compound dose of 20 mg/kg",Other,10377224.0,
795,137724,3,5,,123097261,31703,Unspecified,,,,,Percentage ratio of treated animals to cured animals against P388 leukemia (day 30 surv),Other,3397990.0,
796,137725,3,4,,123097261,31703,Unspecified,,,,,Percentage ratio of treated animals to cured animals against murine B-16 melanoma (day 60 surv),Other,3397990.0,
797,138278,3,5,,123097261,31703,Unspecified,,,,,Effect on life span of mice with intraperitoneally implanted P388 Leukemic cells,Other,8632413.0,
798,138280,3,5,,123097261,31703,Unspecified,,,,,Effect on life span of mice with intraperitoneally implanted P388/ADR Leukemic cells,Other,8632413.0,
799,140022,3,3,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 6 (mg/kg/day) dose; 0/15 -no. of toxic deaths/no. of mice,Other,8145234.0,
800,140024,3,3,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 7.5 (mg/kg/day) dose; 0/16 -no. of toxic deaths/no. of mice,Other,8145234.0,
801,140026,3,3,,123097261,31703,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 9 (mg/kg/day) dose; 3/8 -no. of toxic deaths/no. of mice,Other,8145234.0,
802,143042,6,2,,123097261,31703,Active,,,0.01,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay,Confirmatory,10780913.0,
803,143043,6,2,,123097261,31703,Active,,,0.01,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
804,143360,6,2,,123097261,31703,Active,,,0.001,IC50,Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
805,143741,6,2,,123097261,31703,Active,,,0.23,IC50,Compound was evaluated for inhibitory activity against N 417 human lung cancer cell line,Confirmatory,1479585.0,
806,144491,3,7,,123097261,31703,Unspecified,,,,,Activity of NADH dehydrogenase was determined,Other,8421288.0,
807,144936,6,2,,123097261,31703,Active,,,0.008,IC50,Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
808,144956,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against NCI-H23 lung cancer cell line,Other,11354370.0,
809,144957,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity was evaluated against human lung carcinoma (NCI-H23) as body weight change in human tumor xenograft mice upon intraperitoneal administration at doses of 1,2,3mg/kg",Other,9873387.0,
810,145064,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity was evaluated against human lung carcinoma (NCI-H23) as tumor growth inhibition in human tumor xenograft mice upon intraperitoneal administration at doses of 1,2,3mg/kg",Other,9873387.0,
811,145200,6,2,,123097261,31703,Active,,,0.03,IC50,Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
812,145206,6,2,,123097261,31703,Active,,,0.13,IC50,Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
813,145432,4,4,,123097261,31703,Active,,,0.035,IC50,Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay,Confirmatory,7699715.0,
814,145436,4,4,,123097261,31703,Active,,,0.035,IC50,Antitumor activity against human ovarian OVCAR-3 cell lines.,Confirmatory,8960558.0,
815,145445,4,4,,123097261,31703,Active,,,0.035,IC50,Inhibitory activity against OVCAR-3 cell line,Confirmatory,8648600.0,
816,146558,7,2,,123097261,31703,Unspecified,,,,,Tested for anticancer activity against human lung cancer (NSCLC),Other,11514168.0,
817,147508,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxic concentration against mouse neuroblastoma (neuro 2A) using MTT coloration,Other,15013011.0,
818,147511,6,2,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against mouse neuroblastoma (neuro 2A) using CV coloration,Other,15013011.0,
819,150515,6,2,,123097261,31703,Unspecified,,,0.9,IC50,Growth inhibitory concentration of compound was measured against DOX resistant P388 cell line (P388 /DOX),Confirmatory,10698436.0,
820,150516,6,2,,123097261,31703,Active,,,0.02,IC50,Growth inhibitory concentration of compound was measured against murine leukemia cell line (P388),Confirmatory,10698436.0,
821,150517,6,3,,123097261,31703,Active,,,0.83,IC50,In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound,Confirmatory,,
822,150540,6,2,,123097261,31703,Active,,,0.83,IC50,In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.,Confirmatory,9733489.0,
823,150596,5,3,,123097261,31703,Unspecified,,,,,In vitro inhibitory activity against P-388 tumor cells,Other,,
824,150664,4,4,,123097261,31703,Active,,,0.031,IC50,Inhibitory activity against Murine p38 leukemia,Confirmatory,10395479.0,
825,150670,4,5,,123097261,31703,Active,,,0.015,IC50,Inhibitory concentration to reduce cell number to 50% of Murine P388 leukemia cell culture,Confirmatory,9207945.0,
826,150673,4,4,,123097261,31703,Active,,,0.015,IC50,Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures,Confirmatory,9191970.0,
827,150952,6,2,,123097261,31703,Unspecified,,,,,"In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay",Other,12620075.0,
828,152262,6,3,,123097261,31703,Active,,,0.02,IC50,Compound was evaluated for the cytotoxicity against P-388 tumor cell line after 3 days of incubation,Confirmatory,,
829,152272,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.,Other,9873721.0,
830,152274,5,3,,123097261,31703,Unspecified,,,,,Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells,Other,,
831,152516,3,6,,123097261,31703,Unspecified,,,,,"Activity against P388 leukemia cells in mice, by intraperitoneal dosing and net log tumor cell kill was reported",Other,3806589.0,
832,152684,3,4,,123097261,31703,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity utilizing the murine P388 leukemia system in B6D2F1 male mice.,Other,3806575.0,
833,152708,4,4,,123097261,31703,Active,,,0.015,IC50,Inhibitory activity against murine P388 leukemia (P388) cells.,Confirmatory,11806725.0,
834,152725,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity in P388/ADR (adriamycin resistant), in male BDF1 mice measured as % increase in life span(%ILS) at dose 2.5-4.5 mg/kg/ inj, ip",Other,3351854.0,
835,152726,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity in P388/S(AMD sensitive) in male BDF1 mice measured as % increase in life span(%ILS) at dose 2.5-4.5 mg/kg/ inj, ip",Other,3351854.0,
836,152917,3,4,,123097261,31703,Unspecified,,,,,In vivo antitumor activity was measured on systemic P388 murine leukemia cells. Optimal dose at 7.5 mg/kg/day,Other,9876113.0,
837,152925,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against P388 tumor cell lines.,Other,9871531.0,
838,152988,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against P388/ADR + reserpine cells,Other,8632413.0,
839,153066,3,5,,123097261,31703,Unspecified,,,,,Compound was tested for % increase in life span of P388 tumor,Other,,
840,153068,2,5,,123097261,31703,Unspecified,,,,,Compound was tested for % increase in life span of adriamycin resistant P388 tumor,Other,,
841,153182,3,5,,123097261,31703,Unspecified,,,,,Antitumor activity in mice against leukemia P388 cells at 1.3 uM/kg was expressed as ratio of average survival time,Other,7310810.0,
842,153319,3,5,,123097261,31703,Unspecified,,,,,Antitumor efficacy at optimal dose of compound was measured against P388 leukemia in mice,Other,7086816.0,
843,153338,7,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against murine P388 leukemia cells,Other,15056007.0,
844,153339,4,4,,123097261,31703,Active,,,0.015,IC50,Growth inhibitory activity against murine P388 leukemia cells,Confirmatory,12620081.0,
845,153376,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of P388-D1 (murine leukemia) cell line.,Other,2002477.0,
846,153389,4,4,,123097261,31703,Active,,,0.36,IC50,Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells,Confirmatory,8544183.0,
847,153424,3,4,,123097261,31703,Unspecified,,,,,Compounds was tested against P388 leukemia at % increase in life span (ILS) in mice at 4.5 mg/kg dosage.,Other,8648600.0,
848,153464,3,4,,123097261,31703,Unspecified,,,,,"Compound was evaluated for the antitumor efficacy at optimal dose 7.5 mg/kg against leukemia P388 in mice on day 1,",Other,3761325.0,
849,153466,3,4,,123097261,31703,Unspecified,,,,,"Compound was evaluated for the antitumor efficacy at optimal dose 8.0 mg/kg against leukemia P388 in mice on day q4d 5, 9, 13.,",Other,3761325.0,
850,153528,6,2,,123097261,31703,Active,,,8.2,IC50,Compound was evaluated for the growth inhibition of P388/ADR cells.,Confirmatory,3761325.0,
851,153529,6,2,,123097261,31703,Active,,,8.2,IC50,Compound was evaluated for the growth inhibition of P388/ADR cells.,Confirmatory,3761328.0,
852,153667,7,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity of compound against Murine P388 Leukemia,Other,12459024.0,
853,153986,4,4,,123097261,31703,Active,,,0.019,IC50,Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells,Confirmatory,8544183.0,
854,154065,3,6,,123097261,31703,Unspecified,,,,,"Inhibition of P388 leukemia cells in mice, measured as percent treated to the control values with the number of 30 day survivors",Other,3806589.0,
855,154127,6,2,,123097261,31703,Active,,,0.068,IC50,"Compound was evaluated for the growth inhibition of P388/S, cells.",Confirmatory,3761328.0,
856,154136,6,2,,123097261,31703,Active,,,0.068,IC50,Compound was evaluated for the growth inhibition of P388/s cells.,Confirmatory,3761325.0,
857,154146,3,4,,123097261,31703,Active,,,,,Cytotoxic activity was evaluated against P388D1/ADR cells,Other,8632413.0,
858,154149,3,4,,123097261,31703,Active,,,,,Cytotoxic Activity was evaluated against P388D1 cells,Other,8632413.0,
859,154311,5,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human PAC-2 (pancreatici carcinoma) cell line,Other,,
860,154372,3,5,,123097261,31703,Unspecified,,,,,Optimal dose per injection in mg/kg required to inhibit growth of P388 leukemia cells in mice,Other,3806589.0,
861,154413,3,4,,123097261,31703,Unspecified,,,,,In vitro antitumor activity of compound against P388 leukemia cells at a dose of 3.13 mg/kg,Other,12459024.0,
862,154415,3,4,,123097261,31703,Unspecified,,,,,In vitro antitumor activity of compound against P388 leukemia cells at a dose of 6.25 mg/kg,Other,12459024.0,
863,154430,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human pancreatic carcinoma PaCa-2 cell line,Other,8627602.0,
864,154433,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on pancreatic carcinoma (PACA-2) cell line,Other,8632402.0,
865,154434,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against PACA-2 (human pancreatic carcinoma) cell line,Other,11551759.0,
866,154435,5,2,,123097261,31703,Active,,,0.0063,ED50,In vitro cytotoxicity against Bladder PACA-2 human tumors following a 6 day exposure,Confirmatory,10498214.0,
867,154438,4,4,,123097261,31703,Active,,,0.0087,IC50,Cytotoxicity against Lung cancer cell lines PACA2 was determined,Confirmatory,12392727.0,
868,154473,6,2,,123097261,31703,Unspecified,,,150.0,IC50,Inhibitory activity against PAM cell line,Confirmatory,9554873.0,
869,154474,6,2,,123097261,31703,Unspecified,,,156.0,IC50,Inhibitory activity against PAM-RAS cell line,Confirmatory,9554873.0,
870,154602,6,2,,123097261,31703,Active,,,3.5,GI50,In vitro antiproliferative activity against human PANC-1 pancreas cell line,Confirmatory,14971893.0,
871,154729,6,2,,123097261,31703,Active,,,1.22,IC50,Ability to inhibit growth of P388 leukemic cell line was determined in an in vitro MTT assay.,Confirmatory,1995877.0,
872,154807,6,2,,123097261,31703,Active,,,0.09,CC50,Cytotoxicity for Peripheral blood Lymphocytes,Confirmatory,12431048.0,
873,154808,6,2,,123097261,31703,Active,,,0.04,CC50,Cytotoxicity for Peripheral blood Lymphocytes,Confirmatory,12431048.0,
874,155079,6,8,,123097261,31703,Inactive,119253.0,396766.0,,,Inhibition of Pancreatic elastase at 10e-5 M; NI means no inhibition,Other,1322986.0,
875,155079,6,8,,123097261,31703,Inactive,119258.0,397197.0,,,Inhibition of Pancreatic elastase at 10e-5 M; NI means no inhibition,Other,1322986.0,
876,155913,6,2,,123097261,31703,Active,,,39.4,IC50,Cytotoxicity against normal PMBC cells in clonogenic assay,Confirmatory,10476861.0,
877,155994,6,2,,123097261,31703,Active,,,1.9,IC50,Growth inhibitory concentration of compound was measured against human lung carcinoma cell line (PC-14),Confirmatory,10698436.0,
878,156007,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines PC-3 of lung,Other,11311062.0,
879,156017,5,4,,123097261,31703,Active,,,0.39,IC50,Antiproliferative activity measured against PC-3 human prostate adenocarcinoma,Confirmatory,9876111.0,
880,156018,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against PC-3 prostate cancer cell line,Other,11354370.0,
881,156019,4,4,,123097261,31703,Active,,,0.0498,IC50,Cytotoxicity against prostate cancer cell lines PC-3 was determined,Confirmatory,12392727.0,
882,156022,4,1,,123097261,31703,Unspecified,,,,,Cytotoxic activity was tested against human PC-3 (prostate adenocarcinoma) cell line,Other,,
883,156023,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity concentration against human prostrate adrenocarcinoma PC-3 cell line,Other,8627602.0,
884,156026,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity on prostate adenocarcinoma (PC-3) cell line,Other,8632402.0,
885,156028,5,1,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against PC-3 (human prostate adenocarcinoma) cell line,Other,11551759.0,
886,156029,5,1,,123097261,31703,Active,,,0.057,ED50,In vitro cytotoxicity against Prostrate PC-3 human tumors following a 6 day exposure,Confirmatory,10498214.0,
887,156031,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against PC-3 cell line was determined,Other,11551772.0,
888,156174,6,2,,123097261,31703,Active,,,32.0,IC50,Inhibitory activity against PC-3 prostate cell line using sulforhodamine B (SRB) protein assay,Confirmatory,12039588.0,
889,156325,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human prostate adenocarcinoma PC-3 cell lines,Other,,
890,156633,6,2,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity of compound against human lung adenocarcinoma cell line (PC14),Confirmatory,9822542.0,
891,156652,4,4,,123097261,31703,Active,,,0.1028,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3,Confirmatory,10479282.0,
892,157361,6,2,,123097261,31703,Active,,,0.065,IC50,Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of Panc 02 cells,Confirmatory,9526570.0,
893,157397,6,2,,123097261,31703,Active,,,0.04,CC50,In vitro Antiproliferative activity against peripheral blood lymphocytes (PBL) after stimulating PBL with PHA and then resuspending in IL-2-containing medium in the presence of compound.,Confirmatory,10411476.0,
894,157398,6,2,,123097261,31703,Active,,,0.09,CC50,"In vitro Antiproliferative activity against peripheral blood lymphocytes (PBL) by treating PBL with compound for 3 days, then stimulating with PHA and then resuspending in compound free medium.",Confirmatory,10411476.0,
895,159557,3,3,,123097261,31703,Unspecified,,,,,In vitro concentration required for inhibition of maximum tubulin assembly rate after 20 min at 37 degrees C; Not determined,Other,12852768.0,
896,165907,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human Burkitt lymphoma Raji cells.,Confirmatory,12431049.0,
897,166201,6,3,,123097261,31703,Active,,,0.1,IC50,Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.,Confirmatory,,
898,166398,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human Burkitt lym phoma Raji cells,Confirmatory,12431048.0,
899,166680,6,2,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity assessed in the RENCA murine renal cell carcinoma using the BrdU,Confirmatory,12459020.0,
900,166681,6,2,,123097261,31703,Active,,,0.01,IC50,Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay,Confirmatory,11454467.0,
901,167223,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against RPTEC cell line was determined,Other,11551772.0,
902,170463,3,3,,123097261,31703,Unspecified,,,,,Cardiotoxicity by a neonatal rat heart myocyte assay,Other,8648600.0,
903,171537,3,3,,123097261,31703,Unspecified,,,,,Cardiotoxicity measured by the ATP/protein ratio compared with untreated controls using neonatal rat heart myocyte assay.,Other,8960558.0,
904,178762,6,2,,123097261,31703,Unspecified,,,,,Effective dose was measured in rats,Other,10698441.0,
905,189629,3,3,,123097261,31703,Unspecified,,,,,The capillary permeability of radioligand was measured in Rat brain,Other,7392035.0,
906,196905,3,3,,123097261,31703,Active,,,,,Cardiotoxicity was measured by using Neonatal rat heart myocyte assay,Other,7699715.0,
907,198974,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect administered at dose of 1.5 mg/kg/day given in the schedule of 1,2,3,4,7 day against Sarcoma S-180 tumor transplanted in male JRC mice at eleventh day was determined",Other,15013011.0,
908,198975,3,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect administered at dose of 1.5 mg/kg/day given in the schedule of 1,2,3,4,7 day against Sarcoma S-180 tumor transplanted in male JRC mice at fourteenth day was determined",Other,15013011.0,
909,198979,6,2,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 2.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against Sarcoma S-180 tumor transplanted in male JRC mice at fourteenth day was determined",Other,15013011.0,
910,199109,6,2,,123097261,31703,Inconclusive,,,,,"Growth inhibitory effect when administered at dose of 2.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against Sarcoma S-180 tumor transplanted in male JRC mice at fourteenth day was determined; ND= No data",Other,15013011.0,
911,199110,4,4,,123097261,31703,Unspecified,,,,,"Growth inhibitory effect when administered at dose of 5.0 mg/kg/day given in the schedule of 1,2,3,4,7 day against Sarcoma S-180 tumor transplanted in male JRC mice at fourteenth day was determined",Other,15013011.0,
912,200269,6,2,,123097261,31703,Active,,,0.02,IC50,Compound was tested for its antitumor activity against SKOV3 human ovarian cancer cell line,Confirmatory,9873394.0,
913,200271,4,4,,123097261,31703,Active,,,0.036000000000000004,IC50,Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line ),Confirmatory,8576914.0,
914,200278,6,2,,123097261,31703,Active,,,0.0251,IC50,Inhibitory concentration the viability of SKOV 3 cell population by 50%.,Confirmatory,9003520.0,
915,200289,4,4,,123097261,31703,Active,,,5.6,IC50,Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line ),Confirmatory,8576914.0,
916,200293,4,4,,123097261,31703,Active,,,5.65,IC50,Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay,Confirmatory,7853331.0,
917,200294,6,2,,123097261,31703,Active,,,6.54,IC50,Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.,Confirmatory,9003520.0,
918,200301,6,3,,123097261,31703,Unspecified,,,,,Compound was evaluated for the growth inhibition of SKm12 melanoma cell line.,Other,9873640.0,
919,200420,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines SBC-3 of lung,Other,11311062.0,
920,200421,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines SBC-3 /ADR of lung (adriamycin resistant),Other,11311062.0,
921,200620,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human small-cell lung cancer (SCLC),Confirmatory,8258835.0,
922,200624,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP),Confirmatory,8258835.0,
923,200813,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against SNB19 CNS cancer cell line,Other,11354370.0,
924,200818,6,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human tumor SNU 1 (stomach) cell line,Other,,
925,200819,6,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human tumor SNU 354 (liver) cell line,Other,,
926,200820,6,4,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against human tumor SNU C-4(colon) cell line,Other,,
927,200822,6,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against SNU-1(stomach cancer cell) by using SRB assay after 72 hr of drug exposure,Other,,
928,200824,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.,Other,9873721.0,
929,200828,6,3,,123097261,31703,Unspecified,,,,,In vitro cytotoxic activity against SNU-354(liver cancer cell) by using SRB assay after 72 hr of drug exposure,Other,,
930,200831,6,2,,123097261,31703,Active,,,0.69,IC50,In vitro cytotoxicity against human SNU-638 (stomach cancer) cell line.,Confirmatory,15177438.0,
931,200832,6,2,,123097261,31703,Unspecified,,,,,In vitro cytotoxicity against SNU16 tumor cell lines.,Other,9871531.0,
932,201314,6,2,,123097261,31703,Active,,,0.035,IC50,In vitro cytotoxic activity against SF-295 (CNS carcinoma) cell lines by using SRB assay,Confirmatory,9873661.0,
933,201626,6,2,,123097261,31703,Active,,,1.1,GI50,In vitro antiproliferative activity against human SK-BR-3 breast cell line,Confirmatory,14971893.0,
934,201793,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against SK-MEL-2 cell line was determined,Other,11551772.0,
935,201797,6,2,,123097261,31703,Active,,,4.78,IC50,"Cytotoxic activity against SK-MEL-2 human melanoma cell line, using sulforhodamine B (SRB) assay.",Confirmatory,14643344.0,
936,202035,6,3,,123097261,31703,Active,,,0.06,IC50,In vitro antitumor activity against SW480 (colon) human tumor cell lines.,Confirmatory,,
937,202226,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against SW620 colon cancer cell line,Other,11354370.0,
938,202354,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity was evaluated against human colon carcinoma (SW620) as body weight change in human tumor xenograft mice upon intraperitoneal administration at doses of 1,2,3mg/kg",Other,9873387.0,
939,202362,6,2,,123097261,31703,Active,,,0.75,IC50,Antiproliferative activity tested as 50% inhibition of DNA synthesis in human SW620 colon carcinoma cell line,Confirmatory,11720862.0,
940,202370,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity was evaluated against human colon carcinoma (SW620) as tumor growth inhibition in human tumor xenograft mice upon intraperitoneal administration at doses of 1,2,3mg/kg",Other,9873387.0,
941,202486,6,2,,123097261,31703,Unspecified,,,,,Antitumor cytotoxic activity against SK-OV-3 cell line was determined,Other,11551772.0,
942,202491,6,2,,123097261,31703,Active,,,0.043,IC50,"Compound was tested for cytotoxicity against ovarian adenocarcinoma, multidrug resistant",Confirmatory,8182705.0,
943,202502,6,2,,123097261,31703,Active,,,4.15,IC50,Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay,Confirmatory,9873387.0,
944,202503,4,4,,123097261,31703,Active,,,0.036000000000000004,IC50,Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay,Confirmatory,7853331.0,
945,202506,6,2,,123097261,31703,Active,,,0.02,IC50,In vitro cytotoxic activity against SK-OV-3 (ovarian carcinoma) cell lines by using SRB assay,Confirmatory,9873661.0,
946,202507,6,2,,123097261,31703,Active,,,0.02,IC50,In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
947,202659,6,2,,123097261,31703,Unspecified,,,10.0,IC50,Compound was tested for cytotoxicity against colon adenocarcinoma,Confirmatory,8182705.0,
948,202679,6,2,,123097261,31703,Active,,,0.02,IC50,"Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)",Confirmatory,10780913.0,
949,202771,3,5,,123097261,31703,Unspecified,,,,,Percent ratio of treated to control mice after intraperitoneal injection of 1x10E7 S180 cells for antitumor activity was determined,Other,11055343.0,
950,202826,6,2,,123097261,31703,Active,,,0.06,IC50,Antitumor activity against human skin melanoma SKMEK-28 cells,Confirmatory,12431048.0,
951,202827,8,1,,123097261,31703,Active,,,0.032,ED50,Cytotoxic concentration required to inhibit 50% cell growth in SKMEL-5 melanoma cell lines,Confirmatory,1875350.0,
952,202833,6,2,,123097261,31703,Active,,,0.03,IC50,Antitumor activity against human lung squamous carcinoma SK-MES-1 cells,Confirmatory,12431048.0,
953,202839,6,2,,123097261,31703,Active,,,0.078,IC50,The compound was tested for cytotoxic activity against SKOV-3 cell line(human ovarian carcinoma ),Confirmatory,11123989.0,
954,202844,6,2,,123097261,31703,Active,,,0.078,IC50,Concentration required to inhibit SKOV-3-cell growth by 50%,Confirmatory,9703471.0,
955,202959,6,2,,123097261,31703,Active,,,1.17,IC50,"Cytotoxic activity against SKOV-3 human ovarian tumor cell line, using sulforhodamine B (SRB) assay.",Confirmatory,14643344.0,
956,202974,6,2,,123097261,31703,Active,,,0.078,IC50,In vitro cytotoxicity was tested against human Ovarian carcinoma SKOV-3 cell line,Confirmatory,10411474.0,
957,205641,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus ATCC 25923,Other,3018245.0,
958,205642,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus ATCC 9144,Other,3018245.0,
959,205643,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus WSU-196E,Other,3018245.0,
960,206365,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Staph. epidermidis ATCC 12228,Other,3018245.0,
961,208526,6,2,,123097261,31703,Active,,,0.64,IC50,Growth inhibitory concentration of compound was measured against human bladder carcinoma cell line (T24),Confirmatory,10698436.0,
962,208540,4,4,,123097261,31703,Unspecified,,,10.0,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) resistant variant cell proliferation,Confirmatory,11606141.0,
963,208541,4,4,,123097261,31703,Active,,,0.02,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of T24 (bladder) sensitive variant cell proliferation,Confirmatory,11606141.0,
964,208681,4,4,,123097261,31703,Active,,,0.07200000000000001,IC50,Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay,Confirmatory,7853331.0,
965,208685,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,"Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)",Confirmatory,10780913.0,
966,209299,6,2,,123097261,31703,Unspecified,,,,,Compound was tested for antibacterial activity against Strep. pyogenes ATCC 19615,Other,3018245.0,
967,210114,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay,Confirmatory,14980672.0,
968,210138,8,1,,123097261,31703,Active,,,0.01,ID50,Compound concentration required to reduce by 50% the number of T-C8166 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
969,210141,8,1,,123097261,31703,Active,,,0.01,ID50,Compound concentration required to reduce by 50% the number of T-H9 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
970,210264,8,1,,123097261,31703,Active,,,0.01,ID50,Compound concentration required to reduce by 50% the number of T-MT4 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
971,211288,9,5,,123097261,31703,Inconclusive,13959709.0,7153.0,,EC50,Inhibition of topoisomerase II purified from HeLa cells,Confirmatory,,
972,211288,9,5,,123097261,31703,Inconclusive,20141946.0,7155.0,,EC50,Inhibition of topoisomerase II purified from HeLa cells,Confirmatory,,
973,211484,5,3,,123097261,31703,Inconclusive,,,,,Lethality of the compound in Brine shrimp lethality test; not tested,Other,,
974,212420,4,8,,123097261,31703,Active,118828.0,,,,Inhibition of Taq polymerase at 10 uM (Significant inhibition),Other,9703471.0,
975,212547,5,7,,123097261,31703,Active,118828.0,,,,Inhibition of Taq polymerase at 50 uM (Total inhibition),Other,9703471.0,
976,212871,6,3,,123097261,31703,Unspecified,,,,,Compound was tested for lethal concentration in Brine shrimp lethality test (BST),Other,,
977,212910,3,8,,123097261,31703,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from DNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3),Other,11591511.0,
978,212911,3,8,,123097261,31703,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from RNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3),Other,11591511.0,
979,212912,3,8,,123097261,31703,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from underivatized resin,Other,11591511.0,
980,213356,6,4,,123097261,31703,Inactive,,,,,Inhibitory activity against trypsin at 10e-5 M; NI = no inhibition,Other,1322986.0,
981,214106,8,1,,123097261,31703,Unspecified,,,,,Antimycotic activity against Trichophyton mentagrophytes was evaluated. MIC was defined as compound concentration at which no macroscopic signs of fungal growth were detected.,Other,10411476.0,
982,214236,6,2,,123097261,31703,Active,,,0.09,IC50,Inhibitory activity against U251 CNS cell line using sulforhodamine B (SRB) protein assay,Confirmatory,12039588.0,
983,214259,4,4,,123097261,31703,Active,,,0.01,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) sensitive variant cell proliferation,Confirmatory,11606141.0,
984,214394,4,3,,123097261,31703,Active,,,0.13,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of U373 (glioblastoma) resistant variant cell proliferation,Confirmatory,11606141.0,
985,214396,4,4,,123097261,31703,Active,,,0.14,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) resistant variant cell proliferation,Confirmatory,11606141.0,
986,214397,4,4,,123097261,31703,Active,,,0.06,IC50,In vitro cytotoxicity expressed as concentration that inhibits 50% of U87 (glioblastoma) sensitive variant cell proliferation,Confirmatory,11606141.0,
987,214411,5,2,,123097261,31703,Active,,,0.1,IC50,Minimal drug concentration necessary to inhibit incorporation of [3H]thymidine in U937 Leukemia cells,Confirmatory,10780911.0,
988,214778,4,4,,123097261,31703,Active,,,0.11199999999999999,IC50,Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay,Confirmatory,7699715.0,
989,214779,4,4,,123097261,31703,Active,,,0.11199999999999999,IC50,Antitumor activity against human melanoma UACC375 cell line.,Confirmatory,8960558.0,
990,214782,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration required against UACC62 melanoma cell line,Other,11354370.0,
991,215072,4,4,,123097261,31703,Active,,,0.07400000000000001,IC50,An average for IC50 values in the two solid tumor cell lines.,Confirmatory,8648600.0,
992,215105,4,4,,123097261,31703,Active,,,0.0092,IC50,Cytotoxicity against bladder cancer cell lines UMUC3 was determined,Confirmatory,12392727.0,
993,216116,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against WIDR tumor cell line,Other,10602713.0,
994,216127,6,3,,123097261,31703,Active,,,0.2,IC50,Compound was tested for its effect on the proliferation of WIL-2-NS cell line.,Confirmatory,,
995,216260,7,1,,123097261,31703,Unspecified,,,,,"Compound was evaluated for amount of net intracellular accumulation per 1 E6 hydroxyrubicin-resistant (WP159/R) cells, after exposure to 1.0 uM for 2 hrs",Other,,
996,216261,7,1,,123097261,31703,Unspecified,,,,,"Compound was evaluated for amount of net intracellular accumulation per 1 E6 hydroxyrubicin-resistant (WP159/R) cells, after exposure to 2.0 uM for 2 hrs",Other,,
997,216262,4,5,,123097261,31703,Active,,,0.3684,IC50,Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells,Confirmatory,,
998,216434,4,4,,123097261,31703,Active,,,0.13,IC50,Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).,Confirmatory,10956214.0,
999,216435,4,4,,123097261,31703,Active,,,0.053,IC50,Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).,Confirmatory,10956214.0,
1000,216452,6,2,,123097261,31703,Active,,,0.62,IC50,Inhibition of WiDr human cancer cell proliferation with 10e-2 uM estradiol,Confirmatory,8784443.0,
1001,216575,4,4,,123097261,31703,Active,,,0.053,IC50,Tested against WiDr colon (sensitive) in the sulforhodamine B assay.,Confirmatory,8648600.0,
1002,216582,4,4,,123097261,31703,Active,,,0.13,IC50,Compound was tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.,Confirmatory,8648600.0,
1003,216595,4,4,,123097261,31703,Active,,,0.053,IC50,Activity against human colon carcinoma sensitive WiDr cell line.,Confirmatory,8960558.0,
1004,216596,4,4,,123097261,31703,Active,,,0.13,IC50,Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.,Confirmatory,8960558.0,
1005,217174,4,4,,123097261,31703,Active,,,5.0,IC50,In vitro cytotoxicity expressed as conc. that inhibits 50% of VERO(monkey kidney) cell proliferation,Confirmatory,11606141.0,
1006,219231,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human splenic B-lymphoblastoid Wil-NS cells.,Confirmatory,12431049.0,
1007,219232,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity was evaluated against lymphoma cell line Wil2-NS (human splenic B lymphoblastoid cells).,Confirmatory,10411476.0,
1008,219236,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human splenic B-lympho blastoid Wil2-NS cells,Confirmatory,12431048.0,
1009,220262,6,3,,123097261,31703,Active,,,0.02,IC50,Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats,Confirmatory,1322986.0,
1010,220399,8,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human cancer cell lines ZR-75-1 of breast.,Other,11311062.0,
1011,220406,6,2,,123097261,31703,Active,,,0.009000000000000001,IC50,"Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)",Confirmatory,10780913.0,
1012,221330,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,"Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
1013,221342,6,2,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity for lymphoblastoid cell lines,Confirmatory,12431048.0,
1014,221796,8,1,,123097261,31703,Active,,,2.9,ED50,Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line.,Confirmatory,1613753.0,
1015,221797,8,1,,123097261,31703,Active,,,0.01,ID50,Compound concentration required to reduce by 50% the number of human B (Raji)cells after three cell cycles,Confirmatory,1548681.0,
1016,221812,8,1,,123097261,31703,Active,,,5.5,ED50,Cytotoxicity against human HT-29 colon cell line.,Confirmatory,1613753.0,
1017,221827,8,1,,123097261,31703,Active,,,1.3,ED50,Compound was evaluated for cytotoxicity against human MLM melanoma cell line.,Confirmatory,1613753.0,
1018,221962,8,1,,123097261,31703,Active,,,3.2,ED50,Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line.,Confirmatory,1613753.0,
1019,222140,8,2,,123097261,31703,Unspecified,,,,,Inhibition of cellular growth was evaluated in vitro against human colon carcinoma LOVO.,Other,1875336.0,
1020,222141,8,2,,123097261,31703,Unspecified,,,,,Inhibition of cellular growth was evaluated in vitro against human colon carcinoma subline resistant to DOXO (LOVO/DOXO).,Other,1875336.0,
1021,222934,3,3,,123097261,31703,Unspecified,,,,,Activity against internally growing human tumor A-549 tested in subrenal capsule assay,Other,8496904.0,
1022,222935,3,3,,123097261,31703,Unspecified,,,,,Activity against internally growing human tumor HT-29 tested in subrenal capsule assay,Other,8496904.0,
1023,222936,3,3,,123097261,31703,Unspecified,,,,,Activity against internally growing human tumor LXF tested in subrenal capsule assay,Other,8496904.0,
1024,222937,3,3,,123097261,31703,Unspecified,,,,,Activity against internally growing human tumor LXF / ADM tested in subrenal capsule assay,Other,8496904.0,
1025,223628,4,4,,123097261,31703,Active,,,0.035,IC50,"Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
1026,223791,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against P-388 leukemia cell line in BDF1 mice after injecting 8.0 mg/kg ip dose,Other,2391681.0,
1027,223826,6,2,,123097261,31703,Unspecified,,,,,Compound was evaluated for the growth inhibition of p388/0 leukemia cell line.,Other,9873640.0,
1028,226658,4,4,,123097261,31703,Active,,,0.061,IC50,An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.,Confirmatory,8648600.0,
1029,226888,3,3,,123097261,31703,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia A (JLA) and Human Jurkat leukemia C (JLC),Other,9207945.0,
1030,226889,3,3,,123097261,31703,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia D (JLD) and Human Jurkat leukemia C (JLC),Other,9207945.0,
1031,227259,3,3,,123097261,31703,Unspecified,,,,,Degree of improvement in the selective cytotoxicity of the prodrug (drug 10) to that of the parent drug (drug 1) at 24 hr of treatment; Value is measured as 6.8 times,Other,6302253.0,
1032,227260,3,3,,123097261,31703,Unspecified,,,,,Degree of improvement in the selective cytotoxicity of the prodrug (drug 10) to that of the parent drug (drug 1) at 5 hr of treatment; Value is measured as 5.8 times,Other,6302253.0,
1033,227414,3,3,,123097261,31703,Unspecified,,,,,Relative inhibition (IC50) in presence and absence of reserpine,Other,15012986.0,
1034,227417,3,3,,123097261,31703,Unspecified,,,,,Fold reversal effect determined as ratio of IC50 for compound to IC50 for compound + modulating agent,Other,15012986.0,
1035,227574,3,3,,123097261,31703,Unspecified,,,,,Relative resistance is the ratio of IC50 values of drug with or without the JTV-519 in absence of the reversing agent,Other,15012986.0,
1036,228673,3,3,,123097261,31703,Unspecified,,,,,Evaluated for the degree of cross resistance as the ratio of degree of resistance of doxorubicin to degree of resistance of the compound,Other,8496904.0,
1037,228674,3,3,,123097261,31703,Unspecified,,,,,Evaluated for the degree of resistance as the ratio of IC50 L1210 / ADM to IC50 of L1210,Other,8496904.0,
1038,228736,3,3,,123097261,31703,Unspecified,,,,,"MDR ratio as the ratio of IC50 value against SKVLB to that of SKOV3,",Other,7853331.0,
1039,229270,3,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 in the cell -amsacrine-resistant Jurkat (JL A) / JL C,Other,11806725.0,
1040,229271,3,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 in the cell -doxorubicin-resistant Jurkat (JL D) / JL C,Other,11806725.0,
1041,229289,3,4,,123097261,31703,Unspecified,,,,,"Ratio of IC50 of Jurkat leukemia amsacrine (JLA) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)",Other,9191970.0,
1042,229325,3,4,,123097261,31703,Unspecified,,,,,"Ratio of IC50 of mutant Jurkat leukemia (JLD) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)",Other,9191970.0,
1043,229683,3,3,,123097261,31703,Unspecified,,,,,Selectivity ratio was determined for P-170 glycoprotein mediated multidrug resistant variant SKVLB to the ovarian cancer cell line SK-OV3.,Other,9873394.0,
1044,230368,3,3,,123097261,31703,Unspecified,,,,,Resistance factor was determined using the ratio of resistance of cisplatin resistant cell line and doxorubicin resistant cell line,Other,11170623.0,
1045,230369,3,5,,123097261,31703,Unspecified,,,,,Resistant Factor against MDR cell lines. Value expressed as ratio of IC50 on the resistant cell and on the corresponding sensitive cells.,Other,,
1046,230375,3,4,,123097261,31703,Unspecified,,,,,IC50 ratio of LoVo/Dx on LoVo expressed as resistance index,Other,10411474.0,
1047,230376,3,5,,123097261,31703,Unspecified,,,,,RI is the ratio of cytotoxicity against MCF-7/VP-16 cell line to that of MCF-7 cell line,Other,9022792.0,
1048,230379,3,5,,123097261,31703,Unspecified,,,,,Resistance index measured as the ratio of IC50 of LoVo/Dx cell line to that of LoVo cell line.,Other,9876113.0,
1049,230380,3,5,,123097261,31703,Unspecified,,,,,Resistance index as the ratio of IC50 against L1210/L-PAM to that of L1210 cell lines,Other,7996544.0,
1050,230383,3,4,,123097261,31703,Unspecified,,,,,Resistance index as the ratio of IC50 against LoVo/Dx to that of LoVo,Other,7996544.0,
1051,230386,3,5,,123097261,31703,Unspecified,,,,,Resistance index as the ratio of IC50 value against LoVo/Dx to that of LoVo cell lines.,Other,7853345.0,
1052,230412,3,3,,123097261,31703,Unspecified,,,,,It is the ratio of IC50 for LOVO tumor cell line to that of LOVO/DOXO cell line.,Other,1875336.0,
1053,230569,3,4,,123097261,31703,Unspecified,,,,,The compound was tested for resistance index is IC50 ratio of A2780 and A2780cisR,Other,10411474.0,
1054,230570,3,4,,123097261,31703,Unspecified,,,,,The compound was tested for resistance index is IC50 ratio of CH1 and CH1cisR,Other,10411474.0,
1055,230835,3,3,,123097261,31703,Unspecified,,,,,MDR ratio is defined as the quotient of SKVLB IC50/SKOV3 IC50,Other,8576914.0,
1056,231124,3,4,,123097261,31703,Inconclusive,,,,,Ratio of the extracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ and carboxypeptidase stCPG2 of the prodrug.; Not available,Other,10395490.0,
1057,231133,3,4,,123097261,31703,Inconclusive,,,,,Ratio of the intracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase) and carboxypeptidase G2(CPG2) of the prodrug; Not available,Other,10395490.0,
1058,231136,3,4,,123097261,31703,Inconclusive,,,,,Ratio of the intracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase). between prodrug and drug; Not available,Other,10395490.0,
1059,231332,3,4,,123097261,31703,Unspecified,,,,,Ratio of toxicity in areobic conditions to hypoxic condition of EMT6 cells,Other,7452674.0,
1060,231477,3,4,,123097261,31703,Unspecified,,,,,Ratio between IC50 value of DOX/R and WP159/R was determined,Other,,
1061,231949,3,4,,123097261,31703,Unspecified,,,,,Ratio of cytotoxicity of DOX1V/S cells,Other,12570378.0,
1062,232012,3,4,,123097261,31703,Unspecified,,,,,Relative resistance value of Adriamycin resistant L-1210/L-1210 parental cell line,Other,,
1063,232016,3,3,,123097261,31703,Unspecified,,,,,Resistance index is the ratio of IC50 of resistant cell line/IC50 of sensitive cell line,Other,8145234.0,
1064,232017,3,3,,123097261,31703,Unspecified,,,,,Resistance index measured as ratio of IC50 value of P388/ ADR to that of P388/ S,Other,3761325.0,
1065,232022,3,3,,123097261,31703,Unspecified,,,,,Resistance index was measured as ratio of IC50 of P388/S to that of P388/ ADR,Other,3761328.0,
1066,232174,3,4,,123097261,31703,Unspecified,,,,,Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLA- resistant to amsacrine) to that of Jurkat leukemia cell line,Other,12620081.0,
1067,232175,3,4,,123097261,31703,Unspecified,,,,,Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLD- resistant to doxorubicin) to that of Jurkat leukemia cell line,Other,12620081.0,
1068,232808,3,4,,123097261,31703,Unspecified,,,,,The quotient of the IC50 in the myocytes divided by the mean IC50 in the three cell lines,Other,8960558.0,
1069,232811,3,4,,123097261,31703,Unspecified,,,,,Toxicity ratio determined by the quotient of IC50 values in the myocytes divided by the average value in the three tumor lines.,Other,8648600.0,
1070,232812,3,5,,123097261,31703,Unspecified,,,,,Toxicity ratio of quotient of the IC50 in myocytes divided by the average IC50 for three tumor cell lines,Other,7699715.0,
1071,234396,3,4,,123097261,31703,Unspecified,,,,,Ratio of inhibitory activity against amsacrine resistant jurkat cells to inhibitory activity against wild type human jurkat cells,Other,10395479.0,
1072,234397,3,4,,123097261,31703,Unspecified,,,,,Ratio of inhibitory activity against doxorubicin resistant jurkat cells to inhibitory activity against wild type human jurkat cells,Other,10395479.0,
1073,234842,3,3,,123097261,31703,Unspecified,,,,,NADH oxidation by the compound was determined,Other,8421288.0,
1074,235118,3,3,,123097261,31703,Unspecified,,,,,Resistance index measured as the IC50 for resistant cells (KBM-3/DOX) to that of IC50 for sensitive cells(KBM-3),Other,1995877.0,
1075,235119,3,3,,123097261,31703,Unspecified,,,,,Resistance index measured as the IC50 for resistant cells (MES-SA/DOX) to that of IC50 for sensitive cells(MES-SA),Other,1995877.0,
1076,235123,3,3,,123097261,31703,Unspecified,,,,,Resistance index was determined by ratio of cytotoxicities of human colon adenocarcinoma (LoVo) cells to human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.,Other,10698460.0,
1077,235127,3,4,,123097261,31703,Unspecified,,,,,Resistance index expressed as the ratio of IC50 of resistant cell line (MCF-7/R) to IC50 of sensitive cell line (MCF-7),Other,,
1078,235899,3,3,,123097261,31703,Unspecified,,,,,Selectivity index between the ED50 value for normal cells to that of transformed chicken embryo fibroblast cells at 24 hr of treatment,Other,6302253.0,
1079,235900,3,3,,123097261,31703,Unspecified,,,,,Selectivity index between the ED50 value for normal cells to that of transformed chicken embryo fibroblast cells at 5 hr of treatment,Other,6302253.0,
1080,238010,8,1,,123097261,31703,Unspecified,,,,,Binding constant tested against CT DNA from human; (average number of binding sites = 0.62),Other,15715467.0,
1081,238025,6,1,,123097261,31703,Unspecified,,,,,Binding constant tested against DNA/C1 = 2.2; (average number of binding sites = 0.09),Other,15715467.0,
1082,238026,6,1,,123097261,31703,Unspecified,,,,,Binding constant tested against DNA/C1 = 5.6; (average number of binding sites = 0.09),Other,15715467.0,
1083,238028,6,1,,123097261,31703,Unspecified,,,,,Binding constant tested against DNA at DNA/C1 = 2.2; (average number of binding sites = 0.25),Other,15715467.0,
1084,238029,6,1,,123097261,31703,Unspecified,,,,,Binding constant tested against DNA at DNA/C1 = 5.6; (average number of binding sites = 0.27),Other,15715467.0,
1085,245895,6,2,,123097261,31703,Unspecified,,,235.0,CC50,Selectivity index of compound towards human malignant cell lines,Confirmatory,15745812.0,
1086,245954,6,3,,123097261,31703,Unspecified,,,233.0,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HGF neoplastic cell line,Confirmatory,15745812.0,
1087,245955,6,3,,123097261,31703,Unspecified,,,414.0,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HPC neoplastic cell line,Confirmatory,15745812.0,
1088,245956,6,3,,123097261,31703,Active,,,1.9,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HSG neoplastic cell line,Confirmatory,15745812.0,
1089,245957,6,3,,123097261,31703,Unspecified,,,400.0,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HPLF neoplastic cell line,Confirmatory,15745812.0,
1090,245959,6,2,,123097261,31703,Active,,,0.47,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HL-60 neoplastic cell line,Confirmatory,15745812.0,
1091,245960,6,2,,123097261,31703,Active,,,0.68,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-2 neoplastic cell line,Confirmatory,15745812.0,
1092,245961,6,2,,123097261,31703,Active,,,2.9,CC50,Concentration for 50% cytotoxicity towards malignant cells expressed in HSC-3 neoplastic cell line,Confirmatory,15745812.0,
1093,247538,6,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against SKMEL-2 cell line,Other,15922597.0,
1094,247659,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxic activity of compound against MEL-28 (Human melanoma) cell line,Confirmatory,15225700.0,
1095,247666,6,2,,123097261,31703,Active,,,0.82,IC50,Inhibitory concentration against MeVo melanoma cell line,Confirmatory,15715481.0,
1096,247762,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxic activity against A-549 (Human lung carcinoma) cell line,Confirmatory,15225700.0,
1097,247779,6,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxic activity of compound against HT-29 (Human colon carcinoma) cell line,Confirmatory,15225700.0,
1098,247784,6,2,,123097261,31703,Active,,,0.064,IC50,Inhibitory concentration against A549 lung carcinoma cell line,Confirmatory,15715481.0,
1099,247795,6,2,,123097261,31703,Active,,,0.1,IC50,Intrinsic cytotoxic activity against wild type HCT116 cell line,Confirmatory,15546712.0,
1100,247813,6,2,,123097261,31703,Active,,,0.033,IC50,Inhibitory concentration against LoVo colon carcinoma cell line,Confirmatory,15715481.0,
1101,247825,4,4,,123097261,31703,Active,,,0.0113,IC50,Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69; n=3,Confirmatory,15743178.0,
1102,247834,6,2,,123097261,31703,Active,,,23.94,IC50,Concentration required to inhibit growth of african green monkey kidney cell line,Confirmatory,15317455.0,
1103,247844,6,2,,123097261,31703,Active,,,0.021,IC50,Inhibitory concentration against KB epidermal carcinoma cell line,Confirmatory,15715481.0,
1104,247861,6,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against XF498 cell line (human CNS solid tumor),Other,15922597.0,
1105,247869,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,Inhibitory concentration against A2780 ovarian carcinoma cell line,Confirmatory,15715481.0,
1106,247871,6,2,,123097261,31703,Active,,,0.01,IC50,Inhibitory concentration against NCI-H460 lung carcinoma cell line,Confirmatory,15715481.0,
1107,247914,4,4,,123097261,31703,Active,,,1.8,IC50,Inhibitory concentration againstHuman cell lung carcinoma cell line NCI-H69/LX4; n=3,Confirmatory,15743178.0,
1108,247917,6,2,,123097261,31703,Active,,,0.059000000000000004,IC50,Inhibitory concentration against Hep-2 epidermal carcinoma cell line,Confirmatory,15715481.0,
1109,247933,6,2,,123097261,31703,Active,,,0.33,IC50,Concentration required to inhibit growth of human cervical carcinoma (HeLa) cell line,Confirmatory,15317455.0,
1110,247934,6,2,,123097261,31703,Active,,,0.03,IC50,Concentration required to inhibit growth of human epidermoid carcinoma (KB) cell line,Confirmatory,15317455.0,
1111,247980,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Inhibitory concentration against MCF-7 human breast carcinoma cell line,Confirmatory,15715481.0,
1112,247982,6,2,,123097261,31703,Active,,,0.17800000000000002,IC50,Inhibitory concentration against SW 620 human colon carcinoma cell line,Confirmatory,15715481.0,
1113,247993,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human LoVo cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
1114,248006,6,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against A549 cell line (non-small cell lung carcinoma),Other,15922597.0,
1115,248059,6,2,,123097261,31703,Active,,,0.4,IC50,Concentration required to inhibit growth of human hepatocellular carcinoma (HepG2) cell line,Confirmatory,15317455.0,
1116,248060,4,4,,123097261,31703,Active,,,0.81,IC50,Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
1117,248108,6,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against HCT15 cell line (human colon solid tumor cell line),Other,15922597.0,
1118,248142,6,2,,123097261,31703,Active,,,0.006,IC50,Inhibitory concentration against A2780 ovarian carcinoma resistant to cisplatin,Confirmatory,15715481.0,
1119,248175,6,2,,123097261,31703,Unspecified,,,,,Cytotoxic activity against SKOV-3 cell line (human solid ovarian tumor cell line),Other,15922597.0,
1120,248177,6,2,,123097261,31703,Active,,,0.29,IC50,Inhibitory concentration against A2780 ovarian carcinoma resistant to doxorubicin,Confirmatory,15715481.0,
1121,248268,6,2,,123097261,31703,Active,,,5.3,IC50,Inhibitory concentration against MCF-7 human breast carcinoma resistant to doxorubicin,Confirmatory,15715481.0,
1122,248276,4,4,,123097261,31703,Active,,,9.1,IC50,Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 1 hour,Confirmatory,15456268.0,
1123,248307,4,4,,123097261,31703,Active,,,2.3,IC50,Cytotoxicity against doxorubicin resistant LoVo cell line was determined against 144 hrs,Confirmatory,15456268.0,
1124,248395,6,2,,123097261,31703,Unspecified,,,,,Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay,Other,15715467.0,
1125,250129,3,4,,123097261,31703,Unspecified,,,,,Percent of cells with COMET measured after single cell gel electrophoresis with the compound,Other,15715467.0,
1126,252851,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 against sensitive LoVo cell line and that of doxorubicin resistance LoVo cell line was determined after 1 hr exposure,Other,15456268.0,
1127,252852,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 against sensitive LoVo cell line and that of doxorubicin resistance LoVo cell line was determined after 144 hrs exposure,Other,15456268.0,
1128,255441,3,4,,123097261,31703,Unspecified,,,,,Resistant factor as ability to overcome multidrug resistance of MES-SA/Dx5 cells compared to MES-SA cells,Other,16169719.0,
1129,255777,6,2,,123097261,31703,Active,,,1.56,IC50,In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells,Confirmatory,16169719.0,
1130,255789,6,2,,123097261,31703,Active,,,0.016,IC50,In vitro cytotoxicity against uterine sarcoma MES-SA cells,Confirmatory,16169719.0,
1131,255803,6,2,,123097261,31703,Active,,,0.08,IC50,In vitro cytotoxicity against murine leukemia cell line L1210,Confirmatory,16169719.0,
1132,255826,6,2,,123097261,31703,Active,,,0.32,IC50,In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells,Confirmatory,16169719.0,
1133,256063,3,4,,123097261,31703,Inconclusive,,,,,Ratio of cytotoxic activity against human MCF-7 cells to that of antiplasmodial activity against Plasmodium falciparum FcB1; ND = Not determined,Other,16168652.0,
1134,256084,5,2,,123097261,31703,Inconclusive,,,,,Antiplasmodial activity for Plasmodium falciparum F-32; Not determined,Other,16168652.0,
1135,256085,5,2,,123097261,31703,Inconclusive,,,,,Antiplasmodial activity for Plasmodium falciparum FcB1; Not determined,Other,16168652.0,
1136,256107,5,2,,123097261,31703,Inconclusive,,,,,Antileishmanial activity against leishmania amazonensis promastigotes stage; ND = Not determined,Other,16168652.0,
1137,256110,5,2,,123097261,31703,Inconclusive,,,,,Antileishmanial activity against leishmania amazonensis axenic amastigotes stage; ND = Not determined,Other,16168652.0,
1138,256541,7,1,,123097261,31703,Active,,,,,Cytotoxic activity against human MCF-7 cells,Other,16168652.0,
1139,256681,3,4,,123097261,31703,Unspecified,,,,,Percentage intracellular concentration in MCF7 breast cancer cells,Other,16168650.0,
1140,256682,3,5,,123097261,31703,Unspecified,,,,,Percentage intracellular concentration in MCF7/ADR drug-resistant cell line,Other,16168650.0,
1141,256683,3,4,,123097261,31703,Unspecified,,,,,Percentage intracellular concentration in AT3B1 drug-resistant cell line,Other,16168650.0,
1142,256684,6,2,,123097261,31703,Active,,,0.25,IC50,Tumor killing activity in MCF7 breast cancer cells by MTT assay,Confirmatory,16168650.0,
1143,256685,6,3,,123097261,31703,Active,,,45.2,IC50,Tumor killing activity in MCF7/ADR drug-resistant cell line by MTT assay,Confirmatory,16168650.0,
1144,256686,6,2,,123097261,31703,Unspecified,,,167.5,IC50,Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay,Confirmatory,16168650.0,
1145,256687,3,4,,123097261,31703,Inconclusive,,,,,Tumor killing activity in MCF7 breast cancer cells with 10 uM verapamil (P-gp inhibitor),Other,16168650.0,
1146,256688,6,3,,123097261,31703,Active,,,6.7,IC50,Tumor killing activity in MCF7/ADR drug-resistant cell line with 10 uM verapamil (P-gp inhibitor),Confirmatory,16168650.0,
1147,256689,6,2,,123097261,31703,Active,,,42.4,IC50,Inhibition of tumor killing activity in AT3B1 drug-resistant cell line with 10 uM verapamil (P-gp inhibitor),Confirmatory,16168650.0,
1148,256690,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity on drug-sensitive MCF7 cells,Other,16168650.0,
1149,257308,8,1,,123097261,31703,Active,,,1.8,LD50,Cytotoxicity against human cancer HT29 cell line by MTT assay,Confirmatory,16203143.0,
1150,257309,8,1,,123097261,31703,Active,,,1.1,LD50,Cytotoxicity against human cancer HL60 cell line by MTT assay,Confirmatory,16203143.0,
1151,257310,8,1,,123097261,31703,Active,,,14.2,LD50,Cytotoxicity against human cancer SKOV3 cell line by MTT assay,Confirmatory,16203143.0,
1152,257311,8,1,,123097261,31703,Active,,,1.2,LD50,Cytotoxicity against human cancer AGS cell line by MTT assay,Confirmatory,16203143.0,
1153,257312,8,1,,123097261,31703,Active,,,1.3,LD50,Cytotoxicity against human cancer A549 cell line by MTT assay,Confirmatory,16203143.0,
1154,258103,7,1,,123097261,31703,Unspecified,13959709.0,7153.0,,,Inhibition of Topoisomerase 2,Other,16242325.0,
1155,258103,7,1,,123097261,31703,Unspecified,20141946.0,7155.0,,,Inhibition of Topoisomerase 2,Other,16242325.0,
1156,264031,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human PC-3M-1E8 cell line by MTT assay,Other,16504508.0,
1157,264032,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human Bel7402 cell line by MTT assay,Other,16504508.0,
1158,264033,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human HeLa cell line by MTT assay,Other,16504508.0,
1159,265031,6,2,,123097261,31703,Active,,,0.15,IC50,Antitumor activity against mouse L1210 cell line assessed as inhibition of [3H]thymidine incorporation,Confirmatory,16563756.0,
1160,265034,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing L1210 leukemia assessed as loss of body weight at 8 ug/kg, ip",Other,16563756.0,
1161,265035,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing L1210 leukemia assessed as loss of body weight at 5 ug/kg, ip",Other,16563756.0,
1162,265039,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing L1210 leukemia assessed as increase in life span at 5 ug/kg, ip relative to control",Other,16563756.0,
1163,265041,3,3,,123097261,31703,Inactive,,,,,"Antitumor activity in BDF1 mouse bearing L1210 leukemia assessed as survival for 30 days at 8 ug/kg, ip",Other,16563756.0,
1164,265042,3,3,,123097261,31703,Inactive,,,,,"Antitumor activity in BDF1 mouse bearing L1210 leukemia assessed as survival for 30 days at 5 ug/kg, ip",Other,16563756.0,
1165,265045,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing B16 melanoma assessed as loss of body weight at 5 mg/kg, ip",Other,16563756.0,
1166,265048,3,3,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing B16 melanoma assessed as inhibition of tumor growth at 5 mg/kg, ip relative to control",Other,16563756.0,
1167,265841,5,4,,123097261,31703,Unspecified,,,,,"Inhibition of cell viability of panel of 10 cell lines (LCL H460, MACL MCF7, LXFL 529L, LXFA 629L, MEXF 462NL, MEXF 514L, MAXF 401NL, RXF 944L, RXF 486L, UXF 1138L) at 1 ug/mL",Other,16621542.0,
1168,265842,4,4,,123097261,31703,Active,,,,,"Cytotoxicity against panel of 12 cell lines (LCL H460, MACL MCF7, LXFL 529L, LXFA 629L, MEXF 462NL, MEXF 514L, MAXF 401NL, RXF 944L, RXF 486L, UXF 1138L, PR PC3M, PRCL 22RV1)",Other,16621542.0,
1169,269026,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human MOLT4 cell line by MTT assay,Confirmatory,16913700.0,
1170,269027,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human Wil2-NS cells by MTT assay,Confirmatory,16913700.0,
1171,269028,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human C8166 cell line by MTT assay,Confirmatory,16913700.0,
1172,269029,6,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human MT4 cell line by MTT assay,Confirmatory,16913700.0,
1173,269030,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human CCRF-SB cell line by MTT assay,Confirmatory,16913700.0,
1174,269031,6,2,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human CCRF-CEM cell line by MTT assay,Confirmatory,16913700.0,
1175,269032,6,2,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human G361 cell line by MTT assay,Confirmatory,16913700.0,
1176,269033,6,2,,123097261,31703,Active,,,0.15,IC50,Antiproliferative activity against human HT29 cell line by MTT assay,Confirmatory,16913700.0,
1177,269034,6,2,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human HeLa cells by MTT assay,Confirmatory,16913700.0,
1178,269035,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human Hep2 cell line by MTT assay,Confirmatory,16913700.0,
1179,269036,6,2,,123097261,31703,Active,,,0.001,IC50,Antiproliferative activity against human ACHN cell line by MTT assay,Confirmatory,16913700.0,
1180,269037,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human 5637 cell line by MTT assay,Confirmatory,16913700.0,
1181,269038,6,2,,123097261,31703,Active,,,0.15,IC50,Antiproliferative activity against human KB cell line by MTT assay,Confirmatory,16913700.0,
1182,270549,6,2,,123097261,31703,Active,,,2.37,IC50,Cytotoxicity against HT29 cell line,Confirmatory,16777412.0,
1183,270853,6,2,,123097261,31703,Active,,,0.153,IC50,Antiproliferative activity against HT29 cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
1184,270854,6,2,,123097261,31703,Active,,,0.0097,IC50,Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
1185,270855,6,3,,123097261,31703,Active,,,0.7040000000000001,IC50,Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
1186,270856,3,5,,123097261,31703,Unspecified,,,,,"Resistant factor, IC50 for MES-SA/Dx5/ IC50 for MES-SA cells by MTT assay after 72 hrs",Other,16824751.0,
1187,271692,3,3,,123097261,31703,Unspecified,,,,,Binding affinity to DNA measured as hypochromicity of UV-vis spectra,Other,17064069.0,
1188,272491,4,5,,123097261,31703,Active,,,4.69,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
1189,272492,4,5,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
1190,272493,4,4,,123097261,31703,Active,,,1.7380000000000002,IC50,Antiproliferative activity against adriamycin resistant P388 cells by ELISA,Confirmatory,17154505.0,
1191,272494,4,4,,123097261,31703,Active,,,0.022000000000000002,IC50,Antiproliferative activity against P388 cells by ELISA,Confirmatory,17154505.0,
1192,272510,4,5,,123097261,31703,Active,,,0.55,IC50,"Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
1193,272511,4,5,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
1194,272512,3,5,,123097261,31703,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells",Other,17154505.0,
1195,272513,3,5,,123097261,31703,Unspecified,,,,,"Relative fold, IC50 in absence to presence of verapamil in multidrug resistant MDA435/LCC6 cells",Other,17154505.0,
1196,272514,4,4,,123097261,31703,Active,,,0.12300000000000001,IC50,"Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
1197,272515,4,4,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
1198,272516,3,4,,123097261,31703,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant P388 cells",Other,17154505.0,
1199,272788,5,2,,123097261,31703,Active,,,0.31623,IC50,Growth inhibition of MCF7 cells by crystal violet assay after 3 hrs,Confirmatory,17125253.0,
1200,272789,5,3,,123097261,31703,Active,,,6.30957,IC50,Growth inhibition of MCF7/Adr cells by crystal violet assay after 3 hrs,Confirmatory,17125253.0,
1201,272790,5,2,,123097261,31703,Active,,,0.01259,IC50,Growth inhibition of MCF7 cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1202,272791,5,3,,123097261,31703,Active,,,2.51189,IC50,Growth inhibition of MCF7/Adr cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1203,272792,5,2,,123097261,31703,Active,,,0.1,IC50,Growth inhibition of SK-HEP-1 cells by crystal violet assay after 3 hrs,Confirmatory,17125253.0,
1204,272793,5,2,,123097261,31703,Active,,,0.05012,IC50,Growth inhibition of SK-HEP-1 cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1205,272794,5,2,,123097261,31703,Active,,,0.19952999999999999,IC50,Growth inhibition of HepG2 cells by crystal violet assay after 3 hrs,Confirmatory,17125253.0,
1206,272795,5,2,,123097261,31703,Active,,,0.03162,IC50,Growth inhibition of HepG2 cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1207,272796,5,2,,123097261,31703,Active,,,0.03162,IC50,Growth inhibition of rat H9c2(2-1) cells by MTT assay after 3 hrs,Confirmatory,17125253.0,
1208,272797,5,2,,123097261,31703,Active,,,0.01995,IC50,Growth inhibition of H9c2(2-1) cells by MTT assay after 24 hrs,Confirmatory,17125253.0,
1209,272798,5,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Vero cells by MTT assay after 3 hrs,Confirmatory,17125253.0,
1210,272799,5,2,,123097261,31703,Active,,,0.5011899999999999,IC50,Cytotoxicity against Vero cells by MTT assay after 24 hrs,Confirmatory,17125253.0,
1211,272801,5,2,,123097261,31703,Active,,,0.12589,IC50,Growth inhibition of SHP77 cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1212,272802,5,2,,123097261,31703,Active,,,0.03162,IC50,Growth inhibition of DU145 cells by crystal violet assay after 24 hrs,Confirmatory,17125253.0,
1213,273096,3,4,,123097261,31703,Unspecified,,,,,"Reduction in tumor volume of human MCF7 cell xenografted in nude mice at 1 mg/kg, ip",Other,17034133.0,
1214,273519,4,4,,123097261,31703,Active,,,0.0075,IC50,Inhibition of A2780 cell growth,Confirmatory,17125254.0,
1215,273520,4,4,,123097261,31703,Active,,,0.061,IC50,Inhibition of Doxorubicin-resistant A2780 cell growth,Confirmatory,17125254.0,
1216,273521,4,4,,123097261,31703,Active,,,0.003,IC50,Inhibition of cisplatin-resistant A2780 cell growth,Confirmatory,17125254.0,
1217,273522,3,4,,123097261,31703,Unspecified,,,,,"Resistance factor, IC50 for A2780 AD cells/ IC50 for A2780 cells",Other,17125254.0,
1218,273523,3,4,,123097261,31703,Unspecified,,,,,"Resistance factor, IC50 for A2780/cp70 cells/ IC50 for A2780 cells",Other,17125254.0,
1219,274712,6,2,,123097261,31703,Active,,,0.21,GI50,Growth inhibition of Jurkat cell,Confirmatory,17181155.0,
1220,274713,6,7,,123097261,31703,Active,231632.0,596.0,26.0,GI50,Growth inhibition of Jurkat cell overexpressing Bcl2,Confirmatory,17181155.0,
1221,274714,6,7,,123097261,31703,Active,728955.0,598.0,24.0,GI50,Growth inhibition of Jurkat cell overexpressing BclXL,Confirmatory,17181155.0,
1222,274715,3,5,,123097261,31703,Unspecified,,,,,Ratio of GI50 for Jurkat cells overexpressing Bcl2 or BclXL to normal Jurkat cells,Other,17181155.0,
1223,274718,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cell line,Other,17253840.0,
1224,274719,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-OV-3 cell line,Other,17253840.0,
1225,274720,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cell line,Other,17253840.0,
1226,274721,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cell line,Other,17253840.0,
1227,274722,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cell line,Other,17253840.0,
1228,274784,6,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human K562 cell line,Confirmatory,17181164.0,
1229,274785,6,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of tubulin polymerization in porcine brain,Confirmatory,17181164.0,
1230,274869,5,3,,123097261,31703,Active,,,0.0204,GI50,Growth inhibition of mouse C1A cells after 72 hrs by MTT assay,Confirmatory,17181166.0,
1231,274870,5,3,,123097261,31703,Active,,,0.0158,GI50,Growth inhibition of mouse C2H cells after 72 hrs by MTT assay,Confirmatory,17181166.0,
1232,274871,5,3,,123097261,31703,Active,,,0.0453,GI50,Growth inhibition of human LNCaP cells after 72 hrs by MTT assay,Confirmatory,17181166.0,
1233,274874,3,4,,123097261,31703,Active,,,,,Cell cycle arrest in LNCaP cells by accumulation at G2/M phase at 50 nM after 72 hrs by PI staining,Other,17181166.0,
1234,274886,3,4,,123097261,31703,Active,,,,,Induction of late apoptosis in LNCaP cells at 50 nM after 72 hrs relative to control by V-PE/7-AAD staining,Other,17181166.0,
1235,274889,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human LNCaP cells at 100 nM after 72 hrs by MTT assay,Other,17181166.0,
1236,274916,9,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against Candida albicans ATCC 90028,Other,17181171.0,
1237,274917,8,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against fluconazole-susceptible Candida albicans,Other,17181171.0,
1238,274918,8,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against fluconazole-resistant Candida albicans,Other,17181171.0,
1239,274919,9,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against Cryptococcus neoformans ATCC 90113,Other,17181171.0,
1240,274920,9,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against Aspergillus fumigatus ATCC 90906,Other,17181171.0,
1241,274921,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Vero cells by neutral red method,Other,17181171.0,
1242,274922,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against LLC-PK1 cells by neutral red method,Other,17181171.0,
1243,275527,6,2,,123097261,31703,Active,,,0.028999999999999998,IC50,Cytotoxicity against mouse L1210 cell line,Confirmatory,17228871.0,
1244,275528,6,2,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human HT29 cell line,Confirmatory,17228871.0,
1245,275532,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in mouse L1210 cell line by accumulation at G2/M phase at 1 uM after 24 hrs,Other,17228871.0,
1246,276023,6,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human KB cells,Confirmatory,16919455.0,
1247,276024,6,3,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human BC cells,Confirmatory,16919455.0,
1248,276025,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human NCI-H187 cells,Confirmatory,16919455.0,
1249,276492,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against SF268 cell line at 3 uM,Other,16962775.0,
1250,276493,3,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against 251L cell line at 3 uM,Other,16962775.0,
1251,276494,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against H460 cell line at 3 uM,Other,16962775.0,
1252,276495,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against MCF7 cell line at 3 uM,Other,16962775.0,
1253,276496,3,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against MDA231 cell line at 3 uM,Other,16962775.0,
1254,276497,3,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against MDA467 cell line at 3 uM,Other,16962775.0,
1255,276498,3,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against 394NL cell line at 3 uM,Other,16962775.0,
1256,276499,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against OVCAR-3 cell line at 3 uM,Other,16962775.0,
1257,276500,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against DU145 cell line at 3 uM,Other,16962775.0,
1258,276501,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against LNCAP cell line at 3 uM,Other,16962775.0,
1259,276502,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against A498 cell line at 3 uM,Other,16962775.0,
1260,276503,3,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against 1138L cell line at 3 uM,Other,16962775.0,
1261,277524,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against murine B16 cells by MTT assay,Confirmatory,17256903.0,
1262,277808,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay,Confirmatory,17286429.0,
1263,277809,6,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,17286429.0,
1264,277810,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17286429.0,
1265,277811,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human SF268 cells after 72 hrs by MTT assay,Confirmatory,17286429.0,
1266,277988,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human hepa59T/VGH cells by MTT assay,Other,17315955.0,
1267,277989,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human WiDr cells by MTT assay,Other,17315955.0,
1268,277990,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,17315955.0,
1269,277991,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,17315955.0,
1270,280519,6,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs,Confirmatory,17323939.0,
1271,280520,6,3,,123097261,31703,Active,,,3.71,IC50,Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs,Confirmatory,17323939.0,
1272,280521,6,3,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs,Confirmatory,17323939.0,
1273,280522,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for vinblastine-resistant CEM/VLB100 cells over IC50 for drug-sensitive CCRF-CEM cells,Other,17323939.0,
1274,280523,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for teniposide-resistant CEM/VM1 cells over IC50 for drug-sensitive CCRF-CEM cells,Other,17323939.0,
1275,281409,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,17375902.0,
1276,281410,6,2,,123097261,31703,Active,,,0.17800000000000002,IC50,Cytotoxicity against human SW620 cells,Confirmatory,17375902.0,
1277,281411,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,Cytotoxicity against human A2780 cells,Confirmatory,17375902.0,
1278,281412,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human NCI-H460 cells,Confirmatory,17375902.0,
1279,281414,6,2,,123097261,31703,Active,,,0.033,IC50,Cytotoxicity against human LoVo cells,Confirmatory,17375902.0,
1280,281415,6,3,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human MeVo cells,Confirmatory,17375902.0,
1281,281417,6,2,,123097261,31703,Active,,,5.3,IC50,Cytotoxicity against doxorubicin-resistant human MCF7 cells,Confirmatory,17375902.0,
1282,281418,6,2,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against doxorubicin-resistant human A2780 cells,Confirmatory,17375902.0,
1283,281419,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,Cytotoxicity against cisplatin-resistant human A2780 cells,Confirmatory,17375902.0,
1284,281420,3,4,,123097261,31703,Unspecified,,,,,"Resistance index, IC50 for doxorubicin-resistant human MCF7 cells/IC50 for doxorubicin-sensitive human MCF7 cells",Other,17375902.0,
1285,281421,3,4,,123097261,31703,Unspecified,,,,,"Resistance index, IC50 for doxorubicin-resistant human A2780 cells/IC50 for doxorubicin- sensitive human A2780 cells",Other,17375902.0,
1286,281425,3,7,,123097261,31703,Inactive,,,,,Inhibition of topoisomerase 2 mediated DNA relaxation at 50 uM,Other,17375902.0,
1287,281445,6,2,,123097261,31703,Active,,,0.9,EC50,Cytotoxicity against human A549 cells after 72 hrs,Confirmatory,17378530.0,
1288,281446,6,2,,123097261,31703,Active,,,2.0,EC50,Cytotoxicity against human PC3 cells after 72 hrs,Confirmatory,17378530.0,
1289,281447,6,2,,123097261,31703,Active,,,0.1,EC50,Cytotoxicity against human 1A9 cells after 72 hrs,Confirmatory,17378530.0,
1290,281448,6,2,,123097261,31703,Active,,,0.2,EC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,17378530.0,
1291,281449,6,2,,123097261,31703,Active,,,0.4,EC50,Cytotoxicity against human KB cells after 72 hrs,Confirmatory,17378530.0,
1292,281450,6,3,,123097261,31703,Active,,,1.7,EC50,Cytotoxicity against human multidrug-resistant KB-VIN cells after 72 hrs,Confirmatory,17378530.0,
1293,282019,5,6,,123097261,31703,Active,17374795.0,10682.0,0.2,IC50,Growth inhibition of MCF7 cells expressing ER and antiestrogen binding sites,Confirmatory,15588086.0,
1294,282019,5,6,,123097261,31703,Active,20138066.0,1717.0,0.2,IC50,Growth inhibition of MCF7 cells expressing ER and antiestrogen binding sites,Confirmatory,15588086.0,
1295,282021,4,3,,123097261,31703,Active,,,0.2,IC50,Growth inhibition of ER expressing Rtx6 cells after 4 hrs,Confirmatory,15588086.0,
1296,282022,5,6,,123097261,31703,Active,17374795.0,10682.0,0.3,IC50,Growth inhibition of MDA-MB-231 cells containing antiestrogen binding sites,Confirmatory,15588086.0,
1297,282022,5,6,,123097261,31703,Active,20138066.0,1717.0,0.3,IC50,Growth inhibition of MDA-MB-231 cells containing antiestrogen binding sites,Confirmatory,15588086.0,
1298,282023,5,6,,123097261,31703,Active,17374795.0,10682.0,0.15,IC50,Growth inhibition of MDA-MB-435 cells containing antiestrogen binding sites,Confirmatory,15588086.0,
1299,282023,5,6,,123097261,31703,Active,20138066.0,1717.0,0.15,IC50,Growth inhibition of MDA-MB-435 cells containing antiestrogen binding sites,Confirmatory,15588086.0,
1300,282024,3,4,,123097261,31703,Unspecified,,,,,Drug uptake in ER expressing MCF7 cells,Other,15588086.0,
1301,283791,6,3,,123097261,31703,Unspecified,,,,,Growth inhibition of human WI38 cells,Other,17358082.0,
1302,283792,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human VA13 cells,Other,17358082.0,
1303,283793,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human HepG2 cells,Other,17358082.0,
1304,283913,5,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MDR1 gene transfected mouse L5178 Y cells after 72 hrs,Other,17035027.0,
1305,284051,6,2,,123097261,31703,Inconclusive,,,,IC50,Growth inhibition of human NCI-H460 cells by MTT assay,Confirmatory,17049252.0,
1306,284052,6,2,,123097261,31703,Inconclusive,,,,IC50,Growth inhibition of human HCT116 cells by MTT assay,Confirmatory,17049252.0,
1307,284053,6,2,,123097261,31703,Active,,,0.05,IC50,Growth inhibition of human A431 cells by MTT assay,Confirmatory,17049252.0,
1308,284054,6,2,,123097261,31703,Inconclusive,,,,IC50,Growth inhibition of human CCRF-HSB-2 cells by MTT assay,Confirmatory,17049252.0,
1309,284055,6,2,,123097261,31703,Inconclusive,,,,IC50,Growth inhibition of human KB cells by MTT assay,Confirmatory,17049252.0,
1310,284257,7,2,,123097261,31703,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by Alamar blue assay,Other,17070063.0,
1311,284259,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Vero cells by neutral red assay,Other,17070063.0,
1312,284261,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against LLC-PK1 cells by neutral red assay,Other,17070063.0,
1313,284263,7,2,,123097261,31703,Inconclusive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus,Other,17070063.0,
1314,284265,7,2,,123097261,31703,Inconclusive,,,,,Antifungal activity against Candida albicans,Other,17070063.0,
1315,284267,7,2,,123097261,31703,Inconclusive,,,,,Antifungal activity against Cryptococcus neoformans,Other,17070063.0,
1316,284269,7,2,,123097261,31703,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum D6,Other,17070063.0,
1317,284270,7,2,,123097261,31703,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum W2,Other,17070063.0,
1318,284273,3,4,,123097261,31703,Inactive,,,,,Antimicrobial activity against Mycobacterium intracellular,Other,17070063.0,
1319,284274,3,3,,123097261,31703,Inactive,,,,,Antifungal activity against Aspergillus fumigatus,Other,17070063.0,
1320,284750,6,2,,123097261,31703,Active,,,0.26,IC50,Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay,Confirmatory,17107806.0,
1321,284751,6,3,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human HA22T cells after 72 hrs by MTT assay,Confirmatory,17107806.0,
1322,284752,6,3,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against SKBR3 cells after 72 hrs by MTT assay,Confirmatory,17107806.0,
1323,284753,6,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against MOLT4 cells after 72 hrs by MTT assay,Confirmatory,17107806.0,
1324,284754,7,1,,123097261,31703,Active,,,,,Binding affinity to Escherichia coli JM83 pUC19 DNA assessed as DNA intercalation assay,Other,17107806.0,
1325,284755,3,3,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse,Other,17107806.0,
1326,286447,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT method,Other,17417907.0,
1327,286448,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT method,Other,17417907.0,
1328,286449,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT method,Other,17417907.0,
1329,286450,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT method,Other,17417907.0,
1330,286451,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT method,Other,17417907.0,
1331,286452,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MRC5 cells by MTT method,Other,17417907.0,
1332,287143,6,2,,123097261,31703,Active,,,0.013000000000000001,IC50,Cytotoxicity against HL60 cells after 72 hrs by dye exclusion assay,Confirmatory,17069934.0,
1333,287144,6,3,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against adriamycin-resistant HL60/ADR cells expressing MRP1 after 72 hrs by dye exclusion assay,Confirmatory,17069934.0,
1334,287154,6,2,,123097261,31703,Active,,,0.11800000000000001,IC50,Anticancer activity against human A549 cells after 48 hrs by SRB assay,Confirmatory,17070967.0,
1335,287155,6,2,,123097261,31703,Active,,,0.18100000000000002,IC50,Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay,Confirmatory,17070967.0,
1336,287156,6,2,,123097261,31703,Active,,,0.09699999999999999,IC50,Anticancer activity against human SK-MEL-2 cells after 48 hrs by SRB assay,Confirmatory,17070967.0,
1337,287157,6,2,,123097261,31703,Active,,,0.11199999999999999,IC50,Anticancer activity against human XF498 cells after 48 hrs by SRB assay,Confirmatory,17070967.0,
1338,287158,6,2,,123097261,31703,Active,,,0.225,IC50,Anticancer activity against human HCT15 cells after 48 hrs by SRB assay,Confirmatory,17070967.0,
1339,287703,6,2,,123097261,31703,Active,,,0.14,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT test,Confirmatory,17276690.0,
1340,287704,6,2,,123097261,31703,Active,,,2.0,IC50,Antiproliferative activity against human multidrug-resistant K562i/S9 cells expressing Pgp after 72 hrs by MTT test,Confirmatory,17276690.0,
1341,287705,3,4,,123097261,31703,Unspecified,,,,,"Resistance index, Ratio of IC50 for human drug-resistant K562i/S9 cells to IC50 for human K562 cells",Other,17276690.0,
1342,287706,6,2,,123097261,31703,Active,,,1.4,IC50,Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test,Confirmatory,17276690.0,
1343,287707,6,2,,123097261,31703,Active,,,4.4,IC50,Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test,Confirmatory,17276690.0,
1344,287708,3,3,,123097261,31703,Unspecified,,,,,"Resistance index, Ratio of IC50 for human p53 deficient HCT116 p53-/- cells to IC50 for human wild type HCT116 cells",Other,17276690.0,
1345,287712,3,7,,123097261,31703,Active,,,,,Inhibition of topoisomerase 1 at >50 uM,Other,17276690.0,
1346,288486,8,1,,123097261,31703,Active,,,8.0,ED50,Antitumor activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,17482824.0,
1347,288487,8,1,,123097261,31703,Unspecified,,,102.0,ED50,Antitumor activity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,17482824.0,
1348,288488,8,1,,123097261,31703,Unspecified,,,274.0,ED50,Antitumor activity against human HT29 cells after 24 hrs by MTT assay,Confirmatory,17482824.0,
1349,288489,8,1,,123097261,31703,Unspecified,,,152.0,ED50,Antitumor activity against human A549 cells after 24 hrs by MTT assay,Confirmatory,17482824.0,
1350,288490,8,1,,123097261,31703,Unspecified,,,173.0,ED50,Antitumor activity against human MES-SA cells after 24 hrs by MTT assay,Confirmatory,17482824.0,
1351,288491,8,1,,123097261,31703,Unspecified,,,500.0,ED50,Antitumor activity against doxorubucin-resistant human MES-SA/Dx5 cells by MTT assay after 24 hrs,Confirmatory,17482824.0,
1352,288849,9,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human MDA-MB-231 cells by SRB assay,Confirmatory,17512741.0,
1353,288850,9,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,17512741.0,
1354,288851,9,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human HT29 cells by SRB assay,Confirmatory,17512741.0,
1355,289061,6,3,,123097261,31703,Unspecified,,,,,Growth inhibition of WI38 cells,Other,17547458.0,
1356,289062,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of VA13 cells,Other,17547458.0,
1357,289063,6,2,,123097261,31703,Unspecified,,,,,Growth inhibition of HepG2 cells,Other,17547458.0,
1358,289258,6,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of serum-induced proliferation of human A375 cells,Confirmatory,17601739.0,
1359,289259,6,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of serum-induced proliferation of human HeLa cells,Confirmatory,17601739.0,
1360,289260,6,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of serum-induced proliferation of human A549 cells,Confirmatory,17601739.0,
1361,289261,6,2,,123097261,31703,Active,,,0.0071,IC50,Inhibition of serum-induced proliferation of human MCF7 cells,Confirmatory,17601739.0,
1362,289262,6,2,,123097261,31703,Active,,,17.0,IC50,Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells,Confirmatory,17601739.0,
1363,289301,8,1,,123097261,31703,Active,,,0.0428,GI50,Growth inhibition of human MCF7 cells,Confirmatory,17614292.0,
1364,289302,8,1,,123097261,31703,Active,,,0.094,GI50,Growth inhibition of human NCI-H460 cells,Confirmatory,17614292.0,
1365,289303,8,1,,123097261,31703,Active,,,0.09300000000000001,GI50,Growth inhibition of human SF268 cells,Confirmatory,17614292.0,
1366,289304,8,1,,123097261,31703,Active,,,0.094,GI50,Growth inhibition of human UACC62 cells,Confirmatory,17614292.0,
1367,289790,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human HT1080 cells by MTT assay,Confirmatory,17141923.0,
1368,289791,6,2,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against human HT29 cells by MTT assay,Confirmatory,17141923.0,
1369,289792,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,17141923.0,
1370,290030,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against HL60 cells,Confirmatory,17175071.0,
1371,290031,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against HCT8 cells,Confirmatory,17175071.0,
1372,290032,6,2,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against MDA-MB-435 cells,Confirmatory,17175071.0,
1373,290033,6,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against SF295 cells,Confirmatory,17175071.0,
1374,290034,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at first cleavage stage at 10 ug/mL,Other,17175071.0,
1375,290035,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at first cleavage stage at 100 ug/mL,Other,17175071.0,
1376,290036,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at third cleavage stage at 10 ug/mL,Other,17175071.0,
1377,290037,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at third cleavage stage at 100 ug/mL,Other,17175071.0,
1378,290038,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at blastulae stage at 10 ug/mL,Other,17175071.0,
1379,290039,3,3,,123097261,31703,Unspecified,,,,,Antimitotic effect in Lytechinus variegatus at blastulae stage at 100 ug/mL,Other,17175071.0,
1380,291420,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells,Other,17567069.0,
1381,291421,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BC1 cells,Other,17567069.0,
1382,291422,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H187 cells,Other,17567069.0,
1383,291924,6,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human A549 cells after 48 hrs,Confirmatory,17583953.0,
1384,291925,6,3,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against human BGC823 cells after 48 hrs,Confirmatory,17583953.0,
1385,291926,6,2,,123097261,31703,Active,,,0.58,IC50,Cytotoxicity against human K562 cells after 48 hrs,Confirmatory,17583953.0,
1386,291927,6,2,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human A549 cells by SRB microtiter plate assay,Confirmatory,17585747.0,
1387,291928,6,2,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human KB cells by SRB microtiter plate assay,Confirmatory,17585747.0,
1388,291929,6,2,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human DU145 cells by SRB microtiter plate assay,Confirmatory,17585747.0,
1389,291930,6,3,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human ZR751cells by SRB microtiter plate assay,Confirmatory,17585747.0,
1390,291931,6,3,,123097261,31703,Unspecified,,,4.0,IC50,Cytotoxicity against multidrug resistant human KB-Vin cells by SRB microtiter plate assay,Confirmatory,17585747.0,
1391,292168,6,2,,123097261,31703,Unspecified,,,700.0,IC50,Growth inhibition of human WI38 cells,Confirmatory,17595134.0,
1392,292169,6,2,,123097261,31703,Unspecified,,,400.0,IC50,Growth inhibition of human VA13 cells,Confirmatory,17595134.0,
1393,292170,6,2,,123097261,31703,Unspecified,,,1300.0,IC50,Growth inhibition of human HepG2 cells,Confirmatory,17595134.0,
1394,293470,6,2,,123097261,31703,Active,,,0.15,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,17194596.0,
1395,293471,6,3,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human SNU638 cells by SRB assay,Confirmatory,17194596.0,
1396,293472,6,2,,123097261,31703,Active,,,0.62,IC50,Cytotoxicity against human HCT116 cells by SRB assay,Confirmatory,17194596.0,
1397,293473,6,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HT1080 cells by SRB assay,Confirmatory,17194596.0,
1398,293474,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells by SRB assay,Confirmatory,17194596.0,
1399,293475,6,2,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against human SK-OV-3 cells by SRB assay,Confirmatory,17194596.0,
1400,293476,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,17194596.0,
1401,293477,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human XF498 cells by SRB assay,Confirmatory,17194596.0,
1402,293479,3,3,,123097261,31703,Unspecified,,,,,Inhibition of human topoisomerase 2-mediated KDNA decatenation activity at 5 uM after 10 mins relative to control,Other,17194596.0,
1403,293482,6,2,,123097261,31703,Active,,,2.67,IC50,Inhibition of human topoisomerase 2 at 5 uM,Confirmatory,17194596.0,
1404,295626,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human A375 cells after 24 hrs by MTT assay,Confirmatory,17400463.0,
1405,295627,6,3,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay,Confirmatory,17400463.0,
1406,295628,6,3,,123097261,31703,Unspecified,,,10.0,IC50,Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay,Confirmatory,17400463.0,
1407,295629,6,2,,123097261,31703,Active,,,15.51,IC50,Cytotoxicity against human PBMCs after 24 hrs by MTT assay,Confirmatory,17400463.0,
1408,295908,6,2,,123097261,31703,Active,,,1.38,IC50,Binding affinity to DNA by DNA-methyl green bioassay,Confirmatory,17418916.0,
1409,296138,6,2,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against U937 GTB cells,Confirmatory,17442577.0,
1410,296139,6,3,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against RPMI 8226/s cells,Confirmatory,17442577.0,
1411,296140,6,3,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against CEM/s cells,Confirmatory,17442577.0,
1412,296141,6,2,,123097261,31703,Active,,,14.2,IC50,Cytotoxicity against ACHN cells,Confirmatory,17442577.0,
1413,296681,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method,Confirmatory,17622129.0,
1414,296682,6,3,,123097261,31703,Active,,,0.62,IC50,Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method,Confirmatory,17622129.0,
1415,296683,6,2,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT colorimetric method,Confirmatory,17622129.0,
1416,296684,6,2,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT colorimetric method,Confirmatory,17622129.0,
1417,296685,6,2,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method,Confirmatory,17622129.0,
1418,297084,3,4,,123097261,31703,Inactive,,,,,Induction of senescence in human PC3 cells,Other,17658777.0,
1419,297085,3,4,,123097261,31703,Active,,,,,Induction of senescence in human DU145 cells,Other,17658777.0,
1420,297699,6,1,,123097261,31703,Unspecified,,,1.0,IC50,Growth inhibition of human SHP77 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1421,297700,6,1,,123097261,31703,Active,,,0.19952999999999999,IC50,Growth inhibition of human A375 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1422,297701,6,1,,123097261,31703,Active,,,0.31623,IC50,Growth inhibition of human PC3 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1423,297702,6,1,,123097261,31703,Active,,,0.15849000000000002,IC50,Growth inhibition of human MDA-MB-435 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1424,297703,6,1,,123097261,31703,Active,,,0.31623,IC50,Growth inhibition of human MiaPaCa2 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1425,297704,6,2,,123097261,31703,Active,,,0.31623,IC50,Growth inhibition of human BxPc3 cells after 3 hrs by MTT assay,Confirmatory,17696516.0,
1426,297705,6,1,,123097261,31703,Active,,,0.058879999999999995,IC50,Growth inhibition of human HL60(TB) cells after 48 hrs by crystal violet assay,Confirmatory,17696516.0,
1427,297706,6,1,,123097261,31703,Active,,,0.00603,IC50,Growth inhibition of human NCIH460 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1428,297707,6,1,,123097261,31703,Active,,,0.07078999999999999,IC50,Growth inhibition of human HCT116 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1429,297708,6,1,,123097261,31703,Active,,,0.0912,IC50,Growth inhibition of human SF268 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1430,297709,6,1,,123097261,31703,Active,,,0.20893,IC50,Growth inhibition of human UACC257 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1431,297710,6,1,,123097261,31703,Active,,,0.10965,IC50,Growth inhibition of human IGROVI cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1432,297711,6,2,,123097261,31703,Active,,,0.17783,IC50,Growth inhibition of human RXF393 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1433,297712,6,1,,123097261,31703,Active,,,0.10965,IC50,Growth inhibition of human DU145 cells after 48 hrs by MTT assay,Confirmatory,17696516.0,
1434,297714,3,4,,123097261,31703,Active,,,,,Cell cycle arrest in human HCT116 cells by accumulation at G2/M phase at 400 nM for 3 hrs by flow cytometry,Other,17696516.0,
1435,297716,3,4,,123097261,31703,Inactive,,,,,Effect on G2/M arrest in human HL60 cells at 100 nM after 24 hrs,Other,17696516.0,
1436,297718,3,3,,123097261,31703,Active,,,,,Inhibition of topoisomerase 2 at 500 nM by decatenation assay,Other,17696516.0,
1437,297722,3,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in HL60 cells assessed as annexin V positive cells,Other,17696516.0,
1438,297723,3,3,,123097261,31703,Unspecified,,,,,Induction of apoptosis in topoisomerase 2 deficient HL60/MX2 cells assessed as annexin V positive cells,Other,17696516.0,
1439,298735,6,2,,123097261,31703,Active,,,4.6,IC50,Cytotoxicity against human LnCap cells after 4 days by MTT assay,Confirmatory,17194586.0,
1440,298736,6,2,,123097261,31703,Active,,,4.5,IC50,Cytotoxicity against human MCF7 cells after 4 days by MTT assay,Confirmatory,17194586.0,
1441,298737,6,2,,123097261,31703,Active,,,7.7,IC50,Cytotoxicity against human HCT116 cells after 4 days by MTT assay,Confirmatory,17194586.0,
1442,298738,6,2,,123097261,31703,Active,,,17.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay,Confirmatory,17194586.0,
1443,298739,6,2,,123097261,31703,Active,,,3.3,IC50,Cytotoxicity against human HeLa cells after 4 days by MTT assay,Confirmatory,17194586.0,
1444,300495,8,1,,123097261,31703,Active,,,0.1,ED50,Cytotoxicity against human KB cells,Confirmatory,17591444.0,
1445,300496,8,1,,123097261,31703,Active,,,4.97,ED50,Cytotoxicity against human KB-VIN cells,Confirmatory,17591444.0,
1446,300497,8,1,,123097261,31703,Active,,,0.18,ED50,Cytotoxicity against human A549 cells,Confirmatory,17591444.0,
1447,300498,8,1,,123097261,31703,Active,,,0.02,ED50,Cytotoxicity against human 1A9 cells,Confirmatory,17591444.0,
1448,300499,8,1,,123097261,31703,Active,,,1.2,ED50,Cytotoxicity against human HCT8 cells,Confirmatory,17591444.0,
1449,300500,8,1,,123097261,31703,Active,,,0.04,ED50,Cytotoxicity against human ZR751 cells,Confirmatory,17591444.0,
1450,300501,8,1,,123097261,31703,Active,,,0.26,ED50,Cytotoxicity against human PC3 cells,Confirmatory,17591444.0,
1451,300502,8,1,,123097261,31703,Active,,,0.15,ED50,Cytotoxicity against human DU145 cells,Confirmatory,17591444.0,
1452,300503,8,1,,123097261,31703,Active,,,0.04,ED50,Cytotoxicity against human LN-Cap cells,Confirmatory,17591444.0,
1453,300795,6,2,,123097261,31703,Active,,,0.0037,IC50,Antitumor activity against human NCI-H460 cells by methylene blue staining method,Confirmatory,17656091.0,
1454,300796,6,2,,123097261,31703,Active,,,0.1,IC50,Antitumor activity against human MDA-MB-231 cells by methylene blue staining method,Confirmatory,17656091.0,
1455,300797,6,2,,123097261,31703,Active,,,0.027000000000000003,IC50,Antitumor activity against human T47D cells by methylene blue staining method,Confirmatory,17656091.0,
1456,300798,6,2,,123097261,31703,Active,,,0.035,IC50,Antitumor activity against human A498 cells by methylene blue staining method,Confirmatory,17656091.0,
1457,300799,6,2,,123097261,31703,Active,,,0.2,IC50,Antitumor activity against human PC3 cells by methylene blue staining method,Confirmatory,17656091.0,
1458,300800,6,2,,123097261,31703,Active,,,0.1,IC50,Antitumor activity against human DLD1 cells by methylene blue staining method,Confirmatory,17656091.0,
1459,300801,6,2,,123097261,31703,Active,,,0.037000000000000005,IC50,Antitumor activity against human HCT116 cells by methylene blue staining method,Confirmatory,17656091.0,
1460,300802,6,2,,123097261,31703,Active,,,0.1,IC50,Antitumor activity against human UO31 cells by methylene blue staining method,Confirmatory,17656091.0,
1461,301073,6,2,,123097261,31703,Active,,,1.92,IC50,Cytotoxicity against human A549 cells,Confirmatory,17723301.0,
1462,301075,6,3,,123097261,31703,Active,,,2.32,IC50,Cytotoxicity against human Zr75-1 cells,Confirmatory,17723301.0,
1463,301076,6,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human KB cells,Confirmatory,17723301.0,
1464,301077,6,3,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human Gurav cells,Confirmatory,17723301.0,
1465,301078,6,3,,123097261,31703,Active,,,24.9,IC50,Cytotoxicity against human DWD cells,Confirmatory,17723301.0,
1466,301079,6,2,,123097261,31703,Active,,,2.26,IC50,Cytotoxicity against human PC3 cells,Confirmatory,17723301.0,
1467,301213,6,2,,123097261,31703,Unspecified,,,,,Antimitotic activity against Lytechinus variegatus at primary cleavage stage of egg development,Other,17764956.0,
1468,301214,6,2,,123097261,31703,Unspecified,,,,,Antimitotic activity against Lytechinus variegatus at tertiary cleavage stage of egg development,Other,17764956.0,
1469,301215,6,2,,123097261,31703,Unspecified,,,,,Antimitotic activity against Lytechinus variegatus at blastulae stage of egg development,Other,17764956.0,
1470,301216,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells by MTT assay,Other,17764956.0,
1471,301217,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by MTT assay,Other,17764956.0,
1472,301218,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells by MTT assay,Other,17764956.0,
1473,301514,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human Hop62 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1474,301515,6,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human SiHa cells by sulforhodamine B assay,Confirmatory,17822905.0,
1475,301516,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MCF7 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1476,301517,6,3,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human ZR-75-1 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1477,301518,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human PC3 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1478,301519,6,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human Colo205 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1479,301520,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human A2780 cells by sulforhodamine B assay,Confirmatory,17822905.0,
1480,301683,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,17827021.0,
1481,301684,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Other,17827021.0,
1482,301685,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Other,17827021.0,
1483,301686,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Other,17827021.0,
1484,301687,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Other,17827021.0,
1485,301688,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Other,17827021.0,
1486,301689,7,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay,Other,17827021.0,
1487,302186,7,1,,123097261,31703,Active,,,,,Cytotoxicity against LT12 cells by XTT assay,Other,17904839.0,
1488,302187,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against multidrug resistant LT12 cells by XTT assay,Other,17904839.0,
1489,302188,7,1,,123097261,31703,Active,,,,,Cytotoxicity against P388 cells by XTT assay,Other,17904839.0,
1490,302189,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against adriamycin-resistant P388 Cells by XTT assay,Other,17904839.0,
1491,302190,7,1,,123097261,31703,Active,,,,,Cytotoxicity against L1210 cells by XTT assay,Other,17904839.0,
1492,302191,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against vincristine-resistant L1210 cells by XTT assay,Other,17904839.0,
1493,302865,6,3,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against human Hep2 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
1494,302866,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
1495,302867,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
1496,302868,6,2,,123097261,31703,Active,,,0.02,IC50,Antitumor activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
1497,302869,6,2,,123097261,31703,Active,,,0.04,IC50,Antitumor activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
1498,302870,6,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human WI39 fibroblast after 72 hrs by MTT assay,Confirmatory,17935309.0,
1499,303274,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 1 uM after 48 hrs,Other,17950603.0,
1500,303275,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DU145 cells at 1 uM after 48 hrs,Other,17950603.0,
1501,303276,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SW620 cells at 1 uM after 48 hrs,Other,17950603.0,
1502,303277,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human 502713 cells at 1 uM after 48 hrs,Other,17950603.0,
1503,303278,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Colo205 cells at 1 uM after 48 hrs,Other,17950603.0,
1504,306139,4,4,,123097261,31703,Active,,,0.909,IC50,Cytotoxicity againt multidrug-resistant human 2780AD cells,Confirmatory,17239597.0,
1505,306140,4,4,,123097261,31703,Active,,,0.013000000000000001,IC50,Cytotoxicity againt human A2780 cells,Confirmatory,17239597.0,
1506,307488,6,2,,123097261,31703,Active,,,0.1,GI50,Antitumor activity against human K562 cells after 48 hrs by sulforhodamine B protein assay,Confirmatory,17448574.0,
1507,307489,6,3,,123097261,31703,Active,,,0.2,GI50,Antitumor activity against human MDA-MB435 cells after 48 hrs by sulforhodamine B protein assay,Confirmatory,17448574.0,
1508,307733,6,2,,123097261,31703,Active,,,0.66,IC50,Growth inhibition of human WI38 cells,Confirmatory,17490878.0,
1509,307734,6,2,,123097261,31703,Active,,,0.38,IC50,Growth inhibition of human VA13 cells,Confirmatory,17490878.0,
1510,307735,6,2,,123097261,31703,Active,,,1.2,IC50,Growth inhibition of human HepG2 cells,Confirmatory,17490878.0,
1511,307745,8,1,,123097261,31703,Active,,,0.0057,IC50,Growth inhibition of human A2780 cells,Confirmatory,17490878.0,
1512,307749,4,3,,123097261,31703,Active,,,0.298,IC50,Growth inhibition of multidrug-resistant human 2780AD cells,Confirmatory,17490878.0,
1513,309600,6,2,,123097261,31703,Active,,,0.97,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,17827007.0,
1514,309601,6,2,,123097261,31703,Active,,,1.67,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,17827007.0,
1515,309602,6,3,,123097261,31703,Active,,,1.17,IC50,Cytotoxicity against human OV3 cells by SRB assay,Confirmatory,17827007.0,
1516,309603,6,2,,123097261,31703,Active,,,4.78,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,17827007.0,
1517,310050,6,2,,123097261,31703,Active,,,0.34700000000000003,IC50,Growth inhibition of doxorubicin-sensitive human MES-SA cells after 48 hrs by MTT assay,Confirmatory,17888666.0,
1518,310051,6,2,,123097261,31703,Active,,,1.55,IC50,Growth inhibition of doxorubicin-resistant human MES-SA/Dx5 cells after 48 hrs by MTT assay,Confirmatory,17888666.0,
1519,310118,5,3,,123097261,31703,Active,,,13.4896,IC50,Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
1520,310119,6,1,,123097261,31703,Active,,,0.09333,IC50,Cytotoxicity against human A2780 cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
1521,311152,8,1,,123097261,31703,Active,,,0.0595,ED50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,17655260.0,
1522,311153,8,1,,123097261,31703,Active,,,0.0595,ED50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,17655260.0,
1523,311630,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,17918910.0,
1524,311631,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,17918910.0,
1525,311632,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells by MTT assay,Other,17918910.0,
1526,311776,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells,Other,17970595.0,
1527,311777,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,17970595.0,
1528,312029,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells,Other,18052129.0,
1529,312030,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against multidrug-resistant human KB-C2 cells,Other,18052129.0,
1530,312032,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against multidrug-resistant human K562 cells,Other,18052129.0,
1531,312033,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against doxorubicin-resistant human K562/Adr cells,Other,18052129.0,
1532,312045,6,3,,123097261,31703,Active,,,1.26,IC50,Cytotoxicity against human PC3M cells by MTT assay,Confirmatory,18052324.0,
1533,312047,6,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human NCI-H460 cells by MTT assay,Confirmatory,18052326.0,
1534,312048,6,2,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human MCF7 cells by MTT assay,Confirmatory,18052326.0,
1535,312049,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human SF268 cells by MTT assay,Confirmatory,18052326.0,
1536,312657,6,1,,123097261,31703,Active,,,0.15849000000000002,IC50,Growth inhibition of human U373MG cells containing U373IRES plasmid after 1 hr,Confirmatory,18173233.0,
1537,312658,6,1,,123097261,31703,Active,,,0.15849000000000002,IC50,Growth inhibition of human U373MG cells containing UhCE1 expressing plasmid after 1 hr,Confirmatory,18173233.0,
1538,312659,6,1,,123097261,31703,Active,,,0.19952999999999999,IC50,Growth inhibition of human U373MG cells containing UhiCE expressing plasmid after 1 hr,Confirmatory,18173233.0,
1539,313468,5,2,,123097261,31703,Unspecified,,,2360.0,GI50,Photocytotoxicity against human HL60 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1540,313469,5,2,,123097261,31703,Unspecified,,,1450.0,GI50,Photocytotoxicity against human HL60 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1541,313470,5,3,,123097261,31703,Unspecified,,,3040.0,GI50,Photocytotoxicity against human NCTC 2544 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1542,313471,6,3,,123097261,31703,Unspecified,,,1320.0,GI50,Photocytotoxicity against human NCTC 2544 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1543,313472,5,2,,123097261,31703,Unspecified,,,8540.0,GI50,Photocytotoxicity against human LoVo cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1544,313473,5,2,,123097261,31703,Unspecified,,,5480.0,GI50,Photocytotoxicity against human LoVo cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay,Confirmatory,18023182.0,
1545,313794,6,2,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1546,313795,6,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1547,313796,6,3,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1548,313797,6,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human T47D cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1549,313798,6,2,,123097261,31703,Active,,,0.6,IC50,Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1550,313799,6,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,18063366.0,
1551,313800,6,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human A549 cells after 72 hrs by SRB assay,Confirmatory,18063366.0,
1552,314056,6,2,,123097261,31703,Active,,,1.57,IC50,Cytotoxicity against human DU145 cells,Confirmatory,18178085.0,
1553,314057,6,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human HCT116 cells,Confirmatory,18178085.0,
1554,314058,6,2,,123097261,31703,Active,,,3.09,IC50,Cytotoxicity against human HeLa cells,Confirmatory,18178085.0,
1555,314059,6,3,,123097261,31703,Active,,,1.39,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,18178085.0,
1556,314060,6,2,,123097261,31703,Active,,,0.72,IC50,Cytotoxicity against human HL60 cells,Confirmatory,18178085.0,
1557,315502,3,5,,123097261,31703,Inconclusive,,,,,Survival of human SIHA cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1558,315503,4,5,,123097261,31703,Unspecified,,,,,Survival of human SIHA cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1559,315504,3,5,,123097261,31703,Unspecified,,,,,Survival of human SIHA cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1560,315505,3,5,,123097261,31703,Unspecified,,,,,Survival of human SIHA cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1561,315506,4,5,,123097261,31703,Inconclusive,,,,,Survival of human SIHA cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1562,315507,3,5,,123097261,31703,Unspecified,,,,,Survival of human K562 cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1563,315508,3,5,,123097261,31703,Unspecified,,,,,Survival of human K562 cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1564,315509,3,5,,123097261,31703,Unspecified,,,,,Survival of human K562 cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1565,315510,3,5,,123097261,31703,Unspecified,,,,,Survival of human K562 cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1566,315511,3,5,,123097261,31703,Unspecified,,,,,Survival of human K562 cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1567,315512,3,5,,123097261,31703,Unspecified,,,,,Survival of human Raji cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1568,315513,3,5,,123097261,31703,Unspecified,,,,,Survival of human Raji cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1569,315514,3,5,,123097261,31703,Unspecified,,,,,Survival of human Raji cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1570,315515,3,5,,123097261,31703,Unspecified,,,,,Survival of human Raji cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1571,315516,3,5,,123097261,31703,Unspecified,,,,,Survival of human Raji cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1572,315517,3,5,,123097261,31703,Unspecified,,,,,Survival of human HeLa cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1573,315518,3,5,,123097261,31703,Unspecified,,,,,Survival of human HeLa cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1574,315519,3,5,,123097261,31703,Unspecified,,,,,Survival of human HeLa cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1575,315520,3,5,,123097261,31703,Unspecified,,,,,Survival of human HeLa cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1576,315521,3,5,,123097261,31703,Unspecified,,,,,Survival of human HeLa cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1577,315522,3,5,,123097261,31703,Unspecified,,,,,Survival of human H69 cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1578,315523,3,5,,123097261,31703,Unspecified,,,,,Survival of human H69 cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1579,315524,3,5,,123097261,31703,Unspecified,,,,,Survival of human H69 cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1580,315525,3,5,,123097261,31703,Unspecified,,,,,Survival of human H69 cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1581,315526,3,5,,123097261,31703,Unspecified,,,,,Survival of human H69 cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1582,315527,3,4,,123097261,31703,Unspecified,,,,,Survival of human H209 cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1583,315528,3,4,,123097261,31703,Unspecified,,,,,Survival of human H209 cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1584,315529,3,4,,123097261,31703,Unspecified,,,,,Survival of human H209 cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1585,315530,3,4,,123097261,31703,Unspecified,,,,,Survival of human H209 cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1586,315531,3,4,,123097261,31703,Unspecified,,,,,Survival of human H209 cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1587,315532,3,4,,123097261,31703,Unspecified,,,,,Survival of human 2780.9S cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1588,315533,3,4,,123097261,31703,Unspecified,,,,,Survival of human 2780.9S cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1589,315534,3,4,,123097261,31703,Unspecified,,,,,Survival of human 2780.9S cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1590,315535,3,4,,123097261,31703,Unspecified,,,,,Survival of human 2780.9S cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1591,315536,3,4,,123097261,31703,Unspecified,,,,,Survival of human 2780.9S cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1592,315537,3,4,,123097261,31703,Unspecified,,,,,Survival of human MDA-MB cells at 0.01 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1593,315538,3,4,,123097261,31703,Unspecified,,,,,Survival of human MDA-MB cells at 0.1 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1594,315539,3,4,,123097261,31703,Unspecified,,,,,Survival of human MDA-MB cells at 10 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1595,315540,3,4,,123097261,31703,Unspecified,,,,,Survival of human MDA-MB cells at 50 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1596,315541,3,4,,123097261,31703,Unspecified,,,,,Survival of human MDA-MB cells at 100 uM under deem light after 96 hrs by MTT assay relative to control,Other,17993275.0,
1597,315542,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human SIHA cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1598,315543,6,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human Raji cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1599,315544,6,3,,123097261,31703,Active,,,9.0,IC50,Cytotoxicity against human MDA-MB cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1600,315545,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human K562 cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1601,315546,6,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1602,315547,6,2,,123097261,31703,Active,,,3.0,IC50,Cytotoxicity against human H69 cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1603,315548,6,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1604,315549,6,3,,123097261,31703,Active,,,15.0,IC50,Cytotoxicity against human 2780.9S cells under deem light after 96 hrs by MTT assay,Confirmatory,17993275.0,
1605,315550,3,3,,123097261,31703,Unspecified,,,,,Photohemolysis in human RBC in absence of light,Other,17993275.0,
1606,316203,4,5,,123097261,31703,Active,,,0.0062,IC50,Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay,Confirmatory,18243696.0,
1607,317173,6,2,,123097261,31703,Active,,,0.027999999999999997,IC50,Antiproliferative activity against human NCI-H460 cells after 72 hrs by trypan blue test,Confirmatory,18077173.0,
1608,317333,3,5,,123097261,31703,Unspecified,,,,,Metabolic stability in human liver microsomal fraction assessed as formation of doxorubicin aglycone after 60 mins,Other,18024139.0,
1609,317334,3,4,,123097261,31703,Unspecified,,,,,Metabolic stability in human liver cytosolic fraction assessed as formation of doxorubicinol after 60 mins,Other,18024139.0,
1610,317475,6,2,,123097261,31703,Active,,,1.46,IC50,Cytotoxicity against human LoVo cells after 48 hrs by MTT assay,Confirmatory,18251492.0,
1611,317476,6,2,,123097261,31703,Active,,,44.89,IC50,Cytotoxicity against human multidrug resistant LoVo cells after 48 hrs by MTT assay,Confirmatory,18251492.0,
1612,317477,6,2,,123097261,31703,Active,,,30.74,IC50,"Resistant factor, ratio of IC50 for human multi drug resistant LoVo cells to IC50 for human LoVo cells",Confirmatory,18251492.0,
1613,317897,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Ehrlich Ascites carcinoma assessed as non viable cells at 200 umol/mL after 2 hrs by trypan blue exclusion assay,Other,18086527.0,
1614,317898,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Ehrlich Ascites carcinoma assessed as non viable cells at 100 umol/mL after 2 hrs by trypan blue exclusion assay,Other,18086527.0,
1615,317899,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Ehrlich Ascites carcinoma assessed as non viable cells at 75 umol/mL after 2 hrs by trypan blue exclusion assay,Other,18086527.0,
1616,317900,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Ehrlich Ascites carcinoma assessed as non viable cells at 50 umol/mL after 2 hrs by trypan blue exclusion assay,Other,18086527.0,
1617,317901,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Ehrlich Ascites carcinoma assessed as non viable cells at 25 umol/mL after 2 hrs by trypan blue exclusion assay,Other,18086527.0,
1618,317902,5,2,,123097261,31703,Unspecified,,,81.5,IC50,Cytotoxicity against mouse Ehrlich Ascites carcinoma after 2 hrs by trypan blue exclusion assay,Confirmatory,18086527.0,
1619,318575,7,1,,123097261,31703,Active,399134.0,,,,Binding affinity to Clostridium botulinum neurotoxin B,Other,18075579.0,
1620,319341,8,1,,123097261,31703,Active,,,0.18,IC50,Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay,Confirmatory,18313307.0,
1621,319342,6,2,,123097261,31703,Active,,,31.98,IC50,Growth inhibition of human KB V1 cells after 72 hrs by MTT assay,Confirmatory,18313307.0,
1622,319343,6,2,,123097261,31703,Unspecified,,,178.0,IC50,"Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells",Confirmatory,18313307.0,
1623,319344,8,1,,123097261,31703,Active,,,0.1,IC50,Growth inhibition of human HepG2 cells after 72 hrs by MTT assay,Confirmatory,18313307.0,
1624,319345,6,2,,123097261,31703,Active,,,36.74,IC50,Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay,Confirmatory,18313307.0,
1625,319346,6,2,,123097261,31703,Unspecified,,,334.0,IC50,"Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells",Confirmatory,18313307.0,
1626,319347,8,1,,123097261,31703,Active,,,0.24,IC50,Growth inhibition of human K562 cells after 72 hrs by SRB assay,Confirmatory,18313307.0,
1627,319348,6,2,,123097261,31703,Active,,,24.14,IC50,Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay,Confirmatory,18313307.0,
1628,319349,6,2,,123097261,31703,Unspecified,,,101.0,IC50,"Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells",Confirmatory,18313307.0,
1629,320405,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse Ehrlich ascites carcinoma cells at 100 ug/ml relative to doxorubicin after 2 hrs,Other,17962022.0,
1630,320406,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse Ehrlich ascites carcinoma cells at 50 ug/ml relative to doxorubicin after 2 hrs,Other,17962022.0,
1631,320407,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse Ehrlich ascites carcinoma cells at 25 ug/ml relative to doxorubicin after 2 hrs,Other,17962022.0,
1632,320408,6,2,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse Ehrlich ascites carcinoma cells,Other,17962022.0,
1633,321293,6,2,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human Zr-75-1 cells by SRB method,Confirmatory,18207392.0,
1634,321294,6,2,,123097261,31703,Active,,,0.18,GI50,Growth inhibition of human MCF7 cells by SRB method,Confirmatory,18207392.0,
1635,321295,6,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells by SRB method,Confirmatory,18207392.0,
1636,321296,6,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human Gurav cells by SRB method,Confirmatory,18207392.0,
1637,321297,6,2,,123097261,31703,Active,,,0.1,GI50,Growth inhibition of human DWD cells by SRB method,Confirmatory,18207392.0,
1638,321298,6,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human A2780 cells by SRB method,Confirmatory,18207392.0,
1639,321299,6,2,,123097261,31703,Active,,,0.15,GI50,Growth inhibition of human Colo205 cells by SRB method,Confirmatory,18207392.0,
1640,321300,6,2,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells by SRB method,Confirmatory,18207392.0,
1641,321301,6,2,,123097261,31703,Active,,,1.81,GI50,Growth inhibition of human PC3 cells by SRB method,Confirmatory,18207392.0,
1642,321302,6,2,,123097261,31703,Active,,,0.18,GI50,Growth inhibition of human SiHa cells by SRB method,Confirmatory,18207392.0,
1643,321727,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,17981462.0,
1644,321728,7,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human THP1 cells by MTT assay,Confirmatory,17981462.0,
1645,321884,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against adriamycin resistant human MCF7 cells at 5 uM after 48 hrs by MTT assay,Other,17936633.0,
1646,322365,6,2,,123097261,31703,Active,,,47.8,IC50,Antiproliferative activity against adriamycin resistant human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17964170.0,
1647,322366,6,2,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against wild type human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17964170.0,
1648,322372,3,4,,123097261,31703,Unspecified,,,,,Selectivity for IC50 for adriamycin resistant human MCF7 cells over IC50 for wild type human MCF7 cells,Other,17964170.0,
1649,322389,8,1,,123097261,31703,Active,,,0.0428,GI50,Cytotoxicity against human MCF7 cells after 48 hrs,Confirmatory,17964791.0,
1650,322390,8,1,,123097261,31703,Active,,,0.094,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs,Confirmatory,17964791.0,
1651,322391,8,1,,123097261,31703,Active,,,0.09300000000000001,GI50,Cytotoxicity against human SF268 cells after 48 hrs,Confirmatory,17964791.0,
1652,322404,6,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,18164206.0,
1653,322585,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKMEL cells by neutral red assay,Other,17976995.0,
1654,322586,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by neutral red assay,Other,17976995.0,
1655,322587,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells by neutral red assay,Other,17976995.0,
1656,322588,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-OV3 cells by neutral red assay,Other,17976995.0,
1657,322589,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells by neutral red assay,Other,17976995.0,
1658,322590,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK11 cells by neutral red assay,Other,17976995.0,
1659,323076,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by SRB assay,Other,17981473.0,
1660,323077,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells by SRB assay,Other,17981473.0,
1661,323078,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells by SRB assay,Other,17981473.0,
1662,324885,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PBL cells after 72 hrs by alamar blue assay,Other,18053728.0,
1663,327574,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human A549 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1664,327575,6,2,,123097261,31703,Active,,,0.040999999999999995,IC50,Cytotoxicity against human SKOV3 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1665,327576,6,2,,123097261,31703,Active,,,0.019,IC50,Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1666,327577,6,2,,123097261,31703,Active,,,0.044000000000000004,IC50,Cytotoxicity against human XF498 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1667,327578,6,2,,123097261,31703,Active,,,0.251,IC50,Cytotoxicity against human HCT15 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1668,327579,6,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human SNU638 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1669,327580,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human HT1080 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1670,327581,6,2,,123097261,31703,Active,,,0.044000000000000004,IC50,Cytotoxicity against human HL60 cells after 3 days by SRB assay,Confirmatory,18321715.0,
1671,327913,6,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human K562 cells by SRB method,Confirmatory,18181575.0,
1672,327914,6,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HepG2 cells by SRB method,Confirmatory,18181575.0,
1673,327915,8,1,,123097261,31703,Unspecified,,,400.0,IC50,Cytotoxicity against human KB cells by SRB method,Confirmatory,18181575.0,
1674,327916,8,1,,123097261,31703,Unspecified,,,400.0,IC50,Cytotoxicity against human LoVo cells by SRB method,Confirmatory,18181575.0,
1675,328131,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells at 0.5 ug/mL by MTT assay,Other,18198839.0,
1676,328132,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 0.5 ug/mL by MTT assay,Other,18198839.0,
1677,328133,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-23 cells at 0.5 ug/mL by MTT assay,Other,18198839.0,
1678,328134,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells at 0.5 ug/mL by MTT assay,Other,18198839.0,
1679,329215,6,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human NCI-H460 cells by MTT assay,Confirmatory,18247573.0,
1680,329216,6,2,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human MCF7 cells by MTT assay,Confirmatory,18247573.0,
1681,329217,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human SF268 cells by MTT assay,Confirmatory,18247573.0,
1682,329218,6,3,,123097261,31703,Active,,,1.11,IC50,Antiproliferative activity against human PC3M cells by MTT assay,Confirmatory,18247573.0,
1683,329219,6,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human MIAPaCa2 cells by MTT assay,Confirmatory,18247573.0,
1684,330746,6,2,,123097261,31703,Active,,,10.0,IC50,Growth inhibition of Saccharomyces cerevisiae W301,Confirmatory,18040043.0,
1685,331356,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human K562/A02 cells xenografted in nude mouse assessed as tumor weight at 2 mg/kg,Other,18502125.0,
1686,332396,6,3,,123097261,31703,Unspecified,,,,,Toxicity in brine shrimp larvae,Other,8201311.0,
1687,332397,4,4,,123097261,31703,Inconclusive,,,,,Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors in potato by disk test relative to control,Other,8201311.0,
1688,332398,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days,Other,8201311.0,
1689,332399,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days,Other,8201311.0,
1690,332400,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days,Other,8201311.0,
1691,332431,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days,Other,8021648.0,
1692,332432,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days,Other,8021648.0,
1693,332433,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days,Other,8021648.0,
1694,332873,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse doxorubicin-sensitive P388 cells after 3 days,Other,3819736.0,
1695,332874,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse doxorubicin-resistant P388 cells after 3 days,Other,3819736.0,
1696,332886,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human 9KB cells after 3 days,Other,3819736.0,
1697,333254,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Other,15387653.0,
1698,333255,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells after 3 days by MTT assay,Other,15387653.0,
1699,333256,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Other,15387653.0,
1700,333257,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 3 days by MTT assay,Other,15387653.0,
1701,333258,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Other,15387653.0,
1702,333305,6,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human KB cells,Confirmatory,15387664.0,
1703,333354,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,15497935.0,
1704,333355,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,15497935.0,
1705,333356,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,15497935.0,
1706,333357,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,15497935.0,
1707,333358,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,15497935.0,
1708,333688,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human NCI-H460 cells by MTT assay,Confirmatory,15620238.0,
1709,333689,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,15620238.0,
1710,333690,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human SF268 cells by MTT assay,Confirmatory,15620238.0,
1711,333691,6,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human MIAPaCa2 cells by MTT assay,Confirmatory,15620238.0,
1712,333692,6,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human WI38 cells by MTT assay,Confirmatory,15620238.0,
1713,333751,6,2,,123097261,31703,Active,,,0.09300000000000001,GI50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,15620248.0,
1714,333752,6,2,,123097261,31703,Active,,,0.043,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,15620248.0,
1715,333753,6,2,,123097261,31703,Active,,,0.094,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,15620248.0,
1716,333754,3,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as fragmentation of genomic DNA at 0.043 uM after 48 hrs by TUNEL assay,Other,15620248.0,
1717,334001,10,1,,123097261,31703,Inconclusive,,,,,Toxicity to brine shrimp,Other,9322367.0,
1718,334002,7,2,,123097261,31703,Inconclusive,,,,,Insecticidal activity against yellow fever mosquito larvae by microtiter plate assay,Other,9322367.0,
1719,334003,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9322367.0,
1720,334004,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9322367.0,
1721,334005,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,9322367.0,
1722,334006,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9322367.0,
1723,334007,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9322367.0,
1724,334008,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9322367.0,
1725,334384,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days,Other,1593281.0,
1726,334385,10,1,,123097261,31703,Inconclusive,,,,,Toxicity against brine shrimp larvae,Other,1593281.0,
1727,334386,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days,Other,1593281.0,
1728,334387,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days,Other,1593281.0,
1729,334780,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8377016.0,
1730,334781,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8377016.0,
1731,334782,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,8377016.0,
1732,335264,6,1,,123097261,31703,Inconclusive,,,,,Toxicity against brine shrimp,Other,2348205.0,
1733,335265,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,2348205.0,
1734,335266,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,2348205.0,
1735,335267,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,2348205.0,
1736,335554,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human LOXIMVI cells by sulforhodamine B method,Other,12193011.0,
1737,335555,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B method,Other,12193011.0,
1738,335556,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SNB19 cells by sulforhodamine B method,Other,12193011.0,
1739,335557,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human U251 cells by sulforhodamine B method,Other,12193011.0,
1740,335558,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SW620 cells by sulforhodamine B method,Other,12193011.0,
1741,335559,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by sulforhodamine B method,Other,12193011.0,
1742,335560,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by sulforhodamine B method,Other,12193011.0,
1743,335561,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by sulforhodamine B method,Other,12193011.0,
1744,336014,3,5,,123097261,31703,Unspecified,,,,,Growth inhibition of mouse P388 cells at 1 ug/mL after 48 hrs relative to control,Other,1479379.0,
1745,336015,3,5,,123097261,31703,Unspecified,,,,,Growth inhibition of mouse P388 cells at 0.1 ug/mL after 48 hrs relative to control,Other,1479379.0,
1746,336016,3,5,,123097261,31703,Unspecified,,,,,Growth inhibition of mouse P388 cells at 0.01 ug/mL after 48 hrs relative to control,Other,1479379.0,
1747,336118,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,12350153.0,
1748,336119,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,12350153.0,
1749,336120,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,12350153.0,
1750,336121,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,12350153.0,
1751,336122,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,12350153.0,
1752,336584,6,3,,123097261,31703,Unspecified,,,,,Toxicity in brine shrimp,Other,1453182.0,
1753,336585,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days,Other,1453182.0,
1754,336586,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days,Other,1453182.0,
1755,336587,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days,Other,1453182.0,
1756,336784,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,12662097.0,
1757,336785,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,12662097.0,
1758,336786,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,12662097.0,
1759,336787,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,12662097.0,
1760,336788,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,12662097.0,
1761,337060,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,12662102.0,
1762,337061,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,12662102.0,
1763,337062,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,12662102.0,
1764,337063,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,12662102.0,
1765,337064,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,12662102.0,
1766,337092,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,12762820.0,
1767,337093,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,12762820.0,
1768,337094,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,12762820.0,
1769,337095,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,12762820.0,
1770,337096,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,12762820.0,
1771,337805,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells at 1 g/ml after 48 hrs by coulter counter method,Other,1791470.0,
1772,337806,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells at 0.1 g/ml after 48 hrs by coulter counter method,Other,1791470.0,
1773,337807,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells at 0.01 g/ml after 48 hrs by coulter counter method,Other,1791470.0,
1774,338111,9,1,,123097261,31703,Unspecified,,,,,Toxicity against brine shrimp,Other,1791471.0,
1775,338112,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,1791471.0,
1776,338113,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,1791471.0,
1777,338114,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,1791471.0,
1778,338424,8,1,,123097261,31703,Unspecified,,,,,Toxicity against brine shrimp,Other,1665173.0,
1779,338425,5,4,,123097261,31703,Unspecified,,,,,Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumor in potato tubers,Other,1665173.0,
1780,338426,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,1665173.0,
1781,338427,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,1665173.0,
1782,338428,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,1665173.0,
1783,338793,8,1,,123097261,31703,Unspecified,,,,,Toxicity in Artemia salina,Other,1602301.0,
1784,338795,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,1602301.0,
1785,338796,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,1602301.0,
1786,338797,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,1602301.0,
1787,338835,7,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against mouse EAC after 3 days by MTT assay,Confirmatory,8350087.0,
1788,338849,10,1,,123097261,31703,Unspecified,,,,,Toxicity in brine shrimp,Other,8350089.0,
1789,338850,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8350089.0,
1790,338851,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8350089.0,
1791,338852,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,8350089.0,
1792,338914,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days,Other,11975482.0,
1793,338915,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2(2.2.15) cells after 3 days,Other,11975482.0,
1794,340028,6,2,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A549 cells after 72 hrs by SRB assay,Confirmatory,18585035.0,
1795,340029,6,2,,123097261,31703,Active,,,0.06,GI50,Growth inhibition of human DU145 cells after 72 hrs by SRB assay,Confirmatory,18585035.0,
1796,340030,6,2,,123097261,31703,Active,,,0.21,GI50,Growth inhibition of human HT29 cells after 72 hrs by SRB assay,Confirmatory,18585035.0,
1797,340031,6,2,,123097261,31703,Active,,,0.11,GI50,Growth inhibition of human SK-MEL-2 cells after 72 hrs by SRB assay,Confirmatory,18585035.0,
1798,340032,6,2,,123097261,31703,Active,,,0.12,GI50,Growth inhibition of human SKOV3 cells after 72 hrs by SRB assay,Confirmatory,18585035.0,
1799,340327,9,5,,123097261,31703,Inconclusive,12644067.0,8913.0,,IC50,Inhibition of T-type calcium channel Cav3.1 alpha1G expressed in HEK293 cells by whole cell patch-clamp method,Confirmatory,18585035.0,
1800,340420,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 72 hrs by SRB assay,Other,18590312.0,
1801,340421,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Other,18590312.0,
1802,340422,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay,Other,18590312.0,
1803,340423,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay,Other,18590312.0,
1804,340424,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Other,18590312.0,
1805,340425,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Other,18590312.0,
1806,342725,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,18590313.0,
1807,342726,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,18590313.0,
1808,342727,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,18590313.0,
1809,342728,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,18590313.0,
1810,342729,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,18590313.0,
1811,342730,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human sCa9-22 cells by MTT assay,Other,18590313.0,
1812,342738,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells by MTT assay,Other,18590313.0,
1813,343504,6,2,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,18547115.0,
1814,343505,6,3,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human Hep3B cells after 3 days by MTT assay,Confirmatory,18547115.0,
1815,343506,6,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human A549 cells after 3 days by MTT assay,Confirmatory,18547115.0,
1816,343507,6,3,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Confirmatory,18547115.0,
1817,343508,6,2,,123097261,31703,Active,,,0.65,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,18547115.0,
1818,347581,6,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human K562 cells after 48 hrs,Confirmatory,19220018.0,
1819,347582,6,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetric assay,Confirmatory,19220018.0,
1820,348351,6,3,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human KB 3.1 cells after 24 hrs by MTT assay,Confirmatory,17949859.0,
1821,348352,6,3,,123097261,31703,Active,,,0.0004,IC50,Antiproliferative activity against human KB 3.1 cells after 72 hrs by MTT assay,Confirmatory,17949859.0,
1822,348353,3,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human KB 3.1 cells after 24 hrs to IC50 for human KB 3.1 cells after 72 hrs by MTT assay,Other,17949859.0,
1823,348354,6,2,,123097261,31703,Active,,,0.018000000000000002,IC50,Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,17949859.0,
1824,348355,6,2,,123097261,31703,Active,,,0.0007,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17949859.0,
1825,348356,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human sMCF7 cells after 24 hrs to IC50 for human MCF7 cells after 72 hrs by MTT assay,Other,17949859.0,
1826,351328,6,3,,123097261,31703,Active,,,0.0051,GI50,Antiproliferative activity against human MESSA cells by SRB assay,Confirmatory,19394218.0,
1827,351329,6,2,,123097261,31703,Active,,,0.93,GI50,Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay,Confirmatory,19394218.0,
1828,351330,6,2,,123097261,31703,Active,,,0.19,GI50,Antiproliferative activity against human HCT15 cells by SRB assay,Confirmatory,19394218.0,
1829,351331,6,2,,123097261,31703,Active,,,7.92,GI50,Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay,Confirmatory,19394218.0,
1830,351332,6,2,,123097261,31703,Active,,,0.021,GI50,Antiproliferative activity against human SKOV3 cells by SRB assay,Confirmatory,19394218.0,
1831,351333,6,2,,123097261,31703,Active,,,0.0012,GI50,Antiproliferative activity against human A431 cells by SRB assay,Confirmatory,19394218.0,
1832,351336,6,2,,123097261,31703,Active,,,0.003,GI50,Antiproliferative activity against human A549 cells by SRB assay,Confirmatory,19394218.0,
1833,351578,6,2,,123097261,31703,Active,,,0.078,IC50,Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1834,351579,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1835,351580,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1836,351581,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1837,351582,6,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1838,351583,6,2,,123097261,31703,Active,,,1.9,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
1839,352210,6,2,,123097261,31703,Active,,,8.3,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,19329312.0,
1840,352211,6,2,,123097261,31703,Active,,,10.2,IC50,Cytotoxicity against human MDA-MB-231 cells MTT assay,Confirmatory,19329312.0,
1841,352212,6,2,,123097261,31703,Active,,,14.3,IC50,Cytotoxicity against human HepG2 cells MTT assay,Confirmatory,19329312.0,
1842,352213,3,4,,123097261,31703,Unspecified,,,,,Drug uptake in human MCF7 cells by by flow cytometry,Other,19329312.0,
1843,352214,3,4,,123097261,31703,Unspecified,,,,,Drug uptake in human MDA-MB-231 cells by by flow cytometry,Other,19329312.0,
1844,353085,8,1,,123097261,31703,Active,,,0.0041600000000000005,IC50,Cytotoxicity against human SKOV3 cells by MTT assay,Confirmatory,19345581.0,
1845,353089,8,1,,123097261,31703,Active,,,0.0011300000000000001,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19345581.0,
1846,353090,8,1,,123097261,31703,Active,,,0.00445,IC50,Cytotoxicity against human U937 cells by MTT assay,Confirmatory,19345581.0,
1847,353091,8,1,,123097261,31703,Active,,,0.006659999999999999,IC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,19345581.0,
1848,353094,8,2,,123097261,31703,Active,,,0.00473,IC50,Cytotoxicity against human GOTO cells by MTT assay,Confirmatory,19345581.0,
1849,353095,8,2,,123097261,31703,Active,,,0.00515,IC50,Cytotoxicity against human NB-1 cells by MTT assay,Confirmatory,19345581.0,
1850,353190,10,1,,123097261,31703,Active,,,0.016,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19285863.0,
1851,353191,10,2,,123097261,31703,Active,,,0.013000000000000001,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,19285863.0,
1852,353192,10,1,,123097261,31703,Active,,,0.049,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19285863.0,
1853,353193,10,1,,123097261,31703,Active,,,0.0037,IC50,Cytotoxicity against human SMMC-7541 cells after 72 hrs by MTT assay,Confirmatory,19285863.0,
1854,353194,10,1,,123097261,31703,Active,,,0.026000000000000002,IC50,Cytotoxicity against human A-5408 cells after 72 hrs by MTT assay,Confirmatory,19285863.0,
1855,354426,6,2,,123097261,31703,Active,,,0.23,IC50,Cytotoxicity against human HCT15 cells,Confirmatory,12608854.0,
1856,354427,6,2,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,12608854.0,
1857,354428,6,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human U251 cells,Confirmatory,12608854.0,
1858,354429,6,2,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human PC3 cells,Confirmatory,12608854.0,
1859,354430,6,2,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against human K562 cells,Confirmatory,12608854.0,
1860,354437,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay,Other,12608856.0,
1861,354438,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A375 cells after 24 hrs by MTT assay,Other,12608856.0,
1862,354439,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Other,12608856.0,
1863,354440,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HPC cells after 24 hrs by MTT assay,Other,12608856.0,
1864,354505,10,1,,123097261,31703,Unspecified,,,,,Toxicity in Artemia salina,Other,8991957.0,
1865,354506,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8991957.0,
1866,354507,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8991957.0,
1867,354508,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells,Other,8991957.0,
1868,354509,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells,Other,8991957.0,
1869,354510,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells,Other,8991957.0,
1870,354511,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells,Other,8991957.0,
1871,354520,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells,Other,8778247.0,
1872,354522,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8778247.0,
1873,354523,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8778247.0,
1874,354524,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells,Other,8778247.0,
1875,354525,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells,Other,8778247.0,
1876,354526,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells,Other,8778247.0,
1877,354538,3,4,,123097261,31703,Inactive,,,,,Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Other,8988604.0,
1878,354542,3,4,,123097261,31703,Inactive,,,,,Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs,Other,8988604.0,
1879,354543,3,4,,123097261,31703,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
1880,354582,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,8882434.0,
1881,354583,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,8882434.0,
1882,354584,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,8882434.0,
1883,354585,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,8882434.0,
1884,354586,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,8882434.0,
1885,354587,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,8882434.0,
1886,354680,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB assay,Other,,
1887,354681,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by SRB assay,Other,,
1888,354682,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Other,,
1889,354683,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells by SRB assay,Other,,
1890,354684,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by SRB assay,Other,,
1891,354690,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,8882437.0,
1892,354691,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,8882437.0,
1893,354692,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,8882437.0,
1894,354693,7,2,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp,Other,8882437.0,
1895,354853,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,8759170.0,
1896,354855,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells,Other,8759170.0,
1897,355125,11,1,,123097261,31703,Unspecified,,,,,Toxicity to brine shrimp,Other,8946744.0,
1898,355126,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8946744.0,
1899,355127,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8946744.0,
1900,355128,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells,Other,8946744.0,
1901,355129,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells,Other,8946744.0,
1902,355130,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells,Other,8946744.0,
1903,355131,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells,Other,8946744.0,
1904,355166,7,2,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp larvae,Other,8904848.0,
1905,355167,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,8904848.0,
1906,355168,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,8904848.0,
1907,355169,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,8904848.0,
1908,355170,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,8904848.0,
1909,355171,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,8904848.0,
1910,355172,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,8904848.0,
1911,355174,11,1,,123097261,31703,Unspecified,,,,,Toxicity to Artemia salina,Other,8946743.0,
1912,355175,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,8946743.0,
1913,355176,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,8946743.0,
1914,355177,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,8946743.0,
1915,355178,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,8946743.0,
1916,355179,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,8946743.0,
1917,355180,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,8946743.0,
1918,355290,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB assay,Other,9392887.0,
1919,355291,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by SRB assay,Other,9392887.0,
1920,355292,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Other,9392887.0,
1921,355293,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells by SRB assay,Other,9392887.0,
1922,355294,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by SRB assay,Other,9392887.0,
1923,355428,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,15104515.0,
1924,355429,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,15104515.0,
1925,355430,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,15104515.0,
1926,355431,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,15104515.0,
1927,355432,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,15104515.0,
1928,355578,9,1,,123097261,31703,Active,,,0.037000000000000005,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
1929,355580,3,5,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1930,355581,3,5,,123097261,31703,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1931,355582,3,5,,123097261,31703,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1932,355583,9,1,,123097261,31703,Active,,,0.07400000000000001,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
1933,355584,3,5,,123097261,31703,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1934,355585,3,5,,123097261,31703,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1935,355586,3,5,,123097261,31703,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1936,355863,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,12762806.0,
1937,355864,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,12762806.0,
1938,356016,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,12828475.0,
1939,356017,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells,Other,12828475.0,
1940,356018,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells,Other,12828475.0,
1941,356099,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells,Other,12880315.0,
1942,356100,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells,Other,12880315.0,
1943,356101,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells,Other,12880315.0,
1944,356102,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,12880315.0,
1945,356568,10,1,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp larvae,Other,14575439.0,
1946,356569,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,14575439.0,
1947,356570,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,14575439.0,
1948,356571,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,14575439.0,
1949,356572,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,14575439.0,
1950,356573,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,14575439.0,
1951,356574,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,14575439.0,
1952,356575,3,3,,123097261,31703,Inactive,,,,,Neuritogenic activity in mouse Neuro2a cells assessed as morphological changes at 3 ug/mL after 24 or 48 hrs,Other,14575440.0,
1953,356599,4,4,,123097261,31703,Active,,,0.059000000000000004,IC50,Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,14640513.0,
1954,356605,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,14640517.0,
1955,356606,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,14640517.0,
1956,356607,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,14640517.0,
1957,356608,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,14640517.0,
1958,356609,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,14640517.0,
1959,356623,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,14640526.0,
1960,356624,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,14640526.0,
1961,356625,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,14640526.0,
1962,356626,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,14640526.0,
1963,356627,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,14640526.0,
1964,356639,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,14640527.0,
1965,356640,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,14640527.0,
1966,356641,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,14640527.0,
1967,356642,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,14640527.0,
1968,356643,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,14640527.0,
1969,356688,9,5,,123097261,31703,Active,18202057.0,,25.0,IC50,Inhibition of Streptomyces caespitosus Sca 1 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
1970,356689,9,5,,123097261,31703,Unspecified,6226780.0,7015.0,73.0,IC50,Inhibition of telomerase from human COLO201 cell,Confirmatory,11430001.0,
1971,356691,3,3,,123097261,31703,Active,,,,,Binding affinity to salmon sperm DNA assessed as DNA intercalation by circular dichroism,Other,11430001.0,
1972,356998,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method,Other,11473425.0,
1973,356999,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2(2.2.15) cells after 12 days by methylene blue colorimetric method,Other,11473425.0,
1974,357047,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Other,11473441.0,
1975,357229,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay,Other,12502329.0,
1976,357251,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by MTT assay,Other,12502336.0,
1977,357252,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HEPA 59T/VGH cells by MTT assay,Other,12502336.0,
1978,357331,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,11520227.0,
1979,357332,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,11520227.0,
1980,357333,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,11520227.0,
1981,357334,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,11520227.0,
1982,357335,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,11520227.0,
1983,357642,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human KB cells,Confirmatory,11575949.0,
1984,357845,4,4,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method,Other,1812211.0,
1985,357846,4,4,,123097261,31703,Unspecified,,,,,Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method,Other,1812211.0,
1986,357952,8,1,,123097261,31703,Active,,,0.055,GI50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,11678649.0,
1987,357953,8,1,,123097261,31703,Active,,,0.57,GI50,Cytotoxicity against human TK10 cells by SRB assay,Confirmatory,11678649.0,
1988,357954,8,1,,123097261,31703,Active,,,0.094,GI50,Cytotoxicity against human UACC62 cells by SRB assay,Confirmatory,11678649.0,
1989,357955,8,1,,123097261,31703,Active,,,0.0081,GI50,Cytotoxicity against human NCI-H460 cells by SRB assay,Confirmatory,11678649.0,
1990,357956,8,1,,123097261,31703,Active,,,0.09300000000000001,GI50,Cytotoxicity against human SF268 cells by SRB assay,Confirmatory,11678649.0,
1991,358225,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,11678655.0,
1992,358226,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,11678655.0,
1993,358227,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,11678655.0,
1994,358228,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,11678655.0,
1995,358229,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,11678655.0,
1996,358555,7,2,,123097261,31703,Active,,,0.0072,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,11170674.0,
1997,358642,6,3,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human multidrug-resistant SKVLB1 cells,Confirmatory,11754602.0,
1998,358643,6,2,,123097261,31703,Active,,,0.008,IC50,Cytotoxicity against human SKOV3 cells,Confirmatory,11754602.0,
1999,359244,3,4,,123097261,31703,Active,,,,,"Antitumor activity in Brca1 and p53 deficient K14cre mouse hereditary breast cancer model at 5 mg/kg, iv",Other,17626183.0,
2000,359247,6,1,,123097261,31703,Unspecified,,,,,"Antitumor activity in Brca1 and p53 deficient mouse mammary tumor cell xenografted mouse hereditary breast cancer model assessed as median survival at 5 mg/kg, iv",Other,17626183.0,
2001,359377,6,3,,123097261,31703,Unspecified,,,,,Toxicity in brine shrimp,Other,1479382.0,
2002,359378,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,1479382.0,
2003,359379,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,1479382.0,
2004,359380,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,1479382.0,
2005,359651,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,1294696.0,
2006,359652,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,1294696.0,
2007,359653,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,1294696.0,
2008,359696,8,2,,123097261,31703,Inconclusive,,,,,Toxicity to Artemia salina,Other,11325235.0,
2009,359697,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,11325235.0,
2010,359698,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,11325235.0,
2011,359699,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,11325235.0,
2012,359700,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,11325235.0,
2013,359701,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,11325235.0,
2014,359702,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,11325235.0,
2015,359757,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,11325244.0,
2016,359758,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay,Other,11325244.0,
2017,359759,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay,Other,11325244.0,
2018,359760,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells after 48 hrs by SRB assay,Other,11325244.0,
2019,359761,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay,Other,11325244.0,
2020,359889,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7714532.0,
2021,359890,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7714532.0,
2022,359891,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7714532.0,
2023,359892,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by MTT assay,Other,7714533.0,
2024,359893,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells by MTT assay,Other,7714533.0,
2025,359894,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A431 cells by MTT assay,Other,7714533.0,
2026,359895,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,7714533.0,
2027,359896,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,7714533.0,
2028,359897,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,7714533.0,
2029,359898,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells by MTT assay,Other,7714533.0,
2030,359899,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-5 cells by MTT assay,Other,7714533.0,
2031,359927,7,3,,123097261,31703,Inconclusive,,,,,Toxicity to brine shrimp larvae,Other,8676130.0,
2032,359928,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,8676130.0,
2033,359929,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,8676130.0,
2034,359930,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,8676130.0,
2035,359931,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,8676130.0,
2036,359932,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,8676130.0,
2037,359933,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,8676130.0,
2038,360002,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay,Other,11374943.0,
2039,360003,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay,Other,11374943.0,
2040,360004,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay,Other,11374943.0,
2041,360005,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay,Other,11374943.0,
2042,360017,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs by neutral red staining,Other,11374944.0,
2043,360196,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human CRL1579 cells after 48 hrs by SRB assay,Other,,
2044,360197,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay,Other,,
2045,360198,4,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KM12 cells after 48 hrs by SRB assay,Other,,
2046,360199,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human UO31 cells after 48 hrs by SRB assay,Other,,
2047,360200,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MOLT4F cells after 48 hrs by SRB assay,Other,,
2048,360499,10,1,,123097261,31703,Unspecified,,,,,Toxicity in ip dosed mouse,Other,8594149.0,
2049,361230,6,2,,123097261,31703,Unspecified,,,200.0,IC50,Inhibition of wheat germ topoisomerase 1 assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2050,361231,9,2,,123097261,31703,Unspecified,,,200.0,IC50,Inhibition calf thymus gland topoisomerase 1 assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2051,361232,9,5,,123097261,31703,Unspecified,158518540.0,21969.0,200.0,IC50,Inhibition topoisomerase 1 in mouse NIH/3T3 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2052,361233,9,5,,123097261,31703,Unspecified,38503303.0,,200.0,IC50,Inhibition topoisomerase 1 in african green monkey Vero cells assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2053,361234,9,5,,123097261,31703,Unspecified,12644118.0,7150.0,200.0,IC50,Inhibition topoisomerase 1 in human A549 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2054,361235,9,5,,123097261,31703,Unspecified,12644118.0,7150.0,200.0,IC50,Inhibition topoisomerase 1 in human COLO201 cells assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2055,361236,9,5,,123097261,31703,Unspecified,12644118.0,7150.0,200.0,IC50,Inhibition topoisomerase 1 in human HeLa cells assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2056,361237,9,5,,123097261,31703,Active,13959709.0,7153.0,1.0,IC50,Inhibition human placenta topoisomerase 2 assessed as conversion of supercoiled pBR322 DNA to relaxed form,Confirmatory,11430001.0,
2057,361238,9,5,,123097261,31703,Active,13959709.0,7153.0,1.0,IC50,Inhibition human placenta topoisomerase 2 assessed as conversion of catenated kinetoplast DNA to minicircle monomer,Confirmatory,11430001.0,
2058,361239,9,5,,123097261,31703,Active,48429071.0,282340.0,25.0,IC50,Inhibition of bovine pancreas RNase A assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2059,361240,6,7,,123097261,31703,Unspecified,6015029.0,282217.0,200.0,IC50,Inhibition of bovine pancreas DNase 1 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2060,361241,6,7,,123097261,31703,Unspecified,3913520.0,397398.0,200.0,IC50,Inhibition of porcine spleen DNase 2 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2061,361242,6,7,,123097261,31703,Unspecified,118770.0,1258680.0,200.0,IC50,Inhibition of T4 ligase from bacteriophage infected Escherichia coli assessed as ligation of supercoiled pBR322 DNA,Confirmatory,11430001.0,
2062,361244,6,2,,123097261,31703,Active,,,24.0,IC50,Inhibition of Arthrobacter luteus AluI assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2063,361245,6,7,,123097261,31703,Unspecified,135217.0,,200.0,IC50,Inhibition of Bacillus amyloliquifaction Bam H1 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2064,361246,6,7,,123097261,31703,Unspecified,135227.0,,200.0,IC50,Inhibition of Escherichia coli Eco R1 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2065,361247,10,5,,123097261,31703,Unspecified,1174568.0,,96.0,IC50,Inhibition of Haemophilus influenzae Hind 3 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2066,361248,10,5,,123097261,31703,Unspecified,135244.0,,200.0,IC50,Inhibition of Providencia stuartii Pst 1 assessed as undigested supercoiled pBR322 DNA concentration,Confirmatory,11430001.0,
2067,361301,6,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,17227762.0,
2068,361302,6,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,17227762.0,
2069,361303,6,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human PBMC after 72 hrs by MTT assay,Confirmatory,17227762.0,
2070,361304,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs,Confirmatory,17227762.0,
2071,362654,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human CEM-TART cells after 72 hrs by MTT assay,Other,18710283.0,
2072,364570,6,2,,123097261,31703,Unspecified,,,10.0,IC50,Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay,Confirmatory,18281125.0,
2073,364571,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human A375 cells after 24 hrs by MTT assay,Confirmatory,18281125.0,
2074,364572,6,3,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay,Confirmatory,18281125.0,
2075,364573,6,2,,123097261,31703,Active,,,15.51,IC50,Cytotoxicity against human PBMC cells after 24 hrs by MTT assay,Confirmatory,18281125.0,
2076,365412,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
2077,365416,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HOP62 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
2078,365420,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
2079,365436,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
2080,365444,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
2081,366084,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human Hop62 cells by SRB assay,Confirmatory,18656370.0,
2082,366085,6,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human SiHa cells by SRB assay,Confirmatory,18656370.0,
2083,366086,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,18656370.0,
2084,366087,6,3,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human ZR751 cells by SRB assay,Confirmatory,18656370.0,
2085,366088,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human PC3 cells by SRB assay,Confirmatory,18656370.0,
2086,366089,6,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human Colo205 cells by SRB assay,Confirmatory,18656370.0,
2087,366090,6,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human A2780 cells by SRB assay,Confirmatory,18656370.0,
2088,366461,6,2,,123097261,31703,Active,,,7.25,GI50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2089,366462,6,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2090,366463,6,2,,123097261,31703,Active,,,1.79,GI50,Cytotoxicity against human Zr-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2091,366464,6,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2092,366465,6,3,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human AW13516 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2093,366466,6,3,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human AW8507 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2094,366467,6,2,,123097261,31703,Active,,,1.72,GI50,Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2095,366468,6,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2096,366469,6,2,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human SiHa cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2097,366470,6,2,,123097261,31703,Active,,,1.81,GI50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2098,366471,6,2,,123097261,31703,Active,,,0.16,GI50,Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18657979.0,
2099,368050,3,4,,123097261,31703,Inactive,,,,,"Antitumor activity against adriablastin-resistant human MT3 cells expressing p-glycoprotein xenografted in NMRI nude mouse at 6 mg/kg, iv administered on day 13 and 20",Other,19131246.0,
2100,368230,6,2,,123097261,31703,Active,,,0.018000000000000002,IC50,Anticancer activity against human HL60 cells by MTT assay,Confirmatory,19136263.0,
2101,368374,7,1,,123097261,31703,Active,,,,,Reversal of P-glycoprotein-mediated multidrug resistance in human doxorubicin-resistant K562 cells assessed as drug level causing maximum increase in nuclear concentration of pirarubicin by spectrofluorimetry relative to control,Other,19140665.0,
2102,368379,6,2,,123097261,31703,Active,,,0.032,IC50,Cytotoxicity against human doxorubicin-sensitive K562 cells after 72 hrs by MTT assay,Confirmatory,19140665.0,
2103,368380,6,2,,123097261,31703,Active,,,2.84,IC50,Cytotoxicity against human doxorubicin-resistant K562 cells expressing Pgp after 72 hrs by MTT assay,Confirmatory,19140665.0,
2104,370458,6,2,,123097261,31703,Active,,,3.4,IC50,Cytotoxicity against mouse wild type MEF cells after 72 hrs by SRB assay,Confirmatory,19186946.0,
2105,370459,6,3,,123097261,31703,Active,,,1.4,IC50,Cytotoxicity against human Hs888Lu cells after 72 hrs by SRB assay,Confirmatory,19186946.0,
2106,371454,6,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human SKHEP1 cells by SRB assay,Other,18023932.0,
2107,371455,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MDA-MB-231 cells by SRB assay,Other,18023932.0,
2108,371456,6,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NUGC3 cells by SRB assay,Other,18023932.0,
2109,371561,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,18990572.0,
2110,371562,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,18990572.0,
2111,371563,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,18990572.0,
2112,371564,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,18990572.0,
2113,371565,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,18990572.0,
2114,375433,9,5,,123097261,31703,Unspecified,21263835.0,64805.0,10.0,Ki,Displacement of [3H]PSB0413 from human platelet P2Y12 receptor,Confirmatory,19463000.0,
2115,375434,4,7,,123097261,31703,Unspecified,21263835.0,64805.0,,,Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM,Other,19463000.0,
2116,375536,6,2,,123097261,31703,Active,,,1.15,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by Alamar Blue assay,Confirmatory,19473028.0,
2117,375537,6,3,,123097261,31703,Active,,,0.76,IC50,Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar Blue assay,Confirmatory,19473028.0,
2118,375538,6,2,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay,Confirmatory,19473028.0,
2119,376078,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 2 mg/kg/day, ip after 9 days",Other,541685.0,
2120,376079,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 1 mg/kg/day, ip after 9 days",Other,541685.0,
2121,376080,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 0.5 mg/kg/day, ip after 9 days",Other,541685.0,
2122,376081,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 0.25 mg/kg/day, ip after 9 days",Other,541685.0,
2123,376082,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 2 mg/kg/day, iv after 9 days",Other,541685.0,
2124,376083,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 1 mg/kg/day, iv after 9 days",Other,541685.0,
2125,376084,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 0.5 mg/kg/day, iv after 9 days",Other,541685.0,
2126,376085,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 0.25 mg/kg/day, iv after 9 days",Other,541685.0,
2127,376086,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells xenografted in mouse assessed as increase in life span at 2 mg/kg/day, ip after 9 days",Other,541685.0,
2128,376087,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells xenografted in mouse assessed as increase in life span at 1 mg/kg/day, ip after 9 days",Other,541685.0,
2129,376088,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells xenografted in mouse assessed as increase in life span at 0.5 mg/kg/day, ip after 9 days",Other,541685.0,
2130,376089,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells xenografted in mouse assessed as increase in life span at 0.25 mg/kg/day, ip after 9 days",Other,541685.0,
2131,376090,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells xenografted in mouse assessed as increase in life span at 2 mg/kg/day, ip after 9 days",Other,541685.0,
2132,376091,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells xenografted in mouse assessed as increase in life span at 1 mg/kg/day, ip after 9 days",Other,541685.0,
2133,376092,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells xenografted in mouse assessed as increase in life span at 0.5 mg/kg/day, ip after 9 days",Other,541685.0,
2134,376093,3,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells xenografted in mouse assessed as increase in life span at 0.25 mg/kg/day, ip after 9 days",Other,541685.0,
2135,376094,4,5,,123097261,31703,Inactive,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as increase in life span at 12.5 mg/kg/day, po after 9 days",Other,541685.0,
2136,376673,6,3,,123097261,31703,Active,,,1.21,IC50,Cytotoxicity against human WI38 cells,Confirmatory,16724842.0,
2137,376674,6,2,,123097261,31703,Active,,,0.6990000000000001,IC50,Cytotoxicity against human VA13 cells,Confirmatory,16724842.0,
2138,376694,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2(2.2.15) cells after 3 day,Other,10654411.0,
2139,376820,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,,
2140,376821,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,,
2141,376822,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,,
2142,376823,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,,
2143,376824,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,,
2144,376825,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,,
2145,376831,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9584396.0,
2146,376832,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9584396.0,
2147,376833,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9584396.0,
2148,376834,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9584396.0,
2149,376835,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9584396.0,
2150,376836,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9584396.0,
2151,376932,6,2,,123097261,31703,Active,,,2.21,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,16724842.0,
2152,376998,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,16724859.0,
2153,376999,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,16724859.0,
2154,377000,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,16724859.0,
2155,377001,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,16724859.0,
2156,377087,8,2,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp,Other,15730242.0,
2157,377088,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,15730242.0,
2158,377089,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,15730242.0,
2159,377090,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,15730242.0,
2160,377091,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells after 7 days by MTT assay,Other,15730242.0,
2161,377092,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay,Other,15730242.0,
2162,377093,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A-498 cells after 7 days by MTT assay,Other,15730242.0,
2163,377096,6,3,,123097261,31703,Active,,,0.66,IC50,Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay,Confirmatory,15730243.0,
2164,377097,6,2,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay,Confirmatory,15730243.0,
2165,377098,6,3,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay,Confirmatory,15730243.0,
2166,377259,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,11000028.0,
2167,377260,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,11000028.0,
2168,377261,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells by MTT assay,Other,11000028.0,
2169,377262,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-5 cells by MTT assay,Other,11000028.0,
2170,377263,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MALME-3M cells by MTT assay,Other,11000028.0,
2171,377350,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cell,Other,15730249.0,
2172,377351,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells,Other,15730249.0,
2173,377352,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF-268 cells,Other,15730249.0,
2174,377393,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,15730260.0,
2175,377461,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,15787438.0,
2176,377462,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells,Other,15787438.0,
2177,377463,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells,Other,15787438.0,
2178,377926,7,2,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp,Other,9917277.0,
2179,377927,7,2,,123097261,31703,Inconclusive,,,,,Pesticidal activity against yellow fever mosquito larvae by microtiter plate assay,Other,9917277.0,
2180,377928,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,9917277.0,
2181,377929,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,9917277.0,
2182,377930,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,9917277.0,
2183,377931,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A-498 cells by MTT assay,Other,9917277.0,
2184,377932,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells by MTT assay,Other,9917277.0,
2185,377933,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PaCa2 cells by MTT assay,Other,9917277.0,
2186,378025,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,Cytotoxicity against human KB cells,Confirmatory,16872155.0,
2187,378067,6,3,,123097261,31703,Active,,,0.66,IC50,Cytotoxicity against human WI38 cells by WST-8 assay,Confirmatory,16933868.0,
2188,378068,6,3,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against human VA-13 cells by by WST-8 assay,Confirmatory,16933868.0,
2189,378069,6,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human Hep G2 by WST-8 assay,Confirmatory,16933868.0,
2190,378173,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,15787431.0,
2191,378174,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,15787431.0,
2192,378175,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,15787431.0,
2193,378176,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,15787431.0,
2194,378177,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells,Other,15787431.0,
2195,378223,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,11087592.0,
2196,378224,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,11087592.0,
2197,378225,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,11087592.0,
2198,378226,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,11087592.0,
2199,378227,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,11087592.0,
2200,378228,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MiaPaCa2 cells after 7 days by MTT assay,Other,11087592.0,
2201,378431,10,1,,123097261,31703,Active,,,0.21899999999999997,IC50,Cytotoxicity against human KB cells by SRB assay,Confirmatory,16933890.0,
2202,378432,10,1,,123097261,31703,Active,,,0.28800000000000003,IC50,Cytotoxicity against human BC cells by SRB assay,Confirmatory,16933890.0,
2203,378433,10,2,,123097261,31703,Active,,,0.0405,IC50,Cytotoxicity against human NCI-H187 cells by SRB assay,Confirmatory,16933890.0,
2204,378445,3,4,,123097261,31703,Unspecified,,,,,Inhibition of invasion of human HT1080 cells into Matrigel at 0.17 uM,Other,16989517.0,
2205,378532,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Other,15787450.0,
2206,378533,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,15787450.0,
2207,378534,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Other,15787450.0,
2208,378535,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Other,15787450.0,
2209,378536,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Other,15787450.0,
2210,378790,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by colorimetric method,Other,16989536.0,
2211,378791,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BC cells by colorimetric method,Other,16989536.0,
2212,379019,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,16441084.0,
2213,379020,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,16441084.0,
2214,379021,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,16441084.0,
2215,379022,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,16441084.0,
2216,379023,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,16441084.0,
2217,379139,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,10217707.0,
2218,379140,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,10217707.0,
2219,379141,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,10217707.0,
2220,379142,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,10217707.0,
2221,379143,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT-15 cells,Other,10217707.0,
2222,379150,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay,Other,17067159.0,
2223,379151,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay,Other,17067159.0,
2224,379152,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay,Other,17067159.0,
2225,379204,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep G2 cells by MTT colorimetric method,Other,17125220.0,
2226,379205,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT colorimetric method,Other,17125220.0,
2227,379206,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT colorimetric method,Other,17125220.0,
2228,379207,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT colorimetric method,Other,17125220.0,
2229,379234,6,2,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human U251 cells after 48 hrs by SRB assay,Confirmatory,17125233.0,
2230,379235,6,3,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against human K-562 cells after 48 hrs by SRB assay,Confirmatory,17125233.0,
2231,379250,5,3,,123097261,31703,Active,,,0.0038,GI50,Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay,Confirmatory,10691710.0,
2232,379251,5,3,,123097261,31703,Active,,,0.012,GI50,Cytotoxicity against mouse P388 cells by MTT assay,Confirmatory,10691710.0,
2233,379528,6,2,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,17125240.0,
2234,379531,6,2,,123097261,31703,Active,,,0.66,IC50,Cytotoxicity against human NCI-H460 cells by MTT assay,Confirmatory,17125240.0,
2235,379532,6,2,,123097261,31703,Active,,,1.55,IC50,Cytotoxicity against human SF-268 cells by MTT assay,Confirmatory,17125240.0,
2236,379533,6,2,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human AGS cells by MTT assay,Confirmatory,17125240.0,
2237,379534,6,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human HCT116 cells by MTT assay,Confirmatory,17125240.0,
2238,379559,6,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human HCT8 cells by MTT assay,Confirmatory,17190442.0,
2239,379560,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human Bel-7402 cells by MTT assay,Confirmatory,17190442.0,
2240,379561,6,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human BGC-823 cells by MTT assay,Confirmatory,17190442.0,
2241,379562,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,17190442.0,
2242,379563,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human A2780 cells by MTT assay,Confirmatory,17190442.0,
2243,379722,6,2,,123097261,31703,Active,,,0.38,IC50,Growth inhibition of human WI38 cells after 48 hrs by WST8 assay,Confirmatory,16499322.0,
2244,379723,6,2,,123097261,31703,Active,,,0.22,IC50,Growth inhibition of human VA13 cells after 48 hrs by WST8 assay,Confirmatory,16499322.0,
2245,379724,6,2,,123097261,31703,Active,,,0.69,IC50,Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay,Confirmatory,16499322.0,
2246,379804,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human UACC-62 cells,Other,10346965.0,
2247,379805,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,10346965.0,
2248,379806,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H23 cells,Other,10346965.0,
2249,379807,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human ACHN cells,Other,10346965.0,
2250,379808,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human UO-31 cells,Other,10346965.0,
2251,379809,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells,Other,10346965.0,
2252,379810,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SW620 cells,Other,10346965.0,
2253,379811,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT-15 cells,Other,10346965.0,
2254,379812,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF-539 cells,Other,10346965.0,
2255,379838,10,1,,123097261,31703,Inconclusive,,,,,Toxicity in brine shrimp,Other,10395501.0,
2256,379839,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,10395501.0,
2257,379840,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,10395501.0,
2258,379841,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells after 7 days by MTT assay,Other,10395501.0,
2259,379842,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,10395501.0,
2260,379843,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells after 7 days by MTT assay,Other,10395501.0,
2261,379844,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PACA2 cells after 7 days by MTT assay,Other,10395501.0,
2262,379948,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,17190456.0,
2263,379949,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,17190456.0,
2264,379950,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,17190456.0,
2265,379951,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,17190456.0,
2266,379952,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT-15 cells,Other,17190456.0,
2267,380280,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human NCI-H460 cells after 24 hrs by MTT assay,Confirmatory,17190470.0,
2268,380281,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,17190470.0,
2269,380282,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human SF-268 cells after 24 hrs by MTT assay,Confirmatory,17190470.0,
2270,380283,6,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human MIA PaCa2 cells after 24 hrs by MTT assay,Confirmatory,17190470.0,
2271,380284,6,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human WI38 cells after 24 hrs by MTT assay,Confirmatory,17190470.0,
2272,380380,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against PLCgamma1 expressing human HCT15 cells,Other,10869194.0,
2273,380381,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against PLCgamma1 expressing human MCF7 cells,Other,10869194.0,
2274,380382,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against PLCgamma1 expressing human A549 cells,Other,10869194.0,
2275,380383,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against PLCgamma1 expressing human HT1197 cells,Other,10869194.0,
2276,380461,6,2,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay,Confirmatory,16562840.0,
2277,380462,6,3,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human RPMI 8226/s cells after 72 hrs by fluorometric microculture cytotoxicity assay,Confirmatory,16562840.0,
2278,380463,6,3,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human CEM/s cells after 72 hrs by fluorometric microculture cytotoxicity assay,Confirmatory,16562840.0,
2279,380464,6,2,,123097261,31703,Active,,,14.2,IC50,Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay,Confirmatory,16562840.0,
2280,380480,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,16562847.0,
2281,380481,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells,Other,16562847.0,
2282,380482,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells,Other,16562847.0,
2283,380847,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,10479316.0,
2284,380848,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,10479316.0,
2285,380849,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells,Other,10479316.0,
2286,380850,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A298 cells,Other,10479316.0,
2287,380851,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells,Other,10479316.0,
2288,380852,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PaCa2 cells,Other,10479316.0,
2289,381084,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,16643027.0,
2290,381085,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-OV-3 cells,Other,16643027.0,
2291,381086,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,16643027.0,
2292,381087,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,16643027.0,
2293,381088,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,16643027.0,
2294,381189,6,1,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human MRC5 cells after 5 days by MTT assay,Other,10514301.0,
2295,381190,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 5 days by MTT assay,Other,10514301.0,
2296,381191,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells after 5 days by MTT assay,Other,10514301.0,
2297,381192,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse L1210 cells after 5 days by MTT assay,Other,10514301.0,
2298,381201,7,2,,123097261,31703,Inconclusive,,,,,Toxicity to brine shrimp larvae,Other,10514307.0,
2299,381202,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,10514307.0,
2300,381203,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,10514307.0,
2301,381204,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,10514307.0,
2302,381205,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A-498 cells after 7 days by MTT assay,Other,10514307.0,
2303,381206,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC-3 cells after 7 days by MTT assay,Other,10514307.0,
2304,381207,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay,Other,10514307.0,
2305,381208,3,4,,123097261,31703,Unspecified,,,,,Selectivity for human A498 cells over human HT29 cells,Other,10514307.0,
2306,381209,3,5,,123097261,31703,Unspecified,,,,,Selectivity for human A498 cells over human MIA PaCa2 cells,Other,10514307.0,
2307,381805,3,5,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in thermal stability at 2 uM in tris-HCl buffer at pH 7.5 by thermal denaturation assay,Other,18258442.0,
2308,381806,6,2,,123097261,31703,Active,,,0.08,IC50,Growth inhibition of human K562 cells after 72 hrs by MTS method,Confirmatory,18258442.0,
2309,381807,6,2,,123097261,31703,Active,,,0.41,IC50,Growth inhibition of etoposide-resistant human K/VP.5 cells after 72 hrs by MTS method,Confirmatory,18258442.0,
2310,381808,3,4,,123097261,31703,Unspecified,,,,,"Resistance factor, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells",Other,18258442.0,
2311,381809,9,5,,123097261,31703,Inconclusive,13959709.0,7153.0,,IC50,Inhibition of human topoisomerase 2alpha decantation activity,Confirmatory,18258442.0,
2312,381817,6,2,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human MCF7 cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2313,381818,6,2,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human SiHa cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2314,381819,6,2,,123097261,31703,Active,,,7.25,GI50,Cytotoxicity against human A549 cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2315,381820,6,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human Colo205 cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2316,381821,6,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human KB cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2317,381822,6,3,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human GURAV cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2318,381823,6,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human A2780 cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2319,381824,6,2,,123097261,31703,Active,,,1.81,GI50,Cytotoxicity against human PC3 cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2320,381839,6,3,,123097261,31703,Active,,,0.11,GI50,Cytotoxicity against human DWD cells after 24 hrs by SRB method,Confirmatory,18262426.0,
2321,382169,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human HL60 cells at 1 uM after 3 days,Other,18375126.0,
2322,382170,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human HL60 cells at 10 uM after 3 days,Other,18375126.0,
2323,382171,6,2,,123097261,31703,Active,,,0.1,IC50,Growth inhibition of human HL60 cells after 3 days,Confirmatory,18375126.0,
2324,382551,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells assessed as viable cells at 0.3 ug/ml by trypan blue exclusion assay,Other,17512094.0,
2325,382555,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells assessed as apoptotic cells at 0.3 ug/ml by trypan blue exclusion assay,Other,17512094.0,
2326,382559,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells assessed as necrotic cells at 0.3 ug/ml by trypan blue exclusion assay,Other,17512094.0,
2327,382563,3,4,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in human KB cells assessed as 5-bromo-2'-deoxyuridin incorporation at 0.3 ug/ml,Other,17512094.0,
2328,382567,3,4,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in human KB cells assessed as ratio of DNA in treated to control cells at 0.3 ug/ml,Other,17512094.0,
2329,382836,8,1,,123097261,31703,Active,,,0.16399999999999998,ED50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,18314958.0,
2330,383495,6,2,,123097261,31703,Active,,,0.018000000000000002,GI50,Antiproliferative activity against human HL60 cells by trypan blue assay,Confirmatory,18357994.0,
2331,383756,11,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human A549 cells,Confirmatory,17618015.0,
2332,383757,12,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,17618015.0,
2333,383766,11,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human HT29 cells,Confirmatory,17618015.0,
2334,383787,11,1,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells,Confirmatory,17618015.0,
2335,383788,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells,Other,17618015.0,
2336,383789,10,1,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human NCI-H460 cells,Confirmatory,17618015.0,
2337,383792,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MEL28 cells,Other,17618015.0,
2338,383795,7,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HeLa cells,Other,17618015.0,
2339,384028,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIA-PaCa2 cells,Other,17618015.0,
2340,384118,6,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human A549 cells after 48 hrs,Confirmatory,17673337.0,
2341,384119,6,2,,123097261,31703,Active,,,0.23,IC50,Cytotoxicity against human SK-OV3 cells after 48 hrs,Confirmatory,17673337.0,
2342,384120,6,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human SK-MEL-2 cells after 48 hrs,Confirmatory,17673337.0,
2343,384121,6,2,,123097261,31703,Active,,,0.27,IC50,Cytotoxicity against human HCT15 cells after 48 hrs,Confirmatory,17673337.0,
2344,384289,8,1,,123097261,31703,Active,,,0.0428,GI50,Growth inhibition of human MCF7 cells after 48 hrs,Confirmatory,17692432.0,
2345,384290,8,1,,123097261,31703,Active,,,0.09300000000000001,GI50,Growth inhibition of human SF268 cells after 48 hrs,Confirmatory,17692432.0,
2346,384291,8,1,,123097261,31703,Active,,,0.094,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs,Confirmatory,17692432.0,
2347,385428,8,1,,123097261,31703,Active,,,0.006999999999999999,ED50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,18314958.0,
2348,385429,8,1,,123097261,31703,Active,,,0.055999999999999994,ED50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,18314958.0,
2349,385430,8,1,,123097261,31703,Active,,,0.11699999999999999,ED50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,18314958.0,
2350,386569,3,5,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA at 1 uM in BPES buffer by fluorescence titration relative to daunomycin,Other,18788722.0,
2351,386570,8,1,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA in BPES buffer assessed as binding constant K/10'5 by fluorescence titration,Other,18788722.0,
2352,387409,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor volume at 2 mg/kg, ip after 21 days",Other,18762427.0,
2353,387410,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity in human SW620 cells xenografted nude mouse assessed as decrease in tumor weight at 2 mg/kg, ip after 21 days",Other,18762427.0,
2354,387444,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in SW480 cells xenografted nude mouse assessed as change in body weight 2 mg/kg/day, ip after 21 days",Other,18762427.0,
2355,387691,6,2,,123097261,31703,Active,,,0.92,IC50,Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay,Confirmatory,18783950.0,
2356,387692,6,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,18783950.0,
2357,387693,6,2,,123097261,31703,Active,,,2.98,IC50,Cytotoxicity against human Raji cells after 72 hrs by MTT assay,Confirmatory,18783950.0,
2358,387694,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,18783950.0,
2359,387695,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,18783950.0,
2360,389021,6,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human MDA-MB-231 cells by SRB assay,Confirmatory,19007287.0,
2361,389022,6,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,19007287.0,
2362,389023,6,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human HT-29 cells by SRB assay,Confirmatory,19007287.0,
2363,389437,4,4,,123097261,31703,Active,,,0.0039,IC50,Anticancer activity against human DU145 cells after 72 hrs by XTT assay,Confirmatory,18829316.0,
2364,389438,3,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human DU145 cells after 72 hrs 25 ug/ml by XTT assay,Other,18829316.0,
2365,393147,5,2,,123097261,31703,Active,,,1.2,GI50,Antiproliferative activity against mouse L929 cells,Confirmatory,19188072.0,
2366,393148,5,2,,123097261,31703,Active,,,1.0,GI50,Antiproliferative activity against human K562 cells,Confirmatory,19188072.0,
2367,393149,5,2,,123097261,31703,Active,,,2.0,CC50,Cytotoxicity against human HeLa cells,Confirmatory,19188072.0,
2368,393311,3,4,,123097261,31703,Unspecified,,,,,"Resistance index, ratio IC50 for human K562 cells to IC50 for P-gp positive human K562 cells",Other,19208482.0,
2369,393314,3,4,,123097261,31703,Unspecified,,,,,"Resistance index, ratio IC50 for HCT116 cells to IC50 for p53 deleted human HCT116 cells",Other,19208482.0,
2370,395134,3,4,,123097261,31703,Unspecified,,,,,Binding affinity to poly(dA).poly(dT) DNA assessed as change in melting temperature,Other,18403056.0,
2371,397610,3,3,,123097261,31703,Active,,,,,Cell cycle arrest in human TK6 cells expressing wild type p53 assessed as accumulation at sub-G0/G1 phase at 0.1 uM after 72 hrs by flow cytometry,Other,19349174.0,
2372,397611,3,4,,123097261,31703,Inactive,,,,,Cell cycle arrest in p53 deficient human NH32 cells assessed as accumulation at sub-G0/G1 phase at 0.1 uM after 72 hrs by flow cytometry,Other,19349174.0,
2373,397612,3,3,,123097261,31703,Inactive,,,,,Cell cycle arrest in human WTK1 cells expressing p53 M237I mutant assessed as accumulation at sub-G0/G1 phase at 0.1 uM after 72 hrs by flow cytometry,Other,19349174.0,
2374,397613,3,3,,123097261,31703,Active,,,,,Induction of p53 phosphorylation at Ser15 in human TK6 cells expressing wild type p53 at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2375,397614,3,3,,123097261,31703,Active,,,,,Induction of p53 transcriptional activity in human TK6 cells expressing wild type p53 assessed as p21-Cip1/Waf1 expression at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2376,397615,3,3,,123097261,31703,Active,,,,,Induction of p53 phosphorylation at Ser15 in human WTK1 cells expressing p53 M237I mutant at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2377,397616,3,3,,123097261,31703,Inactive,,,,,Induction of p53 transcriptional activity in human WTK1 cells expressing p53 M237I mutant assessed as p21-Cip1/Waf1 expression at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2378,397617,3,3,,123097261,31703,Inactive,,,,,Induction of p53 phosphorylation at Ser15 in human TK6 cells expressing wild type p53 at 25 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2379,397618,3,3,,123097261,31703,Inactive,,,,,Induction of p53 transcriptional activity in human TK6 cells expressing wild type p53 assessed as p21-Cip1/Waf1 expression at 25 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2380,397619,3,3,,123097261,31703,Inactive,,,,,Induction of p53 phosphorylation at Ser15 in human WTK1 cells expressing p53 M237I mutant at 25 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2381,397620,3,3,,123097261,31703,Inactive,,,,,Induction of p53 transcriptional activity in human WTK1 cells expressing p53 M237I mutant assessed as p21-Cip1/Waf1 expression at 25 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2382,397626,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human TK6 cells expressing wild type p53 assessed as increase in cleaved caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2383,397627,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in p53 deficient human NH32 cells assessed as increase in cleaved caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2384,397628,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human WTK1 cells expressing p53 M237I mutant assessed as increase in cleaved caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2385,397632,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human TK6 cells expressing wild type p53 assessed as decrease in pro-caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2386,397633,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in p53 deficient human NH32 cells assessed as decrease in pro-caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2387,397634,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human WTK1 cells expressing p53 M237I mutant assessed as decrease in pro-caspase 3 level at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2388,397638,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human TK6 cells expressing wild type p53 assessed as increase in PARP cleavage at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2389,397639,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in p53 deficient human NH32 cells assessed as increase in PARP cleavage at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2390,397640,3,3,,123097261,31703,Active,,,,,Induction of apoptosis in human WTK1 cells expressing p53 M237I mutant assessed as increase in PARP cleavage at 0.1 uM after 8 hrs by Western blot analysis,Other,19349174.0,
2391,397759,6,3,,123097261,31703,Active,,,1.82,GI50,Cytotoxicity against human breast cancer cells,Confirmatory,11473418.0,
2392,397760,6,3,,123097261,31703,Active,,,1.69,GI50,Cytotoxicity against human CNS cancer cells,Confirmatory,11473418.0,
2393,397761,6,3,,123097261,31703,Active,,,2.55,GI50,Cytotoxicity against human colon cancer cells,Confirmatory,11473418.0,
2394,397762,6,3,,123097261,31703,Active,,,0.4,GI50,Cytotoxicity against human lung cancer cells,Confirmatory,11473418.0,
2395,397763,6,3,,123097261,31703,Active,,,4.35,GI50,Cytotoxicity against human ovarian cancer cells,Confirmatory,11473418.0,
2396,397764,6,3,,123097261,31703,Active,,,5.82,GI50,Cytotoxicity against human stomach cancer cells,Confirmatory,11473418.0,
2397,398034,8,1,,123097261,31703,Active,,,8e-07,GI50,Cytotoxicity against human MCF7 cells,Confirmatory,14640532.0,
2398,398035,8,1,,123097261,31703,Active,,,3e-07,GI50,Cytotoxicity against human H460 cells,Confirmatory,14640532.0,
2399,398036,8,1,,123097261,31703,Active,,,8.5e-07,GI50,Cytotoxicity against human SF268 cells,Confirmatory,14640532.0,
2400,398318,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 hrs by MTT assay,Other,7623031.0,
2401,398319,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 hrs by MTT assay,Other,7623031.0,
2402,398320,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 hrs by MTT assay,Other,7623031.0,
2403,398396,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7673926.0,
2404,398397,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7673926.0,
2405,398398,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7673926.0,
2406,398446,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7673935.0,
2407,398447,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7673935.0,
2408,398448,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7673935.0,
2409,398450,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7673936.0,
2410,398451,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7673936.0,
2411,398452,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7673936.0,
2412,398536,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells,Other,12608866.0,
2413,398537,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2(2.2.15) cells,Other,12608866.0,
2414,398646,6,3,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against mouse L1210 cells after 48 hrs by MTT method,Confirmatory,7561901.0,
2415,398713,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7494147.0,
2416,398714,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7494147.0,
2417,398716,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,7494147.0,
2418,398717,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,7494147.0,
2419,398718,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7494147.0,
2420,398719,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,7494147.0,
2421,398741,10,1,,123097261,31703,Unspecified,,,,,Toxicity to brine shrimp,Other,7494150.0,
2422,398742,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,7494150.0,
2423,398743,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,7494150.0,
2424,398744,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,7494150.0,
2425,398850,7,2,,123097261,31703,Unspecified,,,,,Toxicity against brine shrimp,Other,9214729.0,
2426,398851,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9214729.0,
2427,398852,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9214729.0,
2428,398853,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9214729.0,
2429,398854,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9214729.0,
2430,398855,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9214729.0,
2431,398856,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9214729.0,
2432,398857,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse L1210 cells,Other,9249977.0,
2433,398858,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,9249977.0,
2434,398859,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse Adriamycin-resistant P388 cells,Other,9249977.0,
2435,398860,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells,Other,9249977.0,
2436,398861,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against CHO cells,Other,9249977.0,
2437,398862,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against MDR1 gene transfected CHO cells,Other,9249977.0,
2438,399025,6,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human HepG2 cells after 6 days by MTT method,Confirmatory,16309317.0,
2439,399026,6,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human A549 cells after 6 days by MTT method,Confirmatory,16309317.0,
2440,399027,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MDA-MB-231cells after 6 days by MTT method,Confirmatory,16309317.0,
2441,399195,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse LLC cells after 48 hrs by SRB assay,Other,14738384.0,
2442,399338,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9461654.0,
2443,399339,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9461654.0,
2444,399425,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9461654.0,
2445,399426,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9461654.0,
2446,399427,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9461654.0,
2447,399428,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9461654.0,
2448,399532,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human U937/GTB cells after 72 hrs by trypan blue exclusion method,Confirmatory,14987049.0,
2449,399533,6,4,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human RPMI8226/S cells after 72 hrs by trypan blue exclusion method,Confirmatory,14987049.0,
2450,400306,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 2 to 7 days by neutral red assay,Other,8984156.0,
2451,400308,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay,Other,8984156.0,
2452,400310,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay,Other,8984156.0,
2453,400312,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay,Other,8984156.0,
2454,400314,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 2 to 7 days by neutral red assay,Other,8984156.0,
2455,400316,7,2,,123097261,31703,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 48 hrs as LDH activity by Makler assay,Other,8984156.0,
2456,400318,7,2,,123097261,31703,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs as LDH activity by Makler assay,Other,8984156.0,
2457,400348,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 6 days by coulter counted assay,Other,8984151.0,
2458,400349,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 6 days by BCA assay,Other,8984151.0,
2459,400536,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,15043429.0,
2460,400537,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H460 cells,Other,15043429.0,
2461,400538,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells,Other,15043429.0,
2462,400617,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8991955.0,
2463,400618,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8991955.0,
2464,400619,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells,Other,8991955.0,
2465,400712,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9599253.0,
2466,400713,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9599253.0,
2467,400714,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9599253.0,
2468,400715,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9599253.0,
2469,400716,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9599253.0,
2470,400717,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9599253.0,
2471,400747,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9599260.0,
2472,400748,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9599260.0,
2473,400749,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9599260.0,
2474,400750,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9599260.0,
2475,400751,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9599260.0,
2476,400752,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9599260.0,
2477,400936,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,15104487.0,
2478,400937,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,15104487.0,
2479,400938,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,15104487.0,
2480,400939,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,15104487.0,
2481,400940,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,15104487.0,
2482,400941,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HEPA 59T/VGH cells by MTT assay,Other,15104488.0,
2483,400942,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by MTT assay,Other,15104488.0,
2484,400943,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H661 cells by MTT assay,Other,15104488.0,
2485,400944,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Medulloblastoma cells by MTT assay,Other,15104488.0,
2486,400945,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DLD1 cells by MTT assay,Other,15104488.0,
2487,400946,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,15104488.0,
2488,401107,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,9644064.0,
2489,401108,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,9644064.0,
2490,401109,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,9644064.0,
2491,401110,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells by MTT assay,Other,9644064.0,
2492,401111,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells by MTT assay,Other,9644064.0,
2493,401112,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells by MTT assay,Other,9644064.0,
2494,401286,3,3,,123097261,31703,Active,,,,,Reversal of P-gp-mediated multidrug resistance in human MCF cells assessed as enhancement in cytotoxicity of adriamycin,Other,8984151.0,
2495,401333,9,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,8991944.0,
2496,401334,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,8991944.0,
2497,401335,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT29 cells,Other,8991944.0,
2498,401575,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red staining,Other,15165136.0,
2499,401576,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by neutral red staining,Other,15165136.0,
2500,401577,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining,Other,15165136.0,
2501,401578,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red staining,Other,15165136.0,
2502,401678,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,15921415.0,
2503,401679,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay,Other,15921415.0,
2504,401680,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay,Other,15921415.0,
2505,401681,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells after 48 hrs by SRB assay,Other,15921415.0,
2506,401682,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay,Other,15921415.0,
2507,401701,6,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human NCI-H460 cells by MTT assay,Confirmatory,15921417.0,
2508,401702,6,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,15921417.0,
2509,401703,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human SF268 cells,Confirmatory,15921417.0,
2510,401704,6,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human MIAPaCa2 cells,Confirmatory,15921417.0,
2511,401705,6,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human WI38 cells,Confirmatory,15921417.0,
2512,401837,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 7 days by MTT assay,Other,9014350.0,
2513,401839,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 7 days by MTT assay,Other,9014350.0,
2514,401840,11,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 7 days by MTT assay,Other,9014350.0,
2515,401967,6,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against doxorubicin-sensitive human MCF7 cells,Confirmatory,15921419.0,
2516,401968,8,1,,123097261,31703,Unspecified,,,50.0,IC50,Cytotoxicity against doxorubicin-resistant human MCF7 cells,Confirmatory,15921419.0,
2517,401977,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by methylene blue staining method,Other,15921421.0,
2518,401978,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells by methylene blue staining method,Other,15921421.0,
2519,401979,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HEPA 59T/VGH cells by methylene blue staining method,Other,15921421.0,
2520,401994,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB assay,Other,15921426.0,
2521,401995,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by SRB assay,Other,15921426.0,
2522,401996,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Other,15921426.0,
2523,401997,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells by SRB assay,Other,15921426.0,
2524,401998,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by SRB assay,Other,15921426.0,
2525,402017,6,2,,123097261,31703,Active,,,0.27,IC50,Cytotoxicity against human KB cells after 72 hrs,Confirmatory,15921436.0,
2526,402191,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells after 7 days by MTT assay,Other,9134750.0,
2527,402192,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 7 days by MTT assay,Other,9134750.0,
2528,402193,10,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay,Other,9134750.0,
2529,402292,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human KB cells,Confirmatory,15974615.0,
2530,402293,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,15974615.0,
2531,402486,6,2,,123097261,31703,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL MB5393,Other,9051915.0,
2532,402493,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse L1210 cells by MTT assay,Other,9051915.0,
2533,402494,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay,Other,9051915.0,
2534,402495,3,4,,123097261,31703,Inactive,,,,,Cytotoxicity against mouse L1210 cells assessed as cell lysis after 24 hrs by trypan blue assay,Other,9051915.0,
2535,402539,6,2,,123097261,31703,Active,,,42.8,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,15165162.0,
2536,402540,6,2,,123097261,31703,Unspecified,,,94.0,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,15165162.0,
2537,402619,6,2,,123097261,31703,Unspecified,,,93.0,GI50,Growth inhibition of human SF268 cells after 48 hrs by SRB assay,Confirmatory,15165162.0,
2538,402786,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human OVCAR-3 cells assessed as cell survival at 10 ug/ml after 48 hrs by MTT assay relative to control,Other,9834149.0,
2539,402787,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as cell survival at 10 ug/ml after 48 hrs by MTT assay relative to control,Other,9834149.0,
2540,402788,3,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human FS5 cells assessed as cell survival at 10 ug/ml after 48 hrs by MTT assay relative to control,Other,9834149.0,
2541,403322,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,15270579.0,
2542,403323,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells,Other,15270579.0,
2543,403324,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,15270579.0,
2544,403325,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells,Other,15270579.0,
2545,403326,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells,Other,15270579.0,
2546,403336,8,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,15270581.0,
2547,403337,8,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,15270581.0,
2548,403338,8,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,15270581.0,
2549,403680,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB method,Other,16252909.0,
2550,403681,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by SRB method,Other,16252909.0,
2551,403682,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by SRB method,Other,16252909.0,
2552,403683,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells by SRB method,Other,16252909.0,
2553,403684,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by SRB method,Other,16252909.0,
2554,403685,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by MTT assay,Other,16252910.0,
2555,403686,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days by MTT assay,Other,16252910.0,
2556,403687,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DLD1 cells after 3 days by MTT assay,Other,16252910.0,
2557,403688,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Other,16252910.0,
2558,403689,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 3 days by MTT assay,Other,16252910.0,
2559,403690,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Medulloblastoma cells after 3 days by MTT assay,Other,16252910.0,
2560,403695,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 3 days by MTT assay,Other,16252914.0,
2561,403696,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Other,16252914.0,
2562,403697,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Other,16252914.0,
2563,403698,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Other,16252914.0,
2564,404179,6,3,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2565,404180,6,3,,123097261,31703,Active,,,8.05,IC50,Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2566,404181,6,3,,123097261,31703,Active,,,8.04,IC50,Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2567,404182,6,2,,123097261,31703,Active,,,7.88,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2568,404183,6,2,,123097261,31703,Active,,,0.68,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2569,404184,6,2,,123097261,31703,Active,,,9.32,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
2570,404304,3,10,,123097261,31703,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
2571,405949,3,4,,123097261,31703,Active,,,,,Binding affinity to supercoiled pRYG plasmid DNA assessed as DNA intercalation at 50 uM after 21 hrs by electrophoresis,Other,18505284.0,
2572,405975,4,4,,123097261,31703,Active,,,0.182,IC50,Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine uptake after 48 hrs,Confirmatory,18508273.0,
2573,405981,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing mouse L1210 cells assessed as increase of life span at 10 mg/kg, iv",Other,18508273.0,
2574,406131,4,1,,123097261,31703,Unspecified,,,,,"Antitumor activity in BALB/c mouse bearing JC cells assessed as tumor growth inhibition at 8.0 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
2575,406132,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity in BALB/c mouse bearing JC cells assessed as cell death at 8.0 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
2576,406133,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity in BALB/c mouse bearing JC cells assessed as maximum weight loss at 8.0 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
2577,406138,3,4,,123097261,31703,Unspecified,,,,,"Anticancer activity in CD1 mouse xenografted with human SKOV3 cells assessed as weight change at 5 mg/kg, iv",Other,18508273.0,
2578,406139,4,1,,123097261,31703,Unspecified,,,,,"Anticancer activity in CD1 mouse xenografted with human SKOV3 cells assessed as tumor growth inhibition at 5 mg/kg, iv",Other,18508273.0,
2579,406141,3,4,,123097261,31703,Active,,,,,Cell cycle arrest in mouse L1210 cells by accumulation at G2/M phase at 1 ug/ml after 12 hrs by flow cytometry,Other,18508273.0,
2580,406181,10,1,,123097261,31703,Active,,,8.6,IC50,Growth inhibition of multidrug resistant human HepG2/Dox cells after 72 hrs by SRB assay,Confirmatory,18512984.0,
2581,406328,10,1,,123097261,31703,Active,,,0.17,IC50,Growth inhibition of human HepG2 cells after 72 hrs by SRB assay,Confirmatory,18512984.0,
2582,406345,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as accumulation in subG1 phase at 0.2 uM,Other,18512984.0,
2583,406346,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as accumulation in G0/G1 phase at 0.2 uM,Other,18512984.0,
2584,406347,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as accumulation in S phase at 0.2 uM,Other,18512984.0,
2585,406348,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as accumulation in G2/M phase at 0.2 uM,Other,18512984.0,
2586,406349,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in subG1 phase at 1 uM,Other,18512984.0,
2587,406350,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G0/G1 phase at 1 uM,Other,18512984.0,
2588,406351,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in S phase at 1 uM,Other,18512984.0,
2589,406352,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G2/M phase at 1 uM,Other,18512984.0,
2590,406353,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in subG1 phase at 10 uM,Other,18512984.0,
2591,406354,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G0/G1 phase at 10 uM,Other,18512984.0,
2592,406355,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in S phase at 10 uM,Other,18512984.0,
2593,406356,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G2/M phase at 10 uM,Other,18512984.0,
2594,406357,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in subG1 phase at 50 uM,Other,18512984.0,
2595,406358,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G0/G1 phase at 50 uM,Other,18512984.0,
2596,406359,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in S phase at 50 uM,Other,18512984.0,
2597,406360,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in multidrug resistant human HepG2/Dox cells assessed as accumulation in G2/M phase at 50 uM,Other,18512984.0,
2598,406726,6,2,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,18513976.0,
2599,407924,8,1,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Confirmatory,18419154.0,
2600,407925,8,1,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,18419154.0,
2601,407926,8,1,,123097261,31703,Active,,,0.86,IC50,Cytotoxicity against human A549 cells after 3 days by MTT assay,Confirmatory,18419154.0,
2602,407927,8,1,,123097261,31703,Active,,,0.64,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,18419154.0,
2603,407928,6,3,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human Hep3B cells after 3 days by MTT assay,Confirmatory,18419154.0,
2604,408253,6,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2605,408254,6,2,,123097261,31703,Active,,,0.17800000000000002,IC50,Cytotoxicity against human SW620 cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2606,408255,6,2,,123097261,31703,Active,,,0.031,IC50,Cytotoxicity against human A549 cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2607,408256,6,2,,123097261,31703,Active,,,0.064,IC50,Cytotoxicity against HEK293 cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2608,408257,6,2,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human M14 cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2609,408258,6,2,,123097261,31703,Active,,,1.0090000000000001,IC50,Cytotoxicity against human HeLa cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2610,408259,6,3,,123097261,31703,Active,,,5.3,IC50,Cytotoxicity against human doxorubicin-resistant MCF7/Dx cells after 24 hrs by SRB method,Confirmatory,18429610.0,
2611,408260,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Caco-2 cells assessed as cell proliferation at 50 nM after 24 hrs relative to control,Other,18429610.0,
2612,408261,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Caco-2 cells assessed as cell proliferation at 50 nM after 48 hrs relative to control,Other,18429610.0,
2613,408262,3,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Caco-2 cells assessed as cell proliferation at 50 nM after 78 hrs relative to control,Other,18429610.0,
2614,408263,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human Caco-2 cells assessed as accumulation at G1 phase at 50 nM after 48 hrs by flow cytometry,Other,18429610.0,
2615,408264,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human Caco-2 cells assessed as accumulation at S phase at 50 nM after 48 hrs by flow cytometry,Other,18429610.0,
2616,408265,3,4,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human Caco-2 cells assessed as accumulation at G2/M phase at 50 nM after 48 hrs by flow cytometry,Other,18429610.0,
2617,408267,3,4,,123097261,31703,Inactive,,,,,Decrease in cyclin A expression in human Caco-2 cells at 50 nM,Other,18429610.0,
2618,408523,3,4,,123097261,31703,Active,,,,,Genotoxicity against mouse L929 cells assessed as number of micronuclei at 0.01 ug/ml,Other,18487049.0,
2619,408621,8,1,,123097261,31703,Active,,,0.0428,GI50,Antitumor activity against human MCF7 cells after 48 hrs,Confirmatory,18439831.0,
2620,408622,8,1,,123097261,31703,Active,,,0.094,GI50,Antitumor activity against human NCI-H460 cells after 48 hrs,Confirmatory,18439831.0,
2621,408623,8,1,,123097261,31703,Active,,,0.094,GI50,Antitumor activity against human SF268 cells after 48 hrs,Confirmatory,18439831.0,
2622,408909,6,2,,123097261,31703,Active,,,0.003,IC50,Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2623,408910,6,2,,123097261,31703,Active,,,0.002,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2624,408911,6,2,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2625,408912,6,2,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2626,408913,6,2,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2627,408914,6,2,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2628,408915,6,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2629,408916,6,2,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2630,408917,6,2,,123097261,31703,Active,,,0.16,IC50,Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2631,408918,6,2,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
2632,408919,3,7,,123097261,31703,Active,,,,,Inhibition of DNA topoisomerase 1-mediated supercoiled pBR322 DNA relaxation at 25 uM by agarose gel electrophoresis,Other,19053767.0,
2633,408922,3,10,,123097261,31703,Active,118770.0,1258680.0,,,Inhibition of T4 DNA ligase by DNA unwinding assay,Other,19053767.0,
2634,408923,3,7,,123097261,31703,Active,,,,,Inhibition of DNA topoisomerase 1-mediated supercoiled pBR322 DNA relaxation at 5 uM by agarose gel electrophoresis,Other,19053767.0,
2635,409942,11,2,,123097261,31703,Inactive,113978.0,4128.0,,IC50,Inhibition of human recombinant MAOA by fluorimetric method,Confirmatory,18834112.0,
2636,409943,11,2,,123097261,31703,Inactive,113980.0,4129.0,,IC50,Inhibition of human recombinant MAOB by fluorimetric method,Confirmatory,18834112.0,
2637,409954,4,9,,123097261,31703,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
2638,409956,4,9,,123097261,31703,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
2639,410955,6,3,,123097261,31703,Active,,,0.021,IC50,Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay,Confirmatory,19028425.0,
2640,410956,6,3,,123097261,31703,Unspecified,,,10.0,IC50,Cytotoxicity against human WI38 cells after 72 hrs by SRB assay,Confirmatory,19028425.0,
2641,410957,6,2,,123097261,31703,Active,,,0.025,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,19028425.0,
2642,410962,6,2,,123097261,31703,Active,,,0.018000000000000002,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay,Confirmatory,19028425.0,
2643,411048,7,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human A2780 cells after 3 days by MTT assay,Confirmatory,19093883.0,
2644,411049,7,1,,123097261,31703,Active,,,2.21,IC50,Antiproliferative activity against human A2780/DX3 cells after 3 days by MTT assay,Confirmatory,19093883.0,
2645,411050,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human A2780/DX3 cells to IC50 for human A2780 cells assessed as mean resistance index,Other,19093883.0,
2646,411055,3,4,,123097261,31703,Active,,,,,Reversal of P-gp 170-mediated multidrug resistance in human A2780/DX3 cells assessed as increase in intracellular doxorubicin accumulation at 5 times IC5 pretreated for 2 hrs before doxorubicin administration measured after 2 hrs by epifluorescent microscopic analysis,Other,19093883.0,
2647,416673,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Other,18586355.0,
2648,416674,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Other,18586355.0,
2649,416675,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,18586355.0,
2650,416676,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Other,18586355.0,
2651,416677,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Other,18586355.0,
2652,416678,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Other,18586355.0,
2653,416679,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Other,18586355.0,
2654,416680,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of first cleavage at 18.4 uM relative to control,Other,18586355.0,
2655,416681,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of first cleavage at 184 uM relative to control,Other,18586355.0,
2656,416692,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of third cleavage at 18.4 uM relative to control,Other,18586355.0,
2657,416693,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of third cleavage at 184 uM relative to control,Other,18586355.0,
2658,416706,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of blastula formation at 18.4 uM relative to control,Other,18586355.0,
2659,416707,3,4,,123097261,31703,Unspecified,,,,,Antimitotic activity in Lytechinus variegatus embryo assessed as inhibition of blastula formation at 184 uM relative to control,Other,18586355.0,
2660,418785,6,2,,123097261,31703,Active,,,0.57,EC50,Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs,Confirmatory,19282188.0,
2661,418786,6,2,,123097261,31703,Active,,,0.29,EC50,Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs,Confirmatory,19282188.0,
2662,418787,6,3,,123097261,31703,Active,,,,EC50,Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs,Confirmatory,19282188.0,
2663,418800,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against human MX1 cell xenografted Crl:Nu/Nu-nuBr mouse model assessed as inhibition of tumor growth at 8 mg/kg, ip once daily for 5 days",Other,19282188.0,
2664,418801,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against human MX1 cell xenografted Crl:Nu/Nu-nuBr mouse model assessed as inhibition of tumor growth at 10 mg/kg, iv administered as single dose",Other,19282188.0,
2665,419583,6,2,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human A431 cells after 72 hrs by MTT assay,Confirmatory,18692939.0,
2666,419584,6,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,18692939.0,
2667,419585,6,2,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,18692939.0,
2668,420180,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human BT474 cells xenografted in nude-foxn1nu mouse assessed as reduction in tumor growth at 3 mg/kg after 14 days relative to control,Other,19610651.0,
2669,420181,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human BT474 cells xenografted in nude-foxn1nu mouse assessed as reduction in tumor growth at 0.3 mg/kg after 14 days relative to control,Other,19610651.0,
2670,420477,6,2,,123097261,31703,Unspecified,,,94.0,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,19070942.0,
2671,420478,6,2,,123097261,31703,Unspecified,,,94.0,GI50,Cytotoxicity against human CNS cells after 48 hrs by SRB assay,Confirmatory,19070942.0,
2672,420479,6,2,,123097261,31703,Active,,,42.8,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,19070942.0,
2673,420494,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,19084293.0,
2674,420495,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Other,19084293.0,
2675,420496,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Other,19084293.0,
2676,421809,7,2,,123097261,31703,Inconclusive,,,,,Antiplasmodial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcB1 by [3H]hypoxanthine uptake,Other,19296616.0,
2677,421810,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs,Other,19296616.0,
2678,421869,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 3 days by MTT assay,Other,19159272.0,
2679,421870,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 3 days by MTT assay,Other,19159272.0,
2680,421871,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay,Other,19159272.0,
2681,421872,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells after 3 days by MTT assay,Other,19159272.0,
2682,421965,6,2,,123097261,31703,Active,,,0.006999999999999999,GI50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,19405508.0,
2683,421966,6,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,19405508.0,
2684,421967,6,2,,123097261,31703,Active,,,0.06,GI50,Cytotoxicity against human HT-29 cells by MTT assay,Confirmatory,19405508.0,
2685,421968,6,2,,123097261,31703,Active,,,0.12,EC50,Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay,Confirmatory,19405508.0,
2686,422289,6,2,,123097261,31703,Active,,,0.016,IC50,Cytotoxicity against human HL60 cells by SRB assay,Confirmatory,19341288.0,
2687,422290,6,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human HT-29 cells by SRB assay,Confirmatory,19341288.0,
2688,422291,6,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,19341288.0,
2689,422519,6,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay,Confirmatory,19072548.0,
2690,422764,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay,Other,19105653.0,
2691,422765,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by neutral red assay,Other,19105653.0,
2692,422766,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay,Other,19105653.0,
2693,422767,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay,Other,19105653.0,
2694,422768,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay,Other,19105653.0,
2695,422769,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay,Other,19105653.0,
2696,423636,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,19278239.0,
2697,425652,7,2,,123097261,31703,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2698,425653,7,2,,123097261,31703,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2699,426316,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by sulforhodamine B assay,Other,19555123.0,
2700,426317,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H187 cells by sulforhodamine B assay,Other,19555123.0,
2701,426957,6,2,,123097261,31703,Active,,,0.006999999999999999,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,19435339.0,
2702,426958,6,2,,123097261,31703,Active,,,0.055999999999999994,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,19435339.0,
2703,426959,6,2,,123097261,31703,Active,,,0.11699999999999999,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,19435339.0,
2704,426960,6,2,,123097261,31703,Active,,,0.16399999999999998,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,19435339.0,
2705,426989,6,2,,123097261,31703,Active,,,1.6,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,19583252.0,
2706,426990,6,2,,123097261,31703,Active,,,2.8,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,19583252.0,
2707,426993,6,2,,123097261,31703,Active,,,4.0,IC50,Cytotoxicity against human SNU1 cells by rapid colorimetric assay,Confirmatory,19585998.0,
2708,426994,6,2,,123097261,31703,Active,,,2.5,IC50,Cytotoxicity against human K562 cells by rapid colorimetric assay,Confirmatory,19585998.0,
2709,426995,6,2,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human A549 cells by rapid colorimetric assay,Confirmatory,19585998.0,
2710,426996,6,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human HepG2 cells by rapid colorimetric assay,Confirmatory,19585998.0,
2711,427232,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by resazurin microplate assay,Other,19456117.0,
2712,427233,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by resazurin microplate assay,Other,19456117.0,
2713,427234,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H187 cells by resazurin microplate assay,Other,19456117.0,
2714,427682,6,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human K562 cells after 72 hrs by flow cytometry,Confirmatory,19482476.0,
2715,427683,6,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,19482476.0,
2716,427714,4,4,,123097261,31703,Active,,,0.063,IC50,Anticancer activity against human 2008/P cells after 5 days by MTS assay,Confirmatory,19725578.0,
2717,427715,4,4,,123097261,31703,Active,,,0.5770000000000001,IC50,Anticancer activity against human 2008/MRP1 cells after 5 days by MTS assay,Confirmatory,19725578.0,
2718,427716,3,3,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human 2008/MRP1 cells to IC50 for human 2008/P cells,Other,19725578.0,
2719,428026,7,1,,123097261,31703,Active,,,,,Growth inhibition of mouse P388 cells after 72 hrs by trypan blue exclusion assay,Other,19501507.0,
2720,428027,7,1,,123097261,31703,Active,,,,,Growth inhibition of adriamycin-resistant mouse P388 cells after 72 hrs by trypan blue exclusion assay,Other,19501507.0,
2721,428309,6,2,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19523827.0,
2722,428310,3,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human MCF7/ADR cells to IC50 for human MCF7 cells,Other,19523827.0,
2723,428565,6,2,,123097261,31703,Active,,,4.18,IC50,Cytotoxicity against mouse EAC after 24 hrs by MTT assay,Confirmatory,19128861.0,
2724,428566,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Other,19128861.0,
2725,428567,6,2,,123097261,31703,Active,,,3.24,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,19128861.0,
2726,429348,6,2,,123097261,31703,Active,,,1.64,GI50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,19596579.0,
2727,429352,6,2,,123097261,31703,Active,,,0.61,GI50,Cytotoxicity against human MDA-MB-231 cells by SRB assay,Confirmatory,19596579.0,
2728,429353,6,2,,123097261,31703,Active,,,0.51,GI50,Cytotoxicity against human NCI-H23 cells by SRB assay,Confirmatory,19596579.0,
2729,429354,6,3,,123097261,31703,Active,,,0.25,GI50,Cytotoxicity against human NUGC3 cells by SRB assay,Confirmatory,19596579.0,
2730,429355,6,2,,123097261,31703,Active,,,0.73,GI50,Cytotoxicity against human PC3 cells by SRB assay,Confirmatory,19596579.0,
2731,429356,6,2,,123097261,31703,Active,,,0.41,GI50,Cytotoxicity against human ACHN cells by SRB assay,Confirmatory,19596579.0,
2732,429375,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Jurkat cells by MTT assay,Other,19371979.0,
2733,429376,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Raji cells by MTT assay,Other,19371979.0,
2734,429377,6,1,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,19371979.0,
2735,429378,6,1,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human Kga1 cells by MTT assay,Other,19371979.0,
2736,429841,6,2,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,19422203.0,
2737,429973,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT474 cells after 3 days by MTT assay,Other,19456120.0,
2738,429974,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KATO III cells after 3 days by MTT assay,Other,19456120.0,
2739,429975,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SW620 cells after 3 days by MTT assay,Other,19456120.0,
2740,429976,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Other,19456120.0,
2741,429977,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human ChaGo cells after 3 days by MTT assay,Other,19456120.0,
2742,430792,4,4,,123097261,31703,Active,,,0.001,IC50,Cytotoxicity against human KB cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2743,430793,4,4,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2744,430794,4,4,,123097261,31703,Active,,,0.057999999999999996,IC50,Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay,Confirmatory,19655762.0,
2745,430795,4,4,,123097261,31703,Active,,,0.006,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2746,430796,4,4,,123097261,31703,Active,,,0.081,IC50,Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2747,430797,4,4,,123097261,31703,Active,,,0.013000000000000001,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2748,430801,3,5,,123097261,31703,Unspecified,,,,,Induction of apoptosis in rat H9c2 cells at 1 uM after 24 hrs by FACS analysis,Other,19655762.0,
2749,430804,4,4,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay,Confirmatory,19655762.0,
2750,430807,3,4,,123097261,31703,Active,,,,,Cell cycle arrest in human HL60 cells assessed as accumulation of cells in G2/M phase at 20 nM after 48 hrs by FACS analysis,Other,19655762.0,
2751,430813,3,5,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as increase in caspase 3/7-mediated at 1 uM after 48 hrs measured by spectroscopy,Other,19655762.0,
2752,431395,6,2,,123097261,31703,Active,,,0.4654,EC50,Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
2753,431396,6,3,,123097261,31703,Active,,,3.0780000000000003,EC50,Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
2754,431398,7,2,,123097261,31703,Active,,,1.508,EC50,Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
2755,431399,7,3,,123097261,31703,Active,,,8.046,EC50,Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
2756,431506,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in human SK-N-SH cells at 0.5 to 5 uM by fluorescence assay,Other,19631549.0,
2757,431507,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in human SK-N-SH cells assessed as caspase 3 activity at 1 uM by fluorescence assay,Other,19631549.0,
2758,431508,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in human SK-N-SH cells assessed as caspase 3 activity at 5 uM by fluorescence assay,Other,19631549.0,
2759,432033,6,2,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2760,432034,6,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2761,432035,6,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2762,432036,6,2,,123097261,31703,Active,,,0.96,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2763,432037,6,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human UACC257 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2764,432038,6,2,,123097261,31703,Active,,,0.72,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2765,432039,6,2,,123097261,31703,Active,,,0.51,IC50,Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2766,432040,6,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human A704 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2767,432041,6,2,,123097261,31703,Active,,,1.32,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,19406535.0,
2768,432042,6,2,,123097261,31703,Active,,,1.77,IC50,Cytotoxicity against human PBMC cells after 72 hrs by alamar blue assay,Confirmatory,19406535.0,
2769,433942,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A375 cells assessed as inhibition of DNA synthesis in 10 ug/mL,Other,19615898.0,
2770,434344,7,2,,123097261,31703,Unspecified,,,,,Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay,Other,19342127.0,
2771,434345,7,2,,123097261,31703,Unspecified,,,,,Anticancer activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay,Other,19342127.0,
2772,434346,7,2,,123097261,31703,Unspecified,,,,,Anticancer activity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay,Other,19342127.0,
2773,434347,7,2,,123097261,31703,Unspecified,,,,,Anticancer activity against human XF498 cells after 72 hrs by sulforhodamine B assay,Other,19342127.0,
2774,434348,7,2,,123097261,31703,Unspecified,,,,,Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay,Other,19342127.0,
2775,434551,6,3,,123097261,31703,Active,,,0.63,IC50,Cytotoxicity against human PA1 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2776,434553,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2777,434555,6,2,,123097261,31703,Active,,,3.0,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2778,434557,6,2,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2779,434559,6,3,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2780,434561,6,2,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2781,434563,6,2,,123097261,31703,Active,,,0.15,IC50,Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2782,434565,6,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2783,434567,6,3,,123097261,31703,Inactive,,,,IC50,Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2784,434569,6,3,,123097261,31703,Active,,,0.39,IC50,Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay,Confirmatory,19361894.0,
2785,434959,1,1,,85787258,31703,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2786,436162,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,18973388.0,
2787,436163,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,18973388.0,
2788,436164,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,18973388.0,
2789,436165,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,18973388.0,
2790,436166,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,18973388.0,
2791,436167,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Ca9-22 cells by MTT assay,Other,18973388.0,
2792,436289,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 48 hrs by SRB assay,Other,18973387.0,
2793,436761,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,19540022.0,
2794,437272,3,3,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 2 uM by thermal denaturation assay,Other,19457675.0,
2795,437273,5,2,,123097261,31703,Active,,,0.3,IC50,Growth inhibition of human K562 cells by MTS method,Confirmatory,19457675.0,
2796,437274,5,2,,123097261,31703,Active,,,0.5,IC50,Growth inhibition of human K/VP.5 cells by MTS method,Confirmatory,19457675.0,
2797,437275,3,4,,123097261,31703,Unspecified,,,,,"Resistance factor, ratio of IC50 for human K/VP.5 cells to IC50 for human K562 cells",Other,19457675.0,
2798,437276,8,5,,123097261,31703,Inconclusive,13959709.0,7153.0,,IC50,Inhibition of decatenation activity of human topoisomerase 2alpha,Confirmatory,19457675.0,
2799,441064,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Other,19700322.0,
2800,442340,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2801,442341,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human Hep2 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2802,442342,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2803,442343,3,3,,123097261,31703,Unspecified,,,,,Growth inhibition of human 502713 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2804,442344,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2805,442346,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human A549 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2806,442348,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human IMR32 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
2807,442351,8,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human K562 cells after 72 hrs by flow cytometry,Confirmatory,19926173.0,
2808,442352,8,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,19926173.0,
2809,442503,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,19932530.0,
2810,442504,7,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Other,19932530.0,
2811,442559,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human A549 cells at 1 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
2812,442562,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human Hep2 cells at 1 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
2813,442565,3,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human IMR32 cells at 1 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
2814,442571,8,3,,123097261,31703,Active,,,1.7,IC50,Growth inhibition of human IMR32 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19939522.0,
2815,442664,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 100 ug/ml after 2 hrs by trypan blue exclusion,Other,19944497.0,
2816,442665,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 50 ug/ml after 2 hrs by trypan blue exclusion,Other,19944497.0,
2817,442666,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 25 ug/ml after 2 hrs by trypan blue exclusion,Other,19944497.0,
2818,442667,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 10 ug/ml after 2 hrs by trypan blue exclusion,Other,19944497.0,
2819,442668,7,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion,Other,19944497.0,
2820,443451,5,3,,123097261,31703,Unspecified,,,68.13,IC50,Cytotoxicity against mouse EAC cells,Confirmatory,19879135.0,
2821,443452,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as nonviable cell at 100 ug/mL relative to doxorubicin,Other,19879135.0,
2822,443453,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as nonviable cell at 50 ug/mL relative to doxorubicin,Other,19879135.0,
2823,443454,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as nonviable cell at 25 ug/mL relative to doxorubicin,Other,19879135.0,
2824,443455,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as nonviable cell at 10 ug/mL relative to doxorubicin,Other,19879135.0,
2825,444050,7,1,,123097261,31703,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
2826,444051,6,2,,123097261,31703,Unspecified,,,,,Total clearance in human,Other,20070106.0,
2827,444052,6,2,,123097261,31703,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
2828,444053,6,2,,123097261,31703,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
2829,444054,6,1,,123097261,31703,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
2830,444055,3,3,,123097261,31703,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
2831,444056,3,3,,123097261,31703,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
2832,444057,3,3,,123097261,31703,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
2833,444058,6,2,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
2834,444495,5,2,,123097261,31703,Active,,,0.35,IC50,Anticancer activity against human XF498 cells by sulforhodamine B assay,Confirmatory,19819696.0,
2835,444496,5,2,,123097261,31703,Active,,,0.027999999999999997,IC50,Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay,Confirmatory,19819696.0,
2836,444497,5,2,,123097261,31703,Active,,,0.075,IC50,Anticancer activity against human A549 cells by sulforhodamine B assay,Confirmatory,19819696.0,
2837,444498,5,2,,123097261,31703,Active,,,0.046,IC50,Anticancer activity against human SKOV3 cells by sulforhodamine B assay,Confirmatory,19819696.0,
2838,444500,5,2,,123097261,31703,Active,,,0.037000000000000005,IC50,Anticancer activity against human HCT15 cells by sulforhodamine B assay,Confirmatory,19819696.0,
2839,445394,5,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,19947600.0,
2840,445395,5,2,,123097261,31703,Active,,,0.88,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,19947600.0,
2841,445396,5,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,19947600.0,
2842,445397,5,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,19947600.0,
2843,445398,5,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human PBMC after 72 hrs by alamar blue assay,Confirmatory,19947600.0,
2844,445399,3,4,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC to IC50 for human HL60 cells",Other,19947600.0,
2845,445400,3,4,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC to IC50 for human MDA-MB-435 cells",Other,19947600.0,
2846,445401,3,4,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC to IC50 for human HCT8 cells",Other,19947600.0,
2847,445402,3,4,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC to IC50 for human SF295 cells",Other,19947600.0,
2848,445403,7,3,,123097261,31703,Unspecified,,,,,Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry,Other,19947600.0,
2849,445794,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC assessed as non viable cells at 100 ug/ml after 2 hrs by trypan blue exclusion assay,Other,19853327.0,
2850,445795,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC assessed as non viable cells at 75 ug/ml after 2 hrs by trypan blue exclusion assay,Other,19853327.0,
2851,445796,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC assessed as non viable cells at 50 ug/ml after 2 hrs by trypan blue exclusion assay,Other,19853327.0,
2852,445797,3,3,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC assessed as non viable cells at 25 ug/ml after 2 hrs by trypan blue exclusion assay,Other,19853327.0,
2853,445798,7,2,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay,Other,19853327.0,
2854,449546,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Jurkat cells assessed as growth inhibition at 100 uM after 48 hrs by MTT assay,Other,19679380.0,
2855,449548,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Raji cells assessed as growth inhibition at 100 uM after 48 hrs by MTT assay,Other,19679380.0,
2856,449549,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 100 uM after 72 hrs by MTT assay,Other,19679380.0,
2857,450673,5,2,,123097261,31703,Active,,,0.027000000000000003,IC50,Cytotoxicity against human HL60 cells after 72 hrs by XTT assay,Confirmatory,19647439.0,
2858,450674,5,2,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against human A549 cells after 72 hrs by XTT assay,Confirmatory,19647439.0,
2859,450675,5,2,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human HeLa cells after 72 hrs by XTT assay,Confirmatory,19647439.0,
2860,450676,5,2,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay,Confirmatory,19647439.0,
2861,453389,5,2,,123097261,31703,Active,,,1.73,IC50,Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2862,453390,5,2,,123097261,31703,Active,,,2.04,IC50,Cytotoxicity against human KB cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2863,453391,5,2,,123097261,31703,Active,,,1.96,IC50,Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2864,453392,5,2,,123097261,31703,Active,,,2.04,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2865,453393,4,1,,123097261,31703,Unspecified,,,,TC50,Toxicity against african green monkey Vero cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2866,453394,4,2,,123097261,31703,Active,,,1.29,TC50,Toxicity against pig LLC-PK11 cells after 48 hrs by neutral red assay,Confirmatory,19879765.0,
2867,454904,5,3,,123097261,31703,Active,,,0.85,IC50,Cytotoxicity against pig LLC-PK11 cells,Confirmatory,19910192.0,
2868,454905,5,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,19910192.0,
2869,454906,5,2,,123097261,31703,Active,,,20.0,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,19910192.0,
2870,455182,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human IMR32 cells at 1 uM after 48 hrs by Sulforhodamine assay,Other,19913412.0,
2871,455465,5,2,,123097261,31703,Active,,,0.73,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19819703.0,
2872,455466,5,2,,123097261,31703,Active,,,1.03,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19819703.0,
2873,455986,3,5,,123097261,31703,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
2874,457017,3,3,,123097261,31703,Active,,,,,Cellular uptake in human MES-SA cells at 25 uM after 2 hrs by fluorescence microscopy,Other,20151639.0,
2875,457020,5,3,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human MES-SA cells after 96 hrs by SRB assay,Confirmatory,20151639.0,
2876,457021,5,3,,123097261,31703,Active,,,3.1,IC50,Antiproliferative activity against human MES-SA/Dx5 cells after 96 hrs by SRB assay,Confirmatory,20151639.0,
2877,457023,3,3,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human MES-SA cells to IC50 for human MES-SA/Dx5 cells,Other,20151639.0,
2878,457024,3,3,,123097261,31703,Active,,,,,Cellular uptake in human MES-SA cells after 2 hrs by flow cytometry,Other,20151639.0,
2879,457027,3,3,,123097261,31703,Active,,,,,Induction of DNA damage in human MES-SA cells assessed as increase in comet-tail length by alkaline comet assay,Other,20151639.0,
2880,457028,3,3,,123097261,31703,Active,,,,,Induction of DNA damage in human MES-SA/Dx5 cells assessed as increase in comet-tail length by alkaline comet assay,Other,20151639.0,
2881,457055,6,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human QGY7703 cells,Other,20022253.0,
2882,457058,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human LoVo cells,Other,20022253.0,
2883,457322,3,3,,123097261,31703,Unspecified,,,,,"Octanol-water partition coefficient, log P by RP-HPLC method",Other,20153202.0,
2884,457323,6,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay,Other,20153202.0,
2885,457324,8,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay,Other,20153202.0,
2886,457325,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining,Other,20153202.0,
2887,457326,5,7,,123097261,31703,Inconclusive,113576.0,213.0,,Kd,Binding affinity to HSA after 30 mins assessed as quenching of intrinsic HSA fluorescence emission by spectrofluorimetric assay,Confirmatory,20153202.0,
2888,458201,3,5,,123097261,31703,Unspecified,,,,,Bone marrow toxicity in mouse bone marrow assessed as reticulocyte count at 2 umol/kg qd for 10 days,Other,20060717.0,
2889,458202,3,5,,123097261,31703,Unspecified,,,,,Bone marrow toxicity in mouse bone marrow assessed as reticulocyte count at 4 umol/kg qd for 10 days,Other,20060717.0,
2890,458203,3,5,,123097261,31703,Unspecified,,,,,Bone marrow toxicity in mouse bone marrow assessed as reticulocyte count at 6 umol/kg qd for 10 days,Other,20060717.0,
2891,458204,3,5,,123097261,31703,Unspecified,,,,,Bone marrow toxicity in mouse bone marrow assessed as reticulocyte count at 14 umol/kg qd for 10 days,Other,20060717.0,
2892,458205,3,4,,123097261,31703,Unspecified,,,,,Ratio of drug level in tumor to heart in mouse bearing human HT1080 cells relative to doxorubicin,Other,20060717.0,
2893,458206,7,1,,123097261,31703,Unspecified,,,,,Biodistribution in tumor in mouse bearing human HT1080 relative to doxorubicin,Other,20060717.0,
2894,459219,3,3,,123097261,31703,Unspecified,,,,,Binding affinity to d(CGTACG)2 assessed as average residence time,Other,20116264.0,
2895,459220,3,3,,123097261,31703,Unspecified,,,,,Binding affinity to d(CGATCG)2 assessed as average residence time,Other,20116264.0,
2896,459768,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells,Other,20036537.0,
2897,459769,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells,Other,20036537.0,
2898,459770,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells,Other,20036537.0,
2899,459771,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,20036537.0,
2900,459772,8,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human A549 cells,Confirmatory,20036537.0,
2901,459773,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Ca9-22 cells,Other,20036537.0,
2902,462641,3,3,,123097261,31703,Active,,,,,Induction of conformational changes in Escherichia coli pBR322 DNA assessed as DNA relaxation at 100 uM after 2 hrs by gel electrophoresis,Other,20170164.0,
2903,462642,3,7,,123097261,31703,Active,,,,,Inhibition of DNA topoisomerase 2-mediated kDNA decatenation at 100 uM,Other,20170164.0,
2904,462736,6,2,,123097261,31703,Active,,,0.33,IC50,Antiproliferative activity against human HeLa cells by MTT assay,Confirmatory,20171108.0,
2905,462737,5,2,,123097261,31703,Active,,,2.23,IC50,Antiproliferative activity against human A549 cells by MTT assay,Confirmatory,20171108.0,
2906,462738,5,3,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human SKHep cells by MTT assay,Confirmatory,20171108.0,
2907,462739,5,2,,123097261,31703,Active,,,1.76,IC50,Antiproliferative activity against human PC3 cells by MTT assay,Confirmatory,20171108.0,
2908,462740,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human Detroit 551 cells by MTT assay,Confirmatory,20171108.0,
2909,462764,3,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as tumor weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=1.602 +/- 0.391 g)",Other,20171109.0,
2910,462768,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as body weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=33.3 +/- 2.32 g)",Other,20171109.0,
2911,462769,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as heart weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=0.17 +/- 0.01 g)",Other,20171109.0,
2912,462770,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as brain weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=0.31 +/- 0.01 g)",Other,20171109.0,
2913,462771,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as liver weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=2.36 +/- 0.20 g)",Other,20171109.0,
2914,462772,3,5,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as spleen weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=0.22 +/- 0.04 g)",Other,20171109.0,
2915,462773,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as kidney weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=0.23 +/- 0.02 g)",Other,20171109.0,
2916,462774,3,5,,123097261,31703,Unspecified,,,,,"Toxicity in ICR mouse xenografted with mouse S180 cells assessed as femur weight at 1 mg/kg, ip administered 24 hrs after tumor implantation daily for 7 consecutive days measured after 24 hrs of last dose (Rvb=0.056 +/- 0.006 g)",Other,20171109.0,
2917,463448,5,2,,123097261,31703,Active,,,0.038,GI50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay,Confirmatory,20014800.0,
2918,463449,5,2,,123097261,31703,Active,,,0.066,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay,Confirmatory,20014800.0,
2919,463450,5,2,,123097261,31703,Active,,,0.062,GI50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,20014800.0,
2920,464198,7,1,,123097261,31703,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by radiometric method,Other,20035557.0,
2921,464199,7,1,,123097261,31703,Inconclusive,,,,,Antibacterial activity against Mycobacterium smegmatis MC2 155 by microplate dilution method,Other,20035557.0,
2922,464201,7,1,,123097261,31703,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human U937 cells by radiometric method,Other,20035557.0,
2923,464202,4,3,,123097261,31703,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in human U937 cells at MBC by radiometric method,Other,20035557.0,
2924,464203,5,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human U937 cells,Confirmatory,20035557.0,
2925,464246,5,2,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human KB cells by SRB assay,Confirmatory,20038128.0,
2926,464247,5,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human BC cells by SRB assay,Confirmatory,20038128.0,
2927,464248,5,3,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against human NCI-H187 cells by SRB assay,Confirmatory,20038128.0,
2928,464482,5,2,,123097261,31703,Active,,,0.18,GI50,Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay,Confirmatory,20045222.0,
2929,464483,5,2,,123097261,31703,Active,,,0.13,GI50,Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay,Confirmatory,20045222.0,
2930,464579,5,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,20176479.0,
2931,464580,5,2,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,20176479.0,
2932,464581,5,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,20176479.0,
2933,464582,5,2,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,20176479.0,
2934,465597,4,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells at 100 uM after 2 days by sulforhodamine B assay,Other,20138760.0,
2935,465598,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DU145 cells at 100 uM after 2 days by sulforhodamine B assay,Other,20138760.0,
2936,465599,4,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human A549 cells at 100 uM after 2 days by sulforhodamine B assay,Other,20138760.0,
2937,465600,4,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human SK-MEL-2 cells at 100 uM after 2 days by sulforhodamine B assay,Other,20138760.0,
2938,465601,4,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human SKOV3 cells at 100 uM after 2 days by sulforhodamine B assay,Other,20138760.0,
2939,465602,5,2,,123097261,31703,Active,,,0.85,GI50,Growth inhibition of human HT-29 cells after 2 days by MTT assay,Confirmatory,20138760.0,
2940,465603,5,2,,123097261,31703,Active,,,0.35,GI50,Growth inhibition of human DU145 cells after 2 days by MTT assay,Confirmatory,20138760.0,
2941,465616,5,2,,123097261,31703,Active,,,8.5,IC50,Cytotoxicity against human K562 cells assessed as viable cells after 72 hrs by MTS/PMS assay,Confirmatory,20055495.0,
2942,467034,5,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human HepG2 cells after 4 days by MTT assay,Confirmatory,19824618.0,
2943,467035,5,3,,123097261,31703,Active,,,0.64,IC50,Cytotoxicity against HuCCa1 cells after 4 days by MTT assay,Confirmatory,19824618.0,
2944,467036,5,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human A549 cells after 4 days by MTT assay,Confirmatory,19824618.0,
2945,467037,5,3,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,19824618.0,
2946,468175,5,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay,Confirmatory,19914747.0,
2947,468195,5,2,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,19919052.0,
2948,468594,4,4,,123097261,31703,Active,,,,,"Antitumor activity against human HepG2 cells expressing CES2 gene xenografted in NOD/SCID mouse assessed as inhibition of tumor growth at 4 to 5 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2949,468598,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in NOD/SCID mouse xenografted with human HepG2 cells expressing CES2 gene assessed as mortality rate at 3 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2950,468879,4,4,,123097261,31703,Active,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in athymic nude mouse assessed as inhibition of tumor growth at 2.5 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2951,468883,4,4,,123097261,31703,Inactive,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in pentyl PABC-doxazolidine-pretreated athymic nude mouse assessed as inhibition of tumor growth at 2.5 mg/kg, iv administered on day 56 after tumor implantation",Other,19634903.0,
2952,468884,4,4,,123097261,31703,Inactive,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in pentyl PABC-doxazolidine-pretreated athymic nude mouse assessed as inhibition of tumor growth at 2.5 mg/kg, iv administered on day 63 after tumor implantation",Other,19634903.0,
2953,468885,4,4,,123097261,31703,Inactive,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in pentyl PABC-doxazolidine-pretreated athymic nude mouse assessed as inhibition of tumor growth at 2.5 mg/kg, iv administered on day 70 after tumor implantation",Other,19634903.0,
2954,468886,3,3,,123097261,31703,Unspecified,,,,,"Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene at 3 to 4 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2955,468887,3,3,,123097261,31703,Unspecified,,,,,"Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as occurrence of diarrhea at 3 to 4 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2956,468888,3,4,,123097261,31703,Unspecified,,,,,"Toxicity in NOD/SCID mouse xenografted with human HepG2 cells expressing CES2 gene assessed as occurrence of diarrhea at 3 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2957,468890,3,4,,123097261,31703,Active,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in athymic nude mouse assessed as reduction in tumor size at 2.5 mg/kg, iv administered on day 7, 14 and 21 after tumor implantation",Other,19634903.0,
2958,468892,3,4,,123097261,31703,Active,,,,,"Antitumor activity against human NCI-H1435 cells expressing CES2 gene xenografted in athymic nude mouse assessed as slowing of tumor growth at 2.5 mg/kg, iv administered as three weekly infusion from day 21 to 56 after tumor implantation",Other,19634903.0,
2959,468893,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as myofibril disorganization and vacuolization of heart tissue administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2960,468894,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as occurrence of cardiomyocyte necrosis administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2961,468895,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as appearance of fibrotic damage in heart tissue administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2962,468898,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as uniformity in punktate staining pattern of hepatocytes administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2963,468900,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as lipid peroxidation in hepatocytes administered with six iv injection of 3 to 4 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2964,468901,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as occurrence of fatty liver administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2965,468904,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as vacuolar degeneration of kidney tissue administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2966,468907,3,4,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as vacuolar damage in ileum administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2967,468908,3,3,,123097261,31703,Unspecified,,,,,Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as inflammatory cell infiltration in ileum administered with six iv injection of 2.5 mg/kg by hematoxylin/eosin staining-based microscopy,Other,19634903.0,
2968,469260,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H187 cells by SRB assay,Other,19778068.0,
2969,469261,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by SRB assay,Other,19778068.0,
2970,469262,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by SRB assay,Other,19778068.0,
2971,469287,5,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human HL60 cells after 69 hrs by MTT assay,Confirmatory,19780590.0,
2972,469288,5,2,,123097261,31703,Active,,,1.67,IC50,Cytotoxicity against human MDA-MB-435 cells after 69 hrs by MTT assay,Confirmatory,19780590.0,
2973,469289,5,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human SF295 cells after 69 hrs by MTT assay,Confirmatory,19780590.0,
2974,469290,5,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay,Confirmatory,19780590.0,
2975,469291,5,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human PBMC after 72 hrs by alamar blue assay,Confirmatory,19780590.0,
2976,469420,5,2,,123097261,31703,Active,,,0.8370000000000001,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19860383.0,
2977,469818,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye staining,Other,19928902.0,
2978,469820,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by neutral red dye staining,Other,19928902.0,
2979,469822,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining,Other,19928902.0,
2980,469824,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye staining,Other,19928902.0,
2981,469826,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red dye staining,Other,19928902.0,
2982,469929,5,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral red assay,Confirmatory,19658408.0,
2983,469930,5,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral red assay,Confirmatory,19658408.0,
2984,469931,5,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay,Confirmatory,19658408.0,
2985,469932,5,2,,123097261,31703,Active,,,6.3,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral red assay,Confirmatory,19658408.0,
2986,470662,5,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
2987,470663,5,2,,123097261,31703,Active,,,0.84,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
2988,470664,5,2,,123097261,31703,Active,,,0.62,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
2989,470665,5,3,,123097261,31703,Active,,,3.12,IC50,Cytotoxicity against mouse Colon 26-L5 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
2990,470666,5,3,,123097261,31703,Active,,,3.07,IC50,Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
2991,470684,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Other,19783438.0,
2992,470685,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by sulforhodamine B assay,Other,19783438.0,
2993,470686,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay,Other,19783438.0,
2994,470687,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human XF498 cells after 48 hrs by sulforhodamine B assay,Other,19783438.0,
2995,470688,7,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Other,19783438.0,
2996,471091,5,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxic activity against human HL60 cells after 69 hrs by MTT assay,Confirmatory,19788290.0,
2997,471092,5,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay,Confirmatory,19788290.0,
2998,471093,5,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxic activity against human MDA-MB-453 cells after 69 hrs by MTT assay,Confirmatory,19788290.0,
2999,471094,5,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxic activity against human SF295 cells after 69 hrs by MTT assay,Confirmatory,19788290.0,
3000,471280,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells after 3 days by MTT assay,Other,19691312.0,
3001,471281,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Other,19691312.0,
3002,471282,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Other,19691312.0,
3003,471283,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Other,19691312.0,
3004,471284,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay,Other,19691312.0,
3005,471285,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 3 days by MTT assay,Other,19691312.0,
3006,471377,5,2,,123097261,31703,Active,,,0.92,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,19795842.0,
3007,471931,7,1,,123097261,31703,Active,,,0.094,GI50,Antitumor activity against human NCI-H460 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye,Confirmatory,19428155.0,
3008,471932,7,1,,123097261,31703,Active,,,0.0428,GI50,Antitumor activity against human MCF7 cells expressing estrogen receptor assessed as inhibition of growth after 48 hrs using sulforhodamine B dye,Confirmatory,19428155.0,
3009,471933,7,1,,123097261,31703,Active,,,0.01086,GI50,Antitumor activity against human estrogen receptor deficient MDA-MB-231 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye,Confirmatory,19428155.0,
3010,471934,7,1,,123097261,31703,Active,,,0.094,GI50,Antitumor activity against human SF268 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye,Confirmatory,19428155.0,
3011,471995,5,3,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human NCI-H187 cells by resazurin microplate assay,Confirmatory,19739600.0,
3012,471996,5,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human MCF7 cells by resazurin microplate assay,Confirmatory,19739600.0,
3013,471997,5,2,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against human KB cells by resazurin microplate assay,Confirmatory,19739600.0,
3014,471998,5,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 8 days by green fluorescent protein microplate assay,Confirmatory,19739600.0,
3015,472376,5,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry,Confirmatory,19748781.0,
3016,472809,5,2,,123097261,31703,Active,,,2.6,IC50,Inhibition of HCV genotype 1b NS5B polymerase deltaC21 mutant,Confirmatory,20363140.0,
3017,472812,5,3,,123097261,31703,Active,,,0.3,CC50,Cytotoxicity against human HBI10A cells,Confirmatory,20363140.0,
3018,472813,5,2,,123097261,31703,Active,,,0.3,EC50,Antiviral activity against Hepatitis C virus H2B2,Confirmatory,20363140.0,
3019,472814,3,3,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HBI10A cells to EC50 for Hepatitis C virus",Other,20363140.0,
3020,472816,5,2,,123097261,31703,Active,,,12.0,IC50,Inhibition of HCV genotype 1b NS5B polymerase deltaC21 M423K mutant,Confirmatory,20363140.0,
3021,475883,3,4,,123097261,31703,Active,,,0.018000000000000002,IC50,Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
3022,475884,3,4,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
3023,475885,3,4,,123097261,31703,Active,,,0.011000000000000001,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
3024,475887,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at G0/G1 phase at 100 nM after 24 hrs by flow cytometry,Other,20210346.0,
3025,475890,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at S phase at 100 nM after 24 hrs by flow cytometry,Other,20210346.0,
3026,475894,3,3,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at G2/M phase at 100 nM after 24 hrs by flow cytometry,Other,20210346.0,
3027,475898,3,5,,123097261,31703,Unspecified,,,,,Drug uptake in perfused mouse brain assessed as blood-brain transfer coefficient,Other,20210346.0,
3028,476194,5,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay,Confirmatory,20303768.0,
3029,476195,5,2,,123097261,31703,Active,,,5.95,IC50,Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay,Confirmatory,20303768.0,
3030,476929,3,3,,123097261,31703,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
3031,476948,5,2,,123097261,31703,Active,,,2.62,IC50,Cytotoxicity against human MCF7 after 24 hrs by MTT assay,Confirmatory,20056520.0,
3032,476949,5,2,,123097261,31703,Active,,,3.24,IC50,Cytotoxicity against human HeLa after 24 hrs by MTT assay,Confirmatory,20056520.0,
3033,477016,3,3,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as temperature required to cause 50% of DNA denatured at 10 uM by thermal denaturation assay,Other,20064676.0,
3034,477017,3,3,,123097261,31703,Inconclusive,,,,,Displacement of ethidium bromide from calf thymus DNA assessed as decrease of fluorescence of bound ethidium bromide by fluorometric assay,Other,20064676.0,
3035,477019,5,2,,123097261,31703,Active,,,14.35,IC50,Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay,Confirmatory,20064676.0,
3036,477020,5,2,,123097261,31703,Active,,,3.61,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20064676.0,
3037,477021,5,3,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human MCF10A cells after 24 hrs by MTT assay,Confirmatory,20064676.0,
3038,477022,5,3,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay,Confirmatory,20064676.0,
3039,477295,3,3,,123097261,31703,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
3040,477399,7,1,,123097261,31703,Active,,,0.055,IC50,Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay,Confirmatory,20180542.0,
3041,477401,3,4,,123097261,31703,Active,,,0.037000000000000005,IC50,Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay,Confirmatory,20180542.0,
3042,477971,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells by resazurin microplate assay,Other,20329738.0,
3043,477972,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by resazurin microplate assay,Other,20329738.0,
3044,477973,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H187 cells by resazurin microplate assay,Other,20329738.0,
3045,478070,5,2,,123097261,31703,Active,,,0.912,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,20356064.0,
3046,478740,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC cells assessed as non viable cells at 100 ug/mL after 2 hrs by trypan blue exclusion test,Other,20149941.0,
3047,478741,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC cells assessed as non viable cells at 50 ug/mL after 2 hrs by trypan blue exclusion test,Other,20149941.0,
3048,478742,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC cells assessed as non viable cells at 25 ug/mL after 2 hrs by trypan blue exclusion test,Other,20149941.0,
3049,478743,3,4,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC cells assessed as non viable cells at 10 ug/mL after 2 hrs by trypan blue exclusion test,Other,20149941.0,
3050,478744,6,3,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test,Other,20149941.0,
3051,479036,3,4,,123097261,31703,Inactive,,,,,Cytotoxicity in human Jurkat cells overexpressing Bcl2 assessed as cell death at 2 uM after 72 hrs by propidium iodide-staining based flow cytometry,Other,20346684.0,
3052,479981,3,4,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 10 uM relative to control,Other,20356739.0,
3053,481850,5,2,,123097261,31703,Active,,,2.05,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
3054,481851,5,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
3055,481852,5,2,,123097261,31703,Active,,,3.16,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
3056,481863,5,3,,123097261,31703,Active,,,3.7,IC50,Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
3057,481921,5,2,,123097261,31703,Active,,,6.1,EC50,Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay,Confirmatory,20455578.0,
3058,481922,5,3,,123097261,31703,Active,,,5.6,EC50,Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay,Confirmatory,20455578.0,
3059,481923,5,3,,123097261,31703,Unspecified,,,10.0,EC50,Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay,Confirmatory,20455578.0,
3060,481924,5,2,,123097261,31703,Unspecified,,,10.0,EC50,Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay,Confirmatory,20455578.0,
3061,485536,4,6,,123097261,31703,Inconclusive,,,,,Inhibition of topoisomerase 1-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 20 mins using ethidium bromide staining by electrophoresis relative to control,Other,20471276.0,
3062,485537,3,4,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as increase in melting temperature at 1 uM by spectrophotometer analysis,Other,20471276.0,
3063,485538,4,8,,123097261,31703,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 alpha-mediated Crithidia fasciculate kDNA decatenation at 20 uM relative to control,Other,20471276.0,
3064,485539,4,8,,123097261,31703,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 alpha assessed as stabilization of enzyme-PBR322 DNA complex at 100 uM relative to control,Other,20471276.0,
3065,485540,5,2,,123097261,31703,Active,,,0.033,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTS assay,Confirmatory,20471276.0,
3066,485541,5,3,,123097261,31703,Active,,,0.52,IC50,Cytotoxicity against human K/VP.5 cells after 72 hrs by MTS assay,Confirmatory,20471276.0,
3067,485542,3,4,,123097261,31703,Unspecified,,,,,"Resistant factor, ratio of IC50 human K/VP.5 cells to IC50 for human K562 cells",Other,20471276.0,
3068,486186,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity HUVEC after 20 hrs by MTT assay,Confirmatory,20149494.0,
3069,486187,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity human A549 cells after 20 hrs by MTT assay,Confirmatory,20149494.0,
3070,486188,5,3,,123097261,31703,Active,,,0.58,IC50,Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay,Confirmatory,20149494.0,
3071,486189,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity human MCF7 cells after 20 hrs by MTT assay,Confirmatory,20149494.0,
3072,486190,5,2,,123097261,31703,Inconclusive,,,,CC50,Antiproliferative activity human CCC-HPF1 cells after 20 hrs by MTT assay,Confirmatory,20149494.0,
3073,486957,5,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,20207049.0,
3074,486958,5,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,20207049.0,
3075,486959,5,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,20207049.0,
3076,486960,5,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,20207049.0,
3077,486961,5,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human H460 cells after 72 hrs by MTT assay,Confirmatory,20207049.0,
3078,487174,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Caco-2 cells after 24 hrs,Other,20207452.0,
3079,487175,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 24 hrs,Other,20207452.0,
3080,487722,7,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3081,487723,7,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3082,487724,7,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3083,487725,7,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3084,487726,7,1,,123097261,31703,Active,,,1.3,IC50,Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3085,487727,7,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,20334960.0,
3086,487903,7,1,,123097261,31703,Active,,,4.16,IC50,Cytotoxicity against human SKOV3 cells after 3 days by MTT assay,Confirmatory,20356655.0,
3087,487907,5,2,,123097261,31703,Active,,,0.0011300000000000001,IC50,Cytotoxicity against human HL60 cells after 3 days by MTT assay,Confirmatory,20356655.0,
3088,487908,7,1,,123097261,31703,Active,,,0.00445,IC50,Cytotoxicity against human U937 cells after 3 days by MTT assay,Confirmatory,20356655.0,
3089,487909,7,1,,123097261,31703,Active,,,0.0061200000000000004,IC50,Cytotoxicity against human K562 cells after 3 days by MTT assay,Confirmatory,20356655.0,
3090,487912,7,2,,123097261,31703,Active,,,0.00473,IC50,Cytotoxicity against human GOTO cells after 3 days by MTT assay,Confirmatory,20356655.0,
3091,487913,7,2,,123097261,31703,Active,,,0.00515,IC50,Cytotoxicity against human NB-1 cells after 3 days by MTT assay,Confirmatory,20356655.0,
3092,489900,5,2,,123097261,31703,Active,,,0.4,GI50,Growth inhibition of human HCT116 cells after 2 days by MTT assay,Confirmatory,20570145.0,
3093,489901,5,2,,123097261,31703,Active,,,0.02,GI50,Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay,Confirmatory,20570145.0,
3094,490013,5,2,,123097261,31703,Active,,,0.25,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3095,490014,5,2,,123097261,31703,Active,,,0.92,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3096,490015,5,2,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3097,490016,5,2,,123097261,31703,Active,,,2.98,IC50,Antiproliferative activity against human Raji cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3098,490017,5,2,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3099,490018,5,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,20359789.0,
3100,490032,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1/Columbia after 48 hrs,Confirmatory,20362359.0,
3101,490033,5,2,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32 after 48 hrs,Confirmatory,20362359.0,
3102,490034,5,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,20362359.0,
3103,490035,5,2,,123097261,31703,Active,,,7.4,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,20362359.0,
3104,490334,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay,Other,20399544.0,
3105,490335,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Other,20399544.0,
3106,490336,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Other,20399544.0,
3107,490491,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 10 ug/ml after 2 hrs by trypan blue exclusion assay,Other,20413187.0,
3108,490492,8,1,,123097261,31703,Unspecified,,,69.9,IC50,Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay,Confirmatory,20413187.0,
3109,490493,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 25 ug/ml after 2 hrs by trypan blue exclusion assay,Other,20413187.0,
3110,490494,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 100 ug/ml after 2 hrs by trypan blue exclusion assay,Other,20413187.0,
3111,490495,3,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as non-viable cells at 50 ug/ml after 2 hrs by trypan blue exclusion assay,Other,20413187.0,
3112,490496,5,2,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human UACC62 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3113,490497,5,2,,123097261,31703,Active,,,0.04,GI50,Cytotoxicity against human MCF7 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3114,490498,5,3,,123097261,31703,Active,,,5.99,GI50,Cytotoxicity against human NCI/ADR cells by sulforhodamine B assay,Confirmatory,20413188.0,
3115,490499,5,2,,123097261,31703,Active,,,0.05,GI50,Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3116,490500,5,3,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human PCO3 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3117,490501,5,2,,123097261,31703,Active,,,0.07,GI50,Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3118,490502,5,2,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human HT-29 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3119,490503,5,2,,123097261,31703,Active,,,0.03,GI50,Cytotoxicity against human K562 cells by sulforhodamine B assay,Confirmatory,20413188.0,
3120,491633,7,1,,123097261,31703,Active,,,0.0369,IC50,Cytotoxicity against human CCRF-CEM by XTT assay,Confirmatory,20527917.0,
3121,491634,5,2,,123097261,31703,Unspecified,,,5.2,IC50,Cytotoxicity against human CEM/ADR5000 by XTT assay,Confirmatory,20527917.0,
3122,491638,3,4,,123097261,31703,Active,,,,,Induction of apoptosis in human CEM/ADR5000 cells at 1 ug/mL after 24 hrs using propidium iodide staining by flow cytometry,Other,20527917.0,
3123,491642,3,4,,123097261,31703,Inactive,,,,,"Increase in ROS generation in human CEM/ADR5000 cells at at 1 ug/ml after 6 hrs 2',7'-dichlorodihydrofluoresceine diacetate staining by flow cytometry",Other,20527917.0,
3124,491956,5,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human GXF251L cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3125,491957,5,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human LXFL529 cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3126,491958,5,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human MAXF 401NL cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3127,491959,5,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human MEXF 462NL cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3128,491960,5,3,,123097261,31703,Unspecified,,,0.052000000000000005,IC50,Cytotoxicity against human RXF 486L cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3129,491961,5,3,,123097261,31703,Active,,,0.052000000000000005,IC50,Cytotoxicity against human PAXF 1657L cells after 24 hrs by CellTiter-BlueCell viability assay,Confirmatory,20545334.0,
3130,491991,8,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cell after 48 hrs by Neutral Red dye,Other,20550123.0,
3131,492002,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral Red dye,Other,20550123.0,
3132,492004,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by Neutral Red dye,Other,20550123.0,
3133,492006,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye,Other,20550123.0,
3134,492008,6,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral Red dye,Other,20550123.0,
3135,492011,6,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by Neutral Red dye,Other,20550123.0,
3136,492169,5,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20593838.0,
3137,492170,5,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,20593838.0,
3138,492171,5,3,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay,Confirmatory,20593838.0,
3139,492190,7,1,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay,Confirmatory,20538470.0,
3140,492191,7,1,,123097261,31703,Active,,,0.324,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay,Confirmatory,20538470.0,
3141,492192,7,1,,123097261,31703,Active,,,0.264,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay,Confirmatory,20538470.0,
3142,492193,7,1,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human SF268 cells after 72 hrs by XTT assay,Confirmatory,20538470.0,
3143,492194,3,4,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature,Other,20538470.0,
3144,493705,4,2,,123097261,31703,Active,,,0.021,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,20594848.0,
3145,493706,4,2,,123097261,31703,Active,,,0.003,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,20594848.0,
3146,493707,4,2,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,20594848.0,
3147,493708,4,2,,123097261,31703,Active,,,0.038,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,20594848.0,
3148,494469,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,20537433.0,
3149,494470,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Other,20537433.0,
3150,494471,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Other,20537433.0,
3151,494472,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay,Other,20537433.0,
3152,494676,4,2,,123097261,31703,Active,,,0.17800000000000002,GI50,Cytotoxicity against human NCI-H23 cells,Confirmatory,20579876.0,
3153,494677,4,2,,123097261,31703,Active,,,0.317,GI50,Cytotoxicity against human PC3 cells,Confirmatory,20579876.0,
3154,494678,4,2,,123097261,31703,Active,,,0.182,GI50,Cytotoxicity against human ACHN cells,Confirmatory,20579876.0,
3155,494679,4,2,,123097261,31703,Active,,,2.177,GI50,Cytotoxicity against human HCT15 cells,Confirmatory,20579876.0,
3156,494680,4,2,,123097261,31703,Active,,,0.19399999999999998,GI50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,20579876.0,
3157,494681,4,3,,123097261,31703,Active,,,0.20199999999999999,GI50,Cytotoxicity against human NUGC3 cells,Confirmatory,20579876.0,
3158,497177,4,2,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs,Confirmatory,20634081.0,
3159,497178,4,3,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs,Confirmatory,20634081.0,
3160,497179,4,2,,123097261,31703,Active,,,5.12,IC50,Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs,Confirmatory,20634081.0,
3161,499272,4,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry,Confirmatory,20638854.0,
3162,502064,4,2,,123097261,31703,Active,,,0.02,GI50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,20675130.0,
3163,502401,4,2,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,20718475.0,
3164,502402,4,2,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,20718475.0,
3165,502403,4,2,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,20718475.0,
3166,502404,4,3,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human Hep3B cells by MTT assay,Confirmatory,20718475.0,
3167,502405,4,2,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,20718475.0,
3168,502412,4,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,20719504.0,
3169,502413,4,2,,123097261,31703,Active,,,0.001,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,20719504.0,
3170,502414,4,2,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,20719504.0,
3171,502415,4,2,,123097261,31703,Active,,,0.027999999999999997,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,20719504.0,
3172,502659,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay,Other,20722446.0,
3173,502660,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,20722446.0,
3174,502661,5,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3M cells after 72 hrs by MTT assay,Other,20722446.0,
3175,502662,5,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Other,20722446.0,
3176,502663,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H446 cells at 100 ug/ml after 72 hrs by MTT assay,Other,20722446.0,
3177,502664,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells at 100 ug/ml after 72 hrs by MTT assay,Other,20722446.0,
3178,502665,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3M cells at 100 ug/ml after 72 hrs by MTT assay,Other,20722446.0,
3179,502666,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 100 ug/ml after 72 hrs by MTT assay,Other,20722446.0,
3180,504206,4,2,,123097261,31703,Active,,,7.25,GI50,Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3181,504211,4,2,,123097261,31703,Active,,,1.81,GI50,Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3182,504213,4,3,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human Gurav cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3183,504214,4,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3184,504215,4,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3185,504216,4,2,,123097261,31703,Active,,,1.79,GI50,Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3186,504217,4,2,,123097261,31703,Active,,,0.16,GI50,Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3187,504218,4,3,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human DWD cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3188,504219,4,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human KB cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3189,504220,4,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3190,504221,4,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay,Confirmatory,20732817.0,
3191,504300,4,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human KB cells,Confirmatory,20815366.0,
3192,504301,4,2,,123097261,31703,Active,,,2.18,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,20815366.0,
3193,510200,4,2,,123097261,31703,Active,,,0.32,TGI,Cytotoxicity against human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3194,510201,4,2,,123097261,31703,Active,,,10.99,TGI,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3195,510202,4,3,,123097261,31703,Active,,,2.83,TGI,Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3196,510203,4,2,,123097261,31703,Active,,,7.86,TGI,Cytotoxicity against human 786-0 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3197,510204,4,2,,123097261,31703,Active,,,2.37,TGI,Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3198,510205,4,3,,123097261,31703,Active,,,4.03,TGI,Cytotoxicity against human PCO3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3199,510206,4,2,,123097261,31703,Active,,,10.25,TGI,Cytotoxicity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3200,510207,4,2,,123097261,31703,Active,,,16.4,TGI,Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3201,510208,4,2,,123097261,31703,Active,,,1.42,TGI,Cytotoxicity against human U251 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20729093.0,
3202,510225,2,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of increase in tumor volume at 3 mg/kg, ip administered every 3 days measured on day 7 relative to control",Other,20729093.0,
3203,510226,2,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of increase in tumor volume at 3 mg/kg, ip administered every 3 days measured on day 15 relative to control",Other,20729093.0,
3204,510228,2,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as reduction of tumor weight at 3 mg/kg, ip administered every 3 days measured on day 15 relative to control",Other,20729093.0,
3205,510232,2,3,,123097261,31703,Unspecified,,,,,"Acute toxicity in BALB/C mouse assessed as reduction of body weight at up to 3 mg/kg, ip after 15 days",Other,20729093.0,
3206,510241,3,3,,123097261,31703,Active,,,,,"Antiinflammatory activity in BALB/C mouse assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, ip administered 30 mins before carrageenan challenge measured before 24 hrs by plethysmometer",Other,20729093.0,
3207,510242,3,3,,123097261,31703,Unspecified,,,,,Antiinflammatory activity in ip dosed BALB/C mouse assessed as inhibition of carrageenan-induced paw edema administered 30 mins before carrageenan challenge measured after 24 hrs by plethysmometer,Other,20729093.0,
3208,510362,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human HepG2 cells after 48 hrs by MTT assay,Other,20599299.0,
3209,510363,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human MCF7 cells after 48 hrs by MTT assay,Other,20599299.0,
3210,510364,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human HeLa cells after 48 hrs by MTT assay,Other,20599299.0,
3211,510837,6,1,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against human HeLa cells after 72 hrs by XTT assay,Confirmatory,20619940.0,
3212,510838,6,1,,123097261,31703,Active,,,0.26,IC50,Cytotoxicity against human A549 cells after 72 hrs by XTT assay,Confirmatory,20619940.0,
3213,510839,6,1,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay,Confirmatory,20619940.0,
3214,511232,2,3,,123097261,31703,Inconclusive,,,,,Binding affinity to pBR322,Other,20662543.0,
3215,511233,3,8,,123097261,31703,Unspecified,12644118.0,7150.0,,,Inhibition of human topoisomerase 1 assessed as decrease in pBR322 mobility on agarose gel at 10 uM by electrophoresis,Other,20662543.0,
3216,511234,7,5,,123097261,31703,Active,12644118.0,7150.0,20.0,IC50,Inhibition of human topoisomerase 1 assessed as decrease in pBR322 mobility on agarose gel by electrophoresis,Confirmatory,20662543.0,
3217,511235,3,3,,123097261,31703,Unspecified,,,,,Inhibition of human topoisomerase 2 assessed as decrease in pBR322 mobility on agarose gel at 10 uM by electrophoresis,Other,20662543.0,
3218,511236,4,2,,123097261,31703,Active,,,1.9,IC50,Inhibition of human topoisomerase 2 assessed as decrease in pBR322 mobility on agarose gel by electrophoresis,Confirmatory,20662543.0,
3219,511769,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as survival fraction at 10 uM after 48 hrs by SRB assay,Other,20684857.0,
3220,511770,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as survival fraction at 25 uM after 48 hrs by SRB assay,Other,20684857.0,
3221,511771,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as survival fraction at 50 uM after 48 hrs by SRB assay,Other,20684857.0,
3222,511772,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as survival fraction at 100 uM after 48 hrs by SRB assay,Other,20684857.0,
3223,511773,4,2,,123097261,31703,Unspecified,,,71.8,IC50,Anticancer activity against human MCF7 cells assessed as survival fraction after 48 hrs by SRB assay,Confirmatory,20684857.0,
3224,512064,2,4,,123097261,31703,Active,,,0.081,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20690624.0,
3225,512065,2,4,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,20690624.0,
3226,512066,2,4,,123097261,31703,Unspecified,,,1.0,IC50,Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay,Confirmatory,20690624.0,
3227,513196,3,9,,123097261,31703,Inactive,269849759.0,7157.0,,,Inhibition of p53-mediated transactivation in human MCF7 cells in presence of 0.5 ug/ml of doxorubicin after 24 hrs by beta-galactosidase reporter gene assay,Other,16862141.0,
3228,514990,3,2,,123097261,31703,Active,,,2.5704,GI50,Cytotoxicity against human K562 cells after 48 hrs by SRB,Confirmatory,20667627.0,
3229,514991,3,2,,123097261,31703,Active,,,2.0893,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB,Confirmatory,20667627.0,
3230,514992,3,2,,123097261,31703,Active,,,0.1349,GI50,Cytotoxicity against human HepG2 cells after 48 hrs by SRB,Confirmatory,20667627.0,
3231,514993,4,2,,123097261,31703,Active,,,35.4813,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by SRB,Confirmatory,20667627.0,
3232,514994,3,2,,123097261,31703,Active,,,2.0893,GI50,Cytotoxicity against human PC3 cells after 48 hrs by SRB,Confirmatory,20667627.0,
3233,514995,4,3,,123097261,31703,Active,,,0.15849000000000002,GI50,Cytotoxicity against human Gurav cells after 48 hrs by SRB,Confirmatory,20667627.0,
3234,514996,3,2,,123097261,31703,Active,,,0.14125,GI50,Cytotoxicity against human KB cells after 48 hrs by SRB,Confirmatory,20667627.0,
3235,515926,4,2,,123097261,31703,Active,,,0.008,IC50,Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry,Confirmatory,20833057.0,
3236,516596,4,2,,123097261,31703,Active,,,0.22,GI50,Anticancer activity against human ACHN cells by SRB assay,Confirmatory,20732810.0,
3237,516598,4,2,,123097261,31703,Active,,,0.28,GI50,Anticancer activity against human PC3 cells by SRB assay,Confirmatory,20732810.0,
3238,516599,4,2,,123097261,31703,Active,,,0.18,GI50,Anticancer activity against human MDA-MB-231 cells by SRB assay,Confirmatory,20732810.0,
3239,516648,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by SRB assay,Other,20732814.0,
3240,516649,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,20732814.0,
3241,516650,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,20732814.0,
3242,516651,5,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human C33A cells after 48 hrs by SRB assay,Other,20732814.0,
3243,516652,5,3,,123097261,31703,Inconclusive,,,,,Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay,Other,20732814.0,
3244,516698,4,2,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human T47D cells after 2 days by MTT assay,Confirmatory,20800481.0,
3245,516700,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human T47D cells assessed as survival at 0.25 uM after 2 days by MTT assay,Other,20800481.0,
3246,526253,4,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3247,526254,4,3,,123097261,31703,Active,,,0.049,IC50,Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3248,526255,4,3,,123097261,31703,Active,,,1.06,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3249,526256,4,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3250,526257,4,2,,123097261,31703,Active,,,9.2,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3251,526258,4,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human A431 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3252,526259,4,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3253,526260,4,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,20846862.0,
3254,526320,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 24 hrs by SRB assay,Other,20850305.0,
3255,526321,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 24 hrs by SRB assay,Other,20850305.0,
3256,526322,5,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay,Other,20850305.0,
3257,526323,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human RPMI cells after 24 hrs by SRB assay,Other,20850305.0,
3258,526324,6,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human U251 cells after 24 hrs by SRB assay,Other,20850305.0,
3259,526333,4,2,,123097261,31703,Active,,,5.23,IC50,Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay,Confirmatory,20850308.0,
3260,526334,4,2,,123097261,31703,Active,,,3.22,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay,Confirmatory,20850308.0,
3261,527124,1,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against human A549 cells xenografted in BALB/c mouse assessed as inhibition of tumor weight at 2 mg/kg, iv administered once per 2 days for 4 weeks measured post last dose",Other,20884207.0,
3262,527186,4,2,,123097261,31703,Active,,,2.57,IC50,Cytotoxicity against human MCF7 cells after 48 hrs,Confirmatory,20873721.0,
3263,527187,4,2,,123097261,31703,Active,,,6.06,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs,Confirmatory,20873721.0,
3264,527188,4,2,,123097261,31703,Active,,,6.4,IC50,Cytotoxicity against human HT-29 cells after 48 hrs,Confirmatory,20873721.0,
3265,527189,4,2,,123097261,31703,Active,,,3.14,IC50,Cytotoxicity against human CEM cells after 48 hrs,Confirmatory,20873721.0,
3266,527943,4,2,,123097261,31703,Active,,,2.03,IC50,Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,20932754.0,
3267,527944,4,3,,123097261,31703,Active,,,0.9,IC50,Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay,Confirmatory,20932754.0,
3268,536296,4,2,,123097261,31703,Active,,,2.94,IC50,Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay,Confirmatory,20810194.0,
3269,536297,4,2,,123097261,31703,Active,,,2.94,IC50,Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay,Confirmatory,20810194.0,
3270,536449,4,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay,Other,20813435.0,
3271,536450,5,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against mouse LLC cells after 24 hrs by MTS assay,Other,20813435.0,
3272,536477,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells at 1 uM after 72 hrs by relative to control,Other,20817326.0,
3273,536478,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells at 5 uM after 72 hrs by relative to control,Other,20817326.0,
3274,536479,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells at 10 uM after 72 hrs by relative to control,Other,20817326.0,
3275,536480,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells at 20 uM after 72 hrs by relative to control,Other,20817326.0,
3276,536481,4,2,,123097261,31703,Active,,,3.3,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,20817326.0,
3277,536596,2,5,,123097261,31703,Unspecified,,,,,Antitumor activity against human BGC823 cells assessed as growth inhibition at 10 uM after 24 hrs by relative to control,Other,20817326.0,
3278,536597,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay,Other,20817327.0,
3279,536598,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,20817327.0,
3280,536599,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,20817327.0,
3281,536600,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells at 0.1 to 5 uM by SRB assay,Other,20817327.0,
3282,536601,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells at 0.1 to 5 uM by SRB assay,Other,20817327.0,
3283,536602,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 0.1 to 5 uM by SRB assay,Other,20817327.0,
3284,536661,4,2,,123097261,31703,Active,,,0.9540000000000001,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,20832916.0,
3285,536662,4,2,,123097261,31703,Active,,,2.4,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20832916.0,
3286,536663,4,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay,Confirmatory,20832916.0,
3287,536664,4,2,,123097261,31703,Active,,,2.3,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20832916.0,
3288,537050,4,3,,123097261,31703,Active,,,1.23,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3289,537052,4,4,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3290,537053,4,3,,123097261,31703,Active,,,0.95,IC50,Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3291,537054,4,3,,123097261,31703,Active,,,1.63,IC50,Cytotoxicity against human PC3 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3292,537055,4,4,,123097261,31703,Active,,,0.76,IC50,Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3293,537056,4,3,,123097261,31703,Active,,,1.54,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3294,537057,4,3,,123097261,31703,Active,,,0.85,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3295,537058,4,4,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against HMEC1 cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3296,537059,4,3,,123097261,31703,Active,,,2.33,IC50,Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay,Confirmatory,20931970.0,
3297,537060,2,6,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human ARPE19 cells to IC50 for human LAMA-84 cells",Other,20931970.0,
3298,537475,1,5,,123097261,31703,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 5 nM after 96 hrs by sulforhodamine B assay relative to control,Other,20943401.0,
3299,537476,1,5,,123097261,31703,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 10 nM after 96 hrs by sulforhodamine B assay relative to control,Other,20943401.0,
3300,537652,1,5,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 20 uM by thermal denaturation assay,Other,20716468.0,
3301,537729,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human MCF7 cells,Other,20739102.0,
3302,537730,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human HCT116 cells,Other,20739102.0,
3303,537731,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human HeLa cells,Other,20739102.0,
3304,537732,4,2,,123097261,31703,Unspecified,,,,,Antitumor activity against human HepG2 cells,Other,20739102.0,
3305,537733,2,3,,123097261,31703,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
3306,537734,5,2,,123097261,31703,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
3307,537735,2,3,,123097261,31703,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
3308,537736,5,2,,123097261,31703,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
3309,538208,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,21106454.0,
3310,538209,5,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,21106454.0,
3311,538210,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Ca9-22 cells by MTT assay,Other,21106454.0,
3312,538211,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,21106454.0,
3313,538212,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,21106454.0,
3314,538213,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,21106454.0,
3315,538369,2,4,,123097261,31703,Active,,,0.0776,IC50,Cytotoxicity against human LNCAP cells,Confirmatory,20936874.0,
3316,538858,5,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3317,538859,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3318,538860,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3319,538861,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3320,538862,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3321,538863,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3322,538864,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3323,538865,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3324,538866,4,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay,Other,21041092.0,
3325,539706,2,4,,123097261,31703,Active,,,0.00022999999999999998,IC50,Antiproliferative activity against human KB cells after 72 hrs by methylene blue staining,Confirmatory,21067930.0,
3326,539707,2,4,,123097261,31703,Active,,,0.00037999999999999997,IC50,Antiproliferative activity against human H460 cells after 72 hrs by methylene blue staining,Confirmatory,21067930.0,
3327,539708,2,5,,123097261,31703,Active,,,0.00018999999999999998,IC50,Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue staining,Confirmatory,21067930.0,
3328,539835,4,2,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,21071221.0,
3329,539836,4,3,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay,Confirmatory,21071221.0,
3330,539837,4,2,,123097261,31703,Active,,,0.61,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21071221.0,
3331,539838,4,2,,123097261,31703,Active,,,0.52,IC50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21071221.0,
3332,539839,4,4,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21071221.0,
3333,540209,4,3,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
3334,540210,4,3,,123097261,31703,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
3335,540211,2,5,,123097261,31703,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
3336,540212,4,3,,123097261,31703,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
3337,540213,4,3,,123097261,31703,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
3338,540214,4,3,,123097261,31703,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
3339,540215,3,2,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
3340,540216,4,3,,123097261,31703,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
3341,540217,4,3,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
3342,540218,4,3,,123097261,31703,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
3343,540219,4,3,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
3344,540220,4,3,,123097261,31703,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
3345,540221,4,3,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
3346,541405,4,2,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay,Confirmatory,21058726.0,
3347,541406,4,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human M14 cells after 24 to 48 hrs by MTT assay,Confirmatory,21058726.0,
3348,541407,4,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human U937 cells after 24 to 48 hrs by MTT assay,Confirmatory,21058726.0,
3349,545989,4,2,,123097261,31703,Active,,,3.6,IC50,Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry,Confirmatory,20961671.0,
3350,548078,4,2,,123097261,31703,Active,,,0.065,GI50,Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
3351,548079,4,2,,123097261,31703,Active,,,0.065,GI50,Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
3352,548080,4,2,,123097261,31703,Active,,,0.065,GI50,Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
3353,548451,4,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20971532.0,
3354,548452,4,2,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,20971532.0,
3355,548453,4,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,20971532.0,
3356,548454,4,2,,123097261,31703,Active,,,0.96,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,20971532.0,
3357,548455,4,2,,123097261,31703,Active,,,1.66,IC50,Cytotoxicity against human PBMC after 72 hrs by Alamar Blue assay,Confirmatory,20971532.0,
3358,548935,4,3,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,21035234.0,
3359,548936,4,4,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human KB3-1 cells after 72 hrs by MTT assay,Confirmatory,21035234.0,
3360,548937,4,4,,123097261,31703,Active,,,3.3,IC50,Cytotoxicity against human multi drug resistant subclone KB 8.5 cells after 72 hrs by MTT assay,Confirmatory,21035234.0,
3361,548938,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 25 ug/ml after 24 hrs by MTT colorimetric assay,Other,21035921.0,
3362,548939,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 50 ug/ml after 24 hrs by MTT colorimetric assay,Other,21035921.0,
3363,548940,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells at 25 ug/ml after 24 hrs by MTT colorimetric assay,Other,21035921.0,
3364,548941,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells at 50 ug/ml after 24 hrs by MTT colorimetric assay,Other,21035921.0,
3365,548942,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human T47D cells at 25 ug/ml after 24 hrs by MTT colorimetric assay,Other,21035921.0,
3366,549192,6,1,,123097261,31703,Active,,,0.0433,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20934235.0,
3367,549193,6,1,,123097261,31703,Active,,,0.1302,GI50,Growth inhibition of human A375-C5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20934235.0,
3368,549194,6,1,,123097261,31703,Active,,,0.0356,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20934235.0,
3369,549984,4,2,,123097261,31703,Active,,,0.092,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay,Confirmatory,20949916.0,
3370,549985,4,3,,123097261,31703,Active,,,0.067,IC50,Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay,Confirmatory,20949916.0,
3371,549986,4,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay,Confirmatory,20949916.0,
3372,550988,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
3373,550989,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay,Other,21094049.0,
3374,550990,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
3375,550991,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay,Other,21094049.0,
3376,550992,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
3377,550993,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 16 uM after 24 hrs by MTS assay,Other,21094049.0,
3378,550994,4,2,,123097261,31703,Active,,,16.8,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
3379,550995,4,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
3380,550996,4,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
3381,551000,4,3,,123097261,31703,Unspecified,,,25.0,IC50,Cytotoxicity against human CRL7761 cells after 3 days by MTS assay,Confirmatory,21094049.0,
3382,551001,4,2,,123097261,31703,Active,,,10.4,IC50,Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay,Confirmatory,21094049.0,
3383,551002,4,3,,123097261,31703,Active,,,3.5,IC50,Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay,Confirmatory,21094049.0,
3384,551010,3,9,,123097261,31703,Active,12644118.0,7150.0,,,Inhibition of human recombinant DNA topoisomerase 1-mediated DNA cleavage assessed as decrease in relaxation of supercoiled plasmid substrate DNA at 5 uM after 30 mins by agarose gel electrophoresis,Other,21094049.0,
3385,551012,3,9,,123097261,31703,Inactive,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2alpha-mediated DNA cleavage assessed as decrease in relaxation of supercoiled plasmid substrate DNA at 20 uM after 30 mins by agarose gel electrophoresis,Other,21094049.0,
3386,551013,2,10,,123097261,31703,Inactive,13959709.0,7153.0,,,Induction of poisoning activity in human recombinant DNA topoisomerase 2alpha assessed as enhancement of in relaxation of supercoiled plasmid substrate DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,21094049.0,
3387,551259,6,1,,123097261,31703,Active,,,4.78,IC50,Cytotoxicity against human SK-MEL-2 cells,Confirmatory,21095131.0,
3388,551260,4,2,,123097261,31703,Active,,,0.97,IC50,Cytotoxicity against human A549 cells,Confirmatory,21095131.0,
3389,551261,4,2,,123097261,31703,Active,,,1.17,IC50,Cytotoxicity against human SKOV3 cells,Confirmatory,21095131.0,
3390,551262,4,2,,123097261,31703,Active,,,1.67,IC50,Cytotoxicity against human HCT15 cells,Confirmatory,21095131.0,
3391,551263,2,7,,123097261,31703,Inconclusive,,,,,Inhibition of topoisomerase 1,Other,21095131.0,
3392,552395,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as viable cells at 200 nM after24 hrs by annexin-V-PE/7-AAD staining (Rvb = 97.2%),Other,21146994.0,
3393,552396,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as early apoptosis cells at 200 nM after24 hrs by annexin-V-PE/7-AAD staining (Rvb = 2.6%),Other,21146994.0,
3394,552397,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as late apoptosis cells at 200 nM after24 hrs by annexin-V-PE/7-AAD staining (Rvb = 0.2%),Other,21146994.0,
3395,552566,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as viable cells at 200 nM after 48 hrs by annexin-V-PE/7-AAD staining (Rvb = 97.4%),Other,21146994.0,
3396,552567,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as early apoptosis cells at 200 nM after 48 hrs by annexin-V-PE/7-AAD staining (Rvb = 2.5%),Other,21146994.0,
3397,552568,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as late apoptosis cells at 200 nM after 48 hrs by annexin-V-PE/7-AAD staining (Rvb = 0.1%),Other,21146994.0,
3398,552710,4,2,,123097261,31703,Active,,,1.69,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,21115246.0,
3399,552711,4,2,,123097261,31703,Active,,,1.33,IC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,21115246.0,
3400,552712,4,2,,123097261,31703,Active,,,1.75,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,21115246.0,
3401,552713,4,2,,123097261,31703,Active,,,1.25,IC50,Cytotoxicity against human HCT15 cells by MTT assay,Confirmatory,21115246.0,
3402,552973,2,5,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3403,552974,2,5,,123097261,31703,Active,,,0.99,IC50,Cytotoxicity against human HL60R cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3404,552975,2,5,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human KB cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3405,553041,2,5,,123097261,31703,Active,,,4.7e-05,IC50,Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3406,553042,2,5,,123097261,31703,Active,,,0.0035,IC50,Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3407,553043,2,5,,123097261,31703,Active,,,0.040999999999999995,IC50,Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3408,553044,2,5,,123097261,31703,Active,,,0.18600000000000003,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3409,553099,2,5,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay,Confirmatory,21142180.0,
3410,565852,6,1,,123097261,31703,Active,,,0.0433,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,21138784.0,
3411,565853,6,1,,123097261,31703,Active,,,0.1302,GI50,Growth inhibition of human A375-C5 cells after 48 hrs by SRB assay,Confirmatory,21138784.0,
3412,565854,6,1,,123097261,31703,Active,,,0.0356,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,21138784.0,
3413,565855,1,4,,123097261,31703,Unspecified,,,,,Solubility of the compound in DMSO at 150 uM,Other,21138784.0,
3414,565879,4,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay,Confirmatory,21144624.0,
3415,565880,4,3,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3416,565881,4,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3417,565882,4,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3418,565883,4,3,,123097261,31703,Active,,,9.7,IC50,Cytotoxicity against human K562/4 cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3419,565884,2,4,,123097261,31703,Unspecified,,,,,"Resistance index, IC50 for human K562/4 cells to human K562 cells",Other,21144624.0,
3420,565885,4,2,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3421,565886,4,2,,123097261,31703,Active,,,0.52,IC50,Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay,Confirmatory,21144624.0,
3422,565887,2,3,,123097261,31703,Unspecified,,,,,"Resistance index, IC50 for human p53 knockout HCT116 cells to IC50 for human HCT116 cells",Other,21144624.0,
3423,566728,4,2,,123097261,31703,Active,,,0.54,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21087017.0,
3424,566730,4,2,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,21087017.0,
3425,566731,4,3,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,21087017.0,
3426,566732,4,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,21087017.0,
3427,566733,4,3,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human KB/VCR cells after 48 hrs by MTT assay,Confirmatory,21087017.0,
3428,566775,4,3,,123097261,31703,Active,,,0.098,IC50,Cytotoxicity against human NCI-H187 cells by resazurin microplate assay,Confirmatory,21090800.0,
3429,566777,4,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human KB cells by resazurin microplate assay,Confirmatory,21090800.0,
3430,566778,4,2,,123097261,31703,Active,,,2.3,IC50,Cytotoxicity against human MCF7 cells by resazurin microplate assay,Confirmatory,21090800.0,
3431,566894,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell surviving fraction at 50 uM after 48 hrs by SRB assay,Other,21093116.0,
3432,566895,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell surviving fraction at 100 uM after 48 hrs by SRB assay,Other,21093116.0,
3433,566896,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell surviving fraction at 25 uM after 48 hrs by SRB assay,Other,21093116.0,
3434,566897,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell surviving fraction at 10 uM after 48 hrs by SRB assay,Other,21093116.0,
3435,566898,4,2,,123097261,31703,Active,,,32.02,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,21093116.0,
3436,567091,2,6,,123097261,31703,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
3437,567097,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as non-viable cells at 100 ug/ml after 2 hrs by trypan blue exclusion test,Other,21112675.0,
3438,567098,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as non-viable cells at 50 ug/ml after 2 hrs by trypan blue exclusion test,Other,21112675.0,
3439,567099,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as non-viable cells at 25 ug/ml after 2 hrs by trypan blue exclusion test,Other,21112675.0,
3440,567100,2,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as non-viable cells at 10 ug/ml after 2 hrs by trypan blue exclusion test,Other,21112675.0,
3441,567101,5,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test,Other,21112675.0,
3442,567387,7,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3443,567388,7,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3444,567389,4,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3445,567390,4,2,,123097261,31703,Inconclusive,,,,GI50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3446,567391,4,2,,123097261,31703,Active,,,0.25,GI50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3447,567392,4,3,,123097261,31703,Inconclusive,,,,GI50,Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
3448,567493,4,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay,Confirmatory,21115213.0,
3449,567494,4,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,21115213.0,
3450,567495,4,2,,123097261,31703,Active,,,0.88,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,21115213.0,
3451,567496,4,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,21115213.0,
3452,567497,4,2,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,21115213.0,
3453,568208,4,2,,123097261,31703,Active,,,5.12,IC50,Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs,Confirmatory,21256013.0,
3454,568514,4,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,21215623.0,
3455,568515,4,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay,Confirmatory,21215623.0,
3456,568516,4,3,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay,Confirmatory,21215623.0,
3457,568517,2,4,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human IMR90 cells to IC50 for human MCF7 cells,Other,21215623.0,
3458,568518,2,3,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human IMR90 cells to IC50 for human HCT116 cells,Other,21215623.0,
3459,568562,4,3,,123097261,31703,Active,,,0.67,IC50,Cytotoxicity against human HuCCA1 cells by MTT assay,Confirmatory,21174408.0,
3460,568563,4,2,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,21174408.0,
3461,568564,4,2,,123097261,31703,Active,,,0.34,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21174408.0,
3462,568565,4,3,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,21174408.0,
3463,568720,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Other,21158422.0,
3464,572147,5,2,,123097261,31703,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
3465,572150,5,2,,123097261,31703,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
3466,572151,5,2,,123097261,31703,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
3467,575164,2,4,,123097261,31703,Unspecified,,,,,Inhibition of acrAB AcrAB-TolC in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as [3H]TMG accumulation at 100 uM by scintillation counter method,Other,20606071.0,
3468,575167,2,4,,123097261,31703,Unspecified,,,,,Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay,Other,20606071.0,
3469,575168,2,4,,123097261,31703,Unspecified,,,,,Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in marR mutant containing Escherichia coli K-12 3-AG102 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay,Other,20606071.0,
3470,575169,2,4,,123097261,31703,Unspecified,,,,,Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay,Other,20606071.0,
3471,575170,2,4,,123097261,31703,Unspecified,,,,,Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay,Other,20606071.0,
3472,576508,4,3,,123097261,31703,Active,,,13.0,IC50,Cytotoxicity activity against human HAEC cells after 24 hrs,Confirmatory,20547797.0,
3473,576509,4,2,,123097261,31703,Unspecified,,,69.0,IC50,Cytotoxicity activity against human HepG2 cells after 24 hrs,Confirmatory,20547797.0,
3474,578665,4,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human DU145 cells after 2 days by MTT assay,Confirmatory,21353544.0,
3475,578666,4,2,,123097261,31703,Active,,,0.82,IC50,Cytotoxicity against human HT-29 cells after 2 days by MTT assay,Confirmatory,21353544.0,
3476,578667,4,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human HCT116 cells after 2 days by MTT assay,Confirmatory,21353544.0,
3477,578668,4,3,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human A375P cells after 2 days by MTT assay,Confirmatory,21353544.0,
3478,578669,4,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells after 2 days by MTT assay,Confirmatory,21353544.0,
3479,578670,3,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human DU145 cells at 10 uM after 2 days by MTT assay,Other,21353544.0,
3480,578671,3,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HT-29 cells at 10 uM after 2 days by MTT assay,Other,21353544.0,
3481,578672,3,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HCT116 cells at 10 uM after 2 days by MTT assay,Other,21353544.0,
3482,578673,3,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human A375P cells at 10 uM after 2 days by MTT assay,Other,21353544.0,
3483,578674,3,4,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human MCF7 cells at 10 uM after 2 days by MTT assay,Other,21353544.0,
3484,578763,7,1,,123097261,31703,Active,,,0.044000000000000004,IC50,Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry,Confirmatory,21354800.0,
3485,578764,4,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MCF7 cells assessed as intracellular ATP level after 72 hrs by luminometry,Confirmatory,21354800.0,
3486,579803,2,5,,123097261,31703,Active,,,0.0264,IC50,Antiproliferative activity against human MES-SA cells assessed as growth inhibition,Confirmatory,21324686.0,
3487,579804,2,4,,123097261,31703,Active,,,2.70233,IC50,Antiproliferative activity against P-gp overexpressing human MES-SA/Dx5-Rx1 cells assessed as growth inhibition,Confirmatory,21324686.0,
3488,579805,2,4,,123097261,31703,Unspecified,,,,,"Fold resistance, ratio of IC50 for antiproliferative activity for human MES-SA cells to IC50 for antiproliferative activity for P-gp overexpressing human MES-SA/Dx5-Rx1cells",Other,21324686.0,
3489,579806,2,4,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human DLD1 cells assessed as growth inhibition,Confirmatory,21324686.0,
3490,579807,2,4,,123097261,31703,Active,,,0.15395,IC50,Antiproliferative activity against human HCT15 cells assessed as growth inhibition,Confirmatory,21324686.0,
3491,579808,2,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human IMR90 cells up to 1 uM,Other,21324686.0,
3492,579980,2,4,,123097261,31703,Active,,,0.0264,IC50,Cytotoxicity against human MES-SA cells,Confirmatory,21324692.0,
3493,579981,2,4,,123097261,31703,Active,,,2.70233,IC50,Cytotoxicity against human MES-SA/Dx5-Rx1 cells,Confirmatory,21324692.0,
3494,579982,2,3,,123097261,31703,Unspecified,,,,,Fold resistant ratio of IC50 for human MES-SA cells to IC50 for MES-SA/Dx5-Rx1 cells,Other,21324692.0,
3495,579983,2,4,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human DLD1 cells,Confirmatory,21324692.0,
3496,579984,2,4,,123097261,31703,Active,,,0.15395,IC50,Cytotoxicity against human HCT15 cells,Confirmatory,21324692.0,
3497,588208,2,3,,123097261,31703,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
3498,588209,2,3,,123097261,31703,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
3499,588210,2,4,,123097261,31703,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
3500,588211,2,3,,123097261,31703,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
3501,588212,2,3,,123097261,31703,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
3502,588213,2,3,,123097261,31703,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
3503,588214,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
3504,588215,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
3505,588216,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
3506,588217,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
3507,588218,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
3508,588219,2,3,,123097261,31703,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
3509,588220,2,3,,123097261,31703,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
3510,588579,1,1,,124886887,31703,Active,7705344.0,51426.0,26.6795,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
3511,588974,1,11,,123097261,31703,Unspecified,238054374.0,5243.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MDR1",Other,20190787.0,
3512,589496,1,4,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in human K562 cells assessed as [14C]thymidine incorporation at 0.47 uM after 120 mins,Other,21376582.0,
3513,589497,1,4,,123097261,31703,Unspecified,,,,,Inhibition of protein synthesis in human K562 cells assessed as [14C]L-leucine incorporation at 0.47 uM after 120 mins,Other,21376582.0,
3514,589498,1,4,,123097261,31703,Unspecified,,,,,Inhibition of transcription in human K562 cells at 0.47 uM after 120 mins,Other,21376582.0,
3515,590185,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells for 72 hrs by MTT assay,Other,21334795.0,
3516,590186,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells for 72 hrs by MTT assay,Other,21334795.0,
3517,590187,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay,Other,21334795.0,
3518,590188,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF295 cells for 72 hrs by MTT assay,Other,21334795.0,
3519,590353,5,1,,123097261,31703,Active,,,0.0303,IC50,Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
3520,590356,5,1,,123097261,31703,Active,,,0.019,IC50,Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
3521,590358,5,1,,123097261,31703,Active,,,0.0179,IC50,Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
3522,590359,5,1,,123097261,31703,Active,,,0.0375,IC50,Antiproliferative activity against human Jurkat cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
3523,590362,5,1,,123097261,31703,Active,,,0.4198,IC50,Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
3524,590856,3,2,,123097261,31703,Active,,,25.3,IC50,Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3525,590857,3,2,,123097261,31703,Unspecified,,,66.2,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3526,590858,3,2,,123097261,31703,Active,,,6.8,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3527,590859,3,2,,123097261,31703,Active,,,12.3,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3528,590860,3,2,,123097261,31703,Unspecified,,,124.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3529,590861,3,2,,123097261,31703,Active,,,6.3,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay,Confirmatory,21429743.0,
3530,591647,2,8,,123097261,31703,Active,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2-mediated decatenation of catenated kinetoplast DNA at 5 uM after 1 hr by agarose gel electrophoresis,Other,21388138.0,
3531,592681,1,4,,123097261,31703,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
3532,592896,3,3,,123097261,31703,Active,,,0.0428,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21435889.0,
3533,592897,3,3,,123097261,31703,Active,,,0.094,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21435889.0,
3534,592898,3,3,,123097261,31703,Active,,,0.094,GI50,Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21435889.0,
3535,593280,1,3,,123097261,31703,Unspecified,,,,,"Octanol-water distribution coefficient, log P of the compound",Other,21443194.0,
3536,593288,1,5,,123097261,31703,Active,,,,,Cytotoxicity against human MDA-MB-435 cells at 1 uM after 24 hrs using crystal violet staining by colony formation assay,Other,21443194.0,
3537,594794,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,21507635.0,
3538,594796,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Other,21507635.0,
3539,594797,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay,Other,21507635.0,
3540,595061,3,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
3541,595062,3,3,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
3542,595063,3,3,,123097261,31703,Active,,,2.398,IC50,Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
3543,595064,1,4,,123097261,31703,Unspecified,,,,,"Resistant factor, ratio of IC50 for doxorubicin-resistant human MES-SA/Dx5 cells to IC50 for doxorubicin-sensitive human MES-SA cells",Other,21444205.0,
3544,595435,3,2,,123097261,31703,Active,,,9.7,LC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,21341710.0,
3545,595626,3,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,21381705.0,
3546,595627,3,2,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,21381705.0,
3547,595628,3,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,21381705.0,
3548,595629,3,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,21381705.0,
3549,596547,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell growth inhibition at 1 uM after 48 hrs by sulforhodamine B assay,Other,21482109.0,
3550,596550,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as cell growth inhibition at 1 uM after 48 hrs by sulforhodamine B assay,Other,21482109.0,
3551,597194,3,2,,123097261,31703,Active,,,42.8,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21504224.0,
3552,597195,3,2,,123097261,31703,Unspecified,,,94.0,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21504224.0,
3553,597196,3,2,,123097261,31703,Unspecified,,,94.0,GI50,Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21504224.0,
3554,597197,3,2,,123097261,31703,Unspecified,,,94.0,GI50,Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21504224.0,
3555,598247,3,2,,123097261,31703,Unspecified,,,53.3,IC50,Antitumor activity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,20884091.0,
3556,598248,3,3,,123097261,31703,Active,,,4.8,IC50,Antitumor activity against human BGC823 cells after 48 hrs by SRB assay,Confirmatory,20884091.0,
3557,598249,3,3,,123097261,31703,Active,,,5.0,IC50,Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay,Confirmatory,20884091.0,
3558,598250,3,2,,123097261,31703,Active,,,5.8,IC50,Antitumor activity against human KB cells after 48 hrs by SRB assay,Confirmatory,20884091.0,
3559,599186,3,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,21425785.0,
3560,599187,3,3,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human Hep3B cells by MTT assay,Confirmatory,21425785.0,
3561,599188,3,2,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,21425785.0,
3562,599189,3,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,21425785.0,
3563,599190,3,2,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21425785.0,
3564,599245,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by Sulforhodamine B assay,Other,21429629.0,
3565,599527,3,3,,123097261,31703,Active,,,1.0,IC50,Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3566,599528,3,2,,123097261,31703,Active,,,1.9,IC50,Antiproliferative activity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3567,599529,3,2,,123097261,31703,Active,,,1.0,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3568,599530,3,2,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3569,599531,3,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3570,599532,3,2,,123097261,31703,Active,,,1.3,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3571,599533,3,2,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against human KB cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3572,599534,3,3,,123097261,31703,Active,,,2.4,IC50,Antiproliferative activity against human L78 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3573,599535,3,2,,123097261,31703,Active,,,0.7,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3574,599536,3,2,,123097261,31703,Active,,,0.002,IC50,Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3575,599537,3,3,,123097261,31703,Active,,,5.4,IC50,Antiproliferative activity against human OS-RC2 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3576,599538,3,3,,123097261,31703,Active,,,0.9,IC50,Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3577,599539,3,2,,123097261,31703,Active,,,0.6,IC50,Antiproliferative activity against human U251 cells after 72 hrs by MTT assay,Confirmatory,19632833.0,
3578,599836,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells assessed as cell viability at 0.1 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3579,599837,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell viability at 0.1 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3580,599838,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells assessed as cell viability at 1 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3581,599839,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell viability at1 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3582,599840,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3583,599841,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to untreated control,Other,21440337.0,
3584,599842,3,2,,123097261,31703,Active,,,19.9,IC50,Cytotoxicity against human SK-N-SH cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,21440337.0,
3585,600929,3,2,,123097261,31703,Active,,,0.13,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,21496972.0,
3586,600930,3,2,,123097261,31703,Active,,,0.19,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21496972.0,
3587,600931,3,2,,123097261,31703,Active,,,0.19,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21496972.0,
3588,600932,3,2,,123097261,31703,Active,,,0.14,IC50,Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,21496972.0,
3589,600933,3,2,,123097261,31703,Active,,,0.13,IC50,Antiproliferative activity against human A375 cells after 72 hrs by MTT assay,Confirmatory,21496972.0,
3590,602332,1,1,,124886887,31703,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3591,603034,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 100 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
3592,603035,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 50 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
3593,603036,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 25 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
3594,603953,1,3,,123097261,31703,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
3595,604070,3,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,21555166.0,
3596,605508,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3597,605509,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human A2780 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3598,605510,3,2,,123097261,31703,Active,,,0.11,GI50,Cytotoxicity against human KB cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3599,605511,3,2,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3600,605512,3,2,,123097261,31703,Active,,,2.1,GI50,Cytotoxicity against human SiHa cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3601,605513,3,3,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human Gurav cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3602,605514,3,3,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human DWD cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3603,605515,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3604,605516,3,2,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3605,605517,3,2,,123097261,31703,Active,,,0.13,GI50,Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3606,605518,3,2,,123097261,31703,Active,,,0.15,GI50,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Confirmatory,20673627.0,
3607,605844,3,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis,Confirmatory,21563750.0,
3608,605956,3,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of pig tubulin polymerization determined after 45 mins at 37 degC by turbidimetric analysis,Confirmatory,21563750.0,
3609,606505,3,2,,123097261,31703,Active,,,1.64,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,21534590.0,
3610,606896,3,3,,123097261,31703,Active,,,1.13,IC50,Antitumor activity against human MDA231 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3611,606897,3,2,,123097261,31703,Active,,,0.12,IC50,Antitumor activity against human SW620 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3612,606898,3,2,,123097261,31703,Active,,,0.93,IC50,Antitumor activity against human U937 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3613,606899,3,2,,123097261,31703,Active,,,1.3,IC50,Antitumor activity against human MDA-MB-435 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3614,606900,3,2,,123097261,31703,Active,,,0.6,IC50,Antitumor activity against human SK-MEL-28 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3615,606901,3,3,,123097261,31703,Active,,,1.3,IC50,Antitumor activity against human IGROV cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3616,606902,3,2,,123097261,31703,Active,,,4.4,IC50,Antitumor activity against human SF295 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3617,606903,3,2,,123097261,31703,Active,,,0.8,IC50,Antitumor activity against human SNB19 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3618,606904,3,2,,123097261,31703,Active,,,1.5,IC50,Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3619,606905,3,2,,123097261,31703,Active,,,1.1,IC50,Antitumor activity against human HT-29 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3620,606906,3,2,,123097261,31703,Active,,,6.7,IC50,Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3621,606907,3,2,,123097261,31703,Active,,,0.6,IC50,Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay,Confirmatory,21553829.0,
3622,606908,1,4,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio IC50 for undifferentiated human Caco2 cells to IC50 for differentiated human Caco2 cells",Other,21553829.0,
3623,606959,1,3,,123097261,31703,Active,,,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled pBR322 DNA relaxation at 5 uM after 6 mins by agarose gel electrophoresis,Other,21553829.0,
3624,606960,1,3,,123097261,31703,Active,,,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled pBR322 DNA relaxation at 10 uM after 6 mins by agarose gel electrophoresis,Other,21553829.0,
3625,606962,1,3,,123097261,31703,Active,,,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled pBR322 DNA relaxation at 0.04 to 0.92 uM after 6 mins by agarose gel electrophoresis,Other,21553829.0,
3626,607035,1,4,,123097261,31703,Unspecified,,,,,Cardiotoxicity in rat H9c2 cells at 1 uM measured up to 120 hrs by MTT assay,Other,21553829.0,
3627,607281,1,4,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3628,607288,1,4,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3629,607289,1,4,,123097261,31703,Active,,,13.15,IC50,Antiproliferative activity against human doxorubicin-resistant LoVo cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3630,607290,1,4,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3631,607291,1,3,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human vinblastine-resistant CEM/VBL100 cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3632,607292,1,3,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human taxol-resistant A549-T12 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,21663319.0,
3633,607443,1,4,,123097261,31703,Unspecified,,,,,"Fold resistance, ratio of IC50 for human doxorubicin-resistant LoVo cells overexpressing P-gp to IC50 for human LoVo cells",Other,21663319.0,
3634,607892,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by sulforhodamine B assay,Other,21684168.0,
3635,607893,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT15 cells by sulforhodamine B assay,Other,21684168.0,
3636,607894,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by sulforhodamine B assay,Other,21684168.0,
3637,607895,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay,Other,21684168.0,
3638,608161,1,4,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse xenografted with mouse S180 cells assessed as effect on liver weight at 2 umol/kg,Other,21620529.0,
3639,608162,3,2,,123097261,31703,Active,,,29.2,IC50,Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay,Confirmatory,21620529.0,
3640,608163,3,2,,123097261,31703,Active,,,17.23,IC50,Antiproliferative activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,21620529.0,
3641,608164,3,2,,123097261,31703,Active,,,21.5,IC50,Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,21620529.0,
3642,608165,3,2,,123097261,31703,Active,,,36.51,IC50,Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay,Confirmatory,21620529.0,
3643,608166,3,2,,123097261,31703,Active,,,17.54,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,21620529.0,
3644,608168,1,4,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as tumor growth inhibition at 8.9 umol/kg, ip administered 1 day after tumor inoculation qd for 7 days",Other,21620529.0,
3645,608260,1,4,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse xenografted with mouse S180 cells assessed as effect on brain weight at 2 umol/kg,Other,21620529.0,
3646,608261,1,4,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse xenografted with mouse S180 cells assessed as effect on kidney weight at 2 umol/kg,Other,21620529.0,
3647,608262,1,4,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse xenografted with mouse S180 cells assessed as increase in body weight at 2 umol/kg,Other,21620529.0,
3648,608263,1,5,,123097261,31703,Unspecified,,,,,Toxicity in ICR mouse xenografted with mouse S180 cells assessed as increase in spleen index at 2 umol/kg,Other,21620529.0,
3649,608339,3,2,,123097261,31703,Active,,,0.47700000000000004,IC50,Anticancer activity against human A549 cells by MTT assay,Confirmatory,21570750.0,
3650,608340,3,2,,123097261,31703,Active,,,0.4,IC50,Anticancer activity against human COLO205 cells by MTT assay,Confirmatory,21570750.0,
3651,608341,3,3,,123097261,31703,Active,,,4.38,IC50,Anticancer activity against human KATO III cells by MTT assay,Confirmatory,21570750.0,
3652,608342,3,2,,123097261,31703,Active,,,0.198,IC50,Anticancer activity against human K562 cells by MTT assay,Confirmatory,21570750.0,
3653,608343,3,2,,123097261,31703,Active,,,2.947,IC50,Anticancer activity against human SKOV3 cells by MTT assay,Confirmatory,21570750.0,
3654,608344,3,3,,123097261,31703,Active,,,0.33799999999999997,IC50,Anticancer activity against mouse P388D1 cells by MTT assay,Confirmatory,21570750.0,
3655,608346,1,4,,123097261,31703,Unspecified,,,,,"Toxicity in human NCI-H23 cells xenografted BALB/c nu/nu mouse assessed as change in body weight at 1 mg/kg, ip qd for 11 days followed by 2 mg/kg, ip qd on day 12 to day 14 and 3 mg/kg, ip qd on day 15 to day 18 measured on day 20 (Rvb = 1.2 g)",Other,21570750.0,
3656,608348,1,4,,123097261,31703,Unspecified,,,,,"Toxicity in human SW620 cells xenografted BALB/c nu/nu mouse assessed as change in body weight at 1 mg/kg, ip qd for 11 days followed by 2 mg/kg, ip qd on day 12 to day 14 and 3 mg/kg, ip qd on day 15 to day 18 measured on day 20 (Rvb = 1.1 g)",Other,21570750.0,
3657,608350,2,1,,123097261,31703,Unspecified,,,,,"Anticancer activity against human NCI-H23 cells xenografted in BALB/c nu/nu mouse assessed as tumor growth inhibition at 1 mg/kg, ip qd for 11 days followed by 2 mg/kg, ip qd on day 12 to day 14 and 3 mg/kg, ip qd on day 15 to day 18 measured on day 19",Other,21570750.0,
3658,608352,2,1,,123097261,31703,Unspecified,,,,,"Anticancer activity against human SW620 cells xenografted in BALB/c nu/nu mouse assessed as tumor growth inhibition at 1 mg/kg, ip qd for 11 days followed by 2 mg/kg, ip qd on day 12 to day 14 and 3 mg/kg, ip qd on day 15 to day 18 measured on day 19",Other,21570750.0,
3659,608687,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Other,21708464.0,
3660,608688,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Other,21708464.0,
3661,608689,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Other,21708464.0,
3662,608690,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Other,21708464.0,
3663,608691,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,21708464.0,
3664,608833,3,2,,123097261,31703,Active,,,1.03,IC50,Anticancer activity against human PC3 cells after 24 hrs by MTT assay,Confirmatory,21600678.0,
3665,608834,3,2,,123097261,31703,Inconclusive,,,,IC50,Anticancer activity against human LNCAP cells after 24 hrs by MTT assay in presence of testosterone,Confirmatory,21600678.0,
3666,608835,1,5,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF10A cells at 1 uM,Other,21600678.0,
3667,608836,1,4,,123097261,31703,Active,,,,,Cytotoxicity against human MCF7 cells,Other,21600678.0,
3668,608847,3,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human HL60 cells after 2 days,Confirmatory,21601964.0,
3669,608848,3,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,21601964.0,
3670,608849,3,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,21601964.0,
3671,608850,3,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HeLa cells after 2 days,Confirmatory,21601964.0,
3672,608852,1,4,,123097261,31703,Active,,,,,Cytotoxicity against human MDA-MB-231 cells after 2 days,Other,21601964.0,
3673,609459,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay,Other,21723735.0,
3674,609460,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Other,21723735.0,
3675,610074,1,9,,123097261,31703,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 at 100 uM after 30 mins by electrophoresis analysis,Other,21741833.0,
3676,610076,3,2,,123097261,31703,Active,,,2.01,IC50,Cytotoxicity against human KB cells after 3 days by MTT assay,Confirmatory,21741833.0,
3677,610077,3,2,,123097261,31703,Active,,,42.52,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,21741833.0,
3678,610078,3,3,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human NCI-H187 cells after 3 days by MTT assay,Confirmatory,21741833.0,
3679,610079,3,2,,123097261,31703,Active,,,0.23,IC50,Cytotoxicity against human SW620 cells after 3 days by MTT assay,Confirmatory,21741833.0,
3680,610080,3,3,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human KATO cells after 3 days by MTT assay,Confirmatory,21741833.0,
3681,610081,3,3,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human ChaGo cells after 3 days by MTT assay,Confirmatory,21741833.0,
3682,610082,3,3,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human BT474 cells after 3 days by MTT assay,Confirmatory,21741833.0,
3683,610083,3,2,,123097261,31703,Active,,,0.26,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,21741833.0,
3684,610588,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3685,610589,3,2,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3686,610590,3,2,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3687,610591,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human HOP62 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3688,610592,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human SiHa cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3689,610593,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human COLO205 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3690,610594,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3691,610595,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human Gurav cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3692,610596,3,2,,123097261,31703,Active,,,0.1,GI50,Growth inhibition of human DWD cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3693,610647,3,2,,123097261,31703,Active,,,1.81,GI50,Growth inhibition of human PC3 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3694,610648,3,2,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A2780 cells after 48 hrs by SRB assay,Confirmatory,20031423.0,
3695,611164,3,2,,123097261,31703,Active,,,0.31,IC50,Cytostatic activity against human LoVo cells after 72 hrs by SRB assay,Confirmatory,21704523.0,
3696,611165,3,2,,123097261,31703,Active,,,12.2,IC50,Cytostatic activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay,Confirmatory,21704523.0,
3697,611176,3,2,,123097261,31703,Active,,,0.11,GI50,Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3698,611177,3,2,,123097261,31703,Active,,,0.13,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3699,611178,3,3,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3700,611179,3,3,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3701,611180,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3702,611181,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3703,611182,3,2,,123097261,31703,Active,,,0.15,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3704,611183,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
3705,611267,3,2,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer,Confirmatory,21705223.0,
3706,611278,3,2,,123097261,31703,Inconclusive,,,,IC50,Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry analysis,Confirmatory,21705223.0,
3707,611368,3,2,,123097261,31703,Active,,,0.016,GI50,Cytostatic activity against human A549 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3708,611369,3,2,,123097261,31703,Active,,,0.005,GI50,Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3709,611370,3,2,,123097261,31703,Inconclusive,,,,GI50,Cytostatic activity against human DU145 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3710,611371,3,2,,123097261,31703,Active,,,0.021,GI50,Cytostatic activity against human PC3 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3711,611372,3,2,,123097261,31703,Active,,,0.011000000000000001,GI50,Cytostatic activity against human HCT116 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3712,611373,3,2,,123097261,31703,Inconclusive,,,,GI50,Cytostatic activity against human HCT15 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3713,611374,3,3,,123097261,31703,Active,,,0.006,GI50,Cytostatic activity against human Hs578 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3714,611375,3,2,,123097261,31703,Active,,,0.01,GI50,Cytostatic activity against human BT549 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3715,611376,3,2,,123097261,31703,Inconclusive,,,,GI50,Cytostatic activity against human MT4 cells after 5 days by SRB assay,Confirmatory,21711054.0,
3716,611677,3,2,,123097261,31703,Active,,,2.8,IC50,Growth inhibition of human A549 cells by MTT assay,Confirmatory,21721519.0,
3717,611678,3,3,,123097261,31703,Active,,,2.8,IC50,Growth inhibition of human MG63 cells by MTT assay,Confirmatory,21721519.0,
3718,613180,3,2,,123097261,31703,Active,,,3.7,IC50,Cytotoxicity against human HeLa cells after 4 days by MTT assay,Confirmatory,21704436.0,
3719,613181,3,3,,123097261,31703,Active,,,2.5,IC50,Cytotoxicity against human HCT29 cells after 4 days by MTT assay,Confirmatory,21704436.0,
3720,613182,3,2,,123097261,31703,Active,,,1.9,IC50,Cytotoxicity against human DU145 cells after 4 days by MTT assay,Confirmatory,21704436.0,
3721,613183,3,2,,123097261,31703,Active,,,1.4,IC50,Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay,Confirmatory,21704436.0,
3722,613184,3,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human HL60 cells after 4 days by MTT assay,Confirmatory,21704436.0,
3723,613249,3,2,,123097261,31703,Active,,,0.23,IC50,Anticancer activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,21641694.0,
3724,613250,3,2,,123097261,31703,Active,,,0.06,IC50,Anticancer activity against human SW480 cells after 48 hrs by MTT assay,Confirmatory,21641694.0,
3725,613251,3,2,,123097261,31703,Active,,,0.36,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,21641694.0,
3726,613252,3,2,,123097261,31703,Active,,,0.5,IC50,Anticancer activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,21641694.0,
3727,613253,3,2,,123097261,31703,Active,,,0.45,IC50,Anticancer activity against human SiHa cells after 48 hrs by MTT assay,Confirmatory,21641694.0,
3728,613825,1,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,21780800.0,
3729,613826,1,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for homoharringtonine300-resistant human K562 cells to IC50 for human K562 cells,Other,21780800.0,
3730,613827,1,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for vinblastine100-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells,Other,21780800.0,
3731,614003,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A498 cells assessed as cell growth at 10 ug/mL by sulforhodamine B assay,Other,21802797.0,
3732,614004,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A498 cells assessed as cell growth at 20 ug/mL by sulforhodamine B assay,Other,21802797.0,
3733,614005,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A498 cells assessed as cell growth at 40 ug/mL by sulforhodamine B assay,Other,21802797.0,
3734,614006,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A498 cells assessed as cell growth at 80 ug/mL by sulforhodamine B assay,Other,21802797.0,
3735,614007,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A498 cells,Other,21802797.0,
3736,614008,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A549 cells assessed as cell growth at 10 ug/mL by sulforhodamine B assay,Other,21802797.0,
3737,614009,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A549 cells assessed as cell growth at 20 ug/mL by sulforhodamine B assay,Other,21802797.0,
3738,614010,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A549 cells assessed as cell growth at 40 ug/mL by sulforhodamine B assay,Other,21802797.0,
3739,614011,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human A549 cells assessed as cell growth at 80 ug/mL by sulforhodamine B assay,Other,21802797.0,
3740,614012,4,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,21802797.0,
3741,614147,3,2,,123097261,31703,Active,,,13.0,LC50,Cytotoxicity against human K562 cells,Confirmatory,21827183.0,
3742,614577,1,4,,123097261,31703,Active,,,,,Cellular uptake in human HeLa cells at 10 uM after 48 hrs by confocal microscopic analysis,Other,21873067.0,
3743,615303,3,2,,123097261,31703,Active,,,1.79,GI50,Anticancer activity against human ZR-75-1 cells by SRB method,Confirmatory,21676506.0,
3744,615304,3,2,,123097261,31703,Active,,,0.17,GI50,Anticancer activity against human MCF7 cells by SRB method,Confirmatory,21676506.0,
3745,615305,3,2,,123097261,31703,Active,,,0.14,GI50,Anticancer activity against human HOP62 cells by SRB method,Confirmatory,21676506.0,
3746,615306,3,3,,123097261,31703,Active,,,0.17,GI50,Anticancer activity against human Gurav cells by SRB method,Confirmatory,21676506.0,
3747,615307,3,2,,123097261,31703,Active,,,7.25,GI50,Anticancer activity against human A549 cells by SRB method,Confirmatory,21676506.0,
3748,615308,3,2,,123097261,31703,Active,,,0.16,GI50,Anticancer activity against human A2780 cells by SRB method,Confirmatory,21676506.0,
3749,615309,3,3,,123097261,31703,Active,,,0.1,GI50,Anticancer activity against human DWD cells by SRB method,Confirmatory,21676506.0,
3750,615310,3,2,,123097261,31703,Active,,,0.17,GI50,Anticancer activity against human KB cells by SRB method,Confirmatory,21676506.0,
3751,615311,3,2,,123097261,31703,Active,,,0.14,GI50,Anticancer activity against human COLO205 cells by SRB method,Confirmatory,21676506.0,
3752,615312,3,2,,123097261,31703,Active,,,1.81,GI50,Anticancer activity against human PC3 cells by SRB method,Confirmatory,21676506.0,
3753,615313,3,2,,123097261,31703,Active,,,0.17,GI50,Anticancer activity against human SiHa cells by SRB method,Confirmatory,21676506.0,
3754,616030,3,2,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21741131.0,
3755,616033,3,2,,123097261,31703,Active,,,0.03,CC50,Cytotoxicity against human HFF cells after 72 hrs by MTT assay,Confirmatory,21741131.0,
3756,616034,1,5,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella Typhimurium TA97a assessed as number of spontaneous and drug-induced revertants at 25 to 125 nM after 48 hrs by Ames test,Other,21741131.0,
3757,616035,1,5,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella Typhimurium TA98 assessed as number of spontaneous and drug-induced revertants at 25 to 125 nM after 48 hrs by Ames test,Other,21741131.0,
3758,616110,1,5,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella Typhimurium TA100 assessed as number of spontaneous and drug-induced revertants at 25 to 125 nM after 48 hrs by Ames test,Other,21741131.0,
3759,616111,1,5,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella Typhimurium TA102 assessed as number of spontaneous and drug-induced revertants at 25 to 125 nM after 48 hrs by Ames test,Other,21741131.0,
3760,616508,1,4,,123097261,31703,Unspecified,,,,,"Drug resistance index, ratio of IC50 for adriyamycin-resistant human MCF7 cells to IC50 for human MCF7 cells",Other,21761866.0,
3761,616509,1,4,,123097261,31703,Inconclusive,,,,,"Drug resistance index, ratio of IC50 for vincristine-resistant human KB cells to IC50 for human KB cells",Other,21761866.0,
3762,616510,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against vincristine-resistant human KB cells over expressing P-glycoprotein after 72 hrs by SRB assay,Confirmatory,21761866.0,
3763,616511,3,2,,123097261,31703,Active,,,43.44,IC50,Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay,Confirmatory,21761866.0,
3764,616513,3,2,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay,Confirmatory,21761866.0,
3765,616587,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,21761866.0,
3766,616985,1,4,,123097261,31703,Active,,,0.0012,IC50,Cytotoxicity against human A2780 cells,Confirmatory,21774499.0,
3767,616986,1,4,,123097261,31703,Active,,,0.19399999999999998,IC50,Cytotoxicity against human A2780/ADR cells,Confirmatory,21774499.0,
3768,616987,1,4,,123097261,31703,Active,,,0.005,IC50,Cytotoxicity against human A2780cis cells,Confirmatory,21774499.0,
3769,617324,3,3,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human LAMA-84 cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3770,617325,3,2,,123097261,31703,Active,,,0.85,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3771,617326,3,4,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3772,617327,3,2,,123097261,31703,Active,,,1.54,IC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3773,617328,3,2,,123097261,31703,Active,,,0.95,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3774,617329,3,2,,123097261,31703,Active,,,1.63,IC50,Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3775,617331,3,2,,123097261,31703,Active,,,2.33,IC50,Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,21797280.0,
3776,618033,3,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay,Confirmatory,21794959.0,
3777,618702,6,1,,123097261,31703,Active,,,0.04,IC50,Inhibition of GST-tagged Aurora A kinase expressed in insect cells assessed as inhibition of [33P]gamma-ATP incorporation in substrate after 60 mins by scintillation counting,Confirmatory,21664013.0,
3778,618703,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as cell survival at 1 ug/ml after 48 hrs by sulforhodamine B method relative to control,Other,21664013.0,
3779,618704,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as cell survival at 2.5 ug/ml after 48 hrs by sulforhodamine B method relative to control,Other,21664013.0,
3780,618705,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as cell survival at 5 ug/ml after 48 hrs by sulforhodamine B method relative to control,Other,21664013.0,
3781,618706,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as cell survival at 10 ug/ml after 48 hrs by sulforhodamine B method relative to control,Other,21664013.0,
3782,618707,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method,Other,21664013.0,
3783,618800,5,1,,123097261,31703,Active,,,1.29,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,21784631.0,
3784,618801,3,3,,123097261,31703,Active,,,1.57,IC50,Cytotoxicity against human Hep3B cells,Confirmatory,21784631.0,
3785,620174,3,2,,123097261,31703,Active,,,0.49,GI50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay,Confirmatory,21885166.0,
3786,620175,3,2,,123097261,31703,Active,,,0.66,GI50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,21885166.0,
3787,620176,3,2,,123097261,31703,Active,,,1.13,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay,Confirmatory,21885166.0,
3788,620206,1,5,,123097261,31703,Active,,,,,Antiproliferative activity against human BT20 cells at 10 uM after 72 hrs relative to control,Other,21852023.0,
3789,620207,1,4,,123097261,31703,Active,,,,,Antiproliferative activity against human CCRF-CEM cells at 10 uM after 72 hrs relative to control,Other,21852023.0,
3790,620331,3,2,,123097261,31703,Active,,,2.17,IC50,Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay,Confirmatory,21868138.0,
3791,620332,3,2,,123097261,31703,Active,,,2.03,IC50,Cytotoxicity against human MDA-MB-361 cells after 94 hrs by MTT assay,Confirmatory,21868138.0,
3792,620333,3,2,,123097261,31703,Active,,,3.092,IC50,Cytotoxicity against human SK-MEL-1 cells after 94 hrs by MTT assay,Confirmatory,21868138.0,
3793,620334,3,2,,123097261,31703,Active,,,3.6,IC50,Cytotoxicity against human A549 cells after 94 hrs by MTT assay,Confirmatory,21868138.0,
3794,620335,3,2,,123097261,31703,Active,,,3.137,IC50,Cytotoxicity against human HL60 cells after 94 hrs by MTT assay,Confirmatory,21868138.0,
3795,620336,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HFL1 cells after 94 hrs by MTT assay,Other,21868138.0,
3796,620405,3,2,,123097261,31703,Unspecified,,,71.8,IC50,Anticancer activity against human MCF7 cells assessed as viable cells after 48 hrs by SRB assay,Confirmatory,21890248.0,
3797,620406,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as viable cells at 10 uM after 48 hrs by SRB assay relative to control,Other,21890248.0,
3798,620407,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as viable cells at 25 uM after 48 hrs by SRB assay relative to control,Other,21890248.0,
3799,620408,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as viable cells at 50 uM after 48 hrs by SRB assay relative to control,Other,21890248.0,
3800,620409,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as viable cells at 100 uM after 48 hrs by SRB assay relative to control,Other,21890248.0,
3801,620604,3,2,,123097261,31703,Active,,,0.425,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,21843940.0,
3802,620605,3,3,,123097261,31703,Active,,,17.84,IC50,Cytotoxicity against adriamycin-resistant human K562/A02 cells after 48 hrs by MTT assay,Confirmatory,21843940.0,
3803,621615,1,3,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as increase in melting temperature at 10 uM,Other,21859103.0,
3804,622534,3,2,,123097261,31703,Active,,,1.22,IC50,Cytotoxicity against androgen receptor-negative human PC3 cells after 48 hrs by MTT assay,Confirmatory,21885273.0,
3805,622535,3,2,,123097261,31703,Active,,,4.1,IC50,Cytotoxicity against androgen receptor-negative human PC3 cells after 24 hrs by MTT assay,Confirmatory,21885273.0,
3806,622536,3,2,,123097261,31703,Active,,,0.58,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,21885273.0,
3807,622537,3,2,,123097261,31703,Active,,,6.24,IC50,Cytotoxicity against human DU145 cells after 24 hrs by MTT assay,Confirmatory,21885273.0,
3808,622538,3,2,,123097261,31703,Active,,,1.66,IC50,Cytotoxicity against androgen receptor-positive human LNCAP cells after 48 hrs by MTT assay,Confirmatory,21885273.0,
3809,622539,3,2,,123097261,31703,Active,,,7.42,IC50,Cytotoxicity against androgen receptor-positive human LNCAP cells after 24 hrs by MTT assay,Confirmatory,21885273.0,
3810,622542,3,2,,123097261,31703,Active,,,8.94,IC50,Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay,Confirmatory,21885273.0,
3811,622543,3,2,,123097261,31703,Active,,,1.51,IC50,Cytotoxicity against estrogen receptor-positive human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21885273.0,
3812,623656,3,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3813,623657,3,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3814,623658,3,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3815,623659,3,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3816,623660,3,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human PC3 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3817,623661,3,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3818,623662,3,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human MIAPaCa2 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3819,623663,3,3,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human WI38 cells after 72 hrs by Alamar blue assay,Confirmatory,21999655.0,
3820,624101,1,2,,85787258,31703,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3821,624151,1,1,,85787258,31703,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
3822,624156,1,1,,85787258,31703,Inconclusive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
3823,624173,1,3,,124886893,31703,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
3824,624349,1,2,,92308822,31703,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3825,624476,1,1,,124886893,31703,Active,,,0.0332,Potency,Cytotoxicity counterscreen for NFkB agonists and antagonists,Confirmatory,,
3826,624478,1,1,,124886893,31703,Inactive,,,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway.,Confirmatory,,
3827,624479,1,1,,124886893,31703,Active,,,6.6769,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,Confirmatory,,
3828,624606,1,9,,123097261,31703,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
3829,624612,1,9,,123097261,31703,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
3830,624622,3,1,,123097261,31703,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
3831,624623,3,1,,123097261,31703,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
3832,624626,1,9,,123097261,31703,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
3833,624628,1,9,,123097261,31703,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
3834,624629,1,9,,123097261,31703,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
3835,625144,5,5,,123097261,31703,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
3836,625145,4,7,,123097261,31703,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
3837,625146,5,5,,123097261,31703,Active,126397.0,100009114.0,13.59,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
3838,625147,4,7,,123097261,31703,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3839,625148,4,7,,123097261,31703,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3840,625149,4,7,,123097261,31703,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3841,625150,5,5,,123097261,31703,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
3842,625151,4,7,,123097261,31703,Active,113118.0,1128.0,15.335999999999999,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3843,625152,4,7,,123097261,31703,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3844,625153,4,7,,123097261,31703,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3845,625154,4,7,,123097261,31703,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3846,625155,4,7,,123097261,31703,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3847,625156,1,9,,123097261,31703,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
3848,625157,6,2,,123097261,31703,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
3849,625158,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
3850,625159,5,5,,123097261,31703,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
3851,625160,1,9,,123097261,31703,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
3852,625161,4,7,,123097261,31703,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
3853,625162,4,7,,123097261,31703,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3854,625163,4,7,,123097261,31703,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3855,625164,1,6,,123097261,31703,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
3856,625165,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3857,625166,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3858,625167,5,5,,123097261,31703,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
3859,625168,4,7,,123097261,31703,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
3860,625169,1,6,,123097261,31703,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
3861,625170,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
3862,625171,4,7,,123097261,31703,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
3863,625172,4,7,,123097261,31703,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
3864,625173,5,5,,123097261,31703,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
3865,625174,5,5,,123097261,31703,Active,266321.0,834.0,12.192,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
3866,625175,5,5,,123097261,31703,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
3867,625176,1,9,,123097261,31703,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
3868,625177,5,5,,123097261,31703,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3869,625178,5,5,,123097261,31703,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3870,625179,1,9,,123097261,31703,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
3871,625180,5,5,,123097261,31703,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3872,625181,5,5,,123097261,31703,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3873,625182,5,5,,123097261,31703,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3874,625183,5,5,,123097261,31703,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
3875,625184,5,5,,123097261,31703,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3876,625185,5,5,,123097261,31703,Active,125370.0,2534.0,5.147,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3877,625186,5,5,,123097261,31703,Active,119533.0,2064.0,2.485,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3878,625187,5,5,,123097261,31703,Active,125474.0,3932.0,31.913,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3879,625188,1,9,,123097261,31703,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
3880,625189,1,7,,123097261,31703,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
3881,625190,4,5,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
3882,625191,4,7,,123097261,31703,Active,112815.0,25075.0,34.464,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3883,625192,4,7,,123097261,31703,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
3884,625193,5,5,,123097261,31703,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
3885,625194,4,7,,123097261,31703,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
3886,625195,4,7,,123097261,31703,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
3887,625196,5,6,,123097261,31703,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
3888,625197,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
3889,625198,4,7,,123097261,31703,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3890,625199,4,7,,123097261,31703,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3891,625200,4,7,,123097261,31703,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3892,625201,4,7,,123097261,31703,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
3893,625202,4,7,,123097261,31703,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
3894,625203,4,7,,123097261,31703,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
3895,625204,4,7,,123097261,31703,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3896,625205,4,7,,123097261,31703,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
3897,625206,4,7,,123097261,31703,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3898,625207,4,7,,123097261,31703,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3899,625208,5,5,,123097261,31703,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
3900,625209,4,7,,123097261,31703,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
3901,625210,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
3902,625211,1,6,,123097261,31703,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
3903,625212,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
3904,625213,4,7,,123097261,31703,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
3905,625214,1,9,,123097261,31703,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
3906,625215,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
3907,625216,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
3908,625217,4,7,,123097261,31703,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3909,625218,4,7,,123097261,31703,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
3910,625219,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
3911,625220,4,7,,123097261,31703,Active,6224984.0,100135548.0,12.468,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
3912,625221,4,7,,123097261,31703,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3913,625222,4,7,,123097261,31703,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
3914,625223,4,7,,123097261,31703,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
3915,625224,3,4,,123097261,31703,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
3916,625225,3,4,,123097261,31703,Active,,,15.245,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
3917,625226,4,7,,123097261,31703,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
3918,625227,4,7,,123097261,31703,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
3919,625228,4,7,,123097261,31703,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
3920,625229,5,5,,123097261,31703,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
3921,625230,1,6,,123097261,31703,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
3922,625231,4,7,,123097261,31703,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
3923,625232,1,9,,123097261,31703,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
3924,625233,4,7,,123097261,31703,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
3925,625234,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
3926,625235,4,7,,123097261,31703,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
3927,625236,5,5,,123097261,31703,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
3928,625237,4,7,,123097261,31703,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
3929,625238,4,7,,123097261,31703,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
3930,625239,4,7,,123097261,31703,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
3931,625240,1,9,,123097261,31703,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
3932,625241,4,7,,123097261,31703,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
3933,625242,4,7,,123097261,31703,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
3934,625243,5,5,,123097261,31703,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3935,625244,5,5,,123097261,31703,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3936,625245,5,5,,123097261,31703,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3937,625246,1,9,,123097261,31703,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
3938,625247,5,5,,123097261,31703,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3939,625248,5,5,,123097261,31703,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3940,625249,5,5,,123097261,31703,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3941,625250,5,5,,123097261,31703,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3942,625251,5,5,,123097261,31703,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
3943,625252,4,7,,123097261,31703,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
3944,625253,4,7,,123097261,31703,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3945,625254,4,7,,123097261,31703,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3946,625255,4,7,,123097261,31703,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3947,625256,4,7,,123097261,31703,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3948,625257,4,7,,123097261,31703,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
3949,625258,4,7,,123097261,31703,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3950,625259,4,7,,123097261,31703,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3951,625260,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
3952,625261,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
3953,625262,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
3954,625263,4,7,,123097261,31703,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
3955,625264,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
3956,625265,1,6,,123097261,31703,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
3957,625266,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
3958,625267,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
3959,625268,4,2,,123097261,31703,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3960,625268,4,2,,123097261,31703,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3961,625268,4,2,,123097261,31703,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3962,625268,4,2,,123097261,31703,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3963,625269,4,7,,123097261,31703,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
3964,625270,4,7,,123097261,31703,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
3965,625271,5,5,,123097261,31703,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
3966,625272,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
3967,625273,4,6,,123097261,31703,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
3968,625274,1,6,,123097261,31703,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
3969,625275,3,4,,123097261,31703,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
3970,625279,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
3971,625280,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
3972,625281,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
3973,625282,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
3974,625283,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
3975,625284,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
3976,625285,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
3977,625286,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
3978,625287,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
3979,625288,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
3980,625289,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
3981,625290,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
3982,625291,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
3983,625292,1,3,,123097261,31703,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
3984,625520,3,2,,123097261,31703,Active,,,0.18,GI50,Growth inhibition of human A431 cells after 2 days by SRB assay,Confirmatory,22000924.0,
3985,625522,3,3,,123097261,31703,Active,,,0.13,GI50,Growth inhibition of human HCT116 cells after 2 days by SRB assay,Confirmatory,22000924.0,
3986,625630,3,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22014995.0,
3987,625631,3,3,,123097261,31703,Active,,,8.7,IC50,Cytotoxicity against human Hep2 cells by MTT assay,Confirmatory,22014995.0,
3988,625632,3,2,,123097261,31703,Active,,,0.71,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,22014995.0,
3989,625860,3,2,,123097261,31703,Active,,,0.47700000000000004,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21983438.0,
3990,625861,3,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human HCT116 cells by MTT assay,Confirmatory,21983438.0,
3991,625862,3,2,,123097261,31703,Active,,,0.456,IC50,Cytotoxicity against human NCI-H460 cells by MTT assay,Confirmatory,21983438.0,
3992,626596,3,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,21996519.0,
3993,626598,3,3,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MDA231 cells by MTT assay,Confirmatory,21996519.0,
3994,626599,3,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,21996519.0,
3995,626600,3,3,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against mouse Neuro2a cells by MTT assay,Confirmatory,21996519.0,
3996,626601,3,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21996519.0,
3997,626674,3,2,,123097261,31703,Active,,,2.5,EC50,Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay relative to control,Confirmatory,21882827.0,
3998,626680,1,4,,123097261,31703,Unspecified,,,,,Potentiation of doxorubicin-induced cytotoxicity against human HL60 cells assessed as reduction in cell viability at 0.1 to 1 uM after 24 hrs by MTT assay relative to control,Other,21882827.0,
3999,627143,3,3,,123097261,31703,Active,,,0.27,GI50,Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,21875046.0,
4000,627144,3,3,,123097261,31703,Active,,,0.01,GI50,Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,21875046.0,
4001,627145,3,3,,123097261,31703,Active,,,0.12,GI50,Antiproliferative activity against human HT-29 assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,21875046.0,
4002,627146,3,3,,123097261,31703,Active,,,0.09,GI50,Antiproliferative activity against human PC3 assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,21875046.0,
4003,627619,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for KBV1 cells selected at 1 ug/mL vinblastine to IC50 for IC50 for human KB-3-1 cells,Other,21721528.0,
4004,627620,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for adriamycin-selected human NCI/ADR-RES cells to IC50 for human OVCAR8 cells,Other,21721528.0,
4005,627621,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for human HEK293 cells transfected with MDR1 expressing plasmid to IC50 for human HEK293 cells,Other,21721528.0,
4006,627622,1,5,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for human ZR-75B cells selected at 600 ng/mL doxorubicin to IC50 for human ZR-75B cells,Other,21721528.0,
4007,627623,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for MDA-MB-231 cells selected at 100 ng/mL vinblastine to IC50 for human MDA-MB-231 cells,Other,21721528.0,
4008,627624,1,6,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for NIH/3T3 cells selected at 30 ug/mL vincristine to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4009,627625,1,6,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for NIH/3T3 cells selected at 600 ug/mL vincristine to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4010,627626,1,6,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for NIH/3T3 cells selected at 2400 ug/mL vincristine to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4011,627627,1,6,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant selected at 2.4 ug/mL vincristine to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4012,627629,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for human Ew36 cells selected at 120 ng/mL vincristine to IC50 for human Ew36 cells,Other,21721528.0,
4013,627630,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for adriamycin-selected human MES-SA cells to IC50 for human MES-SA cells,Other,21721528.0,
4014,627631,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for human SW620 cells selected at 20 ng/mL adriamycin to IC50 for human SW620 cells,Other,21721528.0,
4015,627632,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for pig LLC-PK1 cells to IC50 for pig LLC-PK1 cells transfected with empty vector,Other,21721528.0,
4016,627633,1,4,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for CHO cells selected at 1 ug/mL colchicine to IC50 for CHO cells,Other,21721528.0,
4017,627736,1,6,,123097261,31703,Unspecified,,,,,Drug resistance ratio of IC50 for mouse NIH/3T3 cells transfected with P-gp G185 to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4018,627737,1,6,,123097261,31703,Unspecified,,,,,Drug resistance ratio of IC50 for colchicine-selected mouse NIH/3T3 cells to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4019,628253,3,2,,123097261,31703,Active,,,0.77,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,21800859.0,
4020,628254,3,2,,123097261,31703,Active,,,1.93,IC50,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Confirmatory,21800859.0,
4021,628255,3,2,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human A549 cells after 3 days by MTT assay,Confirmatory,21800859.0,
4022,628256,3,2,,123097261,31703,Active,,,0.26,IC50,Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay,Confirmatory,21800859.0,
4023,628257,3,3,,123097261,31703,Active,,,1.03,IC50,Cytotoxicity against human Hep3B cells after 3 days by MTT assay,Confirmatory,21800859.0,
4024,628258,3,2,,123097261,31703,Active,,,0.63,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,21800859.0,
4025,628715,1,6,,123097261,31703,Unspecified,,,,,Drug resistant ratio of IC50 for mouse NIH/3T3 cells transfected with P-gp Ser to Arg phosphorylation mutant selected at 2400 ug/mL vincristine to IC50 for mouse NIH/3T3 cells,Other,21721528.0,
4026,628717,3,3,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4027,628718,3,3,,123097261,31703,Active,,,4.7,IC50,Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4028,628719,3,2,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4029,628720,3,2,,123097261,31703,Active,,,9.3,IC50,Cytotoxicity against adriamycin-selected human NCI/ADR-RES cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4030,628721,3,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4031,628722,3,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay,Confirmatory,21721528.0,
4032,628723,3,3,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human ZR-75B cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4033,628724,3,3,,123097261,31703,Active,,,2.02,IC50,Cytotoxicity against doxorubicin-selected human ZR-75B cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4034,628725,3,2,,123097261,31703,Active,,,0.39,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4035,628796,3,2,,123097261,31703,Active,,,3.06,IC50,Cytotoxicity against human MDA-MB-231 cells selected at 100 ug/ml vinblastine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4036,628797,3,4,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4037,628798,3,4,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against mouse NIH/3T3 cells selected at 30 ug/ml vincristine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4038,628799,3,4,,123097261,31703,Active,,,0.69,IC50,Cytotoxicity against mouse NIH/3T3 cells transfected with wild type p-glycoprotein ABCB1 selected at 600 ug/ml vincristine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4039,628800,3,4,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring four Ser to Arg mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4040,628801,3,4,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring Ser to Asp mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4041,628802,3,4,,123097261,31703,Active,,,17.48,IC50,Cytotoxicity against 2.4 ug/mL vincristine selected mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant after 72 hrs by MTT assay,Confirmatory,21721528.0,
4042,628803,3,4,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against mouse NIH/3T3 cells transfected with wild-type P-gp G185 after 72 hrs by MTT assay,Confirmatory,21721528.0,
4043,628804,3,4,,123097261,31703,Active,,,1.58,IC50,Cytotoxicity against mouse NIH/3T3 cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4044,628805,3,3,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human Ew36 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4045,628806,3,3,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human Ew36 cells selected at 120 ng/mL vincristine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4046,628807,3,3,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4047,628808,3,3,,123097261,31703,Active,,,0.87,IC50,Cytotoxicity against adriamycin-selected human MES-SA cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4048,628809,3,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4049,628810,3,2,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human SW620 cells selected at 20 ng/mL adriamycin after 72 hrs by MTT assay,Confirmatory,21721528.0,
4050,628811,3,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against pig LLC-PK1 cells transfected with empty vector after 72 hrs by MTT assay,Confirmatory,21721528.0,
4051,628812,3,2,,123097261,31703,Active,,,19.72,IC50,Cytotoxicity against pig LLC-PK1 cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4052,628813,3,2,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against CHO cells after 72 hrs by MTT assay,Confirmatory,21721528.0,
4053,628814,3,2,,123097261,31703,Active,,,9.7,IC50,Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay,Confirmatory,21721528.0,
4054,629602,3,2,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4055,629603,3,2,,123097261,31703,Active,,,13.1,IC50,Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4056,629604,3,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human CEM cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4057,629605,3,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human vinblastine-resistant CEM/VBL100 cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4058,629655,3,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4059,629656,3,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human taxol-resistant A549-T12 cells after 72 hrs by MTT assay,Confirmatory,22027100.0,
4060,629687,1,4,,123097261,31703,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human LoVo cells to IC50 for human LoVo cells,Other,22027100.0,
4061,629702,3,2,,123097261,31703,Active,,,4.5,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,22000946.0,
4062,629703,3,2,,123097261,31703,Active,,,2.9,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay,Confirmatory,22000946.0,
4063,629704,1,4,,123097261,31703,Active,,,,,Reduction in VEGF mRNA expression in human MCF7 cells by RT-PCR relative to control,Other,22000946.0,
4064,629705,1,4,,123097261,31703,Active,,,,,Reduction in CYP19 mRNA expression in human MCF7 cells by RT-PCR relative to control,Other,22000946.0,
4065,629706,1,4,,123097261,31703,Active,,,,,Reduction in AP-2 gamma mRNA expression in human MCF7 cells by RT-PCR relative to control,Other,22000946.0,
4066,631026,1,4,,123097261,31703,Active,,,,,Growth inhibition of human MDA-MB-435 cells at 15 uM by MTT assay,Other,21967660.0,
4067,632368,3,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human HCT8 cells by MTT assay,Confirmatory,22070654.0,
4068,632369,3,3,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against human Bel7402 cells by MTT assay,Confirmatory,22070654.0,
4069,632370,3,2,,123097261,31703,Active,,,0.72,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22070654.0,
4070,632371,3,3,,123097261,31703,Active,,,0.98,IC50,Cytotoxicity against human BCG823 cells by MTT assay,Confirmatory,22070654.0,
4071,632372,3,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human A2780 cells by MTT assay,Confirmatory,22070654.0,
4072,632672,1,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human BGC823 cells assessed as growth inhibition at 10 uM by SRB method,Other,22004723.0,
4073,632673,1,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human Bel7402 cells assessed as growth inhibition at 10 uM by SRB method,Other,22004723.0,
4074,632674,1,4,,123097261,31703,Unspecified,,,,,Antitumor activity against human KB cells assessed as growth inhibition at 10 uM by SRB method,Other,22004723.0,
4075,634029,3,2,,123097261,31703,Active,,,13.6,IC50,Cytotoxicity against human K562 cells by spectrophotometric analysis,Confirmatory,22148280.0,
4076,634094,3,2,,123097261,31703,Active,,,2.18,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
4077,634095,3,2,,123097261,31703,Active,,,5.51,IC50,Anticancer activity against human A375 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
4078,634096,3,2,,123097261,31703,Active,,,2.02,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
4079,634097,3,2,,123097261,31703,Active,,,1.06,IC50,Anticancer activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
4080,634098,3,2,,123097261,31703,Active,,,0.79,IC50,Anticancer activity against human ACHN cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
4081,634821,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
4082,634822,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
4083,634823,3,2,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
4084,634824,3,2,,123097261,31703,Unspecified,,,56.83,IC50,Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
4085,634826,1,4,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for adriamycin-selected multi drug-resistant human K562 cells to IC50 for human K562 cells",Other,22119124.0,
4086,634931,3,2,,123097261,31703,Active,,,5.46,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119131.0,
4087,634991,3,2,,123097261,31703,Active,,,6.86,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119131.0,
4088,634992,3,2,,123097261,31703,Active,,,7.36,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119131.0,
4089,634993,3,2,,123097261,31703,Active,,,6.86,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119132.0,
4090,634994,3,2,,123097261,31703,Active,,,5.46,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119132.0,
4091,634995,3,2,,123097261,31703,Active,,,7.36,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22119132.0,
4092,635081,3,2,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,22100139.0,
4093,636133,3,2,,123097261,31703,Active,,,1.02,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22209733.0,
4094,636134,3,2,,123097261,31703,Active,,,0.03,IC50,Anticancer activity against human A431 cells after 48 hrs by MTT assay,Confirmatory,22209733.0,
4095,636135,3,2,,123097261,31703,Active,,,1.69,IC50,Anticancer activity against human COLO205 cells after 48 hrs by MTT assay,Confirmatory,22209733.0,
4096,636136,3,2,,123097261,31703,Active,,,2.51,IC50,Anticancer activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,22209733.0,
4097,636345,5,1,,123097261,31703,Active,,,0.0688,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,22177409.0,
4098,636346,5,1,,123097261,31703,Active,,,0.086,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,22177409.0,
4099,636347,5,1,,123097261,31703,Active,,,0.0915,GI50,Growth inhibition of human A375-C5 cells after 48 hrs by SRB assay,Confirmatory,22177409.0,
4100,636846,3,2,,123097261,31703,Active,,,0.04,IC50,Antineoplastic activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
4101,636847,3,2,,123097261,31703,Active,,,1.67,IC50,Antineoplastic activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
4102,636848,3,2,,123097261,31703,Active,,,0.02,IC50,Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
4103,636849,3,2,,123097261,31703,Inconclusive,,,,IC50,Antineoplastic activity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
4104,636850,3,2,,123097261,31703,Active,,,0.96,IC50,Antineoplastic activity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
4105,636970,3,2,,123097261,31703,Active,,,6.61,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
4106,636971,3,3,,123097261,31703,Active,,,8.65,IC50,Cytotoxicity against human QGY7701 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
4107,636972,3,2,,123097261,31703,Active,,,1.12,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
4108,636973,3,2,,123097261,31703,Unspecified,,,65.25,IC50,Cytotoxicity against human SW480 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
4109,637683,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 by sulforhodamie B colorimetric assay,Other,22178093.0,
4110,638298,1,4,,123097261,31703,Active,,,,,Antiproliferative activity against human HT-29 cells overexpressing c-Src at 50 uM after 72 hrs by Cell titer assay,Other,22119472.0,
4111,638299,1,4,,123097261,31703,Active,,,,,Antiproliferative activity against human SKOV3 cells overexpressing c-Src at 50 uM after 72 hrs by Cell titer assay,Other,22119472.0,
4112,638320,3,2,,123097261,31703,Active,,,5.23,IC50,Cytotoxicity against human LNCAP cells,Confirmatory,22123320.0,
4113,638321,3,2,,123097261,31703,Active,,,11.67,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,22123320.0,
4114,638322,3,2,,123097261,31703,Active,,,3.07,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,22123320.0,
4115,638407,3,2,,123097261,31703,Active,,,15.65,IC50,Cytotoxicity against human DU145 cells,Confirmatory,22123320.0,
4116,638408,3,2,,123097261,31703,Active,,,18.23,IC50,Cytotoxicity against human MIAPaCa2 cells,Confirmatory,22123320.0,
4117,638409,3,2,,123097261,31703,Unspecified,,,62.26,IC50,Cytotoxicity against human PC3 cells,Confirmatory,22123320.0,
4118,638412,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4119,638413,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4120,638414,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4121,638415,1,5,,123097261,31703,Unspecified,,,,,Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4122,638416,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4123,638417,1,4,,123097261,31703,Unspecified,,,,,Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
4124,638672,1,4,,123097261,31703,Active,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay,Other,22129061.0,
4125,638673,1,4,,123097261,31703,Active,,,,,Cytotoxicity against human PC3 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay,Other,22129061.0,
4126,640401,3,2,,123097261,31703,Active,,,1.7,IC50,Cytotoxicity against human MCF7 cells by WST-1 assay,Confirmatory,22197145.0,
4127,640402,3,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay,Confirmatory,22197145.0,
4128,640404,3,2,,123097261,31703,Active,,,2.1,IC50,Cytotoxicity against human MDA-MB-231 cells by WST-1 assay,Confirmatory,22197145.0,
4129,640574,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as viable cells at 100 nM after 24 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 90.8 %),Other,22257529.0,
4130,640575,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 100 nM after 24 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 7.5 %),Other,22257529.0,
4131,640576,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as late apoptotic cells at 100 nM after 24 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 0.8 %),Other,22257529.0,
4132,640577,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as viable cells at 100 nM after 48 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 83.9 %),Other,22257529.0,
4133,640584,3,2,,123097261,31703,Active,,,7.0,LC50,Cytotoxicity against human K562 cells,Confirmatory,22182501.0,
4134,640750,1,5,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human U138MG cells at 2 ug/ml after 48 hrs by hemocytometric analysis,Other,22209415.0,
4135,640751,1,4,,123097261,31703,Unspecified,,,,,Antiproliferative activity against rat C6 cells at 2 ug/ml after 48 hrs by hemocytometric analysis,Other,22209415.0,
4136,640894,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as early apoptotic cells at 100 nM after 48 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 14.7 %),Other,22257529.0,
4137,640895,1,4,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as late apoptotic cells at 100 nM after 48 hrs using annexin-V-PE/7-AAD staining by flow cytometry analysis (Rvb = 0.6 %),Other,22257529.0,
4138,641494,3,2,,123097261,31703,Active,,,0.16,GI50,Anticancer activity against human KB cells by SRB method,Confirmatory,22104151.0,
4139,641622,3,3,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human NCI-H187 cells by SRB assay,Confirmatory,22004007.0,
4140,641785,3,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human KB cells by SRB assay,Confirmatory,22004007.0,
4141,641786,3,2,,123097261,31703,Active,,,2.29,IC50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,22004007.0,
4142,642054,3,2,,123097261,31703,Active,,,1.5,IC50,Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22044164.0,
4143,642055,3,2,,123097261,31703,Active,,,1.7,IC50,Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22044164.0,
4144,642056,3,2,,123097261,31703,Active,,,1.0,IC50,Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22044164.0,
4145,642057,3,2,,123097261,31703,Active,,,1.0,IC50,Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22044164.0,
4146,642665,3,2,,123097261,31703,Active,,,0.1,GI50,Anticancer activity against human MCF7 cells by SRB method,Confirmatory,22104151.0,
4147,642666,3,2,,123097261,31703,Active,,,0.1,GI50,Anticancer activity against human ZR-75-1 cells by SRB method,Confirmatory,22104151.0,
4148,642667,3,2,,123097261,31703,Active,,,0.1,GI50,Anticancer activity against human A2780 cells by SRB method,Confirmatory,22104151.0,
4149,642668,3,2,,123097261,31703,Active,,,14.7,GI50,Anticancer activity against human COLO205 cells by SRB method,Confirmatory,22104151.0,
4150,642669,3,2,,123097261,31703,Active,,,1.9,GI50,Anticancer activity against human SiHa cells by SRB method,Confirmatory,22104151.0,
4151,642670,3,2,,123097261,31703,Active,,,13.01,GI50,Anticancer activity against human A549 cells by SRB method,Confirmatory,22104151.0,
4152,644102,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells at 1 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
4153,644103,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of human A549 cells at 1 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
4154,644229,1,4,,123097261,31703,Active,,,,,Induction of apoptosis in human LNCAP cells assessed as increase in caspase 3/7 activation at 20 ug/ml after 24 hrs by Western blotting,Other,22264758.0,
4155,644322,3,2,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human KB cells after 3 days by resazurin microplate assay,Confirmatory,22280818.0,
4156,644323,3,3,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human NCI-H187 cells after 5 days by resazurin microplate assay,Confirmatory,22280818.0,
4157,644324,3,2,,123097261,31703,Active,,,17.9,IC50,Cytotoxicity against human MCF7 cells after 3 days by resazurin microplate assay,Confirmatory,22280818.0,
4158,644325,3,2,,123097261,31703,Active,,,28.81,IC50,Cytotoxicity against african green monkey Vero cells expressing GFP after 4 days by fluorescence assay,Confirmatory,22280818.0,
4159,644534,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells assessed as cell viability at 3 uM after 24 hrs by MTT assay,Other,22304849.0,
4160,644536,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 3 uM after 24 hrs by MTT assay,Other,22304849.0,
4161,644780,3,2,,123097261,31703,Active,,,1.28,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,22318164.0,
4162,644781,3,2,,123097261,31703,Active,,,2.85,IC50,Cytotoxicity against human K562 cells after 2 days,Confirmatory,22318164.0,
4163,644782,3,2,,123097261,31703,Active,,,0.86,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,22318164.0,
4164,644783,3,2,,123097261,31703,Active,,,3.69,IC50,Cytotoxicity against human MCF7 cells after 2 days,Confirmatory,22318164.0,
4165,644784,3,2,,123097261,31703,Active,,,1.45,IC50,Cytotoxicity against human HeLa cells after 2 days,Confirmatory,22318164.0,
4166,644953,1,3,,123097261,31703,Unspecified,,,,,Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis,Other,22257890.0,
4167,644999,3,2,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells by SRB assay,Confirmatory,22361684.0,
4168,645000,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human Gurav cells by SRB assay,Confirmatory,22361684.0,
4169,645001,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human HOP62 cells by SRB assay,Confirmatory,22361684.0,
4170,645002,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human MCF7 cells by SRB assay,Confirmatory,22361684.0,
4171,645003,3,2,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human ZR-75-1 cells by SRB assay,Confirmatory,22361684.0,
4172,645004,3,2,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A2780 cells by SRB assay,Confirmatory,22361684.0,
4173,645005,3,2,,123097261,31703,Active,,,0.1,GI50,Growth inhibition of human DWD cells by SRB assay,Confirmatory,22361684.0,
4174,645006,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells by SRB assay,Confirmatory,22361684.0,
4175,645007,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human COLO205 cells by SRB assay,Confirmatory,22361684.0,
4176,645008,3,2,,123097261,31703,Active,,,1.81,GI50,Growth inhibition of human PC3 cells by SRB assay,Confirmatory,22361684.0,
4177,645009,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human SiHa cells by SRB assay,Confirmatory,22361684.0,
4178,647959,1,3,,123097261,31703,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 1 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
4179,647960,1,3,,123097261,31703,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 10 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
4180,647961,1,3,,123097261,31703,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 100 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
4181,647962,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 1 uM after 48 hrs by MTT assay,Other,22357112.0,
4182,647963,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 10 uM after 48 hrs by MTT assay,Other,22357112.0,
4183,647964,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 100 uM after 48 hrs by MTT assay,Other,22357112.0,
4184,648275,1,4,,123097261,31703,Inactive,,,,,Growth inhibition of Drosophila melanogaster expressing Hrb87F mutant KG02089 assessed as reduction in eclosion rate at 25 uM after 15 days,Other,22071521.0,
4185,648288,3,2,,123097261,31703,Active,,,5.8,IC50,Cytotoxicity against human androgen-independent DU145 cells by MTT assay,Confirmatory,22326399.0,
4186,648289,3,2,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human androgen-independent PC3 cells by MTT assay,Confirmatory,22326399.0,
4187,648290,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human androgen-dependent LNCAP cells by MTT assay,Confirmatory,22326399.0,
4188,648296,3,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22330634.0,
4189,648297,3,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,22330634.0,
4190,649520,3,2,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4191,649521,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4192,649522,3,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4193,649523,3,2,,123097261,31703,Active,,,0.1,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4194,649524,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4195,649525,3,2,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4196,649526,3,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4197,649527,3,2,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
4198,650444,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay,Other,22370339.0,
4199,650445,3,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay,Other,22370339.0,
4200,650532,1,4,,123097261,31703,Unspecified,,,,,"n-Octanol-water partition coefficient, log P of the compound by shake flask method",Other,21420207.0,
4201,651645,1,1,,124886893,31703,Inactive,,,,Potency,Cell Proliferation Assay against the TMD8 Cell Line,Confirmatory,,
4202,651646,1,1,,124886893,31703,Inactive,,,,Potency,Cell Proliferation Assay against the HBL1 Cell Line,Confirmatory,,
4203,651696,1,1,,124886893,31703,Inactive,,,,Potency,Cell Proliferation Assay against a hMSC Cell Line,Confirmatory,,
4204,651712,1,1,,124886893,31703,Active,,,0.0372,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 16 hrs),Confirmatory,,
4205,651713,1,1,,124886893,31703,Active,,,3.3173,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 8 hrs),Confirmatory,,
4206,651828,1,2,,92308822,31703,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
4207,652685,2,2,,123097261,31703,Active,,,8.14,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,22386528.0,
4208,652686,2,2,,123097261,31703,Active,,,0.97,IC50,Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay,Confirmatory,22386528.0,
4209,652687,2,2,,123097261,31703,Active,,,15.07,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22386528.0,
4210,652688,2,2,,123097261,31703,Active,,,14.84,IC50,Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,22386528.0,
4211,653303,2,3,,123097261,31703,Active,,,46.69,IC50,Cytotoxicity against human K562/A02 cells expressing p-glycoprotein after 72 hrs by MTS assay,Confirmatory,22405646.0,
4212,653304,2,2,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTS assay,Confirmatory,22405646.0,
4213,653305,1,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human K562/A02 cells expressing p-glycoprotein to IC50 for human K562 cells,Other,22405646.0,
4214,654124,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4215,654125,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4216,654126,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4217,654127,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4218,654128,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4219,654129,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4220,654130,2,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay,Other,22410248.0,
4221,654513,2,2,,123097261,31703,Active,,,2.5,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay,Confirmatory,22272829.0,
4222,654514,2,2,,123097261,31703,Active,,,6.06,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by alamar blue assay,Confirmatory,22272829.0,
4223,654515,2,2,,123097261,31703,Active,,,6.04,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay,Confirmatory,22272829.0,
4224,654516,2,2,,123097261,31703,Active,,,3.14,IC50,Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay,Confirmatory,22272829.0,
4225,654525,2,2,,123097261,31703,Active,,,19.51,IC50,Cytotoxicity against human PC3 cells after 24 hrs by MTT assay,Confirmatory,22276650.0,
4226,654526,2,2,,123097261,31703,Active,,,23.48,IC50,Cytotoxicity against human DU145 cells after 24 hrs by MTT assay,Confirmatory,22276650.0,
4227,654527,2,2,,123097261,31703,Active,,,16.02,IC50,Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay,Confirmatory,22276650.0,
4228,654560,2,2,,123097261,31703,Active,,,5.0,IC50,Cytotoxicity against human HeLa cells,Confirmatory,22283451.0,
4229,654561,2,2,,123097261,31703,Active,,,7.0,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,22283451.0,
4230,654562,2,2,,123097261,31703,Active,,,7.0,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,22283451.0,
4231,654563,2,2,,123097261,31703,Active,,,4.0,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,22283451.0,
4232,654564,2,2,,123097261,31703,Active,,,11.0,IC50,Cytotoxicity against human NCI-H460 cells,Confirmatory,22283451.0,
4233,654565,2,3,,123097261,31703,Unspecified,,,172.0,IC50,Cytotoxicity against human SMMC7721 cells,Confirmatory,22283451.0,
4234,654566,2,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human SW1990 cells,Confirmatory,22283451.0,
4235,654657,2,2,,123097261,31703,Active,,,8.09,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,22444025.0,
4236,654659,2,2,,123097261,31703,Active,,,5.7,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay,Confirmatory,22444025.0,
4237,654660,2,2,,123097261,31703,Active,,,6.86,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay,Confirmatory,22444025.0,
4238,654895,2,2,,123097261,31703,Active,,,1.7,IC50,Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4239,654896,2,2,,123097261,31703,Active,,,7.1,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4240,654897,2,2,,123097261,31703,Unspecified,,,100.0,IC50,Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4241,654898,2,2,,123097261,31703,Active,,,5.3,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4242,654899,2,2,,123097261,31703,Active,,,11.0,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4243,654900,2,2,,123097261,31703,Active,,,6.9,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
4244,655726,2,2,,123097261,31703,Unspecified,,,2500.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22440624.0,
4245,655727,2,2,,123097261,31703,Unspecified,,,5000.0,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,22440624.0,
4246,655728,2,3,,123097261,31703,Unspecified,,,2500.0,IC50,Cytotoxicity against human QG56 cells after 48 hrs by MTT assay,Confirmatory,22440624.0,
4247,656194,2,2,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,22414612.0,
4248,656195,2,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22414612.0,
4249,656816,2,2,,123097261,31703,Active,,,46.69,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTS assay,Confirmatory,22429509.0,
4250,656817,2,3,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against human K562/A02 cells overexpress P-gp after 72 hrs by MTS assay,Confirmatory,22429509.0,
4251,656818,1,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human K562/A02 cells overexpress P-gp to IC50 for human K562 cells,Other,22429509.0,
4252,656827,1,3,,123097261,31703,Inactive,,,,,Growth inhibition of human K562/A02 cells at 3.5 uM after 72 hrs by MTS assay,Other,22429509.0,
4253,656828,1,3,,123097261,31703,Inactive,,,,,Growth inhibition of human K562 cells at 0.2 uM after 72 hrs by MTS assay,Other,22429509.0,
4254,657110,2,2,,123097261,31703,Active,,,10.0,IC50,Growth inhibition of human MDA-MB-231 cells,Confirmatory,22464458.0,
4255,657112,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HEK293 cells at 10 uM,Other,22464458.0,
4256,657120,2,2,,123097261,31703,Active,,,3.69,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22472043.0,
4257,657121,2,2,,123097261,31703,Active,,,1.18,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22472043.0,
4258,657122,1,3,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human A549 cells after 48 hrs to IC50 for human A549 cells after 72 hrs,Other,22472043.0,
4259,657127,1,3,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF7 cells at 1 uM after 48 hrs by SRB assay,Other,22472045.0,
4260,657282,2,2,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Confirmatory,22483395.0,
4261,657283,2,2,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay,Confirmatory,22483395.0,
4262,657284,2,2,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay,Confirmatory,22483395.0,
4263,657285,2,2,,123097261,31703,Active,,,0.015,IC50,Cytotoxicity against human XF498 cells after 48 hrs by SRB assay,Confirmatory,22483395.0,
4264,657286,2,2,,123097261,31703,Active,,,0.035,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay,Confirmatory,22483395.0,
4265,657868,2,2,,123097261,31703,Active,,,1.54,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by CellTiter-Glo assay,Confirmatory,22316168.0,
4266,657869,2,2,,123097261,31703,Active,,,1.9,IC50,Cytotoxicity against human T47D cells after 72 hrs by CellTiter-Glo assay,Confirmatory,22316168.0,
4267,657870,2,2,,123097261,31703,Active,,,0.21,IC50,Cytotoxicity against human SK-BR-3 cells after 72 hrs by CellTiter-Glo assay,Confirmatory,22316168.0,
4268,657871,2,3,,123097261,31703,Active,,,0.546,IC50,Cytotoxicity against human Hs578T cells after 72 hrs by CellTiter-Glo assay,Confirmatory,22316168.0,
4269,657872,2,3,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human Hs578Bst cells after 72 hrs by CellTiter-Glo assay,Confirmatory,22316168.0,
4270,657873,2,3,,123097261,31703,Unspecified,,,98.32,IC50,Cytotoxicity against human Hs578T cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control,Confirmatory,22316168.0,
4271,657874,2,3,,123097261,31703,Unspecified,,,64.3,IC50,Cytotoxicity against human Hs578Bst cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control,Confirmatory,22316168.0,
4272,659462,2,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,22250891.0,
4273,659838,2,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay,Confirmatory,22264149.0,
4274,659839,2,2,,123097261,31703,Active,,,0.62,IC50,Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay,Confirmatory,22264149.0,
4275,659840,2,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay,Confirmatory,22264149.0,
4276,659841,2,3,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay,Confirmatory,22264149.0,
4277,659842,2,2,,123097261,31703,Active,,,0.58,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay,Confirmatory,22264149.0,
4278,660311,2,3,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human MOLT4 cells after 24 hrs by XTT assay,Confirmatory,24900344.0,
4279,660312,2,3,,123097261,31703,Unspecified,,,20.0,IC50,Cytotoxicity against human OVCAR3 cells after 24 hrs by XTT assay,Confirmatory,24900344.0,
4280,660313,2,3,,123097261,31703,Unspecified,,,20.0,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay,Confirmatory,24900344.0,
4281,660314,2,3,,123097261,31703,Unspecified,,,20.0,IC50,Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay,Confirmatory,24900344.0,
4282,660315,2,3,,123097261,31703,Unspecified,,,100.0,IC50,Cytotoxicity against human NAR cells after 24 hrs by XTT assay,Confirmatory,24900344.0,
4283,660316,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human OVCAR3 cells assessed as cell viability at 20 uM after 24 hrs by XTT assay,Other,24900344.0,
4284,660317,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against doxorubicin-resistant human MCF7 cells assessed as cell viability at 20 uM after 24 hrs by XTT assay,Other,24900344.0,
4285,660318,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells assessed as cell viability at 20 uM after 24 hrs by XTT assay,Other,24900344.0,
4286,660319,1,3,,123097261,31703,Inactive,,,,,Cytotoxicity against doxorubicin-resistant human NAR cells assessed as cell viability at 100 uM after 24 hrs by XTT assay,Other,24900344.0,
4287,660320,1,3,,123097261,31703,Active,,,,,Binding affinity to Escherichia coli pBR322 DNA assessed as DNA migration at 20 uM after 15 mins by agarose gel electrophoresis,Other,24900344.0,
4288,660321,1,3,,123097261,31703,Active,,,,,Binding affinity to Escherichia coli pBR322 DNA assessed as DNA migration at 200 uM after 15 mins by agarose gel electrophoresis,Other,24900344.0,
4289,660323,1,4,,123097261,31703,Inactive,,,,,Cytotoxicity against human OVCAR3 cells assessed as induction of cell death at 10 uM after 24 hrs by trypan blue dye exclusion test,Other,24900344.0,
4290,660324,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human lymphocytes assessed as cell viability at 20 uM after 24 hrs by XTT assay relative to untreated control,Other,24900344.0,
4291,660326,1,3,,123097261,31703,Unspecified,,,,,Toxicity in Wistar rat erythrocytes assessed as hemolysis at 50 uM after 1 hr,Other,24900344.0,
4292,660327,1,3,,123097261,31703,Active,,,,,Drug uptake in doxorubicin-resistant human NAR cell plasma membrane at 5 uM after 2 hrs by confocal microscopic analysis,Other,24900344.0,
4293,660330,1,3,,123097261,31703,Inactive,,,,,Cytotoxicity against human NAR cells assessed as induction of cell death at 10 uM after 24 hrs by trypan blue dye exclusion test,Other,24900344.0,
4294,660388,1,3,,123097261,31703,Active,,,0.045,IC50,Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay,Confirmatory,22276998.0,
4295,660389,1,3,,123097261,31703,Unspecified,,,,,Inhibition of cell proliferation of human MDA-MB-468 cells at 1 uM after 120 hrs by CellTiter assay,Other,22276998.0,
4296,660391,1,3,,123097261,31703,Active,,,,,Drug uptake in doxorubicin-resistant human SKOV3 cell nucleus at 5 uM after 1 hr by confocal microscopic analysis,Other,22276998.0,
4297,660393,1,3,,123097261,31703,Inactive,,,,,Cellular uptake in doxorubicin-resistant human SKOV3 cells at 5 uM incubated for 1 hr followed by incubation with fresh media for 24 hrs measured by confocal microscopic analysis,Other,22276998.0,
4298,660394,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells at 10 uM incubated for 2 hrs followed by incubation in compound-free medium for 72 hrs by MTT assay,Other,22276998.0,
4299,660397,1,5,,123097261,31703,Active,,,,,Inhibition of topoisomerase 2-mediated KDNA decatenation at 5 uM after 30 mins by gel electrophoretic analysis,Other,22276998.0,
4300,660411,2,2,,123097261,31703,Active,,,5.0,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs,Confirmatory,22276998.0,
4301,663212,2,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Ca9-22 cells by MTT assay,Other,22413887.0,
4302,663213,2,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,22413887.0,
4303,663816,1,4,,123097261,31703,Active,,,0.114,IC50,Cytotoxicity against human PC3 cells assessed as viability after 96 hrs,Confirmatory,24900437.0,
4304,663982,2,2,,123097261,31703,Active,,,0.54,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
4305,663984,2,2,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
4306,663985,2,3,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human KB/VCR cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
4307,663986,2,3,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
4308,663987,2,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
4309,663989,1,3,,123097261,31703,Active,,,,,Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4310,663990,1,3,,123097261,31703,Active,,,,,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4311,663991,1,3,,123097261,31703,Active,,,,,Growth inhibition of human NCI/ADR cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4312,663992,1,3,,123097261,31703,Active,,,,,Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4313,663993,1,3,,123097261,31703,Active,,,,,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4314,663994,1,3,,123097261,31703,Active,,,,,Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4315,663995,1,3,,123097261,31703,Active,,,,,Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4316,663996,1,3,,123097261,31703,Active,,,,,Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B assay,Other,22537680.0,
4317,664313,2,2,,123097261,31703,Active,,,9.0,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,22520152.0,
4318,664314,2,2,,123097261,31703,Active,,,9.0,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,22520152.0,
4319,664315,2,2,,123097261,31703,Active,,,8.0,IC50,Cytotoxicity against human HeLa cells after 3 days by MTT assay,Confirmatory,22520152.0,
4320,664537,2,2,,123097261,31703,Active,,,1.7,IC50,Cytotoxicity against human KB cells by resazurin reduction assay,Confirmatory,22482432.0,
4321,664538,2,2,,123097261,31703,Active,,,16.8,IC50,Cytotoxicity against human MCF7 cells by resazurin reduction assay,Confirmatory,22482432.0,
4322,664539,2,3,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human NCI-H187 cells by resazurin reduction assay,Confirmatory,22482432.0,
4323,664924,2,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,22413887.0,
4324,664925,2,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,22413887.0,
4325,664926,2,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,22413887.0,
4326,664927,2,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,22413887.0,
4327,665008,2,2,,123097261,31703,Active,,,1.3,IC50,Cytostatic activity against mouse L1210/0 after 48 hrs by cell counting,Confirmatory,22555152.0,
4328,665009,2,2,,123097261,31703,Active,,,0.39,IC50,Cytostatic activity against human CEM/0 after 72 hrs by cell counting,Confirmatory,22555152.0,
4329,665010,2,2,,123097261,31703,Active,,,0.06,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4330,665011,2,2,,123097261,31703,Active,,,0.06,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4331,665012,2,2,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4332,665013,2,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4333,665014,2,2,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4334,665015,2,3,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
4335,665525,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 10 uM after 48 hrs by sulforhodamine B assay,Other,22583778.0,
4336,665526,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 25 uM after 48 hrs by sulforhodamine B assay,Other,22583778.0,
4337,665527,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 50 uM after 48 hrs by sulforhodamine B assay,Other,22583778.0,
4338,665528,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 100 uM after 48 hrs by sulforhodamine B assay,Other,22583778.0,
4339,665529,2,2,,123097261,31703,Active,,,32.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22583778.0,
4340,665672,2,2,,123097261,31703,Active,,,2.82,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,22542958.0,
4341,665673,2,2,,123097261,31703,Active,,,3.28,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,22542958.0,
4342,665674,2,3,,123097261,31703,Active,,,5.22,IC50,Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay,Confirmatory,22542958.0,
4343,666583,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell death at 2.5 uM after 48 hrs by MTT assay,Other,22633832.0,
4344,666588,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as cell death at 2.5 uM after 48 hrs by MTT assay,Other,22633832.0,
4345,666772,2,2,,123097261,31703,Active,,,2.8,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22647719.0,
4346,666773,2,3,,123097261,31703,Active,,,3.2,IC50,Cytotoxicity against human MG63 cells by MTT assay,Confirmatory,22647719.0,
4347,666805,2,2,,123097261,31703,Active,,,5.57,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22647723.0,
4348,666806,2,2,,123097261,31703,Active,,,17.67,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22647723.0,
4349,666807,2,3,,123097261,31703,Active,,,0.168,IC50,Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay,Confirmatory,22647723.0,
4350,666937,2,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,22647723.0,
4351,666975,2,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK-8 assay,Other,22658083.0,
4352,666976,2,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay,Other,22658083.0,
4353,667175,2,2,,123097261,31703,Active,,,5.9,IC50,Anticancer activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,22668451.0,
4354,667177,2,2,,123097261,31703,Active,,,19.3,IC50,Anticancer activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,22668451.0,
4355,667179,2,2,,123097261,31703,Active,,,0.03,IC50,Anticancer activity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,22668451.0,
4356,667181,2,2,,123097261,31703,Active,,,5.6,IC50,Anticancer activity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,22668451.0,
4357,667388,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 50 uM after 72 hrs by MTT assay relative to control,Other,22677031.0,
4358,667389,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells assessed as cell survival at 50 uM after 72 hrs by MTT assay relative to control,Other,22677031.0,
4359,667390,2,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human T47D cells after 72 hrs by MTT assay,Confirmatory,22677031.0,
4360,667391,2,2,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22677031.0,
4361,667392,2,2,,123097261,31703,Active,,,1.41,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,22677031.0,
4362,667427,2,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4363,667428,2,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4364,667430,2,2,,123097261,31703,Unspecified,,,95.61,IC50,Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4365,667431,2,2,,123097261,31703,Active,,,1.17,IC50,Cytotoxicity against human HeLa cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4366,667432,2,2,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human HT-29 cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4367,667433,2,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human MRC5 cells after 1 hr by SRB assay,Confirmatory,22770744.0,
4368,667474,1,5,,123097261,31703,Active,,,,,Induction of senescence in human HuH7 cells assessed as increase in senescence associated beta-galactosidase activity at 25 ng/mL after 3 to 6 days by X-GAL based staining method,Other,22409771.0,
4369,667476,1,5,,123097261,31703,Active,,,,,Antiproliferative activity in human HuH7 cells assessed as inhibition of BrdU incorporation at 25 ng/mL after 3 to 6 days,Other,22409771.0,
4370,668288,2,2,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,22608675.0,
4371,668289,2,2,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22608675.0,
4372,668694,2,2,,123097261,31703,Active,,,5.0,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,22632935.0,
4373,668902,2,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human U937/GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay,Confirmatory,21434649.0,
4374,668910,2,2,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21852132.0,
4375,669333,2,2,,123097261,31703,Active,,,1.6,IC50,Cytotoxicity against human SK-MEL cells assessed as viable cells by neutral red dye method,Confirmatory,22530813.0,
4376,669334,2,2,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against human KB cells assessed as viable cells by neutral red dye method,Confirmatory,22530813.0,
4377,669335,2,2,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method,Confirmatory,22530813.0,
4378,669336,2,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human SKOV3 cells assessed as viable cells by neutral red dye method,Confirmatory,22530813.0,
4379,669337,2,3,,123097261,31703,Active,,,1.6,IC50,Cytotoxicity against pig LLC-PK11 cells assessed as viable cells by neutral red dye method,Confirmatory,22530813.0,
4380,669849,2,2,,123097261,31703,Active,,,0.43,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTS assay,Confirmatory,22450134.0,
4381,669850,2,2,,123097261,31703,Active,,,46.69,IC50,Antiproliferative activity against multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein after 72 hrs by MTS assay,Confirmatory,22450134.0,
4382,669851,1,3,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein to IC50 for human K562 cells,Other,22450134.0,
4383,670279,2,2,,123097261,31703,Active,,,3.3,LC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22652254.0,
4384,671052,2,2,,123097261,31703,Active,,,1.63,GI50,Antiproliferative activity against human ACHN cells by SRB assay,Confirmatory,22738641.0,
4385,671053,2,2,,123097261,31703,Active,,,1.66,GI50,Antiproliferative activity against human NCI-H23 cells by SRB assay,Confirmatory,22738641.0,
4386,671054,2,2,,123097261,31703,Active,,,1.79,GI50,Antiproliferative activity against human MDA-MB-231 cells by SRB assay,Confirmatory,22738641.0,
4387,671055,2,2,,123097261,31703,Active,,,1.34,GI50,Antiproliferative activity against human HCT15 cells by SRB assay,Confirmatory,22738641.0,
4388,671056,2,3,,123097261,31703,Active,,,1.0,GI50,Antiproliferative activity against human NUGC3 cells by SRB assay,Confirmatory,22738641.0,
4389,671057,2,2,,123097261,31703,Active,,,1.65,GI50,Antiproliferative activity against human PC3 cells by SRB assay,Confirmatory,22738641.0,
4390,673017,1,4,,123097261,31703,Active,,,0.32,IC50,Antiproliferative activity against human NCI-H290 cells after 48 hrs by XTT assay,Confirmatory,22515366.0,
4391,673019,1,3,,123097261,31703,Active,,,0.34,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by XTT assay,Confirmatory,22515366.0,
4392,673021,1,4,,123097261,31703,Active,,,0.79,IC50,Antiproliferative activity against human U87MG cells after 48 hrs by XTT assay,Confirmatory,22515366.0,
4393,673023,4,2,,123097261,31703,Active,,,0.207,IC50,Antiproliferative activity against mouse LLC cells after 48 hrs by XTT assay,Confirmatory,22515366.0,
4394,673026,1,3,,123097261,31703,Unspecified,,,,,"Toxicity in C57BL/6 mouse xenografted with mouse LLC cells assessed as change in body weight at 13.7 umol/kg, iv administered on day 4 and day 11 after tumor transplantation measured on day 17",Other,22515366.0,
4395,673028,1,5,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as decrease in tumor volume at 13.7 umol/kg, iv administered on day 4 and day 11 after tumor transplantation measured on day 17",Other,22515366.0,
4396,673031,1,3,,123097261,31703,Unspecified,,,,,"Nephrotoxicity in C57BL/6 mouse xenografted with mouse LLC cells at 13.7 umol/kg, iv administered on day 4 and day 11 after tumor transplantation measured on day 17 by hematoxylin eosin staining method",Other,22515366.0,
4397,673336,2,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4398,673337,2,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4399,673338,2,2,,123097261,31703,Active,,,3.4,IC50,Cytotoxicity against human U2OS cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4400,673339,2,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4401,673340,2,3,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4402,673342,2,2,,123097261,31703,Active,,,2.1,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,22749279.0,
4403,673596,1,3,,123097261,31703,Active,,,6.4,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,22766218.0,
4404,674242,2,2,,123097261,31703,Active,,,8.46,IC50,Cytotoxicity against human PC3 cells after 24 hrs by MTT assay,Confirmatory,22687747.0,
4405,674243,2,2,,123097261,31703,Active,,,13.24,IC50,Cytotoxicity against human DU145 cells after 24 hrs by MTT assay,Confirmatory,22687747.0,
4406,674244,2,2,,123097261,31703,Active,,,3.79,IC50,Cytotoxicity against human K562 cells after 24 hrs by MTT assay,Confirmatory,22687747.0,
4407,674245,2,2,,123097261,31703,Active,,,1.37,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,22687747.0,
4408,674694,2,2,,123097261,31703,Active,,,8.62,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4409,674695,2,2,,123097261,31703,Active,,,2.76,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4410,674696,2,2,,123097261,31703,Active,,,19.01,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4411,674697,2,2,,123097261,31703,Active,,,10.86,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4412,674698,2,2,,123097261,31703,Active,,,20.93,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4413,674699,2,2,,123097261,31703,Active,,,10.53,IC50,Cytotoxicity against human OVCAR3 cells after 48 hrs by MTT assay,Confirmatory,22818039.0,
4414,674865,2,2,,123097261,31703,Active,,,1.82,IC50,Cytotoxicity against human T47D cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
4415,674866,2,2,,123097261,31703,Active,,,1.76,IC50,Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
4416,674867,2,2,,123097261,31703,Active,,,1.57,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
4417,674868,2,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
4418,675416,2,2,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22889559.0,
4419,676169,2,3,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay,Confirmatory,22616554.0,
4420,676386,2,3,,123097261,31703,Active,,,4.6,IC50,Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay,Confirmatory,22616554.0,
4421,677865,2,2,,123097261,31703,Active,,,2.14,IC50,Cytotoxicity against human CCRF-CEM cells by XTT assay,Confirmatory,22663190.0,
4422,678019,4,1,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,22858298.0,
4423,678020,4,1,,123097261,31703,Active,,,0.013999999999999999,IC50,Cytotoxicity against human K562 cells after 48 hrs by SRB assay,Confirmatory,22858298.0,
4424,678021,4,1,,123097261,31703,Active,,,0.005,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay,Confirmatory,22858298.0,
4425,678022,4,2,,123097261,31703,Active,,,0.0067,IC50,Cytotoxicity against human SKLU1 cells after 48 hrs by SRB assay,Confirmatory,22858298.0,
4426,678061,2,2,,123097261,31703,Active,,,4.7,LC50,Cytotoxicity against human K562 cells,Confirmatory,22742761.0,
4427,678062,2,2,,123097261,31703,Active,,,1.7,LC50,Cytotoxicity against human A549 cells,Confirmatory,22742761.0,
4428,678712,1,8,,123097261,31703,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
4429,678713,1,8,,123097261,31703,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
4430,678714,1,8,,123097261,31703,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
4431,678715,1,8,,123097261,31703,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
4432,678716,1,8,,123097261,31703,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
4433,678717,1,8,,123097261,31703,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
4434,678719,1,5,,123097261,31703,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
4435,678722,1,5,,123097261,31703,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
4436,678783,1,8,,123097261,31703,Unspecified,269849624.0,368.0,,,TP_TRANSPORTER: drug resistance in MRP6-expressing CHO cells,Other,12414644.0,
4437,678804,1,8,,123097261,31703,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells,Other,11437380.0,
4438,678906,1,8,,123097261,31703,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in blood-brain coefficient in mdr1a(-/-) mouse,Other,11405289.0,
4439,679011,3,6,,123097261,31703,Unspecified,296439301.0,4363.0,50.0,IC50,TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells,Confirmatory,8621644.0,
4440,679012,1,8,,123097261,31703,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing NIH/3T3 cells,Other,12765240.0,
4441,679092,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Doxorubicin at a concentration of 10 uM in MDR1-expressing MDCK cells,Other,12948019.0,
4442,679093,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Doxorubicin at a concentration of 10 uM in Caco-2 cells,Other,12948019.0,
4443,679152,1,8,,123097261,31703,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: drug resistance in Mrp1-expressing HEK293 cells,Other,9281595.0,
4444,679351,1,8,,123097261,31703,Unspecified,74756298.0,89845.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, Doxorubicin: 30 uM) in membrane vesicles from MRP7-expressing HEK293 cells",Other,12527806.0,
4445,679468,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: drug resistance in R-HepG2 cells,Other,15211078.0,
4446,679469,2,7,,123097261,31703,Unspecified,238054374.0,5243.0,3.0,Km,TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes,Confirmatory,1356264.0,
4447,679992,1,8,,123097261,31703,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells,Other,9281595.0,
4448,680080,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 uM, Doxorubicin: 400 uM) in membranes from MDR1-expressing LLC-PK1 cells",Other,10746169.0,
4449,680121,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,9914792.0,
4450,680427,1,7,,123097261,31703,Unspecified,74761045.0,,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, DOX;G: 300 uM) in membrane vesicles from MRP3-expressing HEK293 cells",Other,11585759.0,
4451,680994,1,8,,123097261,31703,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: inhibition of E1S uptake by Doxorubicin at a concentration of 1000uM in membrane vesicles from ABCG2-expressing P388 cells,Other,12682043.0,
4452,681064,1,8,,123097261,31703,Unspecified,1170902.0,24646.0,,,"TP_TRANSPORTER: Northern blot in vitro, nonparenchymal ral liver epithelial cells",Other,9210482.0,
4453,681148,1,7,,123097261,31703,Unspecified,262527527.0,8647.0,,,TP_TRANSPORTER: inhibitory effect of typical BSEP inhibitors (Verapamil & Cyclosporin A) in SK-E2 cells (expressing BSEP),Other,12739759.0,
4454,681170,1,8,,123097261,31703,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells,Other,12867490.0,
4455,681383,3,6,,123097261,31703,Unspecified,238054374.0,5243.0,8.5,Ki,TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,11405287.0,
4456,681489,1,7,,123097261,31703,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vitro, nonparenchymal ral liver epithelial cells",Other,9210482.0,
4457,681563,1,8,,123097261,31703,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells,Other,12488537.0,
4458,681572,1,8,,123097261,31703,Unspecified,68052328.0,26357.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells,Other,12649196.0,
4459,681609,1,8,,123097261,31703,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing PEAKSTABEL cells,Other,12657726.0,
4460,681616,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: drug resistance in MDR1-expressing MCF7 cells,Other,12608535.0,
4461,681617,1,8,,123097261,31703,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: drug resistance in MCF-7/Dox cells,Other,14499271.0,
4462,682250,1,8,,123097261,31703,Unspecified,7387886.0,81642.0,,,"TP_TRANSPORTER: inhibition of photolabeling by IAARh123 (IAARh123: 1 uM, DOX: 1000 uM) in membranes from Mrp6-expressing P. pastoris",Other,12069597.0,
4463,682338,1,3,,123097261,31703,Active,,,0.0054,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay,Confirmatory,23085106.0,
4464,682362,2,2,,123097261,31703,Active,,,0.037000000000000005,IC50,Cytotoxicity against human CCRF-CEM cells by CCK-8 assay,Confirmatory,22884578.0,
4465,682363,2,2,,123097261,31703,Unspecified,,,5.2,IC50,Cytotoxicity against human CEM/ADR5000 by CCK-8 assay,Confirmatory,22884578.0,
4466,682364,1,3,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human CEM/ADR5000 cells to IC50 for human CCRF-CEM cells,Other,22884578.0,
4467,683344,2,3,,123097261,31703,Active,,,8.6,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
4468,683345,2,3,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
4469,683346,2,3,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay,Confirmatory,24900509.0,
4470,683399,1,3,,123097261,31703,Unspecified,238054374.0,5243.0,,,Inhibition of P-gp over expressed in human multidrug-resistant KBVIN cells assessed as intracellular accumulation of doxorubicin at 10uM after 3 hrs by fluorescence microplate reader analysis relative to control,Other,22612652.0,
4471,683854,2,2,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4472,683855,2,3,,123097261,31703,Active,,,5.27,IC50,Antiproliferative activity against human LoVo/DX cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4473,683856,1,3,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,22944121.0,
4474,683857,2,3,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4475,683858,2,3,,123097261,31703,Active,,,0.25,IC50,Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4476,683859,1,2,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human MESSA/DX5 cells to IC50 for human MESSA cells",Other,22944121.0,
4477,683860,2,2,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4478,683861,2,3,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
4479,684426,2,2,,123097261,31703,Active,,,0.001,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,22951040.0,
4480,684427,2,2,,123097261,31703,Active,,,0.004,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,22951040.0,
4481,684428,2,2,,123097261,31703,Active,,,0.004,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,22951040.0,
4482,684429,2,2,,123097261,31703,Active,,,0.08199999999999999,IC50,Cytotoxicity against human HCT15 cells by SRB assay,Confirmatory,22951040.0,
4483,685162,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4484,685163,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4485,685164,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human THP1 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4486,685165,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human IMR32 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4487,685166,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4488,685167,1,4,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4489,685168,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PC3 cells after 48 hrs assessed as inhibition of cell growth at 10 uM after 48 hrs by SRB assay relative to control,Other,22982122.0,
4490,685500,2,2,,123097261,31703,Active,,,11.1,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
4491,685501,2,2,,123097261,31703,Active,,,0.8859999999999999,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
4492,685503,2,2,,123097261,31703,Active,,,0.057999999999999996,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection,Confirmatory,22586124.0,
4493,686947,2,2,,124886893,31703,Inactive,4885661.0,7525.0,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
4494,686950,1,1,,124886893,31703,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
4495,686977,2,1,,49698493,31703,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
4496,687157,2,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
4497,687158,4,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
4498,687159,4,1,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
4499,687160,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells,Other,22582991.0,
4500,687161,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells,Other,22582991.0,
4501,687162,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
4502,687163,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
4503,687164,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells,Other,22582991.0,
4504,687165,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells,Other,22582991.0,
4505,687166,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
4506,687167,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
4507,687168,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
4508,689079,2,2,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,22946634.0,
4509,689080,2,2,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human Caco2 cells by MTT assay,Confirmatory,22946634.0,
4510,689834,2,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human SKOV3 cells after 72 hrs by WST8 assay,Confirmatory,23039861.0,
4511,689835,2,3,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human MG63 cells by MTT colorimetric method,Confirmatory,23043498.0,
4512,689836,2,2,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human LoVo cells by MTT colorimetric method,Confirmatory,23043498.0,
4513,689837,2,2,,123097261,31703,Active,,,2.7,IC50,Cytotoxicity against human A549 cells by MTT colorimetric method,Confirmatory,23043498.0,
4514,690481,1,2,,123097261,31703,Active,,,,,"Antitumor activity against human SK-MEL-2 cells xenografted in athymic nu/nu Harlan mouse assessed as tumor growth inhibition at 8 mg/kg, ip administered Q4D for 3 days relative to control",Other,22578073.0,
4515,693238,1,3,,123097261,31703,Unspecified,,,,,Growth inhibition of human MGC803 cells at 10 uM after 72 hrs by MTT assay,Other,23124210.0,
4516,693239,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human Bcap37 cells at 10 uM after 72 hrs by MTT assay,Other,23124210.0,
4517,693240,1,4,,123097261,31703,Unspecified,,,,,Growth inhibition of mouse NIH/3T3 cells at 10 uM after 72 hrs by MTT assay,Other,23124210.0,
4518,693241,2,4,,123097261,31703,Active,,,0.7,IC50,Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,23124210.0,
4519,693242,2,2,,123097261,31703,Active,,,1.28,IC50,Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay,Confirmatory,23124210.0,
4520,695925,2,2,,123097261,31703,Unspecified,,,52.0,IC50,Inhibition of HIV-1 reverse transcriptase using Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay,Confirmatory,22695131.0,
4521,696910,4,1,,123097261,31703,Unspecified,,,5.0,GI50,Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay,Confirmatory,21348461.0,
4522,696915,4,2,,123097261,31703,Unspecified,,,5.0,GI50,Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay,Confirmatory,21348461.0,
4523,696929,1,2,,123097261,31703,Unspecified,,,,,Induction of DNA damage in human HCT15 cells assessed as H2AX phosphorylation after 4 hrs by Western blot analysis,Other,21348461.0,
4524,697006,1,3,,123097261,31703,Unspecified,,,,,Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay relative to control,Other,21348461.0,
4525,697145,2,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay,Confirmatory,23148652.0,
4526,697148,2,2,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human KB cells after 72 hrs by MTS assay,Confirmatory,23148652.0,
4527,699539,1,7,,123097261,31703,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
4528,699540,1,7,,123097261,31703,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
4529,699541,1,7,,123097261,31703,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
4530,699542,2,7,,123097261,31703,Unspecified,12643959.0,10599.0,,IC50,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting,Confirmatory,22541068.0,
4531,699543,2,7,,123097261,31703,Active,27734563.0,28234.0,,IC50,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
4532,699544,2,7,,123097261,31703,Unspecified,313104012.0,11309.0,,IC50,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
4533,701951,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human T98G cells assessed as inhibition of cell growth at 1 uM by MTT assay,Other,22916727.0,
4534,703575,1,2,,123097261,31703,Inactive,,,,,Binding affinity to bovine bone matrix at pH 6 at 300 uM after 4 hrs by spectrophotometric analysis,Other,22882004.0,
4535,703576,1,2,,123097261,31703,Inactive,,,,,Binding affinity to bovine bone matrix at pH 7.4 at 300 uM after 4 hrs by spectrophotometric analysis,Other,22882004.0,
4536,703577,1,2,,123097261,31703,Unspecified,,,,,Toxicity in iv dosed Balb/c nude mouse administered as doxorubicin equivalents once a week for 3 weeks,Other,22882004.0,
4537,703591,1,2,,123097261,31703,Inactive,,,,,Binding affinity to bone mineral hydroxyapatite at pH 7.4 at 300 uM by photometric analysis,Other,22882004.0,
4538,703593,1,2,,123097261,31703,Inactive,,,,,Binding affinity to bone mineral hydroxyapatite at pH 6 at 300 uM by photometric analysis,Other,22882004.0,
4539,704293,2,2,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
4540,704294,2,2,,123097261,31703,Active,,,1.03,IC50,Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
4541,704295,2,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
4542,704296,2,2,,123097261,31703,Active,,,1.34,IC50,Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
4543,704301,1,7,,123097261,31703,Unspecified,113600.0,10327.0,,,Activity of human AKR1A1 expressed in Escherichia coli BL21 assessed per mg protein in presence of 0.2 mM NADPH,Other,22982121.0,
4544,704302,2,8,,123097261,31703,Unspecified,118519.0,873.0,,Km,Activity of human recombinant His6-tagged carbonyl reductase 1 expressed in Escherichia coli BL21(DE3) using menadione as substrate by Michaelis-Menten plot analysis,Confirmatory,22982121.0,
4545,704303,2,4,,123097261,31703,Unspecified,,,247.0,Km,Activity of GST-tagged aldo-keto reductase 1A1,Confirmatory,22982121.0,
4546,704304,2,5,,123097261,31703,Unspecified,,,,Km,Activity of His-tagged carbonyl reductase 1,Confirmatory,22982121.0,
4547,704305,2,8,,123097261,31703,Unspecified,118519.0,873.0,,Km,Activity of human carbonyl reductase 1,Confirmatory,22982121.0,
4548,707305,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in human A549 cells expressing wild type p53 xenografted nude BALB/C mouse assessed as reduction of body weight at 10 mg/kg, iv",Other,23046248.0,
4549,708917,1,2,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay,Confirmatory,23072299.0,
4550,708918,1,2,,123097261,31703,Active,,,0.022000000000000002,IC50,Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay,Confirmatory,23072299.0,
4551,708919,1,3,,123097261,31703,Active,,,0.99,IC50,Cytotoxicity against human HL60R cells overexpressing Pgp incubated for 72 hrs by MTS assay,Confirmatory,23072299.0,
4552,708920,1,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay,Confirmatory,23072299.0,
4553,711683,1,7,,123097261,31703,Inactive,6920069.0,8714.0,,,Inhibition of MRP3 in doxorubicin-resistant human HT-29 cells assessed as nitration of tyrosine residues at 5 uM after 24 hrs by Western blot analysis,Other,24900337.0,
4554,711684,1,3,,123097261,31703,Inactive,,,,,Induction of nitrite production in doxorubicin-resistant human HT-29 cells at 5 uM after 1 to 24 hrs by Griess method,Other,24900337.0,
4555,711689,1,7,,123097261,31703,Unspecified,6920069.0,8714.0,,,Inhibition of MRP3-mediated drug resistance in doxorubicin-resistant human HT-29 cells assessed as drug efflux rate measured per mg of protein at 1 to 200 uM after 10 mins by spectrofluorometric analysis,Other,24900337.0,
4556,711690,1,7,,123097261,31703,Inactive,6920069.0,8714.0,,,Inhibition of MRP3-mediated drug resistance in doxorubicin-resistant human HT-29 cells assessed as increase in drug accumulation at 5 uM after 1 to 24 hrs by spectrofluorometric analysis,Other,24900337.0,
4557,711695,1,7,,123097261,31703,Active,6920069.0,8714.0,,,Inhibition of MRP3-mediated drug resistance in doxorubicin-resistant human HT-29 cells assessed as increase in drug accumulation at 25 uM after 24 hrs by spectrofluorometric analysis,Other,24900337.0,
4558,711696,1,7,,123097261,31703,Inactive,6920069.0,8714.0,,,Inhibition of MRP3-mediated drug resistance in doxorubicin-resistant human HT-29 cells assessed as increase in drug accumulation at 0.5 to 5 uM after 24 hrs by spectrofluorometric analysis,Other,24900337.0,
4559,713092,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human leukemia stem/progenitor cells assessed as viable CD34+ cells at 0.1 uM after 18 hrs by annexin-V labeling-based flow cytometry,Other,22985027.0,
4560,713300,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human leukemia stem/progenitor cells assessed as cell viability at 0.5 uM after 18 hrs by annexin-V labeling-based flow cytometry,Other,22985027.0,
4561,713317,1,3,,123097261,31703,Unspecified,,,,,"Antitumor activity against human leukemia stem/progenitor cells xenografted in NOD/SCID mouse assessed as survival time at 1 mg/kg, po qd administered every other day total of four doses starting from 8 weeks post grafting (Rvb = 43 days)",Other,22985027.0,
4562,713345,1,2,,123097261,31703,Unspecified,,,,,Reduction in colony forming units of leukemia stem/progenitor cells at 0.1 uM after 15 to 20 days,Other,22985027.0,
4563,713346,1,2,,123097261,31703,Unspecified,,,,,Reduction in colony forming units of leukemia stem/progenitor cells at 0.05 uM after 15 to 20 days,Other,22985027.0,
4564,713356,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human HL60/A cells to IC50 for human HL60 cells,Other,22985027.0,
4565,713357,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human leukemia stem/progenitor cells assessed as viable CD34+ cells at 0.5 uM after 18 hrs by annexin-V labeling-based flow cytometry,Other,22985027.0,
4566,713358,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against human leukemia stem/progenitor cells assessed as cell viability at 0.1 uM after 18 hrs by annexin-V labeling-based flow cytometry,Other,22985027.0,
4567,713583,2,3,,123097261,31703,Active,,,6.7,IC50,Cytotoxicity against human HL60/A cells after 18 hrs by annexin-V labeling-based flow cytometry,Confirmatory,22985027.0,
4568,713584,2,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry,Confirmatory,22985027.0,
4569,717118,1,2,,123097261,31703,Unspecified,,,,,Resistance ratio of IC50 for human doxorubicin-resistant LoVo/DX cells overexpressing P-glycoprotein to IC50 for human LoVo cells,Other,23117171.0,
4570,717149,1,2,,123097261,31703,Active,,,13.15,IC50,Antiproliferative activity against human doxorubicin-resistant LoVo/DX cells overexpressing P-glycoprotein after 72 hrs by MTT assay,Confirmatory,23117171.0,
4571,717150,1,2,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay,Confirmatory,23117171.0,
4572,717344,2,2,,123097261,31703,Active,,,1.7,LC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23145909.0,
4573,717345,2,2,,123097261,31703,Active,,,4.7,LC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,23145909.0,
4574,718230,1,2,,123097261,31703,Unspecified,,,,,Downregulation of uPA protein expression in human MCF7 cell extract at 0.60 uM after 48 hrs by ELISA (Rvb = 1 1.4000 +/- 1.40 ng/ml),Other,23123017.0,
4575,718231,1,2,,123097261,31703,Unspecified,,,,,Downregulation of uPA protein expression in human MCF7 cell extract at 0.30 uM after 48 hrs by ELISA (Rvb = 1 1.4000 +/- 1.40 ng/ml),Other,23123017.0,
4576,718232,1,2,,123097261,31703,Unspecified,,,,,Downregulation of uPA protein expression in human MCF7 cell extract at 0.15 uM after 48 hrs by ELISA (Rvb = 1 1.4000 +/- 1.40 ng/ml),Other,23123017.0,
4577,718233,1,2,,123097261,31703,Unspecified,,,,,Downregulation of uPA protein expression in human MCF7 cell extract at 0.075 uM after 48 hrs by ELISA (Rvb = 1 1.4000 +/- 1.40 ng/ml),Other,23123017.0,
4578,718399,2,2,,123097261,31703,Active,,,0.629,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23123017.0,
4579,719326,1,2,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 doxorubicin-resistant human LoVo/DX cells",Other,23079523.0,
4580,719327,1,2,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,23079523.0,
4581,719328,1,2,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human vincristine-resistant human HL60/Vinc cells",Other,23079523.0,
4582,719329,2,2,,123097261,31703,Active,,,1.91,IC50,Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay,Confirmatory,23079523.0,
4583,719330,1,2,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60 cells",Other,23079523.0,
4584,719331,1,2,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for doxorubicin-resistant human LoVo/DX cells to IC50 for parental human LoVo cells",Other,23079523.0,
4585,719332,2,3,,123097261,31703,Active,,,12.14,IC50,Cytotoxicity against doxorubicin-resistant human LoVo/DX cells incubated for 72 hrs by MTT assay,Confirmatory,23079523.0,
4586,719333,1,2,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for vincristine-resistant human HL60/Vinc cells to IC50 for parental human HL60 cells",Other,23079523.0,
4587,719334,2,2,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay,Confirmatory,23079523.0,
4588,719335,2,3,,123097261,31703,Active,,,0.91,IC50,Cytotoxicity against vincristine-resistant human HL60/Vinc cells incubated for 72 hrs by MTT assay,Confirmatory,23079523.0,
4589,719336,2,2,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay,Confirmatory,23079523.0,
4590,719342,2,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,23079527.0,
4591,719343,2,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,23079527.0,
4592,719344,2,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,23079527.0,
4593,719345,2,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,23079527.0,
4594,719694,2,7,,123097261,31703,Unspecified,117289.0,25413.0,100.0,IC50,Inhibition of rat CPT2 in rat mitochondria,Confirmatory,21504156.0,
4595,719696,2,7,,123097261,31703,Unspecified,146345405.0,25757.0,250.0,IC50,Inhibition of rat CPT1 in rat mitochondria,Confirmatory,21504156.0,
4596,720532,1,1,,124886887,31703,Active,420597.0,,0.2818,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
4597,720533,1,1,,124886887,31703,Inconclusive,,,0.3548,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
4598,720641,1,2,,92308822,31703,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
4599,720717,1,3,,92308822,31703,Active,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
4600,721446,1,2,,123097261,31703,Active,,,23.94,IC50,Cytotoxicity against african geen monkey Vero cells after 4 days by GFP reporter assay,Confirmatory,23313636.0,
4601,721447,1,4,,123097261,31703,Active,,,0.96,IC50,Cytotoxicity against human KB cells after 3 days by resazurin microplate assay,Confirmatory,23313636.0,
4602,722215,1,2,,123097261,31703,Active,,,2.84,IC50,Cytotoxicity against human doxorubicin-resistant K562 cells after 72 hrs by MTT assay,Confirmatory,23245571.0,
4603,722216,1,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,23245571.0,
4604,723080,1,2,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23218718.0,
4605,723081,1,3,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human MOLT4 cells after 48 hrs by MTT assay,Confirmatory,23218718.0,
4606,723082,1,4,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,23218718.0,
4607,723083,1,3,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,23218718.0,
4608,723084,1,3,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,23218718.0,
4609,724093,1,2,,123097261,31703,Unspecified,,,85.46,IC50,Cytotoxicity against human adriamycin-resistant HepG2 cells measured after 48 hrs by MTT assay,Confirmatory,23290052.0,
4610,724094,1,3,,123097261,31703,Active,,,0.29,IC50,Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay,Confirmatory,23290052.0,
4611,724095,1,2,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay,Confirmatory,23290052.0,
4612,726301,1,3,,123097261,31703,Active,,,0.63,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23291120.0,
4613,728266,3,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay,Confirmatory,23470139.0,
4614,729774,1,2,,123097261,31703,Unspecified,,,,,"Resistance factor, ratio of IC50 for human MES-SA/Dx5 cells to IC50 for human MES-SA cells",Other,23360284.0,
4615,729776,1,3,,123097261,31703,Active,,,2.3,IC50,Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay,Confirmatory,23360284.0,
4616,729777,3,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human KB-VIN10 cells after 72 hrs by SRB assay,Confirmatory,23360284.0,
4617,729778,1,3,,123097261,31703,Active,,,0.038,IC50,Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay,Confirmatory,23360284.0,
4618,729780,3,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,23360284.0,
4619,730257,3,1,,123097261,31703,Active,,,0.161,IC50,Antiproliferative activity against mouse L929 cells assessed as inhibition of cell viability after 72 hrs by XTT assay,Confirmatory,23360521.0,
4620,730637,1,3,,123097261,31703,Active,,,2.0,IC50,Antiproliferative activity against rat AT6-1 cells assessed as inhibition of cell viability after 72 hrs by XTT assay,Confirmatory,23360521.0,
4621,730638,3,1,,123097261,31703,Active,,,0.09300000000000001,IC50,Antiproliferative activity against rat OSRGA cells assessed as inhibition of cell viability after 72 hrs by XTT assay,Confirmatory,23360521.0,
4622,730639,3,2,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against human KB cells assessed as inhibition of cell viability after 72 hrs by MTT assay,Confirmatory,23360521.0,
4623,730640,3,1,,123097261,31703,Active,,,0.043,IC50,Antiproliferative activity against mouse POS1 cells assessed as inhibition of cell viability after 72 hrs by XTT assay,Confirmatory,23360521.0,
4624,731391,1,3,,123097261,31703,Active,,,,,Cellular uptake in mouse DA-3 cell mitochondria at 10 uM after 10 hrs by mitotracker red staining-based confocal microscopic analysis,Other,24900668.0,
4625,731392,1,3,,123097261,31703,Active,,,,,Cellular uptake in mouse DA-3 cell lysosome at 10 uM after 10 hrs by LysoTracker green staining-based confocal microscopic analysis,Other,24900668.0,
4626,731393,1,3,,123097261,31703,Active,,,,,Cellular uptake in mouse DA-3 cell nucleus at 10 uM after 10 hrs by DRAQ5 deep red staining-based confocal microscopic analysis,Other,24900668.0,
4627,731399,1,2,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human MDA-MB-231 cells under hypoxic condition to IC50 for human MDA-MB-231 cells under normoxic condition,Other,23168081.0,
4628,731870,1,3,,123097261,31703,Unspecified,,,,,Cellular uptake in mouse DA-3 cell lysosome at 10 uM after 30 mins by LysoTracker green staining-based confocal microscopic analysis relative to control,Other,24900668.0,
4629,731871,1,3,,123097261,31703,Inactive,,,,,Cellular uptake in mouse DA-3 cell mitochondria at 10 uM after 30 mins by mitotracker red staining-based confocal microscopic analysis,Other,24900668.0,
4630,731872,1,3,,123097261,31703,Unspecified,,,,,Cellular uptake in mouse DA-3 cell nucleus at 10 uM after 30 mins by DRAQ5 deep red staining-based confocal microscopic analysis relative to control,Other,24900668.0,
4631,731873,1,3,,123097261,31703,Unspecified,,,,,Ratio of idarubicin IC50 to compound IC50 for displacement of YOYO1 from phage lambda DNA,Other,24900668.0,
4632,731876,1,3,,123097261,31703,Active,,,0.73,IC50,Displacement of SYBR from phage lambda DNA by FID assay,Confirmatory,24900668.0,
4633,731877,1,3,,123097261,31703,Active,,,0.6,IC50,Displacement of YOYO1 from phage lambda DNA by FID assay,Confirmatory,24900668.0,
4634,731880,1,3,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 6 hrs by XTT assay relative to control,Other,24900668.0,
4635,731881,1,3,,123097261,31703,Inactive,,,,,Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 180 mins by XTT assay relative to control,Other,24900668.0,
4636,731882,1,3,,123097261,31703,Unspecified,,,60.0,IC50,Cytotoxicity against human ES2 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
4637,731883,1,3,,123097261,31703,Active,,,4.0,IC50,Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
4638,731884,1,4,,123097261,31703,Unspecified,,,55.7,IC50,Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
4639,731885,1,3,,123097261,31703,Unspecified,,,60.0,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
4640,735342,1,4,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against human KB cells by resazurin assay,Confirmatory,23806072.0,
4641,735359,1,2,,123097261,31703,Active,,,0.049,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,23544451.0,
4642,735360,1,2,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,23544451.0,
4643,735529,1,3,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human WHCO1 cells after 24 hrs by MTT assay,Confirmatory,23353747.0,
4644,737105,1,2,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,23445496.0,
4645,737106,1,3,,123097261,31703,Active,,,11.296,IC50,Cytotoxicity against human LoVo/DX cells after 72 hrs by MTT assay,Confirmatory,23445496.0,
4646,737107,1,2,,123097261,31703,Active,,,0.0956,IC50,Cytotoxicity against human LoVo cells after 72 hrs by MTT assay,Confirmatory,23445496.0,
4647,738206,1,2,,123097261,31703,Unspecified,,,9.2,IC50,Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4648,738207,1,2,,123097261,31703,Active,,,1.6,IC50,Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4649,738208,1,2,,123097261,31703,Active,,,3.9,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4650,738209,1,2,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4651,738210,1,3,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4652,738211,1,3,,123097261,31703,Active,,,3.7,IC50,Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4653,738212,1,4,,123097261,31703,Active,,,3.8,IC50,Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4654,738213,1,3,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay,Confirmatory,23547843.0,
4655,739905,1,3,,123097261,31703,Active,,,1.33,IC50,Cytotoxicity against human BGC823 cells by MTT assay,Confirmatory,23434227.0,
4656,739906,1,2,,123097261,31703,Active,,,0.54,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,23434227.0,
4657,739907,1,2,,123097261,31703,Active,,,1.65,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,23434227.0,
4658,739908,1,3,,123097261,31703,Active,,,0.68,IC50,Cytotoxicity against human PC3 cells by MTT assay,Confirmatory,23434227.0,
4659,741697,1,3,,123097261,31703,Active,,,0.5564899999999999,IC50,SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,Confirmatory,,
4660,741698,1,3,,123097261,31703,Active,,,1.71733,IC50,SANGER: Inhibition of human NCI-H1573 cell growth in a cell viability assay.,Confirmatory,,
4661,741699,1,3,,123097261,31703,Active,,,0.98131,IC50,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,Confirmatory,,
4662,741700,1,3,,123097261,31703,Active,,,0.10435,IC50,SANGER: Inhibition of human NCI-H1618 cell growth in a cell viability assay.,Confirmatory,,
4663,741701,1,3,,123097261,31703,Active,,,0.6046,IC50,SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.,Confirmatory,,
4664,741702,1,3,,123097261,31703,Active,,,0.13194,IC50,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,Confirmatory,,
4665,741703,1,3,,123097261,31703,Active,,,0.07862000000000001,IC50,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,Confirmatory,,
4666,741704,1,3,,123097261,31703,Active,,,0.01183,IC50,SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.,Confirmatory,,
4667,741706,1,3,,123097261,31703,Active,,,0.29031999999999997,IC50,SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.,Confirmatory,,
4668,741707,1,3,,123097261,31703,Active,,,0.20026,IC50,SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.,Confirmatory,,
4669,741708,1,3,,123097261,31703,Active,,,0.12642,IC50,SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,Confirmatory,,
4670,741709,1,3,,123097261,31703,Active,,,0.053,IC50,SANGER: Inhibition of human NCI-H1734 cell growth in a cell viability assay.,Confirmatory,,
4671,741710,1,3,,123097261,31703,Active,,,0.8735200000000001,IC50,SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.,Confirmatory,,
4672,741711,1,3,,123097261,31703,Active,,,0.13321,IC50,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,Confirmatory,,
4673,741712,1,3,,123097261,31703,Active,,,0.57243,IC50,SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,Confirmatory,,
4674,741713,1,3,,123097261,31703,Active,,,0.9008700000000001,IC50,SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.,Confirmatory,,
4675,741714,1,3,,123097261,31703,Active,,,0.40505,IC50,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,Confirmatory,,
4676,741715,1,3,,123097261,31703,Active,,,0.49321000000000004,IC50,SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.,Confirmatory,,
4677,741716,1,3,,123097261,31703,Active,,,0.215,IC50,SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.,Confirmatory,,
4678,741717,1,3,,123097261,31703,Active,,,0.43011000000000005,IC50,SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.,Confirmatory,,
4679,741719,1,3,,123097261,31703,Active,,,1.00076,IC50,SANGER: Inhibition of human NCI-H1993 cell growth in a cell viability assay.,Confirmatory,,
4680,741720,1,3,,123097261,31703,Active,,,0.05176,IC50,SANGER: Inhibition of human NCI-H2009 cell growth in a cell viability assay.,Confirmatory,,
4681,741722,1,3,,123097261,31703,Active,,,0.028260000000000004,IC50,SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,Confirmatory,,
4682,741723,1,3,,123097261,31703,Active,,,0.16047,IC50,SANGER: Inhibition of human NCI-H2052 cell growth in a cell viability assay.,Confirmatory,,
4683,741724,1,3,,123097261,31703,Active,,,0.23426999999999998,IC50,SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.,Confirmatory,,
4684,741725,1,3,,123097261,31703,Active,,,0.04942,IC50,SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,Confirmatory,,
4685,741726,1,3,,123097261,31703,Active,,,0.04873,IC50,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,Confirmatory,,
4686,741728,1,3,,123097261,31703,Active,,,0.0379,IC50,SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,Confirmatory,,
4687,741729,1,3,,123097261,31703,Active,,,0.1922,IC50,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,Confirmatory,,
4688,741730,1,3,,123097261,31703,Active,,,0.5736899999999999,IC50,SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.,Confirmatory,,
4689,741731,1,3,,123097261,31703,Active,,,0.10992,IC50,SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,Confirmatory,,
4690,741732,1,3,,123097261,31703,Active,,,0.44067,IC50,SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.,Confirmatory,,
4691,741733,1,3,,123097261,31703,Active,,,0.22915,IC50,SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.,Confirmatory,,
4692,741734,1,3,,123097261,31703,Active,,,5.36231,IC50,SANGER: Inhibition of human NCI-H2227 cell growth in a cell viability assay.,Confirmatory,,
4693,741735,1,3,,123097261,31703,Active,,,0.01348,IC50,SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,Confirmatory,,
4694,741736,1,3,,123097261,31703,Active,,,0.41663999999999995,IC50,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,Confirmatory,,
4695,741738,1,3,,123097261,31703,Active,,,0.28392,IC50,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,Confirmatory,,
4696,741739,1,3,,123097261,31703,Active,,,0.02291,IC50,SANGER: Inhibition of human NCI-H2342 cell growth in a cell viability assay.,Confirmatory,,
4697,741740,1,3,,123097261,31703,Active,,,0.15834,IC50,SANGER: Inhibition of human NCI-H2347 cell growth in a cell viability assay.,Confirmatory,,
4698,741741,1,3,,123097261,31703,Active,,,0.2341,IC50,SANGER: Inhibition of human NCI-H2405 cell growth in a cell viability assay.,Confirmatory,,
4699,741742,1,3,,123097261,31703,Active,,,1.37129,IC50,SANGER: Inhibition of human NCI-H2452 cell growth in a cell viability assay.,Confirmatory,,
4700,741744,1,3,,123097261,31703,Active,,,1.74078,IC50,SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,Confirmatory,,
4701,741745,1,3,,123097261,31703,Active,,,0.04376,IC50,SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,Confirmatory,,
4702,741746,1,3,,123097261,31703,Unspecified,,,194.396,IC50,SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.,Confirmatory,,
4703,741747,1,3,,123097261,31703,Active,,,4.0117400000000005,IC50,SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.,Confirmatory,,
4704,741748,1,3,,123097261,31703,Active,,,0.04108,IC50,SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,Confirmatory,,
4705,741750,1,3,,123097261,31703,Active,,,0.028419999999999997,IC50,SANGER: Inhibition of human NCI-H441 cell growth in a cell viability assay.,Confirmatory,,
4706,741751,1,3,,123097261,31703,Active,,,1.33771,IC50,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,Confirmatory,,
4707,741752,1,3,,123097261,31703,Active,,,0.0127,IC50,SANGER: Inhibition of human NCI-H460 cell growth in a cell viability assay.,Confirmatory,,
4708,741753,1,3,,123097261,31703,Active,,,0.35959,IC50,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,Confirmatory,,
4709,741754,1,3,,123097261,31703,Active,,,0.26661,IC50,SANGER: Inhibition of human NCI-H520 cell growth in a cell viability assay.,Confirmatory,,
4710,741755,1,3,,123097261,31703,Active,,,0.05193,IC50,SANGER: Inhibition of human NCI-H522 cell growth in a cell viability assay.,Confirmatory,,
4711,741756,1,3,,123097261,31703,Active,,,48.8248,IC50,SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.,Confirmatory,,
4712,741757,1,3,,123097261,31703,Active,,,0.049960000000000004,IC50,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,Confirmatory,,
4713,741758,1,3,,123097261,31703,Active,,,0.10801,IC50,SANGER: Inhibition of human NCI-H596 cell growth in a cell viability assay.,Confirmatory,,
4714,741760,1,3,,123097261,31703,Active,,,0.13265,IC50,SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.,Confirmatory,,
4715,741761,1,3,,123097261,31703,Active,,,0.21761,IC50,SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,Confirmatory,,
4716,741762,1,3,,123097261,31703,Active,,,0.049030000000000004,IC50,SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,Confirmatory,,
4717,741763,1,3,,123097261,31703,Active,,,0.5688,IC50,SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,Confirmatory,,
4718,741764,1,3,,123097261,31703,Unspecified,,,69.5111,IC50,SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.,Confirmatory,,
4719,741765,1,3,,123097261,31703,Active,,,0.03965,IC50,SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.,Confirmatory,,
4720,741766,1,3,,123097261,31703,Active,,,41.9726,IC50,SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.,Confirmatory,,
4721,741767,1,3,,123097261,31703,Active,,,0.02279,IC50,SANGER: Inhibition of human NCI-H727 cell growth in a cell viability assay.,Confirmatory,,
4722,741768,1,3,,123097261,31703,Active,,,0.13502,IC50,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,Confirmatory,,
4723,741769,1,3,,123097261,31703,Active,,,0.14731,IC50,SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.,Confirmatory,,
4724,741770,1,3,,123097261,31703,Active,,,0.01876,IC50,SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,Confirmatory,,
4725,741771,1,3,,123097261,31703,Active,,,1.57026,IC50,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,Confirmatory,,
4726,741772,1,3,,123097261,31703,Active,,,0.22473,IC50,SANGER: Inhibition of human NCI-H838 cell growth in a cell viability assay.,Confirmatory,,
4727,741773,1,3,,123097261,31703,Active,,,1.9388599999999998,IC50,SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.,Confirmatory,,
4728,741774,1,3,,123097261,31703,Active,,,0.47991999999999996,IC50,SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,Confirmatory,,
4729,741775,1,3,,123097261,31703,Active,,,0.06586,IC50,SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.,Confirmatory,,
4730,741776,1,3,,123097261,31703,Active,,,31.1836,IC50,SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.,Confirmatory,,
4731,741777,1,3,,123097261,31703,Active,,,0.57015,IC50,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,Confirmatory,,
4732,741778,1,3,,123097261,31703,Active,,,0.03361,IC50,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,Confirmatory,,
4733,741779,1,3,,123097261,31703,Active,,,0.076,IC50,SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.,Confirmatory,,
4734,741780,1,3,,123097261,31703,Active,,,0.02947,IC50,SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.,Confirmatory,,
4735,741781,1,3,,123097261,31703,Active,,,0.13913,IC50,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,Confirmatory,,
4736,741782,1,3,,123097261,31703,Active,,,0.22443000000000002,IC50,SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.,Confirmatory,,
4737,741783,1,3,,123097261,31703,Active,,,0.07914,IC50,SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.,Confirmatory,,
4738,741784,1,4,,123097261,31703,Active,,,0.00137,IC50,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,Confirmatory,,
4739,741785,1,3,,123097261,31703,Active,,,0.0452,IC50,SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,Confirmatory,,
4740,741786,1,3,,123097261,31703,Active,,,0.22849,IC50,SANGER: Inhibition of human NY cell growth in a cell viability assay.,Confirmatory,,
4741,741787,1,3,,123097261,31703,Active,,,0.17884,IC50,SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,Confirmatory,,
4742,741788,1,3,,123097261,31703,Active,,,0.15384,IC50,SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,Confirmatory,,
4743,741790,1,3,,123097261,31703,Active,,,0.04505,IC50,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,Confirmatory,,
4744,741791,1,3,,123097261,31703,Active,,,0.01515,IC50,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,Confirmatory,,
4745,741792,1,3,,123097261,31703,Active,,,0.20018,IC50,SANGER: Inhibition of human OE19 cell growth in a cell viability assay.,Confirmatory,,
4746,741793,1,3,,123097261,31703,Active,,,0.42601999999999995,IC50,SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,Confirmatory,,
4747,741794,1,3,,123097261,31703,Active,,,0.17217000000000002,IC50,SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.,Confirmatory,,
4748,741795,1,3,,123097261,31703,Active,,,0.01891,IC50,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,Confirmatory,,
4749,741796,1,3,,123097261,31703,Active,,,0.5018100000000001,IC50,SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.,Confirmatory,,
4750,741797,1,3,,123097261,31703,Active,,,0.18249,IC50,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,Confirmatory,,
4751,741798,1,3,,123097261,31703,Active,,,0.47041000000000005,IC50,SANGER: Inhibition of human OVCAR-3 cell growth in a cell viability assay.,Confirmatory,,
4752,741799,1,3,,123097261,31703,Active,,,0.15678,IC50,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,Confirmatory,,
4753,741800,1,3,,123097261,31703,Active,,,0.11681,IC50,SANGER: Inhibition of human OVCAR-5 cell growth in a cell viability assay.,Confirmatory,,
4754,741801,1,3,,123097261,31703,Active,,,0.06192,IC50,SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,Confirmatory,,
4755,741802,1,3,,123097261,31703,Active,,,0.04927,IC50,SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,Confirmatory,,
4756,741803,1,3,,123097261,31703,Active,,,0.05757,IC50,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,Confirmatory,,
4757,741804,1,3,,123097261,31703,Active,,,44.3284,IC50,SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.,Confirmatory,,
4758,741805,1,3,,123097261,31703,Active,,,0.04448,IC50,SANGER: Inhibition of human PA-1 cell growth in a cell viability assay.,Confirmatory,,
4759,741806,1,3,,123097261,31703,Active,,,0.02816,IC50,SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,Confirmatory,,
4760,741807,1,3,,123097261,31703,Active,,,1.63084,IC50,SANGER: Inhibition of human PANC-08-13 cell growth in a cell viability assay.,Confirmatory,,
4761,741808,1,3,,123097261,31703,Active,,,0.08845,IC50,SANGER: Inhibition of human PANC-10-05 cell growth in a cell viability assay.,Confirmatory,,
4762,741809,1,3,,123097261,31703,Active,,,0.23611999999999997,IC50,SANGER: Inhibition of human PC-14 cell growth in a cell viability assay.,Confirmatory,,
4763,741810,1,3,,123097261,31703,Active,,,0.9572200000000001,IC50,SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,Confirmatory,,
4764,741811,1,3,,123097261,31703,Active,,,0.06717000000000001,IC50,SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,Confirmatory,,
4765,741812,1,3,,123097261,31703,Active,,,0.67808,IC50,SANGER: Inhibition of human PFSK-1 cell growth in a cell viability assay.,Confirmatory,,
4766,741813,1,3,,123097261,31703,Active,,,0.90135,IC50,SANGER: Inhibition of human PLC-PRF-5 cell growth in a cell viability assay.,Confirmatory,,
4767,741814,1,3,,123097261,31703,Active,,,0.01122,IC50,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,Confirmatory,,
4768,741815,1,3,,123097261,31703,Active,,,0.02072,IC50,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,Confirmatory,,
4769,741816,1,3,,123097261,31703,Active,,,30.0611,IC50,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,Confirmatory,,
4770,741817,1,3,,123097261,31703,Active,,,4.492719999999999,IC50,SANGER: Inhibition of human RCM-1 cell growth in a cell viability assay.,Confirmatory,,
4771,741818,1,3,,123097261,31703,Active,,,0.1801,IC50,SANGER: Inhibition of human RD cell growth in a cell viability assay.,Confirmatory,,
4772,741819,1,3,,123097261,31703,Active,,,0.00811,IC50,SANGER: Inhibition of human REH cell growth in a cell viability assay.,Confirmatory,,
4773,741820,1,3,,123097261,31703,Active,,,0.42505,IC50,SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,Confirmatory,,
4774,741821,1,3,,123097261,31703,Active,,,0.00673,IC50,SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.,Confirmatory,,
4775,741823,1,3,,123097261,31703,Active,,,0.02228,IC50,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,Confirmatory,,
4776,741824,1,3,,123097261,31703,Active,,,1.42066,IC50,SANGER: Inhibition of human RL cell growth in a cell viability assay.,Confirmatory,,
4777,741826,1,3,,123097261,31703,Active,,,0.51398,IC50,SANGER: Inhibition of human RMG-I cell growth in a cell viability assay.,Confirmatory,,
4778,741827,1,3,,123097261,31703,Active,,,1.3433700000000002,IC50,SANGER: Inhibition of human RO82-W-1 cell growth in a cell viability assay.,Confirmatory,,
4779,741828,1,3,,123097261,31703,Active,,,0.01369,IC50,SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,Confirmatory,,
4780,741829,1,3,,123097261,31703,Active,,,0.06599,IC50,SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,Confirmatory,,
4781,741830,1,3,,123097261,31703,Active,,,0.13014,IC50,SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,Confirmatory,,
4782,741831,1,3,,123097261,31703,Active,,,0.21336999999999998,IC50,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,Confirmatory,,
4783,741832,1,3,,123097261,31703,Active,,,0.053860000000000005,IC50,SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,Confirmatory,,
4784,741833,1,3,,123097261,31703,Active,,,0.19213,IC50,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,Confirmatory,,
4785,741834,1,3,,123097261,31703,Active,,,0.01914,IC50,SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.,Confirmatory,,
4786,741835,1,3,,123097261,31703,Active,,,0.03292,IC50,SANGER: Inhibition of human RT-112 cell growth in a cell viability assay.,Confirmatory,,
4787,741836,1,3,,123097261,31703,Active,,,1.84417,IC50,SANGER: Inhibition of human RT4 cell growth in a cell viability assay.,Confirmatory,,
4788,741837,1,3,,123097261,31703,Active,,,0.16913,IC50,SANGER: Inhibition of human RVH-421 cell growth in a cell viability assay.,Confirmatory,,
4789,741838,1,3,,123097261,31703,Active,,,0.33543,IC50,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,Confirmatory,,
4790,741839,1,3,,123097261,31703,Active,,,0.33464,IC50,SANGER: Inhibition of human Raji cell growth in a cell viability assay.,Confirmatory,,
4791,741840,1,3,,123097261,31703,Active,,,0.29455,IC50,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,Confirmatory,,
4792,741841,1,3,,123097261,31703,Active,,,1.7050400000000001,IC50,SANGER: Inhibition of human S-117 cell growth in a cell viability assay.,Confirmatory,,
4793,741842,1,3,,123097261,31703,Active,,,0.11445,IC50,SANGER: Inhibition of human SAS cell growth in a cell viability assay.,Confirmatory,,
4794,741843,1,3,,123097261,31703,Active,,,0.1564,IC50,SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.,Confirmatory,,
4795,741844,1,3,,123097261,31703,Active,,,0.02074,IC50,SANGER: Inhibition of human SBC-5 cell growth in a cell viability assay.,Confirmatory,,
4796,741845,1,3,,123097261,31703,Active,,,0.18824000000000002,IC50,SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.,Confirmatory,,
4797,741846,1,3,,123097261,31703,Active,,,0.15373,IC50,SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,Confirmatory,,
4798,741847,1,3,,123097261,31703,Active,,,0.06727999999999999,IC50,SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,Confirmatory,,
4799,741848,1,3,,123097261,31703,Active,,,0.18370999999999998,IC50,SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,Confirmatory,,
4800,741849,1,3,,123097261,31703,Active,,,3.91309,IC50,SANGER: Inhibition of human SCC-9 cell growth in a cell viability assay.,Confirmatory,,
4801,741850,1,3,,123097261,31703,Unspecified,,,177.11,IC50,SANGER: Inhibition of human SCH cell growth in a cell viability assay.,Confirmatory,,
4802,741851,1,3,,123097261,31703,Active,,,2.00624,IC50,SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.,Confirmatory,,
4803,741852,1,3,,123097261,31703,Active,,,0.10457999999999999,IC50,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,Confirmatory,,
4804,741853,1,3,,123097261,31703,Active,,,0.09242,IC50,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,Confirmatory,,
4805,741854,1,3,,123097261,31703,Active,,,0.04908,IC50,SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,Confirmatory,,
4806,741855,1,3,,123097261,31703,Active,,,0.12172000000000001,IC50,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,Confirmatory,,
4807,741856,1,3,,123097261,31703,Active,,,0.09211,IC50,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,Confirmatory,,
4808,741857,1,3,,123097261,31703,Active,,,9.9029,IC50,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,Confirmatory,,
4809,741858,1,3,,123097261,31703,Active,,,0.025689999999999998,IC50,SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,Confirmatory,,
4810,741859,1,3,,123097261,31703,Active,,,0.38186,IC50,SANGER: Inhibition of human SIMA cell growth in a cell viability assay.,Confirmatory,,
4811,741860,1,3,,123097261,31703,Active,,,0.17294,IC50,SANGER: Inhibition of human SJRH30 cell growth in a cell viability assay.,Confirmatory,,
4812,741861,1,3,,123097261,31703,Active,,,0.11105,IC50,SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.,Confirmatory,,
4813,741862,1,3,,123097261,31703,Active,,,0.12921,IC50,SANGER: Inhibition of human SK-CO-1 cell growth in a cell viability assay.,Confirmatory,,
4814,741863,1,3,,123097261,31703,Active,,,0.02586,IC50,SANGER: Inhibition of human SK-HEP-1 cell growth in a cell viability assay.,Confirmatory,,
4815,741864,1,3,,123097261,31703,Active,,,0.05322,IC50,SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.,Confirmatory,,
4816,741865,1,3,,123097261,31703,Active,,,0.01254,IC50,SANGER: Inhibition of human SK-LU-1 cell growth in a cell viability assay.,Confirmatory,,
4817,741866,1,3,,123097261,31703,Active,,,36.7547,IC50,SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.,Confirmatory,,
4818,741867,1,3,,123097261,31703,Active,,,0.2303,IC50,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,Confirmatory,,
4819,741868,1,3,,123097261,31703,Active,,,0.91435,IC50,SANGER: Inhibition of human SK-MEL-24 cell growth in a cell viability assay.,Confirmatory,,
4820,741869,1,3,,123097261,31703,Active,,,35.5377,IC50,SANGER: Inhibition of human SK-MEL-28 cell growth in a cell viability assay.,Confirmatory,,
4821,741870,1,3,,123097261,31703,Active,,,0.14761,IC50,SANGER: Inhibition of human SK-MEL-3 cell growth in a cell viability assay.,Confirmatory,,
4822,741871,1,3,,123097261,31703,Active,,,0.03561,IC50,SANGER: Inhibition of human SK-MEL-30 cell growth in a cell viability assay.,Confirmatory,,
4823,741873,1,3,,123097261,31703,Active,,,0.0315,IC50,SANGER: Inhibition of human SK-MES-1 cell growth in a cell viability assay.,Confirmatory,,
4824,741875,1,3,,123097261,31703,Active,,,0.9423,IC50,SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.,Confirmatory,,
4825,741876,1,3,,123097261,31703,Active,,,2.73015,IC50,SANGER: Inhibition of human SK-N-AS cell growth in a cell viability assay.,Confirmatory,,
4826,741877,1,3,,123097261,31703,Active,,,2.56592,IC50,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,Confirmatory,,
4827,741878,1,3,,123097261,31703,Active,,,5.22877,IC50,SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.,Confirmatory,,
4828,741879,1,3,,123097261,31703,Active,,,0.11625999999999999,IC50,SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.,Confirmatory,,
4829,741880,1,3,,123097261,31703,Active,,,0.05012,IC50,SANGER: Inhibition of human SK-OV-3 cell growth in a cell viability assay.,Confirmatory,,
4830,741881,1,3,,123097261,31703,Active,,,0.02572,IC50,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,Confirmatory,,
4831,741882,1,3,,123097261,31703,Active,,,0.01996,IC50,SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.,Confirmatory,,
4832,741883,1,3,,123097261,31703,Active,,,0.31114,IC50,SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,Confirmatory,,
4833,741885,1,3,,123097261,31703,Active,,,0.39487,IC50,SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,Confirmatory,,
4834,741886,1,3,,123097261,31703,Active,,,0.14865,IC50,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,Confirmatory,,
4835,741887,1,3,,123097261,31703,Active,,,0.01832,IC50,SANGER: Inhibition of human SNG-M cell growth in a cell viability assay.,Confirmatory,,
4836,741888,1,3,,123097261,31703,Active,,,0.23608,IC50,SANGER: Inhibition of human SNU-387 cell growth in a cell viability assay.,Confirmatory,,
4837,741889,1,3,,123097261,31703,Active,,,0.15534,IC50,SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,Confirmatory,,
4838,741890,1,3,,123097261,31703,Active,,,0.54801,IC50,SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,Confirmatory,,
4839,741891,1,3,,123097261,31703,Active,,,2.92572,IC50,SANGER: Inhibition of human SNU-475 cell growth in a cell viability assay.,Confirmatory,,
4840,741892,1,3,,123097261,31703,Active,,,32.4175,IC50,SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.,Confirmatory,,
4841,741893,1,3,,123097261,31703,Active,,,0.46097,IC50,SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,Confirmatory,,
4842,741894,1,3,,123097261,31703,Active,,,0.02441,IC50,SANGER: Inhibition of human SR cell growth in a cell viability assay.,Confirmatory,,
4843,741895,1,3,,123097261,31703,Active,,,0.01553,IC50,SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,Confirmatory,,
4844,741896,1,3,,123097261,31703,Active,,,0.1025,IC50,SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.,Confirmatory,,
4845,741897,1,3,,123097261,31703,Active,,,0.07972,IC50,SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.,Confirmatory,,
4846,741898,1,3,,123097261,31703,Active,,,2.0693099999999998,IC50,SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,Confirmatory,,
4847,741900,1,3,,123097261,31703,Active,,,0.11525999999999999,IC50,SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,Confirmatory,,
4848,741901,1,3,,123097261,31703,Active,,,0.36323,IC50,SANGER: Inhibition of human SW1417 cell growth in a cell viability assay.,Confirmatory,,
4849,741902,1,3,,123097261,31703,Active,,,1.95701,IC50,SANGER: Inhibition of human SW1463 cell growth in a cell viability assay.,Confirmatory,,
4850,741903,1,3,,123097261,31703,Active,,,0.08281000000000001,IC50,SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,Confirmatory,,
4851,741904,1,3,,123097261,31703,Active,,,0.0174,IC50,SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,Confirmatory,,
4852,741905,1,3,,123097261,31703,Active,,,0.09799,IC50,SANGER: Inhibition of human SW1783 cell growth in a cell viability assay.,Confirmatory,,
4853,741906,1,3,,123097261,31703,Active,,,0.2019,IC50,SANGER: Inhibition of human SW1990 cell growth in a cell viability assay.,Confirmatory,,
4854,741907,1,3,,123097261,31703,Active,,,0.04972,IC50,SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,Confirmatory,,
4855,741908,1,3,,123097261,31703,Active,,,0.02663,IC50,SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,Confirmatory,,
4856,741909,1,3,,123097261,31703,Active,,,0.11170999999999999,IC50,SANGER: Inhibition of human SW626 cell growth in a cell viability assay.,Confirmatory,,
4857,741910,1,3,,123097261,31703,Active,,,34.1561,IC50,SANGER: Inhibition of human SW684 cell growth in a cell viability assay.,Confirmatory,,
4858,741911,1,3,,123097261,31703,Active,,,0.27478,IC50,SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,Confirmatory,,
4859,741912,1,3,,123097261,31703,Unspecified,,,59.0921,IC50,SANGER: Inhibition of human SW780 cell growth in a cell viability assay.,Confirmatory,,
4860,741913,1,3,,123097261,31703,Active,,,0.11795,IC50,SANGER: Inhibition of human SW837 cell growth in a cell viability assay.,Confirmatory,,
4861,741914,1,3,,123097261,31703,Active,,,0.12080999999999999,IC50,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,Confirmatory,,
4862,741916,1,3,,123097261,31703,Unspecified,,,52.3257,IC50,SANGER: Inhibition of human SW948 cell growth in a cell viability assay.,Confirmatory,,
4863,741917,1,3,,123097261,31703,Active,,,0.01693,IC50,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,Confirmatory,,
4864,741918,1,3,,123097261,31703,Active,,,0.06995,IC50,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,Confirmatory,,
4865,741919,1,3,,123097261,31703,Active,,,0.00605,IC50,SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,Confirmatory,,
4866,741920,1,3,,123097261,31703,Active,,,0.32994,IC50,SANGER: Inhibition of human Saos-2 cell growth in a cell viability assay.,Confirmatory,,
4867,741921,1,3,,123097261,31703,Active,,,23.3371,IC50,SANGER: Inhibition of human SiHa cell growth in a cell viability assay.,Confirmatory,,
4868,741922,1,3,,123097261,31703,Active,,,0.24548000000000003,IC50,SANGER: Inhibition of human T-24 cell growth in a cell viability assay.,Confirmatory,,
4869,741923,1,3,,123097261,31703,Active,,,0.46968999999999994,IC50,SANGER: Inhibition of human T47D cell growth in a cell viability assay.,Confirmatory,,
4870,741924,1,3,,123097261,31703,Active,,,0.05706,IC50,SANGER: Inhibition of human T84 cell growth in a cell viability assay.,Confirmatory,,
4871,741925,1,3,,123097261,31703,Active,,,2.80401,IC50,SANGER: Inhibition of human T98G cell growth in a cell viability assay.,Confirmatory,,
4872,741926,1,3,,123097261,31703,Active,,,7.9688,IC50,SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.,Confirmatory,,
4873,741928,1,3,,123097261,31703,Active,,,1.2308299999999999,IC50,SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,Confirmatory,,
4874,741929,1,3,,123097261,31703,Active,,,0.07635,IC50,SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.,Confirmatory,,
4875,741930,1,3,,123097261,31703,Active,,,0.021240000000000002,IC50,SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,Confirmatory,,
4876,741931,1,3,,123097261,31703,Active,,,0.01542,IC50,SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,Confirmatory,,
4877,741932,1,3,,123097261,31703,Active,,,0.031869999999999996,IC50,SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,Confirmatory,,
4878,741933,1,3,,123097261,31703,Active,,,0.01591,IC50,SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,Confirmatory,,
4879,741934,1,3,,123097261,31703,Active,,,0.01881,IC50,SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,Confirmatory,,
4880,741935,1,3,,123097261,31703,Active,,,0.01909,IC50,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,Confirmatory,,
4881,741936,1,3,,123097261,31703,Active,,,0.02076,IC50,SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,Confirmatory,,
4882,741937,1,3,,123097261,31703,Active,,,0.00847,IC50,SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,Confirmatory,,
4883,741938,1,3,,123097261,31703,Active,,,0.022119999999999997,IC50,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,Confirmatory,,
4884,741939,1,3,,123097261,31703,Active,,,0.06312000000000001,IC50,SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,Confirmatory,,
4885,741940,1,3,,123097261,31703,Active,,,0.01956,IC50,SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,Confirmatory,,
4886,741941,1,3,,123097261,31703,Active,,,0.05148,IC50,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,Confirmatory,,
4887,741942,1,3,,123097261,31703,Active,,,0.08055,IC50,SANGER: Inhibition of human A172 cell growth in a cell viability assay.,Confirmatory,,
4888,741943,1,3,,123097261,31703,Active,,,0.01288,IC50,SANGER: Inhibition of human A204 cell growth in a cell viability assay.,Confirmatory,,
4889,741944,1,3,,123097261,31703,Active,,,0.01765,IC50,SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,Confirmatory,,
4890,741945,1,3,,123097261,31703,Active,,,0.04612,IC50,SANGER: Inhibition of human A253 cell growth in a cell viability assay.,Confirmatory,,
4891,741946,1,3,,123097261,31703,Active,,,0.06879,IC50,SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,Confirmatory,,
4892,741947,1,3,,123097261,31703,Active,,,0.040139999999999995,IC50,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,Confirmatory,,
4893,741948,1,3,,123097261,31703,Active,,,0.009170000000000001,IC50,SANGER: Inhibition of human A375 cell growth in a cell viability assay.,Confirmatory,,
4894,741949,1,3,,123097261,31703,Active,,,0.028460000000000003,IC50,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,Confirmatory,,
4895,741950,1,3,,123097261,31703,Active,,,0.16247999999999999,IC50,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,Confirmatory,,
4896,741951,1,3,,123097261,31703,Active,,,0.01181,IC50,SANGER: Inhibition of human A427 cell growth in a cell viability assay.,Confirmatory,,
4897,741952,1,3,,123097261,31703,Active,,,0.02087,IC50,SANGER: Inhibition of human A431 cell growth in a cell viability assay.,Confirmatory,,
4898,741953,1,3,,123097261,31703,Active,,,18.2976,IC50,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,Confirmatory,,
4899,741955,1,3,,123097261,31703,Active,,,0.21579,IC50,SANGER: Inhibition of human A673 cell growth in a cell viability assay.,Confirmatory,,
4900,741956,1,3,,123097261,31703,Active,,,2.29135,IC50,SANGER: Inhibition of human A704 cell growth in a cell viability assay.,Confirmatory,,
4901,741957,1,3,,123097261,31703,Active,,,0.08345,IC50,SANGER: Inhibition of human ABC-1 cell growth in a cell viability assay.,Confirmatory,,
4902,741958,1,3,,123097261,31703,Active,,,0.049339999999999995,IC50,SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,Confirmatory,,
4903,741959,1,3,,123097261,31703,Active,,,0.03112,IC50,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,Confirmatory,,
4904,741960,1,3,,123097261,31703,Active,,,0.013269999999999999,IC50,SANGER: Inhibition of human AGS cell growth in a cell viability assay.,Confirmatory,,
4905,741961,1,3,,123097261,31703,Active,,,0.06502999999999999,IC50,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,Confirmatory,,
4906,741962,1,3,,123097261,31703,Active,,,0.28152,IC50,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,Confirmatory,,
4907,741963,1,3,,123097261,31703,Active,,,0.07232000000000001,IC50,SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,Confirmatory,,
4908,741964,1,3,,123097261,31703,Active,,,0.10999,IC50,SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,Confirmatory,,
4909,741965,1,3,,123097261,31703,Active,,,0.1277,IC50,SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.,Confirmatory,,
4910,741966,1,3,,123097261,31703,Active,,,0.10450999999999999,IC50,SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,Confirmatory,,
4911,741967,1,3,,123097261,31703,Active,,,0.85526,IC50,SANGER: Inhibition of human AsPC-1 cell growth in a cell viability assay.,Confirmatory,,
4912,741969,1,3,,123097261,31703,Active,,,0.02985,IC50,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,Confirmatory,,
4913,741970,1,3,,123097261,31703,Active,,,7.417910000000001,IC50,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,Confirmatory,,
4914,741971,1,3,,123097261,31703,Active,,,0.14931,IC50,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,Confirmatory,,
4915,741972,1,3,,123097261,31703,Active,,,0.08676,IC50,SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.,Confirmatory,,
4916,741973,1,3,,123097261,31703,Active,,,0.16585999999999998,IC50,SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.,Confirmatory,,
4917,741974,1,3,,123097261,31703,Active,,,0.0525,IC50,SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,Confirmatory,,
4918,741975,1,3,,123097261,31703,Active,,,0.051019999999999996,IC50,SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.,Confirmatory,,
4919,741976,1,3,,123097261,31703,Active,,,1.23742,IC50,SANGER: Inhibition of human BEN cell growth in a cell viability assay.,Confirmatory,,
4920,741977,1,3,,123097261,31703,Active,,,0.01618,IC50,SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,Confirmatory,,
4921,741978,1,3,,123097261,31703,Active,,,0.11848,IC50,SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,Confirmatory,,
4922,741979,1,3,,123097261,31703,Active,,,0.39592,IC50,SANGER: Inhibition of human BHT-101 cell growth in a cell viability assay.,Confirmatory,,
4923,741980,1,3,,123097261,31703,Active,,,0.02888,IC50,SANGER: Inhibition of human BHY cell growth in a cell viability assay.,Confirmatory,,
4924,741981,1,3,,123097261,31703,Active,,,0.12222000000000001,IC50,SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,Confirmatory,,
4925,741982,1,3,,123097261,31703,Active,,,0.34201,IC50,SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,Confirmatory,,
4926,741983,1,3,,123097261,31703,Active,,,0.11087000000000001,IC50,SANGER: Inhibition of human BOKU cell growth in a cell viability assay.,Confirmatory,,
4927,741984,1,3,,123097261,31703,Active,,,0.022119999999999997,IC50,SANGER: Inhibition of human BPH-1 cell growth in a cell viability assay.,Confirmatory,,
4928,741985,1,3,,123097261,31703,Active,,,1.74068,IC50,SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,Confirmatory,,
4929,741986,1,3,,123097261,31703,Active,,,0.77881,IC50,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,Confirmatory,,
4930,741988,1,3,,123097261,31703,Active,,,0.25077,IC50,SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.,Confirmatory,,
4931,741989,1,3,,123097261,31703,Active,,,0.52183,IC50,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,Confirmatory,,
4932,741990,1,3,,123097261,31703,Active,,,0.21095999999999998,IC50,SANGER: Inhibition of human BxPC-3 cell growth in a cell viability assay.,Confirmatory,,
4933,741991,1,3,,123097261,31703,Active,,,0.032889999999999996,IC50,SANGER: Inhibition of human C-33-A cell growth in a cell viability assay.,Confirmatory,,
4934,741992,1,3,,123097261,31703,Active,,,0.47256000000000004,IC50,SANGER: Inhibition of human C-4-II cell growth in a cell viability assay.,Confirmatory,,
4935,741993,1,3,,123097261,31703,Active,,,2.51328,IC50,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,Confirmatory,,
4936,741994,1,3,,123097261,31703,Active,,,32.872,IC50,SANGER: Inhibition of human C32 cell growth in a cell viability assay.,Confirmatory,,
4937,741995,1,3,,123097261,31703,Active,,,0.41578999999999994,IC50,SANGER: Inhibition of human C3A cell growth in a cell viability assay.,Confirmatory,,
4938,741996,1,3,,123097261,31703,Active,,,0.03331,IC50,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,Confirmatory,,
4939,741997,1,3,,123097261,31703,Active,,,0.13688,IC50,SANGER: Inhibition of human CA46 cell growth in a cell viability assay.,Confirmatory,,
4940,741998,1,3,,123097261,31703,Active,,,0.37548000000000004,IC50,SANGER: Inhibition of human CAKI-1 cell growth in a cell viability assay.,Confirmatory,,
4941,741999,1,3,,123097261,31703,Active,,,0.77752,IC50,SANGER: Inhibition of human CAL-120 cell growth in a cell viability assay.,Confirmatory,,
4942,742000,1,3,,123097261,31703,Active,,,0.02065,IC50,SANGER: Inhibition of human CAL-12T cell growth in a cell viability assay.,Confirmatory,,
4943,742001,1,3,,123097261,31703,Active,,,0.0269,IC50,SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.,Confirmatory,,
4944,742002,1,3,,123097261,31703,Active,,,0.03257,IC50,SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,Confirmatory,,
4945,742003,1,3,,123097261,31703,Active,,,0.06787,IC50,SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,Confirmatory,,
4946,742004,1,3,,123097261,31703,Active,,,0.09824,IC50,SANGER: Inhibition of human CAL-39 cell growth in a cell viability assay.,Confirmatory,,
4947,742005,1,3,,123097261,31703,Active,,,0.01732,IC50,SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,Confirmatory,,
4948,742006,1,3,,123097261,31703,Active,,,0.30073,IC50,SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,Confirmatory,,
4949,742007,1,3,,123097261,31703,Active,,,0.03279,IC50,SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,Confirmatory,,
4950,742008,1,3,,123097261,31703,Active,,,0.84067,IC50,SANGER: Inhibition of human CAL-72 cell growth in a cell viability assay.,Confirmatory,,
4951,742009,1,3,,123097261,31703,Active,,,0.04452,IC50,SANGER: Inhibition of human CAL-85-1 cell growth in a cell viability assay.,Confirmatory,,
4952,742010,1,3,,123097261,31703,Active,,,0.11268,IC50,SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.,Confirmatory,,
4953,742011,1,3,,123097261,31703,Active,,,0.24088,IC50,SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.,Confirmatory,,
4954,742012,1,3,,123097261,31703,Active,,,0.08106000000000001,IC50,SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.,Confirmatory,,
4955,742013,1,3,,123097261,31703,Active,,,0.02414,IC50,SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.,Confirmatory,,
4956,742014,1,3,,123097261,31703,Active,,,0.08982000000000001,IC50,SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.,Confirmatory,,
4957,742015,1,3,,123097261,31703,Active,,,0.03748,IC50,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,Confirmatory,,
4958,742016,1,3,,123097261,31703,Active,,,0.46981000000000006,IC50,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,Confirmatory,,
4959,742017,1,3,,123097261,31703,Active,,,0.0075,IC50,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,Confirmatory,,
4960,742018,1,3,,123097261,31703,Active,,,0.25747,IC50,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,Confirmatory,,
4961,742020,1,3,,123097261,31703,Active,,,1.06036,IC50,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,Confirmatory,,
4962,742021,1,3,,123097261,31703,Active,,,2.4142900000000003,IC50,SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,Confirmatory,,
4963,742022,1,3,,123097261,31703,Active,,,1.4594200000000002,IC50,SANGER: Inhibition of human TGW cell growth in a cell viability assay.,Confirmatory,,
4964,742023,1,3,,123097261,31703,Active,,,0.9894200000000001,IC50,SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.,Confirmatory,,
4965,742025,1,3,,123097261,31703,Active,,,0.1146,IC50,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,Confirmatory,,
4966,742026,1,3,,123097261,31703,Active,,,9.06966,IC50,SANGER: Inhibition of human TT cell growth in a cell viability assay.,Confirmatory,,
4967,742027,1,3,,123097261,31703,Active,,,0.07632,IC50,SANGER: Inhibition of human TUR cell growth in a cell viability assay.,Confirmatory,,
4968,742028,1,3,,123097261,31703,Active,,,0.66255,IC50,SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,Confirmatory,,
4969,742029,1,3,,123097261,31703,Active,,,0.85634,IC50,SANGER: Inhibition of human U-118-MG cell growth in a cell viability assay.,Confirmatory,,
4970,742030,1,3,,123097261,31703,Active,,,9.813930000000001,IC50,SANGER: Inhibition of human U-2-OS cell growth in a cell viability assay.,Confirmatory,,
4971,742031,1,3,,123097261,31703,Active,,,0.45148999999999995,IC50,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,Confirmatory,,
4972,742032,1,3,,123097261,31703,Active,,,0.1395,IC50,SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.,Confirmatory,,
4973,742033,1,3,,123097261,31703,Active,,,0.34604,IC50,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,Confirmatory,,
4974,742034,1,4,,123097261,31703,Active,,,0.35386999999999996,IC50,SANGER: Inhibition of human U031 cell growth in a cell viability assay.,Confirmatory,,
4975,742035,1,3,,123097261,31703,Active,,,0.06489,IC50,SANGER: Inhibition of human U251 cell growth in a cell viability assay.,Confirmatory,,
4976,742036,1,3,,123097261,31703,Active,,,0.36205,IC50,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,Confirmatory,,
4977,742037,1,3,,123097261,31703,Active,,,1.32145,IC50,SANGER: Inhibition of human UACC-62 cell growth in a cell viability assay.,Confirmatory,,
4978,742038,1,3,,123097261,31703,Active,,,3.3373800000000005,IC50,SANGER: Inhibition of human UACC-812 cell growth in a cell viability assay.,Confirmatory,,
4979,742039,1,3,,123097261,31703,Active,,,0.52151,IC50,SANGER: Inhibition of human UACC-893 cell growth in a cell viability assay.,Confirmatory,,
4980,742040,1,3,,123097261,31703,Active,,,0.08602,IC50,SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,Confirmatory,,
4981,742041,1,3,,123097261,31703,Active,,,0.33128,IC50,SANGER: Inhibition of human UMC-11 cell growth in a cell viability assay.,Confirmatory,,
4982,742042,1,3,,123097261,31703,Active,,,0.03336,IC50,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,Confirmatory,,
4983,742043,1,3,,123097261,31703,Active,,,0.07536,IC50,SANGER: Inhibition of human VM-CUB-1 cell growth in a cell viability assay.,Confirmatory,,
4984,742044,1,3,,123097261,31703,Active,,,0.09326,IC50,SANGER: Inhibition of human VMRC-RCZ cell growth in a cell viability assay.,Confirmatory,,
4985,742045,1,3,,123097261,31703,Unspecified,,,51.0384,IC50,SANGER: Inhibition of human WM-115 cell growth in a cell viability assay.,Confirmatory,,
4986,742046,1,3,,123097261,31703,Active,,,0.15458,IC50,SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.,Confirmatory,,
4987,742047,1,3,,123097261,31703,Active,,,3.3283199999999997,IC50,SANGER: Inhibition of human YAPC cell growth in a cell viability assay.,Confirmatory,,
4988,742049,1,3,,123097261,31703,Active,,,0.01877,IC50,SANGER: Inhibition of human YKG-1 cell growth in a cell viability assay.,Confirmatory,,
4989,742050,1,3,,123097261,31703,Active,,,1.04568,IC50,SANGER: Inhibition of human YT cell growth in a cell viability assay.,Confirmatory,,
4990,742052,1,3,,123097261,31703,Active,,,0.16038,IC50,SANGER: Inhibition of human no-10 cell growth in a cell viability assay.,Confirmatory,,
4991,742053,1,3,,123097261,31703,Active,,,0.32164,IC50,SANGER: Inhibition of human no-11 cell growth in a cell viability assay.,Confirmatory,,
4992,742054,1,3,,123097261,31703,Active,,,0.15933,IC50,SANGER: Inhibition of human CAMA-1 cell growth in a cell viability assay.,Confirmatory,,
4993,742055,1,3,,123097261,31703,Active,,,0.05176,IC50,SANGER: Inhibition of human CAPAN-1 cell growth in a cell viability assay.,Confirmatory,,
4994,742056,1,3,,123097261,31703,Active,,,0.23831,IC50,SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.,Confirmatory,,
4995,742057,1,3,,123097261,31703,Active,,,0.0355,IC50,SANGER: Inhibition of human CCF-STTG1 cell growth in a cell viability assay.,Confirmatory,,
4996,742058,1,3,,123097261,31703,Active,,,0.02452,IC50,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,Confirmatory,,
4997,742059,1,3,,123097261,31703,Active,,,0.03936,IC50,SANGER: Inhibition of human CESS cell growth in a cell viability assay.,Confirmatory,,
4998,742061,1,3,,123097261,31703,Active,,,0.05346,IC50,SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.,Confirmatory,,
4999,742062,1,3,,123097261,31703,Active,,,0.03773,IC50,SANGER: Inhibition of human CHL-1 cell growth in a cell viability assay.,Confirmatory,,
5000,742063,1,3,,123097261,31703,Active,,,0.05924,IC50,SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.,Confirmatory,,
5001,742065,1,3,,123097261,31703,Active,,,0.034960000000000005,IC50,SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,Confirmatory,,
5002,742066,1,3,,123097261,31703,Active,,,0.07742,IC50,SANGER: Inhibition of human CMK cell growth in a cell viability assay.,Confirmatory,,
5003,742067,1,3,,123097261,31703,Active,,,0.026989999999999997,IC50,SANGER: Inhibition of human COLO-205 cell growth in a cell viability assay.,Confirmatory,,
5004,742068,1,3,,123097261,31703,Active,,,0.5131600000000001,IC50,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,Confirmatory,,
5005,742069,1,3,,123097261,31703,Active,,,0.08447,IC50,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,Confirmatory,,
5006,742070,1,3,,123097261,31703,Active,,,0.42718,IC50,SANGER: Inhibition of human COLO-678 cell growth in a cell viability assay.,Confirmatory,,
5007,742071,1,3,,123097261,31703,Active,,,0.015969999999999998,IC50,SANGER: Inhibition of human COLO-679 cell growth in a cell viability assay.,Confirmatory,,
5008,742072,1,3,,123097261,31703,Active,,,0.03387,IC50,SANGER: Inhibition of human COLO-680N cell growth in a cell viability assay.,Confirmatory,,
5009,742073,1,3,,123097261,31703,Active,,,0.21979,IC50,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,Confirmatory,,
5010,742074,1,3,,123097261,31703,Active,,,0.19458,IC50,SANGER: Inhibition of human COLO-741 cell growth in a cell viability assay.,Confirmatory,,
5011,742075,1,3,,123097261,31703,Active,,,3.0287,IC50,SANGER: Inhibition of human COLO-792 cell growth in a cell viability assay.,Confirmatory,,
5012,742076,1,3,,123097261,31703,Active,,,0.1718,IC50,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,Confirmatory,,
5013,742077,1,3,,123097261,31703,Active,,,3.57378,IC50,SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.,Confirmatory,,
5014,742078,1,3,,123097261,31703,Active,,,1.2748700000000002,IC50,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,Confirmatory,,
5015,742079,1,3,,123097261,31703,Active,,,0.18892,IC50,SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,Confirmatory,,
5016,742080,1,3,,123097261,31703,Active,,,0.03196,IC50,SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,Confirmatory,,
5017,742081,1,3,,123097261,31703,Active,,,0.05695,IC50,SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,Confirmatory,,
5018,742082,1,3,,123097261,31703,Active,,,4.3958,IC50,SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.,Confirmatory,,
5019,742083,1,3,,123097261,31703,Active,,,3.9870300000000003,IC50,SANGER: Inhibition of human CP50-MEL-B cell growth in a cell viability assay.,Confirmatory,,
5020,742084,1,3,,123097261,31703,Active,,,2.01767,IC50,SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,Confirmatory,,
5021,742086,1,3,,123097261,31703,Active,,,0.0684,IC50,SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.,Confirmatory,,
5022,742088,1,3,,123097261,31703,Active,,,0.06419,IC50,SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.,Confirmatory,,
5023,742089,1,3,,123097261,31703,Active,,,0.016069999999999997,IC50,SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.,Confirmatory,,
5024,742090,1,3,,123097261,31703,Unspecified,,,213.278,IC50,SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.,Confirmatory,,
5025,742091,1,3,,123097261,31703,Active,,,0.04484,IC50,SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,Confirmatory,,
5026,742092,1,3,,123097261,31703,Active,,,0.050069999999999996,IC50,SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,Confirmatory,,
5027,742093,1,3,,123097261,31703,Active,,,1.7832400000000002,IC50,SANGER: Inhibition of human CaR-1 cell growth in a cell viability assay.,Confirmatory,,
5028,742094,1,3,,123097261,31703,Active,,,0.0736,IC50,SANGER: Inhibition of human Calu-1 cell growth in a cell viability assay.,Confirmatory,,
5029,742095,1,3,,123097261,31703,Active,,,0.055979999999999995,IC50,SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,Confirmatory,,
5030,742096,1,3,,123097261,31703,Active,,,0.25355,IC50,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,Confirmatory,,
5031,742097,1,3,,123097261,31703,Active,,,0.40619,IC50,SANGER: Inhibition of human Caov-3 cell growth in a cell viability assay.,Confirmatory,,
5032,742099,1,3,,123097261,31703,Active,,,0.8981100000000001,IC50,SANGER: Inhibition of human Capan-2 cell growth in a cell viability assay.,Confirmatory,,
5033,742100,1,3,,123097261,31703,Active,,,0.10795,IC50,SANGER: Inhibition of human ChaGo-K-1 cell growth in a cell viability assay.,Confirmatory,,
5034,742102,1,3,,123097261,31703,Active,,,0.30551999999999996,IC50,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,Confirmatory,,
5035,742103,1,4,,123097261,31703,Active,,,0.25013,IC50,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,Confirmatory,,
5036,742105,1,3,,123097261,31703,Active,,,0.2485,IC50,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,Confirmatory,,
5037,742107,1,3,,123097261,31703,Active,,,5.24262,IC50,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,Confirmatory,,
5038,742108,1,3,,123097261,31703,Active,,,1.65305,IC50,SANGER: Inhibition of human D-542MG cell growth in a cell viability assay.,Confirmatory,,
5039,742110,1,3,,123097261,31703,Active,,,0.16171,IC50,SANGER: Inhibition of human DB cell growth in a cell viability assay.,Confirmatory,,
5040,742111,1,3,,123097261,31703,Active,,,0.06711,IC50,SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,Confirmatory,,
5041,742112,1,3,,123097261,31703,Active,,,0.038439999999999995,IC50,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,Confirmatory,,
5042,742113,1,3,,123097261,31703,Active,,,0.66583,IC50,SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.,Confirmatory,,
5043,742114,1,3,,123097261,31703,Active,,,0.10225,IC50,SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.,Confirmatory,,
5044,742115,1,3,,123097261,31703,Unspecified,,,50.6815,IC50,SANGER: Inhibition of human DK-MG cell growth in a cell viability assay.,Confirmatory,,
5045,742116,1,3,,123097261,31703,Active,,,0.39631,IC50,SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.,Confirmatory,,
5046,742117,1,3,,123097261,31703,Active,,,0.69815,IC50,SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.,Confirmatory,,
5047,742118,1,3,,123097261,31703,Active,,,0.0789,IC50,SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,Confirmatory,,
5048,742119,1,3,,123097261,31703,Active,,,6.17106,IC50,SANGER: Inhibition of human DMS-53 cell growth in a cell viability assay.,Confirmatory,,
5049,742120,1,3,,123097261,31703,Active,,,2.90988,IC50,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,Confirmatory,,
5050,742121,1,3,,123097261,31703,Active,,,0.01999,IC50,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,Confirmatory,,
5051,742122,1,3,,123097261,31703,Active,,,1.01762,IC50,SANGER: Inhibition of human DOK cell growth in a cell viability assay.,Confirmatory,,
5052,742123,1,3,,123097261,31703,Active,,,0.37272,IC50,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,Confirmatory,,
5053,742124,1,3,,123097261,31703,Active,,,0.07372999999999999,IC50,SANGER: Inhibition of human DU-145 cell growth in a cell viability assay.,Confirmatory,,
5054,742125,1,3,,123097261,31703,Active,,,0.0121,IC50,SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,Confirmatory,,
5055,742126,1,3,,123097261,31703,Active,,,0.32945,IC50,SANGER: Inhibition of human DV-90 cell growth in a cell viability assay.,Confirmatory,,
5056,742127,1,3,,123097261,31703,Active,,,0.00807,IC50,SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,Confirmatory,,
5057,742128,1,3,,123097261,31703,Active,,,0.06896000000000001,IC50,SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,Confirmatory,,
5058,742129,1,3,,123097261,31703,Active,,,0.23071999999999998,IC50,SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,Confirmatory,,
5059,742130,1,3,,123097261,31703,Active,,,0.03625,IC50,SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,Confirmatory,,
5060,742131,1,3,,123097261,31703,Active,,,0.7710199999999999,IC50,SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.,Confirmatory,,
5061,742132,1,3,,123097261,31703,Active,,,0.03373,IC50,SANGER: Inhibition of human EB2 cell growth in a cell viability assay.,Confirmatory,,
5062,742133,1,3,,123097261,31703,Active,,,8.686860000000001,IC50,SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.,Confirmatory,,
5063,742136,1,3,,123097261,31703,Active,,,4.76541,IC50,SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.,Confirmatory,,
5064,742137,1,3,,123097261,31703,Active,,,8.372160000000001,IC50,SANGER: Inhibition of human EFE-184 cell growth in a cell viability assay.,Confirmatory,,
5065,742138,1,3,,123097261,31703,Active,,,0.47827,IC50,SANGER: Inhibition of human EFM-19 cell growth in a cell viability assay.,Confirmatory,,
5066,742139,1,3,,123097261,31703,Active,,,0.36185,IC50,SANGER: Inhibition of human EFO-21 cell growth in a cell viability assay.,Confirmatory,,
5067,742140,1,3,,123097261,31703,Active,,,0.09744,IC50,SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,Confirmatory,,
5068,742141,1,3,,123097261,31703,Active,,,0.59827,IC50,SANGER: Inhibition of human EGI-1 cell growth in a cell viability assay.,Confirmatory,,
5069,742142,1,3,,123097261,31703,Active,,,0.11259000000000001,IC50,SANGER: Inhibition of human EHEB cell growth in a cell viability assay.,Confirmatory,,
5070,742143,1,3,,123097261,31703,Active,,,0.87187,IC50,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,Confirmatory,,
5071,742144,1,3,,123097261,31703,Active,,,0.32541,IC50,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,Confirmatory,,
5072,742146,1,3,,123097261,31703,Active,,,0.01372,IC50,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,Confirmatory,,
5073,742147,1,3,,123097261,31703,Active,,,0.08947999999999999,IC50,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,Confirmatory,,
5074,742148,1,3,,123097261,31703,Active,,,0.00611,IC50,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,Confirmatory,,
5075,742149,1,3,,123097261,31703,Active,,,0.03922,IC50,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,Confirmatory,,
5076,742150,1,3,,123097261,31703,Active,,,0.13712,IC50,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,Confirmatory,,
5077,742151,1,3,,123097261,31703,Active,,,0.0514,IC50,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,Confirmatory,,
5078,742152,1,3,,123097261,31703,Active,,,0.02107,IC50,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,Confirmatory,,
5079,742153,1,3,,123097261,31703,Active,,,0.011090000000000001,IC50,SANGER: Inhibition of human ESS-1 cell growth in a cell viability assay.,Confirmatory,,
5080,742154,1,3,,123097261,31703,Active,,,0.08301,IC50,SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.,Confirmatory,,
5081,742155,1,3,,123097261,31703,Active,,,2.3008900000000003,IC50,SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.,Confirmatory,,
5082,742156,1,3,,123097261,31703,Active,,,0.06135,IC50,SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.,Confirmatory,,
5083,742157,1,3,,123097261,31703,Active,,,0.34156,IC50,SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.,Confirmatory,,
5084,742159,1,3,,123097261,31703,Active,,,0.00963,IC50,SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.,Confirmatory,,
5085,742160,1,3,,123097261,31703,Active,,,0.0019100000000000002,IC50,SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.,Confirmatory,,
5086,742161,1,3,,123097261,31703,Active,,,0.2509,IC50,SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.,Confirmatory,,
5087,742163,1,3,,123097261,31703,Active,,,0.9704,IC50,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,Confirmatory,,
5088,742164,1,3,,123097261,31703,Active,,,0.27989,IC50,SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,Confirmatory,,
5089,742165,1,3,,123097261,31703,Active,,,0.03063,IC50,SANGER: Inhibition of human EW-7 cell growth in a cell viability assay.,Confirmatory,,
5090,742166,1,3,,123097261,31703,Active,,,0.027780000000000003,IC50,SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.,Confirmatory,,
5091,742167,1,3,,123097261,31703,Active,,,0.10217999999999999,IC50,SANGER: Inhibition of human FADU cell growth in a cell viability assay.,Confirmatory,,
5092,742168,1,3,,123097261,31703,Active,,,0.22937,IC50,SANGER: Inhibition of human FTC-133 cell growth in a cell viability assay.,Confirmatory,,
5093,742169,1,3,,123097261,31703,Active,,,0.027880000000000002,IC50,SANGER: Inhibition of human G-361 cell growth in a cell viability assay.,Confirmatory,,
5094,742170,1,3,,123097261,31703,Active,,,0.0302,IC50,SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,Confirmatory,,
5095,742171,1,3,,123097261,31703,Active,,,0.09909,IC50,SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,Confirmatory,,
5096,742172,1,3,,123097261,31703,Active,,,0.25690999999999997,IC50,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,Confirmatory,,
5097,742173,1,3,,123097261,31703,Active,,,0.05996,IC50,SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,Confirmatory,,
5098,742174,1,3,,123097261,31703,Active,,,0.21273000000000003,IC50,SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.,Confirmatory,,
5099,742175,1,3,,123097261,31703,Active,,,0.72512,IC50,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,Confirmatory,,
5100,742176,1,3,,123097261,31703,Active,,,0.8614799999999999,IC50,SANGER: Inhibition of human GCT cell growth in a cell viability assay.,Confirmatory,,
5101,742177,1,3,,123097261,31703,Active,,,0.1597,IC50,SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.,Confirmatory,,
5102,742178,1,3,,123097261,31703,Active,,,0.06965,IC50,SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.,Confirmatory,,
5103,742179,1,3,,123097261,31703,Active,,,0.09333,IC50,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,Confirmatory,,
5104,742180,1,3,,123097261,31703,Active,,,2.39738,IC50,SANGER: Inhibition of human GMS-10 cell growth in a cell viability assay.,Confirmatory,,
5105,742181,1,3,,123097261,31703,Active,,,0.28556,IC50,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,Confirmatory,,
5106,742182,1,3,,123097261,31703,Active,,,0.04912,IC50,SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,Confirmatory,,
5107,742183,1,3,,123097261,31703,Active,,,0.25542,IC50,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,Confirmatory,,
5108,742184,1,3,,123097261,31703,Active,,,0.06719,IC50,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,Confirmatory,,
5109,742186,1,3,,123097261,31703,Active,,,0.07156,IC50,SANGER: Inhibition of human H4 cell growth in a cell viability assay.,Confirmatory,,
5110,742188,1,3,,123097261,31703,Active,,,0.31344,IC50,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,Confirmatory,,
5111,742189,1,3,,123097261,31703,Active,,,0.03732,IC50,SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.,Confirmatory,,
5112,742190,1,3,,123097261,31703,Active,,,10.4797,IC50,SANGER: Inhibition of human HCC1143 cell growth in a cell viability assay.,Confirmatory,,
5113,742191,1,3,,123097261,31703,Active,,,0.5914699999999999,IC50,SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.,Confirmatory,,
5114,742192,1,3,,123097261,31703,Active,,,8.15122,IC50,SANGER: Inhibition of human HCC1395 cell growth in a cell viability assay.,Confirmatory,,
5115,742193,1,3,,123097261,31703,Active,,,0.63174,IC50,SANGER: Inhibition of human HCC1419 cell growth in a cell viability assay.,Confirmatory,,
5116,742194,1,3,,123097261,31703,Active,,,0.10934,IC50,SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,Confirmatory,,
5117,742195,1,3,,123097261,31703,Active,,,0.07245,IC50,SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.,Confirmatory,,
5118,742196,1,3,,123097261,31703,Active,,,0.07496,IC50,SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,Confirmatory,,
5119,742197,1,3,,123097261,31703,Active,,,0.11584000000000001,IC50,SANGER: Inhibition of human HCC1937 cell growth in a cell viability assay.,Confirmatory,,
5120,742198,1,3,,123097261,31703,Active,,,0.54083,IC50,SANGER: Inhibition of human HCC1954 cell growth in a cell viability assay.,Confirmatory,,
5121,742199,1,3,,123097261,31703,Active,,,0.06395,IC50,SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.,Confirmatory,,
5122,742200,1,3,,123097261,31703,Active,,,0.18166,IC50,SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,Confirmatory,,
5123,742201,1,3,,123097261,31703,Active,,,0.01744,IC50,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,Confirmatory,,
5124,742202,1,3,,123097261,31703,Active,,,0.0425,IC50,SANGER: Inhibition of human HCC38 cell growth in a cell viability assay.,Confirmatory,,
5125,742203,1,3,,123097261,31703,Active,,,2.05463,IC50,SANGER: Inhibition of human HCC70 cell growth in a cell viability assay.,Confirmatory,,
5126,742204,1,3,,123097261,31703,Active,,,0.01807,IC50,SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,Confirmatory,,
5127,742205,1,3,,123097261,31703,Active,,,0.16487000000000002,IC50,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,Confirmatory,,
5128,742206,1,3,,123097261,31703,Active,,,0.20739000000000002,IC50,SANGER: Inhibition of human HCT-116 cell growth in a cell viability assay.,Confirmatory,,
5129,742207,1,3,,123097261,31703,Active,,,2.35466,IC50,SANGER: Inhibition of human HCT-15 cell growth in a cell viability assay.,Confirmatory,,
5130,742208,1,3,,123097261,31703,Active,,,0.27279000000000003,IC50,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,Confirmatory,,
5131,742209,1,3,,123097261,31703,Active,,,0.5685899999999999,IC50,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,Confirmatory,,
5132,742210,1,3,,123097261,31703,Active,,,0.18283,IC50,SANGER: Inhibition of human HEC-1 cell growth in a cell viability assay.,Confirmatory,,
5133,742211,1,3,,123097261,31703,Active,,,0.17515,IC50,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,Confirmatory,,
5134,742212,1,3,,123097261,31703,Active,,,0.01356,IC50,SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,Confirmatory,,
5135,742213,1,3,,123097261,31703,Active,,,0.24145999999999998,IC50,SANGER: Inhibition of human HH cell growth in a cell viability assay.,Confirmatory,,
5136,742214,1,3,,123097261,31703,Active,,,0.06256,IC50,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,Confirmatory,,
5137,742215,1,3,,123097261,31703,Active,,,0.0358,IC50,SANGER: Inhibition of human HLE cell growth in a cell viability assay.,Confirmatory,,
5138,742216,1,3,,123097261,31703,Active,,,0.0226,IC50,SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,Confirmatory,,
5139,742217,1,3,,123097261,31703,Active,,,0.35427,IC50,SANGER: Inhibition of human HN cell growth in a cell viability assay.,Confirmatory,,
5140,742218,1,3,,123097261,31703,Active,,,0.22283000000000003,IC50,SANGER: Inhibition of human HO-1-N-1 cell growth in a cell viability assay.,Confirmatory,,
5141,742219,1,3,,123097261,31703,Active,,,0.03588,IC50,SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,Confirmatory,,
5142,742220,1,3,,123097261,31703,Active,,,0.2907,IC50,SANGER: Inhibition of human HOP-92 cell growth in a cell viability assay.,Confirmatory,,
5143,742221,1,3,,123097261,31703,Active,,,0.04529,IC50,SANGER: Inhibition of human HOS cell growth in a cell viability assay.,Confirmatory,,
5144,742222,1,3,,123097261,31703,Active,,,0.5272399999999999,IC50,SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,Confirmatory,,
5145,742223,1,3,,123097261,31703,Active,,,0.02678,IC50,SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,Confirmatory,,
5146,742224,1,3,,123097261,31703,Active,,,0.07453,IC50,SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,Confirmatory,,
5147,742225,1,3,,123097261,31703,Active,,,0.07576000000000001,IC50,SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,Confirmatory,,
5148,742226,1,3,,123097261,31703,Active,,,0.40515,IC50,SANGER: Inhibition of human HT cell growth in a cell viability assay.,Confirmatory,,
5149,742227,1,3,,123097261,31703,Active,,,0.014819999999999998,IC50,SANGER: Inhibition of human HT-1080 cell growth in a cell viability assay.,Confirmatory,,
5150,742228,1,3,,123097261,31703,Active,,,0.21258000000000002,IC50,SANGER: Inhibition of human HT-1197 cell growth in a cell viability assay.,Confirmatory,,
5151,742229,1,3,,123097261,31703,Active,,,0.18900999999999998,IC50,SANGER: Inhibition of human HT-1376 cell growth in a cell viability assay.,Confirmatory,,
5152,742230,1,3,,123097261,31703,Active,,,0.00351,IC50,SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.,Confirmatory,,
5153,742231,1,3,,123097261,31703,Active,,,0.03657,IC50,SANGER: Inhibition of human HT-29 cell growth in a cell viability assay.,Confirmatory,,
5154,742232,1,3,,123097261,31703,Active,,,0.13304000000000002,IC50,SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,Confirmatory,,
5155,742233,1,3,,123097261,31703,Active,,,1.4716799999999999,IC50,SANGER: Inhibition of human HT55 cell growth in a cell viability assay.,Confirmatory,,
5156,742234,1,3,,123097261,31703,Active,,,0.70394,IC50,SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,Confirmatory,,
5157,742235,1,3,,123097261,31703,Active,,,0.00212,IC50,SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,Confirmatory,,
5158,742236,1,3,,123097261,31703,Active,,,2.01782,IC50,SANGER: Inhibition of human Hs-578-T cell growth in a cell viability assay.,Confirmatory,,
5159,742237,1,3,,123097261,31703,Active,,,0.07293,IC50,SANGER: Inhibition of human HuCCT1 cell growth in a cell viability assay.,Confirmatory,,
5160,742238,1,3,,123097261,31703,Active,,,0.25844,IC50,SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,Confirmatory,,
5161,742239,1,3,,123097261,31703,Active,,,2.36583,IC50,SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,Confirmatory,,
5162,742241,1,3,,123097261,31703,Active,,,0.16555,IC50,SANGER: Inhibition of human HuP-T3 cell growth in a cell viability assay.,Confirmatory,,
5163,742242,1,3,,123097261,31703,Active,,,0.05222,IC50,SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,Confirmatory,,
5164,742243,1,3,,123097261,31703,Active,,,0.06354,IC50,SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,Confirmatory,,
5165,742244,1,3,,123097261,31703,Active,,,0.03388,IC50,SANGER: Inhibition of human IGR-1 cell growth in a cell viability assay.,Confirmatory,,
5166,742245,1,3,,123097261,31703,Active,,,0.0072,IC50,SANGER: Inhibition of human IGROV-1 cell growth in a cell viability assay.,Confirmatory,,
5167,742246,1,3,,123097261,31703,Active,,,0.05143,IC50,SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.,Confirmatory,,
5168,742247,1,3,,123097261,31703,Active,,,0.03468,IC50,SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.,Confirmatory,,
5169,742248,1,3,,123097261,31703,Active,,,0.19621,IC50,SANGER: Inhibition of human IPC-298 cell growth in a cell viability assay.,Confirmatory,,
5170,742249,1,3,,123097261,31703,Active,,,0.04484,IC50,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,Confirmatory,,
5171,742250,1,3,,123097261,31703,Active,,,0.32335,IC50,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,Confirmatory,,
5172,742251,1,3,,123097261,31703,Active,,,0.51742,IC50,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,Confirmatory,,
5173,742252,1,3,,123097261,31703,Active,,,0.07381,IC50,SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,Confirmatory,,
5174,742253,1,3,,123097261,31703,Active,,,0.09631,IC50,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,Confirmatory,,
5175,742254,1,3,,123097261,31703,Active,,,0.02134,IC50,SANGER: Inhibition of human J82 cell growth in a cell viability assay.,Confirmatory,,
5176,742255,1,3,,123097261,31703,Active,,,0.62595,IC50,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,Confirmatory,,
5177,742256,1,3,,123097261,31703,Active,,,0.09512000000000001,IC50,SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,Confirmatory,,
5178,742257,1,3,,123097261,31703,Active,,,0.24216999999999997,IC50,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,Confirmatory,,
5179,742258,1,3,,123097261,31703,Active,,,4.60618,IC50,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,Confirmatory,,
5180,742259,1,4,,123097261,31703,Active,,,0.1378,IC50,SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.,Confirmatory,,
5181,742260,1,3,,123097261,31703,Active,,,0.3858,IC50,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,Confirmatory,,
5182,742261,1,3,,123097261,31703,Active,,,21.4418,IC50,SANGER: Inhibition of human K052 cell growth in a cell viability assay.,Confirmatory,,
5183,742262,1,3,,123097261,31703,Active,,,0.0969,IC50,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,Confirmatory,,
5184,742263,1,3,,123097261,31703,Active,,,0.029330000000000002,IC50,SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.,Confirmatory,,
5185,742264,1,3,,123097261,31703,Active,,,1.47841,IC50,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,Confirmatory,,
5186,742265,1,3,,123097261,31703,Active,,,0.19341,IC50,SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,Confirmatory,,
5187,742266,1,3,,123097261,31703,Active,,,1.26763,IC50,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,Confirmatory,,
5188,742268,1,3,,123097261,31703,Active,,,0.02105,IC50,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,Confirmatory,,
5189,742269,1,3,,123097261,31703,Active,,,0.36152,IC50,SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.,Confirmatory,,
5190,742270,1,3,,123097261,31703,Active,,,0.00634,IC50,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,Confirmatory,,
5191,742271,1,3,,123097261,31703,Active,,,1.0190000000000001,IC50,SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.,Confirmatory,,
5192,742272,1,3,,123097261,31703,Active,,,0.17547000000000001,IC50,SANGER: Inhibition of human KLE cell growth in a cell viability assay.,Confirmatory,,
5193,742273,1,3,,123097261,31703,Active,,,0.09068,IC50,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,Confirmatory,,
5194,742274,1,3,,123097261,31703,Active,,,0.21815,IC50,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,Confirmatory,,
5195,742275,1,3,,123097261,31703,Active,,,0.5763199999999999,IC50,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,Confirmatory,,
5196,742276,1,3,,123097261,31703,Active,,,0.41806000000000004,IC50,SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.,Confirmatory,,
5197,742277,1,3,,123097261,31703,Active,,,0.24266999999999997,IC50,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,Confirmatory,,
5198,742279,1,3,,123097261,31703,Active,,,0.16032000000000002,IC50,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,Confirmatory,,
5199,742280,1,3,,123097261,31703,Active,,,0.24871,IC50,SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,Confirmatory,,
5200,742281,1,3,,123097261,31703,Active,,,0.04077,IC50,SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,Confirmatory,,
5201,742283,1,3,,123097261,31703,Active,,,1.66343,IC50,SANGER: Inhibition of human KP-N-YN cell growth in a cell viability assay.,Confirmatory,,
5202,742284,1,3,,123097261,31703,Active,,,0.2184,IC50,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,Confirmatory,,
5203,742285,1,3,,123097261,31703,Active,,,0.00344,IC50,SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.,Confirmatory,,
5204,742286,1,3,,123097261,31703,Active,,,2.26917,IC50,SANGER: Inhibition of human KU-19-19 cell growth in a cell viability assay.,Confirmatory,,
5205,742287,1,3,,123097261,31703,Active,,,0.03324,IC50,SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,Confirmatory,,
5206,742288,1,3,,123097261,31703,Active,,,0.12675999999999998,IC50,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,Confirmatory,,
5207,742289,1,3,,123097261,31703,Active,,,1.49429,IC50,SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,Confirmatory,,
5208,742290,1,3,,123097261,31703,Active,,,0.05042,IC50,SANGER: Inhibition of human KYSE-140 cell growth in a cell viability assay.,Confirmatory,,
5209,742291,1,3,,123097261,31703,Active,,,0.027780000000000003,IC50,SANGER: Inhibition of human KYSE-150 cell growth in a cell viability assay.,Confirmatory,,
5210,742292,1,3,,123097261,31703,Active,,,0.05975,IC50,SANGER: Inhibition of human KYSE-180 cell growth in a cell viability assay.,Confirmatory,,
5211,742293,1,3,,123097261,31703,Active,,,0.007209999999999999,IC50,SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,Confirmatory,,
5212,742294,1,3,,123097261,31703,Active,,,0.10346,IC50,SANGER: Inhibition of human KYSE-410 cell growth in a cell viability assay.,Confirmatory,,
5213,742295,1,3,,123097261,31703,Active,,,0.04471,IC50,SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,Confirmatory,,
5214,742296,1,3,,123097261,31703,Active,,,0.01548,IC50,SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,Confirmatory,,
5215,742297,1,3,,123097261,31703,Active,,,0.26077,IC50,SANGER: Inhibition of human KYSE-520 cell growth in a cell viability assay.,Confirmatory,,
5216,742298,1,3,,123097261,31703,Active,,,0.22466,IC50,SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,Confirmatory,,
5217,742299,1,3,,123097261,31703,Active,,,0.32443,IC50,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,Confirmatory,,
5218,742300,1,3,,123097261,31703,Active,,,0.7909,IC50,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,Confirmatory,,
5219,742301,1,3,,123097261,31703,Active,,,0.21349,IC50,SANGER: Inhibition of human L-540 cell growth in a cell viability assay.,Confirmatory,,
5220,742302,1,3,,123097261,31703,Active,,,0.4373,IC50,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,Confirmatory,,
5221,742303,1,3,,123097261,31703,Active,,,0.31511,IC50,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,Confirmatory,,
5222,742304,1,3,,123097261,31703,Active,,,0.03597,IC50,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,Confirmatory,,
5223,742305,1,3,,123097261,31703,Active,,,0.23510999999999999,IC50,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,Confirmatory,,
5224,742306,1,3,,123097261,31703,Active,,,0.4131,IC50,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,Confirmatory,,
5225,742307,1,3,,123097261,31703,Active,,,0.34464,IC50,SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,Confirmatory,,
5226,742308,1,3,,123097261,31703,Active,,,0.12335,IC50,SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.,Confirmatory,,
5227,742309,1,3,,123097261,31703,Active,,,6.4680599999999995,IC50,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,Confirmatory,,
5228,742310,1,3,,123097261,31703,Active,,,0.20625,IC50,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,Confirmatory,,
5229,742311,1,3,,123097261,31703,Active,,,0.07845,IC50,SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,Confirmatory,,
5230,742312,1,3,,123097261,31703,Active,,,1.66203,IC50,SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.,Confirmatory,,
5231,742313,1,3,,123097261,31703,Active,,,0.00507,IC50,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,Confirmatory,,
5232,742314,1,3,,123097261,31703,Active,,,0.24089000000000002,IC50,SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.,Confirmatory,,
5233,742315,1,3,,123097261,31703,Active,,,0.02054,IC50,SANGER: Inhibition of human LCLC-103H cell growth in a cell viability assay.,Confirmatory,,
5234,742316,1,3,,123097261,31703,Active,,,0.01183,IC50,SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,Confirmatory,,
5235,742317,1,3,,123097261,31703,Active,,,0.58107,IC50,SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,Confirmatory,,
5236,742318,1,3,,123097261,31703,Active,,,1.8014299999999999,IC50,SANGER: Inhibition of human LN-405 cell growth in a cell viability assay.,Confirmatory,,
5237,742319,1,3,,123097261,31703,Active,,,0.20447,IC50,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,Confirmatory,,
5238,742320,1,3,,123097261,31703,Active,,,0.02132,IC50,SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.,Confirmatory,,
5239,742321,1,3,,123097261,31703,Active,,,0.38919000000000004,IC50,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,Confirmatory,,
5240,742322,1,3,,123097261,31703,Unspecified,,,67.9284,IC50,SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.,Confirmatory,,
5241,742323,1,3,,123097261,31703,Active,,,0.38451,IC50,SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.,Confirmatory,,
5242,742324,1,3,,123097261,31703,Active,,,0.01846,IC50,SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.,Confirmatory,,
5243,742325,1,3,,123097261,31703,Active,,,0.09906000000000001,IC50,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,Confirmatory,,
5244,742326,1,3,,123097261,31703,Active,,,18.6093,IC50,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,Confirmatory,,
5245,742327,1,3,,123097261,31703,Active,,,0.06767999999999999,IC50,SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.,Confirmatory,,
5246,742329,1,3,,123097261,31703,Active,,,0.34492,IC50,SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.,Confirmatory,,
5247,742330,1,3,,123097261,31703,Active,,,0.6394,IC50,SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.,Confirmatory,,
5248,742331,1,4,,123097261,31703,Active,,,0.3464,IC50,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,Confirmatory,,
5249,742332,1,3,,123097261,31703,Active,,,0.14655,IC50,SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,Confirmatory,,
5250,742333,1,3,,123097261,31703,Active,,,0.10924,IC50,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,Confirmatory,,
5251,742334,1,3,,123097261,31703,Active,,,0.08182,IC50,SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,Confirmatory,,
5252,742335,1,3,,123097261,31703,Active,,,0.03137,IC50,SANGER: Inhibition of human M059J cell growth in a cell viability assay.,Confirmatory,,
5253,742336,1,3,,123097261,31703,Active,,,0.90527,IC50,SANGER: Inhibition of human M14 cell growth in a cell viability assay.,Confirmatory,,
5254,742337,1,3,,123097261,31703,Active,,,0.04874,IC50,SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.,Confirmatory,,
5255,742338,1,3,,123097261,31703,Active,,,0.0679,IC50,SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,Confirmatory,,
5256,742339,1,3,,123097261,31703,Active,,,0.39141,IC50,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,Confirmatory,,
5257,742340,1,3,,123097261,31703,Active,,,0.01165,IC50,SANGER: Inhibition of human MCF7 cell growth in a cell viability assay.,Confirmatory,,
5258,742341,1,3,,123097261,31703,Active,,,1.61711,IC50,SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.,Confirmatory,,
5259,742342,1,3,,123097261,31703,Active,,,0.49901,IC50,SANGER: Inhibition of human MDA-MB-157 cell growth in a cell viability assay.,Confirmatory,,
5260,742343,1,3,,123097261,31703,Active,,,0.9715299999999999,IC50,SANGER: Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay.,Confirmatory,,
5261,742344,1,3,,123097261,31703,Active,,,1.53055,IC50,SANGER: Inhibition of human MDA-MB-231 cell growth in a cell viability assay.,Confirmatory,,
5262,742345,1,3,,123097261,31703,Active,,,0.29265,IC50,SANGER: Inhibition of human MDA-MB-361 cell growth in a cell viability assay.,Confirmatory,,
5263,742346,1,3,,123097261,31703,Active,,,7.57303,IC50,SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,Confirmatory,,
5264,742347,1,3,,123097261,31703,Active,,,4.85134,IC50,SANGER: Inhibition of human MDA-MB-453 cell growth in a cell viability assay.,Confirmatory,,
5265,742348,1,3,,123097261,31703,Active,,,0.07618,IC50,SANGER: Inhibition of human MDA-MB-468 cell growth in a cell viability assay.,Confirmatory,,
5266,742349,1,3,,123097261,31703,Active,,,0.18608,IC50,SANGER: Inhibition of human ME-180 cell growth in a cell viability assay.,Confirmatory,,
5267,742350,1,3,,123097261,31703,Active,,,0.1766,IC50,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,Confirmatory,,
5268,742351,1,3,,123097261,31703,Active,,,0.0183,IC50,SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,Confirmatory,,
5269,742352,1,3,,123097261,31703,Active,,,0.0145,IC50,SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,Confirmatory,,
5270,742353,1,3,,123097261,31703,Active,,,0.09953,IC50,SANGER: Inhibition of human MES-SA cell growth in a cell viability assay.,Confirmatory,,
5271,742354,1,3,,123097261,31703,Active,,,1.66812,IC50,SANGER: Inhibition of human MFE-280 cell growth in a cell viability assay.,Confirmatory,,
5272,742355,1,3,,123097261,31703,Active,,,0.07049,IC50,SANGER: Inhibition of human MFE-296 cell growth in a cell viability assay.,Confirmatory,,
5273,742356,1,3,,123097261,31703,Active,,,0.00399,IC50,SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,Confirmatory,,
5274,742357,1,3,,123097261,31703,Unspecified,,,328.305,IC50,SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.,Confirmatory,,
5275,742358,1,3,,123097261,31703,Active,,,0.022080000000000002,IC50,SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,Confirmatory,,
5276,742359,1,3,,123097261,31703,Active,,,0.35921,IC50,SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.,Confirmatory,,
5277,742360,1,3,,123097261,31703,Active,,,0.021580000000000002,IC50,SANGER: Inhibition of human MHH-ES-1 cell growth in a cell viability assay.,Confirmatory,,
5278,742361,1,3,,123097261,31703,Active,,,0.22021999999999997,IC50,SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.,Confirmatory,,
5279,742362,1,3,,123097261,31703,Active,,,0.22981999999999997,IC50,SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.,Confirmatory,,
5280,742363,1,3,,123097261,31703,Active,,,0.03424,IC50,SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,Confirmatory,,
5281,742364,1,3,,123097261,31703,Active,,,0.009859999999999999,IC50,SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,Confirmatory,,
5282,742365,1,3,,123097261,31703,Active,,,0.03191,IC50,SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,Confirmatory,,
5283,742366,1,3,,123097261,31703,Active,,,0.08151,IC50,SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,Confirmatory,,
5284,742367,1,3,,123097261,31703,Active,,,0.68995,IC50,SANGER: Inhibition of human MKN7 cell growth in a cell viability assay.,Confirmatory,,
5285,742368,1,3,,123097261,31703,Active,,,0.13516,IC50,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,Confirmatory,,
5286,742369,1,3,,123097261,31703,Active,,,0.12208,IC50,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,Confirmatory,,
5287,742370,1,3,,123097261,31703,Active,,,0.10647999999999999,IC50,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,Confirmatory,,
5288,742371,1,3,,123097261,31703,Active,,,0.60537,IC50,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,Confirmatory,,
5289,742373,1,3,,123097261,31703,Active,,,0.2905,IC50,SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.,Confirmatory,,
5290,742374,1,3,,123097261,31703,Active,,,0.02286,IC50,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,Confirmatory,,
5291,742375,1,4,,123097261,31703,Active,,,0.15436,IC50,SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,Confirmatory,,
5292,742376,1,3,,123097261,31703,Active,,,0.39294,IC50,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,Confirmatory,,
5293,742377,1,3,,123097261,31703,Active,,,0.043660000000000004,IC50,SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.,Confirmatory,,
5294,742378,1,3,,123097261,31703,Active,,,0.25253000000000003,IC50,SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.,Confirmatory,,
5295,742379,1,3,,123097261,31703,Unspecified,,,214.955,IC50,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,Confirmatory,,
5296,742380,1,3,,123097261,31703,Active,,,0.010029999999999999,IC50,SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.,Confirmatory,,
5297,742381,1,3,,123097261,31703,Active,,,0.023809999999999998,IC50,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,Confirmatory,,
5298,742382,1,3,,123097261,31703,Active,,,0.03392,IC50,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,Confirmatory,,
5299,742383,1,3,,123097261,31703,Active,,,0.11284000000000001,IC50,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,Confirmatory,,
5300,742384,1,3,,123097261,31703,Active,,,3.46086,IC50,SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,Confirmatory,,
5301,742385,1,4,,123097261,31703,Active,,,0.80465,IC50,SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.,Confirmatory,,
5302,742386,1,3,,123097261,31703,Active,,,0.01863,IC50,SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,Confirmatory,,
5303,742387,1,3,,123097261,31703,Active,,,0.045989999999999996,IC50,SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,Confirmatory,,
5304,742388,1,3,,123097261,31703,Active,,,0.18809,IC50,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,Confirmatory,,
5305,742389,1,3,,123097261,31703,Active,,,0.27712,IC50,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,Confirmatory,,
5306,742390,1,3,,123097261,31703,Active,,,0.13455,IC50,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,Confirmatory,,
5307,742393,1,3,,123097261,31703,Active,,,0.35980999999999996,IC50,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,Confirmatory,,
5308,742394,1,3,,123097261,31703,Active,,,2.185,IC50,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,Confirmatory,,
5309,742395,1,3,,123097261,31703,Active,,,0.0792,IC50,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,Confirmatory,,
5310,742398,1,3,,123097261,31703,Active,,,0.020130000000000002,IC50,SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,Confirmatory,,
5311,742400,1,3,,123097261,31703,Active,,,0.73795,IC50,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,Confirmatory,,
5312,742401,1,3,,123097261,31703,Active,,,0.57987,IC50,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,Confirmatory,,
5313,742403,1,3,,123097261,31703,Active,,,0.03759,IC50,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,Confirmatory,,
5314,742404,1,3,,123097261,31703,Active,,,0.32116999999999996,IC50,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,Confirmatory,,
5315,742405,1,3,,123097261,31703,Active,,,0.15224000000000001,IC50,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,Confirmatory,,
5316,742406,1,3,,123097261,31703,Unspecified,,,51.433,IC50,SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.,Confirmatory,,
5317,742407,1,3,,123097261,31703,Active,,,0.37004000000000004,IC50,SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.,Confirmatory,,
5318,742408,1,3,,123097261,31703,Unspecified,,,71.6371,IC50,SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.,Confirmatory,,
5319,742409,1,3,,123097261,31703,Active,,,0.06464,IC50,SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,Confirmatory,,
5320,742410,1,3,,123097261,31703,Active,,,1.43159,IC50,SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.,Confirmatory,,
5321,743244,1,1,,124886893,31703,Active,,,0.5258,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
5322,743322,2,1,,124886893,31703,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
5323,743323,2,1,,124886893,31703,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
5324,743324,2,1,,124886893,31703,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
5325,743470,1,1,,164339434,31703,Inconclusive,,,,AbsAC35_uM,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader_7071-01_Inhibitor_Dose_DryPowder_Activity_Set15,Confirmatory,,
5326,743471,1,1,,164339434,31703,Active,,,0.0577,AbsAC35_uM,HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set12,Confirmatory,,
5327,743472,1,1,,164339434,31703,Active,,,0.33299999999999996,AbsAC35_uM,A549 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-06_Inhibitor_Dose_DryPowder_Activity_Set12,Confirmatory,,
5328,743477,1,1,,164339434,31703,Active,,,0.05,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
5329,743478,1,1,,164339434,31703,Active,,,0.05,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent A673 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-03_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
5330,743479,1,1,,164339434,31703,Active,,,15.09,AbsAC35_uM,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
5331,744294,1,2,,123097261,31703,Active,,,0.5,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
5332,744295,1,2,,123097261,31703,Active,,,6.0,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
5333,744418,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,23511021.0,
5334,744419,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells,Other,23511021.0,
5335,744420,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,23511021.0,
5336,744421,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells,Other,23511021.0,
5337,744422,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Hep3B cells,Other,23511021.0,
5338,745174,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,23548547.0,
5339,745175,1,1,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,23548547.0,
5340,745477,1,1,,123097261,31703,Active,,,0.39,EC50,Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay,Confirmatory,23600925.0,
5341,745481,1,1,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5342,745482,1,2,,123097261,31703,Active,,,0.27,IC50,Cytotoxicity against human RPMI18226 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5343,745483,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human SW872 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5344,745484,1,1,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5345,745485,1,1,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human MNNG-HOS cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5346,745486,1,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MDA-MB-436 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5347,745487,1,1,,123097261,31703,Active,,,0.67,IC50,Cytotoxicity against human U266 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5348,745488,1,2,,123097261,31703,Active,,,0.065,IC50,Cytotoxicity against human NCI-H929 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5349,745489,1,1,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5350,745490,1,1,,123097261,31703,Active,,,0.076,IC50,Cytotoxicity against human SK-UT-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5351,745491,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human T47D cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5352,745492,1,1,,123097261,31703,Active,,,0.042,IC50,Cytotoxicity against human SK-ES-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5353,745493,1,1,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5354,745494,1,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human SK-BR-3 cells after 72 hrs by resazurin/resorufin-based fluorescence assay,Confirmatory,23600925.0,
5355,745736,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition by SRB assay,Confirmatory,23634786.0,
5356,745737,1,1,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay,Confirmatory,23634786.0,
5357,745738,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay,Confirmatory,23634786.0,
5358,745739,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SKOV3 cells assessed as growth inhibition by SRB assay,Confirmatory,23634786.0,
5359,746834,1,1,,123097261,31703,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CD34-positive blood stem/progenitor cells to IC50 for human MA9.3 cells",Other,23578690.0,
5360,746835,3,1,,123097261,31703,Active,,,0.086,IC50,Cytotoxicity against human MA9.3 cells after 48 hrs by MTT assay,Confirmatory,23578690.0,
5361,746836,3,1,,123097261,31703,Active,,,0.076,IC50,Cytotoxicity against human CD34-positive blood stem/progenitor cells after 48 hrs by MTT assay,Confirmatory,23578690.0,
5362,747455,1,1,,123097261,31703,Active,,,0.84,IC50,Cytotoxicity against human SNU638 cells by MTT assay,Confirmatory,23608763.0,
5363,747456,1,1,,123097261,31703,Active,,,2.91,IC50,Cytotoxicity against human T47D cells by MTT assay,Confirmatory,23608763.0,
5364,748704,1,1,,123097261,31703,Active,,,,,Induction of tau K19 (unknown origin) disaggregation assessed as decrease in paired helical filament formation measured disassembly-inducing half maxima after 10 days by thioflavin S fluorescence assay in presence of heparin,Other,23484434.0,
5365,748708,1,1,,123097261,31703,Active,,,1.1,IC50,Inhibition of tau K19 (unknown origin) aggregation assessed as inhibition of paired helical filament formation after 10 days by thioflavin S fluorescence assay in presence of heparin,Confirmatory,23484434.0,
5366,749785,3,1,,123097261,31703,Active,,,0.027999999999999997,GI50,Growth inhibition of human HL60 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23623253.0,
5367,749786,3,1,,123097261,31703,Active,,,0.1448,GI50,Growth inhibition of human A375-C5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23623253.0,
5368,749787,3,1,,123097261,31703,Active,,,0.0641,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23623253.0,
5369,749788,3,1,,123097261,31703,Active,,,0.0654,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23623253.0,
5370,750796,1,1,,123097261,31703,Unspecified,,,5000.0,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay,Confirmatory,23685942.0,
5371,750797,1,1,,123097261,31703,Unspecified,,,2500.0,IC50,Cytotoxicity against human QG56 cells after 24 hrs by MTT assay,Confirmatory,23685942.0,
5372,750798,1,1,,123097261,31703,Unspecified,,,5000.0,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,23685942.0,
5373,750799,1,1,,123097261,31703,Unspecified,,,2500.0,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,23685942.0,
5374,751269,1,1,,123097261,31703,Active,,,0.59,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23806110.0,
5375,751270,1,1,,123097261,31703,Active,,,0.94,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23806110.0,
5376,751271,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23806110.0,
5377,751272,1,1,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23806110.0,
5378,752627,1,1,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay,Confirmatory,23639650.0,
5379,752628,1,1,,123097261,31703,Active,,,0.56,IC50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,23639650.0,
5380,752629,1,1,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,23639650.0,
5381,753558,1,1,,123097261,31703,Active,,,0.08199999999999999,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay,Confirmatory,23664877.0,
5382,753560,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay,Confirmatory,23664877.0,
5383,753932,1,1,,123097261,31703,Unspecified,,,,,"Therapeutic index, ratio of IC50 for PHA-stimulated human PBMC cells to IC50 for human JURKAT-TALL cells",Other,23673218.0,
5384,753933,1,1,,123097261,31703,Active,,,0.271,IC50,Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay,Confirmatory,23673218.0,
5385,753934,1,2,,123097261,31703,Active,,,0.0096,IC50,Cytotoxicity against human JURKAT-TALL cells after 48 hrs by Alamar Blue assay,Confirmatory,23673218.0,
5386,754214,1,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay,Confirmatory,23772699.0,
5387,754217,1,1,,123097261,31703,Active,,,,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,23772699.0,
5388,754849,1,1,,123097261,31703,Unspecified,,,,,Hemolytic activity in rabbit RBC at 100 ug/mL after 3 hrs by colorimetric assay relative to control,Other,23643901.0,
5389,756946,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HGF cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5390,756947,1,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human C643 cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5391,756948,1,2,,123097261,31703,Active,,,1.81,IC50,Cytotoxicity against human Calu cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5392,756949,1,1,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5393,756951,1,1,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human PC3 cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5394,756952,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human U937 cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5395,756953,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,23802716.0,
5396,757700,1,1,,123097261,31703,Active,,,7.36,IC50,Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by SRB assay,Confirmatory,23708013.0,
5397,757701,1,1,,123097261,31703,Active,,,5.46,IC50,Cytotoxicity against human MCF7 cells assessed as cell survival after 48 hrs by SRB assay,Confirmatory,23708013.0,
5398,758718,1,1,,123097261,31703,Active,,,4.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23748152.0,
5399,758719,1,1,,123097261,31703,Active,,,6.0,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,23748152.0,
5400,758720,1,1,,123097261,31703,Active,,,4.1,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23748152.0,
5401,758818,1,1,,123097261,31703,Active,,,1.21,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,23764302.0,
5402,758819,1,1,,123097261,31703,Active,,,0.501,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,23764302.0,
5403,758820,1,1,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,23764302.0,
5404,758821,1,1,,123097261,31703,Active,,,0.451,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,23764302.0,
5405,761445,1,1,,123097261,31703,Active,,,0.065,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay,Confirmatory,23777898.0,
5406,761446,1,1,,123097261,31703,Active,,,0.07200000000000001,IC50,Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay,Confirmatory,23777898.0,
5407,761647,1,1,,123097261,31703,Active,,,15.88,IC50,Cytotoxicity against human MCF7 cells by colorimetric method,Confirmatory,23795891.0,
5408,761648,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human NCI-H187 cells by colorimetric method,Confirmatory,23795891.0,
5409,761649,1,3,,123097261,31703,Active,,,0.38,IC50,Cytotoxicity against human KB cells by colorimetric method,Confirmatory,23795891.0,
5410,761690,1,1,,123097261,31703,Active,,,0.5,LC50,Cytotoxicity against human A549 cells,Confirmatory,23799303.0,
5411,761692,1,1,,123097261,31703,Active,,,0.7,LC50,Cytotoxicity against human K562 cells,Confirmatory,23799303.0,
5412,761772,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human NCI-H187 cells by SRB assay,Confirmatory,23806014.0,
5413,761775,1,3,,123097261,31703,Active,,,0.56,IC50,Cytotoxicity against human KB cells by SRB assay,Confirmatory,23806014.0,
5414,761776,1,1,,123097261,31703,Active,,,7.66,IC50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,23806014.0,
5415,761829,1,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23810282.0,
5416,761830,1,1,,123097261,31703,Active,,,0.63,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23810282.0,
5417,761832,1,2,,123097261,31703,Active,,,0.33,IC50,Cytotoxicity against human 786 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23810282.0,
5418,762023,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SKOV3 cells by sulforhodamine B assay,Confirmatory,23815260.0,
5419,762024,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human A549 cells by sulforhodamine B assay,Confirmatory,23815260.0,
5420,762025,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay,Confirmatory,23815260.0,
5421,762027,1,1,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human HCT15 cells by sulforhodamine B assay,Confirmatory,23815260.0,
5422,762331,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells by SRB assay,Other,23831694.0,
5423,762332,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells by SRB assay,Other,23831694.0,
5424,762391,3,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
5425,762392,3,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
5426,762623,3,1,,123097261,31703,Active,,,0.21,IC50,Cytotoxicity against mouse P388 cells after 3 days by MTT assay,Confirmatory,23848233.0,
5427,762758,1,2,,123097261,31703,Active,,,3.24,IC50,Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay,Confirmatory,23850203.0,
5428,763661,1,1,,123097261,31703,Active,,,26.1,LC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23792351.0,
5429,763662,1,1,,123097261,31703,Active,,,21.4,LC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23792351.0,
5430,763663,1,1,,123097261,31703,Active,,,37.7,LC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,23792351.0,
5431,763664,1,1,,123097261,31703,Active,,,28.3,LC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23792351.0,
5432,764773,1,1,,123097261,31703,Active,,,1.02,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23871222.0,
5433,764774,1,1,,123097261,31703,Active,,,5.72,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,23871222.0,
5434,764826,1,1,,123097261,31703,Active,,,0.4,TGI,Antiproliferative activity against human HaCaT cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5435,764827,1,1,,123097261,31703,Active,,,3.6,TGI,Antiproliferative activity against human HT-29 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5436,764828,1,1,,123097261,31703,Active,,,45.5,TGI,Antiproliferative activity against human K562 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5437,764829,1,1,,123097261,31703,Active,,,2.5,TGI,Antiproliferative activity against human PC3 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5438,764830,1,1,,123097261,31703,Active,,,1.0,TGI,Antiproliferative activity against human 786-0 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5439,764831,1,2,,123097261,31703,Active,,,10.3,TGI,Antiproliferative activity against human NCI-ADR-RES cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5440,764832,1,1,,123097261,31703,Active,,,4.9,TGI,Antiproliferative activity against human MCF7 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5441,764833,1,1,,123097261,31703,Active,,,2.1,TGI,Antiproliferative activity against human U251 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5442,764834,1,1,,123097261,31703,Active,,,0.2,TGI,Antiproliferative activity against human UACC62 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay,Confirmatory,23876338.0,
5443,764943,3,1,,123097261,31703,Active,,,0.023,IC50,Cytotoxicity against human A2780 cells after 72 hrs by MTT assay,Confirmatory,23886686.0,
5444,765510,1,1,,123097261,31703,Active,,,4.3,LC50,Cytotoxicity against HEK293 cells after 24 hrs,Confirmatory,23869452.0,
5445,765575,1,1,,123097261,31703,Active,,,0.05,GI50,Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5446,765576,1,1,,123097261,31703,Active,,,0.23,GI50,Cytotoxicity against human BT549 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5447,765577,1,1,,123097261,31703,Active,,,0.06,GI50,Cytotoxicity against human T47D cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5448,765578,1,1,,123097261,31703,Active,,,0.33,GI50,Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5449,765579,1,1,,123097261,31703,Active,,,0.03,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5450,765580,1,1,,123097261,31703,Active,,,0.51,GI50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5451,765581,1,1,,123097261,31703,Active,,,0.11,GI50,Cytotoxicity against human DU145 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5452,765582,1,1,,123097261,31703,Active,,,0.49,GI50,Cytotoxicity against human UO31 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5453,765583,1,1,,123097261,31703,Active,,,0.32,GI50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5454,765584,1,1,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human TK10 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5455,765585,1,1,,123097261,31703,Active,,,0.07,GI50,Cytotoxicity against human SN12C cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5456,765586,1,1,,123097261,31703,Active,,,0.95,GI50,Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5457,765587,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human RXF393 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5458,765588,1,1,,123097261,31703,Active,,,0.08,GI50,Cytotoxicity against human ACHN cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5459,765589,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human A498 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5460,765590,1,1,,123097261,31703,Active,,,0.13,GI50,Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5461,765591,1,1,,123097261,31703,Active,,,0.22,GI50,Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5462,765592,1,1,,123097261,31703,Active,,,7.16,GI50,Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5463,765593,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5464,765594,1,1,,123097261,31703,Active,,,0.41,GI50,Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5465,765595,1,1,,123097261,31703,Active,,,0.37,GI50,Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5466,765596,1,1,,123097261,31703,Active,,,0.39,GI50,Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5467,765597,1,1,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human IGROV1 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5468,765598,1,1,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5469,765599,1,1,,123097261,31703,Active,,,0.14,GI50,Cytotoxicity against human UACC257 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5470,765600,1,1,,123097261,31703,Active,,,0.08,GI50,Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5471,765601,1,1,,123097261,31703,Active,,,0.21,GI50,Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5472,765602,1,1,,123097261,31703,Active,,,0.17,GI50,Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5473,765603,1,1,,123097261,31703,Active,,,0.25,GI50,Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5474,765604,1,1,,123097261,31703,Active,,,0.18,GI50,Cytotoxicity against human M14 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5475,765605,1,1,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5476,765606,1,1,,123097261,31703,Active,,,0.04,GI50,Cytotoxicity against human U251 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5477,765607,1,3,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5478,765608,1,1,,123097261,31703,Active,,,0.07,GI50,Cytotoxicity against human SNB75 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5479,765609,1,1,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human SF539 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5480,765610,1,1,,123097261,31703,Active,,,0.04,GI50,Cytotoxicity against human SNB19 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5481,765611,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human SF295 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5482,765612,1,1,,123097261,31703,Active,,,0.09,GI50,Cytotoxicity against human SW620 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5483,765613,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5484,765614,1,1,,123097261,31703,Active,,,0.27,GI50,Cytotoxicity against human KM12 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5485,765615,1,1,,123097261,31703,Active,,,6.46,GI50,Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5486,765616,1,1,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5487,765617,1,1,,123097261,31703,Active,,,0.08,GI50,Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5488,765618,1,3,,123097261,31703,Active,,,,GI50,Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5489,765619,1,1,,123097261,31703,Active,,,0.03,GI50,Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5490,765620,1,3,,123097261,31703,Active,,,,GI50,Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5491,765621,1,1,,123097261,31703,Active,,,0.02,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5492,765622,1,1,,123097261,31703,Active,,,0.54,GI50,Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5493,765623,1,1,,123097261,31703,Active,,,0.05,GI50,Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5494,765624,1,1,,123097261,31703,Active,,,0.15,GI50,Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5495,765625,1,1,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human HOP92 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5496,765626,1,1,,123097261,31703,Active,,,0.07,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5497,765627,1,2,,123097261,31703,Active,,,0.41,GI50,Cytotoxicity against human EKVX cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5498,765628,1,1,,123097261,31703,Active,,,0.03,GI50,Cytotoxicity against human SR cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5499,765629,1,1,,123097261,31703,Active,,,0.06,GI50,Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5500,765630,1,1,,123097261,31703,Active,,,0.08,GI50,Cytotoxicity against human RPMI8226 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5501,765631,1,1,,123097261,31703,Active,,,0.03,GI50,Cytotoxicity against human MOLT4 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5502,765632,1,1,,123097261,31703,Active,,,0.19,GI50,Cytotoxicity against human K562 cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5503,765633,1,3,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5504,765634,1,1,,123097261,31703,Active,,,0.08,GI50,Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay,Confirmatory,23871905.0,
5505,766137,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by neutral red,Other,23891181.0,
5506,766138,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red,Other,23891181.0,
5507,766139,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red,Other,23891181.0,
5508,766659,1,1,,123097261,31703,Active,,,1.21,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,23911578.0,
5509,766660,1,1,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,23911578.0,
5510,766661,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,23911578.0,
5511,766662,1,1,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,23911578.0,
5512,767338,1,1,,123097261,31703,Active,,,13.51,IC50,Cytotoxicity against human MCF7 cells after 2 days by MTT assay,Confirmatory,23932340.0,
5513,767339,1,1,,123097261,31703,Active,,,0.91,IC50,Cytotoxicity against human MDA-MB-231 cells after 2 days by MTT assay,Confirmatory,23932340.0,
5514,767340,1,1,,123097261,31703,Active,,,0.509,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay,Confirmatory,23932340.0,
5515,767341,1,1,,123097261,31703,Active,,,0.45899999999999996,IC50,Cytotoxicity against human A549 cells after 2 days by MTT assay,Confirmatory,23932340.0,
5516,767731,1,1,,123097261,31703,Active,,,1.9,GI50,Cytotoxicity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5517,767732,1,1,,123097261,31703,Active,,,0.51,GI50,Cytotoxicity against human NUGC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5518,767733,1,1,,123097261,31703,Active,,,1.8,GI50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5519,767734,1,1,,123097261,31703,Active,,,2.0,GI50,Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5520,767735,1,1,,123097261,31703,Active,,,0.52,GI50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5521,767736,1,1,,123097261,31703,Active,,,1.4,GI50,Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23964644.0,
5522,767887,1,1,,123097261,31703,Active,,,0.52,LC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,24025124.0,
5523,767888,1,1,,123097261,31703,Active,,,0.7,LC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,24025124.0,
5524,768387,1,1,,123097261,31703,Active,,,3.24,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,23835482.0,
5525,768635,1,1,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5526,768636,1,1,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5527,768637,1,1,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5528,768638,1,1,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5529,768639,1,3,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5530,768640,1,1,,123097261,31703,Active,,,0.1,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5531,768641,1,1,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5532,768642,1,3,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5533,768643,1,1,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5534,768644,1,1,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
5535,769114,1,3,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,,
5536,769115,1,3,,123097261,31703,Unspecified,,,,GI50,Cytotoxicity against human HeLa cells by SRB assay,Confirmatory,,
5537,770867,1,1,,123097261,31703,Inactive,,,,,Antioxidant activity in human MDA-MB-231 cells assessed as intracellular malonyldialdehyde level at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5538,770868,1,1,,123097261,31703,Active,,,,,Antioxidant activity in human MCF7 cells assessed as intracellular malonyldialdehyde level at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5539,770869,1,1,,123097261,31703,Active,,,,,Antioxidant activity in rat H9c2 cells assessed as intracellular malonyldialdehyde level at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5540,770870,1,1,,123097261,31703,Inactive,,,,,Antioxidant activity in human MDA-MB-231 cells assessed as intracellular ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5541,770871,1,1,,123097261,31703,Active,,,,,Antioxidant activity in human MCF7 cells assessed as intracellular ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5542,770872,1,1,,123097261,31703,Active,,,,,Antioxidant activity in rat H9c2 cells assessed as intracellular ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5543,770873,1,1,,123097261,31703,Inactive,,,,,Antioxidant activity in human MDA-MB-231 cells assessed as intramitochondrial ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5544,770874,1,1,,123097261,31703,Active,,,,,Antioxidant activity in human MCF7 cells assessed as intramitochondrial ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5545,770875,1,1,,123097261,31703,Active,,,,,Antioxidant activity in rat H9c2 cells assessed as intramitochondrial ROS level at 5 umol/L after 24 hrs by DCFDA-AM staining-based spectrofluorimetry,Other,23973213.0,
5546,770879,1,1,,123097261,31703,Active,,,,,Cellular uptake in human MDA-MB-231 cell nucleus at 5 umol/L after 24 hrs by fluorimetric analysis,Other,23973213.0,
5547,770880,1,1,,123097261,31703,Active,,,,,Cellular uptake in human MCF7 cell nucleus at 5 umol/L after 24 hrs by fluorimetric analysis,Other,23973213.0,
5548,770882,1,1,,123097261,31703,Active,,,,,Inhibition of human topoisomerase 2 using supercoiled pHOT1 as substrate at 1 to 50 umol/L by agarose gel electrophoresis,Other,23973213.0,
5549,770883,1,1,,123097261,31703,Unspecified,,,,,Drug efflux in human MDA-MB-231 cells at 1 to 100 umol/L incubated for 20 mins prior to compound wash out measured after 10 mins by spectrofluorimetry,Other,23973213.0,
5550,770884,1,1,,123097261,31703,Unspecified,,,,,Drug efflux in human MCF7 cells at 1 to 100 umol/L incubated for 20 mins prior to compound wash out measured after 10 mins by spectrofluorimetry,Other,23973213.0,
5551,770885,1,1,,123097261,31703,Unspecified,,,,,Drug efflux in rat H9c2 cells at 1 to 100 umol/L incubated for 20 mins prior to compound wash out measured after 10 mins by spectrofluorimetry,Other,23973213.0,
5552,770886,1,1,,123097261,31703,Active,,,,,Cellular uptake in human MDA-MB-231 cells at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5553,770887,1,1,,123097261,31703,Active,,,,,Cellular uptake in human MCF7 cells at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5554,770888,1,1,,123097261,31703,Active,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as LDH release at 5 umol/L after 24 hrs,Other,23973213.0,
5555,770889,1,1,,123097261,31703,Inactive,,,,,Cellular uptake in rat H9c2 cells at 5 umol/L after 24 hrs by spectrofluorimetry,Other,23973213.0,
5556,770890,1,1,,123097261,31703,Active,,,,,Cytotoxicity against human MCF7 cells assessed as LDH release at 5 umol/L after 24 hrs,Other,23973213.0,
5557,770891,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as LDH release at 5 umol/L after 24 hrs,Other,23973213.0,
5558,771325,1,1,,123097261,31703,Active,,,0.04,EC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
5559,771326,1,1,,123097261,31703,Active,,,0.29,EC50,Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
5560,771327,1,2,,123097261,31703,Active,,,0.25,EC50,Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
5561,771399,1,2,,123097261,31703,Active,,,8.83,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,23994327.0,
5562,771400,1,2,,123097261,31703,Active,,,7.71,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,23994327.0,
5563,771401,1,2,,123097261,31703,Active,,,7.36,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay,Confirmatory,23994327.0,
5564,771559,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by SRB assay,Other,24012683.0,
5565,771666,1,1,,123097261,31703,Active,,,2.8,IC50,Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24044895.0,
5566,771667,1,1,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24044895.0,
5567,771668,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24044895.0,
5568,771695,1,3,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,,
5569,771696,1,3,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,,
5570,771697,1,3,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,,
5571,771772,1,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human SF295 cells at 25 ug/ml after 48 hrs by MTT assay,Other,,
5572,771773,1,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human HCT8 cells at 25 ug/ml after 48 hrs by MTT assay,Other,,
5573,771774,1,3,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MDA-MB-435 cells at 25 ug/ml after 48 hrs by MTT assay,Other,,
5574,771883,3,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay,Confirmatory,,
5575,771884,3,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,,
5576,771885,3,1,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,,
5577,771886,3,1,,123097261,31703,Active,,,0.79,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,,
5578,771910,1,3,,123097261,31703,Active,,,1.006,IC50,Cytotoxicity against HEK293 cells after 24 hrs by MTT assay,Confirmatory,,
5579,771911,1,3,,123097261,31703,Active,,,3.98,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,,
5580,771923,1,3,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human MCF7 cells after 44 hrs by SRB assay,Confirmatory,,
5581,771924,1,3,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human MKN28 cells after 44 hrs by SRB assay,Confirmatory,,
5582,771925,1,3,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human HeLa cells after 44 hrs by SRB assay,Confirmatory,,
5583,771926,1,5,,123097261,31703,Active,,,0.027999999999999997,IC50,Cytotoxicity against human KB cells after 44 hrs by SRB assay,Confirmatory,,
5584,771964,1,3,,123097261,31703,Active,,,2.56,IC50,Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay,Confirmatory,,
5585,771965,1,3,,123097261,31703,Active,,,2.68,IC50,Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay,Confirmatory,,
5586,771966,1,3,,123097261,31703,Active,,,2.44,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,,
5587,772054,1,3,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human MGC803 cells",Other,,
5588,772056,1,3,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human Bcap37 cells",Other,,
5589,772057,1,3,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse NIH3T3 cells to IC50 for human PC3 cells",Other,,
5590,772058,1,3,,123097261,31703,Active,,,1.9,IC50,Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay,Confirmatory,,
5591,772059,1,5,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,,
5592,772060,1,3,,123097261,31703,Active,,,1.01,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,,
5593,772914,1,1,,123097261,31703,Active,,,0.85,IC50,Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23992864.0,
5594,772915,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23992864.0,
5595,772916,1,1,,123097261,31703,Active,,,0.73,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23992864.0,
5596,772917,1,1,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23992864.0,
5597,772918,1,1,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23992864.0,
5598,773702,1,1,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5599,773703,1,1,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5600,773705,1,1,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5601,773706,1,1,,123097261,31703,Active,,,2.98,IC50,Antiproliferative activity against human Raji cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5602,773707,1,1,,123097261,31703,Active,,,0.25,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5603,773708,1,1,,123097261,31703,Active,,,0.92,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,24021462.0,
5604,773711,1,1,,123097261,31703,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells to IC50 for doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells in presence of verapamil,Other,24028446.0,
5605,773713,1,1,,123097261,31703,Active,,,1.56,IC50,Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil,Confirmatory,24028446.0,
5606,773714,1,1,,123097261,31703,Active,,,0.15,IC50,Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil,Confirmatory,24028446.0,
5607,773721,1,1,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay,Confirmatory,24028446.0,
5608,773722,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay,Confirmatory,24028446.0,
5609,773723,1,1,,123097261,31703,Active,,,21.9,IC50,Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay,Confirmatory,24028446.0,
5610,773724,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay,Confirmatory,24028446.0,
5611,773725,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24028446.0,
5612,773726,1,1,,123097261,31703,Active,,,,,Cellular uptake in human MCF7 cells at 5 uM after 2 hrs by FACS analysis in presence of NH2-WxEYAAQkFL-CONH2,Other,24028446.0,
5613,773731,1,1,,123097261,31703,Active,,,,,Cellular uptake in human HUVEC cells at 5 uM after 2 hrs by FACS analysis,Other,24028446.0,
5614,773795,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,24050254.0,
5615,773796,1,1,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,24050254.0,
5616,774418,1,1,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against human A549 cells,Confirmatory,24128115.0,
5617,774419,1,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human HL60 cells,Confirmatory,24128115.0,
5618,774917,1,1,,123097261,31703,Active,,,0.0032,IC50,Inhibition of TRK in human MCF7 cells after 48 hrs by ELISA,Confirmatory,24013411.0,
5619,774918,1,1,,123097261,31703,Active,,,0.0025,IC50,Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA,Confirmatory,24013411.0,
5620,774964,1,1,,123097261,31703,Active,,,3.07,IC50,Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
5621,774965,1,1,,123097261,31703,Active,,,2.68,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
5622,774966,1,1,,123097261,31703,Active,,,1.38,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
5623,774967,1,1,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human T47D cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
5624,775985,1,2,,123097261,31703,Active,,,32.78,IC50,Anticancer activity against human AS49-RAW cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5625,775986,1,1,,123097261,31703,Active,,,30.21,IC50,Anticancer activity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5626,775987,1,1,,123097261,31703,Active,,,24.33,IC50,Anticancer activity against human LoVo cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5627,775988,1,1,,123097261,31703,Active,,,27.11,IC50,Anticancer activity against human HepG2 cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5628,775989,1,1,,123097261,31703,Active,,,19.22,IC50,Anticancer activity against human HT1080 cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5629,775990,1,1,,123097261,31703,Active,,,33.98,IC50,Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,24077528.0,
5630,776318,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,24090920.0,
5631,776388,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay,Other,24095746.0,
5632,776389,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Other,24095746.0,
5633,776390,1,1,,123097261,31703,Unspecified,,,,,Inhibition of uPA protein expression in human MCF7 cells at 0.1 time compound IC50 after 48 hrs by ELISA,Other,24095746.0,
5634,776391,1,1,,123097261,31703,Unspecified,,,,,Inhibition of uPA protein expression in human HepG2 cells at 0.1 time compound IC50 after 48 hrs by ELISA,Other,24095746.0,
5635,776392,1,1,,123097261,31703,Unspecified,,,,,Inhibition of uPA protein expression in human A549 cells at 0.1 time compound IC50 after 48 hrs by ELISA,Other,24095746.0,
5636,776393,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,24095746.0,
5637,776651,1,3,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as melting temperature at 10 uM by UV-Vis spectrophotometer analysis,Other,24099994.0,
5638,776652,1,1,,123097261,31703,Active,,,5.0,IC50,Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay,Confirmatory,24099994.0,
5639,776653,1,1,,123097261,31703,Inactive,,,,,Cytotoxicity against human Caco2 cells up to 40 uM after 24 hrs by MTT assay,Other,24099994.0,
5640,776694,3,1,,123097261,31703,Active,,,0.027999999999999997,GI50,Cytotoxicity against human HL60 cells after 48 hrs by SRB assay,Confirmatory,24113365.0,
5641,776695,3,1,,123097261,31703,Active,,,0.1448,GI50,Cytotoxicity against human A375-C5 cells after 48 hrs by SRB assay,Confirmatory,24113365.0,
5642,776696,3,1,,123097261,31703,Active,,,0.0641,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,24113365.0,
5643,776697,3,1,,123097261,31703,Active,,,0.0654,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,24113365.0,
5644,776708,1,1,,123097261,31703,Active,,,1.21,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,24113366.0,
5645,776709,1,1,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,24113366.0,
5646,776710,1,1,,123097261,31703,Active,,,0.501,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,24113366.0,
5647,776711,1,1,,123097261,31703,Active,,,0.451,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,24113366.0,
5648,779078,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human A549 cells",Other,24012378.0,
5649,779079,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human CCRF-CEM cells",Other,24012378.0,
5650,779080,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human HeLa cells",Other,24012378.0,
5651,779081,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human MDA-MB-231 cells",Other,24012378.0,
5652,779082,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human MCF7 cells",Other,24012378.0,
5653,779084,1,1,,123097261,31703,Active,,,0.0807,IC50,Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay,Confirmatory,24012378.0,
5654,779085,1,1,,123097261,31703,Active,,,1.9,IC50,Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5655,779086,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5656,779087,1,1,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5657,779088,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5658,779089,1,1,,123097261,31703,Active,,,0.078,IC50,Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5659,779090,1,1,,123097261,31703,Active,,,0.5,IC50,Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
5660,779091,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human Jurkat cells",Other,24012378.0,
5661,780208,1,1,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,24080103.0,
5662,780210,1,2,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay,Confirmatory,24080103.0,
5663,780639,1,2,,123097261,31703,Active,,,1.5,IC50,Antiproliferative activity against human H1229 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5664,780640,1,1,,123097261,31703,Active,,,0.3,IC50,Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5665,780641,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5666,780642,1,1,,123097261,31703,Active,,,1.0,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5667,780643,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5668,780644,1,1,,123097261,31703,Active,,,0.6,IC50,Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5669,780645,1,2,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5670,780646,1,1,,123097261,31703,Unspecified,,,20.0,IC50,Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5671,780647,1,1,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5672,780648,1,1,,123097261,31703,Active,,,0.4,IC50,Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay,Confirmatory,24095089.0,
5673,780649,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human U2OS cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5674,780650,1,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human H1229 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5675,780651,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human LNCAP cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5676,780652,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human DU145 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5677,780653,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5678,780654,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human OVCAR8 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5679,780655,1,2,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Caov3 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5680,780656,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI/ADR-RES cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5681,780657,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MIAPaCa2 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5682,780658,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human BxPC3 cells at 20 uM after 72 hrs by MTT assay,Other,24095089.0,
5683,780660,1,1,,123097261,31703,Active,,,,,Increase of cleaved caspase-9 level in human LNCAP cells at 3 uM after 24 hrs by Western blot analysis,Other,24095089.0,
5684,780661,1,1,,123097261,31703,Active,,,,,Up-regulation of p53 expression in human LNCAP cells at 3 uM after 24 hrs by Western blot analysis,Other,24095089.0,
5685,780662,1,1,,123097261,31703,Active,,,,,Antiproliferative activity against human OVCAR8 cells at 20 uM after 72 hrs by MTT assay in presence of glutathione,Other,24095089.0,
5686,780663,1,1,,123097261,31703,Active,,,,,Antiproliferative activity against human OVCAR8 cells at 20 uM after 72 hrs by MTT assay in presence of N-acetylcysteine,Other,24095089.0,
5687,780664,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI/ADR-RES cells at 20 uM after 72 hrs by MTT assay in presence of glutathione,Other,24095089.0,
5688,780665,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI/ADR-RES cells at 20 uM after 72 hrs by MTT assay in presence of N-acetylcysteine,Other,24095089.0,
5689,780730,1,1,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,24095093.0,
5690,780731,1,2,,123097261,31703,Active,,,7.8,IC50,Cytotoxicity against human HL60/A cells after 72 hrs by MTT assay,Confirmatory,24095093.0,
5691,908767,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/13,Other,,
5692,908768,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/13,Other,,
5693,908769,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/13,Other,,
5694,908770,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/13,Other,,
5695,908771,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/13,Other,,
5696,908772,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/13,Other,,
5697,908773,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/13,Other,,
5698,908774,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/13,Other,,
5699,908775,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/13,Other,,
5700,908776,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/14,Other,,
5701,908777,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/14,Other,,
5702,908778,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/14,Other,,
5703,908779,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/14,Other,,
5704,908780,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/14,Other,,
5705,908781,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/14,Other,,
5706,908782,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/14,Other,,
5707,908783,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/14,Other,,
5708,908784,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/14,Other,,
5709,908785,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/14,Other,,
5710,908786,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/14,Other,,
5711,908787,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/14,Other,,
5712,908788,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/14,Other,,
5713,908789,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/14,Other,,
5714,908790,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/14,Other,,
5715,908791,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/14,Other,,
5716,908792,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/14,Other,,
5717,908793,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/14,Other,,
5718,908794,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/14,Other,,
5719,908795,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/14,Other,,
5720,908796,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/14,Other,,
5721,908797,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/15,Other,,
5722,908798,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/15,Other,,
5723,909259,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/15,Other,,
5724,909260,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/15,Other,,
5725,909261,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/15,Other,,
5726,909262,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/15,Other,,
5727,909263,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/15,Other,,
5728,909264,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/15,Other,,
5729,909265,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/15,Other,,
5730,909266,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/15,Other,,
5731,909267,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/15,Other,,
5732,909268,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/15,Other,,
5733,909269,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/15,Other,,
5734,909270,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/15,Other,,
5735,909271,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/15,Other,,
5736,909272,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/15,Other,,
5737,909307,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/10,Other,,
5738,909308,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/10,Other,,
5739,909309,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/10,Other,,
5740,909310,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/10,Other,,
5741,909311,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/10,Other,,
5742,909312,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/10,Other,,
5743,909313,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/10,Other,,
5744,909314,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/10,Other,,
5745,909315,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/10,Other,,
5746,909316,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/10,Other,,
5747,909317,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/10,Other,,
5748,909318,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/10,Other,,
5749,909319,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/10,Other,,
5750,909320,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/10,Other,,
5751,909321,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/10,Other,,
5752,909322,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/10,Other,,
5753,909323,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/10,Other,,
5754,909324,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/11,Other,,
5755,909325,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/11,Other,,
5756,909326,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/11,Other,,
5757,909327,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/11,Other,,
5758,909328,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/11,Other,,
5759,909329,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/11,Other,,
5760,909330,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/11,Other,,
5761,909331,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/11,Other,,
5762,909332,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/11,Other,,
5763,909333,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/11,Other,,
5764,909334,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/11,Other,,
5765,909335,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/11,Other,,
5766,909336,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/11,Other,,
5767,909337,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/11,Other,,
5768,909338,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/11,Other,,
5769,909339,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/11,Other,,
5770,909340,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/11,Other,,
5771,909341,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/11,Other,,
5772,909342,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/11,Other,,
5773,909343,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/11,Other,,
5774,909344,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/11,Other,,
5775,909345,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/12,Other,,
5776,909346,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/12,Other,,
5777,909419,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/5,Other,,
5778,909420,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/5,Other,,
5779,909421,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/5,Other,,
5780,909422,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/5,Other,,
5781,909423,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/5,Other,,
5782,909424,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/5,Other,,
5783,909425,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/5,Other,,
5784,909426,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/5,Other,,
5785,909427,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/5,Other,,
5786,909428,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/5,Other,,
5787,909429,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/5,Other,,
5788,909430,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/5,Other,,
5789,909431,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/5,Other,,
5790,909432,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/5,Other,,
5791,909782,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/12,Other,,
5792,909783,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/12,Other,,
5793,909784,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/12,Other,,
5794,909785,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/12,Other,,
5795,909872,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/5,Other,,
5796,909873,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/5,Other,,
5797,909874,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/5,Other,,
5798,909875,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/5,Other,,
5799,909876,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/5,Other,,
5800,909877,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/5,Other,,
5801,909878,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/5,Other,,
5802,909879,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/6,Other,,
5803,909880,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/6,Other,,
5804,909881,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/6,Other,,
5805,909882,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/6,Other,,
5806,909883,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/6,Other,,
5807,909884,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/6,Other,,
5808,909885,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/6,Other,,
5809,909886,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/6,Other,,
5810,909887,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/6,Other,,
5811,909888,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/6,Other,,
5812,909889,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/6,Other,,
5813,909890,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/6,Other,,
5814,909891,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/6,Other,,
5815,909892,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/6,Other,,
5816,909893,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/6,Other,,
5817,909894,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/6,Other,,
5818,909895,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/6,Other,,
5819,909896,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/6,Other,,
5820,909897,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/6,Other,,
5821,909898,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/6,Other,,
5822,909899,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/6,Other,,
5823,910541,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/7,Other,,
5824,910542,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/7,Other,,
5825,910543,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/7,Other,,
5826,910544,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/8,Other,,
5827,910545,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/8,Other,,
5828,910546,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/8,Other,,
5829,910547,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/8,Other,,
5830,910548,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/8,Other,,
5831,910549,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/8,Other,,
5832,910550,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/8,Other,,
5833,910551,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/8,Other,,
5834,910552,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/8,Other,,
5835,910553,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/8,Other,,
5836,910554,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/8,Other,,
5837,910555,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/8,Other,,
5838,910556,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/8,Other,,
5839,910557,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/8,Other,,
5840,910558,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/8,Other,,
5841,910559,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/8,Other,,
5842,910560,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/8,Other,,
5843,910561,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/8,Other,,
5844,910562,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/8,Other,,
5845,910563,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/8,Other,,
5846,910564,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/8,Other,,
5847,910565,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/9,Other,,
5848,910566,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/9,Other,,
5849,910567,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/9,Other,,
5850,910568,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/9,Other,,
5851,910607,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/15,Other,,
5852,910608,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/15,Other,,
5853,910609,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/15,Other,,
5854,910610,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/15,Other,,
5855,910611,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/15,Other,,
5856,910612,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/16,Other,,
5857,910613,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/16,Other,,
5858,910614,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/16,Other,,
5859,910615,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/16,Other,,
5860,910616,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/16,Other,,
5861,910617,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/16,Other,,
5862,910618,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/16,Other,,
5863,910619,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/16,Other,,
5864,910620,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/16,Other,,
5865,910621,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/16,Other,,
5866,910622,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/16,Other,,
5867,910623,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/16,Other,,
5868,910624,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/16,Other,,
5869,910625,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/16,Other,,
5870,910626,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/16,Other,,
5871,910627,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/16,Other,,
5872,910628,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/16,Other,,
5873,910629,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/16,Other,,
5874,911111,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/16,Other,,
5875,911112,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/16,Other,,
5876,911113,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/16,Other,,
5877,911114,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/5,Other,,
5878,911115,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/5,Other,,
5879,911116,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/5,Other,,
5880,911117,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/5,Other,,
5881,911118,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/5,Other,,
5882,911119,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/5,Other,,
5883,911120,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/5,Other,,
5884,911121,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/5,Other,,
5885,911122,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/5,Other,,
5886,911123,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/5,Other,,
5887,911124,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/5,Other,,
5888,911125,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/5,Other,,
5889,911126,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/5,Other,,
5890,911127,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/5,Other,,
5891,911128,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/5,Other,,
5892,911129,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/5,Other,,
5893,911130,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/5,Other,,
5894,911131,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/5,Other,,
5895,911132,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/5,Other,,
5896,911167,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/12,Other,,
5897,911168,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/12,Other,,
5898,911169,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/12,Other,,
5899,911170,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/12,Other,,
5900,911171,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/12,Other,,
5901,911172,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/12,Other,,
5902,911173,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/12,Other,,
5903,911174,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/12,Other,,
5904,911175,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/12,Other,,
5905,911176,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/12,Other,,
5906,911177,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/12,Other,,
5907,911178,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/12,Other,,
5908,911179,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/12,Other,,
5909,911180,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/12,Other,,
5910,911181,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/12,Other,,
5911,911182,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/13,Other,,
5912,911183,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/13,Other,,
5913,911184,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/13,Other,,
5914,911185,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/13,Other,,
5915,911186,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/13,Other,,
5916,911187,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/13,Other,,
5917,911188,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/13,Other,,
5918,911189,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/13,Other,,
5919,911190,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/13,Other,,
5920,911191,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/13,Other,,
5921,911192,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/13,Other,,
5922,911193,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/13,Other,,
5923,911194,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/13,Other,,
5924,911195,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/13,Other,,
5925,911196,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/13,Other,,
5926,911197,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/13,Other,,
5927,911648,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/13,Other,,
5928,911649,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/13,Other,,
5929,911650,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/13,Other,,
5930,911651,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/13,Other,,
5931,911652,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/13,Other,,
5932,911653,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/14,Other,,
5933,911654,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/14,Other,,
5934,911655,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/14,Other,,
5935,911656,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/14,Other,,
5936,911657,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/14,Other,,
5937,911658,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/14,Other,,
5938,911659,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/14,Other,,
5939,911660,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/14,Other,,
5940,911661,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/14,Other,,
5941,912009,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/9,Other,,
5942,912010,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/9,Other,,
5943,912011,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/9,Other,,
5944,912012,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/9,Other,,
5945,912013,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/9,Other,,
5946,912014,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/9,Other,,
5947,912015,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/9,Other,,
5948,912016,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/9,Other,,
5949,912017,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/9,Other,,
5950,912018,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/9,Other,,
5951,912398,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/9,Other,,
5952,912399,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/9,Other,,
5953,912400,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/9,Other,,
5954,912401,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/9,Other,,
5955,912402,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/9,Other,,
5956,912403,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/9,Other,,
5957,912404,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/9,Other,,
5958,912405,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/10,Other,,
5959,912406,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/10,Other,,
5960,912407,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/10,Other,,
5961,912408,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/10,Other,,
5962,912409,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/10,Other,,
5963,912410,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/10,Other,,
5964,912411,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/10,Other,,
5965,912412,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/10,Other,,
5966,912413,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/10,Other,,
5967,912414,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/10,Other,,
5968,912415,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/10,Other,,
5969,912416,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/10,Other,,
5970,912417,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/10,Other,,
5971,912418,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/10,Other,,
5972,912419,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/10,Other,,
5973,912420,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/10,Other,,
5974,912421,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/10,Other,,
5975,912422,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/10,Other,,
5976,912423,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/10,Other,,
5977,912424,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/10,Other,,
5978,912425,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/10,Other,,
5979,912426,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/11,Other,,
5980,912427,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/11,Other,,
5981,912428,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/11,Other,,
5982,912429,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/11,Other,,
5983,912430,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/11,Other,,
5984,912431,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/11,Other,,
5985,912432,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/11,Other,,
5986,912433,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/11,Other,,
5987,912471,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/5,Other,,
5988,912472,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/5,Other,,
5989,912473,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/6,Other,,
5990,912474,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/6,Other,,
5991,912475,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/6,Other,,
5992,912476,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/6,Other,,
5993,912477,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/6,Other,,
5994,912478,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/6,Other,,
5995,912479,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/6,Other,,
5996,912480,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/6,Other,,
5997,912481,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/6,Other,,
5998,912482,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/6,Other,,
5999,912483,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/6,Other,,
6000,912484,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/6,Other,,
6001,912485,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/6,Other,,
6002,912957,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/6,Other,,
6003,912958,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/6,Other,,
6004,912959,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/6,Other,,
6005,912960,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/6,Other,,
6006,912961,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/6,Other,,
6007,912962,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/6,Other,,
6008,912963,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/6,Other,,
6009,912964,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/6,Other,,
6010,912965,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/7,Other,,
6011,912966,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/7,Other,,
6012,912967,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/7,Other,,
6013,912968,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/7,Other,,
6014,912969,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/7,Other,,
6015,912970,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/7,Other,,
6016,912971,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/7,Other,,
6017,912972,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/7,Other,,
6018,912973,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/7,Other,,
6019,912974,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/7,Other,,
6020,912975,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/7,Other,,
6021,912976,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/7,Other,,
6022,912977,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/7,Other,,
6023,912978,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/7,Other,,
6024,912979,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/7,Other,,
6025,912980,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/7,Other,,
6026,912981,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/7,Other,,
6027,912982,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/7,Other,,
6028,912983,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/7,Other,,
6029,912984,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/7,Other,,
6030,912985,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/7,Other,,
6031,912986,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/8,Other,,
6032,913020,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/14,Other,,
6033,913021,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/14,Other,,
6034,913022,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/14,Other,,
6035,913023,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/14,Other,,
6036,913024,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/14,Other,,
6037,913025,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/14,Other,,
6038,913026,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/14,Other,,
6039,913027,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/14,Other,,
6040,913028,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/14,Other,,
6041,913029,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/14,Other,,
6042,913030,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/14,Other,,
6043,913031,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/14,Other,,
6044,913032,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/15,Other,,
6045,913033,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/15,Other,,
6046,913034,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/15,Other,,
6047,913035,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/15,Other,,
6048,913036,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/15,Other,,
6049,913037,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/15,Other,,
6050,913038,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/15,Other,,
6051,913039,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/15,Other,,
6052,913040,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/15,Other,,
6053,913041,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/15,Other,,
6054,913042,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/15,Other,,
6055,913476,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/15,Other,,
6056,913477,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/15,Other,,
6057,913478,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/15,Other,,
6058,913479,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/15,Other,,
6059,913480,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/15,Other,,
6060,913481,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/15,Other,,
6061,913482,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/15,Other,,
6062,913483,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/15,Other,,
6063,913484,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/15,Other,,
6064,913485,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/15,Other,,
6065,913486,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/16,Other,,
6066,913487,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/16,Other,,
6067,913488,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/16,Other,,
6068,913489,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/16,Other,,
6069,913490,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/16,Other,,
6070,913491,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/16,Other,,
6071,913492,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/16,Other,,
6072,913493,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/16,Other,,
6073,913494,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/16,Other,,
6074,913495,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/16,Other,,
6075,913496,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/16,Other,,
6076,913497,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/16,Other,,
6077,914219,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/11,Other,,
6078,914220,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/11,Other,,
6079,914221,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/11,Other,,
6080,914222,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/11,Other,,
6081,914223,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/11,Other,,
6082,914224,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/11,Other,,
6083,914225,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/11,Other,,
6084,914226,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/11,Other,,
6085,914227,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/11,Other,,
6086,914228,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/11,Other,,
6087,914229,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/11,Other,,
6088,914230,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/11,Other,,
6089,914231,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/11,Other,,
6090,914232,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/12,Other,,
6091,914233,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/12,Other,,
6092,914234,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/12,Other,,
6093,914235,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/12,Other,,
6094,914236,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/12,Other,,
6095,914237,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/12,Other,,
6096,914238,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/12,Other,,
6097,914239,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/12,Other,,
6098,914240,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/12,Other,,
6099,914241,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/12,Other,,
6100,914242,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/12,Other,,
6101,914243,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/12,Other,,
6102,914244,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/12,Other,,
6103,914245,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/12,Other,,
6104,914246,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/12,Other,,
6105,914247,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/12,Other,,
6106,914248,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/12,Other,,
6107,914249,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/12,Other,,
6108,914250,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 616/12,Other,,
6109,914251,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 616/12,Other,,
6110,914252,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 616/12,Other,,
6111,914253,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/13,Other,,
6112,914254,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/13,Other,,
6113,914255,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/13,Other,,
6114,914256,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/13,Other,,
6115,914257,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/13,Other,,
6116,914258,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/13,Other,,
6117,914259,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/13,Other,,
6118,914260,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/13,Other,,
6119,914261,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/13,Other,,
6120,914299,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/8,Other,,
6121,914300,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/8,Other,,
6122,914301,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/8,Other,,
6123,914302,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/8,Other,,
6124,914303,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/8,Other,,
6125,914304,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/8,Other,,
6126,914723,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/13,Other,,
6127,914724,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/13,Other,,
6128,914725,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/13,Other,,
6129,914768,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/8,Other,,
6130,914769,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/8,Other,,
6131,914770,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/8,Other,,
6132,914771,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/8,Other,,
6133,914772,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/8,Other,,
6134,914773,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/8,Other,,
6135,914774,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/8,Other,,
6136,914775,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/8,Other,,
6137,914776,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/8,Other,,
6138,914777,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/8,Other,,
6139,914778,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/8,Other,,
6140,914779,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/8,Other,,
6141,914780,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/8,Other,,
6142,914781,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/8,Other,,
6143,914782,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/9,Other,,
6144,914783,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/9,Other,,
6145,914784,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/9,Other,,
6146,914785,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/9,Other,,
6147,914786,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 617/9,Other,,
6148,914787,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 617/9,Other,,
6149,914788,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 617/9,Other,,
6150,914789,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 617/9,Other,,
6151,914790,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 617/9,Other,,
6152,914791,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 617/9,Other,,
6153,914792,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 617/9,Other,,
6154,914793,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 617/9,Other,,
6155,914794,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/9,Other,,
6156,914795,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/9,Other,,
6157,914796,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/9,Other,,
6158,914797,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/9,Other,,
6159,914798,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/9,Other,,
6160,914799,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/9,Other,,
6161,914800,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/9,Other,,
6162,914801,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/9,Other,,
6163,914802,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/9,Other,,
6164,914803,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 617/10,Other,,
6165,914804,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 617/10,Other,,
6166,914805,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 617/10,Other,,
6167,914806,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 617/10,Other,,
6168,914839,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 617/16,Other,,
6169,914840,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 617/16,Other,,
6170,914841,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 617/16,Other,,
6171,914842,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 617/16,Other,,
6172,914843,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 617/16,Other,,
6173,914844,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 617/16,Other,,
6174,914845,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 617/16,Other,,
6175,914846,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 617/16,Other,,
6176,914847,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 617/16,Other,,
6177,917688,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 616/7,Other,,
6178,917689,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 616/7,Other,,
6179,917690,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 616/7,Other,,
6180,917691,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 616/7,Other,,
6181,917692,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 616/7,Other,,
6182,917693,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 616/7,Other,,
6183,917694,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 616/7,Other,,
6184,917695,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 616/7,Other,,
6185,917696,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 616/7,Other,,
6186,917697,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 616/7,Other,,
6187,917698,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 616/7,Other,,
6188,917699,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 616/7,Other,,
6189,917700,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 616/7,Other,,
6190,917701,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 616/7,Other,,
6191,917702,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 616/7,Other,,
6192,917703,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 616/7,Other,,
6193,917704,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 616/7,Other,,
6194,917705,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 616/7,Other,,
6195,923653,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011106,Other,,
6196,923654,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011106,Other,,
6197,923655,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011106,Other,,
6198,923656,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011106,Other,,
6199,923657,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011106,Other,,
6200,923658,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011106,Other,,
6201,923659,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011106,Other,,
6202,923660,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011106,Other,,
6203,923661,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011106,Other,,
6204,923662,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011106,Other,,
6205,923663,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011106,Other,,
6206,923664,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011106,Other,,
6207,923665,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011106,Other,,
6208,923666,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011106",Other,,
6209,923667,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011106,Other,,
6210,923668,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011106,Other,,
6211,923835,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011106,Other,,
6212,923836,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011106,Other,,
6213,923837,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011106,Other,,
6214,935874,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011106,Other,,
6215,935875,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011106",Other,,
6216,935876,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011106,Other,,
6217,935877,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011106,Other,,
6218,935878,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011106,Other,,
6219,935879,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011106,Other,,
6220,935880,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011106,Other,,
6221,935881,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011106,Other,,
6222,935882,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011106,Other,,
6223,935883,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011106,Other,,
6224,935884,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011106,Other,,
6225,935885,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011106,Other,,
6226,935886,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011106,Other,,
6227,935887,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011106,Other,,
6228,935888,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011106,Other,,
6229,935889,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011106,Other,,
6230,935890,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011106,Other,,
6231,935891,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011106,Other,,
6232,935892,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011106,Other,,
6233,942293,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011106,Other,,
6234,942294,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011106,Other,,
6235,942295,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011106,Other,,
6236,942296,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011106,Other,,
6237,942297,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011106,Other,,
6238,942298,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011106,Other,,
6239,942299,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011106,Other,,
6240,942300,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011106,Other,,
6241,942301,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011106,Other,,
6242,942302,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011106,Other,,
6243,942303,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011106,Other,,
6244,942304,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011106,Other,,
6245,942305,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011106,Other,,
6246,942306,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011106,Other,,
6247,942307,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011106,Other,,
6248,942308,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011106",Other,,
6249,942309,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011106,Other,,
6250,942310,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011106,Other,,
6251,942311,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011106,Other,,
6252,946818,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011106,Other,,
6253,946819,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011106,Other,,
6254,946946,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011106,Other,,
6255,948956,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011106,Other,,
6256,948957,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011106",Other,,
6257,948958,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011106,Other,,
6258,948959,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011106,Other,,
6259,948960,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011106,Other,,
6260,948961,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011106,Other,,
6261,948962,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011106,Other,,
6262,948963,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011106,Other,,
6263,948964,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011106,Other,,
6264,948965,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011106,Other,,
6265,948966,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011106,Other,,
6266,948967,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011106,Other,,
6267,948968,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011106,Other,,
6268,948969,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011106,Other,,
6269,948970,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011106,Other,,
6270,948971,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011106,Other,,
6271,957898,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011106,Other,,
6272,957899,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011106,Other,,
6273,957900,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011106,Other,,
6274,957901,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011106,Other,,
6275,957902,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011106,Other,,
6276,957903,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011106,Other,,
6277,957904,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011106,Other,,
6278,957905,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011106,Other,,
6279,957906,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011106,Other,,
6280,957907,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011106,Other,,
6281,957908,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011106,Other,,
6282,957909,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011106,Other,,
6283,957910,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011106,Other,,
6284,957911,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011106,Other,,
6285,957912,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011106,Other,,
6286,957913,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011106,Other,,
6287,957914,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011106,Other,,
6288,957915,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011106,Other,,
6289,957916,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011106,Other,,
6290,966081,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011106,Other,,
6291,966082,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011106,Other,,
6292,966083,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011106,Other,,
6293,966084,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011106,Other,,
6294,966085,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011106,Other,,
6295,966086,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011106,Other,,
6296,966087,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011106,Other,,
6297,966088,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011106,Other,,
6298,966089,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011106,Other,,
6299,966090,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011106,Other,,
6300,966091,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011106,Other,,
6301,966092,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011106,Other,,
6302,966093,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011106,Other,,
6303,966094,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011106,Other,,
6304,966095,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011106,Other,,
6305,966096,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011106,Other,,
6306,966097,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011106,Other,,
6307,966098,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011106,Other,,
6308,966099,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011106,Other,,
6309,974273,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011106,Other,,
6310,974274,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011106,Other,,
6311,974275,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011106,Other,,
6312,974276,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011106,Other,,
6313,974277,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011106,Other,,
6314,974278,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011106,Other,,
6315,974279,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011106,Other,,
6316,974280,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011106,Other,,
6317,974281,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011106,Other,,
6318,974911,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011106,Other,,
6319,974912,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011106,Other,,
6320,974913,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011106,Other,,
6321,974914,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011106,Other,,
6322,974915,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011106,Other,,
6323,974916,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011106,Other,,
6324,974917,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011106,Other,,
6325,974918,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011106,Other,,
6326,974919,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011106,Other,,
6327,974920,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011106,Other,,
6328,977521,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011106,Other,,
6329,977522,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011106,Other,,
6330,977523,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011106,Other,,
6331,977524,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011106,Other,,
6332,977525,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011106,Other,,
6333,977526,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011106,Other,,
6334,977527,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011106,Other,,
6335,977528,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011106,Other,,
6336,977529,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011106,Other,,
6337,977530,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011106,Other,,
6338,977531,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011106,Other,,
6339,977532,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011106,Other,,
6340,977533,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011106,Other,,
6341,977534,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011106,Other,,
6342,977535,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011106,Other,,
6343,977536,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011106,Other,,
6344,977537,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011106,Other,,
6345,977538,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011106,Other,,
6346,977539,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011106,Other,,
6347,988911,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011106,Other,,
6348,988912,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6349,988913,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011106",Other,,
6350,988914,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6351,988915,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6352,988916,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6353,988917,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6354,988918,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011106",Other,,
6355,988919,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6356,991339,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011106",Other,,
6357,991340,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6358,991341,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011106",Other,,
6359,991342,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011106",Other,,
6360,991343,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6361,991344,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011106",Other,,
6362,991345,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6363,991346,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011106",Other,,
6364,991347,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011106",Other,,
6365,991348,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6366,991349,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6367,991350,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6368,991351,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6369,991352,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6370,991353,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6371,991354,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011106",Other,,
6372,991355,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6373,991356,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6374,991357,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011106",Other,,
6375,991358,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6376,991359,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011106,Other,,
6377,991360,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011106,Other,,
6378,991361,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011106",Other,,
6379,991362,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6380,991363,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011106",Other,,
6381,991364,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011106,Other,,
6382,991365,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6383,991366,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6384,991367,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6385,991368,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011106",Other,,
6386,991369,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011106,Other,,
6387,991954,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011106",Other,,
6388,991955,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011106",Other,,
6389,991956,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6390,991957,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011106",Other,,
6391,991958,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011106",Other,,
6392,991959,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011106",Other,,
6393,991960,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011106,Other,,
6394,991961,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6395,991962,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011106",Other,,
6396,993796,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6397,993797,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011106",Other,,
6398,993798,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011106",Other,,
6399,993799,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011106",Other,,
6400,993800,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6401,993801,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6402,993802,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6403,993803,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011106,Other,,
6404,993804,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011106",Other,,
6405,993805,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011106,Other,,
6406,1017626,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011106,Other,,
6407,1017627,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6408,1017628,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6409,1017629,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6410,1017630,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011106",Other,,
6411,1017631,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011106",Other,,
6412,1017632,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011106",Other,,
6413,1017633,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6414,1017634,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6415,1017635,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011106",Other,,
6416,1017636,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S011106",Other,,
6417,1017637,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S011106",Other,,
6418,1017638,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6419,1017639,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011106,Other,,
6420,1017640,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011106",Other,,
6421,1017641,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011106,Other,,
6422,1017642,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011106",Other,,
6423,1017643,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6424,1017644,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011106",Other,,
6425,1017645,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011106",Other,,
6426,1019516,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6427,1019517,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011106",Other,,
6428,1019518,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6429,1020103,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011106",Other,,
6430,1020104,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011106",Other,,
6431,1020105,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S011106",Other,,
6432,1020106,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6433,1020107,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6434,1020108,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6435,1020109,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6436,1020110,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6437,1020111,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6438,1020112,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6439,1020113,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6440,1020114,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011106",Other,,
6441,1020115,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6442,1020116,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011106",Other,,
6443,1020117,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011106",Other,,
6444,1020118,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6445,1020119,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S011106",Other,,
6446,1020120,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S011106",Other,,
6447,1020121,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011106,Other,,
6448,1020122,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S011106",Other,,
6449,1020123,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S011106",Other,,
6450,1020124,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011106,Other,,
6451,1020125,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011106,Other,,
6452,1020126,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011106",Other,,
6453,1020127,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6454,1020128,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6455,1020129,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011106",Other,,
6456,1020130,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S011106",Other,,
6457,1020131,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6458,1020132,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6459,1020133,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S011106",Other,,
6460,1020134,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6461,1020135,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S011106",Other,,
6462,1020136,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S011106",Other,,
6463,1020137,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011106,Other,,
6464,1020138,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6465,1020139,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6466,1022591,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6467,1022592,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011106",Other,,
6468,1022593,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011106,Other,,
6469,1022594,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011106",Other,,
6470,1022595,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6471,1022596,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S011106",Other,,
6472,1022597,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6473,1022598,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011106",Other,,
6474,1022599,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011106",Other,,
6475,1022600,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011106",Other,,
6476,1022601,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011106",Other,,
6477,1022602,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6478,1022603,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S011106",Other,,
6479,1022604,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S011106",Other,,
6480,1022605,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011106",Other,,
6481,1022606,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011106,Other,,
6482,1022607,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011106",Other,,
6483,1022608,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011106",Other,,
6484,1022609,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S011106",Other,,
6485,1022610,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6486,1022611,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6487,1022612,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S011106",Other,,
6488,1022613,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S011106",Other,,
6489,1022614,1,3,,123097261,31703,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011106,Other,,
6490,1022615,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6491,1022616,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011106",Other,,
6492,1022617,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011106",Other,,
6493,1022618,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6494,1022619,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011106",Other,,
6495,1022620,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011106",Other,,
6496,1022621,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6497,1022622,1,3,,123097261,31703,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S011106",Other,,
6498,1046869,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/11,Other,,
6499,1046870,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/12,Other,,
6500,1046871,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/12,Other,,
6501,1046916,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/9,Other,,
6502,1046917,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/9,Other,,
6503,1046918,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/9,Other,,
6504,1046919,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/10,Other,,
6505,1046920,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/10,Other,,
6506,1046921,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/10,Other,,
6507,1046922,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/10,Other,,
6508,1046923,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/10,Other,,
6509,1046924,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/11,Other,,
6510,1046925,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/11,Other,,
6511,1046926,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/11,Other,,
6512,1046927,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/11,Other,,
6513,1046928,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/11,Other,,
6514,1046929,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/12,Other,,
6515,1046930,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/12,Other,,
6516,1046931,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/12,Other,,
6517,1046932,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/12,Other,,
6518,1046933,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/12,Other,,
6519,1046934,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/13,Other,,
6520,1046935,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/13,Other,,
6521,1046936,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/13,Other,,
6522,1046937,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/13,Other,,
6523,1046938,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/13,Other,,
6524,1046939,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/14,Other,,
6525,1046940,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/14,Other,,
6526,1046941,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/14,Other,,
6527,1046942,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/14,Other,,
6528,1046943,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/14,Other,,
6529,1046944,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/15,Other,,
6530,1046945,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/15,Other,,
6531,1046946,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/15,Other,,
6532,1046947,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/15,Other,,
6533,1046948,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/15,Other,,
6534,1046949,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/16,Other,,
6535,1046950,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/16,Other,,
6536,1046951,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/16,Other,,
6537,1046952,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/16,Other,,
6538,1046953,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/16,Other,,
6539,1047138,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/12,Other,,
6540,1047139,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/12,Other,,
6541,1047140,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/12,Other,,
6542,1047141,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/13,Other,,
6543,1047142,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/13,Other,,
6544,1047143,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/13,Other,,
6545,1047144,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/13,Other,,
6546,1047145,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/13,Other,,
6547,1047146,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/14,Other,,
6548,1047147,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/14,Other,,
6549,1047148,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/14,Other,,
6550,1047149,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/14,Other,,
6551,1047150,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/14,Other,,
6552,1047151,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/15,Other,,
6553,1047152,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/15,Other,,
6554,1047153,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/15,Other,,
6555,1047154,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/15,Other,,
6556,1047155,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/15,Other,,
6557,1047156,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/16,Other,,
6558,1047157,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/16,Other,,
6559,1047158,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/16,Other,,
6560,1047159,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/16,Other,,
6561,1047160,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/16,Other,,
6562,1047161,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/5,Other,,
6563,1047162,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/5,Other,,
6564,1047163,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/5,Other,,
6565,1047164,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/5,Other,,
6566,1047165,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/5,Other,,
6567,1047166,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/6,Other,,
6568,1047167,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/6,Other,,
6569,1047168,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/6,Other,,
6570,1047169,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/6,Other,,
6571,1047170,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/6,Other,,
6572,1047171,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/7,Other,,
6573,1047172,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/7,Other,,
6574,1047173,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/7,Other,,
6575,1047262,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/7,Other,,
6576,1047263,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/7,Other,,
6577,1047264,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/8,Other,,
6578,1047265,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/8,Other,,
6579,1047266,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 617/8,Other,,
6580,1047267,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 617/8,Other,,
6581,1047268,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 617/8,Other,,
6582,1047269,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 617/9,Other,,
6583,1047270,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 617/9,Other,,
6584,1048925,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/5,Other,,
6585,1048926,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/5,Other,,
6586,1048927,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/5,Other,,
6587,1048928,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/5,Other,,
6588,1048929,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/5,Other,,
6589,1048930,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/6,Other,,
6590,1048931,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/6,Other,,
6591,1048932,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/6,Other,,
6592,1048933,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/6,Other,,
6593,1048934,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/6,Other,,
6594,1048935,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/7,Other,,
6595,1048936,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/7,Other,,
6596,1048937,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/7,Other,,
6597,1048938,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/7,Other,,
6598,1048939,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/7,Other,,
6599,1048940,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/8,Other,,
6600,1048941,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/8,Other,,
6601,1048942,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/8,Other,,
6602,1048943,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/8,Other,,
6603,1048944,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/8,Other,,
6604,1048945,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/9,Other,,
6605,1048946,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/9,Other,,
6606,1048947,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/9,Other,,
6607,1048948,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/9,Other,,
6608,1048949,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/9,Other,,
6609,1048950,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/10,Other,,
6610,1048951,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/10,Other,,
6611,1048952,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/10,Other,,
6612,1048953,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/10,Other,,
6613,1048954,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 616/10,Other,,
6614,1048955,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 616/11,Other,,
6615,1048956,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 616/11,Other,,
6616,1048957,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 616/11,Other,,
6617,1048958,1,2,,123097261,31703,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: intravenous injection | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 616/11,Other,,
6618,1053194,1,1,,124886893,31703,Inactive,,,,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,Confirmatory,,
6619,1053195,1,1,,124886893,31703,Inactive,,,,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,Confirmatory,,
6620,1053389,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in NMRI-nu mouse xenografted with HT-29 cells assessed as body weight loss at 5 mg/kg, iv administered on day 3 for 3 weeks",Other,24128000.0,
6621,1053390,1,2,,123097261,31703,Unspecified,,,,,"Antitumor activity against human HT-29 cells xenografted in NMRI-nu mouse assessed as time to reach 4x starting volume of tumor at 5 mg/kg, iv administered on day 3 for 3 weeks (Rvb = 14.07 days)",Other,24128000.0,
6622,1053393,1,2,,123097261,31703,Active,,,,,"Antitumor activity against human HT-29 cells xenografted in NMRI-nu mouse assessed as tumor growth inhibition at 5 mg/kg, iv administered on day 3 for 3 weeks",Other,24128000.0,
6623,1054360,1,1,,123097261,31703,Active,,,,,Antiproliferative activity against human HCT116 cells assessed as cell viability at 10 uM after 72 hrs by CellTiter assay,Other,24138941.0,
6624,1054361,1,2,,123097261,31703,Active,,,,,Antiproliferative activity against human CCRF-CEM cells assessed as cell viability at 10 uM after 72 hrs by CellTiter assay,Other,24138941.0,
6625,1054362,1,2,,123097261,31703,Active,,,,,Antiproliferative activity against human MDA-MB-468 cells assessed as cell viability at 10 uM after 72 hrs by CellTiter assay,Other,24138941.0,
6626,1054655,1,1,,123097261,31703,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae expressing rad52 mutant gene assessed as increase in sensitivity at 20 umol/L by spectrophotometry relative to wild type,Other,24141203.0,
6627,1055192,1,2,,123097261,31703,Active,,,0.09,GI50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24158013.0,
6628,1055193,1,2,,123097261,31703,Active,,,0.07,GI50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24158013.0,
6629,1055194,1,2,,123097261,31703,Active,,,0.1,GI50,Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24158013.0,
6630,1055294,1,2,,123097261,31703,Active,,,2.75,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by cell titer glo assay,Confirmatory,24161704.0,
6631,1055295,1,2,,123097261,31703,Active,,,3.13,IC50,Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay,Confirmatory,24161704.0,
6632,1055484,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Other,24177357.0,
6633,1055486,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay,Other,24177357.0,
6634,1055487,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Other,24177357.0,
6635,1055620,1,1,,123097261,31703,Active,,,1.38,IC50,Cytotoxicity against human HCT116 cells by MTT assay,Confirmatory,24182355.0,
6636,1055621,1,2,,123097261,31703,Active,,,0.97,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,24182355.0,
6637,1055622,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,24182355.0,
6638,1055623,1,1,,123097261,31703,Active,,,0.98,IC50,Cytotoxicity against human H460 cells by MTT assay,Confirmatory,24182355.0,
6639,1055624,1,1,,123097261,31703,Active,,,1.48,IC50,Cytotoxicity against human BGC823 cells by MTT assay,Confirmatory,24182355.0,
6640,1055760,1,1,,123097261,31703,Active,,,0.011000000000000001,IC50,Cytotoxic activity against human SGC7901 cells,Confirmatory,24195466.0,
6641,1055976,1,2,,123097261,31703,Active,,,0.41100000000000003,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,24231309.0,
6642,1055977,1,2,,123097261,31703,Active,,,1.172,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay,Confirmatory,24231309.0,
6643,1055978,1,2,,123097261,31703,Active,,,0.877,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay,Confirmatory,24231309.0,
6644,1056611,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human WI38 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6645,1056613,1,1,,123097261,31703,Active,,,0.79,IC50,Cytotoxicity against human CHP100 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6646,1056614,1,2,,123097261,31703,Active,,,0.68,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6647,1056615,1,1,,123097261,31703,Active,,,0.27,IC50,Cytotoxicity against human PC3M cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6648,1056616,1,2,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6649,1056617,1,2,,123097261,31703,Active,,,0.31,IC50,Cytotoxicity against human SF268 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6650,1056618,1,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar Blue assay,Confirmatory,24251417.0,
6651,1057272,1,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6652,1057273,1,2,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6653,1057274,1,2,,123097261,31703,Active,,,1.17,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6654,1057275,1,1,,123097261,31703,Unspecified,,,95.61,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6655,1057276,1,2,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6656,1057277,1,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,24148837.0,
6657,1057937,1,1,,123097261,31703,Unspecified,,,400.0,GI50,Antiproliferative activity against human HFF1 cells after 2 days by sulforhodamine B assay,Confirmatory,24184076.0,
6658,1057938,1,2,,123097261,31703,Active,,,0.31,GI50,Antiproliferative activity against human MCF7 cells after 2 days by sulforhodamine B assay,Confirmatory,24184076.0,
6659,1057939,1,1,,123097261,31703,Active,,,0.32,GI50,Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay,Confirmatory,24184076.0,
6660,1057940,1,1,,123097261,31703,Active,,,0.24,GI50,Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay,Confirmatory,24184076.0,
6661,1058559,3,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay,Confirmatory,24215890.0,
6662,1060483,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NE3 cells assessed as cell shrinkage after 24 hrs by SRB assay,Other,24269165.0,
6663,1060484,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay,Other,24269165.0,
6664,1060751,1,3,,123097261,31703,Unspecified,,,100.0,IC50,Cytotoxicity against HEK293 cells by MTT assay,Confirmatory,24287557.0,
6665,1060752,1,2,,123097261,31703,Active,,,1.07,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,24287557.0,
6666,1060753,1,2,,123097261,31703,Active,,,0.91,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,24287557.0,
6667,1060754,1,2,,123097261,31703,Active,,,0.509,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,24287557.0,
6668,1060755,1,2,,123097261,31703,Active,,,0.45899999999999996,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,24287557.0,
6669,1060784,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as cell viability at 1 uM after 24 hrs by trypan blue assay relative to untreated control,Other,24287561.0,
6670,1061012,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human COLO205 cells by MTT assay,Confirmatory,24300737.0,
6671,1061013,1,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,24300737.0,
6672,1061014,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,24300737.0,
6673,1061015,1,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,24300737.0,
6674,1061016,1,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,24300737.0,
6675,1061799,1,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
6676,1061801,1,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HeLa cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
6677,1061804,1,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
6678,1061805,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human IMR32 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
6679,1061807,1,1,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human prostate cancer cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
6680,1064032,1,2,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human MGC803 cells after 24 hrs by SRB assay,Confirmatory,24370114.0,
6681,1064033,1,2,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,24370114.0,
6682,1064034,1,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human A549 cells after 24 hrs by SRB assay,Confirmatory,24370114.0,
6683,1064035,1,1,,123097261,31703,Active,,,0.21,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,24370114.0,
6684,1064036,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,24370114.0,
6685,1064265,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human lymphocytes by colorimetric method,Confirmatory,24387625.0,
6686,1064266,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human SF295 cells by colorimetric method,Confirmatory,24387625.0,
6687,1064267,1,1,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human PC3 cells by colorimetric method,Confirmatory,24387625.0,
6688,1064268,1,1,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human HL60 cells by colorimetric method,Confirmatory,24387625.0,
6689,1064269,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human HCT8 cells by colorimetric method,Confirmatory,24387625.0,
6690,1064270,1,2,,123097261,31703,Active,,,1.51,IC50,Cytotoxicity against human MDA-MB-435 cells by colorimetric method,Confirmatory,24387625.0,
6691,1064685,3,1,,123097261,31703,Active,,,0.059770000000000004,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,24411197.0,
6692,1064686,3,1,,123097261,31703,Active,,,0.034069999999999996,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,24411197.0,
6693,1064687,3,1,,123097261,31703,Active,,,0.1362,GI50,Growth inhibition of human A375-C5 cells after 48 hrs by SRB assay,Confirmatory,24411197.0,
6694,1065290,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
6695,1065294,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human MG63 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
6696,1065297,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
6697,1065300,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
6698,1065303,1,2,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
6699,1066513,1,2,,123097261,31703,Active,,,0.99,LC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,24437979.0,
6700,1066514,2,1,,123097261,31703,Active,,,,LC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24437979.0,
6701,1067061,1,2,,123097261,31703,Active,,,1.76,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6702,1067062,1,2,,123097261,31703,Active,,,1.69,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6703,1067063,1,1,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6704,1067064,1,2,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6705,1067065,1,2,,123097261,31703,Active,,,1.99,IC50,Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6706,1067066,1,2,,123097261,31703,Active,,,10.9,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6707,1067067,1,1,,123097261,31703,Active,,,0.39,IC50,Cytotoxicity against human ME180 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
6708,1067369,1,2,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6709,1067370,1,2,,123097261,31703,Active,,,0.24,IC50,Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6710,1067371,1,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6711,1067372,1,1,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human Hs578T cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6712,1067373,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MX1 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6713,1067374,1,2,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6714,1067375,1,1,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6715,1067376,1,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6716,1067377,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6717,1067378,1,1,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6718,1067379,1,2,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6719,1067380,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6720,1067381,1,1,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6721,1067382,1,1,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24530030.0,
6722,1067615,3,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,23827179.0,
6723,1067616,1,2,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23827179.0,
6724,1067617,1,1,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human LS180 cells after 72 hrs by MTT assay,Confirmatory,23827179.0,
6725,1068791,1,1,,123097261,31703,Active,,,0.037000000000000005,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay,Confirmatory,24398294.0,
6726,1068792,1,1,,123097261,31703,Active,,,0.423,IC50,Cytotoxicity against human SF295 cells assessed as growth inhibition by MTT assay,Confirmatory,24398294.0,
6727,1068793,1,1,,123097261,31703,Active,,,0.23,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay,Confirmatory,24398294.0,
6728,1068794,1,1,,123097261,31703,Active,,,0.488,IC50,Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by MTT assay,Confirmatory,24398294.0,
6729,1069286,1,2,,123097261,31703,Active,,,1.65,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24418772.0,
6730,1069287,1,2,,123097261,31703,Active,,,2.43,IC50,Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay,Confirmatory,24418772.0,
6731,1069288,1,2,,123097261,31703,Active,,,3.51,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24418772.0,
6732,1070859,1,4,,123097261,31703,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 100 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
6733,1070860,1,4,,123097261,31703,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 10 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
6734,1070861,1,4,,123097261,31703,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 1 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
6735,1070862,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay,Other,24051300.0,
6736,1070863,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay,Other,24051300.0,
6737,1070864,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay,Other,24051300.0,
6738,1071689,1,2,,123097261,31703,Active,,,1.7,IC50,Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24485783.0,
6739,1071690,1,1,,123097261,31703,Inconclusive,,,,,Antifungal activity against Candida parapsilosis ATCC 22019 assessed as growth inhibition by microdliution method,Other,24485783.0,
6740,1071922,1,2,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay,Confirmatory,24513041.0,
6741,1071923,1,2,,123097261,31703,Active,,,0.65,IC50,Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells after 24 hrs by MTT assay,Confirmatory,24513041.0,
6742,1072974,1,2,,123097261,31703,Unspecified,,,10.0,IC50,Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24484281.0,
6743,1072975,1,1,,123097261,31703,Active,,,4.8,IC50,Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24484281.0,
6744,1072976,1,1,,123097261,31703,Unspecified,,,10.0,IC50,Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24484281.0,
6745,1072977,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24484281.0,
6746,1075766,1,2,,123097261,31703,Unspecified,,,,,Resistance ratio of GI50 for vinblastine-resistant human KBV1 cells to GI50 for human KB 3.1 cells,Other,24502276.0,
6747,1075768,1,2,,123097261,31703,Unspecified,,,1.0,GI50,Cytotoxicity against vinblastine-resistant human KBV1 cells after 72 hrs by MTT assay,Confirmatory,24502276.0,
6748,1075769,1,2,,123097261,31703,Active,,,0.67608,GI50,Cytotoxicity against human KB 3.1 cells after 72 hrs by MTT assay,Confirmatory,24502276.0,
6749,1075869,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24507927.0,
6750,1075870,1,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24507927.0,
6751,1075871,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24507927.0,
6752,1075872,1,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24507927.0,
6753,1076685,1,1,,123097261,31703,Unspecified,,,,,Resistance ratio of IC50 for human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein to IC50 for human CCRF-CEM cells,Other,24561670.0,
6754,1076686,1,1,,123097261,31703,Active,,,23.27,IC50,Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay,Confirmatory,24561670.0,
6755,1076688,1,2,,123097261,31703,Active,,,0.009000000000000001,IC50,Cytotoxicity against human CCRF-CEM cells by resazurin assay,Confirmatory,24561670.0,
6756,1076837,1,2,,123097261,31703,Active,,,1.06,IC50,Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay,Confirmatory,24582982.0,
6757,1076838,1,2,,123097261,31703,Active,,,1.31,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24582982.0,
6758,1076839,1,2,,123097261,31703,Active,,,1.15,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24582982.0,
6759,1077027,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Other,24589485.0,
6760,1077028,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,24589485.0,
6761,1077029,1,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Other,24589485.0,
6762,1077030,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay,Other,24589485.0,
6763,1077031,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Other,24589485.0,
6764,1077227,1,2,,123097261,31703,Active,,,7.41,IC50,Cytotoxicity against HEK293 cells after 48 hrs by MTT assay,Confirmatory,24607876.0,
6765,1077228,1,2,,123097261,31703,Active,,,6.94,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24607876.0,
6766,1077229,1,1,,123097261,31703,Active,,,8.19,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,24607876.0,
6767,1077230,1,2,,123097261,31703,Active,,,7.47,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24607876.0,
6768,1077367,1,2,,123097261,31703,Active,,,10.9,IC50,Cytotoxicity against human AGS cells after 48 hrs by MTT assay,Confirmatory,,
6769,1077368,1,2,,123097261,31703,Active,,,8.7,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,,
6770,1077369,1,2,,123097261,31703,Active,,,6.3,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,,
6771,1077515,1,2,,123097261,31703,Inconclusive,,,,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by Alamar Blue assay,Confirmatory,,
6772,1077516,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for pig LLC-PK1 cells to IC50 for Plasmodium falciparum W2",Other,,
6773,1077517,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum W2",Other,,
6774,1077518,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Plasmodium falciparum W2",Other,,
6775,1077519,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for pig LLC-PK1 cells to IC50 for Plasmodium falciparum D6",Other,,
6776,1077520,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum D6",Other,,
6777,1077521,1,2,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Plasmodium falciparum D6",Other,,
6778,1077522,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay,Confirmatory,,
6779,1077523,1,2,,123097261,31703,Active,,,7.0,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay,Confirmatory,,
6780,1077524,1,2,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay,Confirmatory,,
6781,1077525,1,2,,123097261,31703,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum W2 after 72 hrs by LDH activity assay,Confirmatory,,
6782,1077526,1,2,,123097261,31703,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum D6 after 72 hrs by LDH activity assay,Confirmatory,,
6783,1077611,1,2,,123097261,31703,Unspecified,,,,,Toxicity against HMEC at 0.1 uM after 72hrs by MTT assay,Other,24163729.0,
6784,1077615,1,2,,123097261,31703,Active,,,0.085,GI50,Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay,Confirmatory,24163729.0,
6785,1077616,1,2,,123097261,31703,Active,,,0.15,GI50,Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,24163729.0,
6786,1077673,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human THLE cells assessed as ATP depletion by CellTitre-Glo assay,Other,,
6787,1077674,1,2,,123097261,31703,Active,,,0.53,EC50,Cytotoxicity against human THLE cells assessed as ATP depletion after 72 hrs by CellTitre-Glo assay,Confirmatory,,
6788,1077675,1,2,,123097261,31703,Active,,,1.8,EC50,Cytotoxicity against human THLE cells assessed as ATP depletion after 24 hrs by CellTitre-Glo assay,Confirmatory,,
6789,1077676,1,2,,123097261,31703,Unspecified,,,215.0,EC50,Cytotoxicity against human THLE cells assessed as ATP depletion after 4 hrs by CellTitre-Glo assay,Confirmatory,,
6790,1077677,1,2,,123097261,31703,Unspecified,,,179.0,EC50,Induction of ROS generation assessed as generation of H2O2 measured as oxidation of phenol red after 60 mins by phenol red assay,Confirmatory,,
6791,1077756,1,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human HuCCa1 cells by MTT assay,Confirmatory,,
6792,1077757,1,2,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,,
6793,1077758,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,,
6794,1077759,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,,
6795,1079931,1,1,,123097261,31703,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
6796,1079932,1,1,,123097261,31703,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
6797,1079933,1,1,,123097261,31703,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
6798,1079934,1,1,,123097261,31703,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
6799,1079935,1,1,,123097261,31703,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
6800,1079936,1,1,,123097261,31703,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
6801,1079937,1,1,,123097261,31703,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
6802,1079938,1,1,,123097261,31703,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
6803,1079939,1,1,,123097261,31703,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
6804,1079940,1,1,,123097261,31703,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
6805,1079941,1,1,,123097261,31703,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
6806,1079942,1,1,,123097261,31703,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
6807,1079943,1,1,,123097261,31703,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
6808,1079944,1,1,,123097261,31703,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
6809,1079945,1,1,,123097261,31703,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
6810,1079946,1,1,,123097261,31703,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
6811,1079947,1,1,,123097261,31703,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
6812,1079948,1,1,,123097261,31703,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
6813,1079949,1,1,,123097261,31703,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
6814,1083474,1,2,,123097261,31703,Active,,,,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 96 hr by MTT assay,Confirmatory,,
6815,1083475,1,2,,123097261,31703,Active,,,,IC50,Cytotoxicity against Homo sapiens (human) Raji cells after 96 hr by MTT assay,Confirmatory,,
6816,1083476,1,2,,123097261,31703,Active,,,,IC50,Cytotoxicity against Homo sapiens (human) LS180 cells after 96 hr by MTT assay,Confirmatory,,
6817,1083477,1,2,,123097261,31703,Active,,,,IC50,Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay,Confirmatory,,
6818,1084076,1,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 72 hr by MTT assay,Confirmatory,,
6819,1084077,1,2,,123097261,31703,Active,,,0.07,IC50,Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay,Confirmatory,,
6820,1084078,1,2,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay,Confirmatory,,
6821,1084331,1,2,,123097261,31703,Active,,,,GI50,Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 48 hr by SRB assay,Confirmatory,,
6822,1084332,1,2,,123097261,31703,Active,,,,GI50,Cytotoxicity against Homo sapiens (human) HOP62 cells after 48 hr by SRB assay,Confirmatory,,
6823,1084333,1,2,,123097261,31703,Active,,,,GI50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
6824,1084334,1,2,,123097261,31703,Active,,,,GI50,Cytotoxicity against Homo sapiens (human) A498 cells after 48 hr by SRB assay,Confirmatory,,
6825,1085506,1,2,,123097261,31703,Active,,,32.0,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay,Confirmatory,,
6826,1085507,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 100 uM after 48 hr by SRB assay,Other,,
6827,1085508,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 50 uM after 48 hr by SRB assay,Other,,
6828,1085509,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 25 uM after 48 hr by SRB assay,Other,,
6829,1085510,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 10 uM after 48 hr by SRB assay,Other,,
6830,1085555,1,3,,123097261,31703,Unspecified,,,63.0,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by neutral red assay,Confirmatory,,
6831,1085761,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay,Other,23024574.0,
6832,1085762,1,1,,123097261,31703,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hr by plasmodial LDH assay,Other,23024574.0,
6833,1085763,1,1,,123097261,31703,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hr by plasmodial LDH assay,Other,23024574.0,
6834,1085764,1,1,,123097261,31703,Inconclusive,,,,,Antileishmanial activity against promastigote form of Leishmania donovani after 48 hr by alamar blue assay,Other,23024574.0,
6835,1086116,1,2,,123097261,31703,Unspecified,,,,,Toxicity against Bacopa monnieri assessed as change in leaf colour at 50 ug/ml after 15 days by Bacopa sensor test,Other,,
6836,1086118,1,2,,123097261,31703,Unspecified,,,,,Toxicity against Bacopa monnieri assessed as number of leaves at 50 ug/ml after 15 days by Bacopa sensor test (Rvb = 6),Other,,
6837,1086119,1,2,,123097261,31703,Unspecified,,,,,Toxicity against Bacopa monnieri assessed as number of roots at 50 ug/ml after 15 days by Bacopa sensor test (Rvb = 2),Other,,
6838,1086120,1,2,,123097261,31703,Unspecified,,,,,Toxicity against Bacopa monnieri assessed as shoot elongation at 50 ug/ml after 15 days by Bacopa sensor test (Rvb = 0.8 cm),Other,,
6839,1086121,1,2,,123097261,31703,Unspecified,,,,,Toxicity against Bacopa monnieri assessed as number of shoots at 50 ug/ml after 15 days by Bacopa sensor test (Rvb = 2),Other,,
6840,1086599,1,2,,123097261,31703,Active,,,2.97,IC50,Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay,Confirmatory,,
6841,1086651,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HL60 cells,Other,,
6842,1086681,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Homo sapiens (human) MDA231 cells after 48 hr by MTT assay,Confirmatory,,
6843,1086682,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay,Confirmatory,,
6844,1086683,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay,Confirmatory,,
6845,1086684,1,2,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay,Confirmatory,,
6846,1086891,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells after 72 hr by MTT assay,Other,,
6847,1086893,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HL60 cells after 72 hr by MTT assay,Other,,
6848,1086894,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay,Other,,
6849,1086895,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) SF295 cells after 72 hr by MTT assay,Other,,
6850,1086934,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay,Other,,
6851,1086935,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay,Other,,
6852,1086936,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HuCCa1 cells after 3 days by crystal violet staining,Other,,
6853,1095200,1,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by trypan blue assay,Confirmatory,,
6854,1095617,1,2,,123097261,31703,Unspecified,,,71.8,IC50,Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay relative to control,Confirmatory,,
6855,1095618,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as surviving fraction at 100 uM after 48 hr by SRB assay relative to control,Other,,
6856,1095619,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as surviving fraction at 50 uM after 48 hr by SRB assay relative to control,Other,,
6857,1095620,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as surviving fraction at 25 uM after 48 hr by SRB assay relative to control,Other,,
6858,1095621,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF-7 cells assessed as surviving fraction at 10 uM after 48 hr by SRB assay relative to control,Other,,
6859,1096187,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay,Other,,
6860,1096188,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell survival at 0.1 g/l after 24 hr by MTT assay (Rvb = 78.07 +/- 1.89 to 95.31 +/- 3.09%),Other,,
6861,1096189,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell survival at 0.01 g/l after 24 hr by MTT assay (Rvb = 78.07 +/- 1.89 to 95.31 +/- 3.09%),Other,,
6862,1096190,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell survival at 0.001 g/l after 24 hr by MTT assay (Rvb = 78.07 +/- 1.89 to 95.31 +/- 3.09%),Other,,
6863,1096191,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell survival at 0.0001 g/l after 24 hr by MTT assay (Rvb = 78.07 +/- 1.89 to 95.31 +/- 3.09%),Other,,
6864,1096220,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay,Other,,
6865,1096588,1,2,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against Sus scrofa (pig) LLC-PK1 cells by neutral red staining,Confirmatory,,
6866,1096589,1,3,,123097261,31703,Unspecified,,,5.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by neutral red staining,Confirmatory,,
6867,1096594,1,2,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining,Confirmatory,,
6868,1096595,1,2,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining,Confirmatory,,
6869,1096596,1,2,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining,Confirmatory,,
6870,1096597,1,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against Homo sapiens (human) SKOV3 cells by neutral red staining,Confirmatory,,
6871,1096746,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Other,,
6872,1096766,1,2,,123097261,31703,Active,,,3.22,IC50,Anticancer activity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
6873,1096768,1,2,,123097261,31703,Active,,,5.23,IC50,Anticancer activity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay,Confirmatory,,
6874,1105788,1,2,,123097261,31703,Active,,,24.27,IC50,Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay,Confirmatory,,
6875,1105789,1,2,,123097261,31703,Active,,,19.9,IC50,Cytotoxicity against Homo sapiens (human) SK-N-SH cells assessed as growth inhibition after 48 hr by MTT assay,Confirmatory,,
6876,1105826,1,2,,123097261,31703,Inconclusive,,,,,Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as survival after 3 days by crystal violet staining,Other,,
6877,1105827,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining,Other,,
6878,1105828,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining,Other,,
6879,1105829,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining,Other,,
6880,1106086,1,2,,123097261,31703,Active,,,0.016,IC50,Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay,Confirmatory,,
6881,1106117,1,2,,123097261,31703,Active,,,1.08,IC50,Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay,Confirmatory,,
6882,1106118,1,2,,123097261,31703,Active,,,1.19,IC50,Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay,Confirmatory,,
6883,1106119,1,2,,123097261,31703,Active,,,1.28,IC50,Anticancer activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by SRB assay,Confirmatory,,
6884,1106231,1,2,,123097261,31703,Active,,,,,Induction of apoptotic DNA fragmentation in Homo sapiens (human) MCF-7 cells assessed as increase in olive tail moment at 0.1 uM after 24 hr by comet assay,Other,,
6885,1106233,1,2,,123097261,31703,Active,,,,,Induction of apoptotic DNA fragmentation in Homo sapiens (human) MCF-7 cells assessed as increase in tail length at 0.1 uM after 24 hr by comet assay,Other,,
6886,1106236,1,2,,123097261,31703,Active,,,,,Induction of apoptotic DNA fragmentation in Homo sapiens (human) MCF-7 cells assessed as formation of comets at 54 ug/ml after 24 hr by comet assay,Other,,
6887,1106237,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell survival after 24 hr by MTT assay,Other,,
6888,1106371,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) G361 cells assessed as cell growth at 10'-7 M by SRB assay relative to control,Other,,
6889,1106372,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) G361 cells assessed as cell growth at 10'-6 M by SRB assay relative to control,Other,,
6890,1106373,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) G361 cells assessed as cell growth at 10'-5 M by SRB assay relative to control,Other,,
6891,1106374,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) G361 cells assessed as cell growth at 10'-4 M by SRB assay relative to control,Other,,
6892,1106375,3,1,,123097261,31703,Active,,,,GI50,Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay,Confirmatory,,
6893,1106474,1,2,,123097261,31703,Active,,,2.9,IC50,Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell viability after 72 hr by SRB assay,Confirmatory,,
6894,1106855,1,2,,123097261,31703,Active,,,4.89,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by XTT assay,Confirmatory,,
6895,1106856,1,2,,123097261,31703,Active,,,3.27,IC50,Cytotoxicity against human DU145 cells after 72 hrs by XTT assay,Confirmatory,,
6896,1107004,1,2,,123097261,31703,Active,,,10.9,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,,
6897,1107005,1,2,,123097261,31703,Active,,,1.76,IC50,Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay,Confirmatory,,
6898,1107006,1,2,,123097261,31703,Active,,,1.88,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,,
6899,1107007,1,2,,123097261,31703,Active,,,0.64,IC50,Cytotoxicity against human PA1 cells after 24 hrs by MTT assay,Confirmatory,,
6900,1107009,1,2,,123097261,31703,Active,,,19.0,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,,
6901,1107138,1,2,,123097261,31703,Active,,,3.17,IC50,Cytotoxicity against Homo sapiens (human) MG63 cells assessed as reduction of cell survival after 48 hr by MTT assay,Confirmatory,,
6902,1107139,1,2,,123097261,31703,Active,,,2.67,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as reduction of cell survival after 48 hr by MTT assay,Confirmatory,,
6903,1107140,1,2,,123097261,31703,Active,,,1.69,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay,Confirmatory,,
6904,1107186,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability after 48 hr by MTT assay,Other,,
6905,1107187,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability after 48 hr by MTT assay,Other,,
6906,1107190,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability at 5 uM after 48 hr by MTT assay relative to control,Other,,
6907,1107191,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability at 5 uM after 48 hr by MTT assay relative to control,Other,,
6908,1107278,1,2,,123097261,31703,Active,,,0.03,GI50,Growth inhibition of Homo sapiens (human) SW620 cells after 48 hr by MTT assay,Confirmatory,,
6909,1107279,1,2,,123097261,31703,Active,,,1.76,GI50,Growth inhibition of Homo sapiens (human) PC3 cells after 48 hr by MTT assay,Confirmatory,,
6910,1107280,1,2,,123097261,31703,Active,,,0.09,GI50,Growth inhibition of Homo sapiens (human) SKHep cells after 48 hr by MTT assay,Confirmatory,,
6911,1107281,1,2,,123097261,31703,Active,,,0.11,GI50,Growth inhibition of Homo sapiens (human) H460 cells after 48 hr by MTT assay,Confirmatory,,
6912,1107282,1,2,,123097261,31703,Active,,,0.95,GI50,Growth inhibition of Homo sapiens (human) OVCAR cells after 48 hr by MTT assay,Confirmatory,,
6913,1107283,1,2,,123097261,31703,Active,,,0.33,GI50,Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay,Confirmatory,,
6914,1107284,1,2,,123097261,31703,Active,,,0.02,GI50,Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay,Confirmatory,,
6915,1107285,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell survival after 72 hr by MTT assay,Other,,
6916,1107286,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay,Other,,
6917,1107287,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) SF295 cells assessed as inhibition of cell survival after 72 hr by MTT assay,Other,,
6918,1107288,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell survival after 72 hr by MTT assay,Other,,
6919,1107289,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as growth inhibition at 0.3 ug/ml after 72 hr by MTT assay,Other,,
6920,1107290,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) HCT8 cells assessed as growth inhibition at 0.3 ug/ml after 72 hr by MTT assay,Other,,
6921,1107291,1,2,,123097261,31703,Unspecified,,,,,Anticancer activity against Homo sapiens (human) SF295 cells assessed as growth inhibition at 0.3 ug/ml after 72 hr by MTT assay,Other,,
6922,1113807,1,3,,123097261,31703,Active,,,0.09,GI50,Growth inhibition of Homo sapiens (human) SF268 cells after 48 hr by SRB assay,Confirmatory,,
6923,1113808,1,2,,123097261,31703,Active,,,0.04,GI50,Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
6924,1113809,1,2,,123097261,31703,Active,,,0.09,GI50,Growth inhibition of Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay,Confirmatory,,
6925,1114491,1,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
6926,1114640,1,2,,123097261,31703,Active,,,2.5,EC50,Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay,Confirmatory,,
6927,1114645,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells assessed as cell death at 2.5 uM after 48 hr by MTT assay,Other,,
6928,1115490,1,2,,123097261,31703,Active,,,0.71,IC50,Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay,Confirmatory,,
6929,1115491,1,2,,123097261,31703,Active,,,8.7,IC50,Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay,Confirmatory,,
6930,1115492,1,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay,Confirmatory,,
6931,1115516,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) A549 cells assessed as cell viability at 10 uM after 72 hr by MTT assay,Other,,
6932,1115517,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) DU145 cells assessed as cell viability at 10 uM after 72 hr by MTT assay,Other,,
6933,1115518,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells assessed as cell viability at 10 uM after 72 hr by MTT assay,Other,,
6934,1115799,1,2,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as inhibition of cell growth after 3 days by crystal violet staining,Confirmatory,,
6935,1115800,1,2,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay,Confirmatory,,
6936,1115801,1,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay,Confirmatory,,
6937,1115802,1,2,,123097261,31703,Active,,,0.64,IC50,Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining,Confirmatory,,
6938,1116087,1,2,,123097261,31703,Active,,,0.35,IC50,Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
6939,1116088,1,2,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
6940,1116089,1,2,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against Homo sapiens (human) HT1080 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
6941,1116266,1,2,,123097261,31703,Active,,,4.49,IC50,Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
6942,1116268,1,2,,123097261,31703,Unspecified,,,100.0,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
6943,1116349,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells by tetrazolium-reduction assay,Confirmatory,,
6944,1116350,1,2,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells by tetrazolium-reduction assay,Confirmatory,,
6945,1116745,1,2,,123097261,31703,Active,,,7.36,IC50,Antitumor activity against Homo sapiens (human) HepG2 cells assessed as cell growth inhibition after 48 hr by MTT assay,Confirmatory,,
6946,1116746,1,2,,123097261,31703,Active,,,0.84,IC50,Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay,Confirmatory,,
6947,1116747,1,2,,123097261,31703,Active,,,5.46,IC50,Antitumor activity against Homo sapiens (human) MCF7 cells assessed as cell growth inhibition after 48 hr by MTT assay,Confirmatory,,
6948,1116748,1,2,,123097261,31703,Active,,,6.86,IC50,Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay,Confirmatory,,
6949,1117003,1,2,,123097261,31703,Active,,,7.2,IC50,Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by MTT assay,Confirmatory,,
6950,1117004,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of Homo sapiens (human) MCF7 cells at 60 ug/ml after 48 hr by MTT assay relative to control,Other,,
6951,1117005,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of Homo sapiens (human) MCF7 cells at 30 ug/ml after 48 hr by MTT assay relative to control,Other,,
6952,1117006,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of Homo sapiens (human) MCF7 cells at 15 ug/ml after 48 hr by MTT assay relative to control,Other,,
6953,1117007,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of Homo sapiens (human) MCF7 cells at 7.5 ug/ml after 48 hr by MTT assay relative to control,Other,,
6954,1117483,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against mouse NIH/3T3 cells assessed as dead cells at 12.5 ug/mL after 72 hrs by Alamar Blue assay relative to control,Other,,
6955,1117644,1,1,,123097261,31703,Active,,,,,Growth inhibition of human MCF7 cells assessed as cell viability at 4 uM after 24 hrs by MTT assay,Other,,
6956,1117645,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.04%),Other,,
6957,1117646,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 20.17%),Other,,
6958,1117647,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.79%),Other,,
6959,1117655,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human MCF7 cells expressing P21 promoter -145/+8 with luciferase gene assessed as upregulation of p21 protein expression at 4 uM by Western blot analysis relative to control,Other,,
6960,1117767,1,1,,123097261,31703,Active,,,0.07,GI50,Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay,Confirmatory,,
6961,1117770,1,1,,123097261,31703,Active,,,0.462,GI50,Antiproliferative activity against NHDF assessed as growth inhibition after 24 to 72 hrs by MTS assay,Confirmatory,,
6962,1117771,1,1,,123097261,31703,Active,,,0.223,GI50,Antiproliferative activity against NHLF assessed as growth inhibition after 24 to 72 hrs by MTS assay,Confirmatory,,
6963,1117772,1,1,,123097261,31703,Active,,,0.109,GI50,Antiproliferative activity against HUVEC assessed as growth inhibition after 24 to 72 hrs by MTS assay,Confirmatory,,
6964,1117773,1,1,,123097261,31703,Active,,,0.276,GI50,Antiproliferative activity against HMEC assessed as growth inhibition after 24 to 72 hrs by MTS assay,Confirmatory,,
6965,1117934,1,1,,123097261,31703,Active,,,0.47700000000000004,IC50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,,
6966,1117935,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,,
6967,1117936,1,1,,123097261,31703,Active,,,0.456,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,,
6968,1118095,1,1,,123097261,31703,Active,,,,,Induction of double-strand DNA breaks in chicken BLM-/- DT40 cell nuclear fraction assessed as gamma-H2AX phosphorylation at 0.9 uM after 24 hrs by immunoblot analysis,Other,,
6969,1118097,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in chicken BLM-/- DT40 cells at 0.9 uM after 24 hrs by DAPI staining based immunofluorescence assay,Other,,
6970,1118371,1,1,,123097261,31703,Active,,,1.4,IC50,Antiproliferative against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,,
6971,1118372,1,1,,123097261,31703,Active,,,2.0,IC50,Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,,
6972,1118373,1,1,,123097261,31703,Active,,,2.6,IC50,Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,,
6973,1118374,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human PC3 cells assessed as growth inhibition at 1 uM after 72 hrs by MTT assay relative to control,Other,,
6974,1118375,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human PC3 cells assessed as growth inhibition at 10 uM after 72 hrs by MTT assay relative to control,Other,,
6975,1118376,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human Bcap37 cells assessed as growth inhibition at 1 uM after 72 hrs by MTT assay relative to control,Other,,
6976,1118377,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human Bcap37 cells assessed as growth inhibition at 10 uM after 72 hrs by MTT assay relative to control,Other,,
6977,1118378,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human BGC823 cells assessed as growth inhibition at 1 uM after 72 hrs by MTT assay relative to control,Other,,
6978,1118379,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative against human BGC823 cells assessed as growth inhibition at 10 uM after 72 hrs by MTT assay relative to control,Other,,
6979,1118465,1,2,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human HOP62 cells,Confirmatory,,
6980,1118472,1,1,,123097261,31703,Active,,,0.14,GI50,Growth inhibition of human COLO205 cells,Confirmatory,,
6981,1118502,1,1,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human MCF7 cells,Confirmatory,,
6982,1118509,1,1,,123097261,31703,Active,,,1.83,GI50,Growth inhibition of human PC3 cells,Confirmatory,,
6983,1118515,1,1,,123097261,31703,Active,,,7.25,GI50,Growth inhibition of human A549 cells,Confirmatory,,
6984,1118516,1,2,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human KB cells,Confirmatory,,
6985,1118517,1,1,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human Gurav cells,Confirmatory,,
6986,1118518,1,1,,123097261,31703,Active,,,0.16,GI50,Growth inhibition of human A2780 cells,Confirmatory,,
6987,1118519,1,1,,123097261,31703,Active,,,0.17,GI50,Growth inhibition of human SiHa cells,Confirmatory,,
6988,1118520,1,1,,123097261,31703,Active,,,1.79,GI50,Growth inhibition of human ZR-75-1 cells,Confirmatory,,
6989,1118978,3,1,,123097261,31703,Active,,,0.16399999999999998,IC50,Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay,Confirmatory,,
6990,1118979,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 3 days by MTS assay,Confirmatory,,
6991,1118980,1,1,,123097261,31703,Active,,,0.154,IC50,Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by MTS assay,Confirmatory,,
6992,1118981,1,1,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human FEK4 cells assessed as inhibition of cell proliferation after 3 days by MTS assay,Confirmatory,,
6993,1119097,1,1,,123097261,31703,Active,,,0.25,IC50,Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase,Confirmatory,,
6994,1119244,1,1,,123097261,31703,Active,,,0.11,IC50,Antiproliferative activity against human THP1 cells after 72 hrs by XTT assay,Confirmatory,,
6995,1119246,1,1,,123097261,31703,Active,,,0.7,IC50,Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay,Confirmatory,,
6996,1119247,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for HEK293 cells to IC50 for human THP1 cells",Other,,
6997,1119925,1,1,,123097261,31703,Active,,,8.14,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,,
6998,1119926,1,1,,123097261,31703,Active,,,0.97,IC50,Antiproliferative activity against human SK-N-SH cells after 48 hrs by MTT assay,Confirmatory,,
6999,1119927,1,1,,123097261,31703,Active,,,15.07,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,,
7000,1119928,1,1,,123097261,31703,Active,,,14.84,IC50,Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,,
7001,1121293,1,1,,123097261,31703,Active,,,,,Induction of senescence in human SW116 cells assessed as increase in p16 expression at 4 uM after 24 hrs by Western blot analysis,Other,,
7002,1121294,1,1,,123097261,31703,Active,,,,,Induction of senescence in human HCT116 cells assessed as increase in p16 expression at 4 uM after 24 hrs by Western blot analysis,Other,,
7003,1121295,1,1,,123097261,31703,Active,,,,,Induction of senescence in human SW116 cells assessed as increase in p21 expression at 4 uM after 24 hrs by Western blot analysis,Other,,
7004,1121296,1,1,,123097261,31703,Active,,,,,Induction of senescence in human HCT116 cells assessed as increase in p21 expression at 4 uM after 24 hrs by Western blot analysis,Other,,
7005,1121297,1,1,,123097261,31703,Active,,,,,Induction of senescence in human MCF7 cells assessed as decrease in SKP2 expression at 4 uM after 24 hrs by Western blot analysis,Other,,
7006,1121298,1,1,,123097261,31703,Active,,,,,Induction of senescence in human MCF7 cells assessed as increase in p16 expression at 4 uM after 24 hrs by by Western blot analysis,Other,,
7007,1121299,1,1,,123097261,31703,Active,,,,,Induction of senescence in human MCF7 cells assessed as increase in p21 expression at 4 uM after 24 hrs by by Western blot analysis,Other,,
7008,1121300,1,1,,123097261,31703,Active,,,,,Induction of senescence in human MCF7 cells assessed as increase in p53 expression at 4 uM after 24 hrs by by Western blot analysis,Other,,
7009,1121301,1,1,,123097261,31703,Inactive,,,,,Induction of senescence in human MDA-MB-231 cells expressing mutant p53 at 4 uM after 24 hrs by Western blot analysis,Other,,
7010,1121302,1,1,,123097261,31703,Active,,,,,Induction of senescence in human MCF7 cells expressing wild type p53 at 4 uM after 24 hrs by Western blot analysis,Other,,
7011,1121304,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs using propidium iodide staining by FACS analysis (Rvb = 19%),Other,,
7012,1121305,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs using propidium iodide staining by FACS analysis (Rvb = 11%),Other,,
7013,1121306,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 4 uM after 24 hrs using propidium iodide staining by FACS analysis (Rvb = 70%),Other,,
7014,1121307,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MCF7 cells to IC50 for human MCF10A cells",Other,,
7015,1121308,1,1,,123097261,31703,Active,,,31.0,IC50,Cytotoxicity against human MCF10A cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7016,1121309,1,2,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7017,1121310,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7018,1121311,1,1,,123097261,31703,Active,,,0.73,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7019,1121312,1,1,,123097261,31703,Active,,,0.16,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7020,1121313,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,,
7021,1121325,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human MRC5 cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7022,1121326,1,1,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human HT-29 cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7023,1121327,1,1,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human K562 cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7024,1121328,1,1,,123097261,31703,Active,,,1.17,IC50,Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7025,1121329,1,1,,123097261,31703,Unspecified,,,95.61,IC50,Cytotoxicity against human PC3 cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7026,1121330,1,1,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay,Confirmatory,,
7027,1121331,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,,
7028,1121443,1,1,,123097261,31703,Active,,,10.55,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,,
7029,1121444,1,1,,123097261,31703,Active,,,10.88,IC50,Cytotoxicity against human SK-N-SH cells after 24 hrs by MTT assay,Confirmatory,,
7030,1121445,1,1,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,,
7031,1121446,1,1,,123097261,31703,Active,,,0.95,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,,
7032,1121447,1,1,,123097261,31703,Active,,,1.12,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,,
7033,1122128,1,1,,123097261,31703,Unspecified,,,,,Induction of DNA damage in human A549 cells assessed as inhibition of EGFP translation at 50 uM after 1 hr by fluorescence assay,Other,,
7034,1123500,1,1,,123097261,31703,Unspecified,,,,,Toxicity in Salmonella typhimurium TA98 assessed as growth inhibition after 1 hr,Other,370390.0,
7035,1123501,1,1,,123097261,31703,Unspecified,,,,,Toxicity in Salmonella typhimurium TA100 assessed as growth inhibition after 1 hr,Other,370390.0,
7036,1123502,1,1,,123097261,31703,Unspecified,,,,,Toxicity in Salmonella typhimurium TA1537 assessed as growth inhibition after 1 hr,Other,370390.0,
7037,1123503,1,1,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA98 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
7038,1123504,1,1,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA100 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
7039,1123505,1,1,,123097261,31703,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA1537 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
7040,1123693,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1.56 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,423181.0,
7041,1123694,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,423181.0,
7042,1123695,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.39 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,423181.0,
7043,1123696,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.2 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,423181.0,
7044,1123701,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 16 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control",Other,423181.0,
7045,1123702,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 8 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control",Other,423181.0,
7046,1123703,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 4 mg/kg, ip administered as single dose for every 4 days up to 13 days relative to control",Other,423181.0,
7047,1123704,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip administered as single dose on day 5, 9 and 13 relative to control",Other,423181.0,
7048,1123710,1,1,,123097261,31703,Unspecified,,,,,Cardiotoxicity in rat assessed as minimum cumulative drug dose causing electrocardiographic changes,Other,423181.0,
7049,1123712,1,1,,123097261,31703,Unspecified,,,,,Genotoxicity in Salmonella typhimurium 8907 assessed as number of revertants by Ames test in presence of S9 fraction,Other,423181.0,
7050,1123720,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature,Other,423181.0,
7051,1123721,1,1,,123097261,31703,Active,,,1.5,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,423181.0,
7052,1123722,1,1,,123097261,31703,Active,,,0.7,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,423181.0,
7053,1123727,1,1,,123097261,31703,Active,,,1.5,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,423182.0,
7054,1123728,1,1,,123097261,31703,Active,,,0.58,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,423182.0,
7055,1123755,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as optimal dose,Other,423191.0,
7056,1123757,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as average survival time at 4.4 mg/kg, ip relative to untreated control",Other,423191.0,
7057,1123761,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in mouse allografted with mouse P388 cells at 4.4 mg/kg, ip",Other,423191.0,
7058,1123764,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 4.4 mg/kg, ip relative to untreated control",Other,423191.0,
7059,1123765,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 6.6 mg/kg, ip relative to untreated control",Other,423191.0,
7060,1123766,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as average survival time at 10 mg/kg, ip relative to untreated control",Other,423191.0,
7061,1124695,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 16 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
7062,1124696,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 8 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
7063,1124697,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
7064,1124698,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 2 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
7065,1124699,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 1 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
7066,1124708,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 16 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
7067,1124709,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 8 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
7068,1124710,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
7069,1124711,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 2 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
7070,1124712,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 1 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
7071,1124716,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in CDF1 mouse allografted with mouse B16 cells at 1 to 16 mg/kg, ip on day 5",Other,571021.0,
7072,1124721,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as survival at 1 to 16 mg/kg, ip on days 5, 9 and 13",Other,571021.0,
7073,1124873,1,1,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human HL60 cells,Confirmatory,24631190.0,
7074,1124874,1,1,,123097261,31703,Active,,,1.8,IC50,Antiproliferative activity against human HL60/Vinc cells,Confirmatory,24631190.0,
7075,1124875,1,1,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human LoVo cells,Confirmatory,24631190.0,
7076,1124876,1,1,,123097261,31703,Active,,,6.5,IC50,Antiproliferative activity against human LoVo/DX cells,Confirmatory,24631190.0,
7077,1124877,1,1,,123097261,31703,Active,,,0.5,IC50,Antiproliferative activity mouse BALB/3T3 cells,Confirmatory,24631190.0,
7078,1124880,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60 cells",Other,24631190.0,
7079,1124881,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60/Vinc cells",Other,24631190.0,
7080,1124882,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/Vinc cells to IC50 for human HL60 cells",Other,24631190.0,
7081,1124883,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,24631190.0,
7082,1124884,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/DX cells",Other,24631190.0,
7083,1124885,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,24631190.0,
7084,1125525,1,1,,123097261,31703,Active,,,0.55,GI50,Growth inhibition of human SGC7901 cells by sulforhodamine B assay,Confirmatory,24650643.0,
7085,1125526,1,1,,123097261,31703,Active,,,0.15,GI50,Growth inhibition of human HCT116 cells by sulforhodamine B assay,Confirmatory,24650643.0,
7086,1125527,1,1,,123097261,31703,Active,,,0.33,GI50,Growth inhibition of human HLF cells by sulforhodamine B assay,Confirmatory,24650643.0,
7087,1125528,1,1,,123097261,31703,Active,,,0.18,GI50,Growth inhibition of human 16HBE cells by sulforhodamine B assay,Confirmatory,24650643.0,
7088,1125564,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24650715.0,
7089,1125565,1,2,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24650715.0,
7090,1126611,1,1,,123097261,31703,Active,,,13.6,IC50,Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Confirmatory,24681979.0,
7091,1126612,1,1,,123097261,31703,Active,,,16.0,IC50,Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Confirmatory,24681979.0,
7092,1126613,1,1,,123097261,31703,Active,,,15.4,IC50,Cytotoxicity against human HT1080 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Confirmatory,24681979.0,
7093,1126614,1,1,,123097261,31703,Active,,,16.9,IC50,Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Confirmatory,24681979.0,
7094,1126799,1,1,,123097261,31703,Active,,,0.077,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24684844.0,
7095,1126801,1,1,,123097261,31703,Unspecified,,,68.434,IC50,Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay,Confirmatory,24684844.0,
7096,1126802,1,1,,123097261,31703,Unspecified,,,,,"Resistant factor, ratio of IC50 for human MCF7/ADR cells to IC50 for human MCF7 cells",Other,24684844.0,
7097,1126826,1,1,,123097261,31703,Active,,,0.55,GI50,Antiproliferative activity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24686011.0,
7098,1126827,1,1,,123097261,31703,Active,,,0.15,GI50,Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24686011.0,
7099,1126828,1,1,,123097261,31703,Active,,,0.33,GI50,Antiproliferative activity against human HLF assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24686011.0,
7100,1126852,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 10 uM after 48 hrs by SRB assay relative to control,Other,24686014.0,
7101,1126853,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 25 uM after 48 hrs by SRB assay relative to control,Other,24686014.0,
7102,1126854,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 50 uM after 48 hrs by SRB assay relative to control,Other,24686014.0,
7103,1126855,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as surviving fraction at 100 uM after 48 hrs by SRB assay relative to control,Other,24686014.0,
7104,1126856,1,1,,123097261,31703,Active,,,6.1,IC50,Cytotoxicity against human MCF7 cells assessed as surviving fraction after 48 hrs by SRB assay,Confirmatory,24686014.0,
7105,1127345,1,1,,123097261,31703,Active,,,0.46,IC50,In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay,Confirmatory,24742385.0,
7106,1127346,1,1,,123097261,31703,Active,,,0.51,IC50,In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay,Confirmatory,24742385.0,
7107,1127347,1,1,,123097261,31703,Active,,,0.91,IC50,In vitro cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay,Confirmatory,24742385.0,
7108,1127348,1,1,,123097261,31703,Active,,,1.07,IC50,In vitro cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay,Confirmatory,24742385.0,
7109,1127349,1,1,,123097261,31703,Unspecified,,,200.0,IC50,In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay,Confirmatory,24742385.0,
7110,1127675,1,1,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,23932070.0,
7111,1127800,1,1,,123097261,31703,Active,,,0.5782,IC50,Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay,Confirmatory,24211639.0,
7112,1127801,1,1,,123097261,31703,Active,,,0.0202,IC50,Antiproliferative against human HepG2 cells assessed as cell viability after 96 hrs by MTT assay,Confirmatory,24211639.0,
7113,1130426,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of ED50 for inhibition of DNA synthesis in mouse L1210 cells to ED50 for inhibition of RNA synthesis in mouse L1210 cells,Other,490536.0,
7114,1130427,1,1,,123097261,31703,Active,,,1.5,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,490536.0,
7115,1130428,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature,Other,490536.0,
7116,1130429,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 0.78 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,490536.0,
7117,1130430,1,1,,123097261,31703,Active,,,0.58,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,490536.0,
7118,1130441,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 8 mg/kg, ip administered as qd on day 5, 9, 13",Other,490536.0,
7119,1130449,1,1,,123097261,31703,Unspecified,,,,,Cardiotoxicity in rat assessed as minimum cumulative cardiotoxic dose by Zbinden test,Other,490536.0,
7120,1130455,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, po qd administered from day 1 to day 9 relative to control",Other,490537.0,
7121,1130458,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1 mg/kg, po q4d administered on days 5, 9 and 13 relative to control",Other,490537.0,
7122,1130461,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to DNA (unknown origin) assessed as DNA interaction by measuring change in melting temperature,Other,490537.0,
7123,1130462,1,1,,123097261,31703,Active,,,2.0,ED50,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation,Confirmatory,490537.0,
7124,1130463,1,1,,123097261,31703,Active,,,0.7,ED50,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation,Confirmatory,490537.0,
7125,1130590,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose,Other,490545.0,
7126,1130591,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase of median life span at 5 mg/kg, ip on day 1, 5 and 9 measured up to 60 days relative to control",Other,490545.0,
7127,1130606,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase of median life span at 0.8 mg/kg, ip on day 1 to 9 measured up to 80 days relative to control",Other,490545.0,
7128,1130627,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as once each 4 days for 3 total injection,Other,490545.0,
7129,1130628,1,1,,123097261,31703,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose,Other,490545.0,
7130,1130629,1,1,,123097261,31703,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as once each 4 days for 3 total injection,Other,490545.0,
7131,1130630,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose,Other,490545.0,
7132,1130631,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as once each 4 days for 3 total injection,Other,490545.0,
7133,1130632,1,1,,123097261,31703,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose",Other,490545.0,
7134,1130633,1,1,,123097261,31703,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as once each 4 days for 3 total injection",Other,490545.0,
7135,1132426,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA by spectral analysis,Other,628003.0,
7136,1132427,1,1,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]thymidine addition measured after 1 hr by scintillation counting,Other,628003.0,
7137,1132428,1,1,,123097261,31703,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]uridine addition measured after 1 hr by scintillation counting,Other,628003.0,
7138,1132429,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1.56 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
7139,1132430,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
7140,1132431,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.39 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
7141,1132432,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.20 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
7142,1132443,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 16 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
7143,1132444,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 8 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
7144,1132445,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 4 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
7145,1132446,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
7146,1132447,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
7147,1138595,1,1,,123097261,31703,Active,,,2.0,IC50,Antiinvasive activity against mouse 26-L5 cells after 6 to 8 hrs by matrigel assay,Confirmatory,24592993.0,
7148,1140147,1,1,,123097261,31703,Active,,,0.08,IC50,Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay,Confirmatory,24717154.0,
7149,1140148,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay,Confirmatory,24717154.0,
7150,1140149,1,1,,123097261,31703,Active,,,1.87,IC50,Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay,Confirmatory,24717154.0,
7151,1140150,1,1,,123097261,31703,Active,,,0.98,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay,Confirmatory,24717154.0,
7152,1140151,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay,Confirmatory,24717154.0,
7153,1141937,1,1,,123097261,31703,Active,,,,,Induction of necrosis in human HL60 cells assessed as decrease in total LDH at 1 uM after 48 hrs,Other,24767849.0,
7154,1141938,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human HL60 cells assessed as LDH release at 1 uM after 48 hrs,Other,24767849.0,
7155,1142453,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24780595.0,
7156,1142454,1,2,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24780595.0,
7157,1142455,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24780595.0,
7158,1142456,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24780595.0,
7159,1142459,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 1 uM after 12 hrs by fluorescence assay (Rvb = 1055.6 +/- 108.2 FU/min),Other,24780595.0,
7160,1142460,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 2 uM after 12 hrs by fluorescence assay (Rvb = 1055.6 +/- 108.2 FU/min),Other,24780595.0,
7161,1142463,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 1 uM after 24 hrs by fluorescence assay (Rvb = 2115.3 +/- 83.2 FU/min),Other,24780595.0,
7162,1142464,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein measured per mg of protein at 2 uM after 24 hrs by fluorescence assay (Rvb = 2115.3 +/- 83.2 FU/min),Other,24780595.0,
7163,1142467,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 1 uM after 36 hrs by fluorescence assay (Rvb = 2192.3 +/- 115.9 FU/min),Other,24780595.0,
7164,1142468,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 2 uM after 36 hrs by fluorescence assay (Rvb = 2192.3 +/- 115.9 FU/min),Other,24780595.0,
7165,1142471,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 1 uM after 48 hrs by fluorescence assay (Rvb = 2642.4 +/- 37.5 FU/min),Other,24780595.0,
7166,1142472,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human PC3 cells assessed as activation of caspase-3 using AFC conjugated Ac-DEVD as substrate measured per mg of protein at 2 uM after 48 hrs by fluorescence assay (Rvb = 2642.4 +/- 37.5 FU/min),Other,24780595.0,
7167,1142513,1,1,,123097261,31703,Active,,,0.07,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
7168,1142514,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
7169,1142515,1,1,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human H460 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
7170,1142756,1,1,,123097261,31703,Active,,,0.17800000000000002,GI50,Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay,Confirmatory,24792464.0,
7171,1142865,1,1,,123097261,31703,Active,,,8.4,IC50,Cytotoxicity against human A549 cells,Confirmatory,24793880.0,
7172,1142866,1,2,,123097261,31703,Active,,,6.7,IC50,Cytotoxicity against human DU145 cells,Confirmatory,24793880.0,
7173,1142867,1,1,,123097261,31703,Active,,,10.89,IC50,Cytotoxicity against human HeLa cells,Confirmatory,24793880.0,
7174,1142868,1,1,,123097261,31703,Active,,,8.62,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,24793880.0,
7175,1143516,3,1,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
7176,1143517,3,1,,123097261,31703,Active,,,0.79,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
7177,1143518,3,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
7178,1143519,3,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
7179,1143520,3,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 4 days by GFP detection method,Confirmatory,24836071.0,
7180,1143705,1,1,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay,Confirmatory,24852278.0,
7181,1143706,1,1,,123097261,31703,Active,,,0.64,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,24852278.0,
7182,1143707,1,1,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human A549 cells after 96 hrs by MTT assay,Confirmatory,24852278.0,
7183,1143708,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human PC3 cells after 96 hrs by MTT assay,Confirmatory,24852278.0,
7184,1143709,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay,Other,24852278.0,
7185,1145422,1,1,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 1 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7186,1145423,1,1,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7187,1145424,1,1,,123097261,31703,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7188,1145425,1,1,,123097261,31703,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 1 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7189,1145426,1,1,,123097261,31703,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7190,1145427,1,1,,123097261,31703,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
7191,1145428,1,1,,123097261,31703,Unspecified,,,,,Cellular uptake in mouse L1210 cells assessed per 10'6 cells at 3 uM up to 120 mins,Other,1271407.0,
7192,1145429,1,1,,123097261,31703,Unspecified,,,,,Ratio of inhibition of [3H]-thymidine incorporation into DNA in mouse L1210 cells to cellular uptake in mouse L1210 cells,Other,1271407.0,
7193,1145430,1,1,,123097261,31703,Unspecified,,,,,Ratio of inhibition of [14C]-uridine incorporation into RNA in mouse L1210 cells to cellular uptake in mouse L1210 cells,Other,1271407.0,
7194,1145733,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as increase in melting temperature at 2.1 x 10'-5 M by UV spectrophotometric analysis,Other,176359.0,
7195,1145737,1,1,,123097261,31703,Active,,,0.8,ED50,Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis,Confirmatory,176359.0,
7196,1145738,1,1,,123097261,31703,Active,,,0.9,ED50,Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis,Confirmatory,176359.0,
7197,1145741,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as change in survival time at 4 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7198,1145742,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7199,1145743,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7200,1145744,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.5 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7201,1145745,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.25 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7202,1145746,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.12 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7203,1145747,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.06 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
7204,1145755,1,1,,123097261,31703,Unspecified,,,,,"Acute toxicity in mouse allografted with mouse P388 cells assessed as survival less than 5 days at 0.06 to 4 mg/kg, ip qd",Other,176359.0,
7205,1145758,1,2,,123097261,31703,Active,,,,,Binding affinity to calf thymus DNA assessed as bathochromatic shift at 1:1 to 16:1 compound to DNA ratio by UV-visible spectra analysis,Other,176359.0,
7206,1145759,1,1,,123097261,31703,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,176359.0,
7207,1145760,1,2,,123097261,31703,Active,,,,,Binding affinity to calf thymus DNA assessed as decrease in absorptivity of visible maxima of compound at 1:1 to 16:1 compound to DNA ratio by UV-visible spectra analysis,Other,176359.0,
7208,1149809,1,1,,123097261,31703,Active,,,1.5,ED50,Inhibition of DNA synthesis in mouse L1210 cells after 3 hrs by [3H]thymidine incorporation assay,Confirmatory,915894.0,
7209,1149810,1,1,,123097261,31703,Active,,,0.67,ED50,Inhibition of RNA synthesis in mouse L1210 cells after 3 hrs by [3H]uridine incorporation assay,Confirmatory,915894.0,
7210,1149811,1,1,,123097261,31703,Active,,,0.032,IC50,Cytotoxicity against mouse L1210 cells,Confirmatory,915894.0,
7211,1149812,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in mouse assessed as optimum dose administered qd from day 1 to 9,Other,915894.0,
7212,1149813,1,1,,123097261,31703,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in mouse assessed as tumor growth inhibition at optimum dose administered qd from day 1 to 9 relative to control,Other,915894.0,
7213,1149814,1,2,,123097261,31703,Unspecified,,,,,Binding affinity to calf thymus helical DNA assessed as change in melting temperature by titrimetric analysis,Other,915894.0,
7214,1151351,1,1,,123097261,31703,Active,,,0.13,IC50,Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay,Confirmatory,24824796.0,
7215,1153508,1,1,,123097261,31703,Active,,,1.63,GI50,Antiproliferative activity against human ACHN cells by SRB method,Confirmatory,24835787.0,
7216,1153509,1,1,,123097261,31703,Active,,,1.66,GI50,Antiproliferative activity against human NCI-H23 cells by SRB method,Confirmatory,24835787.0,
7217,1153510,1,1,,123097261,31703,Active,,,1.79,GI50,Antiproliferative activity against human MDA-MB-231 cells by SRB method,Confirmatory,24835787.0,
7218,1153511,1,1,,123097261,31703,Active,,,1.34,GI50,Antiproliferative activity against human HCT15 cells by SRB method,Confirmatory,24835787.0,
7219,1153512,1,1,,123097261,31703,Active,,,1.0,GI50,Antiproliferative activity against human NUGC3 cells by SRB method,Confirmatory,24835787.0,
7220,1153513,1,1,,123097261,31703,Active,,,1.65,GI50,Antiproliferative activity against human PC3 cells by SRB method,Confirmatory,24835787.0,
7221,1153816,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MIAPaCa2 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7222,1153817,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human PLC/PRF/5 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7223,1153818,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SKOV3 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7224,1153819,1,2,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DU145 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7225,1153820,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A172 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7226,1153821,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7227,1153822,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7228,1153823,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human DLD1 cells at 10 uM after 48 hrs by SRB assay,Other,24844196.0,
7229,1153851,1,1,,123097261,31703,Active,,,0.912,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,24844756.0,
7230,1154182,1,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24858544.0,
7231,1154191,1,1,,123097261,31703,Active,,,11.3,IC50,Cytotoxicity against human LoVo/DX cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24858544.0,
7232,1154193,1,1,,123097261,31703,Unspecified,,,,,Resistance ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells,Other,24858544.0,
7233,1155285,1,1,,123097261,31703,Active,,,0.93,IC50,Cytotoxicity against human MCF10A cells after 2 days,Confirmatory,24904965.0,
7234,1155286,1,1,,123097261,31703,Active,,,0.84,IC50,Cytotoxicity against human T47D cells after 2 days,Confirmatory,24904965.0,
7235,1155287,1,2,,123097261,31703,Active,,,4.88,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,24904965.0,
7236,1155288,1,1,,123097261,31703,Active,,,3.76,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,24904965.0,
7237,1155389,1,1,,123097261,31703,Active,,,6.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
7238,1155393,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
7239,1155724,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 0.01 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7240,1155725,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 0.02 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7241,1155726,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 0.05 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7242,1155727,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 0.14 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7243,1155728,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 0.41 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7244,1155729,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 1.23 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7245,1155730,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 3.7 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7246,1155731,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 11.11 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7247,1155732,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 33.33 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7248,1155733,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human A375 cells at 100 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7249,1155734,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 0.01 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7250,1155735,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 0.02 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7251,1155736,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 0.05 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7252,1155737,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 0.14 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7253,1155738,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 0.41 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7254,1155739,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 1.23 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7255,1155740,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 3.7 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7256,1155741,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 11.11 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7257,1155742,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 33.33 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7258,1155743,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human Hep3B cells at 100 ug/ml for 24 hrs by MTT assay,Other,24929289.0,
7259,1155744,1,1,,123097261,31703,Active,,,13.25,IC50,Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay,Confirmatory,24929289.0,
7260,1155745,1,1,,123097261,31703,Active,,,6.35,IC50,Antiproliferative activity against human A375 cells for 24 hrs by MTT assay,Confirmatory,24929289.0,
7261,1156029,1,1,,123097261,31703,Active,,,1.36,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
7262,1156030,1,1,,123097261,31703,Active,,,1.8,IC50,Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
7263,1156031,1,1,,123097261,31703,Active,,,1.5,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
7264,1156430,1,1,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,24946216.0,
7265,1156516,1,1,,123097261,31703,Active,,,0.39,IC50,Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7266,1156517,1,1,,123097261,31703,Active,,,10.9,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7267,1156518,1,1,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7268,1156519,1,1,,123097261,31703,Active,,,1.99,IC50,Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7269,1156520,1,1,,123097261,31703,Active,,,1.69,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7270,1156521,1,1,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7271,1156522,1,1,,123097261,31703,Active,,,1.76,IC50,Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
7272,1156799,1,1,,123097261,31703,Active,,,12.5,IC50,Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24974349.0,
7273,1156973,1,1,,123097261,31703,Active,,,0.455,IC50,Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test,Confirmatory,24996140.0,
7274,1156975,1,1,,123097261,31703,Active,,,0.0051,IC50,Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by formazan dye-based EZ4U test,Confirmatory,24996140.0,
7275,1157288,1,1,,123097261,31703,Inactive,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay,Other,24749951.0,
7276,1157289,1,1,,123097261,31703,Inactive,,,,,Cytotoxicity against human MG63 cells assessed as growth inhibition by MTT assay,Other,24749951.0,
7277,1157878,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells,Other,24828374.0,
7278,1157879,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,24828374.0,
7279,1157888,1,1,,123097261,31703,Unspecified,,,100.0,IC50,Inhibition of sortase A (unknown origin),Confirmatory,24828374.0,
7280,1158017,1,1,,123097261,31703,Active,,,3.24,IC50,Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay,Confirmatory,24856067.0,
7281,1158142,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 10 uM after 48 hrs by MTT assay,Other,24878360.0,
7282,1158143,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 25 uM after 48 hrs by MTT assay,Other,24878360.0,
7283,1158144,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay,Other,24878360.0,
7284,1158145,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 100 uM after 48 hrs by MTT assay,Other,24878360.0,
7285,1158146,1,1,,123097261,31703,Active,,,8.02,IC50,Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay,Confirmatory,24878360.0,
7286,1158369,2,2,,123097261,31703,Inconclusive,2811086.0,1956.0,,IC50,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Confirmatory,24890652.0,
7287,1158370,1,3,,123097261,31703,Inconclusive,9087218.0,3791.0,,IC50,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,Confirmatory,24890652.0,
7288,1158371,2,2,,123097261,31703,Inconclusive,129890.0,5159.0,,IC50,Inhibition of PDGFRbeta in human SH-SY5Y cells by phosphotyrosine ELISA assay,Confirmatory,24890652.0,
7289,1158372,1,1,,123097261,31703,Active,,,0.00135,IC50,Cytotoxicity against human A431 cells by SRB assay,Confirmatory,24890652.0,
7290,1158373,1,1,,123097261,31703,Active,,,4e-05,IC50,Antiangiogenic activity in fertile leghorn chicken egg Chorioallantoic membrane assessed as inhibition of human VEGF-165/bFGF-induced angiogenesis after 48 hrs by CAM assay,Confirmatory,24890652.0,
7291,1159125,1,1,,123097261,31703,Active,,,0.33,IC50,Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7292,1159126,1,1,,123097261,31703,Active,,,0.31,IC50,Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7293,1159127,1,1,,123097261,31703,Active,,,0.35,IC50,Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7294,1159128,1,1,,123097261,31703,Active,,,0.33,IC50,Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7295,1159129,1,1,,123097261,31703,Active,,,0.35,IC50,Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7296,1159130,1,1,,123097261,31703,Active,,,0.34,IC50,Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay,Confirmatory,24941130.0,
7297,1159143,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7298,1159144,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HT-29 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7299,1159145,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human Caco2 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7300,1159146,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human Saos2 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7301,1159147,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human MCF7 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7302,1159148,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HeLa cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7303,1159149,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human HL60 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7304,1159150,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human HT-29 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7305,1159151,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human Caco2 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7306,1159152,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human Saos2 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7307,1159153,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human MCF7 cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7308,1159154,1,1,,123097261,31703,Unspecified,,,,,Induction of necrosis in human HeLa cells at 0.5 uM after 48 hrs by Hoechst 33258/propidium iodide staining based phase contrast microscopic analysis,Other,24941130.0,
7309,1159510,3,1,,124886893,31703,Active,,,0.0118,Potency,Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),Confirmatory,,
7310,1159511,3,1,,124886893,31703,Active,,,0.059000000000000004,Potency,Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,Confirmatory,,
7311,1159512,3,1,,124886893,31703,Active,,,0.0074,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),Confirmatory,,
7312,1159513,3,1,,124886893,31703,Active,,,0.1865,Potency,Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),Confirmatory,,
7313,1159530,2,1,,124886893,31703,Active,,,16.6261,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),Confirmatory,,
7314,1159607,2,1,,312309807,31703,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
7315,1159620,1,1,,123097261,31703,Active,,,,,Summary of drug indications.,Other,,
7316,1161633,1,1,,123097261,31703,Active,,,0.33,IC50,Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7317,1161634,1,1,,123097261,31703,Active,,,2.04,IC50,Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7318,1161635,1,1,,123097261,31703,Active,,,1.07,IC50,Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7319,1161636,1,1,,123097261,31703,Active,,,0.42,IC50,Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7320,1161637,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7321,1161638,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7322,1161639,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human Bel7404 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7323,1161640,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human A549 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7324,1161641,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human BGC832 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7325,1161642,1,1,,123097261,31703,Inconclusive,,,,IC50,Antitumor activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay,Confirmatory,25160837.0,
7326,1161682,1,1,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay,Confirmatory,25163667.0,
7327,1161683,1,1,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human HuH7 cells after 48 hrs by WST8 assay,Confirmatory,25163667.0,
7328,1161684,1,1,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay,Confirmatory,25163667.0,
7329,1161685,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against HUVEC cells after 48 hrs by WST8 assay,Confirmatory,25163667.0,
7330,1161690,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human HeLa cells assessed as DNA fragmentation at 0.2 uM after 48 hrs by TUNEL assay,Other,25163667.0,
7331,1162084,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,25172418.0,
7332,1162085,1,2,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,25172418.0,
7333,1162086,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,25172418.0,
7334,1162087,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,25172418.0,
7335,1162088,1,1,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,25172420.0,
7336,1162089,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,25172420.0,
7337,1162090,1,1,,123097261,31703,Active,,,1.05,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,25172420.0,
7338,1162091,1,1,,123097261,31703,Active,,,1.21,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,25172420.0,
7339,1162626,1,1,,123097261,31703,Active,,,,,Induction apoptosis in PMA-stimulated human MDA-MB-231 cells assessed as mitochondrial disruption at 10 uM after 48 hrs by JC1 staining based fluorescence assay,Other,25190466.0,
7340,1163803,1,2,,123097261,31703,Active,,,0.17,IC50,Growth inhibition of human SW620 cells after 72 hrs by SRB assay,Confirmatory,25215856.0,
7341,1163804,1,1,,123097261,31703,Active,,,28.2,IC50,Growth inhibition of human SW620/AD300 cells after 72 hrs by SRB assay,Confirmatory,25215856.0,
7342,1163805,1,1,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human SW620/AD300 cells to IC50 for human SW620 cells,Other,25215856.0,
7343,1165224,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,25241926.0,
7344,1165225,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,25241926.0,
7345,1165226,1,2,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,25241926.0,
7346,1165227,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,25241926.0,
7347,1165382,1,1,,123097261,31703,Active,,,0.37,IC50,Antiproliferative activity against mouse L1210/0 cells after 48 hrs by MTT assay,Confirmatory,25244612.0,
7348,1165383,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human Molt4/C8 cells after 72 hrs by MTT assay,Confirmatory,25244612.0,
7349,1165384,1,1,,123097261,31703,Active,,,0.8,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,25244612.0,
7350,1165385,1,1,,123097261,31703,Active,,,7.0,IC50,Antiproliferative activity against human K562/4 cells after 72 hrs by MTT assay,Confirmatory,25244612.0,
7351,1165386,1,1,,123097261,31703,Active,,,1.4,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,25244612.0,
7352,1165387,1,1,,123097261,31703,Active,,,4.4,IC50,Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay,Confirmatory,25244612.0,
7353,1165388,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human K562/4 cells to IC50 for human K562 cells",Other,25244612.0,
7354,1165389,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for p53-deficient human HCT116 cells cells to IC50 for human HCT116 cells",Other,25244612.0,
7355,1165404,1,1,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span measured as survival time at 8 mg/kg, ip for 5 days starting one day post inoculation relative to control",Other,25244612.0,
7356,1165405,1,1,,123097261,31703,Unspecified,,,,,Toxicity in mouse P388 cells allografted mouse asessed as increase in life span measured as survival time compound dosed ip as single dose,Other,25244612.0,
7357,1165420,1,1,,123097261,31703,Active,,,0.912,IC50,Cytotoxic activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,25245672.0,
7358,1165756,1,1,,123097261,31703,Active,,,0.34,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,25247771.0,
7359,1165757,1,1,,123097261,31703,Active,,,0.84,IC50,Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay,Confirmatory,25247771.0,
7360,1165758,1,1,,123097261,31703,Active,,,1.47,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,25247771.0,
7361,1165760,1,1,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human HL60 cells after 72 hrs MTT assay,Confirmatory,25247772.0,
7362,1165761,1,1,,123097261,31703,Active,,,0.22,IC50,Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay,Confirmatory,25247772.0,
7363,1165762,1,1,,123097261,31703,Active,,,0.16,IC50,Antiproliferative activity against human SF763 cells after 72 hrs MTT assay,Confirmatory,25247772.0,
7364,1165763,1,1,,123097261,31703,Active,,,0.21,IC50,Antiproliferative activity against human HeLa cells after 72 hrs MTT assay,Confirmatory,25247772.0,
7365,1165764,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay,Confirmatory,25247772.0,
7366,1166269,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 10 uM after 48 hrs by sulforhodamine-B assay,Other,25255434.0,
7367,1166270,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 25 uM after 48 hrs by sulforhodamine-B assay,Other,25255434.0,
7368,1166271,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 50 uM after 48 hrs by sulforhodamine-B assay,Other,25255434.0,
7369,1166272,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival at 100 uM after 48 hrs by sulforhodamine-B assay,Other,25255434.0,
7370,1166273,1,1,,123097261,31703,Active,,,0.008020000000000001,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine-B assay,Confirmatory,25255434.0,
7371,1166335,1,1,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7372,1166336,1,1,,123097261,31703,Active,,,0.92,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7373,1166337,1,1,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7374,1166338,1,1,,123097261,31703,Active,,,2.98,IC50,Cytotoxicity against human Raji cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7375,1166339,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7376,1166340,1,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7377,1166341,1,1,,123097261,31703,Active,,,0.065,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7378,1166342,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,25259516.0,
7379,1166619,1,1,,123097261,31703,Active,,,0.073,GI50,Growth inhibition of human HeLa cells after 48 hrs by SRB assay,Confirmatory,25264072.0,
7380,1166620,1,1,,123097261,31703,Active,,,0.09699999999999999,GI50,Growth inhibition of human MiaPaCa cells after 48 hrs by SRB assay,Confirmatory,25264072.0,
7381,1166621,1,1,,123097261,31703,Active,,,0.085,GI50,Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,25264072.0,
7382,1166622,1,1,,123097261,31703,Active,,,0.023,GI50,Growth inhibition of human IMR32 cells after 48 hrs by SRB assay,Confirmatory,25264072.0,
7383,1167552,1,1,,123097261,31703,Active,,,0.01,CC50,Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay,Confirmatory,25282267.0,
7384,1167555,1,1,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay,Confirmatory,25282267.0,
7385,1168280,1,1,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,25300819.0,
7386,1168281,1,1,,123097261,31703,Active,,,0.69,IC50,Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay,Confirmatory,25300819.0,
7387,1168282,1,2,,123097261,31703,Active,,,0.7,IC50,Antiproliferative activity against human HL-60 cells assessed as reduction in cell growth after 24 hrs by MTS assay,Confirmatory,25300820.0,
7388,1168283,1,1,,123097261,31703,Unspecified,,,10.0,IC50,Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 24 hrs by MTS assay,Confirmatory,25300820.0,
7389,1168284,1,1,,123097261,31703,Active,,,0.7,IC50,Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 24 hrs by MTS assay,Confirmatory,25300820.0,
7390,1168285,1,1,,123097261,31703,Active,,,0.2,IC50,Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth after 24 hrs by MTS assay,Confirmatory,25300820.0,
7391,1168288,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against mouse WEHI13 cells assessed as cell proliferation after 48 hrs by MTT assay,Confirmatory,25300820.0,
7392,1168392,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60/MDR cells assessed as viable cells at 0.02 uM after 48 hrs by WST assay,Other,25302569.0,
7393,1168393,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60/MDR cells assessed as viable cells at 0.2 uM after 48 hrs by WST assay,Other,25302569.0,
7394,1168394,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HL60/MDR cells assessed as viable cells at 0.6 uM after 48 hrs by WST assay,Other,25302569.0,
7395,1168395,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G1 phase at 0.2 uM after 48 hrs by flow cytometry (Rvb = 59.0 %),Other,25302569.0,
7396,1168396,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G2/M phase at 0.2 uM after 48 hrs by flow cytometry (Rvb = 11.3 %),Other,25302569.0,
7397,1168397,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at S phase at 0.2 uM after 48 hrs by flow cytometry (Rvb = 29.9 %),Other,25302569.0,
7398,1168398,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G1 phase at 0.02 uM after 48 hrs by flow cytometry (Rvb = 59.0 %),Other,25302569.0,
7399,1168399,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G2/M phase at 0.02 uM after 48 hrs by flow cytometry (Rvb = 11.3 %),Other,25302569.0,
7400,1168400,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human HL60/MDR cells assessed as accumulation at S phase at 0.02 uM after 48 hrs by flow cytometry (Rvb = 29.9 %),Other,25302569.0,
7401,1169302,1,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7402,1169303,1,1,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7403,1169304,1,1,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human MG63 cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7404,1169305,1,1,,123097261,31703,Active,,,0.65,IC50,Cytotoxicity against human U2OS cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7405,1169306,1,1,,123097261,31703,Active,,,0.46,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7406,1169307,1,1,,123097261,31703,Unspecified,,,1574.2,IC50,Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay,Confirmatory,25314138.0,
7407,1169462,1,1,,123097261,31703,Active,,,0.12,GI50,Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25317694.0,
7408,1169466,1,1,,123097261,31703,Active,,,13.5,GI50,Cytotoxicity against human LoVo/DX cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25317694.0,
7409,1169467,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of GI50 for human LoVo/DX cells to GI50 for human LoVo cells",Other,25317694.0,
7410,1169763,1,1,,123097261,31703,Active,,,,,Binding affinity to DNA (unknown origin) at 0.0625 to 0.5 mM by ethidium bromide dye based agarose gel electrophoresis method,Other,25333769.0,
7411,1170128,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human HL60 cells after 24 hrs by MTT assay,Confirmatory,25353976.0,
7412,1170583,1,1,,123097261,31703,Inactive,,,,,Reduction in EED protein expression in human Toledo cells at 2 to 8 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7413,1170584,1,1,,123097261,31703,Inactive,,,,,Reduction in EZH2 protein expression in human Toledo cells at 2 to 8 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7414,1170585,1,1,,123097261,31703,Inactive,,,,,Reduction in SUZ12 protein expression in human Toledo cells at 2 to 8 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7415,1170586,1,1,,123097261,31703,Inactive,,,,,Reduction in EED protein expression in human DB cells at 7.5 to 30 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7416,1170587,1,1,,123097261,31703,Inactive,,,,,Reduction in EZH2 protein expression in human DB cells at 7.5 to 30 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7417,1170588,1,1,,123097261,31703,Inactive,,,,,Reduction in SUZ12 protein expression in human DB cells at 7.5 to 30 uM after 72 hrs by Western blot analysis,Other,25369470.0,
7418,1170647,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against HUVEC,Other,25372601.0,
7419,1170648,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human K562 cells,Other,25372601.0,
7420,1170649,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,25372601.0,
7421,1170661,1,1,,123097261,31703,Active,,,2.4,IC50,Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method,Confirmatory,25375258.0,
7422,1170662,1,1,,123097261,31703,Active,,,19.6,IC50,Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method,Confirmatory,25375258.0,
7423,1170663,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HCT8 cells under normoxic condition to IC50 for human HCT8 cells under hypoxic condition",Other,25375258.0,
7424,1170664,1,1,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human PANC1 cells under normoxic condition after 24 hrs by crystal violet method,Confirmatory,25375258.0,
7425,1170665,1,1,,123097261,31703,Active,,,5.4,IC50,Cytotoxicity against human PANC1 cells under hypoxic condition after 24 hrs by crystal violet method,Confirmatory,25375258.0,
7426,1170666,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PANC1 cells under normoxic condition to IC50 for human PANC1 cells under hypoxic condition",Other,25375258.0,
7427,1171460,1,2,,123097261,31703,Unspecified,,,,,Growth inhibition of human SW620 cells at 5 uM,Other,25409491.0,
7428,1171651,1,1,,123097261,31703,Active,,,0.74,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25419616.0,
7429,1171652,1,1,,123097261,31703,Active,,,0.88,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,25419616.0,
7430,1171653,1,1,,123097261,31703,Active,,,0.87,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,25419616.0,
7431,1172986,1,1,,123097261,31703,Active,,,2.9,IC50,Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay,Confirmatory,25453798.0,
7432,1172994,1,1,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
7433,1172995,1,1,,123097261,31703,Active,,,0.39,IC50,Cytotoxicity against human ME180 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
7434,1172996,1,1,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
7435,1172997,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
7436,1172998,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
7437,1173027,1,1,,123097261,31703,Active,,,6.0,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25453802.0,
7438,1173028,1,1,,123097261,31703,Active,,,3.4,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25453802.0,
7439,1173029,1,1,,123097261,31703,Active,,,2.0,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,25453802.0,
7440,1173030,1,1,,123097261,31703,Active,,,3.5,IC50,Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay,Confirmatory,25453802.0,
7441,1174119,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MRC5 cells at 50 ug/ml by MTT assay,Other,25462220.0,
7442,1174229,1,1,,123097261,31703,Active,,,2.12,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
7443,1174230,1,2,,123097261,31703,Active,,,4.06,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
7444,1174231,1,1,,123097261,31703,Active,,,3.82,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
7445,1174232,1,1,,123097261,31703,Active,,,0.9,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
7446,1174233,1,1,,123097261,31703,Active,,,2.78,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
7447,1174243,1,1,,123097261,31703,Active,,,0.073,GI50,Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay,Confirmatory,25462234.0,
7448,1174244,1,1,,123097261,31703,Active,,,0.09699999999999999,GI50,Antiproliferative activity against human MiaPaCa cells assessed as reduction in net protein increase after 48 hrs by SRB assay,Confirmatory,25462234.0,
7449,1174245,1,1,,123097261,31703,Active,,,0.085,GI50,Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay,Confirmatory,25462234.0,
7450,1174246,1,1,,123097261,31703,Active,,,0.023,GI50,Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay,Confirmatory,25462234.0,
7451,1174572,1,1,,123097261,31703,Active,,,0.36,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
7452,1174573,1,1,,123097261,31703,Active,,,0.45,IC50,Anticancer activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
7453,1174574,1,1,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
7454,1174575,1,1,,123097261,31703,Unspecified,,,52.5,IC50,Anticancer activity against human MCF7/ADR cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
7455,1174576,1,1,,123097261,31703,Unspecified,,,67.6,IC50,Anticancer activity against human K562/ADR cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
7456,1174639,1,1,,123097261,31703,Active,,,3.45,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay,Confirmatory,25462265.0,
7457,1174640,1,1,,123097261,31703,Active,,,7.7,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay,Confirmatory,25462265.0,
7458,1174641,1,1,,123097261,31703,Active,,,1.17,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay,Confirmatory,25462265.0,
7459,1174727,1,1,,123097261,31703,Inactive,,,,,Induction of necrosis in intact human HL60 cells assessed as cytosolic LDH release at 1 uM,Other,25462273.0,
7460,1174729,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as dead cells level at 100 nM annexin V-PE and 7-AAD staining based by flow cytometry (Rvb = 0.4%),Other,25462273.0,
7461,1174733,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as late apoptosis cells level at 100 nM annexin V-PE and 7-AAD staining based by flow cytometry (Rvb = 0.4%),Other,25462273.0,
7462,1174737,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as intact cells level at 100 nM annexin V-PE and 7-AAD staining based by flow cytometry (Rvb = 80.7%),Other,25462273.0,
7463,1174741,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as early apoptotic cells level at 100 nM annexin V-PE and 7-AAD staining based by flow cytometry (Rvb = 18.5%),Other,25462273.0,
7464,1174746,1,1,,123097261,31703,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G0/G1 phase at 50 nM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 42.9%),Other,25462273.0,
7465,1174747,1,1,,123097261,31703,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 50 nM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 45%),Other,25462273.0,
7466,1174748,1,1,,123097261,31703,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G2/M phase at 50 nM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 11.6%),Other,25462273.0,
7467,1174749,1,1,,123097261,31703,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at subG1 phase at 50 nM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 0.5%),Other,25462273.0,
7468,1174854,1,1,,123097261,31703,Active,,,0.124,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,25462279.0,
7469,1174855,1,1,,123097261,31703,Active,,,0.069,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,25462279.0,
7470,1174856,1,1,,123097261,31703,Active,,,0.154,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25462279.0,
7471,1175186,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay,Other,25466181.0,
7472,1175187,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTS assay,Other,25466181.0,
7473,1175188,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as cell viability at 2 uM after 48 hrs by MTS assay,Other,25466181.0,
7474,1175189,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell viability at 2 uM after 48 hrs by MTS assay,Other,25466181.0,
7475,1175192,1,2,,123097261,31703,Active,10720176.0,8493.0,,,Inhibition of C-terminal truncated PPM1D in human HCT116 cells assessed as increase in Ser15 phosphorylated p53 level at 2 uM after 24 to 48 hrs by western blotting,Other,25466181.0,
7476,1175194,1,2,,123097261,31703,Active,10720176.0,8493.0,,,Inhibition of C-terminal truncated PPM1D in human HCT116 cells assessed as increase in p21 level at 2 uM after 24 to 48 hrs by western blotting,Other,25466181.0,
7477,1175512,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against brine shrimps larvae assessed as mortality after 48 hrs,Other,25468043.0,
7478,1175513,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7479,1175514,1,1,,123097261,31703,Active,,,14.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7480,1175515,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7481,1175516,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human HeLa cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7482,1175517,1,1,,123097261,31703,Active,,,17.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7483,1175518,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by alamar blue assay,Confirmatory,25468043.0,
7484,1175519,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay,Other,25468043.0,
7485,1175560,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity activity against human MDA435 cells,Confirmatory,25478997.0,
7486,1175673,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
7487,1175674,1,1,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
7488,1175675,1,2,,123097261,31703,Active,,,0.86,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
7489,1175676,1,1,,123097261,31703,Active,,,1.08,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
7490,1175814,1,2,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTS assay,Confirmatory,25490132.0,
7491,1175815,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTS assay,Confirmatory,25490132.0,
7492,1175816,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay,Confirmatory,25490132.0,
7493,1175817,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTS assay,Confirmatory,25490132.0,
7494,1176109,1,1,,123097261,31703,Active,,,0.12300000000000001,IC50,Cytotoxicity against human HL60 cells by SRB assay,Confirmatory,25497963.0,
7495,1176110,1,1,,123097261,31703,Active,,,0.414,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,25497963.0,
7496,1176175,1,1,,123097261,31703,Active,,,0.0199,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay,Confirmatory,25499433.0,
7497,1176177,1,1,,123097261,31703,Active,,,,,Cell cycle arrest in human HCT116 cells assessed as decrease in accumulation at S phase at 100 to 200 uM after 24 by flow cytometry,Other,25499433.0,
7498,1176178,1,1,,123097261,31703,Active,,,,,Cell cycle arrest in human HCT116 cells assessed as increase in accumulation at G2/M phase at 100 to 200 uM after 24 by flow cytometry,Other,25499433.0,
7499,1176185,1,1,,123097261,31703,Unspecified,,,,,Induction of DNA damage in human HCT116 cells at S phase at 100 to 200 uM after 24 hrs by gamma-H2AX-staining based-flow cytometry,Other,25499433.0,
7500,1176186,1,1,,123097261,31703,Unspecified,,,,,Induction of DNA damage in human HCT116 cells at G2/M phase at 100 to 200 uM after 24 hrs by gamma-H2AX-staining based-flow cytometry,Other,25499433.0,
7501,1176187,1,1,,123097261,31703,Inactive,,,,,Induction of DNA damage in human HCT116 cells at G0/G1 phase at 100 to 200 uM after 24 hrs by gamma-H2AX-staining based-flow cytometry,Other,25499433.0,
7502,1176189,1,1,,123097261,31703,Inactive,,,,,Cell cycle arrest in human HCT116 cells assessed as cells at M phase at 100 to 200 uM after 24 by flow cytometry,Other,25499433.0,
7503,1176850,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
7504,1176851,1,1,,123097261,31703,Active,,,0.21,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
7505,1176852,1,1,,123097261,31703,Active,,,0.16,IC50,Antiproliferative activity against human SF763 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
7506,1176853,1,1,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
7507,1176854,1,1,,123097261,31703,Active,,,0.22,IC50,Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
7508,1176937,1,1,,123097261,31703,Active,,,0.62,IC50,Cytotoxicity against human SMMC-7221 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25537271.0,
7509,1176938,1,1,,123097261,31703,Active,,,0.77,IC50,Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25537271.0,
7510,1176985,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,25554367.0,
7511,1176986,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human HuH7 cells after 24 hrs by MTT assay,Confirmatory,25554367.0,
7512,1176987,1,2,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay,Confirmatory,25554367.0,
7513,1176988,1,1,,123097261,31703,Active,,,2.9,IC50,Cytotoxicity against human QSG7701 cells after 24 hrs by MTT assay,Confirmatory,25554367.0,
7514,1177405,1,1,,123097261,31703,Active,,,0.69,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay,Confirmatory,25089733.0,
7515,1177406,1,1,,123097261,31703,Active,,,0.47,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay,Confirmatory,25089733.0,
7516,1177407,1,1,,123097261,31703,Active,,,1.22,IC50,Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay,Confirmatory,25089733.0,
7517,1177588,1,1,,123097261,31703,Active,,,2.9,IC50,Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability,Confirmatory,25105722.0,
7518,1177616,1,1,,123097261,31703,Active,,,0.0014,IC50,Cytotoxicity against human A549 cells by sulforhodamine B bioassay,Confirmatory,25098650.0,
7519,1177617,1,1,,123097261,31703,Active,,,0.0217,IC50,Cytotoxicity against human SKOV3 cells by sulforhodamine B bioassay,Confirmatory,25098650.0,
7520,1177618,1,1,,123097261,31703,Active,,,0.0025,IC50,Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B bioassay,Confirmatory,25098650.0,
7521,1177619,1,1,,123097261,31703,Active,,,0.1077,IC50,Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay,Confirmatory,25098650.0,
7522,1177951,1,1,,123097261,31703,Unspecified,,,5490.0,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,24583357.0,
7523,1181212,1,1,,123097261,31703,Active,,,4.23,IC50,Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay,Confirmatory,24969014.0,
7524,1181213,1,1,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay,Confirmatory,24969014.0,
7525,1181214,1,1,,123097261,31703,Active,,,1.53,IC50,Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay,Confirmatory,24969014.0,
7526,1181215,1,1,,123097261,31703,Active,,,1.25,IC50,Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay,Confirmatory,24969014.0,
7527,1181216,1,1,,123097261,31703,Active,,,9.36,IC50,Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay,Confirmatory,24969014.0,
7528,1181217,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for concanavalin-A stimulated human PBMCs to IC50 for human K562 cells",Other,24969014.0,
7529,1181400,1,1,,123097261,31703,Active,,,0.013519999999999999,IC50,Cytotoxicity against human LNCAP cells after 72 hrs by Alamar Blue assay,Confirmatory,24973030.0,
7530,1181401,1,1,,123097261,31703,Active,,,0.1256,IC50,Cytotoxicity against human NFF cells after 72 hrs by Alamar Blue assay,Confirmatory,24973030.0,
7531,1181402,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human NFF cells to IC50 for human LNCaP cells",Other,24973030.0,
7532,1183563,1,1,,123097261,31703,Active,,,0.57,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
7533,1183564,1,1,,123097261,31703,Active,,,0.239,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
7534,1183565,1,1,,123097261,31703,Active,,,0.258,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
7535,1183566,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
7536,1183567,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
7537,1183664,1,1,,123097261,31703,Active,,,0.0956,IC50,Growth inhibition of human LoVo cells after 72 hrs by MTT assay,Confirmatory,25025853.0,
7538,1183665,1,1,,123097261,31703,Active,,,11.296,IC50,Growth inhibition of human LoVo/DX cells after 72 hrs by MTT assay,Confirmatory,25025853.0,
7539,1183666,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,25025853.0,
7540,1184237,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity in brine shrimp assessed as mortality after 24 hrs,Other,25036793.0,
7541,1184473,1,1,,123097261,31703,Unspecified,,,,,Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25042338.0,
7542,1184474,1,1,,123097261,31703,Unspecified,,,,,Anticancer activity against human cells MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25042338.0,
7543,1185390,1,1,,123097261,31703,Active,,,0.66,IC50,Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay,Confirmatory,25059501.0,
7544,1185391,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay,Confirmatory,25059501.0,
7545,1185392,1,1,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human SNO cells assessed as cell survival after 24 hrs by XTT assay,Confirmatory,25059501.0,
7546,1185393,1,2,,123097261,31703,Active,,,0.01,IC50,Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay,Confirmatory,25059501.0,
7547,1185519,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 0.2 uM after 48 hrs by MTT assay relative to untreated control,Other,25062007.0,
7548,1185520,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 2 uM after 48 hrs by MTT assay relative to untreated control,Other,25062007.0,
7549,1185521,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 20 uM after 48 hrs by MTT assay relative to untreated control,Other,25062007.0,
7550,1185539,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7551,1185540,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7552,1185541,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7553,1185542,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7554,1185543,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7555,1185544,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7556,1185545,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7557,1185546,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Other,25062010.0,
7558,1185768,1,1,,123097261,31703,Active,,,15.53,IC50,Anticancer activity against human T47D cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay,Confirmatory,25064350.0,
7559,1185769,1,1,,123097261,31703,Active,,,6.75,IC50,Anticancer activity against human MCF7 cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay,Confirmatory,25064350.0,
7560,1185770,1,1,,123097261,31703,Active,,,7.04,IC50,Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay,Confirmatory,25064350.0,
7561,1185771,1,1,,123097261,31703,Active,,,9.02,IC50,Anticancer activity against human Ishikawa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay,Confirmatory,25064350.0,
7562,1186145,1,1,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
7563,1186146,1,1,,123097261,31703,Active,,,0.79,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
7564,1186147,1,1,,123097261,31703,Active,,,0.44,IC50,Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
7565,1186148,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by XTT assay,Confirmatory,25078311.0,
7566,1186149,1,1,,123097261,31703,Inconclusive,,,,IC50,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 24 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,25078311.0,
7567,1186150,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 4 days by green fluorescent protein detection method,Confirmatory,25078311.0,
7568,1186793,1,1,,123097261,31703,Active,,,3.0,IC50,Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay,Confirmatory,25096298.0,
7569,1186794,1,1,,123097261,31703,Active,,,1.1,IC50,Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay,Confirmatory,25096298.0,
7570,1187962,1,1,,123097261,31703,Active,,,0.54,IC50,Antiproliferative activity against human PC3 cells after 72 hrs,Confirmatory,25127463.0,
7571,1187963,1,1,,123097261,31703,Active,,,0.32,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs,Confirmatory,25127463.0,
7572,1187964,1,1,,123097261,31703,Active,,,0.31,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs,Confirmatory,25127463.0,
7573,1187965,1,1,,123097261,31703,Active,,,7.86,IC50,Antiproliferative activity against human dermal fibroblast cells after 72 hrs,Confirmatory,25127463.0,
7574,1187966,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human dermal fibroblast cells to IC50 for human PC3 cells",Other,25127463.0,
7575,1187967,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human dermal fibroblast cells to IC50 for human MCF7 cells",Other,25127463.0,
7576,1187968,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human dermal fibroblast cells to IC50 for human MDA-MB-231 cells",Other,25127463.0,
7577,1188653,1,1,,123097261,31703,Active,,,8.05,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,25140752.0,
7578,1188654,1,1,,123097261,31703,Active,,,8.5,IC50,Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,25140752.0,
7579,1188655,1,1,,123097261,31703,Active,,,5.96,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,25140752.0,
7580,1188728,1,1,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,25147145.0,
7581,1188729,1,1,,123097261,31703,Active,,,0.88,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,25147145.0,
7582,1188730,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,25147145.0,
7583,1188731,1,1,,123097261,31703,Unspecified,,,,,Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry,Other,25147145.0,
7584,1189146,1,1,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human A2780 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7585,1189147,1,1,,123097261,31703,Active,,,1.9,IC50,Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7586,1189148,1,1,,123097261,31703,Inconclusive,,,,IC50,Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7587,1189149,1,1,,123097261,31703,Active,,,3.4,IC50,Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7588,1189150,1,1,,123097261,31703,Active,,,0.29,IC50,Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7589,1189151,1,1,,123097261,31703,Active,,,15.0,IC50,Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
7590,1189154,1,1,,123097261,31703,Unspecified,,,,,"Drug resistance index, ratio of IC50 for cis-platinum-resistant human A549 cells to IC50 for human A549 cells",Other,25061803.0,
7591,1189155,1,1,,123097261,31703,Unspecified,,,,,"Drug resistance index, ratio of IC50 for doxorubicin-resistant human MCF7 cells to IC50 for human MCF7 cells",Other,25061803.0,
7592,1189706,1,1,,123097261,31703,Active,,,0.63,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Confirmatory,25461322.0,
7593,1189976,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human U251 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7594,1189977,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human MCF7 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7595,1189978,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI/ADR-RES cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7596,1189979,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human 786-0 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7597,1189980,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human NCI-H460 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7598,1189981,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human PC3 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7599,1189982,1,1,,123097261,31703,Unspecified,,,,,Antiproliferative activity against human OVCAR3 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7600,1189983,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HaCaT cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7601,1189984,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay,Other,25510639.0,
7602,1190068,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay,Other,25534608.0,
7603,1190069,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay,Other,25534608.0,
7604,1190345,1,1,,123097261,31703,Active,,,0.12,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25563891.0,
7605,1190346,1,1,,123097261,31703,Active,,,3.13,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25563891.0,
7606,1190347,1,1,,123097261,31703,Active,,,7.2,IC50,Cytotoxicity against human A375 cells after 48 hrs by MTT assay,Confirmatory,25563891.0,
7607,1190348,1,1,,123097261,31703,Active,,,24.0,IC50,Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay,Confirmatory,25563891.0,
7608,1190349,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0 phase at 2 uM after 48 hrs by FACS analysis (Rvb = 1.83 +/- 0.28%),Other,25563891.0,
7609,1190351,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 2 uM after 48 hrs by FACS analysis (Rvb = 62.66 +/- 2.08%),Other,25563891.0,
7610,1190353,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 48 hrs by FACS analysis (Rvb = 7 +/- 1%),Other,25563891.0,
7611,1190355,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 48 hrs by FACS analysis (Rvb = 28.66 +/- 1.52%),Other,25563891.0,
7612,1192290,1,1,,123097261,31703,Active,,,,,Cytotoxic activity against human CEM13 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25737086.0,
7613,1192291,1,1,,123097261,31703,Active,,,,,Cytotoxic activity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25737086.0,
7614,1192292,1,1,,123097261,31703,Active,,,,,Cytotoxic activity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25737086.0,
7615,1192780,1,1,,123097261,31703,Active,,,1.17,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25619894.0,
7616,1192781,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,25619894.0,
7617,1192782,1,1,,123097261,31703,Active,,,0.75,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25619894.0,
7618,1192783,1,1,,123097261,31703,Unspecified,,,95.61,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,25619894.0,
7619,1192784,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,25619894.0,
7620,1192787,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human MDA-MB-231 cells at IC50 after 48 hrs by Giemsa staining-based light microscopy (Rvb = 7%),Other,25619894.0,
7621,1193480,1,1,,123097261,31703,Active,,,0.75,IC50,Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7622,1193481,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7623,1193482,1,1,,123097261,31703,Unspecified,,,95.61,IC50,Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7624,1193483,1,1,,123097261,31703,Active,,,1.17,IC50,Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7625,1193484,1,1,,123097261,31703,Active,,,0.32,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7626,1193485,1,1,,123097261,31703,Active,,,7.86,IC50,Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7627,1193486,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay,Confirmatory,25737400.0,
7628,1193866,1,1,,123097261,31703,Active,,,0.3,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition by MTT assay,Confirmatory,25765907.0,
7629,1193867,1,1,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay,Confirmatory,25765907.0,
7630,1194693,1,1,,123097261,31703,Active,,,0.01,GI50,Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
7631,1194694,1,1,,123097261,31703,Active,,,0.02,GI50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
7632,1194695,1,1,,123097261,31703,Active,,,0.01,GI50,Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
7633,1194696,1,1,,123097261,31703,Active,,,0.01,GI50,Antiproliferative activity against human A549 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
7634,1194919,1,1,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
7635,1194923,1,1,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
7636,1194924,1,2,,123097261,31703,Active,,,0.008,IC50,Cytotoxicity against human THP1 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
7637,1194978,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SGC7901 cells by MTT assay,Other,25862199.0,
7638,1194979,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,25862199.0,
7639,1194980,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,25862199.0,
7640,1195122,1,1,,123097261,31703,Active,,,0.46,IC50,Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay,Confirmatory,25868743.0,
7641,1195254,1,1,,123097261,31703,Active,,,1.3,IC50,Cytotoxicity against human A549 cells after 24 hrs by WST assay,Confirmatory,25881821.0,
7642,1195255,1,2,,123097261,31703,Active,,,4.3,IC50,Cytotoxicity against human KB cells after 24 hrs by WST assay,Confirmatory,25881821.0,
7643,1195256,1,1,,123097261,31703,Active,,,2.2,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by WST assay,Confirmatory,25881821.0,
7644,1196493,1,1,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay,Confirmatory,25559208.0,
7645,1196496,1,2,,123097261,31703,Active,,,0.008,CC50,Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay,Confirmatory,25559208.0,
7646,1197174,1,1,,123097261,31703,Active,,,3.57,IC50,Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7647,1197175,1,1,,123097261,31703,Active,,,3.03,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7648,1197176,1,2,,123097261,31703,Active,,,5.3,IC50,Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7649,1197177,1,1,,123097261,31703,Active,,,2.24,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7650,1197178,1,1,,123097261,31703,Active,,,2.78,IC50,Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7651,1197179,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against HEK293 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25594739.0,
7652,1197250,1,1,,123097261,31703,Active,,,,,Cell cycle arrest in human HL60R cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometry,Other,25596478.0,
7653,1197251,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human HL60R cells assessed as nuclear fragmentation at 10 uM after 24 hrs by hoechst 3342 staining-based fluorescence microscopy,Other,25596478.0,
7654,1197254,1,1,,123097261,31703,Inactive,,,,,Cell cycle arrest in human HL60R cells assessed as exit from mitosis at 10 uM after 24 hrs by propidium iodide staining-based flow cytometry,Other,25596478.0,
7655,1197256,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human HL60R cells assessed as chromatin condensation at 10 uM after 48 hrs by hoechst 3342 staining-based fluorescence microscopy,Other,25596478.0,
7656,1197577,1,1,,123097261,31703,Active,,,0.99,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
7657,1197578,1,1,,123097261,31703,Active,,,1.9,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
7658,1197579,1,2,,123097261,31703,Active,,,1.3,IC50,Anticancer activity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
7659,1197580,1,1,,123097261,31703,Active,,,2.29,IC50,Anticancer activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
7660,1197581,1,1,,123097261,31703,Active,,,1.61,IC50,Anticancer activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
7661,1197650,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio at 5 uM after 48 hrs by SRB assay relative to control,Other,25618015.0,
7662,1197651,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio at 12.5 uM after 48 hrs by SRB assay relative to control,Other,25618015.0,
7663,1197652,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio at 25 uM after 48 hrs by SRB assay relative to control,Other,25618015.0,
7664,1197653,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio at 50 uM after 48 hrs by SRB assay relative to control,Other,25618015.0,
7665,1197654,1,1,,123097261,31703,Active,,,36.3,IC50,Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio after 48 hrs by SRB assay relative to control,Confirmatory,25618015.0,
7666,1197743,1,2,,123097261,31703,Unspecified,12643959.0,10599.0,,,Inhibition of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control,Other,25618019.0,
7667,1197745,1,2,,123097261,31703,Unspecified,27734563.0,28234.0,,,Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control,Other,25618019.0,
7668,1198103,1,1,,123097261,31703,Active,,,9.25,IC50,Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25648297.0,
7669,1198114,1,1,,123097261,31703,Active,,,9.7,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25655719.0,
7670,1198115,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25655719.0,
7671,1198116,1,1,,123097261,31703,Active,,,3.5,IC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25655719.0,
7672,1198117,1,2,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25655719.0,
7673,1198372,1,1,,123097261,31703,Active,,,0.55,IC50,Antiproliferative activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25686590.0,
7674,1198409,1,1,,123097261,31703,Inconclusive,,,,,Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
7675,1198410,1,1,,123097261,31703,Inconclusive,,,,,Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
7676,1198411,1,1,,123097261,31703,Inconclusive,,,,,Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
7677,1198412,1,1,,123097261,31703,Inconclusive,,,,,Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
7678,1198413,1,1,,123097261,31703,Inconclusive,,,,,Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method,Other,25686593.0,
7679,1198414,1,1,,123097261,31703,Inconclusive,,,,,Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method,Other,25686593.0,
7680,1198415,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay,Other,25686593.0,
7681,1198467,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10'-5 M after 72 hrs by MTT assay relative to control,Other,25703298.0,
7682,1198468,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition at 10'-5 M after 72 hrs by MTT assay relative to control,Other,25703298.0,
7683,1198469,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition at 10'-5 M after 72 hrs by MTT assay relative to control,Other,25703298.0,
7684,1198470,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as growth inhibition at 10'-5 M after 72 hrs by MTT assay relative to control,Other,25703298.0,
7685,1198471,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as growth inhibition at 10'-5 M after 72 hrs by MTT assay relative to control,Other,25703298.0,
7686,1198472,1,1,,123097261,31703,Active,,,1.28,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25703298.0,
7687,1198473,1,1,,123097261,31703,Active,,,1.546,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25703298.0,
7688,1198474,1,1,,123097261,31703,Active,,,0.47700000000000004,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25703298.0,
7689,1198493,1,2,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse LLC cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 2.5 mg/kg, ip administered for 14 days measured on day 15 relative to control",Other,25703298.0,
7690,1198497,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in C57BL/6 mouse allografted with mouse LLC cells assessed as decrease in body weight at 2.5 mg/kg, ip administered for 14 days measured during compound dosing",Other,25703298.0,
7691,1199977,1,1,,123097261,31703,Active,,,0.04,IC50,Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25644674.0,
7692,1199978,1,1,,123097261,31703,Active,,,0.88,IC50,Antiproliferative activity against human vincristine-resistant HL60/Vinc cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25644674.0,
7693,1199979,1,1,,123097261,31703,Active,,,0.15,IC50,Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7694,1199980,1,1,,123097261,31703,Active,,,5.46,IC50,Antiproliferative activity against human doxorubicin-resistant LoVo/DX cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7695,1199981,1,1,,123097261,31703,Active,,,0.89,IC50,Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7696,1199982,1,1,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7697,1199983,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7698,1199984,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
7699,1199985,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60 cells",Other,25644674.0,
7700,1199986,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60/Vinc cells",Other,25644674.0,
7701,1199987,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,25644674.0,
7702,1199988,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/DX cells",Other,25644674.0,
7703,1199989,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HT-29 cells",Other,25644674.0,
7704,1199990,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LS180 cells",Other,25644674.0,
7705,1199991,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human SW707 cells",Other,25644674.0,
7706,1199992,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/Vinc cells to IC50 for human HL60 cells",Other,25644674.0,
7707,1199993,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,25644674.0,
7708,1200256,1,2,,123097261,31703,Unspecified,,,,,"Antitumor activity against mouse LLC cells allografted in BD2F mouse assessed as tumor growth inhibition at 1.25 mg/kg, ip administered every other day for 5 treatments relative to control",Other,25668341.0,
7709,1201031,1,1,,123097261,31703,Inactive,,,,IC50,Inhibition of rat intestinal alpha-glucosidase using nitrophenyl-alpha-D-glucopyranoside by spectrophotometrically,Confirmatory,25743216.0,
7710,1201032,1,1,,123097261,31703,Active,,,2.63,IC50,Anticancer activity against human MCF7 cells by MTT assay,Confirmatory,25743216.0,
7711,1201033,1,2,,123097261,31703,Active,,,17.67,IC50,Anticancer activity against human DU145 cells by MTT assay,Confirmatory,25743216.0,
7712,1201034,1,1,,123097261,31703,Active,,,44.4,IC50,Anticancer activity against human IMR32 cells by MTT assay,Confirmatory,25743216.0,
7713,1201035,1,1,,123097261,31703,Unspecified,,,69.33,IC50,Anticancer activity against human A549 cells by MTT assay,Confirmatory,25743216.0,
7714,1201036,1,1,,123097261,31703,Active,,,1.05,IC50,Anticancer activity against human HepG2 cells by MTT assay,Confirmatory,25743216.0,
7715,1201058,1,1,,123097261,31703,Unspecified,,,91.99,IC50,Cytotoxicity against human MRC5 cells by MTT assay,Confirmatory,25747499.0,
7716,1201071,1,1,,123097261,31703,Active,,,0.4,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,25747499.0,
7717,1201072,1,1,,123097261,31703,Active,,,2.39,IC50,Cytotoxicity against human HuCCa1 cells by MTT assay,Confirmatory,25747499.0,
7718,1201073,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,25747499.0,
7719,1201074,1,1,,123097261,31703,Active,,,0.98,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,25747499.0,
7720,1201075,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HepG2 cells",Other,25747499.0,
7721,1201076,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HuCCa1 cells",Other,25747499.0,
7722,1201077,1,1,,123097261,31703,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human MOLT3 cells",Other,25747499.0,
7723,1201078,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human A549 cells",Other,25747499.0,
7724,1201079,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MRC5 cells at 91.99 uM by MTT assay relative to control,Other,25747499.0,
7725,1201137,1,1,,123097261,31703,Active,,,,,Induction of senescence in human HeLa cells at 4 uM after 72 hrs by X-gal staining-based beta-galactosidase assay,Other,25757092.0,
7726,1201138,1,1,,123097261,31703,Active,,,,,Upregulation of p53 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7727,1201139,1,1,,123097261,31703,Active,,,,,Upregulation of p21 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7728,1201140,1,1,,123097261,31703,Active,,,,,Downregulation of EZH2 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7729,1201141,1,1,,123097261,31703,Active,,,,,Downregulation of HDAC-1 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7730,1201142,1,1,,123097261,31703,Active,,,,,Downregulation of HDAC-2 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7731,1201143,1,1,,123097261,31703,Active,,,,,Downregulation of HDAC-5 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7732,1201144,1,1,,123097261,31703,Inactive,,,,,Change in HDAC-6 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7733,1201145,1,1,,123097261,31703,Inactive,,,,,Change in HDAC-7 mRNA expression in human HeLa cells at 4 uM after 48 hrs by RT-PCR analysis,Other,25757092.0,
7734,1201147,1,1,,123097261,31703,Active,,,,,Induction of human p16 promoter activity transfected in human HeLa cells at 4 uM after 48 hrs by luciferase-based luminescence assay,Other,25757092.0,
7735,1201510,1,1,,123097261,31703,Active,,,0.2,CC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,25791675.0,
7736,1201511,1,1,,123097261,31703,Active,,,0.6,CC50,Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,25791675.0,
7737,1201761,1,1,,123097261,31703,Active,,,1.45,IC50,Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
7738,1201762,1,1,,123097261,31703,Active,,,1.22,IC50,Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
7739,1201763,1,2,,123097261,31703,Active,,,1.19,IC50,Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
7740,1201764,1,1,,123097261,31703,Active,,,0.87,IC50,Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
7741,1201818,1,1,,123097261,31703,Active,,,0.009000000000000001,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay,Confirmatory,25817774.0,
7742,1201819,1,1,,123097261,31703,Active,,,9.26,IC50,Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay,Confirmatory,25817774.0,
7743,1201820,1,1,,123097261,31703,Active,,,0.016,IC50,Cytotoxicity against HAF assessed as growth inhibition after 96 hrs by SRB assay,Confirmatory,25817774.0,
7744,1202239,1,2,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,25874331.0,
7745,1202240,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,25874331.0,
7746,1202241,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay,Confirmatory,25874331.0,
7747,1202242,1,1,,123097261,31703,Unspecified,,,,IC50,Cytotoxicity against human A375 cells after 72 hrs by MTT assay,Confirmatory,25874331.0,
7748,1202243,1,1,,123097261,31703,Active,,,1.35,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25874331.0,
7749,1202641,1,1,,123097261,31703,Active,,,33.13,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25912674.0,
7750,1202642,1,1,,123097261,31703,Active,,,26.81,IC50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25912674.0,
7751,1202760,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxic activity against human HeLa cells by MTT method,Confirmatory,25611519.0,
7752,1202761,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxic activity against human Bel7402 cells by MTT method,Confirmatory,25611519.0,
7753,1202762,1,1,,123097261,31703,Active,,,0.04,IC50,Cytotoxic activity against human HEK293 cells by SRB method,Confirmatory,25611519.0,
7754,1202763,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxic activity against human HCT116 cells by SRB method,Confirmatory,25611519.0,
7755,1202764,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxic activity against human A549 cells by SRB method,Confirmatory,25611519.0,
7756,1204140,1,2,,123097261,31703,Active,,,3.11,IC50,Cytotoxicity against human DU145 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
7757,1204141,1,1,,123097261,31703,Active,,,1.11,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
7758,1204142,1,1,,123097261,31703,Active,,,2.31,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
7759,1204143,1,1,,123097261,31703,Active,,,1.43,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB method,Confirmatory,25933593.0,
7760,1204144,1,1,,123097261,31703,Active,,,5.91,IC50,Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
7761,1204349,1,1,,123097261,31703,Active,,,2.87,IC50,Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay,Confirmatory,25965778.0,
7762,1204350,1,1,,123097261,31703,Active,,,2.01,IC50,Cytotoxicity against human MDA-MB-231 cells after 38 hrs by MTT assay,Confirmatory,25965778.0,
7763,1204351,1,1,,123097261,31703,Active,,,3.5,IC50,Cytotoxicity against human SGC7901 cells after 38 hrs by MTT assay,Confirmatory,25965778.0,
7764,1204352,1,2,,123097261,31703,Active,,,3.22,IC50,Cytotoxicity against human MGC803 cells after 38 hrs by MTT assay,Confirmatory,25965778.0,
7765,1204353,1,1,,123097261,31703,Active,,,,,Antiproliferative activity against human MDA-MB-231 cells assessed as breaking and crack at 1 to 10 uM after 24 to 72 hrs by inverted microscopic analysis,Other,25965778.0,
7766,1204580,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human NB4 cells assessed as cell death,Other,26005022.0,
7767,1204780,1,1,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25984840.0,
7768,1204781,1,1,,123097261,31703,Active,,,0.22,IC50,Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25984840.0,
7769,1204782,1,1,,123097261,31703,Active,,,0.16,IC50,Antiproliferative activity against human SF763 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25984840.0,
7770,1204783,1,1,,123097261,31703,Active,,,0.21,IC50,Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25984840.0,
7771,1204784,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25984840.0,
7772,1204837,1,1,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against Plasmodium falciparum D6 infected in human RBC assessed as parasite growth inhibition measured as LDH activity after 72 hrs by plate reader analysis,Confirmatory,26005918.0,
7773,1204838,1,1,,123097261,31703,Inconclusive,,,,IC50,Antiplasmodial activity against Plasmodium falciparum W2 infected in human RBC assessed as parasite growth inhibition measured as LDH activity after 72 hrs by plate reader analysis,Confirmatory,26005918.0,
7774,1204839,1,1,,123097261,31703,Unspecified,,,9.0,IC50,Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7775,1204840,1,1,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against pig LLC-PK1 cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7776,1204841,1,1,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7777,1204842,1,2,,123097261,31703,Active,,,2.6,IC50,Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7778,1204843,1,2,,123097261,31703,Active,,,1.6,IC50,Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7779,1204844,1,2,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red assay,Confirmatory,26005918.0,
7780,1204963,1,1,,123097261,31703,Active,,,1.1,LC50,Cytotoxicity against human A549 cells,Confirmatory,25634623.0,
7781,1204964,1,1,,123097261,31703,Active,,,1.5,LC50,Cytotoxicity against human K562 cells,Confirmatory,25634623.0,
7782,1206987,1,1,,123097261,31703,Active,,,0.2,GI50,Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7783,1206988,1,1,,123097261,31703,Active,,,0.45,GI50,Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7784,1206989,1,1,,123097261,31703,Active,,,0.56,GI50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7785,1206990,1,1,,123097261,31703,Active,,,0.4,GI50,Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7786,1206991,1,1,,123097261,31703,Active,,,0.19,GI50,Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7787,1206992,1,1,,123097261,31703,Active,,,0.91,GI50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay,Confirmatory,25953156.0,
7788,1207788,1,1,,123097261,31703,Unspecified,,,,,Terminal half-life of doxorubicin following intravenous doxorubicin at 1.27 mg.Kg-1 dose in dog,Other,,
7789,1207789,1,1,,123097261,31703,Unspecified,,,,,Terminal half-life of adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7790,1207791,1,1,,123097261,31703,Unspecified,,,,,Terminal half-life ratio of 13-dihydrometabolite of adriamycin to adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7791,1207804,1,1,,123097261,31703,Unspecified,,,,,Volume of distribution of adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7792,1207809,1,1,,123097261,31703,Unspecified,,,,,Plasma clearance of adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7793,1207811,1,1,,123097261,31703,Unspecified,,,,,Plasma clearance ratio of 13-dihydrometabolite of adriamycin to adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7794,1207824,1,1,,123097261,31703,Unspecified,,,,,AUC of adriamycin following intravenous adriamycin at 1.27 mg.Kg-1 dose in dog,Other,,
7795,1207897,1,1,,123097261,31703,Unspecified,,,,,Mortality occurred following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7796,1207901,1,1,,123097261,31703,Unspecified,,,,,Decrease in leukocytes observed following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7797,1207904,1,1,,123097261,31703,Unspecified,,,,,Increase in serum triglycerides level following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7798,1207908,1,1,,123097261,31703,Unspecified,,,,,Increase in serum total cholesterol level following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7799,1207912,1,1,,123097261,31703,Unspecified,,,,,Increase in serum phospholipid level following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7800,1207916,1,1,,123097261,31703,Unspecified,,,,,Incidence of persistent proteinuria following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7801,1207920,1,1,,123097261,31703,Unspecified,,,,,Incidence of leukocyturia following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7802,1207924,1,1,,123097261,31703,Unspecified,,,,,Decrease in albumin due to persistent proteinuria following reference intravenous doxorubicin at 1 mg.Kg-1 per week in rat,Other,,
7803,1207929,1,1,,123097261,31703,Unspecified,,,,,Volume of distribution at steady state following doxorubicin at 60 mg.m-2 dose in patients with cancer,Other,,
7804,1207931,1,1,,123097261,31703,Unspecified,,,,,Binding of doxorubicin to plasma protein of human,Other,,
7805,1207933,1,1,,123097261,31703,Unspecified,,,,,Binding of doxorubicin to albumin,Other,,
7806,1207967,1,1,,123097261,31703,Unspecified,,,,,Percentage of doxorubicin excreted unchanged in urine following doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7807,1207969,1,1,,123097261,31703,Unspecified,,,,,Renal clearance of doxorubicin following doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7808,1207973,1,1,,123097261,31703,Unspecified,,,,,Elimination of doxorubicin following doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7809,1207975,1,1,,123097261,31703,Unspecified,,,,,Mean plasma clearance of doxorubicin following intravenous doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7810,1207977,1,1,,123097261,31703,Unspecified,,,,,Mean terminal half-life of doxorubicin following intravenous doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7811,1207979,1,1,,123097261,31703,Unspecified,,,,,Mean AUC of doxorubicin following intravenous doxorubicin at 60 mg.m-2 dose in cancer patients,Other,,
7812,1208039,1,1,,123097261,31703,Unspecified,,,,,Detection of doxorubicin in plasma following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7813,1208041,1,1,,123097261,31703,Unspecified,,,,,Detection of doxorubicin in heart following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7814,1208043,1,1,,123097261,31703,Unspecified,,,,,Detection of doxorubicin in tumor following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7815,1208063,1,1,,123097261,31703,Unspecified,,,,,Half-life of doxorubicin in plasma following single intravenous epirubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7816,1208065,1,1,,123097261,31703,Unspecified,,,,,Half-life of doxorubicin in heart following single intravenous epirubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7817,1208067,1,1,,123097261,31703,Unspecified,,,,,Half-life of doxorubicin in tumor following single intravenous epirubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7818,1208069,1,2,,123097261,31703,Unspecified,,,,,AUC values (0-48 h) of doxorubicin in plasma following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7819,1208071,1,2,,123097261,31703,Unspecified,,,,,AUC values (0-48 h) of doxorubicin in heart following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7820,1208073,1,2,,123097261,31703,Unspecified,,,,,AUC values (0-48 h) of doxorubicin in tumor following single intravenous doxorubicin at 10 mg.Kg-1 dose in female mouse bearing colon tumor,Other,,
7821,1208143,1,1,,123097261,31703,Unspecified,,,,,Urinary elimination of adriamycin following intravenous bolus adriamycin at 10 mg.Kg-1 dose in rat,Other,,
7822,1208145,1,1,,123097261,31703,Unspecified,,,,,Urinary elimination of adriamycin following intravenous bolus adriamycin at 10 mg.Kg-1 dose in rat,Other,,
7823,1208147,1,1,,123097261,31703,Unspecified,,,,,Urinary elimination of adriamycin following intravenous bolus adriamycin at 10 mg.Kg-1 dose in rat,Other,,
7824,1210968,1,2,,123097261,31703,Unspecified,,,,,"Ratio of drug level in brain to plasma of 5/6 nephrectomized Sprague-Dawley rat chronic renal failure model at 5 mg/kg, iv after 30 mins by beta-counting method relative to control",Other,21969519.0,
7825,1211799,1,2,,123097261,31703,Unspecified,,,,,"Drug excretion in Sprague-Dawley rat assessed as compound excreted into bile at 5 mg/kg, iv",Other,23139379.0,
7826,1211808,1,2,,123097261,31703,Unspecified,,,,,Drug excretion in iv dosed dog assessed as compound excreted into bile,Other,23139379.0,
7827,1211810,1,2,,123097261,31703,Unspecified,,,,,Drug excretion in iv dosed human assessed as compound excreted into bile after 24 hrs by T-tube method,Other,23139379.0,
7828,1211829,1,1,,123097261,31703,Unspecified,,,,,Total biliary clearance in iv dosed human after 24 hrs by T-tube method,Other,23139379.0,
7829,1211849,1,1,,123097261,31703,Unspecified,,,,,Unbound biliary clearance in iv dosed human after 24 hrs by T-tube method,Other,23139379.0,
7830,1211868,1,1,,123097261,31703,Unspecified,,,,,"Total biliary clearance in Sprague-Dawley rat at 5 mg/kg, iv",Other,23139379.0,
7831,1211875,1,1,,123097261,31703,Unspecified,,,,,"Unbound biliary clearance in Sprague-Dawley rat at 5 mg/kg, iv",Other,23139379.0,
7832,1211884,1,1,,123097261,31703,Unspecified,,,,,Total biliary clearance in iv dosed dog,Other,23139379.0,
7833,1211886,1,1,,123097261,31703,Unspecified,,,,,Unbound biliary clearance in iv dosed dog,Other,23139379.0,
7834,1212210,1,1,,123097261,31703,Unspecified,,,,,"Induction of epoxygenase-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 20-HETE formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7835,1212211,1,1,,123097261,31703,Unspecified,,,,,"Induction of omega-1 hydroxylase-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 19-HETE formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7836,1212212,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in EPHX2 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7837,1212213,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in sEH activity in heart microsomes administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7838,1212214,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in sEH activity in heart cytosol administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7839,1212215,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in ANP mRNA expression at 1 uM after 6 hrs in presence of t-AUCB,Other,22867862.0,
7840,1212216,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in BNP mRNA expression at 1 uM after 6 hrs in presence of t-AUCB,Other,22867862.0,
7841,1212217,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in ANP mRNA expression at 1 uM after 6 hrs,Other,22867862.0,
7842,1212218,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in BNP mRNA expression at 1 uM after 6 hrs,Other,22867862.0,
7843,1212219,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in ANP mRNA expression at 1 uM after 6 hrs in presence of HET0016,Other,22867862.0,
7844,1212220,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as reduction in BNP mRNA expression at 1 uM after 6 hrs in presence of HET0016,Other,22867862.0,
7845,1212221,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as sEH gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis",Other,22867862.0,
7846,1212222,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as sEH gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis",Other,22867862.0,
7847,1212223,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of TNF-alpha gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7848,1212224,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of IL-6 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7849,1212225,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP1A1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7850,1212226,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP1A2 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7851,1212227,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP1B1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7852,1212228,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP4F5 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7853,1212229,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as inhibition of CYP2B1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7854,1212230,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as inhibition of CYP2B2 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7855,1212231,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as inhibition of CYP2C11 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7856,1212232,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP2E1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7857,1212233,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP2J3 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7858,1212234,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4A1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7859,1212235,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4A3 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7860,1212236,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP4F5 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7861,1212237,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP4A1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7862,1212238,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP4F4 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7863,1212239,1,1,,123097261,31703,Active,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 5,6-EET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7864,1212240,1,1,,123097261,31703,Active,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 8,9-EET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7865,1212241,1,1,,123097261,31703,Active,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 11,12-EET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7866,1212242,1,1,,123097261,31703,Active,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 14,15-EET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7867,1212243,1,1,,123097261,31703,Unspecified,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 11,12-DHET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7868,1212244,1,1,,123097261,31703,Unspecified,,,,,"Induction of CYP450-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as 14,15-DHET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7869,1212245,1,1,,123097261,31703,Unspecified,,,,,"Induction of epoxygenase-mediated arachidonic acid metabolism in Sprague-Dawley rat heart microsomes assessed as EET/DHET formation administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by LC-ESI-MS analysis relative to control",Other,22867862.0,
7870,1212246,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP2E1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7871,1212247,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in p53 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7872,1212248,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in Bax gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7873,1212249,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in IL-6 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7874,1212250,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in ANP gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7875,1212251,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in beta-MHC gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7876,1212252,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in alpha-MHC gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7877,1212253,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP1A1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7878,1212254,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP1B1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7879,1212255,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP2B1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7880,1212256,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP2C11 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7881,1212257,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP2J3 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7882,1212258,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP4A3 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7883,1212259,1,1,,123097261,31703,Unspecified,,,,,"Cardiotoxicity in Sprague-Dawley rat assessed as increase in CYP4F1 gene expression level administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7884,1212260,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4F1 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7885,1212261,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4F4 gene expression in liver administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7886,1212262,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of TNF-alpha gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7887,1212263,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of IL-6 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7888,1212264,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP1B1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7889,1212265,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP2J3 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7890,1212266,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of CYP4F5 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7891,1212267,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as inhibition of CYP2B2 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7892,1212268,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP1A1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7893,1212269,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP1A2 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7894,1212270,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP2B1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7895,1212271,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP2C11 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7896,1212272,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP2E1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7897,1212273,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4A1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7898,1212274,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4A3 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7899,1212275,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4F1 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7900,1212276,1,2,,123097261,31703,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as CYP4F4 gene expression in kidney administered as cumulative dose of 15 mg/kg, ip divided into 6 injections for 2 weeks followed by compound washout period of 14 days by RT-PCR analysis relative to control",Other,22867862.0,
7901,1215533,1,2,,123097261,31703,Unspecified,,,,,Half life in mouse plasma,Other,21266594.0,
7902,1215534,1,1,,123097261,31703,Unspecified,,,,,Half life in mouse heart,Other,21266594.0,
7903,1224863,1,1,,176484196,31703,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
7904,1224863,1,1,,176484952,31703,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
7905,1224905,2,1,,92308822,31703,Active,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
7906,1224905,2,1,,92308822,31703,Active,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
7907,1225326,1,1,,123097261,31703,Active,,,1.83,IC50,Cytotoxicity against human A549 cells,Confirmatory,25581396.0,
7908,1225327,1,1,,123097261,31703,Active,,,1.46,IC50,Cytotoxicity against human K562 cells,Confirmatory,25581396.0,
7909,1227878,1,1,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay,Confirmatory,25466198.0,
7910,1227879,1,1,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by SRB assay,Confirmatory,25466198.0,
7911,1227880,1,1,,123097261,31703,Active,,,0.001,IC50,Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition after 48 hrs by SRB assay,Confirmatory,25466198.0,
7912,1227881,1,1,,123097261,31703,Active,,,0.129,IC50,Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay,Confirmatory,25466198.0,
7913,1227983,1,1,,123097261,31703,Active,,,0.91,IC50,Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay,Confirmatory,25734623.0,
7914,1227984,1,1,,123097261,31703,Active,,,11.52,IC50,Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay,Confirmatory,25734623.0,
7915,1228076,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human A549 cells by SRB protein staining method,Confirmatory,25781655.0,
7916,1228077,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against mouse P388 cells by MTT method,Confirmatory,25781655.0,
7917,1228078,1,1,,123097261,31703,Active,,,0.057999999999999996,IC50,Cytotoxicity against human HL60 cells by MTT method,Confirmatory,25781655.0,
7918,1228712,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method,Confirmatory,25932671.0,
7919,1228713,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method,Confirmatory,25932671.0,
7920,1228714,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method,Confirmatory,25932671.0,
7921,1228715,1,1,,123097261,31703,Active,,,0.1,IC50,Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method,Confirmatory,25932671.0,
7922,1228828,1,1,,123097261,31703,Active,,,0.3,IC50,Cytotoxic activity against mouse M12.C3.F6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,25966052.0,
7923,1228829,1,1,,123097261,31703,Active,,,1.3,IC50,Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,25966052.0,
7924,1228830,1,1,,123097261,31703,Active,,,0.63,IC50,Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,25966052.0,
7925,1228831,1,1,,123097261,31703,Active,,,1.78,IC50,Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,25966052.0,
7926,1228832,1,1,,123097261,31703,Active,,,3.18,IC50,Cytotoxic activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,25966052.0,
7927,1228928,1,1,,123097261,31703,Active,,,,,Drug uptake in human LCC-6 cells at 20 uM after 150 mins by spectrofluorometry relative to P-gp expressing cells,Other,25985195.0,
7928,1229534,1,1,,123097261,31703,Active,,,,,Cellular uptake in mouse NIH/3T3 cells at 2 uM after 4 hrs by fluorescence microscopic analysis,Other,26005543.0,
7929,1229535,1,1,,123097261,31703,Active,,,,,Cellular uptake in mouse B16F10 cells at 2 uM after 4 hrs by fluorescence microscopic analysis,Other,26005543.0,
7930,1229536,1,1,,123097261,31703,Active,,,,,Cellular uptake in human PANC1 cells at 2 uM after 4 hrs by fluorescence microscopic analysis,Other,26005543.0,
7931,1229537,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7932,1229538,1,1,,123097261,31703,Active,,,0.6629999999999999,IC50,Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7933,1229539,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human OVCAR3 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7934,1229540,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7935,1229541,1,1,,123097261,31703,Active,,,1.026,IC50,Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7936,1229542,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7937,1229543,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against CHO cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7938,1229544,1,1,,123097261,31703,Active,,,7.211,IC50,Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay,Confirmatory,26005543.0,
7939,1229545,1,1,,123097261,31703,Active,,,,,Induction of reactive oxygen species generation in mouse B16F10 cells at 2 uM after 36 hrs by DCFDA dye-based fluorescence microscopic analysis,Other,26005543.0,
7940,1229546,1,1,,123097261,31703,Unspecified,,,,,Induction of reactive oxygen species generation in mouse NIH/3T3 cells at 2 uM after 36 hrs by DCFDA dye-based fluorescence microscopic analysis,Other,26005543.0,
7941,1229547,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as early apoptotic cells at 2 uM after 45 hrs by annexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.1%),Other,26005543.0,
7942,1229548,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as late apoptotic cells at 2 uM after 45 hrs by annexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.8%),Other,26005543.0,
7943,1229549,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as necrotic cells at 2 uM after 45 hrs by annexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 9%),Other,26005543.0,
7944,1229550,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as viable cells at 2 uM after 45 hrs by annexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 90.1%),Other,26005543.0,
7945,1229821,1,1,,123097261,31703,Active,,,0.46,IC50,Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay,Confirmatory,26052884.0,
7946,1230555,1,1,,123097261,31703,Active,,,0.36,IC50,Cytotoxicity against human HuH7 cells after 72 hrs by WST1 assay,Confirmatory,26083682.0,
7947,1230556,1,1,,123097261,31703,Active,,,0.023,IC50,Cytotoxicity against human EJ1 cells after 72 hrs by WST1 assay,Confirmatory,26083682.0,
7948,1231679,1,1,,123097261,31703,Active,,,0.52,IC50,Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
7949,1231680,1,1,,123097261,31703,Active,,,1.23,IC50,Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
7950,1231681,1,1,,123097261,31703,Active,,,1.34,IC50,Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
7951,1231682,1,1,,123097261,31703,Active,,,0.88,IC50,Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
7952,1231684,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7953,1231685,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7954,1231686,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7955,1231687,1,1,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7956,1231688,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7957,1231689,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7958,1231690,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7959,1231691,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7960,1231692,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7961,1231693,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7962,1231694,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7963,1231695,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7964,1231696,1,1,,123097261,31703,Active,,,0.15,IC50,Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7965,1231697,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7966,1231698,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7967,1231699,1,1,,123097261,31703,Active,,,0.02,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7968,1231707,1,1,,123097261,31703,Unspecified,,,,,"Potency index, ratio of IC50 against human MDA-MB-231 cells after 72 hrs by MTS assay under hypoxic conditions to IC50 against human MDA-MB-231 cells after 72 hrs by MTS assay under normoxic conditions",Other,25937235.0,
7969,1231708,1,1,,123097261,31703,Inactive,,,,,Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs under hypoxic conditions by MTS assay,Other,25937235.0,
7970,1231711,1,1,,123097261,31703,Inactive,,,,,Cytotoxicity against human HT-29 cells incubated for 72 hrs under hypoxic conditions by MTS assay,Other,25937235.0,
7971,1231731,1,1,,123097261,31703,Active,,,0.01,IC50,Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7972,1231732,1,1,,123097261,31703,Active,,,0.03,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7973,1231733,1,1,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method,Confirmatory,25937235.0,
7974,1231940,1,1,,123097261,31703,Inconclusive,114304.0,100037716.0,,Kd,Binding affinity to rabbit skeletal muscle SERCA1a preincubated for 5 mins followed by Mg-ATP addition measured over 6 mins by spectrophotometric analysis,Confirmatory,25993619.0,
7975,1231947,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,25993619.0,
7976,1233147,1,1,,123097261,31703,Active,,,0.002,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay,Confirmatory,25981688.0,
7977,1233148,1,1,,123097261,31703,Active,,,0.012,IC50,Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay,Confirmatory,25981688.0,
7978,1233149,1,1,,123097261,31703,Active,,,0.001,IC50,Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay,Confirmatory,25981688.0,
7979,1233150,1,1,,123097261,31703,Active,,,0.109,IC50,Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay,Confirmatory,25981688.0,
7980,1233151,1,1,,123097261,31703,Active,,,0.93,IC50,Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay,Confirmatory,25981689.0,
7981,1233152,1,1,,123097261,31703,Active,,,2.2,IC50,Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25981689.0,
7982,1233153,1,1,,123097261,31703,Active,,,1.13,IC50,Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25981689.0,
7983,1233154,1,1,,123097261,31703,Active,,,1.33,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25981689.0,
7984,1233157,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human U87MG cells assessed as early apoptotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based flow cytometric analysis (Rvb = 3.41%),Other,25981689.0,
7985,1233158,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human U87MG cells assessed as late apoptotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based flow cytometric analysis (Rvb = 3.23%),Other,25981689.0,
7986,1233159,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human U87MG cells assessed as total apoptotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based flow cytometric analysis (Rvb = 6.64%),Other,25981689.0,
7987,1233160,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human U87MG cells assessed as viable cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based flow cytometric analysis (Rvb = 93.12%),Other,25981689.0,
7988,1233165,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human U87MG cells assessed as necrotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based flow cytometric analysis (Rvb = 0.24%),Other,25981689.0,
7989,1233172,1,1,,123097261,31703,Inactive,,,,,Antimicrobial activity against Staphylococcus aureus after 5 to 12 hrs by micro broth dilution assay,Other,25981689.0,
7990,1233173,1,1,,123097261,31703,Inactive,,,,,Antimicrobial activity against Escherichia coli after 5 to 12 hrs by micro broth dilution assay,Other,25981689.0,
7991,1233368,1,1,,123097261,31703,Active,,,0.18,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7992,1233369,1,1,,123097261,31703,Active,,,0.337,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7993,1233370,1,1,,123097261,31703,Active,,,0.12300000000000001,IC50,Antiproliferative activity against human FM3 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7994,1233371,1,1,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7995,1233372,1,1,,123097261,31703,Active,,,0.127,IC50,Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7996,1233373,1,1,,123097261,31703,Active,,,0.035,IC50,Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7997,1233374,1,1,,123097261,31703,Active,,,2.807,IC50,Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
7998,1233375,1,1,,123097261,31703,Unspecified,,,,,Ratio of IC50 for human MES-SA/Dx5 cells to IC50 for human MES-SA cells,Other,25998504.0,
7999,1233441,1,1,,123097261,31703,Active,,,7.36,IC50,Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay,Confirmatory,26022842.0,
8000,1233442,1,1,,123097261,31703,Active,,,6.13,IC50,Cytotoxicity against human A549 cells assessed as cell viability by SRB assay,Confirmatory,26022842.0,
8001,1233443,1,1,,123097261,31703,Active,,,10.78,IC50,Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay,Confirmatory,26022842.0,
8002,1233444,1,1,,123097261,31703,Active,,,12.34,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay,Confirmatory,26022842.0,
8003,1233654,1,1,,123097261,31703,Active,,,2.9,IC50,Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method,Confirmatory,26071861.0,
8004,1233655,1,1,,123097261,31703,Inconclusive,9087218.0,3791.0,,IC50,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,Confirmatory,26071861.0,
8005,1235935,1,1,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human PC3 cells by MTT method,Confirmatory,26287401.0,
8006,1236043,1,1,,123097261,31703,Active,,,17.67,IC50,Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay,Confirmatory,26200396.0,
8007,1236044,1,1,,123097261,31703,Active,,,23.22,IC50,Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 24 hrs by MTT assay,Confirmatory,26200396.0,
8008,1236045,1,1,,123097261,31703,Active,,,34.52,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay,Confirmatory,26200396.0,
8009,1236605,1,1,,123097261,31703,Active,,,0.022000000000000002,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25937236.0,
8010,1236606,1,1,,123097261,31703,Active,,,5.3,IC50,Antiproliferative activity against human doxorubicin-resistant MCF7 cells after 48 hrs by MTT assay,Confirmatory,25937236.0,
8011,1236607,1,1,,123097261,31703,Unspecified,,,,,"Resistance ratio, ratio of IC50 for human doxorubicin-resistant MCF7 cells to IC50 for human MCF7 cells",Other,25937236.0,
8012,1236784,1,1,,123097261,31703,Active,,,0.79,IC50,Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8013,1236786,1,1,,123097261,31703,Active,,,0.92,IC50,Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8014,1236788,1,1,,123097261,31703,Active,,,0.2,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8015,1236790,1,1,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8016,1236792,1,1,,123097261,31703,Active,,,0.22,IC50,Cytotoxicity against human KB cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8017,1236794,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay relative to control,Confirmatory,25975638.0,
8018,1237431,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay,Other,26048808.0,
8019,1237471,1,1,,123097261,31703,Active,,,0.01,GI50,Growth inhibition of human A549 cells after 48 hrs by SRB assay,Confirmatory,26067381.0,
8020,1237472,1,1,,123097261,31703,Active,,,0.031,GI50,Growth inhibition of human HeLa cells after 48 hrs by SRB assay,Confirmatory,26067381.0,
8021,1237473,1,1,,123097261,31703,Active,,,0.01,GI50,Growth inhibition of human PANC1 cells after 48 hrs by SRB assay,Confirmatory,26067381.0,
8022,1237474,1,1,,123097261,31703,Active,,,0.01,GI50,Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,26067381.0,
8023,1237487,1,1,,123097261,31703,Active,,,,,Cytotoxicity against human CEM13 cells assessed as cell death after 72 hrs by MTT assay,Other,26079088.0,
8024,1237488,1,1,,123097261,31703,Active,,,,,Cytotoxicity against human MT4 cells assessed as cell death after 72 hrs by MTT assay,Other,26079088.0,
8025,1237489,1,1,,123097261,31703,Active,,,,,Cytotoxicity against human U937 cells assessed as cell death after 72 hrs by MTT assay,Other,26079088.0,
8026,1239033,1,1,,123097261,31703,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 assessed as reduction in ATP-dependent kDNA decatenation at 100 uM incubated for 30 mins by ethidium bromide staining based electrophoresis method,Other,26211460.0,
8027,1239292,1,1,,123097261,31703,Active,,,0.8,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,26252628.0,
8028,1239293,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay,Confirmatory,26252628.0,
8029,1239294,1,1,,123097261,31703,Active,,,1.3,IC50,Cytotoxicity against human A2780 cells after 24 hrs by MTT assay,Confirmatory,26252628.0,
8030,1239295,1,1,,123097261,31703,Active,,,5.2,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,26252628.0,
8031,1239296,1,1,,123097261,31703,Active,,,1.7,IC50,Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay,Confirmatory,26252628.0,
8032,1239297,1,1,,123097261,31703,Active,,,6.3,IC50,Cytotoxicity against human HUVEC after 24 hrs by MTT assay,Confirmatory,26252628.0,
8033,1239477,1,1,,123097261,31703,Active,,,0.003,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay,Confirmatory,26260339.0,
8034,1239478,1,1,,123097261,31703,Active,,,1.61,IC50,Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay,Confirmatory,26260339.0,
8035,1239480,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human CEM/ADR5000 cells to IC50 for human CCRF-CEM cells",Other,26260339.0,
8036,1239487,1,1,,123097261,31703,Active,,,0.85,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 0.1 to 100 uM after 48 hrs by MTT assay,Confirmatory,26263187.0,
8037,1239489,1,1,,123097261,31703,Active,,,,,Drug uptake in nucleus of human MDA-MB-231 cells at 10 uM after 18 hrs by DAPI staining-based confocal laser scanning microscopic analysis,Other,26263187.0,
8038,1239518,1,1,,123097261,31703,Unspecified,,,,,"Toxicity in Balb-c/nu mouse allografted with mouse SCC7 cells assessed as mortality at 5 mg/kg, iv administered daily measured within 6 days",Other,26263187.0,
8039,1240090,1,1,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human LoVo cells after 72 hrs,Confirmatory,26163197.0,
8040,1240091,1,1,,123097261,31703,Active,,,7.26,IC50,Antiproliferative activity against doxorubicin-resistant human LoVo/DX cells after 72 hrs,Confirmatory,26163197.0,
8041,1240092,1,1,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity against human MV4-11 cells after 72 hrs,Confirmatory,26163197.0,
8042,1240093,1,1,,123097261,31703,Active,,,0.31,IC50,Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs,Confirmatory,26163197.0,
8043,1240094,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,26163197.0,
8044,1240095,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/DX cells",Other,26163197.0,
8045,1240096,1,1,,123097261,31703,Unspecified,,,,,"Resistant index, ratio of IC50 for human LoVo/DX cells to IC50 for LoVo cells",Other,26163197.0,
8046,1240097,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human MV4-11 cells",Other,26163197.0,
8047,1241180,1,1,,123097261,31703,Active,,,1.58,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26264845.0,
8048,1241181,1,1,,123097261,31703,Active,,,0.96,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26264845.0,
8049,1241182,1,1,,123097261,31703,Active,,,1.38,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,26264845.0,
8050,1241183,1,1,,123097261,31703,Active,,,2.63,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,26264845.0,
8051,1241662,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8052,1241663,1,1,,123097261,31703,Active,,,0.25,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8053,1241664,1,1,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8054,1241665,1,1,,123097261,31703,Active,,,0.05,IC50,Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8055,1241666,1,1,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8056,1241667,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against HFF assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay,Confirmatory,26305181.0,
8057,1241976,1,1,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8058,1241977,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8059,1241978,1,1,,123097261,31703,Active,,,0.15,IC50,Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8060,1241979,1,1,,123097261,31703,Active,,,0.19,IC50,Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8061,1241980,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8062,1241981,1,1,,123097261,31703,Active,,,0.04,IC50,Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8063,1241982,1,1,,123097261,31703,Active,,,0.32,IC50,Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8064,1241983,1,1,,123097261,31703,Active,,,0.41,IC50,Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8065,1241984,1,1,,123097261,31703,Active,,,0.51,IC50,Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8066,1241985,1,1,,123097261,31703,Active,,,0.96,IC50,Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8067,1241986,1,1,,123097261,31703,Active,,,0.55,IC50,Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8068,1241987,1,1,,123097261,31703,Active,,,0.28,IC50,Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8069,1241988,1,1,,123097261,31703,Active,,,0.23,IC50,Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8070,1241989,1,1,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,26142490.0,
8071,1241990,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human HL60 cells,Other,26142490.0,
8072,1241991,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human HL60 cells,Other,26142490.0,
8073,1241992,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human HL60 cells,Other,26142490.0,
8074,1241993,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human HL60 cells,Other,26142490.0,
8075,1241994,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human MOLT4 cells,Other,26142490.0,
8076,1241995,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human MOLT4 cells,Other,26142490.0,
8077,1241996,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human MOLT4 cells,Other,26142490.0,
8078,1241997,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human MOLT4 cells,Other,26142490.0,
8079,1241998,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human HCT116 cells,Other,26142490.0,
8080,1241999,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human HCT116 cells,Other,26142490.0,
8081,1242000,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human HCT116 cells,Other,26142490.0,
8082,1242001,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human HCT116 cells,Other,26142490.0,
8083,1242002,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human HCT8 cells,Other,26142490.0,
8084,1242003,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human HCT8 cells,Other,26142490.0,
8085,1242004,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human HCT8 cells,Other,26142490.0,
8086,1242005,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human HCT8 cells,Other,26142490.0,
8087,1242006,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human PC3 cells,Other,26142490.0,
8088,1242007,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human PC3 cells,Other,26142490.0,
8089,1242008,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human PC3 cells,Other,26142490.0,
8090,1242009,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human PC3 cells,Other,26142490.0,
8091,1242010,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human PC3M cells,Other,26142490.0,
8092,1242011,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human PC3M cells,Other,26142490.0,
8093,1242012,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human PC3M cells,Other,26142490.0,
8094,1242013,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human PC3M cells,Other,26142490.0,
8095,1242014,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human OVCAR3 cells,Other,26142490.0,
8096,1242015,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human OVCAR3 cells,Other,26142490.0,
8097,1242016,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human OVCAR3 cells,Other,26142490.0,
8098,1242017,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human OVCAR3 cells,Other,26142490.0,
8099,1242018,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human OVCAR8 cells,Other,26142490.0,
8100,1242019,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human OVCAR8 cells,Other,26142490.0,
8101,1242020,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human OVCAR8 cells,Other,26142490.0,
8102,1242021,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human OVCAR8 cells,Other,26142490.0,
8103,1242022,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human SF295 cells,Other,26142490.0,
8104,1242023,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human SF295 cells,Other,26142490.0,
8105,1242024,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human SF295 cells,Other,26142490.0,
8106,1242025,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human SF295 cells,Other,26142490.0,
8107,1242026,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for human PBMC to IC50 for human MDA-MB-435 cells,Other,26142490.0,
8108,1242027,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for chinese hamster V79 cells to IC50 for human MDA-MB-435 cells,Other,26142490.0,
8109,1242028,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for mouse L929 cells to IC50 for human MDA-MB-435 cells,Other,26142490.0,
8110,1242029,1,1,,123097261,31703,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to IC50 for human MDA-MB-435 cells,Other,26142490.0,
8111,1242126,1,1,,123097261,31703,Active,,,1.6,GI50,Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay,Confirmatory,26163220.0,
8112,1242127,1,1,,123097261,31703,Active,,,0.95,GI50,Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay,Confirmatory,26163220.0,
8113,1242128,1,1,,123097261,31703,Active,,,1.9,GI50,Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay,Confirmatory,26163220.0,
8114,1242129,1,1,,123097261,31703,Active,,,1.4,GI50,Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay,Confirmatory,26163220.0,
8115,1243494,1,1,,123097261,31703,Active,,,2.0,IC50,Cytotoxicity against human RD cells by neutral red method,Confirmatory,26291474.0,
8116,1243495,1,1,,123097261,31703,Active,,,1.5,IC50,Cytotoxicity against human Hep2 cells by neutral red method,Confirmatory,26291474.0,
8117,1243496,1,1,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human HeLa cells by neutral red method,Confirmatory,26291474.0,
8118,1243514,1,1,,123097261,31703,Active,,,0.69,IC50,Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay,Confirmatory,26295905.0,
8119,1243515,1,1,,123097261,31703,Active,,,0.47,IC50,Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay,Confirmatory,26295905.0,
8120,1243516,1,1,,123097261,31703,Active,,,1.22,IC50,Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay,Confirmatory,26295905.0,
8121,1243572,1,1,,123097261,31703,Active,,,5.4,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,26317881.0,
8122,1243573,1,1,,123097261,31703,Active,,,6.2,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,26317881.0,
8123,1243574,1,1,,123097261,31703,Active,,,10.9,IC50,Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,26317881.0,
8124,1243716,1,1,,123097261,31703,Active,,,0.91,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26356746.0,
8125,1243717,1,1,,123097261,31703,Active,,,0.51,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26356746.0,
8126,1243718,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26356746.0,
8127,1243719,1,1,,123097261,31703,Active,,,1.1,IC50,Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26356746.0,
8128,1243736,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay,Other,26371504.0,
8129,1243737,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay,Other,26371504.0,
8130,1243865,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for drug-resistant human K562/ADR cells to IC50 for drug-sensitive human K562 cells",Other,26123642.0,
8131,1244475,1,1,,123097261,31703,Active,,,6.0,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay,Confirmatory,26222449.0,
8132,1244478,1,1,,123097261,31703,Active,,,0.5,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay,Confirmatory,26222449.0,
8133,1244849,1,1,,123097261,31703,Active,,,1.172,IC50,Anticancer against human MCF7 cells assessed as tumor growth inhibition after 72 hrs by SRB assay,Confirmatory,26256032.0,
8134,1245885,1,1,,123097261,31703,Active,,,0.95,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
8135,1245886,1,1,,123097261,31703,Active,,,1.08,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
8136,1245887,1,1,,123097261,31703,Active,,,1.88,IC50,Cytotoxicity against human T47D cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
8137,1245888,1,1,,123097261,31703,Active,,,1.23,IC50,Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
8138,1246242,1,1,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay,Confirmatory,26119992.0,
8139,1246243,1,1,,123097261,31703,Active,,,0.02,CC50,Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay,Confirmatory,26119992.0,
8140,1246244,1,1,,123097261,31703,Active,,,0.03,CC50,Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay,Confirmatory,26119992.0,
8141,1246832,1,1,,123097261,31703,Active,,,0.7,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,26280921.0,
8142,1246833,1,1,,123097261,31703,Active,,,0.6,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,26280921.0,
8143,1246834,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay,Confirmatory,26280921.0,
8144,1246835,1,1,,123097261,31703,Active,,,1.0,IC50,Cytotoxicity against human A375 cells after 72 hrs by MTT assay,Confirmatory,26280921.0,
8145,1246836,1,1,,123097261,31703,Active,,,1.35,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,26280921.0,
8146,1246952,1,1,,123097261,31703,Active,,,0.000414,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer,Confirmatory,26291039.0,
8147,1246953,1,1,,123097261,31703,Active,,,0.0041600000000000005,IC50,Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer,Confirmatory,26291039.0,
8148,1246954,1,1,,123097261,31703,Active,,,0.000294,IC50,Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer,Confirmatory,26291039.0,
8149,1246955,1,1,,123097261,31703,Active,,,0.00558,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer,Confirmatory,26291039.0,
8150,1247180,1,1,,123097261,31703,Active,,,0.75,IC50,Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8151,1247181,1,1,,123097261,31703,Active,,,0.57,IC50,Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8152,1247182,1,1,,123097261,31703,Active,,,0.43,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8153,1247183,1,1,,123097261,31703,Active,,,9.8,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8154,1247184,1,1,,123097261,31703,Active,,,6.29,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8155,1247185,1,1,,123097261,31703,Active,,,7.4,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in presence of 10% FBS,Confirmatory,26298501.0,
8156,1247187,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human HeLa cells assessed as formation of apoptotic nuclei formation at 10 uM after 24 hrs using propidium iodide staining by fluorescence microscopy analysis,Other,26298501.0,
8157,1247188,1,1,,123097261,31703,Active,,,0.84,IC50,Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8158,1247189,1,1,,123097261,31703,Active,,,1.02,IC50,Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8159,1247190,1,1,,123097261,31703,Active,,,0.45,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8160,1247191,1,1,,123097261,31703,Active,,,7.65,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8161,1247192,1,1,,123097261,31703,Active,,,6.03,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8162,1247193,1,1,,123097261,31703,Active,,,6.46,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in absence of 10% FBS,Confirmatory,26298501.0,
8163,1247276,1,1,,123097261,31703,Active,,,1.054,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
8164,1247277,1,1,,123097261,31703,Active,,,1.986,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
8165,1247278,1,1,,123097261,31703,Active,,,1.258,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
8166,1247279,1,1,,123097261,31703,Active,,,1.909,IC50,Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
8167,1247708,1,1,,123097261,31703,Active,,,0.03,EC50,Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8168,1247709,1,1,,123097261,31703,Active,,,0.02,EC50,Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8169,1247710,1,1,,123097261,31703,Active,,,0.04,EC50,Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8170,1247711,1,1,,123097261,31703,Active,,,0.01,EC50,Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8171,1247712,1,1,,123097261,31703,Active,,,0.3,EC50,Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8172,1247713,1,1,,123097261,31703,Active,,,0.9,EC50,Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8173,1247714,1,1,,123097261,31703,Active,,,0.7,EC50,Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8174,1247715,1,1,,123097261,31703,Active,,,0.1,EC50,Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8175,1247716,1,1,,123097261,31703,Active,,,0.2,EC50,Cytotoxicity against human DU145 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8176,1247717,1,1,,123097261,31703,Active,,,0.3,EC50,Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8177,1247718,1,1,,123097261,31703,Active,,,0.3,EC50,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,26320088.0,
8178,1248017,1,1,,123097261,31703,Active,,,0.28,IC50,Antiproliferative activity against human LoVo cells,Confirmatory,26338363.0,
8179,1248018,1,1,,123097261,31703,Active,,,6.73,IC50,Antiproliferative activity against human LoVo/DX cells,Confirmatory,26338363.0,
8180,1248019,1,1,,123097261,31703,Active,,,0.05,IC50,Antiproliferative activity against human MV4-11 cells,Confirmatory,26338363.0,
8181,1248020,1,1,,123097261,31703,Active,,,0.53,IC50,Cytotoxicity against mouse BALB/3T3 cells,Confirmatory,26338363.0,
8182,1248021,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,26338363.0,
8183,1248022,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/Dx cells",Other,26338363.0,
8184,1248023,1,1,,123097261,31703,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,26338363.0,
8185,1248024,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human MV4-11 cells",Other,26338363.0,
8186,1248170,1,1,,123097261,31703,Active,,,1.69,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26381063.0,
8187,1248171,1,1,,123097261,31703,Active,,,0.51,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26381063.0,
8188,1248172,1,1,,123097261,31703,Active,,,0.92,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26381063.0,
8189,1248442,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by SRB assay,Other,26420384.0,
8190,1248443,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 72 hrs by SRB assay,Other,26420384.0,
8191,1248444,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SF268 cells assessed as inhibition of cell viability after 72 hrs by SRB assay,Other,26420384.0,
8192,1248452,1,1,,123097261,31703,Active,,,,,"Antitumor activity against mouse S180 cells allografted in ICR mouse assessed as tumor growth inhibition at 2 umol/kg, ip qd for 7 days measured 24 hrs after last dose",Other,,
8193,1248577,1,1,,123097261,31703,Active,,,0.5,IC50,Anticancer activity against human ME180 cells by MTT assay,Confirmatory,,
8194,1248578,1,1,,123097261,31703,Active,,,1.2,IC50,Anticancer activity against human A375 cells by MTT assay,Confirmatory,,
8195,1248579,1,1,,123097261,31703,Active,,,2.4,IC50,Anticancer activity against human DU145 cells by MTT assay,Confirmatory,,
8196,1248580,1,1,,123097261,31703,Active,,,1.1,IC50,Anticancer activity against human A549 cells by MTT assay,Confirmatory,,
8197,1248585,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human ME180 cells assessed as accumulation at SubG1 phase at 1 uM after 48 hrs by FACS analysis (Rvb = 7.0%),Other,,
8198,1248586,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human ME180 cells assessed as accumulation at G1 phase at 1 uM after 48 hrs by FACS analysis (Rvb = 59.9%),Other,,
8199,1248587,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human ME180 cells assessed as accumulation at S phase at 1 uM after 48 hrs by FACS analysis (Rvb = 19.3%),Other,,
8200,1248588,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human ME180 cells assessed as accumulation at G2/M phase at 1 uM after 48 hrs by FACS analysis (Rvb = 13.2%),Other,,
8201,1248589,1,1,,123097261,31703,Active,,,,,Cell cycle arrest in human ME180 cells assessed as accumulation at G2/M phase at <1 uM,Other,,
8202,1248593,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human ME180 cells assessed as DNA fragmentation at 1 uM after 48 hrs,Other,,
8203,1248594,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human ME180 cells assessed as viable cells at 1 uM for 24 hrs by annexin V/PI staining based flow cytometry (Rvb = 83.1%),Other,,
8204,1248595,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human ME180 cells assessed as early apoptotic cells at 1 uM for 24 hrs by annexin V/PI staining based flow cytometry (Rvb = 0.2%),Other,,
8205,1248596,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human ME180 cells assessed as late apoptotic cells at 1 uM for 24 hrs by annexin V/PI staining based flow cytometry (Rvb = 5%),Other,,
8206,1248597,1,1,,123097261,31703,Unspecified,,,,,Induction of apoptosis in human ME180 cells assessed as necrotic cells at 1 uM for 24 hrs by annexin V/PI staining based flow cytometry (Rvb = 11.7%),Other,,
8207,1248599,1,1,,123097261,31703,Unspecified,,,,,Induction to apoptosis in human ME180 cells assessed as increase in caspase-3 activity at 1 uM for 48 hrs relative to control,Other,,
8208,1248654,1,1,,123097261,31703,Active,,,2.45,IC50,Antiproliferative activity against human DU145 cells by MTT assay,Confirmatory,,
8209,1248655,1,1,,123097261,31703,Active,,,3.41,IC50,Antiproliferative activity against human MDA-MB-231 cells by MTT assay,Confirmatory,,
8210,1248656,1,1,,123097261,31703,Active,,,3.12,IC50,Antiproliferative activity against human MCF7 cells by MTT assay,Confirmatory,,
8211,1248657,1,1,,123097261,31703,Active,,,2.1,IC50,Antiproliferative activity against human A549 cells by MTT assay,Confirmatory,,
8212,1248658,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as accumulation at G0/G1 phase at 3 uM for 24 hrs by flow cytometry (Rvb = 65%),Other,,
8213,1248659,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as accumulation at S phase at 3 uM for 24 hrs by flow cytometry (Rvb = 10%),Other,,
8214,1248660,1,1,,123097261,31703,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as accumulation at G2/M phase at 3 uM for 24 hrs by flow cytometry (Rvb = 25%),Other,,
8215,1248662,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human DU145 cells assessed as caspase-3 activation at 3 uM for 24 hrs by fluorescence analysis,Other,,
8216,1248663,1,1,,123097261,31703,Active,,,,,Induction of apoptosis in human DU145 cells assessed as caspase-8 activation at 3 uM for 24 hrs by fluorescence analysis,Other,,
8217,1248664,1,1,,123097261,31703,Active,,,,,Decrease in cyclin-D1 expression in human DU145 cells at 3 uM for 24 hrs by western blot analysis,Other,,
8218,1248665,1,1,,123097261,31703,Active,,,,,Decrease in CDK4 expression in human DU145 cells at 3 uM for 24 hrs by western blot analysis,Other,,
8219,1249226,1,1,,123097261,31703,Active,,,0.03,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,,
8220,1249227,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,,
8221,1249228,1,1,,123097261,31703,Active,,,0.09,IC50,Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay,Confirmatory,,
8222,1249229,1,1,,123097261,31703,Active,,,0.48,IC50,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,,
8223,1249230,1,1,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human PBMC cells after 72 hrs by MTT assay,Confirmatory,,
8224,1249231,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC cells to IC50 for human HL60 cells",Other,,
8225,1249232,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC cells to IC50 for human HCT116 cells",Other,,
8226,1249233,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC cells to IC50 for human OVCAR8 cells",Other,,
8227,1249234,1,1,,123097261,31703,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC cells to IC50 for human SF295 cells",Other,,
8228,1249663,1,1,,123097261,31703,Active,,,1.11,IC50,Antiproliferative activity against human HuH7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay,Confirmatory,26253231.0,
8229,1249664,1,1,,123097261,31703,Active,,,0.13,IC50,Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay,Confirmatory,26253231.0,
8230,1249665,1,1,,123097261,31703,Active,,,2.25,IC50,Antiproliferative activity against human LN229 cells assessed as growth inhibition incubated for 48 hrs by MTT assay,Confirmatory,26253231.0,
8231,1249666,1,1,,123097261,31703,Active,,,1.78,IC50,Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay,Confirmatory,26253231.0,
8232,1249667,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cells assessed as cell growth at 2.5 uM incubated for 48 hrs by MTT assay relative to control,Other,26253231.0,
8233,1249668,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against rat H9c2 cell membrane assessed as induction of lipid peroxidation at 2.5 uM incubated for 48 hrs by TBARS method,Other,26253231.0,
8234,1249671,1,1,,123097261,31703,Active,,,,,Drug uptake in human LN229 cell nucleus at 0.6 uM incubated for 48 hrs by confocal microscopy,Other,26253231.0,
8235,1249672,1,1,,123097261,31703,Unspecified,,,,,Inhibition of glucose uptake in human LN229 cells assessed as glucose concentration per ug protein at 0.6 uM incubated for 48 hrs by liquid scintillation method (Rvb = 98 +/- 8 mg/dl/ug protein),Other,26253231.0,
8236,1249725,1,1,,123097261,31703,Active,,,0.18,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26280922.0,
8237,1249726,1,1,,123097261,31703,Active,,,0.02,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay,Confirmatory,26280922.0,
8238,1249727,1,1,,123097261,31703,Active,,,0.17,IC50,Cytotoxicity against human QGY7701 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26280922.0,
8239,1249728,1,1,,123097261,31703,Active,,,0.57,IC50,Cytotoxicity against human SMMC7721 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26280922.0,
8240,1249729,1,1,,123097261,31703,Active,,,0.14,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26280922.0,
8241,1249730,1,1,,123097261,31703,Active,,,0.06,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26280922.0,
8242,1249874,1,1,,123097261,31703,Active,269849759.0,7157.0,,,Stabilization of p53 in human U2OS cells assessed as intracellular p53 level at 0.5 uM after 12 hrs by Western blotting,Other,26288684.0,
8243,1249876,1,1,,123097261,31703,Inactive,,,,,Activation of p53 in human U2OS cells assessed as increase of MDM2 expression at 0.5 uM after 12 hrs by Western blotting,Other,26288684.0,
8244,1250190,1,1,,123097261,31703,Active,,,,,Induction of DNA intercalation in Escherichia coli pBR322 plasmid DNA assessed as supercoiled DNA formation at 100 uM after 1 hr by agarose gel electrophoresis,Other,26291037.0,
8245,1250990,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human SV-HUC1 cells assessed as survival rate after 72 hrs by MTT assay,Other,26344783.0,
8246,1250991,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human WPMY-1cells assessed as survival rate after 72 hrs by MTT assay,Other,26344783.0,
8247,1250992,1,1,,123097261,31703,Unspecified,,,,,Cytotoxicity against human RWPE1 cells assessed as survival rate after 72 hrs by MTT assay,Other,26344783.0,
8248,1252043,1,1,,123097261,31703,Active,,,0.12,IC50,Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay,Confirmatory,25799376.0,
8249,1252044,1,1,,123097261,31703,Active,,,0.63,IC50,Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay,Confirmatory,25799376.0,
8250,1252545,1,1,,123097261,31703,Active,,,0.93,IC50,Anticancer activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8251,1252546,1,1,,123097261,31703,Active,,,1.94,IC50,Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8252,1252547,1,1,,123097261,31703,Active,,,1.51,IC50,Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8253,1252548,1,1,,123097261,31703,Active,,,1.58,IC50,Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8254,1252549,1,1,,123097261,31703,Active,,,0.63,IC50,Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8255,1252550,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxic activity against human HEK293 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay,Confirmatory,26330077.0,
8256,1252784,1,1,,123097261,31703,Active,,,0.0051,IC50,Antiproliferative activity against human IMR32 cells assessed as inhibition of cell viability after 48 hrs,Confirmatory,26360048.0,
8257,1252950,1,1,,123097261,31703,Active,,,0.42,IC50,Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
8258,1252951,1,1,,123097261,31703,Active,,,0.57,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
8259,1252952,1,1,,123097261,31703,Active,,,0.37,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
8260,1252953,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay,Confirmatory,26397393.0,
8261,1252954,1,1,,123097261,31703,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells after 4 days by GFP detection method,Confirmatory,26397393.0,
8262,1252955,1,1,,123097261,31703,Inconclusive,,,,IC50,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,26397393.0,
8263,1253925,1,1,,123097261,31703,Active,,,0.0268,GI50,Cytotoxicity against HUVEC cells after 48 hrs by SRB assay,Confirmatory,26462052.0,
8264,1254633,1,1,,123097261,31703,Active,,,,,Induction of DNA damage in human HCT116 cells at G0/G1 phase at 100 nM after 24 hrs by gamma-H2AX-staining based-flow cytometry,Other,,
8265,1254637,1,1,,123097261,31703,Active,,,,,Decrease in mitotic index in human HCT116 cells at 100 nM after 20 and 24 hrs by flow cytometry,Other,,
8266,1254815,1,1,,123097261,31703,Active,,,3.33,IC50,Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
8267,1254816,1,1,,123097261,31703,Active,,,1.9,IC50,Cytotoxicity against human T47D cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
8268,1254817,1,1,,123097261,31703,Active,,,0.52,IC50,Cytotoxicity against human HeLa cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
8269,1255359,1,1,,123097261,31703,Active,,,1.4,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,26398312.0,
8270,1255360,1,1,,123097261,31703,Active,,,1.2,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,26398312.0,
8271,1255361,1,1,,123097261,31703,Active,,,0.68,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,26398312.0,
8272,1255362,1,1,,123097261,31703,Active,,,0.83,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26398312.0,
8273,1256777,1,1,,123097261,31703,Active,,,0.424,IC50,Antiproliferative activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8274,1256778,1,1,,123097261,31703,Active,,,1.12,IC50,Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,26494582.0,
8275,1256779,1,1,,123097261,31703,Active,,,0.62,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8276,1256780,1,1,,123097261,31703,Active,,,0.29,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,26494582.0,
8277,1256781,1,1,,123097261,31703,Active,,,0.26,IC50,Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay,Confirmatory,26494582.0,
8278,1256782,1,1,,123097261,31703,Active,,,0.17,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8279,1256783,1,1,,123097261,31703,Active,,,0.09,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,26494582.0,
8280,1256784,1,1,,123097261,31703,Unspecified,,,89.9,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8281,1256785,1,1,,123097261,31703,Active,,,1.68,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8282,1256786,1,1,,123097261,31703,Active,,,0.1,IC50,Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8283,1256787,1,1,,123097261,31703,Active,,,7.52,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8284,1256788,1,1,,123097261,31703,Active,,,0.11,IC50,Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,26494582.0,
8285,1259325,1,2,,336954211,31703,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
8286,1259357,1,1,,124886893,31703,Inconclusive,,,1.6626,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A2780, Spheroid)",Confirmatory,,
8287,1259358,1,1,,124886893,31703,Active,,,3.3173,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)",Confirmatory,,
8288,1259359,1,1,,124886893,31703,Active,,,5.8992,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Spheroid)",Confirmatory,,
8289,1259360,1,1,,124886893,31703,Active,,,18.6548,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Spheroid)",Confirmatory,,
8290,1259361,1,1,,124886893,31703,Active,,,,Activity at 9.921 uM,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)",Confirmatory,,
8291,1259362,1,1,,124886893,31703,Inconclusive,,,9.3495,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Adherent)",Confirmatory,,
8292,1259407,1,1,,363898689,31703,Active,,,,,CCRIS mutagenicity studies,Other,,
8293,1259408,1,1,,363897058,31703,Active,,,,,GENE-TOX mutagenicity studies,Other,,
8294,1259411,1,1,,363898689,31703,Active,,,,,CCRIS carcinogenicity studies,Other,,
8295,1259416,1,2,,164339434,31703,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
8296,1259416,1,2,,340081215,31703,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
8297,1259421,1,1,,164339434,31703,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
8298,1259421,1,1,,340081215,31703,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
8299,1259423,1,2,,354909895,31703,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
8300,1259423,1,2,,354909916,31703,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
